

EA25
NM WORLD
LEADING
MEETING

40 EA
NM
SINCE 1985

FINAL PROGRAMME

Annual Congress of the European Association of Nuclear Medicine

BARCELONA

OCTOBER 4-8, 2025

eanm25.eanm.org

TABLE OF CONTENTS

WORDS OF WELCOME

4

GENERAL INFORMATION

Board & Scientific Programme Representatives	8
Session Coordinators	9
EANM'25 Reviewers	10
EANM'25 Chairpersons	14
EANM National Societies: Delegates / Deputies	18
UEMS/EBNM National Societies: Delegates / Deputies	20
UEMS/EBNM Committees	22
General Information	25
Floorplans	32
Programme Overview	35

SCIENTIFIC & TECHNOLOGISTS' PROGRAMME

Plenary Sessions	45
Continuing Medical Education – CME Sessions	46
Special Track	47
Joint Symposia	49
Special Symposia	50
EU Policy Symposia	50
Learn & Improve Professional Skills (LIPS) Track	51
Clinical Oncology Track	52

Theranostics Track	53
Cutting Edge Science Track	54
M2M–The 12 th 'From Molecule to Man' Track	55
Further Oral Presentations & Case Report Sessions	56
e-Posters Presentations	58
Technologists' Track	60
Awards	62

ABSTRACTS

Oral Presentations	65
e-Poster Presentation Sessions	118
e-Posters	173

INDUSTRY EXHIBITION

Satellite Symposia	294
List of Exhibitors (A-Z)	300
List of Exhibitors (Booth number)	304
Exhibition Halls	308
Company Profiles	314

CORPORATE MEMBERS

380

USEFUL CONTACTS

384

IMPRINT

384

WORDS OF WELCOME

BY THE CONGRESS CHAIR



VALENTINA GARIBOTTO

EANM CONGRESS CHAIR 2023–2025

Dear Colleagues,

It is with great pleasure that I invite you to the EANM'25—the 38th Annual Congress of the European Association of Nuclear Medicine (EANM). The EANM'25 will be held in the vibrant city of Barcelona from October 4-8, 2025.

This year marks a significant milestone for our association as we celebrate four decades of pioneering advancements and collaborative efforts in the field of nuclear medicine. Our congress will be a unique opportunity to reflect on our journey, celebrate our achievements since 1985, and look ahead to securing the brightest future for our specialty.

The EANM Annual Congress is a truly global event, attracting about 10,000 participants from all over the world. This diverse gathering of professionals provides a rich platform for the exchange of ideas, fostering international collaboration and innovation. We are committed to exploring novel formats and interactions with experts, ensuring that our congress remains at the forefront of scientific discourse and professional development.

One of the highlights of this year's congress will be the continued focus on novel advances in theranostics. This rapidly evolving field continues to revolutionise our approach to diagnosis and treatment, offering unprecedented precision and personalised care for our patients. We have an exciting programme lined up, featuring leading experts who will share their insights and latest research findings.

But our congress is also designed to cater to all fields of research and clinical activity within nuclear medicine. We have specific tracks

dedicated to all the various specialities, ensuring that every participant can find sessions relevant to their interests and expertise. Whether you are involved in clinical practice, research, or education, there will be something for you at the EANM'25.

In addition to the scientific sessions, the EANM'25 will provide ample opportunities for networking, collaboration, and professional development. We are particularly proud of our EANM Next-Gen programme, which was launched last year to support our younger collaborators. This initiative offers free registration and accommodation to selected participants to facilitate their attendance and integration into the scientific community, ensuring that the next generation of nuclear medicine professionals is well-represented and engaged. This year again, we will also offer a Young Professionals Lounge for congress participants under 38.

I am also very happy to travel once again to Barcelona, with its rich cultural heritage and dynamic atmosphere, which will serve as the perfect backdrop for our gathering. We look forward to welcoming you to what promises to be an inspiring and memorable event. Your participation and contributions are invaluable to the continued success and growth of our community.

Warm regards,

Valentina Garibotto
EANM Congress Chair 2023–2025

WORDS OF WELCOME

BY THE CHAIR OF THE TECHNOLOGISTS COMMITTEE



AGATA PIETRZAK

CHAIR, EANM TECHNOLOGISTS COMMITTEE

Dear colleagues and friends,

Dear fellow technologists,

It is an honour and a great pleasure to invite you to the EANM'25 Annual Congress in Barcelona (Spain), on behalf of the EANM Technologists Committee.

Every congress is unique – but regardless of the time or location, it is always highly attended and ever-growing. For the members of the Technologists Committee and myself as Committee Chair, the most rewarding part is seeing Nuclear Medicine Technologists come together, connect, and exchange. As passionate, active, and ambitious professionals dedicated to lifelong learning, technologists are the backbone of Nuclear Medicine procedures. This is a very special group of specialists, who work closely with patients and caregivers, planning procedures and ensuring the highest quality of studies.

During the EANM'25, the Technologists Committee will once again deliver a full dedicated programme – the so-called Technologists' Track. This track is specially tailored for Nuclear Medicine Technologists, and covers daily clinical and scientific routine, as well as educational content. Every year, the Technologists Committee strives to create a multidimensional programme, bringing together interdisciplinary professionals to present the most relevant and up-to-date content. Moreover, this track reflects the true meaning of the word "collaboration", by involving colleagues and friends from other EANM committees and sister societies to highlight the importance of interdisciplinary teamwork in the medical field.

The Technologists Track is your opportunity to:

- Gain deeper insights into Nuclear Medicine as highly specialised technologists
- Access valuable resources such as the European Qualification Framework (EQF 6 & 7) and copies of the Technologist's Guide copies. Do not miss it!

- Explore cutting-edge topics, including: continuous education models for NMTs, FAPI studies, and more!
- Enhance your practical skills through Mini Courses designed to support your daily clinical work.

In addition, we are committed to acknowledging your contributions and celebrating excellence in the field. During the e-poster and oral presentations, we will recognise outstanding work, with awards for the best presentations! As in previous years, we expect these sessions to be of very high quality and to offer valuable opportunities to share knowledge.

At the EANM'25, we hope to create another memorable and enriching congress experience, filled with high-level clinical and scientific knowledge. As Chair of the Technologists Committee, I would like to thank you for your kind acknowledgement of our efforts as well as your precious words of encouragement.

Please continue reaching out, sharing your thoughts, and helping us grow—because together, we can shape the future of Nuclear Medicine Technologists!

With my best regards,

Agata Pietrzak

Chair of the EANM Technologists Committee

BOARD & SCIENTIFIC PROGRAMME REPRESENTATIVES

EANM BOARD	SCIENTIFIC PROGRAMME REPRESENTATIVES
President 2025-2026 Paola A. Erba (Italy)	Congress Chair 2023-2025 Valentina Garibotto (Switzerland)
President Elect 2025-2026 Felix Mottaghy (Germany)	AI Committee Dimitris Visvikis (France), Margarita Kirienko (Italy)
Internal Groups Officer 2025-2026 Val Lewington (United Kingdom)	Bone & Joint Committee Davina Mak (United Kingdom), Franceso Dondi (Italy)
Secretary/Treasurer 2024-2025 Alexis Vrachimis (Cyprus)	Cardiovascular Committee Olivier Lairez (France), Fabien Hyafil (France)
Scientific Liaison Officer 2025-2026 Michel Koole (Belgium)	Dosimetry Committee Johannes Tran-Gia (Germany), Silvano Gnesin (Switzerland)
Congress Chair 2023-2025 Valentina Garibotto (Switzerland)	Inflammation & Infection Committee Domenico Albano (Italy), Olivier Gheysens (Belgium)
Education Chair 2023-2025 Soňa Balagová (Slovak Republic)	Neuroimaging Committee Antoine Verger (France), Igor Yakushev (Germany)
	Oncology & Theranostics Committee , Valentina Ambrosini (Italy), Wolfgang Fendler (Germany)
	Paediatrics Committee Pinar Kiratli (Türkiye), Pietro Zucchetta (Italy)
	Physics Committee Laetitia Imbert (France), Ana Denis-Bacelar (United Kingdom)
	Radiation Protection Committee Uta Eberlein (Germany), Ioannis Iakovou (Greece)
	Radiopharmaceutical Sciences Committee Filippo Lodi (Italy), Harry Hendrikse (Netherlands)
	Thyroid Committee Alfredo Campenni (Italy), Michael Kreissl (Germany)
	Translational Molecular Imaging & Therapy Committee Peter Laverman (Netherlands), Tessa Buckle (Netherlands)
	Technologist Committee Agata Pietrzak (Poland), Luisa Roldao Pereira (United Kingdom)

SESSION COORDINATORS

SESSION COORDINATORS	
EANM thanks all Session Coordinators for their huge engagement in organising the session details and speakers.	
Olivier Gheysens (Belgium)	Bart de Keizer (Netherlands)
Diego Cecchin (Italy)	Pietro Zuchetta (Italy)
Floris van Velden (Netherlands)	Karolien Goffin (Belgium)
Pietro Zuccheto (Italy)	Tatjana Traub-Weidinger (Austria)
Fédérico Caobelli (Switzerland)	Christophe Deroose (Belgium)
Laetitia Imbert (France)	Dimitris Visvikis (France)
Petra Petranovic Ovcaricek (Croatia)	Soren Hess (Denmark)
Clément Bailly (France)	Daniela Oprea-Lager (Netherlands)
David Taieb (France)	Fabien Hyafil (France)
Filipe Elvas (Belgium)	Katharina Luekerath (Germany)
Nathalie Albert (Germany)	Jean-Pierre Pouget (France)
Nelleke Tolboom (Netherlands)	Matthias Brendel (Germany)
Martina Sollini (Italy)	Barbara Geist (Austria)
Mark Konijnenberg (Netherlands)	Lucia Leccisotti (Italy)
Sofia Carrilho Vaz (Portugal)	Valentina Ambrosini (Italy)
Peter Bernhardt (Sweden)	Olivier Lairez (France)
Davina Mak (United Kingdom)	Francoise Bodere (France)
Tessa Buckle (Netherlands)	Johannes Tran-Gia (Germany)
Murat Tuncel (Türkiye)	Eric Guedj (France)
Kuangyu Shi (Switzerland)	Laura Evangelista (Italy)
Marta Cremonesi (Italy)	Domenico Albano (Italy)
Uta Eberlein (Germany)	Peter Laverman (Netherlands)
Samia Massalha (Israel)	Wolfgang Fendler (Germany)
Matteo Baucknet (Italy)	Antoine Verger (France)
Pinar Kiratli (Türkiye)	

EANM'25

REVIEWERS

Abgral, R. (France)
Acampa, W. (Italy)
Adam, J. (Netherlands)
Agostini, D. (France)
Ahmadzadehfar, H. (Germany)
Akdemir, U. (Türkiye)
Albano, D. (Italy)
Albert, N. (Germany)
Altini, C. (Italy)
Ambrosini, V. (Italy)
Ametamey, S. (Switzerland)
Antunovic, L. (Italy)
Armstrong, I. (United Kingdom)
Atay Kapucu, L. (Türkiye)
Baldari, S. (Italy)
Balkay, L. (Hungary)
Ballinger, J. (Canada)
Barthel, H. (Germany)
Bauckneht, M. (Italy)
Bax, J. (Netherlands)
Behe, M. (Switzerland)
Beheshti, M. (Germany)
Ben-Haim, S. (Israel)
Bernhardt, P. (Sweden)
Berti, V. (Italy)
Biassoni, L. (United Kingdom)
Bilgin, B. (Türkiye)
Bogovic Crncic, T. (Croatia)
Booij, J. (Netherlands)
Botelho, M. (Portugal)
Bozkurt, M. (Türkiye)
Brendel, M. (Germany)
Brenner, W. (Germany)
Brouwers, A. (Netherlands)
Bucerius, J. (Austria)
Buchert, R. (Germany)

Buckle, T. (Netherlands)
Buvat, I. (France)
Cai, W. (United States)
Campenni, A. (Italy)
Cantinho-Lopes, M. (Portugal)
Carrilho Vaz, S. (Portugal)
Castell Conesa, J. (Spain)
Cecchin, D. (Italy)
Ceci, F. (Italy)
Celli, M. (Italy)
Chakravartty, R. (United Kingdom)
Chouin, N. (France)
Cicone, F. (Switzerland)
Cook, G. (United Kingdom)
Cornelissen, B. (United Kingdom)
Costa, G. (Portugal)
Covens, P. (Belgium)
Cremonesi, M. (Italy)
Cuocolo, A. (Italy)
Dalm, S. (Netherlands)
Daou, D. (France)
Darcourt, J. (France)
De Bondt, P. (Belgium)
De Geus-Oei, L. (Netherlands)
de Swart, J. (Netherlands)
de Vries, E. (Netherlands)
Deandreis, D. (Italy)
Decristoforo, C. (Austria)
Delgado-Bolton, R. (Spain)
Derlin, T. (Germany)
Deroose, C. (Belgium)
Deuther-Conrad, W. (Germany)
Dickson, J. (United Kingdom)
Dierickx, L. (France)
Dziuk, M. (Poland)
Eberlein, U. (Germany)

Eiber, M. (Germany)
Ekmekcioglu, O. (Türkiye)
Ellis, B. (United Kingdom)
Elsinga, P. (Netherlands)
Ertay, T. (Türkiye)
Evangelista, L. (Italy)
Everaert, H. (Belgium)
Ezziddin, S. (Germany)
Farolfi, A. (Italy)
Farsad, M. (Italy)
Fernández León, A. (Spain)
Ferrari, C. (Italy)
Flamen, P. (Belgium)
Flotats Giralt, A. (Spain)
Flux, G. (United Kingdom)
Forsback, S. (Finland)
Fragoso-Costa, P. (Germany)
Franceschi, M. (Croatia)
Frangos, S. (Cyprus)
Franzius, C. (Germany)
Gaberš?ek, S. (Slovenia)
Gheysens, O. (Belgium)
Giammarile, F. (France)
Gimelli, A. (Italy)
Giovanella, L. (Switzerland)
Glatting, G. (Germany)
Glaudemans, A. (Netherlands)
Gnanasegaran, G. (United Kingdom)
Gourni, E. (Switzerland)
Graf, S. (Austria)
Graham, R. (United Kingdom)
Grana, C. (Italy)
Gratz, S. (Germany)
Grimm, J. (United States)
Guedj, E. (France)
Haberkorn, U. (Germany)

Halldin, C. (Sweden)
Handkiewicz-Junak, D. (Poland)
Hartman, N. (United Kingdom)
Hatt, M. (France)
Herrmann, K. (Germany)
Heskamp, S. (Netherlands)
Hess, S. (Denmark)
Hesse, S. (Germany)
Hicks, R. (Australia)
Hindorf, C. (Sweden)
Hofman, M. (Australia)
Holm, S. (Denmark)
Hubalewska-Dydejczyk, A. (Poland)
Hyafil, F. (France)
Iagaru, A. (United States)
Iakovou, I. (Greece)
Jamar, F. (Belgium)
Kampen, W. (Germany)
Kirac, S. (Türkiye)
Kirienko, M. (Italy)
Kiss, O. (Germany)
Kolenc, P. (Slovenia)
Konijnenberg, M. (Netherlands)
Koole, M. (Belgium)
Koranda, P. (Czech Republic)
Kostkiewicz, M. (Poland)
Kotzerke, J. (Germany)
Koutsikos, J. (Greece)
Kracmerova, T. (Czech Republic)
Kraeber-Bodéré, F. (France)
Krämer, S. (Switzerland)
Kreissl, M. (Germany)
Kucuk, N. (Türkiye)
Kunikowska, J. (Poland)
Kurth, J. (Germany)
Kuwert, T. (Germany)

EANM'25

REVIEWERS

Lairez, O. (France)	Niculae, D. (Romania)
Langsteger, W. (Austria)	Nonnekens, J. (Netherlands)
Lapa, C. (Germany)	Noriega Alvarez, E. (Spain)
Lassmann, M. (Germany)	Ocak, E. (Türkiye)
Lavelli, V. (Italy)	Oebro Fosbøl, M. (Denmark)
Laverman, P. (Netherlands)	Olianti, C. (Italy)
Lazzeri, E. (Italy)	Oprea-Lager, D. (Netherlands)
Leccisotti, L. (Italy)	Orlhac, F. (France)
Lemos Pereira, E. (Portugal)	Ozgen Kiratli, P. (Türkiye)
Lodi, F. (Italy)	Palmedo, H. (Germany)
Lubberink, M. (Sweden)	Panagiotidis, E. (Greece)
Mada, M. (United Kingdom)	Papathanasiou, N. (Greece)
Maes, A. (Belgium)	Pappata, S. (Italy)
Maffioli, L. (Italy)	Pascali, C. (Italy)
Maina-Nock, T. (Greece)	Pascual, T. (Austria)
Maldonado, A. (Spain)	Pereira, L. (United Kingdom)
Manevska, N. (North Macedonia, The Republic Of)	Petranovi? Ov?ari?ek, P. (Hungary)
Manrique, A. (France)	Piciu, D. (Romania)
Mapelli, P. (Italy)	Pirich, C. (Austria)
Marafi, F. (Kuwait)	Poeppel, T. (Germany)
Marengo, M. (Italy)	Prassopoulos, V. (Greece)
Marie, P. (France)	Rajkovaca, Z. (Bosnia And Herzegovina)
Massalha, S. (Israel)	Rausch, I. (Austria)
Mihailovic, J. (Serbia, Republic Of)	Rep, S. (Slovenia)
Mikolajczak, R. (Poland)	Rischpler, C. (Germany)
Milan, E. (Italy)	Rodríguez-Fraile, M. (Spain)
Minguez Gabiña, P. (Spain)	Rogasch, J. (Germany)
Mitjavila Casanovas, M. (Spain)	Rossetti, C. (Italy)
Monteiro, M. (Switzerland)	Rouzet, F. (France)
Morbelli, S. (Italy)	Salaun, P. (France)
Morigi, J. (Australia)	Sandstrom, M. (Sweden)
Mu, L. (Switzerland)	Santos, A. (Portugal)
Mudun, A. (Türkiye)	Santos, A. (Portugal)
Någren, K. (Denmark)	Saraste, A. (Finland)
Neglia, D. (Italy)	Sattler, B. (Germany)
Nekolla, S. (Germany)	Saxtoft, E. (Denmark)

Schäfers, M. (Germany)	Treglia, G. (Switzerland)
Schibli, R. (Switzerland)	Tuncel, M. (Türkiye)
Schildan, A. (Germany)	Turco, P. (Italy)
Schmidt, M. (Germany)	Vaccaro, I. (Italy)
Schottelius, M. (Switzerland)	van Dongen, G. (Netherlands)
Sciagrà, R. (Italy)	van Velden, F. (Netherlands)
Seimbille, Y. (Netherlands)	Vanhove, C. (Belgium)
Semah, F. (France)	Verberne, H. (Netherlands)
Shi, K. (Switzerland)	Verburg, F. (Germany)
Siclari, G. (Italy)	Vercouillie, J. (France)
Signore, A. (Italy)	Verger, A. (France)
Slart, R. (Netherlands)	Versari, A. (Italy)
Smith, G. (United Kingdom)	Vidal Sicart, S. (Spain)
Sollini, M. (Italy)	Violante, L. (Portugal)
Stevens, H. (Netherlands)	Visvikis, D. (France)
Stokkel, M. (Netherlands)	Vlajkovic, M. (Serbia, Republic Of)
Strigari, L. (Italy)	Vriens, D. (Netherlands)
Svegborn, S. (Sweden)	Walz, J. (France)
Taieb, D. (France)	Weber, W. (Germany)
Terry, S. (United Kingdom)	Weiler-Sagie, M. (Israel)
Terwinghe, C. (Belgium)	Windhorst, A. (Netherlands)
Testanera, G. (United Kingdom)	Yakushev, I. (Germany)
Todde, S. (Italy)	Zambo, K. (Hungary)
Tolboom, N. (Netherlands)	Zerizer, I. (United Kingdom)
Tran-Gia, J. (Germany)	Zhang-Yin, J. (France)

EANM'25

CHAIRPERSONS

(AS PER AUGUST 25, 2025)

Acampa, A. (Italy)	de Geus-Oei, L. (Netherlands)
Aguiar Fernandez, P. (Spain)	de Keizer, B. (Netherlands)
Albano, D. (Italy)	Deandreis, D. (France)
Albert, N. (Germany)	Decristoforo, C. (Austria)
Ambrosini, V. (Italy)	Delker, A. (Germany)
Arbizu, J. (Spain)	Denis-Bacelar, A. (United Kingdom)
Armstrong, W. (United States of America)	Deroose, C. (Belgium)
Atay, L. (Türkiye)	Deshayes, E. (France)
Backhaus, P. (Germany)	Dickson, J. (United Kingdom)
Bailly, C. (France)	Diekmann, D. (Germany)
Bajuk Studen, K. (Slovenia)	Dizdarevic, S. (United Kingdom)
Bauckneht, M. (Italy)	Eberlein, U. (Germany)
Behe, M. (Switzerland)	Eiber, M. (Germany)
Bernhardt, P. (Sweden)	Ekmekcioglu, O. (Türkiye)
Bracht, H. (Germany)	Elvas, F. (Belgium)
Brendel, M. (Germany)	Eppard, E. (Germany)
Brosch-Lenz, J. (United States of America)	Erba, P. (Italy)
Bucerius, J. (Austria)	Evangelista, L. (Italy)
Buck, A. (Germany)	Farolfi, A. (Italy)
Buckle, T. (Netherlands)	Fendler, W. (Germany)
Campenni, A. (Italy)	Fragoso Costa, P. (Germany)
Caobelli, F. (Switzerland)	Fraioli, F. (United Kingdom)
Cardoso, A. (Switzerland)	Gaberscek, S. (Slovenia)
Carrilho Vaz, S. (Portugal)	Gafita, A. (United States of America)
Castellucci, P. (Italy)	Garibotto, V. (Switzerland)
Cavinato, L. (Italy)	Garin, E. (France)
Cecchin, D. (Italy)	Geão, A. (Portugal)
Chauvie, S. (Italy)	Geers, J. (Belgium)
Chiti, A. (Italy)	Geist, B. (Austria)
Cleeren, F. (Belgium)	Gheysens, O. (Belgium)
Constantino, C. (Portugal)	Goffin, K. (Belgium)
Costa, P. (Portugal)	Gotthardt, M. (Netherlands)
Cremonesi, M. (Italy)	Gotuzzo, I. (Italy)
Dalm, S. (Netherlands)	Gourni, E. (Switzerland)
de Almeida Coelho, M. (Germany)	Grana, C. (Italy)
de Blois, R. (Netherlands)	Grönroos, T. (Finland)

Guedj, E. (France)	Lund Andersen, T. (Denmark)
Guglielmo, P. (Italy)	Luster, L. (Germany)
Hatt, M. (France)	Ma, M.T.M. (United Kingdom)
Hautzel, H. (Germany)	Mak, D. (United Kingdom)
Hendrikse, N. (Netherlands)	Mansouri, Z. (Switzerland)
Hernandez, H. (United States of America)	Marín Melero, I. (Spain)
Herth, M. (Denmark)	Massalha, S. (Israel)
Heskamp, S. (Netherlands)	Mikolajczak, R. (Poland)
Hess, S. (Denmark)	Mínguez Gabiña, P. (Spain)
Hindorf, C. (Sweden)	Morbelli, S. (Italy)
Holm, S. (Denmark)	Morland, D. (France)
Hyafil, F. (France)	Müller, C. (Switzerland)
Iagaru, A. (United States of America)	Muselaers, S. (Netherlands)
Iakovou, I. (Greece)	Nappi, C. (Italy)
Imbert, L. (France)	Nawwar, A. (United Kingdom)
Kaiser, L. (Germany)	Nekolla, S. (Germany)
Kiratli, P. (Türkiye)	Nicolas, G. (Switzerland)
Kirienko, M. (Italy)	Nonnekens, J. (Netherlands)
Kiß, O. (Germany)	Noriega Álvarez, E. (Spain)
Kleynhans, J. (Belgium)	Øbro Fosbøl, M. (Denmark)
Knudsen, G. (Denmark)	Oflas, M. (Türkiye)
Kolenc, P. (Slovenia)	Olianti, C. (Italy)
Kossatz, S. (Germany)	Oprea-Lager, D. (Netherlands)
Koutsouveli, E. (Greece)	Oyen, W. (Netherlands)
Krarup, M. (Denmark)	Papp, L. (Austria)
Kreissl, M. (Germany)	Peştean, C. (Romania)
Kroselj, M. (Slovenia)	Petranovic Ovčariček, P. (Croatia)
Küper, A. (Germany)	Petrik, M. (Czech Republic)
Lairez, O. (France)	Pietrzak, A. (Poland)
Laverman, P. (Netherlands)	Pisano, G. (Italy)
Law, I. (Denmark)	Portillo, M. (Argentina)
Leccisotti, L. (Italy)	Pouget, J. (France)
Liberini, V. (Italy)	Preusser, M. (Austria)
Liepe, K. (Germany)	Rahbar, R. (Germany)
Lodi, F. (Italy)	Rischpler, C. (Germany)
Lückerath, K. (Germany)	Rogasch, J. (Germany)

EANM'25 CHAIRPERSONS

(AS PER AUGUST 25, 2025)

Roldão Pereira, L. (United Kingdom)	Turco, P. (Italy)
Sahin, D. (Türkiye)	Unterrainer, L. (Germany)
Salas-Ramirez, E. (Germany)	Uribe, C. (Canada)
Sandstrom, M. (Sweden)	Van Der Meulen, N. (Switzerland)
Santos, A. (Portugal)	van Leeuwen, F. (The Netherlands)
Saraste, A. (Finland)	van Nijnatten, T. (Netherlands)
Schmidt, F. (Germany)	van Velden, F. (Netherlands)
Schottelius, M. (Switzerland)	Van Weehaeghe, D. (Belgium)
Schweiger, L. (Austria)	Vanhove, C. (Belgium)
Seifert, R. (Switzerland)	Veldhuijzen van Zanten, S. (Netherlands)
Seimbille, Y. (Netherlands)	Verger, A. (France)
Shi, K. (Switzerland)	Vieira e Vieira, S. (Belgium)
Soeiro, P. (Portugal)	Visvikis, D. (France)
Sollini, M. (Italy)	Visvikis, V. (France)
Sosabowski, J. (United Kingdom)	Voltin, C. A. (Germany)
Stokke, C. (Norway)	Vraka, C. (Austria)
Strigari, L. (Italy)	Vugts, D. (Netherlands)
Taieb, D. (France)	Wakfie-Corieh, C. (Spain)
Tamborino, G. (Netherlands)	Walz, J. (France)
Testanera, G. (United Kingdom)	Wechalekar, K. (United Kingdom)
Tingen, H. (Netherlands)	Withofs, N. (Belgium)
Toolbom, N. (Netherlands)	Yakushev, I. (Germany)
Tran-Gia, T. (Germany)	Ziegler, Z. (Germany)
Traub-Weidinger, T. (Austria)	Zucchetta, P. (Italy)
Treglia, G. (Switzerland)	
Tuncel, M. (Türkiye)	

MEET THE EXPERT



JOIN US AT OUR BOOTH

for an exclusive “Meet the Expert” session with Dr. Julia Fricke, Principal Investigator of the **Beta Plus Study on the SSTR2 antagonist ¹⁶¹Tb-DOTA-LM3** and recipient of the prestigious Marie Curie Award 2024. Dr. Fricke will share in-depth insights into the study’s design, technical aspects, and clinical experience.

Don’t miss this opportunity to engage directly with a leading expert and explore the latest breakthroughs in nuclear medicine.

Dr. Julia Fricke

Division of Nuclear Medicine,
University Hospital Basel,
Switzerland

 **Sunday, October 5th**
16:30 – 17:00

Monday, October 6th
9:30 – 10:00

 **ITM Booth #71**



itm-radiopharma.com



EANM NATIONAL SOCIETIES: DELEGATES / DEPUTIES

SOCIETY	DELEGATE	DEPUTY
 Armenian Society of Nuclear Medicine	V. Barsegian	M. Artashesyan
 Austrian Society of Nuclear Medicine and Theranostic	M. Gabriel	T. Traub-Weidinger
 Azerbaijan Society of Nuclear Medicine	F. Novruzov	A. Aliyev
 Belgian Society of Nuclear Medicine	N. Withofs	A. Deleu
 Bosnian Society of Nuclear Medicine	A. Šadija	S. Zarac Bobic
 British Nuclear Medicine Society	S. Dizdarevic	S. Redman
 Bulgarian Society of Nuclear Medicine	V. Hadzhiyska	Z. Dancheva
 Croatian Society of Nuclear Medicine	A. Barić Žižic	A. Golubic
 Cyprus Society of Nuclear Medicine	D. Kyprianou	O. Demetriadou
 Czech Society of Nuclear Medicine	M. Simanek	P. Koranda
 Danish Society of Clinical Physiology and Nuclear Medicine	P. Hovind	M. Reichkender
 Estonian Nuclear Medicine Society	I. Muoni	T. Karner
 Finnish Society of Nuclear Medicine	K. Timonen	
 French Society of Nuclear Medicine	PY. Salun	F. Cachin
 Georgian Nuclear Medicine Specialists Association	N.Shengelia de Lange K. Shamatava	
 German Society of Nuclear Medicine	M.Luster	M. Schäfers
 Hellenic Society of Nuclear Medicine and Molecular Imaging	S. Chatziioannou	V. Valotassiou
 George de Hevesy Hungarian Society of Nuclear Medicine	T. Györke	G. Trencsenyi
 Icelandic Society of Nuclear Medicine	to be nominated	to be nominated
 Irish Nuclear Medicine Association	R. Killeen	K. O'Regan

SOCIETY	DELEGATE	DEPUTY
 Israeli Society of Nuclear Medicine	Z. Bar-Sever	Z. Keidar
 Italian Society of Nuclear Medicine Molecular Imaging and Therapy	A. Campenní	S. Nuvoli
 Latvian Society of Nuclear Medicine	M. Kalnina	J. Kedrova
 Lithuanian Society of Nuclear Medicine	S. Šedienė	N. Jurkienė
 Luxembourg Society of Nuclear Medicine	C. Picard	C. Als
 Maltese Association of Radiologists and Nuclear Medicine Physicians	M. Aquilina	A.Mallia
 Dutch Society of Nuclear Medicine	S. Jap-A-Joe	S. Veldhuijzen van Zanten
 Macedonian Society of Nuclear Medicine	V. Majstorov	A. Jankulovska
 Norwegian Society of Nuclear Medicine and Molecular Imaging	E.H. Kvernenes	T.C.H. Adamsen
 Polish Society of Nuclear Medicine	A. Mazurek	
 Sociedade Portuguesa de Medicina Nuclear	L. Sobral Violante	S. Fontão de Castro
 Romanian Society of Nuclear Medicine and Molecular Imaging	M. Gherghe	C.R. Stolniceanu
 Serbian Nuclear Medicine Society	M. Radulovic	I. Grozdic Milojevic
 Slovak Society of Nuclear Medicine and Radiation Hygiene	L. Kaliska	E. Takascova
 Slovenian Society of Nuclear Medicine	L. Ležaić	M. Glogovsek
 Spanish Society of Nuclear Medicine and Molecular Imaging	J J.R. Garcia	M. J. Garcia-Velloso
 Swedish Society of Nuclear Medicine	S. Strandberg	E. Trägårdh
 Swiss Society of Nuclear Medicine	F. Forrer	M. Wissmeyer
 Turkish Society of Nuclear Medicine	L.Ö. Atay	C. Soydal
 Ukrainian Society of Nuclear Medicine	Y. Kmetyuk	V. Danylenko

UEMS/EBNM NATIONAL SOCIETIES: DELEGATES / DEPUTIES

COUNTRY	DELEGATE	DEPUTY
 AUSTRIA	Rainer Lipp	Siroos Mirzaei
 BELGIUM	Karoline Spaepen	Gerard Moulin-Romsee
 BULGARIA	Elena Piperkova	Antonia Dencheva Tzonevska
 CROATIA	Drazen Huic	Assist. Sanja Kusačić Kuna
 CYPRUS	Rena K. Demetriadou	
 CZECH REPUBLIC	D. Pavel Koranda	Milan Šimánek
 DENMARK	Julie Bjerglund Andersen	Tatiana Kristensen
 ESTONIA	Eve Kelk	Anne Poksi
 FINLAND	Kirsi Timonen	Jukka Kemppainen
 FRANCE	Eric Gremillet	Jean-Louis Pelletier
 GERMANY	Winfried Brenner	Martin Gotthardt
 GREECE	Sophia Koukouraki	Ioannis Iakovou
 HUNGARY	Laszlo Pavics	Istvan Szilvasi
 IRELAND	Roland Killeen	Kevin O'Regan
 ITALY	Giuseppe Rubini	Desirè Deandreis
 LATVIA	Marika Kalnina	Jelena Kedrova
 LITHUANIA	Donatas Vajauskas	Nemira Jurkienė
 LUXEMBOURG	Patrick Paulus	Christian Picard
 MALTA	Mark Anthony Aquilina	Andrew Mallia

COUNTRY	DELEGATE	DEPUTY
 THE NETHERLANDS	Lenka Pereira Arias Bouda	Wim J. G. Oyen
 NORWAY	Tom Christian Holm Adamsen	Rune Sundset
 POLAND	Mirosław Dziuk	Bożena Birkenfeld
 PORTUGAL	Inês Lucena Sampaio	Rudolfo Silva
 ROMANIA	Gabriel Andries	Raluca Mititelu
 SERBIA	Vera Artiko	Jasna Mihailovic
 SLOVAKIA	Andrej Vondrak	Lucia Kaliska
 SLOVENIA	Simona Gaberscek	Damjana Hrastnik
 SPAIN	Gomez Caminero	Pena Viloría
 SWEDEN	Jesus Lopez Urdaneta	Kristian Valind
 SWITZERLAND	Ariane Boubaker	John Prior
 TÜRKIYE	Gulay Altun	Zehra Ozcan
 UNITED KINGDOM	Humayun Bashir	Yong Du

Nominated by UEMS Observer Countries

 ISRAEL	Adam Steinmetz	Michael Reuben Quastel
 JORDAN	Akam Al-Ibraheem	

UEMS/EBNM COMMITTEES

EXECUTIVE COMMITTEE

President	J. Prior (Switzerland)
Secretary & Treasurer	R. Hustinx (Belgium)
Member	A. Boubaker (Switzerland)

FELLOWSHIP EXAMINATION COMMITTEE - FEBNM

Chair	I. Kulakiene (Lithuania)
Members	Z. Ozcan (Türkiye)
	J. Ramón García Garzón (Spain)
	S. Vaz (Portugal)
	H. Bashir (United Kingdom)
	A.T. Golubic (Croatia)
	M.F. Bozkurt (Türkiye)
	A. Boubaker (Switzerland)

EDUCATION AND SYLLABUS COMMITTEE - ESC

Chair	H. B. Sayman (Turkey)
Members	R. Hustinx (Belgium)
	J. Darcourt (France)
	T.V. Bogsrud (Norway)
	D. Huic (Croatia)
	M. Mitjavila Casaonova (Spain)
	P. Castellucci (Italy)

CME ACCREDITATION COMMITTEE - CME

Chair	M. Farsad (Italy)
Members	E. Lopci (Italy)
	A. Haug (Austria)
	S. Sillanmäki (Finland)

ACCREDITATION OF NUCLEAR MEDICINE DEPARTMENTS & TRAINING CENTRES

Chair	A. Crespo-Jara (Spain)
Committee	
Members	J. Prior (Switzerland)
	S. Mirzaei (Austria) (Ex Officio)
	M. Bajic (Sweden) (Ex Officio)
	A. García-Burillo (Spain)
	N.e Mutlukoca (Norway)
	P. A.L. van Boxem (Belgium)
	M. Hall (United Kingdom)

Corresponding	
Members:	F.k Giesel (Germany)
	A. Jiménez Heffernan (Spain)
	I. E. Sipponen (Finland)
	N. G. Hartman (United Kingdom)
	S.-E. Bouzoucef (Algeria)
	A. Ciarmiello (Italy)
	L. Torres (Cuba)
	I. Iakovou (Greece)
	S. R.I Zakavi (Iran)

Optimizing Outcomes With Radiopharmaceuticals in mCRPC Care From Evidence to Execution

SUNDAY, 5 OCTOBER 2025 | 13:15 – 14:45 CEST

ROOM: 113 | HYBRID 

MODERATOR / COURSE DIRECTOR



Joe O'Sullivan, PhD, MD, BAO, BCH, FRCR, FFRRCSI, FRCPI
Professor of Radiation Oncology
Queen's University Belfast
Consultant Prostate Oncologist
Northern Ireland Cancer Centre
Belfast City Hospital
Belfast, Northern Ireland

FACULTY



Irene Burger, MD
Head
Department of Nuclear Medicine
Kantonsspital Baden
Baden, Switzerland



Elena Castro, MD, PhD
Consultant Medical Oncologist
Genitourinary unit, Department
of Medical Oncology
Hospital Universitario 12 de Octubre
Madrid, Spain



Bertrand Tombal, MD, PhD
Professor of Urology
Université Catholique de Louvain
Chairman, Department of Surgery
Cliniques Universitaires Saint-Luc
Brussels, Belgium

AGENDA

13:15
Welcome and Introduction
Joe O'Sullivan, PhD, MD, BAO, BCH, FRCR, FFRRCSI, FRCPI

13:25
The Fine Print: Exploring the Nuances Behind the Latest Clinical Evidence
Bertrand Tombal, MD, PhD

13:40
Tailored Care in mCRPC: A Tumor Board Approach to Addressing Unique Patient Needs
All Faculty

14:25
Future Outlook and Key Takeaways From Today
All Faculty

14:35
Closing Remarks and Q&A

TARGET AUDIENCE

This educational activity is intended for an audience of oncologists, nuclear medicine specialists, urologists, radiologists, surgeons, and other healthcare specialists involved in the care of patients with prostate cancer.

LEARNING OBJECTIVES

- Upon completion of this activity, participants will:
- Have increased knowledge regarding the
 - Latest clinical trial data related to targeted radionuclide therapies for the management of metastatic castration-resistant prostate cancer (mCRPC)
 - Have greater competence related to
 - Tailoring treatment for patients with mCRPC
 - Demonstrate greater confidence in their ability to
 - Work efficiently in the multidisciplinary team to optimize the care pathway for patients with mCRPC



Learn More!

For more information, visit:
www.medscape.org/symposium/radiopharmaceuticals-mcrpc-care

GENERAL INFORMATION



AUDIO & VIDEO RECORDINGS

Audio and/or video recordings during the congress are strictly prohibited and must not be made without prior written permission of the EANM Executive Office.

BARCELONA INFORMATION DESK

If you wish to get information about the city of Barcelona, please visit the Barcelona Information Desk, which will be in the Entrance Hall near the Registration Desk.

CERTIFICATE OF ATTENDANCE

Your certificate of attendance will be available in your myEANM-Area after the congress. Please be aware that you will need to fill out a congress evaluation form.

CLOSING CEREMONY & FAREWELL COCKTAIL

All registered participants and accompanying persons are cordially invited to the Closing Ceremony and Farewell Cocktail, which will take place on Wednesday, October 8, 2025, from 11:25 to 12:15.

The Closing Session will be held at the Auditorium of the CCIB and the subsequent Farewell Cocktail in the Foyer of the Auditorium.

CCIB – Centre de Convencions Internacional de Barcelona
Placa de Willy Brandt, 11-14
08019 Barcelona, Spain

CME CREDITS AND CERTIFICATES

The EANM'25 – 38th Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain 04/10/2025 – 08/10/2025, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 26.5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

The CME Sessions during EANM'25 – 38th Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain 04/10/2025 – 08/10/2025, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 21.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

To acquire CME credits, attendees must scan their congress badge upon first arrival at the congress venue and upon entering each CME session. For CME sessions, an evaluation form for each session attended and the overall congress evaluation must be completed.

CME Sessions will be streamed live and are also available on-demand after the congress until December 19, 2025 (23:59 CEST).

To obtain your CME certificate(s), please visit your [myEANM-Area](#). In the section EANM'25 > Certificates, the certificate(s) will be available within 24 hours after you have scanned your congress badge and completed the evaluations.

CONGRESS APP

Enhance your congress experience with the EANM'25 Congress App! Access all the essential information right at your fingertips, ranging from the comprehensive Scientific Programme to the Exhibitors' List, the Venue Maps, and much more.

Personalise your congress schedule effortlessly and evaluate sessions conveniently on your smart device, ensuring a smooth process to receive your CME credits. The Congress App will be available for download from all common platforms two weeks before the start of the EANM'25.

[Download the EANM'25 Congress App now.](#)

CONGRESS e-POSTER AREA

Explore all the e-Posters uploaded for the EANM'25 in the e-Poster Area located in the Banquet Hall on Level P2. You can easily find specific posters by searching for the author's name, topics, or keywords.

CONGRESS LANGUAGE

The congress language is English. Please note that no simultaneous translation will be provided.

CONGRESS OFFICE

The congress office at the CCIB – Centre de Convencions Internacional de Barcelona, located on Level M2, will be open during the following days and times:

Saturday, October 4, 2025:	07:30 - 18:00
Sunday, October 5, 2025:	07:30 - 18:00
Monday, October 6, 2025:	07:30 - 18:00
Tuesday, October 7, 2025:	07:30 - 18:00
Wednesday, October 8, 2025:	07:30 - 12:00

CONGRESS SELF CHECK-IN

To ensure a swift badge collection without long queues, please come prepared with your QR code and a valid photo ID to our self-check-in stations, located in the EANM Registration Area (Entrance Hall).

CONGRESS VENUE

Plaça de Willy Brandt, 11-14
08019 Barcelona, Spain
<https://ccib.es/en/>

CCIB – Centre de Convencions Internacional de Barcelona / Barcelona International Convention Centre

DATES & DEADLINES

September 23, 2025:	Advanced Registration Deadline
September 24, 2025:	The On-Site Registration Fee Applies
October 4, 2025:	Opening Ceremony & Welcome Reception
October 8, 2025:	Closing Ceremony & Farewell Cocktail
December 19, 2025:	Deadline for On-Demand Content and Evaluation (23:59 CEST)

EANM EXECUTIVE OFFICE

Should you have any questions or requests ahead of the EANM'25, feel free to reach out to the EANM Office!

EANM Executive Office
Schmalzhofgasse 26
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
office@eanm.org
www.eanm.org

EANM MEMBERS' ASSEMBLY

The EANM Members' Assembly will be held on Saturday, October 4, 2025 from 14:30-16:30 (Room 212, Level P2).

Please note: Only EANM members in good standing (having paid their membership dues for the year 2025) are eligible to attend.

EXPERTS TRAINING LAB

Are you interested in Nuclear Cardiology? Do not miss this unique opportunity to participate in the EANM and ASNC (American Society of Nuclear Cardiology) Experts Training Lab, to get an introduction to PET Myocardial Perfusion Imaging!

Session times:

Sunday, October 5, 2025: 13:15–14:45
Monday, October 6, 2025: 13:15–14:45

Who should attend:

This session is perfect for anyone with an interest in Nuclear Cardiology.

Location:

Purpose-built workshop room,
Foyer Connection Walkway Auditorium

Registration Details:

- Free of charge for all congress participants
- Seating will be available on a first-come, firstserved basis until the room is full
- No online registration is necessary, just join us in person!
- Save the date and do not miss out on this exclusive learning opportunity!

EANM TV

Whether you're attending the EANM'25 Congress in-person or online, you're invited to join Roy Sheppard and his expert guests for two dynamic live online TV shows each day.

Tune in every morning at 08:30 and every afternoon at 14:00 to hear leading experts from all areas of nuclear medicine discuss the latest developments in our field. The YouTube link to access the TV episodes will be shared shortly before the congress begins via all our communication channels. Stay tuned!

EANM VILLAGE

Looking to connect, explore, and be part of something new at EANM'25? Don't miss the very first EANM Village! This brand-new initiative offers all congress attendants a dedicated space to engage with EANM's strategic priorities and community-driven efforts, showcasing the core pillars of our association: ESMIT, EU Affairs & EU Projects, Governance & Community, and Guidelines & Publications.

Don't miss the EANM Village Inauguration! Sunday, October 5, 9:30 - 10:00

Entrance Hall | Open daily throughout the congress

FOOD & BEVERAGE

We are pleased to offer a variety of food and beverage outlets conveniently located throughout the congress venue. Please note, only cashless payment is accepted.

INSURANCE & LIABILITY

The EANM Office, the congress organisers, and the venue will not accept liability for any personal injury, loss or damage to property incurred during the EANM'25. You are strongly encouraged to arrange your own travel and health insurance.

INTERNATIONAL MEETINGS & ANNOUNCEMENT BOARD

Individuals and organisations are invited to showcase and promote their forthcoming events and congresses within the International Meetings & Announcement Board, fostering a collaborative platform for the dissemination of cutting-edge insights and advancements in the field of Nuclear Medicine.

Visit the International Meetings and Announcement Board, which will be in the Societies & Publishers Village, to get information on upcoming events and initiatives.

INTERNET CORNER

Internet access and limited printing facilities are provided at dedicated stations in the Banquet Hall on Level P2. Please be mindful of others and limit your using time to maximum 5 minutes per person.

LIVE STREAM

All ticket holders for the online access will automatically get access to the online content.

Onsite congress ticket holders (except Day Ticket holders, Exhibitors and Accompanying Persons) will also be granted full online access.

The following sessions will be live-streamed and will also be available on-demand until December 19, 2025: Opening Ceremony, incl. Highlights Lecture, all 14 CME Sessions (incl. CME credits collection), all 7 CTE Sessions, and the Closing

Ceremony. All live streamed Satellite Symposia will also be included (approx. 7 symposia).

The credits for the CME sessions can be collected on-demand (for online and onsite participants).

LOST AND FOUND

A lost and found service will be provided at the EANM Registration Desk for the duration of the congress.

MEDIA

By participating in the EANM'25, each congress participant acknowledges and allows the EANM to record, film, or photograph their attendance and use these images or videos in all media forms, now and in the future, without the need for further consent or payment.

MEDICAL FACILITIES

Medical assistance and ambulance service will be available throughout the congress.

MOBILE PHONES

Out of respect for other participants, you are requested to refrain from making phone calls in a lecture room. Your mobile device should always be on silent mode when you are in the congress centre.

NAME BADGES

Badges for the congress will be issued on-site between October 4 and October 8, 2025. The badges must be collected in person. A confirmation e-mail, including a QR code, will be issued upon successful completion of registration. With this QR, along with a valid photo ID, the name badge can be printed onsite in the registration area.

OPENING CEREMONY & WELCOME RECEPTION

All registered participants and accompanying persons are cordially invited to the Opening Ceremony and the Welcome Reception, which will be held on Saturday, October 4, 2025, from 18:00-21:45.

The Opening Ceremony **including the Highlights Lecture** will be held at the Auditorium of the CCIB and the subsequent Welcome Reception at the Forecourt of the Auditorium.

CCIB – Centre de Convencions Internacional de Barcelona
Plaça de Willy Brandt, 11-14
08019 Barcelona, Spain

PARKING

Private cars can be parked at additional cost in parking areas. The closest parking area to the CCIB is Parking Pl. del Fòrum (Address: Pl. d'Ernest Lluch i Martín). For further parking spaces in Barcelona please visit the following website: www.aparcamentsbsm.cat/en

PUBLIC TRANSPORTATION TICKET

Public transportation is by far the easiest way to get around the city. The city's metro, buses, and trams are efficient, affordable, and all-around excellent. One can either buy a single trip ticket for € 2,65 or a T-casual ticket (10 rides in 1 zone) for € 12,55 or a T-dia (valid 24 hours in 1 zone) for € 11,55, which can be used for any transportation within the city. Alternatively, there is the Hola Barcelona Travel Card which offers unlimited travel for 2–5 days on all major public transport, including the airport metro.

Please support the EANM's sustainability efforts by using Barcelona's public transport system. For further information on the public transportation system, please visit the official TMB website: <https://www.tmb.cat/en/home>

Please note that tickets are non-refundable and neither ENITED nor EANM are responsible for the purchase of public transport tickets. All enquiries should be directed to the municipal public transport provider in Barcelona: [TMB Barcelona bus and metro | Transports Metropolitans de Barcelona](#)

REGISTRATION DESK

The Registration Desk at the entrance level of the CCIB will be open:

Saturday, October 4, 2025:	07:30 - 21:45
Sunday, October 5, 2025:	07:30 - 18:00
Monday, October 6, 2025:	07:30 - 18:00
Tuesday, October 7, 2025:	07:30 - 18:00
Wednesday, October 8, 2025:	07:30 - 12:00

REVIEW CENTRE

The Review Centre gives you the opportunity to check the PowerPoint presentations which have already been presented during the EANM'25 Congress. So, in case you have missed a session, you can view the slides here afterwards. The Review Centre is located Level P2. The slides will not be accessible online.

SOCIAL MEDIA

Follow us on our social media channels to get regular and exclusive updates about the EANM'25!

Bluesky	@eanm.org
Facebook	@officialEANM
Flickr	@officialEANM
Instagram	@eanm_nucmed
LinkedIn	@officialEANM
X	@EANM_NucMed
YouTube	@officialEANM

You can also subscribe to the EANM Congress Newsletters here:
www.eanm.org/publicpress/newsletter/.

TACKLE CANCER CHALLENGE

We are delighted to announce that the EANM will again support the annual Tackle Cancer Challenge, organised by the Oncidium Foundation.

The Tackle Cancer Challenge is a global movement created to raise vital awareness about Radiotheranostics in cancer care. Since the challenge dates coincide with our congress, we encourage you to participate whether you are attending in-person or online!

Find more information here:
<https://www.oncidiumfoundation.org/events/tackle-cancer-challenge/>

VISA

All foreign visitors entering Spain must hold a valid passport. For EU citizens, a valid photo ID is sufficient.

PLEASE CHECK THE CURRENT VISA REQUIREMENTS WITH THE NEAREST SPANISH CONSULATE/EMBASSY IN YOUR COUNTRY BEFORE TRAVELLING TO SPAIN.

All registered congress participants with a completed/paid registration can request a visa invitation letter within their [myEANM-Area](#)!

WI-FI

Free Wi-Fi is available throughout the congress venue:

The log-in credentials are:
Network: EANM
Password: eanm2025

YOUNG PROFESSIONAL LOUNGE

Once again, we invite all students and junior attendees to the EANM'25 Young Professionals Lounge, a dedicated space to enjoy refreshments, have a quiet corner to rest, work and network during the Congress (registration type permitting).

Make sure you attend the well curated, interactive presentations featuring high-level nuclear medicine experts and highly motivated EANM volunteers. The speakers will share their experiences within the association and their professional journeys.

Look for the tag  in the EANM'25 scientific programme to find sessions selected for young professionals.

ITM @EANM
SYMPOSIUM

SSTR-Targeting Theranostics
in NETs and Beyond:
Milestones and New Frontiers

Learn more about the development and emerging clinical role of investigational ¹⁷⁷Lu-edotreotide in the treatment of neuroendocrine tumors (NETs), focusing on its scientific origins and current evidence supporting its use in gastroenteropancreatic NETs. Additionally, the session will explore future directions in SSTR-targeted therapies.



Sunday, October 5th



13:30 – 14:30



Room 114



SYMPOSIUM HOST: Prof. Ken Herrmann, M.D., MBA
Nuclear Medicine,
University Clinic Essen, Essen, Germany



**FROM CONCEPT TO CLINIC:
THE ORIGINS OF
¹⁷⁷LU-EDOTREOTIDE IN NETS**

Prof. Vikas Prasad, M.D., PhD
Nuclear Medicine,
Mallinckrodt Institute of Radiology,
St. Louis, USA



**TRANSLATING EVIDENCE
INTO PRACTICE: THE ROLE OF
¹⁷⁷LU-EDOTREOTIDE IN NETS**

Dr. Rocío García-Carbonero, M.D., PhD
Medical Oncology,
University Hospital 12 de Octubre,
Madrid, Spain




**EXPLORING THE FUTURE
OF THE SSTR-TARGETING
LANDSCAPE**

Prof. Damian Wild, M.D., PhD
Nuclear Medicine,
University Hospital Basel,
Basel, Switzerland



Refreshments available
itm-radiopharma.com/events/EANM-2025






LEVEL P2

Banquet Hall (213)	Speaker Preview Room
Banquet Hall (214 + 215)	e-Poster Area, Internet Corner, Review Centre
Room 211	Cutting Edge Science Track
Room 212	TROP Sessions, M2M Track



LEVEL M2

Room M211 + M212	EANM Congress Office
Room M213 - M220	Meeting Rooms & Offices
Room M221	Industry Hospitality Suite



LEVEL P1

Rooms 111 - 117	Lecture Halls
Room 133 + 134	e-Poster Presentations Sessions
Rooms 119, 121	EU Affairs Track, Meeting Rooms
Rooms 122+123, 129 - 132	Industry Hospitality Suites

111	Theranostics Track, EU Policy and Special Symposia, Case Reports, TROP/Featured Sessions
112	Special Track (Debates, Challenge the Expert, Round Table)
Arena	
113	Learn & Improve Professional Skills (LIPS) Track
114	M2M Track
115	TROP / Featured Sessions, Joint Symposia
116	Technologists' Track
117	Clinical Oncology Track



LEVEL M1

VIP Room	Hands-On Workshop Room
----------	------------------------




LEVEL P0
GROUND FLOOR

Entrance Hall	Registration, Self Check-In, Cloakroom, EANM Village, Merch Pick-Up, INSPIRE by EANM, Young Professionals Lounge, Societies Village & Industry Exhibition, EANM TV
Exhibition Hall	Industry Exhibition

Connection Walkway

AUDITORIUM


Connection Walkway Foyer	EANM and ASNC Experts Training Lab
Auditorium	Opening Ceremony Plenary Sessions CME Sessions Closing Session
Foyer	Farewell Drink



The EANM MENTORSHIP PROGRAMME

Bridging generations, bringing together experienced professionals and emerging talents. A one-year programme to shape the future of **Nuclear Medicine!**

For more info:



PROGRAMME OVERVIEW SATURDAY, OCTOBER 4, 2025

Location/ Time	Auditorium	Room 212		Location/ Time
08:00–08:30				08:00–08:30
08:30–09:00				08:30–09:00
09:00–09:30				09:00–09:30
09:30–10:00				09:30–10:00
10:00–10:30				10:00–10:30
10:30–11:00				10:30–11:00
11:00–11:30				11:00–11:30
11:30–12:00		Advisory Council Meeting (11:00–12:30)		11:30–12:00
12:00–12:30				12:00–12:30
12:30–13:00				12:30–13:00
13:00–13:30				13:00–13:30
13:30–14:00		Delegates' Assembly (13:15–14:15)		13:30–14:00
14:00–14:30				14:00–14:30
14:30–15:00		Members' Assembly (14:30–16:30)		14:30–15:00
15:00–15:30				15:00–15:30
15:30–16:00				15:30–16:00
16:00–16:30				16:00–16:30
16:30–17:00				16:30–17:00
17:00–17:30				17:00–17:30
17:30–18:00				17:30–18:00
18:00–18:30	Opening Ceremony including Awards Ceremony (18:00–18:35) 101 Plenary 1 Highlights Lecture (18:35–19:35) Welcome Reception (19:45–21:45)			18:00–18:30
18:30–19:00				19:30–20:30
20:30–21:00				20:30–21:00
21:00–21:30				21:00–21:30
21:30–22:00				21:30–22:00

EANM Committee Meetings
(14:00–17:45)

PROGRAMME OVERVIEW

SUNDAY, OCTOBER 5, 2025

Location/ Time	Auditorium	Room 112 (Arena)	Room 113	Room 114	Room 211	Room 117	Room 212	Room 115	Room 133+134	Room 116	Room 111	Location/ Time
	LIVE STREAM									LIVE STREAM		
08:00–08:30	201 CME 1 Inflammation & Infection Committee	202 Special Track Thyroid Committee	203 Learn & Improve Professional Skills (LIPS) Track Translational Molecular Imaging & Therapy Committee	204 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	205 Cutting Edge Science Track TROP Session AI Committee	206 Clinical Oncology Track TROP Session Oncology & Theranostics Committee	207 TROP Session Neuroimaging Committee	208 TROP Session Cardiovascular Committee	209 e-Poster Presentations Session 1 Translational Molecular Imaging & Therapy Committee	210 Technologists' Track Opening CTE 1 Technologists Committee / SNMMI	211 Theranostics Track TROP Session Oncology & Theranostics Committee	08:00–08:30
08:30–09:00	The Role of FAPI PET/CT in Inflammation Diseases	Challenge the Expert: When to Stop Radioiodine?	Optical and Multimodal/Hybrid Tracers: Similarities with Radiotracers, Pitfalls and Regulatory Issues	New Targets in Oncology	AI for Segmentation in PET/CT	Gynaecological Cancer Staging and Image Guidance	Movement Disorders	From Muscle to Calcifications What's New in Cardiac Amyloidosis?	Preclinical Imaging and Therapy	Technologists' Guide Launch	Novel Theranostic Applications	08:30–09:00
09:00–09:30												09:00–09:30
09:30–10:00												09:30–10:00
10:00–10:30	301 CME 2 Neuroimaging Committee	302 Special Track Oncology & Theranostics Committee	303 Learn & Improve Professional Skills (LIPS) Track Bone & Joint Committee	304 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	305 Cutting Edge Science Track TROP Session Physics Committee	306 Clinical Oncology Track TROP Session Oncology & Theranostics Committee	307 TROP Session Thyroid Committee	308 Joint Symposium 1 Paediatrics Committee / SIOPE	309 e-Poster Presentations Session 2 Inflammation & Infection Committee	310 Technologists' Track CTE 2 Technologists Committee	311 Special Symposium EARL Clinical Implications of EARL PET/CT	10:00–10:30
10:30–11:00	Paradigm Shift for the Diagnosis of Parkinson Diseases	Debate: A Brave New World: Are All PSMA Radiopharmaceuticals Equal?	Bone and Joint Therapies	Tracking/Modulating Pharmacokinetics	SPECT Quantification in Therapeutic Applications	Breast Cancer Imaging	Nuclear Medicine Imaging in Thyroid Disorders: From Thyroid Nodule to Advanced/Refractory Cancer	Imaging Biomarkers in Paediatric Oncology 'Whats Next?'	Best e-Posters in Inflammation & Infection	Continuous Education Models for NMTs + Instrumentation and Data Processing	Accreditation Standards 2 and a New ¹⁷⁷ Lu SPECT/CT Accreditation	10:30–11:00
11:00–11:30												11:00–11:30
11:30–12:00	401 Plenary 2											11:30–12:00
12:00–12:30	World's Best Theranostics Comes to EANM'25											12:00–12:30
12:30–13:00												12:30–13:00
13:00–13:30												13:00–13:30
13:30–14:00	Lunch Break		Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	Young Professionals Lunch Symposium	Satellite Symposium	Satellite Symposium	13:30–14:00
14:00–14:30									Beyond Your CV: How Storytelling Builds Trust and Gets You the Job			14:00–14:30
14:30–15:00												14:30–15:00
15:00–15:30	501 CME 3 Physics + Paediatrics Committee	502 Special Track Oncology & Theranostics Committee	503 Learn & Improve Professional Skills (LIPS) Track Thyroid Committee	504 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	505 Cutting Edge Science Track TROP Session AI Committee	506 Clinical Oncology Track TROP Session Oncology & Theranostics Committee	507 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	508 Joint Symposium 2 Neuroimaging Committee / EAN	509 e-Poster Presentations Session 3 Radiopharmaceutical Sciences Committee	510 Technologists' Track Oral Presentations 1 Technologists Committee	511 Special Symposium 2 EANM Journals - Debate	15:00–15:30
15:30–16:00	Low Dose Imaging	Debate: Will Alpha Therapy be the Main Radionuclide Therapy Approach in the Future?	Imaging Challenges in Nuclear Endocrinology	Tumour Microenvironment as a Therapeutic Target	AI Based Segmentation - Cardiac, Lung Ventilation, Bone	Lung Cancer Imaging	Prostate Cancer: New Tracers	Epilepsy: Who is the Right Candidate for Epilepsy Surgery?	New Tracers for Radioligand Therapy and Imaging	PET-CT Studies: Diagnosis and Treatment	The Evolving World of Scientific Publishing	15:30–16:00
16:00–16:30												16:00–16:30
16:30–17:00												16:30–17:00
17:00–17:30	601 CME 4 Cardiovascular Committee	602 Special Track Oncology & Theranostics Committee + Dosimetry Committee	603 Learn & Improve Professional Skills (LIPS) Track AI Committee	604 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	605 Cutting Edge Science Track TROP Session Dosimetry Committee	606 Clinical Oncology Track TROP Session Oncology & Theranostics Committee	607 TROP Session Neuroimaging Committee	608 Featured Session Thyroid Committee	609 e-Poster Presentations Session 4 Physics Committee	610 Technologists' Track CTE 3 Technologists Committee	611 Featured Session Paediatrics Committee	17:00–17:30
17:30–18:00	Total Body Imaging: Think Big, Think Forward! (Cardio)	Debate: Routes to Optimised Theranostics: Is 'Dose' Escalation Enough?	AI for Young Developers in NM	Combining Imaging with Targeted Therapy	Radiobiological Mechanisms to Overcome Resistance in TRT	Haematology and Lymphoma	Molecular Imaging of Neurodegeneration: FDG, Amyloid PET and Others	Imaging in Medullary and Differentiated Thyroid Cancers	Physics e-Poster Presentations Session	Best Practice in Paediatric Inflammation & Infection Radionuclide Imaging - Heart, Bone and Joint, Kidney and Urinary Tract	Advances in Paediatric Molecular Imaging: Innovations in Oncology, Radiomics and Hybrid Technologies	17:30–18:00
18:00–18:30												18:00–18:30

PROGRAMME OVERVIEW

MONDAY, OCTOBER 6, 2025

Location/ Time	Auditorium	Room 112 (Arena)	Room 113	Room 114	Room 211	Room 117	Room 212	Room 115	Room 133+134	Room 116	Room 111	Location/ Time
	LIVE STREAM									LIVE STREAM		
08:00-08:30	701 CME 5 Thyroid Committee Parathyroid Carcinoma: Rare but Complex	702 Special Track Inflammation & Infection Committee Debate: WBC Scintigraphy Scan vs FDG PET/CT in Musculoskeletal Infections	703 Learn & Improve Professional Skills (LIPS) Track Dosimetry Committee Statistical Analysis in Clinical Studies and Specifically in Dosimetry	704 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee Preclinical Therapy - Various Targets	705 Cutting Edge Science Track TROP Session Physics Committee PET/CT & PET/MR	706 Clinical Oncology Track TROP Session Oncology & Theranostics Committee Imaging Melanoma and New Targets	707 TROP Session Neuroimaging Committee Innovations and Methodologies in Nuclear Neuroimaging	708 Joint Symposium 3 Oncology & Theranostics Committee / EORTC Oncological Response Criteria for PET: Beyond RECIST, EORTC & PERCIST	709 e-Poster Presentations Session 5 Cardiovascular Committee Cardiovascular e-Poster Presentations Session	710 Technologists' Track Oral Presentations 2 Technologists Committee Advanced Practice and Novel Solutions	711 Theranostics Track Oncology & Theranostics Committee Prostate and Novel Targets	08:00-08:30
08:30-09:00												08:30-09:00
09:00-09:30												09:00-09:30
09:30-10:00												09:30-10:00
10:00-10:30	801 CME 6 Oncology & Theranostics Committee PET in mCRPC: Toward Multiparametric Multitracer Biomarkers	802 Special Track Cardiovascular Committee Debate: Myocardial Perfusion Imaging: Should I Stay with SPECT or Go with PET?	803 Learn & Improve Professional Skills (LIPS) Track Radiation Protection Committee What Would You Do If...? Radiation Protection Issues in Special Cases of Everyday Practices	804 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee Optimising Radiolabeling and Quality Control: The Key for Clinical Translation	805 Cutting Edge Science Track TROP Session AI Committee Disease Characterisation and Prediction Models	806 Clinical Oncology Track TROP Session Oncology & Theranostics Committee NET Imaging	807 Featured Session Bone & Joint Committee New Frontiers in Bone and Soft Tissue Imaging	808 TROP Session Thyroid Committee An Overview on Nuclear Medicine Therapy of DTC Patients: Radioiodine and Beyond	809 e-Poster Presentations Session 6 Neuroimaging Committee Neuroimaging e-Posters	810 Technologists' Track CTE 4 Technologists Committee Breathing Knowledge – the New Approaches of PET-CT Lung Scanning	811 Special Symposium 1 Dosimetry Committee Challenges in Dosimetry of Alpha-Emitters	10:00-10:30
10:30-11:00												10:30-11:00
11:00-11:30												11:00-11:30
11:30-12:00	901 Plenary 3 Referring Patients to Nuclear Medicine: When, How, and Mainly Why?											11:30-12:00
12:00-12:30												12:00-12:30
12:30-13:00												12:30-13:00
13:00-13:30												13:00-13:30
13:30-14:00	Lunch Break		Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	13:30-14:00
14:00-14:30												14:00-14:30
14:30-15:00												14:30-15:00
15:00-15:30	1001 CME 7 Oncology & Theranostics Committee Targeted Radionuclide Therapy Across Various SST Expressing Tumor Models: a new Framework for Rethinking	1002 Special Track EANM Sanjiv Sam Gambhir Award – Compete and Win!	1003 Learn & Improve Professional Skills (LIPS) Track Cardiovascular Committee What to Look at in the Heart and in Vessels on Oncological PET Images	1004 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee Innovations in Translational Oncology	1005 Cutting Edge Science Track TROP Session Dosimetry Committee Personalised Dosimetry and Predictive Modeling	1006 Clinical Oncology Track TROP Session Oncology & Theranostics Committee NET and PRRT	1007 TROP Session Neuroimaging Committee Tau PET Imaging	1008 Joint Symposium 4 AI Committee / EFOMP Trustful AI in the Clinics	1009 e-Poster Presentations Session 7 Radiopharmaceutical Sciences Committee Radiochemistry and Quality Control	1010 Technologists' Track Technologists' e-Poster Presentations Session Technologists Committee Techs' e-Posters	1011 Special Symposium 4 EANM Journals Scientific Writing in 2025	15:00-15:30
15:30-16:00												15:30-16:00
16:00-16:30												16:00-16:30
16:30-17:00	1101 CME 8 Radiopharmaceutical Committee Radiotheranostics 2.0: The Power of Emerging Radioisotopes in Translating Imaging into Personalised Radiotherapy	1102 Special Track Neuroimaging Committee Round Table: Tau PET Imaging: Ready for Clinical Use	1103 Learn & Improve Professional Skills (LIPS) Track Physics Committee Getting Imaging Right with Protocol Optimisation	1104 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee Preclinical Neuroimaging	1105 Cutting Edge Science Track TROP Session AI Committee AI for Report Generation and Patient Prognostication	1106 Clinical Oncology Track TROP Session Oncology & Theranostics Committee Gastrointestinal Tumour Imaging	1107 TROP Session Thyroid Committee The Pivotal Role of Nuclear Medicine Imaging to Localise Parathyroid Lesion	1108 Joint Symposium 5 Oncology & Theranostics Committee / EAU EANM & EAU Advances in Renal Cancer Research	1109 e-Poster Presentations Session 8 Oncology & Theranostics Committee Cancer Imaging and Therapy	1110 Technologists' Track CTE 5 Technologists Committee Dynamic Cardiovascular Hybrid Imaging	1111 Featured Session Cardiovascular Committee Innovation in Myocardial Perfusion in SPECT	16:30-17:00
17:00-17:30												17:00-17:30
17:30-18:00												17:30-18:00
18:00-18:30												18:00-18:30

PROGRAMME OVERVIEW

TUESDAY, OCTOBER 7, 2025

Location/ Time	Auditorium	Room 112 (Arena)	Room 113	Room 114	Room 211	Room 117	Room 212	Room 115	Room 133+134	Room 116	Room 111	Location/ Time
	LIVE STREAM									LIVE STREAM		
08:00–08:30	1201 CME 9 Oncology & Theranostics + Neuroimaging Committee	1202 Special Track Physics Committee Debate: Quantitative Imaging: What's the Point? (Focus on Kinetic Modeling)	1203 Learn & Improve Professional Skills (LIPS) Track Oncology & Theranostics Committee Pitfalls in PSMA-Based RLT: Case-Based Review	1204 M2M Track TROP / Featured Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee Combination Therapy - Shaping the Future of TRT	1205 Cutting Edge Science Track ROP Session AI Committee AI Techniques for Patient Classification	1206 Clinical Oncology Track TROP Session Oncology & Theranostics Committee Protate Cancer Therapy: Dosimetry, SPECT/CT, AI	1207 TROP Session Thyroid Committee Current and Future Perspective of Nuclear Medicine Imaging in Endocrinological Disorders	1208 TROP Session Cardiovascular Committee Cardiovascular Infection and Inflammation: Evidence and Novelty	1209 e-Poster Presentations Session 9 Dosimetry Committee Advances in Clinical and Preclinical Dosimetry	1210 Technologists' Track CTE 6 Technologists Committee Fibroblast-Activated: the 68Ga-FAPI in Different Types of Cancer	1211 EU Policy Symposium 1 Policy & Regulatory Affairs Council From Policy to Patients: Building Readiness for Nuclear Medicine Innovation in Europe	08:00–08:30
08:30–09:00	RLT Applications in Neuro-Oncology											08:30–09:00
09:00–09:30												09:00–09:30
09:30–10:00												09:30–10:00
10:00–10:30	1301 CME 10 AI Committee AI as Accelerator for NM Research	1302 Special Track Oncology & Theranostics Committee Debate: Residents for Residents	1303 Learn & Improve Professional Skills (LIPS) Track Paediatrics Committee Update on Pediatric GI Nuclear Studies	1304 M2M Track TROP / Featured Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee Improving Radionuclide Production for Tracer Development	1305 Cutting Edge Science Track TROP Session Dosimetry Committee Quantification and Innovation in Dosimetry	1306 Clinical Oncology Track TROP Session Oncology & Theranostics Committee Prostate Cancer Therapy in HSPC and CRPC	1307 TROP Session Neuroimaging Committee Neuro-Oncology	1308 Joint Symposium 6 Translational Molecular Imaging & Therapy Committee + Radiopharmaceutical Sciences Committee ESTRO Radiobiological Aspects of PRRT	1309 e-Poster Presentations Session 10 Paediatrics Committee Paediatrics e-Poster Presentations Session	1310 Technologists' Track Oral Presentations 3 Technologists Committee Interdisciplinary Nuclear Medicine Workforce Sustainability and Training	1311 TROP Session Case Report Session 1 Case-based Learning in Theranostics	10:00–10:30
10:30–11:00												10:30–11:00
11:00–11:30												11:00–11:30
11:30–12:00	1401 Plenary 4 Quo vadis Nuclear Medicine 2040: Who Wins? Team Red or Team Green?											11:30–12:00
12:00–12:30												12:00–12:30
12:30–13:00												12:30–13:00
13:00–13:30												13:00–13:30
13:30–14:00	Lunch Break		Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	Satellite Symposium	13:30–14:00
14:00–14:30												14:00–14:30
14:30–15:00												14:30–15:00
15:00–15:30	1501 CME 11 Translational Molecular Imaging & Therapy Committee A Comprehensive Approach to Preclinical Dosimetry	1502 Special Track Oncology & Theranostics Committee Challenge the Expert: Lymphoma Evaluation: Do We Need to Go Beyond the Deauville Score?	1503 Learn & Improve Professional Skills (LIPS) Track Neuroimaging Committee Crazy Enough to Do Molecular Imaging in Psychiatric Disorders?	1504 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee Peptides for All Tastes	1505 Cutting Edge Science Track TROP Session Physics Committee Instrumentation, QC & Standardisation	1506 Clinical Oncology Track TROP Session Oncology & Theranostics Committee Prostate Cancer Therapy: New Tracer	1507 TROP Session Cardiovascular Committee Myocardial Perfusion on PET: Where Are We Going?	1508 Joint Symposium 7 Inflammation & Infection Committee / EUSEM The Role of Nuclear Medicine Imaging in Intensive Care Unit (ICU) Patients	1509 e-Poster Presentations Session 11 AI Committee AI e-Poster Presentations Session	1510 Technologists' Track CTE 7 Technologists Committee Hybrid Imaging in Differentiated Thyroid Cancer (DTC) Diagnosis and Treatment	1511 EU Policy Symposium 2 Policy & Regulatory Affairs Council Growing Role of Health Technology Assessment (HTA) in Nuclear Medicine: Implications in Light of the New EU HTA Regulation	15:00–15:30
15:30–16:00												15:30–16:00
16:00–16:30												16:00–16:30
16:30–17:00	1601 CME 12 Oncology & Theranostics Committee Improving Breast Cancer Care: Highlights from Focus Meeting 6: Staging	1602 Special Track Dosimetry Committee Round Table: Unlocking the Potential: Can Total Body PET Revolutionise Dosimetry?	1603 Learn & Improve Professional Skills (LIPS) Track Inflammation & Infection Committee Interpretation of FDG PET/CT in Common Infectious-Inflammatory Diseases	1604 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee Imaging of Non-oncological Targets	1605 Cutting Edge Science Track TROP Session Radiation Protection Committee Radiation Exposure and Protection	1606 Clinical Oncology Track TROP Session Oncology & Theranostics Committee Imaging Prostate Cancer: Prediction and Outcome	1607 TROP Session Neuroimaging Committee Neurology: Psychiatry, Epilepsy, Inflammation and Others	1608 TROP Session Cardiovascular Committee Metabolism, Fibrosis and Innervation: The Basis of Cardiomyopathies	1609 e-Poster Presentations Session 12 Thyroid Committee Diagnostic and Therapeutic Approach in Patients with Endocrinological Disorders		1611 TROP Session Case Report Session 2 Case-based Learning in Nuclear Medicine Beyond Oncology	16:30–17:00
17:00–17:30												17:00–17:30
17:30–18:00												17:30–18:00
18:00–18:30												18:00–18:30

PROGRAMME OVERVIEW

WEDNESDAY, OCTOBER 8, 2025

Location/ Time	Auditorium	Room 112 (Arena)	Room 113	Room 114	Rom 211	Room 117	Room 212	Room 115	Room 133+134	Room 116	Room 111	Location/ Time
	LIVE STREAM									LIVE STREAM		
08:00–08:30	1701 CME 13 Dosimetry Committee Challenges in Red Bone Marrow Dosimetry	1702 Special Track Women Empowerment Initiative + Young Professionals Council Challenge the Expert: Current Challenges in Career and in Leadership for the Future Generations	1703 Learn & Improve Professional Skills (LIPS) Track Oncology & Theranostics Committee Structured PET Reporting in Oncology	1704 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee Antibodies and Co.	1705 Cutting Edge Science Track TROP Session AI Committee Kinetic Modeling and Parametric Imaging	1706 Clinical Oncology Track TROP Session Oncology & Theranostics Committee Theranostic and New Therapies	1707 TROP Session Cardiovascular Committee Atherosclerosis Burden, from Plaque to Perfusion	1708 TROP Session Case Report Session 3 Case-based Learning PET in Oncology	1709 e-Poster Presentations Session 13 Bone & Joint Committee Bone & Joint e-Poster Presentations Session	1710 Technologists' Track Mini Courses Technologists Committee 1710a Mini Course 1 (08:00–09:00) 1710b Mini Course 2 (09:05–10:05) 1710c Mini Course 3 (10:15–11:15)	1711 Theranostics Track TROP Session Oncology & Theranostics Committee Prostate Cancer Theranostic	08:00–08:30
08:30–09:00												08:30–09:00
09:00–09:30												09:00–09:30
09:30–10:00												09:30–10:00
10:00–10:30	1801 CME 14 Bone & Joint Committee NM Sports, it's in the Game	1802 Special Track Translational Molecular Imaging & Therapy Committee Challenge the Expert: How can Lessons from Radiobiology be Applied to the Design of Clinical Trials?	1803 Learn & Improve Professional Skills (LIPS) Track Neuroimaging Committee PET Response Assessment in Neuro-Oncology	1804 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee Advances in Preclinical Cardiovascular Imaging	1805 TROP Session Paediatrics Committee Emerging Roles of Molecular Imaging in Paediatric Oncology, Neurology and Transplant Medicine	1806 Clinical Oncology Track TROP Session Oncology & Theranostics Committee Prostate Cancer Staging and Restaging	1807 TROP Session Inflammation & Infection Committee Infection/Inflammation Under the Lens: Innovations in Nuclear Medicine Imaging	1808 Joint Symposium 8 Cardiovascular Committee / EACVI Controversies in the Evaluation of Coronary Artery Disease	1809 e-Poster Presentations Session 14 Radiation Protection Committee Radiation Protection e-Poster Presentations Session		1811 TROP Session Oncology & Theranostics Committee Radioembolisation and Novel Therapies	10:00–10:30
10:30–11:00												10:30–11:00
11:00–11:30	1901 Closing Session											11:00–11:30
11:30–12:00	Farewell Drinks											11:30–12:00
12:00–12:30												12:00–12:30

- Plenary Sessions
- CME Sessions
- Special Track
- Learn & Improve Professional Skills (LIPS) Track
- Joint Symposia
- M2M Track
- Cutting Edge Science Track
- Clinical Oncology Track
- Special Symposium
- Featured/TROP Session
- e-Poster Presentations
- Technologists' Track Session
- Continuing Medical Education
- Young Professionals



SCIENTIFIC PROGRAMME

INVITED SPEAKER SESSIONS

PLENARY SESSIONS

- 1** Saturday, October 4, 2025 | 18:35 - 19:35 | Auditorium
Highlights: Not to Be Missed at All Costs
Presenters: Ian Law (Copenhagen, Denmark), Samia Massalha (Haifa, Israel), Alexander Maurer (Zurich, Switzerland)
- 2** Sunday, October 5, 2025 | 11:30 - 13:00 | Auditorium
World's Best Theranostics Comes to EANM'25
Chairpersons: Valentina Garibotto (Geneva, Switzerland), Pedro Fragoso Costa (Essen, Germany)
 - » **Grace Kong (Melbourne, Australia):**
Maximizing the Potential of PSMA-Targeted Therapies and Beyond: New Horizons in Oncology
 - » **Mike Sathekge (Pretoria, South Africa):**
The Power of Targeted Alpha Therapy: From Physics to Patient Outcomes
 - » **Heather Jacene (Boston, United States of America):**
Transforming Cancer Care: Advances in Precision Oncology and Theranostic Approaches
 - » **Elba Etchebehere (Campinas, Brazil):**
Radium-223 Through the Ages: From Discovery to Modern Applications
 - » **Rakesh Kumar (New Delhi, India):**
Expanding Horizons: Modernizing Nuclear Medicine Infrastructure for Tomorrow's Challenges
 - » **Tadashi Watabe (Osaka, Japan):**
Astatine-211 - a Targeted Alpha Therapy for Thyroid Cancer: Advances and Challenges
- 3** Monday, October 6, 2025 | 11:30 - 13:00 | Auditorium
Referring Patients to Nuclear Medicine: When, How, and Mainly Why?
Chairpersons: Paola A. Erba (Bergamo, Italy)
 - » **Stijn Muselaers (Nijmegen, Netherlands):**
Never without Nuclear Medicine in Prostate Cancer, is Kidney Cancer Next in Line?
 - » **Liza Lindenberg (Washington, United States of America):**
New Targets in Kidney Cancer
 - » **Alessandra Gennari (Novara, Italy):**
Nuclear Medicine is Routine in Lung Cancer and Optional in the Majority of Breast Cancers
 - » **Gary Ulaner (Irvine, United States of America):**
New Frontiers in Breast Cancer Molecular Imaging
 - » **Daniel Ferreira Padilla (Huddinge, Sweden):**
Nuclear Medicine has Revolutionized the Alzheimer's Disease landscape, is Parkinson's Disease the Next?
 - » **Guenter Hoeglinger (Munich, Germany):**
Parkinson's Disease Can only be Understood with Molecular Imaging
- 4** Tuesday, October 7, 2025 | 11:30 - 13:00 | Auditorium
Quo vadis Nuclear Medicine 2040: Who Wins? Team Red or Team Green?
 - » **Theranostics Involving Radionuclides Will (not) Represent a Major Pillar of Cancer Therapy**
Team RED: **Giorgio Treglia (Lugano, Switzerland)**
Team GREEN: **Sophie Veldhuijzen van Zanten (Rotterdam, Netherlands)**
 - » **AI Will Complement Nuclear Medicine Physicians / AI Will Replace Nuclear Medicine Physicians**
Team RED: **Jens Kleesiek (Essen, Germany)**
Team GREEN: **Irene Buvat (Paris, France)**
 - » **Nuclear Medicine as a Specialty Will Remain Independent / Nuclear Medicine as a Specialty Will Be Taken Over by Radiology and Radiation Oncology**
Team RED: **Ambros Beer (Ulm, Germany)**
Team GREEN: **Laura Evangelista (Milan, Italy)**

CONTINUING MEDICAL EDUCATION (CME) SESSIONS

1	Sunday, October 5, 2025 08:00 - 09:30 Auditorium Inflammation & Infection Committee The Role of FAPI PET/CT in Inflammation Diseases
2	Sunday, October 5, 2025 09:45 - 11:15 Auditorium Neuroimaging Committee Paradigm Shift for the Diagnosis of Parkinson Diseases
3	Sunday, October 5, 2025 15:00 - 16:30 Auditorium Physics + Paediatrics Committee Low Dose Imaging
4	Sunday, October 5, 2025 16:45 - 18:15 Auditorium Cardiovascular Committee Total Body Imaging: Think Big, Think Forward! (Cardio)
5	Monday, October 6, 2025 08:00 - 09:30 Auditorium Thyroid Committee Parathyroid Carcinoma: Rare but Complex
6	Monday, October 6, 2025 09:45 - 11:15 Auditorium Oncology & Theranostics Committee PET in mCRPC: Toward Multiparametric Multitracer Biomarkers
7	Monday, October 6, 2025 15:00 - 16:30 Auditorium Oncology & Theranostics Committee Targeted Radionuclide Therapy Accross Various SST Expressing Tumor Models: a new Framework for Rethinkingg
8	Monday, October 6, 2025 16:45 - 18:15 Auditorium Radiopharmaceutical Sciences Committee Radiotheranostics 2.0: The Power of Emerging Radioisotopes in Translating Imaging into Personalized Radiotherapy
9	Tuesday, October 7, 2025 08:00 - 09:30 Auditorium Oncology & Theranostics + Neuroimaging Committee RLT Applications in Neuro-Oncology
10	Tuesday, October 7, 2025 09:45 - 11:15 Auditorium AI Committee AI as Accelerator for NM Research
11	Tuesday, October 7, 2025 15:00 - 16:30 Auditorium Translational Molecular Imaging & Therapy Committee A Comprehensive Approach to Preclinical Dosimetry

12	Tuesday, October 7, 2025 16:45 - 18:15 Auditorium Oncology & Theranostics Committee Improving Breast Cancer Care: Highlights from Focus Meeting 6: Staging
13	Wednesday, October 8, 2025 08:00 - 09:30 Auditorium Dosimetry Committee Challenges in Red Bone Marrow Dosimetry
14	Wednesday, October 8, 2025 09:45 - 11:15 Auditorium Bone & Joint Committee NM Sports, it's in the Game

SPECIAL TRACK

1	Sunday, October 5, 2025 08:00 - 09:30 EANM Arena (Room 112) Thyroid Committee Challenge the Expert: When to Stop Radioiodine?
2	Sunday, October 5, 2025 09:45 - 11:15 EANM Arena (Room 112) Oncology & Theranostics Committee Debate: A Brave New World: Are All PSMA Radiopharmaceuticals Equal?
3	Sunday, October 5, 2025 15:00 - 16:30 EANM Arena (Room 112) Oncology & Theranostics Committee Debate: Will Alpha Therapy be the Main Radionuclide Therapy Approach in the Futurey
4	Sunday, October 5, 2025 16:45 - 18:15 EANM Arena (Room 112) Oncology & Theranostics Committee + Radiation Protecion Committee Debate: Routes to Optimised Theranostics: Is 'Dose' Escalation Enough?
5	Monday, October 6, 2025 08:00 - 09:30 EANM Arena (Room 112) Inflammation & Infection Committee Debate: WBC Scintigraphy Scan vs FDG PET/CT in Musculoskelet AI Infections
6	Monday, October 6, 2025 09:45 - 11:15 EANM Arena (Room 112) Cardiovascular Committee Debate: Myocardial Perfusion ImagingI : Should I Stay with SPECT or Go with PET?

7	Monday, October 6, 2025 15:00 - 16:30 EANM Arena (Room 112) EANM Sanjiv Sam Gambhir Award Compete and Win!
8	Monday, October 6, 2025 16:45 - 18:15 EANM Arena (Room 112) Neuroimaging Committe Round Table: Tau PET Imaging: Ready for Clinical use
9	Tuesday, October 7, 2025 08:00 - 09:30 EANM Arena (Room 112) Physics Comittee Debate: Quantitative Imaging: What's the Point? (Focus on Kinetic Modeling)
10	Tuesday, October 7, 2025 09:45 - 11:15 EANM Arena (Room 112) Oncology & Theranostics Committee Round Table: Residents for Residents
11	Tuesday, October 7, 2025 15:00 - 16:30 EANM Arena (Room 112) Oncology & Theranostics Committee Challenge the Expert: Lymphoma Evaluation: Do we need to go Beyond the Deauville Score?
12	Tuesday, October 7, 2025 16:45 - 18:15 EANM Arena (Room 112) Dosimetry Committee Round Table: Unlocking the Potential: Can Total Body PET Revolutionise Dosimetry?
13	Wednesday, October 8, 2025 08:00 - 09:30 EANM Arena (Room 112) Women's Empowerment Initiative + Young Professionals Council Challenge the Expert: Current Challanges in Career and in Leadership for the Future Generations
14	Wednesday, October 8, 2025 09:45 - 11:15 EANM Arena (Room 112) Translational Molecular Imaging & Therapy Committee Challenge the Expert: How can Lessons from Radiobiology be Applied to the Design of Clinical Trials?

JOINT SYMPOSIA	
1	Sunday, October 5, 2025 09:45 - 11:15 Paediatrics Committee SIOPE Imaging Biomarkers in Paediatric Oncology 'Whats Next?'
2	Sunday, October 5, 2025 15:00 - 16:30 Neuroimaging Committee European Academy of Neurology (EAN) Joint EAN/EANM Symposium in Epilepsy: Who is the Right Candidate for Epilepsy Surgery?
3	Monday, October 6, 2025 08:00 - 09:30 Oncology & Theranostics Committee European Organisation for Research and Treatment of Cancer (EORTC) Oncological Response Criteria for PET: Beyond RECIST, EORTC & PERCIST
4	Monday, October 6, 2025 15:00 - 16:30 AI Committee European Federation of Organisations for Medical Physics (EFOMP) Trustful AI in the Clinics
5	Monday, October 6, 2025 16:45 - 18:15 Oncology & Theranostics Committee European Association of Urology (EAU) Advances in Renal Cancer Research
6	Tuesday, October 7, 2025 09:45 - 11:15 Translational Molecular Imaging & Therapy Committee European Society for Radiotherapy and Oncology (ESTRO) Radiopharmaceutical Sciences Council (RPSC) Radiobiological Aspects of PRRT
7	Tuesday, October 7, 2025 15:00 - 16:30 Inflammation & Infection Committee European Society for Emergency Medicine (EUSEM) The Role of Nuclear Medicine Imaging in Intensive Care Unit (ICU) Patients
8	Wednesday, October 8, 2025 09:45 - 11:15 Cardiovascular Committee European Association of Cardiovascular Imaging (EACVI) Controversies in the Evaluation of Coronary Artery Disease

SPECIAL SYMPOSIA

- 1

Sunday, October 5, 2025 | 09:45 - 11:15 | EARL

Clinical Implications of EARL PET/CT Accreditation Standards 2 and a New 177Lu SPECT/CT Accreditation
- 2

Sunday, October 5, 2025 | 15:00 - 16:30 | EANM Journals

EANM Journals Debate
- 3

Monday, October 6, 2025 | 09:45 - 11:15 | Dosimetry Committee

Challenges in Dosimetry of Alpha-Emitters
- 4

Monday, October 6, 2025 | 15:00 - 16:30 | EANM Journals

Scientific Writing in 2025

EU POLICY SYMPOSIA

- 1

Tuesday, October 7, 2025 | 08:00 - 09:30 | Policy & Regulatory Affairs Committee

From Policy to Patients: Building Readiness for Nuclear Medicine Innovation in Europe
- 2

Tuesday, October 7, 2025 | 15:00 - 16:30 | Policy & Regulatory Affairs Committee

Growing Role of Health Technology Assessment (HTA) in Nuclear Medicine: Implications in Light of the New EU HTA Regulation



LEARN & IMPROVE PROFESSIONAL SKILLS (LIPS) TRACK

- 1

Sunday, October 5, 2025 | 08:00 - 09:30 | Room 113
Translational Molecular Imaging & Therapy Committee

Optical and Multimodal/Hybrid Tracers: Similarities with Radiotracers, Pitfalls and Regulatory Issues
- 2

Sunday, October 5, 2025 | 09:45 - 11:15 | Room 113
Bone & Joint Committee

Bone and Joint Therapies
- 3

Sunday, October 5, 2025 | 15:00 - 16:30 | Room 113
Thyroid Committee

Imaging Challenges in Nuclear Endocrinology
- 4

Sunday, October 5, 2025 | 16:45 - 18:15 | Room 113
AI Committee

AI for Young Developers in NM
- 5

Monday, October 6, 2025 | 08:00 - 09:30 | Room 113
Dosimetry Committee

Statistical Analysis in Clinical Studies and Specifically in Dosimetry
- 6

Monday, October 6, 2025 | 09:45 - 11:15 | Room 113
Radiation Protection Committee

What would you do if...? Radiation Protection Issues in Special Cases of Everyday Practices
- 7

Monday, October 6, 2025 | 15:00 - 16:30 | Room 113
Cardiovascular Committee

What to look at in the Heart and in Vessels on Oncological PET Images
- 8

Monday, October 6, 2025 | 16:45 - 18:15 | Room 113
Physics Committee

Getting Imaging Right with Protocol Optimisation
- 9

Tuesday, October 7, 2025 | 08:00 - 09:30 | Room 113
Oncology & Theranostics Committee

Pitfalls in PSMA-Based RLT: Case-Based Review
- 10

Tuesday, October 7, 2025 | 09:45 - 11:15 | Room 113
Paediatrics Committee

Update on Pediatric Gastrointestinal Nuclear Studies
- 11

Tuesday, October 7, 2025 | 15:00 - 16:30 | Room 113
Neuroimaging Committee

Crazy Enough to do Molecular Imaging in Psychiatric Disorders?

12	Tuesday, October 7, 2025 16:45 - 18:15 Room 113 Inflammation & Infection Committee Interpretation of FDG PET/CT in Common Infectious-Inflammatory Diseases
13	Wednesday, October 8, 2025 08:00 - 09:30 Room 113 Oncology & Theranostics Committee Structured PET Reporting in Oncology
14	Wednesday, October 8, 2025 09:45 - 11:15 Room 113 Neuroimaging Committee PET Response Assessment in Neurooncology

CLINICAL ONCOLOGY TRACK

206	Sunday, October 5, 2025 08:00 – 09:30 Room 117 Oncology & Theranostics Committee – TROP Session Gynaecological Cancer Staging and Image Guidance
306	Sunday, October 5, 2025 09:45 – 11:15 Room 117 Oncology & Theranostics Committee – TROP Session Breast Cancer Imaging
506	Sunday, October 5, 2025 15:00 – 16:30 Room 117 Oncology & Theranostics Committee – TROP Session Lung Cancer Imaging
606	Sunday, October 5, 2025 16:45 – 18:15 Room 117 Oncology & Theranostics Committee – TROP Session Haematology and Lymphoma
706	Monday, October 6, 2025 08:00 – 09:30 Room 117 Oncology & Theranostics Committee – TROP Session Imaging Melanoma and New Targets
806	Monday, October 6, 2025 09:45 – 11:15 Room 117 Oncology & Theranostics Committee – TROP Session NET Imaging
1006	Monday, October 6, 2025 15:00 – 16:30 Room 117 Oncology & Theranostics Committee – TROP Session NET and PRRT

1106	Monday, October 6, 2025 16:45 – 18:15 Room 117 Oncology & Theranostics Committee – TROP Session Gastrointestinal Tumour Imaging
1206	Tuesday, October 7, 2025 08:00 – 09:30 Room 117 Oncology & Theranostics Committee – TROP Session Protate Cancer Therapy: Dosimetry, SPECT/CT, AI
1306	Tuesday, October 7, 2025 09:45 – 11:15 Room 117 Oncology & Theranostics Committee – TROP Session Prostate Cancer Therapy in HSPC and CRPC
1506	Tuesday, October 7, 2025 15:00 – 16:30 Room 117 Oncology & Theranostics Committee – TROP Session Prostate Cancer Therapy: New Tracer
1606	Tuesday, October 7, 2025 16:45 – 18:15 Room 117 Oncology & Theranostics Committee – TROP Session Imaging Prostate Cancer: Prediction and Outcome
1706	Wednesday, October 8, 2025 08:00 – 09:30 Room 117 Oncology & Theranostics Committee – TROP Session Theranostic and New Therapies
1806	Wednesday, October 8, 2025 09:45 – 11:15 Room 117 Oncology & Theranostics Committee – TROP Session Prostate Cancer Staging and Restaging

THERANOSTICS TRACK

211	Sunday, October 5, 2025 08:00 – 09:30 Room 111 Oncology & Theranostics Committee – TROP Session Novel Theranostic Applications
711	Monday, October 6, 2025 08:00 – 09:30 Room 111 Oncology & Theranostics Committee – TROP Session Prostate and Novel Targets
1711	Wednesday, October 8, 2025 08:00 – 09:30 Room 111 Oncology & Theranostics Committee – TROP Session Prostate Cancer Theranostic

CUTTING EDGE SCIENCE TRACK

205	Sunday, October 5, 2025 08:00 – 09:30 Room 211 AI Committee – TROP Session AI for Segmentation in PET/CT
305	Sunday, October 5, 2025 09:45 – 11:15 Room 211 Physics Committee – TROP Session SPECT Quantification in Therapeutic Applications
505	Sunday, October 5, 2025 15:00 – 16:30 Room 211 AI Committee – TROP Session AI Based Segmentation – Cardiac, Lung Ventilation, Bone
605	Sunday, October 5, 2025 16:45 – 18:15 Room 211 Dosimetry Committee – TROP Session Radiobiological Mechanisms to Overcome Resistance in TRT
705	Monday, October 6, 2025 08:00 – 09:30 Room 211 Physics Committee – TROP Session PET/CT & PET/MRO
805	Monday, October 6, 2025 09:45 – 11:15 Room 211 AI Committee – TROP Session Disease Characterisation and Prediction Models
1005	Monday, October 6, 2025 15:00 – 16:30 Room 211 Dosimetry Committee – TROP Session Personalised Dosimetry and Predictive Modeling
1105	Monday, October 6, 2025 16:45 – 18:15 Room 211 AI Committee – TROP Session AI for Report Generation and Patient Prognostication
1205	Tuesday, October 7, 2025 08:00 – 09:30 Room 211 AI Committee – TROP Session AI Techniques for Patient Classification
1305	Tuesday, October 7, 2025 09:45 – 11:15 Room 211 Dosimetry Committee – TROP Session Quantification and Innovation in Dosimetry
1505	Tuesday, October 7, 2025 15:00 – 16:30 Room 211 Physics Committee – TROP Session Instrumentation, QC & Standardisation

1605	Tuesday, October 7, 2025 16:45 – 18:15 Room 211 Radiation Protection Committee – TROP Session Radiation Exposure and Protection
1705	Wednesday, October 8, 2025 08:00 – 09:30 Room 211 AI Committee – TROP Session Kinetic Modeling and Parametric Imaging
1805	Wednesday, October 8, 2025 09:45 – 11:15 Room 211 Paediatrics Committee – TROP Session Emerging Roles of Molecular Imaging in Paediatric Oncology, Neurology and Transplant Medicine

M2M TRACK

204	Sunday, October 5, 2025 08:00 – 09:30 Room 114 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committees – TROP Session New Targets in Oncology
304	Sunday, October 5, 2025 09:45 – 11:15 Room 114 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committees – TROP Session Tracking/Modulating Pharmacokinetics
504	Sunday, October 5, 2025 15:00 – 16:30 Room 212 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committees – TROP Session Prostate Cancer: New Tracers
604	Sunday, October 5, 2025 16:45 – 18:15 Room 114 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committees – TROP Session Combining Imaging with Targeted Therapy
704	Monday, October 6, 2025 08:00 – 09:30 Room 114 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committees – TROP Session Preclinical Therapy – Various Targets
804	Monday, October 6, 2025 09:45 – 11:15 Room 114 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committees – TROP Session Optimising Radiolabeling and Quality Control: The Key for Clinical Translation
1004	Monday, October 6, 2025 15:00 – 16:30 Room 114 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committees – FEATURED Session Innovations in Translational Oncology
1104	Monday, October 6, 2025 16:45 – 18:15 Room 114 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committees – FEATURED Session Preclinical Neuroimaging

1204	Tuesday, October 7, 2025 08:00 – 09:30 Room 114 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committees – TROP Session Combination Therapy – Shaping the Future of TRT
1304	Tuesday, October 7, 2025 09:45 – 11:15 Room 114 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committees – TROP Session Improving Radionuclide Production for Tracer Development
1504	Tuesday, October 7, 2025 15:00 – 16:30 Room 114 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committees – TROP Session Peptides for All Tastes
1604	Tuesday, October 7, 2025 16:45 – 18:15 Room 114 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committees – FEATURED Session Imaging of Non-oncological Targets
1704	Wednesday, October 8, 2025 08:00 – 09:30 Room 114 Dosimetry Committee – TROP Session Antibodies and Co.
1804	Wednesday, October 8, 2025 09:45 – 11:15 Room 114 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committees – TROP Session Advances in Preclinical Cardiovascular Imaging
FURTHER ORAL PRESENTATIONS & CASE REPORTS	
207	Sunday, October 5, 2025 08:00 – 09:30 Room 212 Neuroimaging Committee – TROP Session Movement Disorders
208	Sunday, October 5, 2025 08:00 – 09:30 Room 115 Cardiovascular Committee – TROP Session From Muscle to Calcifications – What’s New in Cardiac Amyloidosis?
307	Sunday, October 5, 2025 09:45 – 11:15 Room 212 Thyroid Committee – TROP Session Nuclear Medicine Imaging in Thyroid Disorders: From Thyroid Nodule to Advanced/Refractory Cancer
607	Sunday, October 5, 2025 16:45 – 18:15 Room 212 Neuroimaging Committee – TROP Session Molecular Imaging of Neurodegeneration: FDG, Amyloid PET and Other
608	Sunday, October 5, 2025 16:45 – 18:15 Room 115 Thyroid Committee – Featured Session Nuclear Medicine Imaging in Medullary and Differentiated Thyroid Cancers

611	Sunday, October 5, 2025 16:45 – 18:15 Room 111 Paediatrics Committee – Featured Session Advances in Paediatric Molecular Imaging: Innovations in Oncology, Radiomics and Hybrid Technologies
707	Monday, October 6, 2025 08:00 – 09:30 Room 212 Neuroimaging Committee – TROP Session Innovations and Methodologies in Nuclear Neuroimaging
807	Monday, October 6, 2025 09:45 – 11:15 Room 212 Bone & Joint Committee – Featured Session New Frontiers in Bone and Soft Tissue Imaging
808	Monday, October 6, 2025 09:45 – 11:15 Room 115 Thyroid Committee – TROP Session An Overview on Nuclear Medicine Therapy of DTC Patients: Radioiodine and Beyond
1007	Monday, October 6, 2025 15:00 – 16:30 Room 212 Neuroimaging Committee – TROP Session Tau PET Imaging
1107	Monday, October 6, 2025 16:45 – 18:15 Room 212 Thyroid Committee – TROP Session Innovation in Myocardial Perfusion in SPECT
1111	Monday, October 6, 2025 16:45 – 18:15 Room 111 Cardiovascular Committee – Featured Session The Pivotal Role of Nuclear Medicine Imaging to Localise Parathyroid Lesion
1207	Tuesday, October 7, 2025 08:00 – 09:30 Room 212 Thyroid Committee – TROP Session Current and Future Perspective of Nuclear Medicine Imaging in Endocrinological Disorders
1208	Tuesday, October 7, 2025 08:00 – 09:30 Room 115 Cardiovascular Committee – TROP Session Cardiovascular Infection and Inflammation: Evidence and Novelty
1307	Tuesday, October 7, 2025 09:45 – 11:15 Room 212 Neuroimaging Committee – TROP Session Neuro-Oncology
1311	Tuesday, October 7, 2025 09:45 – 11:15 Room 111 Case Report Session 1 – TROP Session Case-based Learning in Theranostics

1507	Tuesday, October 7, 2025 15:00 – 16:30 Room 212 Cardiovascular Committee – TROP Session Myocardial Perfusion on PET: Where Are We Going?
1607	Tuesday, October 7, 2025 16:45 – 18:15 Room 212 Neuroimaging Committee – TROP Session Neurology: Psychiatry, Epilepsy, Inflammation and Others
1608	Tuesday, October 7, 2025 16:45 – 18:15 Room 115 Cardiovascular Committee – TROP Session Metabolism, Fibrosis and Innervation: The Basis of Cardiomyopathies
1611	Tuesday, October 7, 2025 16:45 – 18:15 Room 111 Case Report Session 2 – TROP Session Case-based Learning in Nuclear Medicine Beyond Oncology
1707	Wednesday, October 8, 2025 08:00 – 09:30 Room 212 Cardiovascular Committee – TROP Session Atherosclerosis Burden, from Plaque to Perfusion
1708	Wednesday, October 8, 2025 08:00 – 09:30 Room 115 Case Report Session 3 – TROP Session Case-based Learning PET in Oncology
1807	Wednesday, October 8, 2025 09:45 – 11:15 Room 212 Inflammation & Infection – TROP Session Infection/Inflammation Under the Lens: Innovations in Nuclear Medicine Imaging
1811	Wednesday, October 8, 2025 09:45 – 11:15 Room 111 Oncology & Theranostics Committee – TROP Session Radioembolisation and Novel Therapies
e-POSTER PRESENTATION SESSIONS	
209	Sunday, October 5, 2025 08:00 – 09:30 Room 133+134 Translational Molecular Imaging & Therapy Committee Preclinical Imaging and Therapy
309	Sunday, October 5, 2025 09:45 – 11:15 Room 133+134 Inflammation & Infection Committee Best e-Posters in Inflammation & Infection
509	Sunday, October 5, 2025 15:00 – 16:30 Room 133+134 Radiopharmaceutical Sciences Committee New Tracers for Radioligand Therapy and Imaging

609	Sunday, October 5, 2025 16:45 – 18:15 Room 133+134 Physics Committee Physics e-Poster Presentations Session
709	Monday, October 6, 2025 08:00 – 09:30 Room 133+134 Cardiovascular Committee Cardiovascular e-Poster Presentations Session
809	Monday, October 6, 2025 09:45 – 11:15 Room 133+134 Neuroimaging Committee Neuroimaging e-Posters
1009	Monday, October 6, 2025 15:00 – 16:30 Room 133+134 Radiopharmaceutical Sciences Committee Radiochemistry and Quality Control
1109	Monday, October 6, 2025 16:45 – 18:15 Room 133+134 Oncology & Theranostics Committee Cancer Imaging and Therapy
1209	Tuesday, October 7, 2025 08:00 – 09:30 Room 133+134 Dosimetry Committee Advances in Clinical and Preclinical Dosimetry
1309	Tuesday, October 7, 2025 09:45 – 11:15 Room 133+134 Paediatrics Committee Paediatrics e-Poster Presentations Session
1509	Tuesday, October 7, 2025 15:00 – 16:30 Room 133+134 AI Committee AI e-Poster Presentations Session
1609	Tuesday, October 7, 2025 16:45 – 18:15 Room 133+134 Thyroid Committee Diagnostic and Therapeutic Approach in Patients with Endocrinological Disorders
1709	Wednesday, October 8, 2025 08:00 – 09:30 Room 133+134 Bone & Joint Committee Bone & Joint e-Poster Presentations Session
1809	Wednesday, October 8, 2025 09:45 – 11:15 Room 133+134 Radiation Protection Committee Radiation Protection e-Poster Presentations Session

TECHNOLOGISTS' TRACK

PLENARY SESSIONS

1	Saturday, October 4, 2025 18:35 - 19:35 Auditorium Highlights: Not to Be Missed at All Costs
2	Sunday, October 5, 2025 11:30 - 13:00 Auditorium World's Best Theranostics Comes to EANM'25
3	Monday, October 6, 2025 11:30 - 13:00 Auditorium Referring Patients to Nuclear Medicine: When, How, and Mainly Why?
4	Tuesday, October 7, 2025 11:30 - 13:00 Auditorium Quo vadis Nuclear Medicine 2040: Who Wins? Team Red or Team Green?

INVITED SPEAKER SESSIONS (CTE SESSION)

1	Sunday, October 5, 2025 08:00 - 09:30 Room 133+134 Technologists Committee Society of Nuclear Medicine and Molecular Imaging (SNMMI) EANM Technologists' Guide Launch
2	Sunday, October 5, 2025 09:45 - 11:15 Room 133+134 Technologists Committee Continuous Education Models for NMTs
3	Sunday, October 5, 2025 16:45 - 18:15 Room 133+134 Technologists + Inflammation & Infection Committee Best Practice in Paediatric Inflammation & Infection Radionuclide Imaging - Heart, Bone and Joint, Kidney and Urinary Tract
4	Monday, October 6, 2025 09:45 - 11:15 Room 133+134 Technologists Committee Breathing Knowledge – the new Approaches of PET-CT Lung Scanning
5	Monday, October 6, 2025 16:45 - 18:15 Room 133+134 Technologists + Cardiovascular Committee Dynamic Cardiovascular Hybrid Imaging
6	Tuesday, October 7, 2025 08:00 - 09:30 Room 133+134 Technologists Committee Fibroblast-Activated: the 68Ga-FAPI in Different Types of Cancer

7	Tuesday, October 7, 2025 15:00 - 16:30 Room 133+134 Technologists + Thyroid Committee Hybrid Imaging in Differentiated Thyroid Cancer (DTC) Diagnosis and Treatment
---	---

MINI COURSES

8	Wednesday, October 8, 2025 08:00 - 09:00 Room 133+134 Technologists Committee Nuclear Medicine Applications for Radiotherapy Planning
9	Wednesday, October 8, 2025 09:05 - 10:05 Room 133+134 Technologists Committee Adverse Events and Risk Management
10	Wednesday, October 8, 2025 10:15 - 11:15 Room 133+134 Technologists + Paediatrics Committee Patient Management in Paediatric Nuclear Medicine: from Theory to Practice

PROFFERED PAPER SESSIONS (ORAL PRESENTATIONS)

510	Sunday, October 5, 2025 15:00 – 16:30 Room 116 Technologists' Committee – TROP Session PET-CT Studies: Diagnosis and Treatment
710	Monday, October 6, 2025 08:00 – 09:30 Room 116 Technologists' Committee – TROP Session Advanced Practice and Novel Solutions
1010	Monday, October 6, 2025 15:00 – 16:30 Room 116 Technologists' Committee – e-Poster Presentation Session Techs' e-Posters
1310	Tuesday, October 7, 2025 09:45 – 11:15 Room 116 Technologists' Committee – TROP Session Interdisciplinary Nuclear Medicine Workforce Sustainability and Training

AWARDS

EANM will bestow several awards throughout the EANM'25.

EANM MARIE CURIE AWARD

Each year EANM is awarding the best rated abstract with the prestigious Marie-Curie Award. The Award is bestowed during the EANM Congress Opening Ceremony by the EANM Congress Chair. It is awarding the best rated abstract of all submissions for this year's congress.

EANM YOUNG AUTHORS' AWARD



(Kindly supported by United Imaging Healthcare)

EANM is offering an award to young authors of very good quality abstracts accepted for presentation at the EANM Annual Congress. This award aims to encourage young and talented nuclear medicine investigators to submit their results to the EANM Annual Congress and to have financial aid to attend the meeting and present their work.

EANM SANJIV SAM GAMBHIR YOUNG INVESTIGATOR AWARD



(Kindly supported by Telix Pharmaceuticals)

This award will fund a 3 months visitorship at Stanford University. Six jury picked candidates will compete in an award session for this recognition.

Details: Monday, October 06, 2025 – 15:00-16:30 in the EANM Arena (Room 112).

EANM TECHNOLOGISTS' AWARD



(Kindly supported by United Imaging Healthcare)

The purpose of the EANM Technologists' Award is to encourage Nuclear Medicine Technologists to present the abstract of their research project at the EANM Annual Congress.

A total of 4 awards will be handed over at the EANM'25.

RESEARCH4LIFE[®]

ELEVATE YOUR STANDARDS WITH EARL ACCREDITATION

— your gateway to an elite network
of precision-driven, quality-assured
PET centers.

JOIN THE EARL ACCREDITATIONS:

¹⁸F | ⁶⁸GA | ⁸⁹ZR | BRAIN PET/CT



100 SITES. ONE STANDARD.

A milestone in Theranostics excellence — over 100 EARL Centers of Excellence for Theranostics have achieved Level 1 Certification, setting the benchmark for quality and patient-focused care.

Now it's time to go further
— **Level 2** is coming!



ABSTRACTS

Oral Sessions

OC

Saturday, October 4, 2025, 18:00 - 18:35
Auditorium

Opening Ceremony including Awards Ceremony

OP-001
Opening Ceremony
V. Garibotto; Geneva University and Geneva University Hospitals, Geneva, SWITZERLAND.

101

Saturday, October 4, 2025, 18:35 - 19:35
Auditorium

Plenary 1: Highlights: Not to Be Missed at All Costs

OP-002
Highlights Lecture
I. Law; University of Copenhagen, Faculty of Health and Medical Sciences Consultant, Department of Clinical Physiology and Nuclear Medicine Rigshospitalet, Copenhagen, DENMARK.

OP-003
Highlights Lecture
S. Massalha; Rambam Medical Center, Haifa, ISRAEL.

OP-004
Highlights Lecture
A. Maurer; FMH Nuklearmedizin, FMH Radiologie Universitätsspital Zürich, Klinik für Nuklearmedizin, Zurich, SWITZERLAND.

201

Sunday, October 5, 2025, 08:00 - 09:30
Auditorium

CME 1 - Inflammation & Infection Committee: The Role of FAPI PET/CT in Inflammation Diseases

OP-006
Understanding the biology and function of fibroblasts in inflammation
M. Coles; University of Oxford, Kennedy Institute of Rheumatology, Oxford, Oxford, UNITED KINGDOM.

OP-007
FAPI PET/CT in cardiac diseases
N. Craig; University of Edinburgh, BHF Centre of Cardiovascular Science, Edinburgh, UNITED KINGDOM.

OP-008
FAPI PET/CT in lung diseases
Anne-L. Deleu; Institut Jules Bordet, Brussels, BELGIUM.

OP-009
FAPI PET/CT in rheumatological diseases
M. Sandovici; University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, NETHERLANDS.

202

Sunday, October 5, 2025, 08:00 - 09:30
Room 112 (Arena)

Special Track 1 - Thyroid Committee: Challenge the Expert: When to Stop Radioiodine?

OP-010
Radioiodine Refractory Thyroid Cancer
D. Deandreis; Gustav Roussy, Villejuif, FRANCE.

OP-011
Challengers Cases
B. Pranger; UMC, Utrecht, NETHERLANDS.

OP-012a
Challengers Cases
Milou T. Joe Way; LUMC, Leiden, NETHERLANDS.

OP-012b
Challengers Cases
D. Maccora; Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute of Rome, Rome, ITALY.

OP-012c
Challengers Cases
G. Kaya; Hacettepe Üniversitesi, Ankara, TÜRKİYE.

OP-012d
Challengers Cases
G. Zwezerijnen; Amsterdam UMC, Amsterdam, NETHERLANDS.

203

Sunday, October 5, 2025, 08:00 - 09:30
Room 113

LIPS Session 1 - Translational Molecular Imaging & Therapy Committee: Optical and Multimodal/Hybrid Tracers: Similarities with Radiotracers, Pitfalls and Regulatoy Issues

OP-013
Can Optical Imaging Replace Radioguided Surgery? – NM Perspective

G. Pisano; Gemelli University Hospital, Nuclear Medicine, Rome, ITALY.

OP-014
Surgeon's Perspective – Margins vs. Lymph Nodes
F. Hamdy; University of Oxford, Nuffield Department of Surgical Sciences, Oxford, UNITED KINGDOM.

OP-015
PET Tracers for Surgical Guidance, Optical vs Beta Detection
T. Kahl; University Hospital Essen, Urology, Essen, GERMANY.

OP-016
Placement of Optical Imaging within limage-Guided Interventions
F. van Leeuwen; Leiden University Medical Center, Interventional Molecular Imaging Laboratory, Leiden, NETHERLANDS.

204

Sunday, October 5, 2025, 8:00 - 9:30
Room 114

M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: New Targets in Oncology

OP-017
In vivo detection of tumor senescence by [¹⁸F] FPyGal PET

J. Schwenck, N. Trautwein, S. Mattern, J. Cotton, F. Reche-Perez, A. Wäschle, B. Gückel, M. Pritzkow, B. Zhou, M. Krüger, W. Ehrlichmann, G. Kienzle, A. Maurer, S. Singer, G. Reischl, L. Zender, B. J. Pichler, C. la Fougere; University of Tübingen, Tübingen, GERMANY.

OP-018
Nectin4-Targeted Radiotheranostics Probe: Molecular Imaging-Guided Precision in Cancer Diagnosis and Therapy
M. Hu, N. Wei, D. Zheng, Y. Song, Y. Feng, B. Yang, W. Hu, X. Wang, Y. Gai, Y. Zhang, X. Lan; Wuhan Union Hospital, Wuhan, CHINA.

OP-019
Development and preclinical evaluation of PD-L1-targeted small molecule theranostic radionuclide probe
H. Xie^{1,2};
¹West China Hospital of Sichuan University, Chengdu, Sichuan Province, CHINA, ²Beijing Anzhen Hospital,Capital Medical University, Beijing, CHINA.

OP-020
Development and Translational Study of Mesothelin-Targeted Molecular Imaging Probes for Early Diagnosis of Ovarian Cancer
Y. Deng, X. Zhang, X. Lv, Z. Lin, D. Zheng, R. An, Y. Zhang, D. Jiang, X. Lan; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

OP-021
Theranostic potential of kinin B1 receptor targeting in glioblastoma therapy
S. Ghanaatgar¹, M. Savard¹, M. Gagnon¹, D. Fortin², M. Lepage³, B. Guérin³, Y. Dory⁴, F. Gobeil¹;
¹Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, sherbrooke, QC, CANADA, ²Department of Surgery, Université ´ de Sherbrooke, Sherbrooke, Quebec, Canada, sherbrooke, QC, CANADA, ³Department of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, CANADA, sherbrooke, QC, CANADA, ⁴6Department of Chemistry, Faculté des Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada, Sherbrooke, QC, CANADA.

OP-022
In vitro and in vivo preclinical side by side comparison of ¹⁷⁷Lu-DOTA-A1K2 and ¹⁶¹Tb-DOTA-A1K2 directed against mesothelin.
E. N'Guessan¹, F. Raes¹, M. Ahmadi¹, S. Bacot¹, L. Dumas¹, J. Leenhardt^{2,1}, A. du Moulinet d'Hardemare¹, M. Debiossat¹, C. André¹, J. Durivault³, C. Montemagno³, D. Fagret¹, J. Lenormand⁴, L. Djaileb^{2,1}, U. Köster⁵, C. Ghezzi¹, P. Perret¹, C. Lombardi^{1,4}, A. Broisat¹;
¹Univ. Grenoble Alpes, INSERM U1039, LRB, Grenoble, FRANCE, ²CHU Grenoble Alpes, Department of Nuclear Medicine, LRB, Grenoble, FRANCE, ³Departement Biomédical, Centre Scientifique de Monaco, Monaco, MONACO, ⁴Univ. Grenoble Alpes, CNRS U5525, TIMC-Tree, Grenoble, FRANCE, ⁵Institut Laue-Langevin, Grenoble, FRANCE.

OP-023
Radiosynthesis and Preclinical Evaluation of ⁷⁷Br-hGTS13 for Non-Small Cell Lung Cancer Treatment
R. Malek, P. Cheung, A. Moses, S. Abdi, M. Landry, C. Beinat; Stanford University, Palo Alto, CA, UNITED STATES OF AMERICA.

OP-024
Radiosynthesis and Evaluation of Novel NTSR1 Targeting Theranostic Probes
F. Zhang, X. Liu, J. Li, S. Song; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, CHINA.

OP-025
Selective Killing of Tumor Associated Macrophages with a [¹⁷⁷Lu]Lu-Nanomedicine Unlocks Checkpoint Inhibition
J. Cleland¹, S. S. Minami², M. Paborji², W. Thomas², X. Li², H. Roth², M. Feng², A. Brus³, R. Stagaard³, S. Al-Haidar³, N. Nielsen³, M. A. Islam³;
¹Ironfist Therapeutics, Redwood City, CA, UNITED STATES OF AMERICA, ²Programmable Medicine, Redwood City, CA, UNITED STATES OF AMERICA, ³Minerva Imaging ApS, Ølstykke, DENMARK.

205

Sunday, October 5, 2025, 8:00 - 9:30
Room 211

Cutting Edge Science Track - TROP Session - AI Committee: AI for Segmentation in PET/CT

OP-026
Application of Automatic Organ Segmentation for Audit and Optimisation in FDG PET/CT
L. Bonney^{1,2}, K. M. Bradley³, A. B. Hassan², D. R. McGowan^{1,4};
¹Department of Medical Physics and Clinical Engineering, Oxford University Hospitals NHS Foundation Trust, Oxford, UNITED KINGDOM, ²Sir William Dunn School of Pathology, University of Oxford, Oxford, UNITED KINGDOM, ³Wales Research and Diagnostic Positron Emission Tomography Centre (PETIC), University Hospital of Wales, Cardiff, UNITED KINGDOM, ⁴Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM.

OP-027
A hybrid deep learning model for tumor and pulmonary nodule segmentation in non-small cell lung cancer using MedSAM.
H. Habchi¹, B. Daoud², S. Mensi^{3,4}, K. Chatti⁵;
¹Department of Biophysics and Medical Imaging, Higher Institute of Medical Technologies of Tunis, University of Tunis El Manar, Tunis, TUNISIA, ²University of Texas, MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA, ³Nuclear Medicine department, CHU Sahloul, Sousse, TUNISIA, ⁴Department of biophysics, School of medicine of Sousse, University of Sousse, Sousse, TUNISIA, ⁵School of Medicine of Monastir, University of Monastir, Monastir, TUNISIA.

OP-028
How accurately can artificial intelligence identify metabolic tumour volume (MTV) in large B-cell lymphoma on ¹⁸F-FDG PET/CT? Validation of a Deep Learning tool in a large B-cell lymphoma patient cohort
M. Santoro¹, S. Proto², A. Farolfi³, R. Ussia³, S. Fanti^{3,2}, L. Strigari¹;
¹Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ²Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ³Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-029
Evaluation of Single-Channel PET and Dual-Channel PET/CT nnU-Net Deep Learning 3D Segmentations from Diffuse Large B-Cell Lymphoma to Follicular Lymphoma

M. Luo^{1,2}, F. Yousefirizi², C. Gowdy³, J. O⁴, A. Rahmim^{1,2};
¹Faculty of Medicine, The University of British Columbia, Vancouver, BC, CANADA, ²BC Cancer Research Centre, Vancouver, BC, CANADA, ³BC Children's Hospital, Vancouver, BC, CANADA, ⁴College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF.

OP-030
Deep Learning-Driven Automated Segmentation for Mantle Cell Lymphoma in ¹⁸F-FDG PET: Towards Prognostic and Clinical Applications
Z. Zhang¹, W. Xu², C. Jiang¹, H. Huang¹, X. Zheng², Y. Teng³, Y. Liu¹, Z. Jiang⁴, J. Xu³, S. Liu², R. Tian¹;
¹West China Hospital of Sichuan University, Cheng Du, CHINA, ²School of Computer Science, Nanjing University of Posts and Telecommunications, Nanjing, CHINA, ³Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nan jing, CHINA, ⁴West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Cheng Du, CHINA.

OP-031
Deep-Learning blind-spots in PET/CT tumour segmentation: validating different deep-learning tumour segmentation models against Nuclear Medicine Physicians/Radiologists and describing their limitations.
D. Lim¹, N. Leow², C. Tang¹, W. Chua¹, W. Tham¹, Y. Khor¹, D. Ng¹, W. Lam¹;
¹Singapore General Hospital, Department of Nuclear Medicine and Molecular Imaging, Singapore, SINGAPORE, ²National University Hospital, Department of Diagnostic Imaging, Singapore, SINGAPORE.

OP-032
Deep-Learning-Based Automated Delineation of Non-Hodgkin Lymphoma in [¹⁸F]FDG PET/CT
P. Nikulin¹, S. Hoberück², F. Hofheinz¹, J. Maus¹, C. Hanoun³, A. Hüttmann³, U. Dührsen³, K. Kopka¹, J. Kotzerke², R. A. Bundschuh², A. Braune¹;
¹Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY, ²University Hospital Carl Gustav Carus, Department of Nuclear Medicine, Dresden, GERMANY, ³University Hospital Essen, Department of Hematology, Essen, GERMANY.

OP-033
Tumour Occurrence Maps: A Fully-Automated Approach for Investigating Generalizability of AI-Based Tumour Segmentation
M. Pires¹, S. Gutschmayer¹, D. Amareller², E. Bergalla³, S. Chauvie³, A. Frille^{4,5}, S. Hesse⁴, O. Sabri⁴, E. M. Abenavoli⁶, R. Sciaग्रà⁶, J. Auriac⁷, R. Seban^{7,8}, I. Buvat⁷, T. Beyer¹, L. K. S. Sundar⁹;
¹QIMP Team, Medical University of Vienna, Wien, AUSTRIA, ²Department of Radiology and Nuclear Medicine, Medical University Vienna, Wien, AUSTRIA, ³Medical Physics Division, Santa Croce e Carle Hospital, Cuneo, ITALY, ⁴Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, GERMANY, ⁵Department of Respiratory Medicine, University Hospital Leipzig, Leipzig, GERMANY, ⁶Division of Nuclear Medicine, Azienda Ospedaliero Universitaria Careggi, Florence, ITALY, ⁷Institut Curie, Université Paris-Saclay, Inserm LITO U1288, Orsay, FRANCE, ⁸Institut Curie, Department of Nuclear Medicine, Paris-St-Cloud, FRANCE, ⁹DIGIT-X Lab, Department of Radiology, LMU, Munich, GERMANY.

OP-034
Gaze-Guided Clinician-in-the-Loop AI Platform for total tumor volume segmentation in PET/CT and SPECT/CT

R. Hamidpour¹, A. Toosi^{1,2}, F. Yousefirizi¹, Y. Salimi³, H. Zaidi³, C. Uribe^{1,2}, A. Rahmim^{1,2};
¹BC Cancer Research Institute, Vancouver, BC, CANADA, ²University of British Columbia, Vancouver, BC, CANADA, ³Geneva University Hospital, Geneva, SWITZERLAND.

206

Sunday, October 5, 2025, 8:00 - 9:30
Room 117

Clinical Oncology Track - TROP Session - Oncology & Theranostics Committee: Gynaecological Cancer Stagingand Image Guidance

OP-035
Sentinel Lymph Node Biopsy in Breast Cancer: Guideline Updates and Real-World Insights

F. Silva-Ribeiro, B. Martins, C. V. Pinto, V. C. Sousa; Unidade Local de Saúde de Loures / Odivelas, Lisboa, PORTUGAL.

OP-036
Sentinel Node Scintigraphy for Breast Cancer on CZT-Based Whole-Body SPECT/CT: Description of an 18-Month Monocentric Experience and Workflow Efficiency

F. Serani¹, C. Gagliani¹, P. Zucchetta², R. Simeone², V. Bodanza², G. Grassetto², D. Cecchin¹;
¹Nuclear Medicine Unit, Department of Medicine DIMED, University-Hospital of Padova, Padova, ITALY; ²Nuclear Medicine Unit, University-Hospital of Padova, Padova, ITALY.

OP-037
Systematic evaluation of the performance of hybrid tracers in image-guided sentinel node biopsy

T. Buckle¹, M. Vreeburg², F. van Leeuwen¹, D. Rietbergen¹;
¹Leiden University Medical Center, Leiden, NETHERLANDS, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.

OP-038
Diagnostic accuracy and interrater agreement of FDG-PET/CT lymph node staging in high-risk endometrial cancer: The SENTIREC-endo study

J. Holm^{1,2}, A. H. Dias³, O. Gerke^{1,2}, A. Loft⁴, K. Bouchelouche^{3,5}, M. H. Vilstrup⁶, S. M. Bjørnholt^{2,5}, S. E. Sponholtz⁸, K. M. Jochumsen⁸, M. G. Hildebrandt^{1,2}, P. T. Jensen^{7,9};
¹Department of Nuclear Medicine, Odense University Hospital, Odense C, DENMARK, ²Department of Clinical research, University of Southern Denmark,, 5230 Odense, DENMARK, ³Department of Nuclear Medicine and PET-centre, Aarhus University Hospital, 8000 Aarhus, DENMARK, ⁴Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Copenhagen, DENMARK, ⁵Department of Clinical Medicine, Aarhus University, 8000 Aarhus, DENMARK, ⁶Department of Radiology and Nuclear Medicine, Esbjerg and Grindsted Hospitals, University of Southern Denmark, 6705 Esbjerg, DENMARK, ⁷Department of Gynecology and Obstetrics, Aarhus University Hospital,

Aarhus, DENMARK, ⁸Department of Gynecology and Obstetrics, Odense University Hospital, 5000 Odense, DENMARK, ⁹Department of Clinical Medicine, Aarhus University, 8200 Aarhus, DENMARK.

OP-039
Is Visceral Adipose Tissue Metabolism Linked to Aggressiveness in Endometrial Cancer?

J. Sæterstøl^{1,2}, J. Lavik¹, L. P. Lunde¹, C. Krakstad^{3,4}, I. S. Haldorsen^{1,2}, K. E. Fasmer¹;
¹Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, NORWAY, ²Department of Clinical Medicine, University of Bergen, Bergen, NORWAY, ³Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, NORWAY, ⁴Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, NORWAY.

OP-040
Prediction of Treatment Response Using PET-CT Radiomics Features in Patients Undergoing Radical Chemoradiotherapy with a Diagnosis of Cervical Cancer

O. Senmevsim¹, B. Kocabas¹, I. F. Ozsarikaya², S. Butuner³, B. Erol⁴, Z. Guzeloz¹;
¹Izmir City Hospital, Izmir, TÜRKIYE, ²Ministry of Health Tepecik Training and Research Hospital, Izmir, TÜRKIYE, ³Beykent University, Department of Software Engineering, Istanbul, TÜRKIYE, ⁴Beykent University, Istanbul, TÜRKIYE.

OP-041
FDG-PET/CT response assessment is predictive of survival and recurrence in locally advanced cervical cancer

M. Markus¹, H. Sartor², M. Bjurberg³, D. Minarik⁴, E. Trägårdh¹;
¹Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, SWEDEN, ²Diagnostic Radiology, Department of Translational Medicine, Lund University, Skåne University Hospital, Lund, SWEDEN, ³Department of Hematology, Oncology and radiation Physics, Skåne University Hospital, Lund, SWEDEN, ⁴Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, SWEDEN.

OP-042
Avidination for Radionuclide Therapy (ARTHE) in nonpalpable breast cancer. Phase I IRST “Dino Amadori- IRCSS’ trial”

M. Sansovini¹, P. Sanna², P. Possanzini², I. Grassi¹, P. Caroli¹, M. Amadori², I. Marini¹, S. Nicolini¹, M. Belli¹, L. Fabbri¹, E. Scarpi¹, A. Curcio², R. Cian², V. Mautone¹, V. Di Iorio¹, M. Monti¹, A. Sarnelli¹, A. Miserocchi¹, O. Nanni¹, M. Costantini², G. Paganelli³, F. Falcini², F. Matteucci¹;
¹IRST, Meldola (Fc), ITALY, ²AUSL della Romagna, Forlì, ITALY, ³IOR Istituto Oncologico Romagnolo, Forlì, ITALY.

OP-043
Combined External Beam Radiation Therapy and Peptide Receptor Radionuclide Therapy in Progressive Meningiomas: A Retrospective Analysis of Feasibility, Safety, and Prognostic Factors

N. Hasenauer¹, M. Müller¹, R. Sweeney², B. Polat³, H. Hänscheid¹, R. A. Werner⁴, M. Heinrich¹, A. K. Buck¹, P. E. Hartrampf¹;
¹Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, GERMANY, ²Department of

Radiotherapy and Radiation Oncology, Leopoldina Hospital Schweinfurt, Schweinfurt, GERMANY, ³Department of Radiation Oncology, University Hospital Wuerzburg, Wuerzburg, GERMANY, ⁴Department of Nuclear Medicine, University Hospital Ludwig-Maximilians-Universitaet Muenchen, Muenchen, GERMANY.

207

Sunday, October 5, 2025, 8:00 - 9:30
Room 212

TROP Session - Neuroimaging Committee: Movement Disorders

OP-044
Clinical value of ¹⁸F-PI-2620 Tau-PET in the diagnostic workup of patients with suspected Progressive Supranuclear Palsy

M. Brendel¹, C. Palleis¹, N. Franzmeier¹, J. Gnörich¹, A. Jäck¹, A. Bernhardt¹, S. Katzdobler¹, U. Fietzek¹, E. Weidinger¹, L. Frontzkowski¹, S. Roemer-Cassiano¹, R. Werner¹, A. Zwergal¹, H. Barthel², O. Sabri², J. Levin¹, G. Höglinger¹;
¹LMU Hospital, Munich, GERMANY, ²University of Leipzig, Leipzig, GERMANY.

OP-045
Patterns and their Correlations of PET Imagings with FDG, DAT and Tau in patients with Progressive Supranuclear Palsy

M. Liang¹, C. Jia¹, z. Huang¹, T. Zhang², Q. Li¹, T. Yen³, h. Wang⁴, R. Cui¹;
¹Department of Nuclear Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, ²Beijing Engineering Research Center of Radiographic Techniques and Equipment, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, CHINA, ³APRINOIA Therapeutics Co, Ltd, Suzhou, CHINA, ⁴Department of Neurology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.

OP-046
Association between tau-burden and eye movement disorders in progressive supranuclear palsy

M. Zaganjori¹, J. Gnörich¹, S. Katzdobler², L. Frontzkowski³, U. Fietzek², G. Nübling², J. Levin², N. Franzmeier⁴, G. Höglinger², R. Werner¹, M. Brendel¹, A. Zwergal²;
¹Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, ²Department of Neurology, University Hospital, LMU Munich, Munich, GERMANY, ³Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany, Munich, GERMANY, ⁴Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, GERMANY.

OP-047
DAT-SPECT profiling for biological definition of two prospective Parkinson's disease cohorts

S. Caminiti¹, R. Malito², C. Meneghini¹, A. Galli³, P. Mitrotti¹, M. Inglesse⁴, C. Zatti³, A. Lupini³, A. Pilotto³, A. Padovani³, M. Avenali¹, E. Valente¹, C. Tassorelli¹;
¹University of Pavia, Pavia, ITALY, ²IRCCS San Raffaele Hospital, Milan, ITALY, ³University of Brescia, Brescia, ITALY, ⁴University of Rome Tor Vergata, Rome, ITALY.

OP-048
Dopamine Loss in Putamen and Caudate Drives Distinct Motor and Cognitive Symptoms in Parkinson's Disease Progression

V. Dzialas^{1,2}, K. Gieh^{1,3}, G. N. Bischof^{1,3,4}, A. Ophey⁵, K. Möllenhoff⁶, A. Drzezga^{1,3,7}, T. van Eimeren^{1,8};
¹Nuclear Medicine, Faculty of Medicine, University Hospital and University of Cologne, Cologne, GERMANY, ²Faculty of Mathematics and Natural Sciences, University of Cologne, Cologne, GERMANY, ³Molecular Organization of the Brain, Institute for Neuroscience and Medicine II, Research Centre Juelich, Juelich, GERMANY, ⁴Life Molecular Imaging GmbH, Berlin, GERMANY, ⁵Department of Medical Psychology | Neuropsychology and Gender Studies, Center for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine, University Hospital and University of Cologne, Cologne, GERMANY, ⁶Institute of Medical Statistics and Computational Biology (IMSB), Faculty of Medicine, University of Cologne, Cologne, GERMANY, ⁷German Centre for Neurodegenerative Diseases, Bonn, GERMANY, ⁸Department of Neurology, Faculty of Medicine, University Hospital and University of Cologne, Cologne, GERMANY.

OP-049
Validation of a 360° CZT-SPECT Normal Database for [123I]-FP-CIT SPECT/CT Imaging

P. Schaefer¹, M. Doyen¹, A. El-Barkaoui², A. Flaus², L. Imbert¹, A. Verger¹;
¹Nancy University Hospital of Lorraine, Nancy, FRANCE, ²Hospices Civils de Lyon (Lyon University Hospital), Lyon, FRANCE.

OP-050
Brain Metabolic Contribution in CANVAS

S. Naranjo Sancho, C. Vigil Díaz, A. Álvarez Alonso, D. Santirso Rodríguez, G. Morís de la Tassa, J. Álvarez Carriles, M. Álvarez Martínez, A. Álvarez Amigo, J. Guzmán de la Cerda, F. González García; Central University Hospital of Asturias, Oviedo, SPAIN.

OP-051
In vivo measurement of P-glycoprotein function in the brain and gut of patients with Parkinson's disease: a preliminary [¹⁸F]JMC225 PET study

G. Salvi de Souza^{1,2}, W. Liu², J. F. Somsen², P. Mosse^{2,3}, N. A. Verwey⁴, A. L. Bartels⁵, S. K. Meles⁶, C. R. Furini^{1,7}, R. A. Dierckx², A. A. Lammertsma², C. Tsoumpas², G. Luurtsema²;
¹PUCRS, Porto Alegre, BRAZIL, ²Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, ³Department of Radiology, Leiden University Medical Center,, Leiden, NETHERLANDS, ⁴Memory clinic, Department of Neurology, Medisch Centrum Leeuwarden, Leeuwarden, NETHERLANDS, ⁵Department of Neurology, Ommelander Ziekenhuis Groep, Scheemda, NETHERLANDS, ⁶Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, ⁷Laboratory of Cognition and Memory Neurobiology, Brain Institute, PUCRS, Porto Alegre, BRAZIL.

OP-052
Study on the Value of Whole-Brain Dopamine Transporter Loss in Parkinson's Disease and Its Subtypes Based on ¹¹C-CFT PET Imaging

X. Guo¹, J. Li¹, J. Guo^{2,3,4}, S. Hu^{1,5,6};
¹Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, CHINA, ²Department of Neurology, Xiangya Hospital, Central South University,

Changsha, CHINA, ³Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, CHINA, ⁴Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, CHINA, ⁵National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, CHINA, ⁶Key Laboratory of Biological Nanotechnology, Changsha, CHINA.

208

Sunday, October 5, 2025, 8:00 - 9:30
Room 115

TROP Session - Cardiovascular Committee:
From Muscle to Calcifications, What's New in Cardiac Amyloidosis?

OP-053

Pittsburgh compound B positron emission tomography detects cardiomyopathy in hereditary transthyretin amyloidosis patients with negative bone scintigraphy

H. Tingen, G. N. Stormezand, J. H. van Snick, **Y. Hu**, P. A. van der Zwaag, P. van der Meer, B. P. C. Hazenberg, G. Luurtsema, H. L. A. Nienhuis, R. H. J. A. Slart; University Medical Center Groningen, Groningen, NETHERLANDS.

OP-054

New Quantitative SPECT-CT Parameters in the Diagnosis of Cardiac Amyloidosis

Ü. Aksu¹, E. M. Kaya¹, D. İnan², C. Yağmur¹, B. E. Akkaş¹; ¹Basaksehir Cam and Sakura City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKİYE, ²Basaksehir Cam and Sakura City Hospital, Department of Cardiology, Istanbul, TÜRKİYE.

OP-055

A Diagnostic Nomogram for ATTR Cardiac Amyloidosis: Toward Smarter Use of Scintigraphy

A. Agosti^{1,2}, G. Garelli^{1,2}, C. Dell'acqua^{1,2}, E. Califaretti¹, S. Grimaldi¹, M. Finessi¹, S. D. Morbelli^{1,2}, A. Lesca¹, R. Casoni¹, G. Rovera^{1,2}; ¹Nuclear Medicine Unit, AOU Città della Salute e della Scienza, Turin, ITALY, ²Department of Medical Sciences, University of Turin, Turin, ITALY.

OP-056

Prevalence and Clinical Outcomes of Incidental Cardiac Uptake in Bone Scintigraphies Unrelated to Cardiac Amyloidosis: The Overlooked ATTR Cohort
R. Sá e Silva, J. Escaleira, L. Costa, P. Monteiro, L. Lobato, P. Rodrigues; Centro Hospitalar Universitário do Porto, Porto, PORTUGAL.

OP-057

Implementation of a predictive model for mortality using AI in patients with TTR cardiac amyloidosis confirmed by ^{99m}Tc-DPD scintigraphy.

F. Sebastián Palacid, N. Álvarez Mena, R. C. Zambrano Infantino, M. García Aragón, B. M. Jaramillo López, Á. R. Suazo Montero, J. Gómez Hidalgo, C. Riola Parada, R. Ruano Pérez; Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

OP-058

Myocardium-to-cavity ratio as a novel quantitative index in cardiac amyloidosis: dual-isotope ^{99m}Tc-pyrophosphate/²⁰¹Tl imaging with D-SPECT

K. Nakajima¹, S. Yamashita², T. Kitano², H. Kato², H. Yamamoto², K. Yokoyama²; ¹Kanazawa University, Kanazawa, JAPAN, ²Public Central Hospital of Matto Ishikawa, Hakusan, JAPAN.

OP-059

Early-phase ^{99m}Tc-HDP planar imaging in suspected cardiac amyloidosis: predictive value of heart-to-contralateral lung ratio for late-phase Perugini scoring

G. Fiorillo¹, A. Della Morte¹, M. Coppola¹, M. Scarano¹, M. Bellino², S. Migliarino², L. Pace²; ¹Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona, Salerno, ITALY, ²Dipartimento di Medicina, Chirurgia e Odontoiatria, Università degli Studi di Salerno (UNISA), Salerno, ITALY.

OP-060

Aortic valve calcium score from computed tomography for signal localization by cardiac amyloid radionuclide imaging to predict aortic stenosis and assess prognosis in patients with transthyretin cardiomyopathy

G. Bonnans, R. Engel, E. Cariou, H. Malerbi, S. Cazalbou, Y. Lavie-Badie, E. Cassol, P. Fournier, O. Lairez; CHU Rangueil, Toulouse, FRANCE.

OP-061

Coronary Artery Calcification as a Complementary Marker in ATTRV30M Amyloidosis: Insights Across the ^{99m}Tc-DPD Uptake Spectrum

J. Rei da Cruz Escaleira^{1,2}, R. Sá e Silva³, J. Bessa⁴, A. Campos^{4,2,5}, A. Cunha⁴, J. Silva³, L. Costa³, P. Rodrigues^{6,2}, J. Santos^{4,2,5}, L. Lobato^{4,2,5}; ¹Department of Nuclear Medicine, Unidade Local de Saúde (ULS) de Santo António, Oporto, PORTUGAL, ²Unit for Multidisciplinary Research in Biomedicine (UMIB), Oporto, PORTUGAL, ³Department of Nuclear Medicine, Unidade Local de Saúde (ULS) de Santo António, Oporto, PORTUGAL, ⁴Department of Nephrology, Unidade Local de Saúde (ULS) de Santo António, Oporto, PORTUGAL, ⁵Laboratory for Integrative and Translational Research in Population Health (ITR), Oporto, PORTUGAL, ⁶Department of Cardiology, Unidade Local de Saúde (ULS) de Santo António, Oporto, PORTUGAL.

209

Sunday, October 5, 2025, 8:00 - 9:30
Room 133+134

e-Poster Presentations Session 1 - TMI&T:
Preclinical Imaging and Therapy

EPS-001

3-dimensional Microfluidic “Stacks” Platform for Advanced in vitro Radiobiology Studies

M. Lindsey¹, E. Recchia^{1,2}, A. Thickens¹, M. Bio Idrissou¹, O. Kwon¹, B. Bednarz¹, D. Kosoff^{1,2,3}, R. Hernandez¹; ¹University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA, ²University of Wisconsin Carbone

Cancer Center, Madison, WI, UNITED STATES OF AMERICA, ³William S. Middleton Memorial Veterans' Hospital, Madison, WI, UNITED STATES OF AMERICA.

EPS-002

[¹⁷⁷Lu]Lu-PSMA: impacting the full transcriptome of prostate cancer cells.

F. Amoroso^{1,2}, B. T. Cornelissen^{1,2}; ¹Dept. of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, Groningen, NETHERLANDS, ²Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM.

EPS-003

Using ¹⁸F-FES PET imaging of ERα re-expression in triple-negative breast cancer in response to anti-platelet derived growth factor C therapy

I. Burvenich¹, S. Quazi¹, N. Huynh¹, A. Rigopoulos¹, A. McDonald¹, U. Ackermann², A. Scott¹; ¹Olivia Newton-John Cancer Research Institute, Heidelberg, AUSTRALIA, ²Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, AUSTRALIA.

EPS-004

3D spheroids for analysis of targeted binding and toxicity of radionuclide-labeled affibodies

I. Zelepukin, A. Herlina, A. Vorobyeva, V. Tolmachev; Uppsala University, Uppsala, SWEDEN.

EPS-005

Visualizing cerebral plasticity mechanisms using [¹⁸F]UCB-H and [¹⁸F]FDG in animal models of acute unilateral vestibulopathy

I. Fuxjäger¹, M. Antons², R. Oos³, G. Palumbo³, S. Lindner³, S. Ziegler^{3,4}, K. Matiassek⁵, M. Brendel^{3,6,7}, R. Werner³, A. Zwergal^{1,8}; ¹German Center for Vertigo and Balance Disorders, LMU University Hospital, LMU Munich, München, GERMANY, ²Department of Radiology, LMU University Hospital, LMU Munich, München, GERMANY, ³Department of Nuclear Medicine, LMU University Hospital, LMU Munich, München, GERMANY, ⁴Clinic for Nuclear Medicine, Hannover Medical School (MHH), Hannover, GERMANY, ⁵Section of Clinical & Comparative Neuropathology, Centre for Clinical Veterinary Medicine, LMU Munich, München, GERMANY, ⁶German Center for Neurodegenerative Diseases (DZNE), München, GERMANY, ⁷Munich Cluster for Systems Neurology (SyNergy), München, GERMANY, ⁸Department of Neurology, LMU University Hospital, LMU Munich, München, GERMANY.

EPS-006

ImmunoPET imaging of c-Met using a nanobody-based tracer ⁶⁸Ga-NOTA-PFCM01 in pancreatic ductal adenocarcinoma

L. Kang, X. Sun, T. Wang, Q. Yang, L. Song, Y. Lei, W. Huang, Z. Chen, Y. Qiu; Dept. of Nuclear Medicine, Peking University First Hospital, Beijing, CHINA.

EPS-007

Cancer-associated fibroblasts as a determinant for the tumor cells' response to targeted radionuclide therapy

J. D. Campeiro, M. J. Klomp, C. D. van der Heide, J. W. K. Zhang, S. U. Dalm; Erasmus MC, Rotterdam, NETHERLANDS.

EPS-008

Preclinical evaluation of a ⁶⁸Ga/¹⁷⁷Lu theranostic targeting PARP for PARP-expressing cancers

C. Y. Chan¹, J. Shi², F. Tsoi², U. S. Khoo², E. Parkes³, K. V. Tan⁴; ¹The Institute of Cancer Research, London, UNITED KINGDOM, ²University of Hong Kong, Hong Kong, HONG KONG, ³University of Oxford, Oxford, UNITED KINGDOM, ⁴Perceptive Inc., London, UNITED KINGDOM.

EPS-009

Preclinical Evaluation of a ⁴⁷Sc-labeled Gastrin Releasing Peptide-based Radioantagonist for the Targeted Management of Breast Cancer

N. Kumar¹, A. Bilinska¹, E. Menéndez¹, T. Läppchen¹, E. S. Moon², M. Zoltowska³, D. Pawlak³, I. Cieszykowska³, R. Mikolajczak³, F. Rösch², A. Rominger¹, E. Gourni¹; ¹Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND, ²Department of Chemistry-TRIGA site, Johannes Gutenberg University of Mainz, Mainz, GERMANY, ³Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, POLAND.

EPS-010

Granzyme B-Targeted PET Imaging Enables CarNK Cell Tracking and Prognosis Prediction in Adoptive Immunotherapy

L. Zhang, X. Lan, Y. Gai, W. Cao; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EPS-011

Dual-Modality NIRF/PET Imaging of Pre-targeted Glycoengineered CAR-NK Cells for Theranostic Monitoring in Glioblastoma

W. Cao, L. Zhang; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022, Wuhan, China, Wuhan, CHINA.

EPS-012

²²⁵Ac-NM600 Efficacy in Murine Models of Metastatic and Localized Triple Negative Breast Cancer

Y. Medina Guevara, H. Comas Rojas, O. Bio Idrissou, L. Lambert, L. Wehner, M. Lindsey, A. Pinchuk, A. Carston, N. Clemons, J. Grudzinski, B. Bednarz, J. Weichert, R. Hernandez; University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

EPS-013

Preclinical evaluation of DOTAGA.PEG₂.Glu.(FAPI)₂, a FAP dimeric inhibitor, for developing theranostic radiotracers in FAP-positive malignancies

N. Kumar¹, A. Bilinska¹, E. Menéndez¹, T. Läppchen¹, M. Marcel², F. Rösch², A. Rominger¹, E. Gourni¹; ¹Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND, ²Department of Chemistry-TRIGA site, Johannes Gutenberg University of Mainz, Mainz, GERMANY.

EPS-014

Development and Evaluation of a BCMA-Targeted Bicyclic Peptide Imaging Probe for Multiple Myeloma Detection

L. Kang¹, L. Song¹, Q. Yang¹, Y. Qiu¹, Z. Chen¹, X. Sun¹, W. Huang¹, T. Wang¹, Z. Wang²; ¹Dept. of Nuclear Medicine, Peking University First Hospital,

Beijing, CHINA, ²Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, CHINA.

EPS-015

How does ionizing radiation activate photosensitizers—and how can this improve radiotherapy?

B. Xu¹, R. Eelkema², A. G. Denkova¹;
¹Department of Radiation Science and Technology, Delft University of Technology, Delft, NETHERLANDS, ²Depatment of Chemical Engineering, Delft University of Technology, Delft, NETHERLANDS.

EPS-016

Synergistic Antitumor Effects of B-OT and ¹⁷⁷Lu-PSMA-617 in PSMA-Positive Prostate Cancer via Transketolase Inhibition

Q. Wu^{1,2,3}, T. Zhao^{1,2,3}, X. Yao^{1,2,3}, R. P. Baum⁴, X. Duan^{1,2,3}, J. Zhang^{1,2,3};
¹Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, ²Theranostics Center of Excellence (TCE), Yong Loo Lin School of Medicine, National University of Singapore, 11 Biopolis Way, Helios, Singapore 138667, Singapore, SINGAPORE, ³Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore, SINGAPORE, ⁴Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY.

EPS-017

Efficacy of FAP-targeted radiopharmaceutical treatment: Comparing [¹⁷⁷Lu]Lu-FAP-2286 and [¹⁶¹Tb]Tb-FAP-2286 behavior and efficacy in vitro and in vivo

C. D. van der Heide¹, C. Ntihabose^{1,2}, H. Ma¹, M. Konijnenberg¹, Y. Seimbille¹, M. Doukas³, D. Stuurman¹, C. de Ridder⁴, E. de Blois¹, **S. U. Dalm**¹;
¹Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, ²Department of Hospital Pharmacy, Erasmus MC, Rotterdam, NETHERLANDS, ³Department of Pathology, Erasmus MC, Rotterdam, NETHERLANDS, ⁴Department of Experimental Urology, Erasmus MC, Rotterdam, NETHERLANDS.

EPS-018

Biodistribution Study of Intraperitoneally Administered Annexin A1 in Mouse Ovaria Cancer Models

L. Xu¹, S. K. Singh¹, K. R. Smith¹, C. Mallett¹, D. Agnew¹, J. Schnitzer², K. R. Zinn¹;
¹Michigan State University, East Lansing, MI, UNITED STATES OF AMERICA, ²Proteogenomics Research Institute for Systems Medicine (PRISM), La Jolle, CA, UNITED STATES OF AMERICA.

EPS-019

Design and Preclinical Evaluation of a Small-Molecule Diagnostic and Therapeutic Radionuclide Probe Targeting Tumor Extracellular Nucleotidase CD73

C. Zhao, L. Li, X. Wu;
West China Hospital, Sichuan University, Chengdu, CHINA.

EPS-020

The absorbed dose-response relationship of the Auger electrons from La-135

M. Crabbe, K. Spoormans, T. Opsomer, C. Segers, S. Rodriguez Pérez, K. Vermeulen, C. Saldarriaga Vargas, L. Struelens, M. Ooms;
Belgian Nuclear Research Centre, Mol, BELGIUM.

EPS-021

Development of a ⁶⁴Cu/⁶⁷Cu theranostic radioligand for imaging and therapy in CXCR4-expressing cancers

I. Astiazaran-Rascon¹, M. Jaraquemada-Pelaez², H. Merkens¹, N. Colpo², K. Lin², F. Benard²;
¹BC Cancer/UBC, Vancouver, BC, CANADA, ²BC Cancer, Vancouver, BC, CANADA.

210

Sunday, October 5, 2025, 08:00 - 09:30

Room 116

CTE 1 - Technologists Committee / SNMMI: Technologists' Guide Launch

OP-062a

Why is it important to talk about Women's Health?

A. Pietrzak; Greater Poland Cancer Centre/Poznan University of Medical Sciences, Poznan, POLAND.

OP-062b

Why is it important to talk about Women's Health?

L. Evangelista; Humanitas University, Department of Bioscience, Pieve Emanuele, Milan, ITALY.

OP-063

Nuclear Medicine role in Endometriosis

G. Costa; Unidade Local de Saúde de Coimbra, Serviço de Medicina Nuclear, Coimbra, PORTUGAL.

OP-064

Promising Radiopharmaceuticals

O. Ramsay; Dana Farber Cancer Institute, Nuclear Medicine, Boston, Massachusetts, UNITED STATES OF AMERICA.

OP-065

Radiation Protection Considerations for the Female Worker

V. Rowse; University Hospitals Sussex NHS Foundation Trust, Nuclear Medicine Physics, Brighton, UNITED KINGDOM.

211

Sunday, October 5, 2025, 8:00 - 9:30

Room 111

Theranostics Track - TROP Session - Oncology & Theranostics Committee: Novel Theranostic Applications

OP-066

⁶⁸Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses: A Prospective Phase II Study

X. Yan¹, G. Zheng², M. Liu¹, Y. Zhang¹, Y. Xie¹, W. Zhu¹, L. Huo¹;

¹Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, CHINA, ²Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, CHINA.

OP-067

Relationship between [¹⁸F]PSMA-1007 PET parameters and biochemical recurrence-free survival in high-risk prostate cancer patients receiving neoadjuvant hormonal treatment

N. Ahmadi Bidakhvidi¹, A. Giesen², G. Devos², A. Laenen³, M. Baldewijns⁴, M. Koole¹, C. M. Deroose¹, W. Everaerts⁵, S. Joniau², K. Goffin¹;
¹Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, ²Urology, University Hospitals Leuven; Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, Leuven, BELGIUM, ³Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven, BELGIUM, ⁴Pathology, University Hospitals Leuven, Leuven, BELGIUM, ⁵Urology, University Hospitals Leuven; Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, BELGIUM.

OP-068

Integrating PSMA PET with mpMRI Enhances Specificity and Reduces Unnecessary Biopsies in Suspected Prostate Cancer: Interim Results of the BIOPSTAGE Trial

M. Celli¹, R. Gunelli², F. Ferroni¹, M. Costantini², A. Prochowski Iamurri¹, E. Fragalà², L. Fantini¹, I. Marini¹, D. Bezzi³, V. Rossetti¹, I. Grassi¹, S. Nicolini¹, E. Giunta¹, S. Bellia¹, V. Di Iorio¹, F. Foca¹, F. Matteucci¹, P. Caroli¹;
¹IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC), ITALY, ²Morgagni Pierantoni Hospital, Romagna Local Health Service, 47100 Forlì, Italy, Forlì (FC), Italy, Forlì (FC), ITALY, ³Bufalini Hospital, Romagna Local Health Service, 47100 Cesena, Italy, Cesena (FC), Italy, Cesena (FC), ITALY.

OP-069

Comparison of PET/CT images with ⁶⁸Ga-NY104 and ¹⁸F-FDG in metastatic clear cell renal cell carcinoma

W. Zhu¹, X. Li², G. Zheng³, C. Bai², Y. Zhang³, L. Huo¹;
¹Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, ²Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, ³Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.

OP-070

Influence of the injected peptide mass on imaging of prostate cancer: Phase I clinical study with the GRPR-antagonist [^{99m}Tc]Tc-DB8

A. Orlova¹, V. Chernov², T. Maina³, B. A. Nock³, P. Kanellopoulos¹, M. Larkina², L. Tashireva², A. Rybina², R. Varvashenya², R. Zelchan², O. Bragina², A. Medvedeva², V. Tolmachev¹;
¹Uppsala University, Uppsala, SWEDEN, ²Cancer Research Institute, Tomsk, RUSSIAN FEDERATION, ³NCSR "Demokritos", Athens, GREECE.

OP-071

Deep Learning for Automated Whole-Body Tumor Quantification and Prognostic Stratification of Prostate Cancer on ⁶⁸Ga-PSMA-11 PET/CT

P. Yang¹, Q. Pan², L. Jiang¹, Z. Zhao¹, L. Li¹, Q. Guo³, H. Cai¹;
¹West China Hospital of Sichuan University, ChengDu, CHINA, ²Machine Intelligence Laboratory, College of Computer Science, Sichuan University, ChengDu, CHINA, ³School of Artificial Intelligence, Guangxi Minzu University, Nanning, CHINA.

OP-072

Comparative diagnostic utility and quantification of PSMA-avid lesions on 99mTc-HYNIC-PSMA-11 SPECT/CT with 68Ga-PSMA PET/CT in metastatic prostate cancer patients.

M. Hooda¹, B. Singh¹, R. Mavuduru², H. Singh³, A. P. Sharma²;
¹Department of Nuclear Medicine, Post-graduate institute of medical education and research (PGIMER), Chandigarh, INDIA, ²Department of Urology, Post-graduate institute of medical education and research, (PGIMER), Chandigarh, INDIA, ³Department of Nuclear Medicine, Post-graduate institute of medical education and research, (PGIMER), Chandigarh, INDIA.

OP-073

Radionuclide Therapy with FAP-2286 in FAP expressing Relapsed / Refractory Malignancies - Proof of Concept and Up-to-date Single Centre Experience

S. Dash, V. Malasani, R. Vatsa, A. Raj, V. Hari, D. Pendharkar; Sarvodaya Hospital, Faridabad, INDIA.

OP-074

A FAP-Directed Theranostic Approach Using [²⁰³Pb]/[¹²¹Pb]Pb-PSV359: Design of a First-in-Human Phase I/IIa Clinical Trial

S. Mehr¹, R. Patel², G. Blitzer³, Y. Lu⁴, V. Sukrithan⁵, A. Chauhan⁶, C. Mari Aparici⁷, M. Puhlmann⁸, S. Keefe⁸, L. Baratto⁸, E. van Dam⁷, D. Kurup⁷, H. Tomash⁸, W. Yang⁸, J. Calais⁹;
¹Nebraska Cancer Specialists, Omaha, NE, UNITED STATES OF AMERICA, ²UPMC, Pittsburgh, PA, UNITED STATES OF AMERICA, ³U of Wisconsin, Madison, WI, UNITED STATES OF AMERICA, ⁴MD Anderson, Houston, TX, UNITED STATES OF AMERICA, ⁵Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, ⁶Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, UNITED STATES OF AMERICA, ⁷Stanford University, Standford, CA, UNITED STATES OF AMERICA, ⁸Perspective Therapeutics, Seattle, WA, UNITED STATES OF AMERICA, ⁹UCLA, Los Angeles, CA, UNITED STATES OF AMERICA.

301

Sunday, October 5, 2025, 09:45 - 11:15

Auditorium

CME 2 - Neuroimaging Committee: Paradigm Shift for the Diagnosis of Parkinson's Disease

OP-075

FDG PET: not a physiopathological biomarker but ...

C. Boccalini; Hôpitaux Universitaires de Genève & University of Geneva, Neuroimaging and Innovative Molecular Tracers Lab, Geneva, SWITZERLAND.

OP-076
Dopaminergic imaging: a good old friend
M. Pardin; *University of Genova, Dipartimento di neuroscienze, riabilitazione, oftalmologia, genetica e scienze materno-infantili - DINOGMI, Genova, ITALY.*

OP-077
MIBG: when, why ?
V. Camacho; *NuclearMedicine Department Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, SPAIN.*

OP-078
New tracers under development
M. Brendel; *LMU München, Dept. of Nuclear Medicine, Munich, GERMANY.*

302
Sunday, October 5, 2025, 09:45 - 11:15
Room 112 (Arena)

Special Track 2 - Oncology & Theranostics Committee: Debate: A Brave New World: Are All PSMA Radiopharmaceuticals Equal?

OP-079
Point of View: PSMA diagnostics: all equal
D. Oprea-Lager; *Radboud UMC, Department of Medical Imaging, Nijmegen, NETHERLANDS.*

OP-080
Point of View: PSMA diagnostics: there are differences
I. Burger; *Kantonsspital Baden, Nuklearmedizin, Baden, SWITZERLAND.*

OP-081a
Point of View: PSMA therapeutics: all equal
S. Fanti; *University of Bologna, Department of Medical and Surgical Sciences, Bologna, ITALY.*

OP-081b
Point of View: PSMA therapeutics: there are differences
M. Eiber; *Klinikum rechts der Isar der Technischen Universität, Nuklearmedizin, Munich, GERMANY.*

303
Sunday, October 5, 2025, 09:45 - 11:15
Room 113

LIPS Session 2 - Bone & Joint Committee: LIPS Session 2 - Bone & Joint Committee: Bone Palliation Therapies

OP-082
Bone palliation therapies - bone seeking agent radionuclide therapy
K. Liepe; *Klinikum Frankfurt (Oder), Frankfurt, GERMANY.*

OP-083
Radiosynoviorthesis
G. Santo; *Magna Graecia University, Catanzaro, ITALY.*

OP-084
Dosimetry
P. M. Gabiña; *Unidad de Radiofísica y Protección radiológica. Gurutzeta/Cruces University Hospital, Barakaldo, SPAIN.*

304
Sunday, October 5, 2025, 9:45 - 11:15
Room 114

M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Tracking/Modulating

OP-086
Hydrophobic F-base engineering augments aptamer pharmacokinetics for precision oncology: A PET imaging study

S. Yang¹, Q. Chen¹, D. Ding², X. Lan¹, D. Jiang¹;
¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²Institute of Molecular Medicine (IMM), Renji Hospital, State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, and College of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai, CHINA.

OP-087
Linker Modifications in Radiolabeled Rm26-based Antagonists to Gastrin-releasing Peptide Receptor (GRPR) Improved Pharmacokinetics

E. Bezverkhniaia, A. Abouzayed, P. Kanellopoulos, V. Tolmachev, U. Rosenström, A. Orlova;
Uppsala university, Uppsala, SWEDEN.

OP-088
[¹⁸F]F-FPy prosthetic group lowers kidney accumulation while retaining tumor uptake in a Glypican-3 targeted nanobody

S. Fayn^{1,2}, F. Basuli¹, H. Makala¹, W. Lee¹, M. Ho¹, R. E. Swenson¹, P. L. Choyke¹, O. Jacobson¹, F. E. Escorcia¹;
¹National Institutes of Health, Bethesda, MD, UNITED STATES OF AMERICA, ²University of Oxford, Oxford, UNITED KINGDOM.

OP-089
Selection of the optimal format of albumin-binding domain-fused CAECAM5-specific affibody for targeted delivery of cytotoxic payload to malignant tumours

V. Tolmachev¹, E. Papalanis¹, R. Li², M. Oroujeni¹, A. J. Herlina¹, Y. Liu¹, A. Orlova³, E. Bezverkhniaia³, P. Nygren², T. Gräslund²;
¹Department of Immunology, Genetics and Pathology (IGP), Uppsala University, Uppsala, SWEDEN, ²KTH-Royal Institute of Technology, Stockholm, SWEDEN, ³Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN.

OP-090
Oligonucleotide modification minimizes renal uptake of nanobodies

S. Yang¹, X. Long¹, W. Wei², X. Lan¹, D. Jiang¹;
¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and

Technology, Wuhan, CHINA, ²Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA.

OP-091
Assessing the generalizability of a preclinical PBPK model for DOTA-TATE-based radiopharmaceuticals: application to ¹⁶¹Tb, ¹⁷⁷Lu, ¹⁵³Sm and ⁶⁸Ga

J. Henriot¹, L. Struelens², M. Andersson³, S. Rodriguez Pérez², M. Koole⁴, C. Saldarriaga Vargas²;
¹SCK CEN & KU Leuven, Mol, BELGIUM, ²SCK CEN, Mol, BELGIUM, ³SCK CEN & ULB, Mol, BELGIUM, ⁴KU Leuven, Leuven, BELGIUM.

OP-092
Association of different forms of non-conjugated astatine-211 to albumin

E. Aneheim^{1,2}, S. Lindegren¹, H. J. Jensen³, T. Bäck¹;
¹University of Gothenburg, Göteborg, SWEDEN, ²Sahlgrenska University Hospital, Göteborg, SWEDEN, ³Copenhagen University Hospital, Copenhagen, DENMARK.

OP-093
Kinetic modelling of [⁸⁹Zr]Zr-DFO-anti-VEGF PET at different stages of glioblastoma progression

E. Ramos-Docampo^{1,2}, M. Muñoz-González¹, J. Codesido¹, X. García-Otero¹, C. Domínguez-Borrero¹, S. Groba-de Antas¹, N. Gómez-Lado¹, P. Aguiar^{1,2}, L. García-Varela^{1,2};
¹Molecular Imaging and Pharmacokinetic Modelling Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, SPAIN, ²Nuclear Medicine and Molecular Imaging Group, Health Research Institute of Santiago de Compostela (IDIS), University Hospital Santiago de Compostela, Santiago de Compostela, SPAIN.

OP-094
Pharmacokinetics, Tumour and Normal Tissue Uptake, SPECT/CT and Cerenkov Imaging of Radiolabeled Hybrid Gold-Lipid Nanoparticles vs. Gold Nanoparticles in a Human Breast Cancer Xenograft Mouse Model

Z. Cai¹, A. Momeni², M. K. Brown¹, L. Messier², M. H. Y. Cheng², C. A. Brimacombe³, P. R. Cullis², R. M. Reilly¹;
¹University of Toronto, Toronto, ON, CANADA, ²University of British Columbia, Vancouver, BC, CANADA, ³Polymorphic BioSciences, Vancouver, BC, CANADA.

305
Sunday, October 5, 2025, 9:45 - 11:15
Room 211

Cutting Edge Science Track - TROP Session - Physics Committee: SPECT Quantification in Therapeutic Applications

OP-095
Evaluation of observer accuracy among eight observers in measuring kidney phantom activity concentration of ¹⁷⁷Lu using two measurement methods

E. Ilan^{1,2}, C. Widström¹, T. Sjöholm^{1,2}, A. Moreno Moreno^{1,2}, S. Kvernby³, C. Held¹, S. Jacobsson Svärd¹, M. Sandström^{1,2};

¹Medical Physics, Uppsala University, SWEDEN, ²Nuclear medicine & PET, Uppsala University, SWEDEN, ³Medical Physics, Lund University, SWEDEN.

OP-096
Towards harmonised quantitative SPECT imaging: experiences from the EARL ¹⁷⁷Lu SPECT/CT Accreditation pilot study

L. Vávrová¹, W. Claeys², A. Denis-Bacelar³, I. Hristova⁴, M. Lassmann¹, M. Koole², J. Dickson⁵, J. Tran-Gia¹;
¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²KU Leuven, Leuven, BELGIUM, ³National Physical Laboratory, Teddington, UNITED KINGDOM, ⁴EANM Forschungs GmbH, Vienna, AUSTRIA, ⁵Institute of Nuclear Medicine, University College London Hospitals, London, UNITED KINGDOM.

OP-097
Multicenter Comparison of SPECT/CT Protocols for Quantitative ¹⁷⁷Lu Imaging

W. Claeys¹, K. Baete², L. Beels³, C. Bernard⁴, R. Danielli⁵, Y. D'Asseler⁶, A. De Crop⁷, M. Hesse⁸, V. Nuttens⁹, B. Vanderlinden⁵, M. Koole¹;
¹KU Leuven, Leuven, BELGIUM, ²UZ Leuven, Leuven, BELGIUM, ³AZ Groeninge, Kortrijk, BELGIUM, ⁴C.H.U. Liège, Liège, BELGIUM, ⁵Institut Jules Bordet, Brussels, BELGIUM, ⁶UZ Gent, Gent, BELGIUM, ⁷AZ Delta, Roeselare, BELGIUM, ⁸Cliniques Universitaires Saint-Luc, Brussels, BELGIUM, ⁹OLVZ Aalst, Aalst, BELGIUM.

OP-098
Dual-Peak Image Reconstruction for ¹⁷⁷Lu SPECT with CZT Gamma-Camera: Phantom-Based Optimization of Acquisition Time for ¹⁷⁷Lu-DOTATATE and ¹⁷⁷Lu-PSMA617 Protocols
Y. Cras, H. Noamen, A. Benhamla, G. Rovera, P. Lacassagne, L. Ferreol, D. Deandreis;
Gustave Roussy, Villejuif, FRANCE.

OP-099
Evaluation of modified window-based scatter correction in quantitative ¹⁷⁷Lu-SPECT for a ring-configured CZT SPECT

I. Ceric Andelius^{1,2}, A. Stenvall¹, E. Nilsson¹, E. Larsson¹, J. Gustafsson³;
¹Radiation Physics, Department of Haematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, SWEDEN, ²Department of Translational Medicine and Wallenberg Centre of Molecular Medicine, Lund University, Malmö, SWEDEN, ³Medical Radiation Physics, Lund, Lund University, Lund, SWEDEN.

OP-100
Recovery coefficients in Lu-177-SPECT-CT are reduced as a function of activity concentration

V. Reijonen¹, S. E. A. Kokkonen², M. Tenhunen¹;
¹Helsinki University Hospital, Helsinki, FINLAND, ²University of Helsinki, Helsinki, FINLAND.

OP-101
Assessment of an ultra-fast dual-energy whole-body 360° ¹⁷⁷Lu-CZT-SPECT recording developed for the monitoring of ¹⁷⁷Lu-PSMA therapy
C. Boursier, T. Zaragori, A. Zouaoui, A. Verger, P. Marie, L. Imbert;
CHRU Nancy, Vandoeuvre-les-Nancy, FRANCE.

OP-102
Optimal SPECT Acquisition Settings for Quantitative Ac-225 Dosimetry

L. Polson¹, S. Kurkowska², C. Li¹, P. Esquinas³, C. Uribe¹, A. Rahmim¹;
¹University of British Columbia, Vancouver, BC, CANADA, ²Pomeranian Medical University, Szczecin, POLAND, ³BC Cancer, Vancouver, BC, CANADA.

OP-103
Comparative Ac225 performance evaluation for a dual-collimator 3D CZT Camera

R. Zananiri, A. Devir-Wolfman, L. Tsukerman, J. Bouhnik; GE HeathCare, Haifa, ISRAEL.

306

Sunday, October 5, 2025, 9:45 - 11:15
Room 117

Clinical Oncology Track - TROP Session - Oncology & Theranostics Committee: Breast Cancer Imaging

OP-104
Pre-treatment [¹⁸F]FDG PET/CT and Histopathological Biomarkers in Early Triple-Negative Breast Cancer: Correlation with pCR and Prognostic Value in the SCANDARE Trial

R. Seban¹, I. Buvat², L. Cabel³, L. Djerroudi⁴, L. Champion¹, N. Jehanno⁵, T. Gaillard⁶, L. Darrigues⁶, E. Laas⁶, J. Feron⁶, V. Fourchotte⁶, N. Pouget⁷, C. Bonneau⁷, C. Le Tourneau⁸, M. Sablin⁸, C. Lamy⁸;
¹Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, Saint-Cloud, FRANCE, ²Laboratory of Translational Imaging in Oncology, Paris Sciences et Lettres University (PSL) Research, Institut Curie, Orsay, FRANCE, ³Department of Medical Oncology, Institut Curie, Paris, FRANCE, ⁴Department of Pathology, Institut Curie, Paris-Sciences-Lettres Research University, Paris, FRANCE, ⁵Department of Nuclear Medicine, Institut Curie, Paris, FRANCE, ⁶Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Paris, FRANCE, ⁷Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Saint-Cloud, FRANCE, ⁸Department of Drug Development and Innovation (D3i), Paris-Saclay University, Institut Curie, Paris, FRANCE.

OP-105
The impact of [¹⁸F]FDG PET/CT in guiding the change of management of triple-negative breast cancer patients: a sub-analysis of the TRINE-PET trial

L. Urso¹, S. Panareo², A. Iudicello^{2,3}, D. Albano⁴, M. L. Calcagni⁵, A. Mazzeletti⁶, R. Sciuto⁷, L. Fantini⁸, G. Rovera⁹, L. Sofia¹⁰, P. Guglielmo¹¹, S. Sorbello¹², M. Bambaci¹³, S. Ialuna¹⁴, A. Miceli¹⁵, E. Rizza¹⁶, C. Ferrari¹⁷, A. Marongiu¹⁸, F. Garrou¹⁹, D. Bertin²⁰, A. Arnone²¹, C. Colombo²², A. M. Maffione²³, D. Donner²⁴, L. Evangelista²⁵;
¹University of Ferrara, Ferrara, ITALY, ²University-Hospital of Modena, Modena, ITALY, ³University-Hospital of Ferrara, Ferrara, ITALY, ⁴University of Brescia, Brescia, ITALY, ⁵Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Rome, ITALY, ⁶Fondazione Poliambulanza Istituto Ospedaliero, Brescia, ITALY, ⁷IRCCS Istituto Nazionale Tumori Regina Elena, Rome, ITALY, ⁸IRCCS IRST "Dino Amadori, Meldola, Meldola, ITALY, ⁹University of Turin, Turin, ITALY, ¹⁰University of Genoa, Genoa, ITALY, ¹¹Humanitas Gavazzeni, Bergamo,

ITALY, ¹²Ospedale GPII, Ragusa, ITALY, ¹³Humanitas Istituto Clinico Catanese, Catania, ITALY, ¹⁴Osp. Riuniti Villa Sofia Cervello, Palermo, ITALY, ¹⁵AOU SS. Antonio e Biagio.e c. Arrigo, Alessandria, ITALY, ¹⁶Vito Fazzi Hospital, Lecce, ITALY, ¹⁷University Aldo Moro, Bari, ITALY, ¹⁸University of Sassari, Sassari, ITALY, ¹⁹A.O.U. Maggiore della Carità, Novara, ITALY, ²⁰IOV, Padua, ITALY, ²¹Arcispedale S. Maria Nuova, Reggio Emilia, ITALY, ²²Fondazione IRCCS Ca' Granda, Milan, ITALY, ²³Santa Maria della Misericordia Hospital, Rovigo, ITALY, ²⁴Santa Chiara Hospital, Trento, ITALY, ²⁵Department of Biomedicine, Humanitas University, Pieve Emanuele, Milan, ITALY.

OP-106
The PET/CT Response Monitoring in Oncology (PREMIO) criteria: A first suggestion to adapt the PERCIST criteria for patient-centric response monitoring of solid tumors in PET/CT scans

S. Hein¹, N. M. Jakobsen², M. Naghavi-Behzad², W. A. Weber¹, W. Vach³, M. Grubbe Hildebrandt^{2,4}, M. Vogsen^{5,4};
¹Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY, ²Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, ³Basel Academy for Quality and Research in Medicine, Basel, SWITZERLAND, ⁴Department of Clinical Research, University of Southern Denmark, Odense, DENMARK, ⁵Department of Oncology, Odense University Hospital, Odense, DENMARK.

OP-107
HER2-Targeted⁶⁸Ga-ABS011 positron emitted tomography (PET) in Metastatic Breast Cancer: Intermediate analysis of the HERMIA study.

G. Gebhart¹, R. Lhomme², H. Everaert³, O. De Winter⁴, M. Lonnew⁵, K. Goffin⁶, D. Frijns⁷, E. De Azambuja¹;
¹Hôpital Universitaire de Bruxelles (HUB)-Institut Jules Bordet, Brussels, BELGIUM, ²Cliniques Universitaires Saint-Luc, Brussels, BELGIUM, ³Universitair Ziekenhuis Brussel, Brussels, BELGIUM, ⁴Onze Lieve Vrouw Ziekenhuis, Aalst, BELGIUM, ⁵CHIREC AZ Delta, Brussels, BELGIUM, ⁶Universitair Ziekenhuis Gasthuisberg, Leuven, BELGIUM, ⁷ABSCINT NV/SA, Liège, BELGIUM.

OP-108
AI¹⁸F-HER2-BCHImaging as a Non-invasive Approach to Assess Whole-Body HER2 StatusinHER2-Negative, -Low, and -PositiveBreast Cancer

X. Guo¹, N. Zhou¹, J. Liu¹, H. Zhu², Z. Yang¹;
¹Beijing Cancer Hospital, Beijing, CHINA, ²Beijing Cancer Hospital, Beijing, CHINA.

OP-109
Diagnostic Accuracy of 99mTc-FAPI-46 SPECT/CT in Differentiating Malignant and Benign Breast Masses Classified as BIRADS IV and V: A Prospective Clinical Study

S. Barashki, K. Aryana, N. Raeisi, R. Sabzi, A. J. Noughabi, H. Soleimani Bami, M. Emadzadeh;
Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-110
The Contribution of Ga-68 FAPI PET/CT in Newly Diagnosed Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

M. Oflas¹, D. Has Simsek¹, R. Yilmaz², N. Cabioglu³, S. Onder⁴, E. Isik¹, Z. Ozkan¹, A. Aydiner⁵, Y. Sanli¹, S. Kuyumcu¹;
¹Istanbul Faculty Of Medicine Department Of Nuclear Medicine, Istanbul, TÜRKIYE, ²istanbul Faculty Of Medicine Department Of Radiology, Istanbul, TÜRKIYE, ³istanbul Faculty Of Medicine Department Of General

Surgery, Istanbul, TÜRKIYE, ⁴Istanbul Faculty Of Medicine Department Of Pathology, Istanbul, TÜRKIYE, ⁵Istanbul University Institute Of Oncology, Department Of Clinical Oncology, Istanbul, TÜRKIYE.

OP-111
Prostate-specific membrane antigen expression in patients with metastatic triple negative breast cancer: Final results of the PRISMA study

M. Manley¹, G. Nader Marta², A. Arcay Ozturk¹, M. Kassas¹, L. Taraji¹, P. Aftimos¹, Z. Wimana¹, P. Flamen¹, G. Gebhart¹;
¹Institute Jules Bordet, Anderlecht, BELGIUM, ²Dana-Farber Cancer Institute, Boston, MA, UNITED STATES OF AMERICA.

OP-112
Integrin $\alpha\beta_6$ -Targeted ⁶⁸Ga-Trivehexin PET/CT in Breast Cancer: A Prospective Comparison with ¹⁸F-FDG

Z. Liu¹, L. Li¹, H. Wu¹, Q. Chen², C. Li¹, Y. He¹;
¹Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA, ²Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, CHINA.

307

Sunday, October 5, 2025, 9:45 - 11:15
Room 212

TROP Session - Thyroid Committee: Nuclear Medicine Imaging in Thyroid Disorders: From Thyroid Nodule to Advanced/Refractory Cancer

OP-113
A non-invasive approach integrating PET/CT radiomics and ultrasound to improve risk stratification of thyroid incidentalomas detected on FDG PET/CT.

M. Roncali, G. Ferrulli, R. Durmo, A. Frasoldati, A. Ghidini, S. Piana, M. Bertolini, L. Braglia, A. Filice;
AUSL-IRCCS di Reggio Emilia, Reggio Emilia, ITALY.

OP-114
Diagnostic ¹³¹I whole-body scans in the Detection of Differentiated Thyroid Cancer: Comparison with different doses

T. Ming, f. Kang, w. Ma, j. Wang;
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

OP-115
[18F]AIF-NOTA-FAPI-04 PET/CT improves detection of subcentimeter recurrent lesions in differentiated thyroid cancer: acomparative study with [18F]FDG

K. Zheng, H. Ye;
Hunan Cancer Hospital, Changsha, CHINA.

OP-116
Diagnostic value of [18F]-FDG and [68Ga]-FAPI-04 PET/MRI for lymph node metastasis in papillary thyroid cancer

T. Han¹, Z. Quan¹, H. Wei², J. Wang¹, F. Kang¹;
¹Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA, ²Department of Thyroid and Breast Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

OP-117
Trop2-Targeted PET/CT with ⁶⁸Ga-MY6349 for Detecting Metastatic Lesions in Recurrent/ Metastatic Thyroid Cancer: Prospective Comparison of Diagnostic Efficacy with ¹⁸F-FDG PET/CT

H. Fu¹, J. Huang¹, W. Guo¹, H. Wu¹, F. Wang², H. Chen¹;
¹The First Affiliated Hospital of Xiamen University, Xiamen, CHINA, ²Peking University, Beijing, CHINA.

OP-118
Diagnostic Utility of ⁶⁸Ga-PSMA PET/CT in Differentiated Thyroid Cancer Patients with Biochemical Recurrence and Negative Conventional Imaging.

C. Sgro¹, E. Greco¹, G. Fuso¹, G. Bianciardi¹, L. Carrara¹, G. Cuzzani¹, E. Fortunati², L. Zanon², R. Mei², L. Vetrone², A. Golemi², E. Lodi Rizzini³, L. Calderoni², E. Tabacchi², S. Fanti^{1,2};
¹Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Radiation Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-119
Diagnostic accuracy of ¹⁸F-FDG PET/CT compare to 18F-PSMA PET/CT in Radioiodine-Refractory Differentiated Thyroid Carcinoma Patients

A. J. S. Portilho, M. O. Cerci, S. Kuba, N. T. T. P. Silva, R. N. Tineo, C. A. de Souza, D. E. Zantut-Wittmann, C. D. Ramos;
University of Campinas (UNICAMP), Campinas, BRAZIL.

OP-120
Unlocking the Potential of Liquid Biopsy in Advanced Differentiated Thyroid Cancer (DTC): Could [¹⁸F]FDG PET/CT Increase the Rate of Informative Liquid Biopsies?

G. Rovera¹, C. Moneta², S. Moog², M. Bani³, J. Hadoux², A. Ghuzlan³, D. Hart⁴, I. Breuskin⁵, L. Lacroix⁶, Y. Lorient⁷, A. Italiano⁸, B. Besse⁹, E. Baudin², L. Lamartina², D. Deandreis¹;
¹Nuclear Medicine Department, Gustave Roussy, University Paris Saclay, Villejuif, FRANCE, ²Department of Imaging, Endocrine Oncology Unit, Gustave Roussy, University Paris Saclay, Villejuif, FRANCE, ³Department of Pathology, Gustave Roussy, Villejuif, FRANCE, ⁴Department of Otolaryngology Head and Neck Surgery, Gustave Roussy, University Paris Saclay, Villejuif, FRANCE, ⁵Department of Head and Neck Oncology, Gustave Roussy, Villejuif, FRANCE, ⁶Department of Biopathology, Gustave Roussy, Villejuif, FRANCE, ⁷Early Drug Development Department, Gustave Roussy, Villejuif, FRANCE, ⁸DITEP, Gustave Roussy, Villejuif, FRANCE, ⁹Department of Cancer Medicine, Gustave Roussy, Villejuif, FRANCE.

OP-121
Intraoperative PET/CT imaging for thyroid cancer, parathyroid adenoma and oncological work-up of cervical lymph nodes with a high resolution mobile PET/CT-camera for surgical specimens

B. Lambert¹, V. Vergucht², D. Berwouts¹, B. Van Den Bossche¹, J. Mertens¹, C. Van Haverbeke², M. Coppens², C. Gabriel³, M. Rottiers², A. Decock², V. Galle², T. Van Oostveldt², K. Decaestecker²;
¹Maria Middelaers Hospital - Jan Palfijn Hospital, Gent, Gent, BELGIUM, ²Maria Middelaers Hospital, Gent, BELGIUM, ³Maria Middelaers Hospital, Gent, BELGIUM.

308

Sunday, October 5, 2025, 09:45 - 11:15

Room 115

Joint Symposium 1 - Paediatrics Committee / SIOPE: Imaging Biomarkers in Paediatric Oncology 'Whats Next?'

OP-122

The clinical Role of Imaging Biomarkers in Paediatric Oncology

H. Deubzer; Charité – Universitätsmedizin Berlin, Berlin, GERMANY.

OP-123

Imaging Biomarkers in Paediatric Oncology - Radiology

A. Littooi; UMC Utrecht, Utrecht, NETHERLANDS.

OP-124

Imaging Viomarkers in Paediatric Oncology – Nuclear Medicine

J. Rogasch; Charité-Universitätsmedizin Berlin, Berlin, GERMANY.

309

Sunday, October 5, 2025, 9:45 - 11:15

Room 133+134

e-Poster Presentations Session 2 - Inflammation & Infection Committee: Best e-posters in Inflammation & Infection

EPS-022

Utility of [18F]FDG-PET/CT in the Detection of Infection in Patients with Aortic Prostheses

B. Hervás-Sanz¹, L. M. Gràcia-Sánchez¹, F. Escrinhuela-Vidal^{2,3}, I. E. Sánchez-Rodríguez¹, P. C. Notta¹, J. L. Díaz-Moreno¹, C. García-Alcober⁴, A. Blasco-Lucas⁵, D. Toral-Sepúlveda⁵, F. Sbraga⁵, M. Potocnik⁵, O. Alegre-Canals⁶, M. P. Mañas-Jiménez⁶, J. Sánchez-Vega⁶, I. C. Grau-Garriga², D. Berbel-Palau⁷, M. Cortés-Romera¹;

¹Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Infectious Diseases Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ³Centro de Investigación Biomédica en Red - Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, SPAIN, ⁴Radiopharmay Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ⁵Cardiovascular Surgery Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ⁶Cardiology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ⁷Microbiology and parasitology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EPS-023

Is ¹⁸F-FDG PET/CT useful in suspected Cardiac Implantable Electronic Device infection?

R. Dobson, D. Bartholomeusz, S. Jo, M. Bills; Royal Adelaide Hospital, SA Medical Imaging, South Australia, AUSTRALIA.

EPS-024

Diagnostic value of [¹⁸F]FDG PET/CT imaging in LVAD infection

G. Metzger¹, C. Hosse², I. Schobert², I. Just-Lauer³, J. Mulzer⁴, J. Kolck², W. Lüdemann², E. Sodemann², T. Wallter-Rittelp², E. Potapov⁴, C. Furth¹, G. Böning²;

¹Charité Universitätsmedizin Berlin - Klinik für Nuklearmedizin, Berlin, GERMANY, ²Charité Universitätsmedizin Berlin - Klinik für Radiologie, Berlin, GERMANY, ³Charité Universitätsmedizin Berlin - Klinik für Herz-, Thorax- und Gefäßchirurgie, Berlin, GERMANY, ⁴Charité Universitätsmedizin Berlin - Klinik für Herz-, Thorax- und Gefäßchirurgie, Berlin, GERMANY.

EPS-025

Feasibility of Shortened Total-body ¹⁸F-FDG PET/CT Dynamic Acquisition for Parametric Imaging in the Quantitative Evaluation of Takayasu's Arteritis

L. Gao¹, Y. Ng², Y. Duan¹, Z. Cheng¹;

¹The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, CHINA, ²United Imaging Healthcare Group Co., Ltd. Shanghai 201807, China, Shanghai, CHINA.

EPS-026

Impact of [¹⁸F]FDG PET/CT on therapeutic intent in patients with large vessel vasculitis treated with tocilizumab

N. Canchumanya Huatuco, A. Caresia Aroztegui, J. Font-Urgelles, V. Vallejos Arroyo, M. Boronat de Ferrater, S. Lafuente Carrasco, M. Salcedo Pujantell, J. Deportós Moreno, M. Solà Suárez, I. Casafont-Solé, A. Riveros Frutos, R. Ugena-García, G. Moragas Freixa; Hospital Universitario Hermanos Trias I Pujol, Badalona, SPAIN.

EPS-027

Diagnostic value of 18F-FDG-PET/CT in detecting vascular graft infection and the role of a complementary labelled leucocyte scan

S. Georga¹, D. Katsampoukas¹, A. Morfes¹, N. Vavlas¹, A. Georgiou¹, D. Karamanos², V. Mpalaris¹, K. Lazaridis¹, E. Moralidis¹, G. Arsos¹;

¹Department of Nuclear Medicine, Aristotle University Medical School, Papageorgiou General Hospital, Thessaloniki, GREECE, ²Department of Surgery, Aristotle University Medical School, Papageorgiou General Hospital, Thessaloniki, GREECE.

EPS-028

The post-therapy follow-up of [F¹⁸]FDG PET in vasculitis

R. Park, J. McCormick, S. Olson, R. Staff; NHS Grampian, Aberdeen, UNITED KINGDOM.

EPS-029

Tailored Management of Non-Typhoid Salmonella Bacteremia: Insights from 2-[¹⁸F]FDG PET/CT Imaging

P. Chuang¹, C. Huang², T. Hong¹, M. Chiang³, C. Hung², C. Lu¹;

¹National Taiwan University Cancer Center, Taipei, TAIWAN, ²National Taiwan University Hospital, Taipei, TAIWAN, ³Taipei Medical University Hospital, Taipei, TAIWAN.

EPS-030

Preliminary diagnostic evaluation of CROhn's disease with DYnamic total-body pOSitron emission tomography/computed tomography (CRODYN0) - A single-center prospective study

A. Farolfi¹, G. Calini^{2,3}, I. Brusa¹, D. Dall'Olio³, C. Nanni¹, L. Romagnoli¹, V. Lucidi⁴, B. Spencer⁵, G. Wang⁵, L. Nardo⁵, S. Fanti¹, A. Di Giorgio⁶;

¹Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ²Surgery of Alimentary Tract, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, ITALY, ⁴Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ITALY, ⁵Department of Radiology, University of California Davis Health, Sacramento, CA, UNITED STATES OF AMERICA, ⁶Nuclear Medicine, Alma Mater Studiorum - University of Bologna, Bologna, Italy, Bologna, ITALY.

EPS-031

Clinical impact of [¹⁸F]FDG PET/CT in the assessment of incidental findings related to aesthetic procedures: implications for complication detection and oncological management.

M. Pudis¹, P. Notta¹, C. S. Salomón-Duhalde², C. Cases-Pellise³, L. Rodríguez-Bel¹, L. M. Gracia-Sánchez¹, V. A. Carrero-Vasquez¹, J. J. Robles-Barba¹, A. I. Fritsch-Medina¹, P. Perlaza-Jiménez¹, A. Tapias-Mesa¹, M. Suarez-Piñera¹, M. Cortés-Romera¹;

¹Nuclear Medicine - PET (IDI), Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Nuclear Medicine, Hospital Universitari Son Espases, Palma de Mallorca, SPAIN, ³Nuclear Medicine, Hospital Universitario Virgen del Rocío, Sevilla, SPAIN.

EPS-032

[¹⁸F]FAPI Total-Body PET in Metabolic-Dysfunction Associated Steatotic Liver Disease: Preliminary Results

S. Shivani¹, Y. G. Abdelhafez¹, B. A. Spencer¹, V. Medici¹, V. Lyo¹, M. T. Corwin¹, K. Chung¹, X. Duan¹, O. R. Vigil¹, I. Tunali², P. Laco², A. T. Hoye², M. Flitter², A. McGeehan², M. Johnson², E. C. Collins², G. Wang¹, R. Badawi¹;

¹University of California at Davis, Sacramento, CA, UNITED STATES OF AMERICA, ²Eli Lilly, Inc., Indianapolis, IN, UNITED STATES OF AMERICA.

EPS-033

A Prospective Study on the Diagnosis and Severity Assessment of Interstitial Lung Disease Complicated by Dermatomyositis in Adults Using ⁶⁸Ga-FAPI PET/CT

J. Hu¹, X. Sun¹, X. Shao², Q. Qu¹, J. Hu², Q. Zhao², Y. Jin¹, Z. Cheng³, W. Hai¹, B. Li¹, H. Cao²;

¹Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ²Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ³Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

EPS-034

[99mTc]DTPA aerosol clearance as an assessment of pulmonary alveolar permeability in long COVID

T. Biggans, J. Asogan Vaishnavi, P. Guntur Ramkumar; NHS Tayside, Dundee, UNITED KINGDOM.

EPS-035

Emotional Stress During the COVID-19 Lockdown: How Negative X/Twitter Posts Correlated with Changes in the Brain's Fear Network

E. Guedj¹, J. Y. Campion², T. Horowitz², F. Barthelemy³, S. Khalfa⁴, W. El-Hage²;

¹Aix-Marseille University, Marseille, FRANCE, ²CHRU Tours, Tours, FRANCE, ³APHM, Marseille, FRANCE, ⁴CNRS, Marseille, FRANCE.

EPS-036

TSPO PET relates to blood markers of vascular regulation, immune cell survival and brain damage in post-COVID syndrome

D. Visser¹, H. L. D. M. Willemsen², S. S. V. Golla¹, R. Boellaard¹, H. Knoop³, B. N. M. van Berckel¹, J. Bosch³, J. den Dunnen⁴, N. Eijkelkamp², N. Tolboom⁵;

¹Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, NETHERLANDS, ²Center for Translational Immunology, UMC Utrecht, Utrecht, NETHERLANDS, ³Department of Medical Psychology, Amsterdam UMC, Amsterdam, NETHERLANDS, ⁴Center for Experimental and Molecular Medicine, Amsterdam UMC, Amsterdam, NETHERLANDS, ⁵Department of Radiology & Nuclear Medicine, UMC Utrecht, Utrecht, NETHERLANDS.

EPS-037

Synergistic FAPI and PSMA PET/CT Imaging in Primary Sjögren's Syndrome: Comprehensive Evaluation of Inflammatory Burden and Functional Parameters for Clinical Translation

J. Wang, J. Xiang, R. Wang, X. Peng, Y. Wang, Z. Zhu; Peking Union Medical College Hospital, Beijing, CHINA.

EPS-038

Imaging Phenotypes of Idiopathic Inflammatory Myositis using ¹⁸F-FDG PET/MR

Y. Zhang, B. Zhang, B. Li, X. Zhang; The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, CHINA.

EPS-039

Role of ⁶⁸Ga-FAPI PET/CT in assessing liver fibrosis in chronic liver disease

S. Singh, M. Ora, S. Gambhir; SGP GIMS, Lucknow, INDIA.

EPS-040

[18F]FDG-PET/CT value in the assessment of treatment response in patients with extrapulmonary tuberculosis

M. Tormo Ratera¹, M. Cortés-Romera¹, M. Santin², A. Fritsch-Medina¹, S. Pérez-Recio², M. Grijota-Camino², P. Perlaza-Jiménez¹, J. Diaz-Moreno¹, A. Bagán-Trejo¹, J. Robles-Barba¹;

¹Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Infectious Diseases Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EPS-041

FDG-PET/CT Patlak Parametric Imaging in Patients with Alveolar Echinococcosis

B. Sah¹, L. Husmann¹, F. Kotasidis², A. Maurer¹, C. Meyer zu Schwabedissen¹, A. Deibel¹, M. Huellner¹;

¹University Zurich/University Hospital Zurich, Zurich, SWITZERLAND, ²University Zurich/GE Healthcare, Zurich/Waukesha, USA, SWITZERLAND.

EPS-042

Neuroimmune activation in temporal lobe epilepsy patients with worsening seizure following the COVID-19 pandemic: A [¹⁸F]DPA-714 PET/MR study

L. Xiao¹, L. Feng¹, Y. Tang¹, S. Hu¹, K. Shi²;
¹Xiangya Hospital Central South University, Changsha, CHINA, ²University Hospital Bern, Bern, SWITZERLAND.

310

Sunday, October 5, 2025, 09:45 - 11:15

Room 116

CTE 2 - Technologists Committee: Continuous Education Models for NMTs + Instrumentation and Data Processing

OP-126

Entry Level Education in Nuclear Medicine: Establishing the Foundations for Lifelong Learning

R. McDade; Dept of Clinical Physics & Bio-Engineering, Glasgow Royal Infirmary, Nuclear Cardiology, Glasgow, UNITED KINGDOM.

OP-127

Continuous Professional Development: A World of Opportunities

A. Geão; Hospital Cuf Descobertas, Medicina Nuclear, Lisboa, PORTUGAL.

OP-128

Instrumentation, Data Processing and Dosimetry– a Learning Gap?

T. Yamamoto; Kyorin University, Department of Medical Radiological Technology, Mitaka, Tokyo, JAPAN.

311

Sunday, October 5, 2025, 09:45 - 11:15

Room 111

Special Symposium 1 - EARL: Clinical Implications of EARL PET/CT Accreditation Standards 2 and a New ¹⁷⁷Lu SPECT/CT Accreditation: Results, Specifications and Future Directions

OP-130

Clinical Implications of EARL PET/CT Accreditation Standards 2: Enhancing Diagnostic Quality and Patient Outcomes

R. Boellaard; VU University Medical Center, Amsterdam, NETHERLANDS.

OP-131

¹⁷⁷Lu SPECT/CT Accreditation: Results, Specifications, and Future Directions

A. Denis-Bacelar; National Physical Laboratory, Teddington, UNITED KINGDOM.

401

Sunday, October 5, 2025, 11:30 - 13:00

Auditorium

Plenary 2: World's Best Theranostics Comes to EANM'25

OP-132

Maximising the Potential of PSMA-Targeted Therapies: New Horizons in Oncology

G. Kong; Peter MacCallum Cancer Centre, Molecular Imaging and Therapeutic Nuclear Medicine, University of Melbourne, Melbourne, AUSTRALIA.

OP-133

The Power of Targeted Alpha Therapy: From Physics to Patient Outcomes

M. Sathekge; Steve Biko Academic Hospital, Department of Nuclear Medicine, Pretoria, SOUTH AFRICA.

OP-134

Transforming Cancer Care: Advances in Precision Oncology and Theranostic Approaches

H. Jacene; Dana-Farber Cancer Institute, Department of Imaging, Boston, UNITED STATES OF AMERICA.

OP-135

Radium-223 Through the Ages: From Discovery to Modern Applications

E. Etchebehere; University of Campinas (UNICAMP), Division of Nuclear Medicine, Campinas, BRAZIL.

OP-136

Expanding Horizons: Modernising Nuclear Medicine Infrastructure for Tomorrow's Challenges

R. Kumar; All India Institute of Medical Sciences, Department of Nuclear Medicine, New Delhi, INDIA.

OP-137

Astatine-211 - a Targeted Alpha Therapy for Thyroid Cancer: Advances and Challenges

T. Watabe; Graduate School of Medicine, The University of Osaka, Osaka, JAPAN.

501

Sunday, October 5, 2025, 15:00 - 16:30

Auditorium

CME 3 - Physics + Paediatrics Committee: Low Dose Imaging

OP-138

Where Are We Now, and How Low Can We Go?

J. Dickson; University College London Hospitals, Institute of Nuclear Medicine, London, UNITED KINGDOM.

OP-139

Role of AI in Low Dose Imaging

L. Imbert; University Hospital of Nancy, Department of Nuclear Medicine, Nancy, FRANCE.

OP-140

Nuclear Medicine Imaging of Vulnerable Patients

P. Zucchetta; Padua University Hospital, Department of Nuclear Medicine, Padua, ITALY.

OP-141

Role of Total Body PET in Low Dose Imaging

S. Ivashchenko; University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS.

502

Sunday, October 5, 2025, 15:00 - 16:30

Room 112 (Arena)

Special Track 3 - Oncology & Theranostics Committee: Challenge the Expert: Will Alpha Therapy be the Main Radionuclide Therapy Approach in the Future?

OP-142

Pro: A Breakthrough that Should Improve Response and Long Term Outcome

D. Deandreis; Institut Gustave Roussy, University of Turin, Villejuif/Turin, FRANCE / ITALY.

OP-143

Contra: Complex Techniques Difficult to Validate at the Era of Effective ¹⁷⁷Lu-Theranostic Approaches

C. Bailly; Nantes University Hospital, Nuclear Medicine, Nantes, FRANCE.

503

Sunday, October 5, 2025, 15:00 - 16:30

Room 113

LIPS Session 3 - Thyroid Committee: Imaging Challenges in Nuclear Endocrinology

OP-145

Challenges in Scintigraphic Imaging of Hyperparathyroidism

P. Petranovic Ovčariček; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CROATIA.

OP-146

Challenges in Staging and Restaging of Sporadic and MEN-related MTC

D. Taieb; APHM-AMU, Marseille, FRANCE.

OP-147

Challenges in Nuclear Endocrinology Resolved by Ultrasonography

S. Ilgan; GATA Medical Faculty, Ankara, TÜRKIYE.

504

Sunday, October 5, 2025, 15:00 - 16:30

Room 114

M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Tumor Microenvironment as a Therapeutic Target

OP-149

Tumour Heterogeneity in FAP Expression Exposes a Dual Role for FAP-Expressing CAFs in FAP-Targeted Radionuclide Therapy

C. Wu, A. Kurniawan, Z. Ming, G. Li, W. Noordzij, A. W. J. M. Glaudemans, I. F. Antunes, B. Cornelissen; University Medical Center Groningen, Groningen, NETHERLANDS.

OP-150

Investigating Fibroblast Activation Protein Binding of the dimeric DOTAGA.Glu.(FAPI)₂ labelled with Terbium-161 in Ovarian Cancer Models Incorporating the Tumor Microenvironment

S. Van Mechelen^{1,2}, K. Vermeulen¹, T. Opsomer¹, Z. Janssen¹, J. Buset¹, M. Ooms¹, F. Rösch³, A. Coosemans², K. Tabury¹, I. Primac¹;
¹SCK CEN, Mol, BELGIUM, ²KU Leuven, Leuven, BELGIUM, ³Johannes Gutenberg University, Mainz, GERMANY.

OP-151

Safety, Biodistribution, and Dosimetry of Fibroblast Activation Protein and Integrin α_vβ₃ dual Targeting radioligand ¹⁷⁷Lu-DOTA-FAPI-RGD: Preclinical and First-in-Human Results

J. Xiang^{1,2}, X. Wen³, R. Wang^{1,2}, J. Wang^{1,2}, X. Peng¹, Y. Wang^{1,2}, Z. Zhu¹, J. Zhang⁴;
¹Peking Union Medical College Hospital, Beijing, CHINA, ²Peking Union Medical College, Beijing, CHINA, ³Theranostics Center of Excellence (TCE), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, ⁴Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.

OP-152

Head-to-head comparison of FAP-targeting single domain antibody 4AH29 vs peptide FAP-2286

N. Dumauthioz, L. Navarro, M. Berdal, S. Nagachinta, S. Massa, A. R. Pombo Antunes, J. Dewulf, D. Mantzilas, M. D'Huyvetter;
Precirix, Brussels, BELGIUM.

OP-153

eFAP-51: a promising dimeric FAP inhibitor with prolonged tumor retention for cancer radionuclide therapy

H. Ma, L. Li, A. Piet, C. de Ridder, D. Stuurman, P. Paraiso, Y. Seimбилle;
Erasmus MC, Rotterdam, NETHERLANDS.

OP-154
⁶⁷Cu-, ¹⁶¹Tb- and ¹⁷⁷Lu-radiolabeled antibody derivatives addressing fibroblast activation protein for radionuclide therapy

C. Neuber, M. Kubeil, L. Loureiro, S. Brühlmann, N. Berndt, C. Arndt, A. Feldmann, K. Kopka, M. Bachmann, J. Pietzsch; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY.

OP-155
A Phase I Clinical Study of Evaluating the Safety and Preliminary Efficacy of ¹⁷⁷Lu-FAPI-XT in Advanced Solid Tumors with Fibroblast Activation Protein Expression

H. Liu¹, R. Guo², X. Zhang¹, H. Ji¹, S. Sun¹, S. Sun³, J. Liu⁴, Z. Yang², R. Wang¹;

¹Department of Nuclear Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing, CHINA,

²Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, CHINA, ³Sinotau Pharmaceutical Group, Beijing, CHINA, ⁴Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, Beijing, CHINA.

OP-156
Increasing the Residence Time of FAP Radioligands Using a Ketoamide FAPI

A. de Groot¹, P. Brzeminski², D. Wilcox³, E. Verhulst¹, S. Peeters³, A. Fabisiak², I. De Meester¹, P. Van Der Veken², F. Elvas³;

¹Laboratory of Medical Biochemistry (LMB), University of Antwerp, Antwerp, BELGIUM, ²Laboratory of Medicinal Chemistry (UAMC), University of Antwerp, Antwerp, BELGIUM, ³Molecular Imaging and Radiology (MIRA), University of Antwerp, Antwerp, BELGIUM.

OP-157
An MAE₃-DOTA-Conjugated FAP Inhibitor for TargetedRhenium-188 Radionuclide Therapy

M. Xu, Z. Liu; Changping Laboratory, Beijing, CHINA.

505

Sunday, October 5, 2025, 15:00 - 16:30
Room 211

Cutting Edge Science Track - TROP Session - AI Committee: AI Based Segmentation - Cardiac, Lung Ventilation, Bone

OP-158
Towards reliable automation of anatomical segmentation in whole-body bone scintigraphy using deep learning

I. Correia^{1,2}, F. Oliveira¹, C. S. Constantino¹, L. C. Silva¹, J. Castanheira¹, Á. Ferreira¹, R. Teixeira¹, D. C. Costa¹;

¹Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, PORTUGAL, ²Faculdade de Ciências, Universidade de Lisboa, Lisbon, PORTUGAL.

OP-159
Deep Learning Segmentation for Myocardial Perfusion Imaging SPECT

T. Huxohl¹, M. Günter²;
¹Heart and Diabetes Center NRW, Bad Oeynhausen, GERMANY, ²Bielefeld University, Bielefeld, GERMANY.

OP-160
Left Ventricle Segmentation in Dynamic⁸²Rb PET/CT Using Deep Convolutional Neural Networks

M. Amirian^{1,2}, A. Chevalley^{1,2}, V. Andrearczyk^{1,2}, R. Klein³, R. DeKemp⁴, E. Moulton⁵, C. Kamani², J. Prior², M. Jreige², A. Depeursinge^{1,2};

¹University of Applied Sciences and Arts of Western Switzerland (HES-SO), Sierre, SWITZERLAND, ²Department of Nuclear Medicine and Molecular Imaging, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SWITZERLAND, ³Division of Nuclear Medicine and Molecular Imaging, University of Ottawa, Ottawa, ON, CANADA, ⁴Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, CANADA, ⁵Jubilant DraxImage Inc, Kirkland, QC, CANADA.

OP-162
Segmenting Pulmonary Embolism in Ventilation/Perfusion (V/Q) Scans: Benchmarking nnUnet, SwinUnet, and BTUnet

A. Jabbarpour^{1,2}, S. Kaviani^{3,4,5}, E. Moulton⁴, W. Zeng⁶, S. Ghassel⁷, R. Akbarian⁶, A. Couture⁸, A. Roy⁹, R. Liu⁹, Y. A. Lucinian⁸, N. Hejji¹⁰, S. AlSulaiman⁶, F. Shirazi⁶, E. Leung^{11,12}, R. Klein^{12,13,5};

¹Department of Medical Physics, Carleton University, Ottawa, Ontario, Canada, Ottawa, ON, CANADA, ²Ottawa Hospital Research Institute, Ottawa, ON, CANADA, ³Division of Nuclear Medicine and Molecular Imaging, Faculty of Medicine, University of Ottawa, Ottawa, ON, CANADA, ⁴Jubilant DraxImage, Montreal, QC, CANADA, ⁵Electrical Engineering and Computer Science, University of Ottawa, Ottawa, Ontario, Canada, Ottawa, ON, CANADA, ⁶Department of Nuclear Medicine and Molecular Imaging, The Ottawa Hospital, Ottawa, Ontario, Canada, Ottawa, ON, Canada, Ottawa, ON, CANADA, ⁷Electrical Engineering and Computer Science, University of Ottawa, Ottawa, ON, Canada, Ottawa, ON, CANADA, ⁸Hôpital Maisonneuve-Rosemont, Montreal, QC, CANADA, ⁹McGill University Faculty of Medicine, Montreal, QC, CANADA, ¹⁰Department of Nuclear Medicine and Molecular Imaging, The Ottawa Hospital, Ottawa, Ontario, Canada, Ottawa, ON, Canada, Montreal, QC, CANADA, ¹¹Division of Nuclear Medicine and Molecular Imaging, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada, Ottawa, ON, CANADA, ¹²Department of Nuclear Medicine and Molecular Imaging, The Ottawa Hospital, Ottawa, Ontario, Canada, Ottawa, ON, CANADA, ¹³Department of Medical Physics, Carleton University, Ottawa, Ontario, Canada, Ottawa, ON, CANADA, Ottawa, ON, CANADA.

OP-163
Improved Differential Diagnosis of Parkinsonian Syndromes Using Quantitative Dual-Phase [¹⁸F]FP-CIT PET

H. Yoon¹, D. Kim², S. Lee², S. Lee¹, M. Park³, M. Yun¹;

¹Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, ²Yonsei University, Seoul, KOREA, REPUBLIC OF, ³UT Southwestern Medical Center, Dallas, TX, UNITED STATES OF AMERICA.

OP-164
Seg V/Q: Building a Large-Scale Database of Lung Ventilation-Perfusion Scintigraphy Annotated for Pulmonary Embolism Mismatch Defects (VQ4PEDB) With the Help of AI

A. Jabbarpour¹, S. Kaviani^{2,3}, E. Moulton^{3,4}, S. Ghassel⁵, W. Zeng⁶, R. Akbarian⁷, A. Couture⁸, A. Roy⁹, R. Liu⁹, Y. A. Lucinian⁸, N. Hejji⁶, S. AlSulaiman⁶, F. Shirazi⁶, E. Leung⁶, R. Klein⁶;

¹Carleton University, Ottawa, ON, CANADA, ²Division

of Nuclear Medicine and Molecular Imaging, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada, Ottawa, ON, CANADA, Ottawa, ON, CANADA, ³Jubilant DraxImage, Montreal, QC, CANADA, Montreal, QC, CANADA, ⁴Electrical Engineering and Computer Science, University of Ottawa, Ottawa, Ontario, Canada, Ottawa, ON, CANADA, Ottawa, ON, CANADA, ⁵Electrical Engineering and Computer Science, University of Ottawa, Ottawa, Ontario, Canada, Ottawa, ON, CANADA, ⁶Department of Nuclear Medicine and Molecular Imaging, The Ottawa Hospital, Ottawa, Ontario, Canada, Ottawa, ON, CANADA, ⁷Electrical Engineering and Computer Science, University of Ottawa, Ottawa, Ontario, Canada, Ottawa, ON, CANADA, ⁸Hôpital Maisonneuve-Rosemont, Montreal, QC, CANADA, Montreal, QC, CANADA, ⁹McGill University Faculty of Medicine, Montreal, QC, CANADA, Montreal, QC, CANADA.

OP-165
Long-term surveillance of an AI segmentation tool in clinical practice

J. Taylor, P. Metherall; Sheffield Teaching Hospitals, Sheffield, UNITED KINGDOM.

OP-166
Deep Learning-Based Segmentation of Carotid Arteries for Reliable PET Metric Extraction on a Clinical Dataset of 192 [⁶⁴Cu]Cu-DOTATATE PET/CT Scans

A. Kristensen Vølund, V. M. B. Frederiksen, J. S. Madsen, M. E. K. Jensen, A. Clemmensen, R. S. Ripa, A. Kjaer; Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, DENMARK.

506

Sunday, October 5, 2025, 15:00 - 16:30
Room 117

Clinical Oncology Track - TROP Session - Oncology & Theranostics Committee: Lung Cancer Imaging

OP-167
Integrin α_vβ₃ Targeting ⁶⁸Ga-Trivehexin PET/CT for Imaging Non-Small Cell Lung Cancer: A Prospective Study

W. Hq¹, C. Li¹, L. Li¹, Q. Chen², Y. He¹;

¹Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA, ²Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, CHINA.

OP-168
[⁶⁸Ga]Ga-FAPI-46 PET/CT for Staging Suspected/Confirmed Lung Cancer: Results on the Non-Surgical Cohort within a Monocentric Prospective Trial

E. Fortunati¹, L. Zanon², G. Cuzzani³, C. Nanni¹, C. Malizia¹, F. Lodi¹, V. Cabitza¹, I. Brusa¹, S. Emiliani¹, M. Assenza⁴, L. Vetrone¹, F. Antonacci⁵, F. Giunchi⁶, A. Degiovanni⁶, M. Ferrari⁷, F. Natali⁷, T. Galasso⁷, G. Bandelli⁷, P. Candoli⁷, A. D'Errico⁶, P. Solli⁵, S. Fanti^{1,3};

¹Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ²Nuclear Medicine, AST Pesaro-Urbino, Pesaro, ITALY, ³Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna,

ITALY, ⁴Professional Development and Implementation of Research in Health Professional Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Division of Thoracic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁶Pathology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁷Interventional Pulmonology Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-169
FAPI PET/CT response assessment in non-small cell lung cancer (NSCLC) patients: interim results of a prospective exploratory imaging study

A. Deleu, T. Berghmans, M. Brandão, A. Goudsmit, K. Stathopoulos, A. Arçay Öztürk, C. Marin, L. Taraji, S. Nisar, Z. Wimana, S. Vercauteren, B. Vanderlinden, P. Flamen; Jules Bordet Institute - H.U.B., Brussels, BELGIUM.

OP-170
Imaging tumor-infiltrating CD8+ T-cells upon neo-adjuvant treatment with aPD-L1 in non-small cell lung cancer patients

E. Van Genugten¹, B. Piet¹, I. A. E. van der Hoorn¹, K. Schmiedehausen², F. Ciompi¹, C. Jacobs¹, M. M. van den Heuvel¹, J. J. M. de Vries¹, E. H. J. G. Aarntzen¹;
¹Radboud UMC, Nijmegen, NETHERLANDS, ²ImaginAb, Calabasas, CA, UNITED STATES OF AMERICA.

OP-171
Integrating PET/CT Radiomics from Primary Tumors and Metastatic Lymph Nodes for Enhanced Survival Prediction in NSCLC Patients Undergoing Radical Radiotherapy

K. Albattat; Cardiff University, Cardiff, UNITED KINGDOM.

OP-172
All you need is Δ SUVmax! Response prediction of preoperative immune checkpoint inhibition by dual time point FDG PET/CT in patients with resectable NSCLC in a prospective setting.

H. Hautzel¹, M. Wiesweg², T. Plönes^{3,4}, D. Theegarten⁵, D. Kersting¹, C. Aigner^{3,6}, K. Herrmann¹, M. Schuler²;

¹Department of Nuclear Medicine, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY, ²Department of Medical Oncology, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY, ³Department of Thoracic Surgery, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY, ⁴Department of Surgery, Division of Thoracic Surgery, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, GERMANY, ⁵Institute for Pathology, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY, ⁶General Hospital Vienna, Department of Thoracic Surgery, Medical University Vienna, Vienna, AUSTRIA.

OP-173
A Three-Factor Model for Clinical Decision-making in NSCLC Patients treated with Tyrosine Kinase Inhibitors

F. Orlhac¹, N. Hovhannisyan-Baghdasarian¹, H. Fokem-Fosso¹, M. Luporsi¹, C. Nioche¹, H. Tissot^{1,2}, G. Lemoudda¹, F. Beltgens³, D. Bruyat⁴, E. Dansin⁵, P. Demontrond⁶, P. Dubray-Longeras⁷, R. Gervais⁶, A. Lagrange⁸, A. Madroszyk⁴, M. Pérol⁹, X. Quantin¹⁰, C. Quere⁹, P. Saintigny⁹, R. Seban^{1,2}, J. Simonnet¹¹, Q. Thomas¹⁰, A. Livartowski¹², P. Salamoun-Feghali¹², N. Hegarat¹², N. Girard¹², I. Buvat¹;
¹Institut Curie, Université PSL, Inserm, U1288, LITO, Orsay, FRANCE, ²Institut Curie, Department of Nuclear Medicine, Paris-St Cloud, FRANCE, ³Centre Georges-François Leclerc,

Department of Anatomopathology, Dijon, FRANCE, ⁴Institut Paoli-Calmettes, Department of Oncology, Marseille, FRANCE, ⁵Centre Oscar Lambret, Department of Oncology, Lille, FRANCE, ⁶Centre François Baclesse, Department of Oncology, Caen, FRANCE, ⁷Centre Jean Perrin, Department of Oncology, Clermont-Ferrand, FRANCE, ⁸Centre Georges-François Leclerc, Department of Oncology, Dijon, FRANCE, ⁹Centre Léon Bérard, Department of Oncology, Lyon, FRANCE, ¹⁰Institut du Cancer, Department of Oncology, Montpellier, FRANCE, ¹¹Centre Bergonié, Department of Oncology, Bordeaux, FRANCE, ¹²Institut Curie, Institut du Thorax Curie-Montsouris, Paris, FRANCE.

OP-174
 PET/CT Metabolic Parameters Correlation of Invasive Lung Adenocarcinoma Histological Grading to Optimize Surgical Decisions

X. Shen, T. Chen, J. Wen, J. Deng, Y. She, D. Xie, C. Chen; Shanghai Pulmonary Hospital, Shanghai, CHINA.

OP-175
 Added Value of Zero-Time Echo (ZTE) Sequence in Evaluating ¹⁸F-FDG Positive Pulmonary Nodules on ¹⁸F-FDG PET/MRI in Oncologic Patients: Preliminary Findings

S. Gulbahar Ates, U. Aydos, S. B. Kucukali, S. Demir, U. O. Akdemir, L. O. Atay; Gazi University Faculty of Medicine, Ankara, TÜRKIYE.

507

Sunday, October 5, 2025, 15:00 - 16:30
 Room 212

M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Prostate Cancer: New Tracers

OP-176
 Preclinical development of novel AR-targeted PET radioactive probe in prostate cancer

S. Lin, B. Gu, X. Wang, S. Song; Fudan University Shanghai Cancer Center, Shanghai, CHINA.

OP-177
 Uncovering the Mechanisms of Action of ²¹²Pb-based PSMA-targeting Radioligand Therapies

F. Liu, A. Prior, M. E. Monterosso, D. Boucher, S. Shakti, K. Li, A. Sydes, A. Jones, J. Hesse, C. Kim, A. Horsfall, K. Kuan, W. Tieu, S. Rose, A. Karmann, S. Puttick, G. Li, T. Kryza; AdvanCell Pty Ltd, Brisbane, AUSTRALIA.

OP-178
 First-in-human study of novel PSMA-targeted agents, [⁶⁸Ga]Ga-AAZTA-PSMA-093 and [⁶⁸Ga]Ga-AAZTA-NI-PSMA-093: dosimetry and initial evaluation in prostate cancer patients

G. Wang¹, Y. Lai¹, W. Jin², Y. Luo², H. F. Kung³, L. Zhu², W. Miao¹; ¹the First Affiliated Hospital, Fujian Medical University, Fuzhou, CHINA, ²Beijing Normal University, Beijing, CHINA, ³University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

OP-179
 Preclinical Assessment of Novel [^{99m}Tc][Tc(N) (PNP3OH)]²⁺-labelled PSMA inhibitor with Improved Pharmacokinetics for Enhanced Prostate Cancer Detection

C. Bolzati¹, J. Kleynhans², C. Gobbi¹, I. Hawala³, S. Ghiani⁴, A. Maiocchi⁵, F. Cleeren², N. Salvarese¹; ¹Institute of Condensed Matter Chemistry and Energy Technologies ICMATE-CNR, PADOVA, ITALY, ²Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BELGIUM, ³Dipartimento di Biotecnologie Molecolari e Scienze per la salute, Centro di Imaging Molecolare, Università degli Studi di Torino, Torino, ITALY, ⁴Bracco Research Centre, Bracco Imaging SpA, Torino, ITALY, ⁵Bracco SpA, Milano, ITALY.

OP-180
 Mouse digital twin for [¹⁷⁷Lu]Lu-PSMA10.1 to enable individualised therapy.

G. Costa^{1,2}, E. Yousefzadeh-Nowshahr¹, V. Vasic¹, B. Sun³, L. Nagel³, A. Wurzer³, F. Schilling³, A. Beer², W. Weber³, S. Kossatz³, G. Glatting^{1,2}; ¹Uni Ulm, Ulm, GERMANY, ²Uniklinik Ulm, Ulm, GERMANY, ³Technische Universität München, Munich, GERMANY.

OP-181
 A Preclinical Evaluation on the Radiohybrid Tandem [¹⁸F]La- and [²²⁵Ac]Ac-rhPSMA-10.1 for Targeted Alpha Therapy of Prostate Cancer

B. Sun^{1,2}, A. Morgenstern³, F. Bruchertseifer³, S. Kossatz^{1,2}, M. Eiber¹, W. Weber¹, C. D'Alessandria¹, A. Wurzer¹; ¹Department of Nuclear Medicine, TUM University Hospital, School of Medicine and Health, Technical University of Munich, Munich, GERMANY, ²Central Institute for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, GERMANY, ³European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, GERMANY.

OP-182
 From DNA-encoded chemistry to ACP3-targeted radioligand therapeutics against prostate cancer

S. Cazzamalli¹, S. Oehler¹, T. Georgiev¹, F. Migliorini¹, A. Ciamarone¹, P. Faviana², F. Bartoli², J. Mock¹, E. Puca¹, D. Neri¹; ¹Philochem AG, Otelfingen, SWITZERLAND, ²University of Pisa, Pisa, ITALY.

OP-183
 Radiolabeling of PSMA-functionalized Gold Nanoparticles with Terbium-161 for prostate cancer theranostics

A. Apostolopoulou¹, D. Bajwa¹, E. Salvanou¹, S. Koelewijn², P. van Overeem², C. Liolios¹, S. Xanthopoulos¹, P. Koźmiński³, P. Bouziotis¹; ¹National Center for Scientific Research "Demokritos", Athens, GREECE, ²Terthera b.v., Breda, NETHERLANDS, ³Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Warsaw, POLAND.

OP-184
 From Beta to Alpha: A Preclinical Comparison of ¹⁷⁷Lu-, ²²⁵Ac- and ²¹²Pb-labeled PSMA-N139

L. Joosten¹, G. Franssen¹, D. Löwik², P. Laverman¹, J. Nagarajah¹, Y. Buchatskaya³, M. Konijnenberg⁴, S. Heskamp¹, Y. Derks¹; ¹Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Radboud University, Nijmegen,

NETHERLANDS, ³Nuclear Research & Consultancy Group, Petten, NETHERLANDS, ⁴Erasmus University Medical Center, Rotterdam, NETHERLANDS.

508

Sunday, October 5, 2025, 15:00 - 16:30
 Room 115

Joint Symposium 2 - Neuroimaging Committee / EAN: Epilepsy: Who is the Right Candidate for Epilepsy Surgery?

509

Sunday, October 5, 2025, 15:00 - 16:30
 Room 133+134

e-Poster Presentations Session 3 - Radiopharmaceutical Sciences Committee: New Tracers for Radioligand Therapy and Imaging

EPS-043
 Preclinical Evaluation of a Novel NK-1R-Targeting Radiotracers for Theranostic Applications in Cancers

S. Chopra¹, H. Yushchyshyna¹, T. Xu¹, O. Vorontsova¹, P. Jha¹, H. Westin², U. Rosenström³, U. Yngve^{4,3}, M. Nestor¹; ¹Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, Uppsala, SWEDEN, ²Ridgeview Instruments AB, Uppsala, SWEDEN, ³Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN, ⁴Science for Life Laboratory (SciLifeLab), Drug Discovery and Development platform, Uppsala, SWEDEN.

EPS-044
 Preclinical and first-in-human study of dosimetry and safety for a novel radiopharmaceutical targeting the EGFR mutation in patients with non-small cell lung cancer (NSCLC)

S. Jedidi^{1,2}, A. Courteau^{1,2}, B. Presles², P. S. Bellaye¹, B. Collin^{1,2}, N. Isambert³, M. Chafai El Alaoui¹, A. Daoust⁴, C. Berthet⁴, A. Cochet^{1,2}, J. M. Vrigneaud^{1,2}; ¹Centre Georges-François Leclerc, Dijon, FRANCE, ²Institut de Chimie Moléculaire de l'Université de Bourgogne (ICMUB), UMR CNRS6302, Université Bourgogne Europe, Dijon, FRANCE, ³CHU Poitiers, Poitiers, FRANCE, ⁴Oncodesign Precision Medicine, Dijon, FRANCE.

EPS-045
 Design, Synthesis and Preclinical Evaluation of Small Molecular Radiotracers Targeting AVPR2 for PET Imaging in Renal Cell Cancer Xenograft Mice

S. Huang, T. Tian, R. Huang; West China Hospital of Sichuan University, Chengdu, Sichuan, CHINA.

EPS-046
 Replacing Ahx with Pip-Lys and the C-terminal Pro with Tic for [⁶⁸Ga]Ga-Z01115 to improve its bradykinin B1 receptor-targeting capability for positron emission tomography

F. Radnia, S. Jozi, C. Chen, L. Wang, H. Merkens, P. Ng, F. Bénard, K. Lin; BC Cancer Research Institute, Vancouver, BC, CANADA.

EPS-047
 Radiosynthesis and evaluation of a novel ⁶⁸Ga labeled B7-H3 targeted peptide

F. Zhang, J. Li, S. Song; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, shanghai, CHINA.

EPS-048
 Preclinical evaluation of a novel click-cleavable radioimmunoconjugate for improved therapy of HER2 expressing tumours

M. H. M. E. van Stevendaal¹, K. E. de Roode¹, L. H. M. Zijlmans¹, B. Matthee¹, M. W. Konijnenberg², M. S. Robillard¹, R. Rossin¹; ¹Tagworks Pharmaceuticals, Nijmegen, NETHERLANDS, ²Erasmus Medical Center, Rotterdam, NETHERLANDS.

EPS-049
 PET imaging of PARP-1 expression using a novel ¹⁸F-labeled probe based on Quinazoline-2,4(1 H,3 H)-dione Scaffold

Y. Zou, H. Wang, M. Hu, W. Chen, R. Tian; Sichuan University, west china hospital, Chengdu, Sichuan, CHINA.

EPS-050
 ¹⁷⁷Lu-labelled CEACAM5-binding affibody for radionuclide therapy

E. Papalanis¹, R. Li², M. Oroujeni¹, A. Orlova¹, E. Bezverkhniaia¹, P. Nygren², T. Gräslund², V. Tolmachev¹; ¹Uppsala University, Uppsala, SWEDEN, ²KTH, Stockholm, SWEDEN.

EPS-051
 Preparation and application of novel EBNA1-targeted PET radioactive probe

B. Gu, F. Zhang, J. Li, S. Song; Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EPS-052
 PET imaging of TIM-3 enables sensitive monitoring of immunotherapy

H. Yang, L. Feng, D. Jiang; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EPS-053
 Tissue Factor-targeted PET imaging for Early Diagnosis of Pancreatic Cancer

W. Li, S. Cheng, R. An, Y. Zhang, X. Lan, D. Jiang; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EPS-054
 First in Man Microdose Trial of [⁶⁸Ga]Ga-R54, CXCR4 Targeted PET tracer. Comparison with [¹⁸F]-FDG and proof of concept in lung cancer models

A. Trotta¹, L. Portella¹, M. Aurilio¹, C. D'alterio¹, L. D'Ambrosio¹, C. Maisto¹, A. Morisco¹, F. Manna¹, A. Luciano¹, G. Palma¹, G. Di Maiolo¹, F. Bruzzese¹, R. De Marino¹, A. Esposito¹, A. Rossi¹, F. Ricci¹, M. Cerrone¹, G. De Feo¹, S. Di Maro², S. Lastoria¹, S. Scala¹;

¹Istituto Nazionale Tumori, Fondazione “G. Pascale” -IRCCS, Napoli, ITALY, ²Università della Campania L. Vanvitelli, Caserta, ITALY.

EPS-056

Drug Kinetics and Therapeutic Efficacy of Non-targeted Astatine-labeled Gold Nanoparticles Administered Locally to Tongue Cancer

H. Kato¹, H. Shimamoto², Y. Kadonaga¹, K. Ooe¹, S. Yamamoto³, X. Huang⁴, E. Hilmayanti⁵, A. Shimoyama⁵, K. Kabayama¹, A. Toyoshima⁶, S. Murakami², K. Fukase⁶; ¹Institute for Radiation Sciences, The University of Osaka, Suita, Osaka, JAPAN, ²School & Graduate School of Dentistry The University of Osaka, Suita, Osaka, JAPAN, ³Waseda Research Institute for Science and Engineering, Tokyo, JAPAN, ⁴Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka, JAPAN, ⁵Department of Chemistry, Osaka University Graduate School of Science, Toyonaka, Osaka, JAPAN, ⁶Institute for Radiation Sciences, The University of Osaka, Toyonaka, Osaka, JAPAN.

EPS-057

Development of fluorinated D-peptide radiopharmaceutical with significantly high tumor uptake for potential combination immunotherapy

C. Liu¹, S. Zhang¹, W. Liu¹, Q. Lu¹, F. Wang², R. Wang¹, K. Hu¹; ¹Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, ²Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA.

EPS-058

Preclinical Evaluation of a PSMA-targeting Theranostic Candidate with Reduced Gland Uptake

G. Chen, X. Hu, Y. Cao, M. Hong, S. Xu, J. Wen; RadAlliance Therapeutics Inc, San Diego, CA, UNITED STATES OF AMERICA.

EPS-059

Development and Preclinical Evaluation of Novel PSMA-Targeted Nanobody Radiopharmaceuticals for Prostate Cancer Treatment

B. Yang, Y. Gai, Y. Liu, J. Hu, X. Zhang, M. Li, Y. Zhang, R. An, X. Lan; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EPS-060

Development of [⁶⁸Ga]Ga-B6FA-01 as a Novel Radiotracer for Dual α_vβ₃ and FAP-targeted Tumor PET Imaging

K. Xu¹, Y. Wang¹, Y. Gai², P. Lei³, Z. Xiao¹, Y. He¹; ¹Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Wu Han, CHINA, ²Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wu Han, CHINA, ³Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wu Han, CHINA.

EPS-061

Preclinical Evaluation of [⁶⁴Cu]CuNODAGAPSMaI&T for Prostate Cancer Theranostics

D. Rodrigues¹, A. I. Fonseca², J. Sereno¹, S. do Carmo^{1,2}, V. Marques², I. Hrynchak², J. N. Moreira^{3,4,5}, C. Gomes^{5,6,7}, A. Abrunhosa¹; ¹ICNAS/CIBIT, Coimbra, PORTUGAL, ²ICNAS Pharma, Coimbra, PORTUGAL, ³CNC, Coimbra, PORTUGAL,

⁴Faculty of Pharmacy, Coimbra, PORTUGAL, ⁵CIBB, Coimbra, PORTUGAL, ⁶Faculty of Medicine, iCBR, Coimbra, PORTUGAL, ⁷CACC, Coimbra, PORTUGAL.

EPS-062

Discovery and preclinical characterization of ETN029, a novel radiotherapeutic agent for the treatment of DLL3-expressing cancers

A. Savinainen, L. Wu, T. Bruton, A. Chonkar, J. Cupido, J. Dearling, C. Huang, K. Lee, Z. Ma, H. Mok, K. Nabi, A. Salih, A. Sutton, L. Tavera, M. Wan, Z. Weng, X. Xu, J. Xu, A. Zidell, A. Ricardo; Mariana Oncology a Novartis Company, Watertown, MA, UNITED STATES OF AMERICA.

EPS-063

High and Flow-Independent Extraction Fraction of ^{99m}Tc-4BOH in Langendorff Rat Hearts vs. Clinical SPECT Tracers

D. Ding¹, Y. Gu¹, Y. Zhang², Z. Lv², L. Sun², J. Wang², F. Guo³, W. Fang¹, T. Ma², L. Wang¹; ¹Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, CHINA, ²Tsinghua University, Beijing, CHINA, ³Greater bay area national center of technology innovation, Guangdong, CHINA.

510

Sunday, October 5, 2025, 15:00 - 16:30

Room 116

Technologists’ Track Oral Presentations 1 - Technologists Committee: PET-CT Studies: Diagnosis and Treatment

OP-883

Evaluation of Automatic Selective Body Part Reconstruction on a Long Axial Field of View PET/CT System

M. Olhaye, H. Danielsen; Aarhus University Hospital, Aarhus, DENMARK.

OP-884

Personnel dose in the [¹⁸F]FDG workflow: LAFOV PET/CT versus SAFOV PET/CT

J. Effing, T. Young-Mylvaganan, E. C. Streefkerk, J. Maarsen, E. A. Aalbersberg; The Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP-885

Optimising Zr-89-Trastuzumab PET/CT Imaging: Protocol Design for Short and Long Axial Field-of-View Systems

M. van der Vegt, A. I. van Erp - Zeilstra, A. W. J. M. Glaudemans, W. Noordzij, R. H. J. A. Slart, E. H. J. G. Aarntzen, A. H. Brouwers, O. V. Ivashchenko; University Medical Centre Groningen, Groningen, NETHERLANDS.

OP-886

Optimising Post-Yttrium-90 Radioembolization PET/CT Scan Times: A Comparative Evaluation of Standard and Long Axial Field-of-View Digital PET/CT in Clinical Practice

T. Stark, N. Reitsma, W. Noordzij, O. V. Ivashchenko; UMCG, Groningen, NETHERLANDS.

OP-887

Optimization and harmonization of image reconstructions in [¹⁸F]-FDG brain PET/CT for dementia

R. Klausen¹, P. Braad²; ¹Department of Radiology, Hospital of Southern Denmark, Aabenraa, DENMARK, ²Department of Clinical Imaging, Odense, DENMARK.

OP-888

PET/CT imaging of Blood-Brain Barrier Integrity and inflammatory tracers during Alzheimer’s Disease

B. Alenezi¹, S. Paisey², T. Hughes³, T. Webberley⁴, D. Michael⁵, S. Plummer⁶, S. Plummer; ¹Cardiff University, CF10 5NG, UNITED KINGDOM, ²Wales Research and Diagnostic PET Imaging Centre, school of Medicine, Cardiff University Heath Park., Cardiff. CF14 4XN, UNITED KINGDOM, ³Division of Infection and Immunity, Henry Wellcome Building, School of Medicine, Cardiff University Heath Park., Cardiff. CF14 4XN, UNITED KINGDOM, ⁴Cultech Limited, Unit 2 Christchurch Road, Baglan Industrial Park, Port Talbot SA12 7BZ, UK., UNITED KINGDOM, ⁵Cultech Limited, Unit 2 Christchurch Road, Baglan Industrial Park, Port Talbot SA12 7BZ, UK., UNITED KINGDOM, ⁶Cultech Limited, Unit 2 Christchurch Road., Baglan Industrial Park, Port Talbot SA12 7BZ, UK., UNITED KINGDOM.

OP-889

Dynamic Dual-PET imaging for simultaneous metabolic and perfusion information for cardiac imaging

Â. Cardoso¹, A. Lopez-Montes¹, H. Sari^{1,2}, K. Zeimpekis¹, N. Rathod¹, N. Encina³, J. L. Herraiz², A. Rominger¹, K. Shi¹, F. Caobelli¹; ¹Inselspital, University Hospital Bern, Department of Nuclear Medicine, Bern, SWITZERLAND, ²Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, SWITZERLAND, ³Universidad Complutense de Madrid, Madrid, SPAIN.

OP-890

Defining the Optimal Timeframe For Left Ventricular Volume Measurements in Gated Reconstructions of ¹³N[NH₃] PET/CT in Adenosine-stressed Patients

L. Does¹, R. J. J. Knol¹, S. T. Martínez-Lucio², F. M. van der Zant¹, S. V. Lazarenko¹; ¹Noordwest Ziekenhuis, Alkmaar, NETHERLANDS, ²UMCG, Groningen, NETHERLANDS.

OP-891

Data-driven energy efficiency in a high-throughput PET/CT department: a model for sustainable nuclear medicine

M. De Summa¹, S. Spinosa¹, S. Fusaro¹, S. Annunziata², M. Calcagni²; ¹MEDIPASS Ergèa Group, Rome, ITALY, ²Nuclear Medicine Unit, Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Fondazione Policlinico Universitario Agostino Gemelli, Rome, ITALY.

511

Sunday, October 5, 2025, 15:00 - 16:30

Room 111

Special Symposium 2 - EANM Journals - Debate: The Evolving World of Scientific Publishing

OP-189

Ethics and Metrics in 2030

E. Bertran, Elsevier B.V., Amsterdam, NETHERLANDS.

OP-190

Publications, Journals and Clinical Excellence

A. Scott; ONJCRI and Austin Health, Melbourne, AUSTRALIA.

OP-191

Portrait of a Perfect journal

A. Lazar; Vita-Salute San Raffaele University, Dep. Nuclear Medicine, San Raffaele Hospital; Milan, ITALY.

601

Sunday, October 5, 2025, 16:45 - 18:15

Auditorium

CME 4 - Cardiovascular Committee: Total Body Imaging: Think Big, Think Forward! (Cardio)

OP-193

Long axial field of view CZT cameras: physical principles CZT cameras

L. Imbert; Department of Nuclear Medicine and Nancyclotep Imaging Platform, IADI, INSERM U1254, Université de Lorraine, CHRU Nancy, Nancy, FRANCE.

OP-194

Advances in cardiovascular imaging with CZT cameras

J. Diekmann; Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY.

OP-195

New PET systems: more than a longer field of view

S. Vanderberghe; Department of Electronics and Information Systems, Medical Image and Signal Processing, Ghent University, C. Heymanslaan 10, Ghent, BELGIUM.

OP-196

LAFOV PET in cardiovascular imaging

F. Caobelli; Department of Nuclear Medicine, University of Bern, Bern, SWITZERLAND.

602

Sunday, October 5, 2025, 16:45 - 18:15
Room 112 (Arena)

Special Track 4 - Oncology & Theranostics
Committee + Dosimetry Committee: Debate:
Routes to Optimised Theranostics: Is 'Dose'
Escalation Enough?

OP-197
**'Targeted radionuclide therapy trials should follow
models from drug-based oncology – with activity
escalation similar to chemotherapy paradigms'**
F. Kraeber Bodéré; Nuclear Medicine Center, CHU Nantes,
Nantes, FRANCE.

OP-198
**'Targeted radionuclide therapy trials should follow
radiotherapy logic – guided by absorbed dose, not
just injected activity'**
J. Wadsley; Sheffield Teaching Hospitals NHS Foundation
Trust, Sheffield, UNITED KINGDOM.

603

Sunday, October 5, 2025, 16:45 - 18:15
Room 113

LIPS Session 4 - AI Committee: AI for Young
Developers in Nuclear Medicine

OP-200
Data Preparation for AI
D. Kersting; University of Essen, Department of Nuclear
medicine, Essen, GERMANY.

OP-201
Basics of Coding for AI
C. Constantino; Champalimaud Foundation, Nuclear
Medicine-Radiopharmacology, Lisbon, PORTUGAL.

OP-202
Best Practices for Model Development
L. Cavinato; Politecnico di Milano, Department of
Mathematics, Milan, ITALY.

OP-203
**Large Language Models for Coding and Scientific
Writing**
G. Prenosil; University of Bern, Department of Nuclear
Medicine, Bern, SWITZERLAND.

604

Sunday, October 5, 2025, 16:45 - 18:15
Room 114

M2M Track - TROP Session -
Radiopharmaceutical Sciences + Translational
Molecular Imaging & Therapy Committee:
Combining Imaging with Targeted Therapy

OP-204
**IL-13Ra2-Targeted Radiotheranostics for Sarcoma:
Advancing Precision Antibody-Based Therapy**
**P. Jeanjean¹, M. Kumpf¹, S. Lee¹, L. Carter¹, S. Lovibond¹, L.
Gajecik¹, S. Krebs², D. Veach¹;**
¹Memorial Sloan Kettering Cancer Center, New York, NY,
UNITED STATES OF AMERICA, ²MD Anderson Cancer Center,
Houston, TX, UNITED STATES OF AMERICA.

OP-205
**High Activity, Pain Relief, and Low Toxicity of
¹⁷⁷Lu-Labeled DOTA-IBA in the theranostics of Bone
Metastases from Multiple Tumors: A Preliminary
Clinical Trial**
**C. Qi^{1,2}, C. Tian^{1,2}, F. Wu^{1,2}, J. Yang^{1,2}, W. Wang^{1,2}, X. Li³, Y.
Chen^{1,2};**
¹Affiliated Hospital of Southwest Medical University, Luzhou,
CHINA, ²Nuclear Medicine and Molecular Imaging Key
Laboratory of Sichuan Province, Southwest Medical
University, Luzhou, CHINA, ³Vienna General Hospital,
Vienna, AUSTRIA.

OP-206
**Preclinical Evaluation of NYM096: A Novel
⁶⁸Ga/¹⁷⁷Lu-Labeled CAIX-Targeting Theranostic Pair
for Clear Cell Renal Cell Carcinoma**
W. Zhu¹, S. Yang², W. Lv², W. Eng², P. Fang², L. Huo¹;
¹Peking Union Medical College Hospital, Beijing, CHINA,
²Norroy Bioscience Co., Ltd., Wuxi, CHINA.

OP-207
**Preclinical Evaluation of NYM097: A Novel
⁶⁸Ga/¹⁷⁷Lu-Labeled FAP-Targeting Theragnostic Pair
for Pan-Cancer**
F. Cui¹, S. Yang², W. Lv², M. Ren², W. Eng², P. Fang²;
¹Department of Oncology, The People's Hospital of Ma
Anshan, Ma Anshan, CHINA, ²Norroy Bioscience Co., Ltd.,
Wuxi, CHINA.

OP-208
**Identification and characterization of ⁶⁴Cu- and
²²⁵Ac-PD-32766, a Carbonic Anhydrase IX targeting
macrocytic peptide radiotheranostic pair for clear
cell renal cell carcinoma (ccRCC)**
**S. Tsuchida¹, Y. Mizukoshi¹, S. Kato¹, H. Inaba¹, T. Kotake¹, T.
Aoki¹, H. Shimizu¹, Y. Funase², N. Kanazawa², H. Yanagida¹,
H. Kitamura¹, K. Matsuhara², K. Suzuki², S. Matsushima², M.
Murakami^{1,2};**
¹PeptiDream Inc., Kanagawa, JAPAN, ²PDRadiopharma Inc.,
Chiba, JAPAN.

OP-209
**A Novel [¹¹C]/[²¹¹At]-Labeled Radiopharmaceutical
Pair Targeting mGluR1 for Melanoma Imaging and
Therapy**
**L. Xie¹, M. Hanyu¹, M. Fujinaga¹, Y. Zhang¹, T. Kokufuta¹, W.
Mori¹, K. Minegishi¹, L. Zhang^{1,2}, R. Luo^{1,2}, H. Wakizaka¹, M.
Zhang¹;**
¹National Institutes for Quantum Science and Technology,
Chiba, JAPAN, ²Department of Nuclear Medicine, Nanjing
First Hospital, Nanjing Medical University, Nanjing, CHINA.

OP-210
**Theranostic role of ⁸⁹Zr and ¹⁷⁷Lu labeled B7H3 probe
in prostate cancer**
L. Kang, Y. Qiu, T. Wang, Q. Yang, L. Song, Y. Lei, X. Sun;
Dept. of Nuclear Medicine, Peking University First Hospital,
Beijing, CHINA.

OP-211
**Theranostic Anti-CD38 Antibody for Combined
Positron Emission Tomography and Lutetium-177
Radionuclide Therapy in Lymphoma**
**C. Petitot^{1,2,3}, A. Kownacka^{1,3}, A. M. M. Dias^{2,3}, D. Vivier², M.
Moreau^{2,3}, M. Claron², M. Guillemin³, J. Simonet³, J. Frenay^{3,4},
A. Helbling^{2,3}, A. Courteau^{2,3}, A. Cochet^{2,3}, F. Denat², P.
Bellay^{1,3}, C. Rossi^{1,5}, F. Girodon^{1,5}, B. Collin^{2,3};**
¹CTM - UMR INSERM 1231, Dijon, FRANCE, ²ICMUB - UMR
CNRS 6302, Dijon, FRANCE, ³IMATHERA, BioSanD - UMS
INSERM 58, Centre Georges-François Leclerc, Dijon, FRANCE,
⁴ICB - UMR CNRS 6303, Dijon, FRANCE, ⁵CHU François
Mitterrand, Dijon, FRANCE.

OP-212
**A Novel CEA-Targeted Nanobody Conjugated with
Radionuclides for the Theranostics of Colorectal
Cancer**
W. Wang, C. Lu, M. Zhou, S. Hu;
Xiangya Hospital of Central South University, Changsha
City, CHINA.

605

Sunday, October 5, 2025, 16:45 - 18:15
Room 211

Cutting Edge Science Track - TROP Session
- Dosimetry Committee: Radiobiological
Mechanisms to Overcome Resistance in TRT

OP-213
**Can antigenicity counterbalance tumor low
absorbed dose in targeted alpha therapy?**
**J. Pouget¹, A. Parach¹, T. David¹, J. Karam¹, F. Bruchertseifer²,
A. Morgenstern², M. Jarlier³, M. Bardiès¹, E. Deshayes¹,
A. Gudin-De-Vallerin³, F. Boissière-Michot³, E. Crapez³, J.
Constanzo¹;**
¹INSERM, Montpellier, FRANCE, ²European Commission,
Joint Research Centre, Karlsruhe, GERMANY, ³Institut
régional du Cancer, Montpellier, FRANCE.

OP-214
**Targeted Radionuclide Therapy as Immune
Adjuvant for Cancer Treatment: Comparing Beta
and Alpha Emitter Absorbed Doses to Stimulate
Anti-Tumor Responses.**
**J. Pouget¹, T. David¹, S. Atis¹, A. Pichard^{2,3}, S. Frost^{3,4}, J.
Constanzo¹;**
¹INSERM, Montpellier, FRANCE, ²Institut Roche, Boulogne-
Billancourt, FRANCE, ³Roche Pharma Research and Early
Development, Roche Innovation Center Basel, Basel,
SWITZERLAND, ⁴Roche Pharma Research and Early
Development, Roche Innovation Center Welwyn, Welwyn
Garden City, UNITED KINGDOM.

OP-215
**Targeted Radionuclide Therapy Against Cancer-
Associated Fibroblasts: A Promising Alternative or
Complement to External Beam Radiotherapy**
**J. Pouget¹, L. Ordas¹, S. Atis², S. Poty¹, A. Parach¹, T.
Lahoutte², L. Navarro², M. D'Huyvetter²;**
¹INSERM, Montpellier, FRANCE, ²PRECIRIX, Brussels, BELGIUM.

OP-216
**Mechanistic insights into HSP90 inhibition as a
sensitization strategy for PRRT**
**M. Sabatella, P. Engbers, T. Reuvers, T. Heredia Genestar, J.
Chang, N. Verkaik, J. Nonnekens;**
Erasmus Mc, Rotterdam, NETHERLANDS.

OP-217
**Synthetically Lethal DNA Damage Response
Inhibition Enhances [¹⁷⁷Lu]Lu-PSMA-617 Cure Rates
in Advanced Prostate Cancer**
**M. Bio Idrissou, E. Santos, H. Comas Rojas, A. Carston,
O. Kwon, L. Wehner, N. Clemons, J. Munson, L. Batley, Y.
Medina Guevara, I. Lambert, A. Pinchuk, B. Bednarz, G. Iyer,
R. Hernandez;**
University of Wisconsin-Madison (UW-Madison), Madison,
WI, UNITED STATES OF AMERICA.

OP-218
**Transcriptional Silencing of DNA Repair Improves
Targeted Alpha Therapy in Advanced Prostate
Cancer**
**M. Bio Idrissou, E. Santos, H. Comas Rojas, A. Carston,
O. Kwon, L. Wehner, N. Clemons, J. Munson, L. Batley, Y.
Medina Guevara, L. Lambert, A. Pinchuk, B. Bednarz, G. Iyer,
R. Hernandez;**
University of Wisconsin-Madison (UW-Madison), Madison,
WI, UNITED STATES OF AMERICA.

OP-219
**Dissecting the Transcriptional and Cell Cycle effects
of Alpha and Beta emitting Radionuclides on
Prostate Cancer Cells**
**M. Bio Idrissou, E. Santos, O. Kwon, B. Bednarz, G. Iyer, R.
Hernandez;**
University of Wisconsin-Madison (UW-Madison), Madison,
WI, UNITED STATES OF AMERICA.

OP-220
**Phosphoproteomics Analysis of Signaling Networks
in Response to Terbium-161 and Lutetium-177
Radioimmunotherapy in Ovarian Cancer and
Lymphoma Models**
**M. Grzmil¹, E. Rioja-Blanco^{1,2}, T. Todorov^{1,2}, P. Grundler¹, A.
Moiseeva¹, N. van der Meulen^{1,3}, Y. Banz⁴, C. Schlappbach⁵, U.
Novak⁶, J. Grünberg¹, R. Schibli^{1,2}, M. Behe¹;**
¹Center for Radiopharmaceutical Sciences, PSI Center for
Life Sciences, Villigen PSI, SWITZERLAND, ²Department of
Chemistry and Applied Biosciences, ETH Zurich, Zurich,
SWITZERLAND, ³Laboratory of Radiochemistry, PSI
Center for Nuclear Engineering and Sciences, Villigen PSI,
SWITZERLAND, ⁴Institute of Tissue Medicine and Pathology,
University of Bern, Bern, SWITZERLAND, ⁵Department of
Dermatology, Inselspital, Bern University Hospital, University
of Bern, Bern, SWITZERLAND, ⁶Department of Medical
Oncology, Inselspital, Bern University Hospital, University of
Bern, Bern, SWITZERLAND.

OP-221
**Live-cell imaging of [¹⁷⁷Lu]Lu-DOTA-TATE: towards
linking intracellular distribution and DNA damage
kinetics for improved dosimetry**
**J. Nonnekens, P. Engbers, T. de Wolf, G. Tamborino, J. Zink,
D. Chapeau, Y. Seimбилle, M. Sabatella;**
Erasmus MC, Rotterdam, NETHERLANDS.

606

Sunday, October 5, 2025, 16:45 - 18:15

Room 117

Clinical Oncology Track - TROP Session
- Oncology & Theranostics Committee:
Haematology and Lymphoma

OP-222

Dual time point lymphoma [¹⁸F]FDG Total-Body PET/CT - a prospective single center AI-aided study to assess therapy response prediction

C. Mingels¹, **F. Sen**², H. Nalbant², K. Chung², N. S. Esteghamat³, M. Rokni², J. M. Tuscano³, A. Rominger¹, Y. Abdelhafez², R. D. Badawi², B. Spencer², L. Nardo²;
¹Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND, ²Department of Radiology, University of California Davis, Sacramento, CA, UNITED STATES OF AMERICA, ³Department of Bone Marrow Transplant, University of California Davis, Sacramento, CA, UNITED STATES OF AMERICA.

OP-223

Quantitative Dual-Tracer PET Biomarkers for Optimizing Patient Selection in CXCR4-Targeted Radioligand Therapy for Multiple Myeloma

N. Dreher¹, S. Xue², S. Kraus³, J. S. Enke¹, K. Michalski⁴, M. Hacker², H. Einsele³, A. K. Buck⁴, X. Li², C. Lapa¹;
¹Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY, ²Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, AUSTRIA, ³Department of Internal Medicine II, University Hospital Würzburg, Würzburg, GERMANY, ⁴Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY.

OP-224

SAFOV vs LAFOV PET/CT in Lymphoma: Impact on Staging and Metabolic Response Assessment

S. Proto¹, A. Di Giorgio¹, C. Malizia², M. Assenza³, M. Stasolla¹, E. Fortunati², A. Farolfi³, C. Pellegrini⁴, B. Casadei⁴, P. L. Zinzani^{4,5}, S. Fanti^{1,2}, C. Nanni²;
¹Nuclear Medicine, Alma Mater Studiorum Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Professional Development and Implementation of Research in Health Professional Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Istituto di Ematologia e Oncologia Medica “L. & A. Seragnoli” IRCCS Azienda Ospedaliero-Universitaria Policlinico-S.Orsola Malpighi, Bologna, ITALY, ⁵Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, ITALY.

OP-225

Prognostic Value of Baseline ¹⁸F-FDG PET/CT-Derived Total Metabolic Tumor Volume of Bone Marrow in Multiple Myeloma Patients (CASSIOPE Cohort)

S. Ahrari¹, B. Jamet¹, S. Zweegman², A. Perrot³, C. Hulin⁴, D. Caillot⁵, T. Facon⁶, X. Leleu⁷, K. Belhadj⁸, E. Itt⁹, L. Karlin¹⁰, C. Bailly^{1,11}, M. Levin¹², M. C. Minnema¹³, C. Bodet-Milin^{1,11}, B. De Keizer¹⁴, J. Corre¹⁵, P. Sonneveld¹⁶, C. Touzeau^{17,11}, P. Moreau^{17,11}, F. Kraeber-Bodéré^{1,11}, T. Carlier^{1,11};
¹Service de Médecine Nucléaire, University Hospital Hôtel-Dieu, Nantes, FRANCE, ²Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam,

Department of Hematology, Amsterdam, NETHERLANDS, ³CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, FRANCE, ⁴Department of Hematology, Hôpital Haut Lévêque, University Hospital Bordeaux, Pessac, FRANCE, ⁵CHU Dijon, Hôpital Du Bocage, Dijon, FRANCE, ⁶University of Lille, CHU Lille, Service des Maladies du Sang, Lille, FRANCE, ⁷CHU Poitiers, Hôpital la Milétrie, Poitiers, FRANCE, ⁸Hôpital Henri Mondor, Lymphoid Malignancies Unit, Créteil, FRANCE, ⁹Department of Nuclear Medicine, Hôpital Henri Mondor, Créteil, FRANCE, ¹⁰Centre Hospitalier Lyon-Sud Hématologie (HCL), Pierre-Bénite, FRANCE, ¹¹CRCI2NA, INSERM, CNRS, Université d’Angers, Université de Nantes, Nantes, FRANCE, ¹²Albert Schweitzer Ziekenhuis, Dordrecht, NETHERLANDS, ¹³Department of Hematology, University Medical Center Utrecht, Utrecht, NETHERLANDS, ¹⁴Department of Nuclear Medicine and Radiology, University Medical Center Utrecht, Utrecht, NETHERLANDS, ¹⁵Unité de Genomique du Myélome, IUC-T Oncopole, Toulouse, FRANCE, ¹⁶Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS, ¹⁷Hematology, University Hospital Hôtel-Dieu, Nantes, FRANCE.

OP-226

Baseline [¹⁸F]FDG PET Biomarkers of Host and Tumor Predict Efficacy and CRS in Multiple Myeloma Patients Treated with CAR T Cells

S. Xue¹, Y. Jia¹, J. Chen², G. Hu³, M. Hacker¹, X. Li¹, Z. Cai²;
¹Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, AUSTRIA, ²Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, CHINA, ³Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

OP-227

FAST Score : A Machine Learning-Based Model Predicting Early Relapse after CAR T-cells in Follicular Lymphoma:Results from the French DESCAR-T Registry

Y. Al Tabaa¹, X. Palard-Novello², G. Cartron³, C. Thieblemont⁴, D. Blaise⁵, C. Rossi⁶, R. Houot⁷, F. Bodere⁸, B. Tessoulin⁹, F. Lebras¹⁰, O. Hermine¹¹, F. Morshhauser¹², E. Van Zele¹³, V. Dupont¹⁴, R. Ricci¹³, E. Bachy¹⁵, L. Ysaebert¹⁶;
¹Scintidoc Nuclear Medicine Center, Montpellier, FRANCE, ²Nuclear Medicine Center, Rennes, FRANCE, ³Hematology Department, CHU Montpellier, Montpellier, FRANCE, ⁴Hematology Department, Saint-Louis Hospital, Paris, FRANCE, ⁵Hematology Department, Insitiut Paoli Clamettes, Marseille, FRANCE, ⁶Hematology Department, CHU Dijon, Dijon, FRANCE, ⁷Hematology Department, CHU Rennes, Rennes, FRANCE, ⁸Nuclear Medicine Center, CHU Nantes, Nantes, FRANCE, ⁹Hematology Department, CHU Nantes, Nantes, FRANCE, ¹⁰Hematology Department, CHU Henri Mondor, Créteil, FRANCE, ¹¹Hematology Department, CHU Necker, Paris, FRANCE, ¹²Hematology Department, CHU Lille, Lille, FRANCE, ¹³LYSA-IM, Créteil, FRANCE, ¹⁴LYSARC, Pierre Bénite, FRANCE, ¹⁵Hematology Department, CHU Lyon Sud, Lyon, FRANCE, ¹⁶Hematology Department, Oncopole Toulouse, Toulouse, FRANCE.

OP-228

Prognostic significance of image-based biomarkers in baseline FDG PET/CTs of patients with DLBCL from the CALGB50303 study - Comparison of manual and AI-based segmentation

D. Hellwig^{1,2}, J. Mikolajczak², V. Langguth², A. Hellwig², D. Schmidt²;

¹University Regensburg, Regensburg, GERMANY,

²Department of Nuclear Medicine, University Hospital Regensburg, Regensburg, GERMANY.

OP-229

Irregular, Highly Metabolically Active Lesions Predict Early Progression in B-cell Lymphoma Patients Treated with CAR T-cells.

S. Sabir^{1,2}, Y. Chen², A. Martínez-Rubio³, L. Martín-Martín⁴, L. Lopez-Corral⁵, J. C. Canadas Salazar⁵, C. Montes-Fuentes⁵, M. Tamayo Alonso⁵, A. Cedillo⁶, P. Balsalobre⁶, P. Barba⁷, A. Perez-Martinez⁸, V. M. Pérez García²;
¹University Carlos III, Madrid, SPAIN, ²Mathematical Oncology Laboratory (MOLAB), Instituto de Matemática Aplicada a la Ciencia y la Ingeniería, University of Castilla-La Mancha, Ciudad Real, SPAIN, ³Universidad de Cádiz, Cadiz, SPAIN, ⁴University of Salamanca, Salamanca, SPAIN, ⁵Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, SPAIN, ⁶Grupo Español de Trasplante Hematopoyético y Terapia Celular, Madrid, SPAIN, ⁷Hospital Universitari Vall d’Hebron, Barcelona, SPAIN, ⁸University Hospital La Paz, Madrid, SPAIN.

OP-230

Risk Prediction of ⁶⁸Ga-FAPI-46 PET/CT-Derived Parameters in Lymphoma Patients

X. Chen¹, T. Yuan², X. Wang³;
¹Beijing Tsinghua Changgung Hospital, School of Clinical Medicine , Tsinghua University, Beijing, CHINA, ²Peking University First Hospital, Beijing, CHINA, ³National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.

607

Sunday, October 5, 2025, 16:45 - 18:15

Room 212

TROP Session - Neuroimaging Committee:
Molecular Imaging of Neurodegeneration:
FDG, Amyloid PET and Others

OP-231

Wavelet Diffusion Modeling Enables Individualized FDG-PET Synthesis for Early Diagnosis of Neurodegenerative Diseases

S. Xue¹, J. Ding², M. Hacker¹, J. Zhao², X. Li¹;
¹Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, AUSTRIA, ²Department of Nuclear Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, CHINA.

OP-232

Fronto-striatal disconnection contributes to striatal degeneration in behavioural variant frontotemporal dementia: preliminary results

S. Xie^{1,2}, Y. Mayr^{1,2}, T. Gimmer³, I. Yakushev^{1,2};
¹Department of Nuclear Medicine, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, GERMANY, ²Graduate School of Systemic Neurosciences, Ludwig Maximilian University of Munich, Munich, GERMANY, ³Department of Psychiatry and Psychotherapy, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, GERMANY.

OP-233

Multimodal Characterisation of Cerebral Amyloid Angiopathy in Mild Cognitive Impairment Using Amyloid PET/MRI and FDG-PET

M. Pudi¹, L. Rodríguez-Bel¹, M. Suarez-Piñera¹, B. Hervás-Sanz¹, J. Diaz-Moreno¹, M. Zamorano-Rivas¹, A. Bagan-Trejo¹, A. Dacosta-Escobar¹, C. Martínez-Ramos¹, M. Cortés-Romera¹; Nuclear Medicine - PET (IDI), Bellvitge University Hospital - IDIBELL, L’Hospitalet de Llobregat, SPAIN.

OP-234

Robustness of the Centiloid Scale to Data Decimation using Florbetaben PET

J. Perucho¹, B. Spottiswoode¹, R. Fahmi¹; Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

OP-235

Impact of Deep Learning-Based Noise Reduction on Centiloid Quantification in Reduced-Dose Amyloid PET Imaging

A. Tahmazov¹, M. Doyen^{2,1}, S. Heyer¹, L. Imbert^{1,2}, A. Verger^{1,2};
¹Department of Nuclear Medicine and Nancyclotep Imaging Platform, University of Lorraine, Nancy Regional Hospital Centre, Nancy, FRANCE, ²University of Lorraine, IADI, INSERM U1254, Nancy, FRANCE.

OP-236

Synthetic [18F]AV45 PET Image Generation from [18F]FDG PET and MRI Using Multimodal Deep Learning: A High-Accuracy Alternative for Amyloid-β Assessment

Y. Zhang¹, X. Fu², H. Shao¹, Y. Jin², N. Zhang², Z. Hu², Y. Wang¹, G. Huang¹, J. Liu¹;
¹Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ²Research Center for Medical AI, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences Key Laboratory of Biomedical Imaging Science and System, Chinese Academy of Sciences, State Key Laboratory of Biomedical Imaging Science and System, Shenzhen, CHINA.

OP-237

Assessment of reactive astrogliosis by [¹⁸F]F-DED PET imaging across all stages of the Alzheimer’s continuum

M. Zeinaki¹, B. S. Rauchmann^{2,3,4}, J. S. Dorneich¹, L. Tagnin¹, L. Vogler¹, J. Gnörich¹, G. Höglinger^{4,5,6}, R. A. Werner¹, L. Frontzkowski^{1,7}, F. Hirsch⁷, D. Janowitz⁷, K. Bürger^{4,7}, J. Vögler^{4,5,6}, S. Lindner¹, J. Levin^{4,5,6}, G. N. Bischof^{8,9}, N. Franzmeier^{5,7}, R. Perneczky^{3,4}, M. Brendel^{1,4,5};
¹Department of Nuclear Medicine, University Hospital LMU, Munich, GERMANY, ²Institute of Neuroradiology, University Hospital LMU, Munich, GERMANY, ³Department of Psychiatry and Psychotherapy, University Hospital LMU, Munich, GERMANY, ⁴German Center for Neurodegenerative Diseases, DZNE, Munich, GERMANY, ⁵Munich Cluster for Systems Neurology, SyNergy, Munich, GERMANY, ⁶Department of Neurology, University Hospital LMU, Munich, GERMANY, ⁷Institute for Stroke and Dementia Research (ISD), University Hospital LMU, Munich, GERMANY, ⁸Department of Nuclear Medicine, University Hospital of Cologne, Cologne, GERMANY, ⁹Life Molecular Imaging (LMI), Berlin, GERMANY.

OP-238
 Metabotropic Glutamate Receptor 5 is associated with Plasma GFAP Dependent on Age

T. Hu¹, Y. Wang¹, J. Wang¹, X. Mao^{1,2}, S. Ren¹, K. He¹, Z. Lin³, Y. Wei³, Y. Yang⁴, Y. Guan¹, Q. Huang¹, B. Li⁵, F. Xie¹;
¹Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ²Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, CHINA, ³United Imaging Healthcare Co., Ltd., Shanghai, 201807, China, Shanghai, CHINA, ⁴Beijing United Imaging Healthcare Co., Ltd., Beijing, 100094, China, Beijing, CHINA, ⁵Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

OP-239
 Cardiac Amyloid Deposits as a Cause of Cardiac Dysfunction in Alzheimer's Disease (CACAO-PET): A Prospective Study

D. Kersting¹, T. Goerttler², I. Trender-Gerhard², M. Chodyla³, A. Küper¹, A. Gerhard⁴, L. Kessler³, T. Schlosser³, G. Davidzon⁵, M. Papathanasiou⁶, C. Rischpler¹, W. Fendler¹, C. Deuschl³, T. Rassa⁶, K. Herrmann¹, R. Dodel⁶, S. Settelmeier⁸;
¹Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ²Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ³Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ⁴Department of Geriatric Medicine, Klinikum Hochsauerland GmbH, Arnsberg, GERMANY, ⁵Department of Radiology, Stanford University School of Medicine, Stanford, CA, UNITED STATES OF AMERICA, ⁶Department of Cardiology and Angiology, University Hospital Frankfurt, Frankfurt am Main, GERMANY, ⁷Department of Nuclear Medicine, Klinikum Stuttgart, Stuttgart, GERMANY, ⁸Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ⁹Department of Geriatric Medicine, University of Duisburg-Essen, Essen, GERMANY.

608

Sunday, October 5, 2025, 16:45 - 18:15

Room 115

Featured Session - Thyroid Committee: Nuclear Medicine Imaging in Medullary and Differentiated Thyroid Cancers

OP-240
 Invited Speaker

M. Tuncel;
 Nuclear Medicine, Ankara, TÜRKIYE.

OP-241
 Evaluation of F-18 FDG PET/CT and Ga-68 DOTATOC PET/CT scans in Assessing Patients with Differentiated Thyroid Carcinoma Exhibiting Elevated Serum Thyroglobulin Levels and Negative Whole-Body Scans with I-131 (TENIS Syndrome)

A. Aghaee, M. Esmatinia, K. Aryana;
 Nuclear Medicine Research Center, Mashhad University Of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-242
 Evaluating the Detection Rate of DTC Metastatic Lesions Using Technetium-99m FAPI Scan in Patients with Elevated Thyroglobulin and Negative Iodine Scan

A. Aghaee¹, S. Soltani², K. Aryana¹, A. Vasei¹, S. Zakavi¹, F. Karamian¹;
¹Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ²Kidney Transplantation Research Center, Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-243
 Identification of Rare and Unusual Sites of Metastatic Localizations in Differentiated Thyroid Carcinoma by Means of I-124 PET-CT. A National Cancer Institute of Malaysia Review.

M. Abdul Onny^{1,2}, N. Mokhtar¹, N. Sulaiman¹, A. Kindu¹, N. Ali¹;
¹National Cancer Institute Malaysia, Putrajaya, MALAYSIA, ²University Medical Center Groningen, Groningen, NETHERLANDS.

OP-244
 Diagnostic performance of [⁶⁸Ga]OncoFAP-PET compared with [¹⁸F]DOPA-PET in patients with recurrent medullary thyroid carcinoma

W. Roll, D. Ventura, M. Schäfers, B. Noto, P. Backhaus, K. Rahbar, B. Riemann, P. Schindler;
 University Hospital Münster, Münster, GERMANY.

OP-245
 Comparison of ⁶⁸Ga-FAPI and ¹⁸F-DOPA PET/CT in patients with medullary thyroid cancer

D. Hescheler¹, D. Atiyat¹, A. Heinzel², K. Lorenz³, P. Reschke⁴, E. Epphard¹, J. Wuestemann¹, M. C. Kreissl¹;
¹Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany, Magdeburg, GERMANY, ²Department of Nuclear Medicine, University Medicine Halle, Halle, Germany,, Halle, GERMANY, ³Department of Visceral, Vascular and Endocrine Surgery, University Medicine Halle, Halle, Germany, Halle, GERMANY, ⁴University Hospital Frankfurt, Frankfurt, GERMANY.

OP-246
 Early or delayed 18F-DOPA PET/CT for MTC primary tumour detection

G. Bianciardi¹, E. Fortunati², E. Tabacchi², I. Brusa², D. Dall'Olio³, M. Assenza⁴, E. Greco¹, C. M. P. Sgro¹, G. A. Fuso¹, L. Carrara¹, G. Cuzzani¹, L. Zanon⁵, L. Calderoni², S. Fanti^{1,2}, V. Ambrosini^{1,2};
¹Nuclear Medicine, Alma Mater Studiorum, University of Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITALY, ⁴Professional Development and Implementation of Research in Health Professional Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Nuclear Medicine, AST Pesaro-Urbino, Pesaro, ITALY.

OP-247
 Feasibility of ⁶⁸Ga-SSO-120 PET/CT Imaging in Medullary Thyroid Carcinoma: A Retrospective Analysis

I. Ciuciulkaite, T. Brandenburg, W. Jentzen, W. Fendler, P. Fragoso Costa, M. Nader, S. Himmen, H. Lahner, L. Umutlu, D. Führer-Sakel, K. Herrmann, H. Hautzel, D. Kersting;
 Essen University Hospital, Essen, GERMANY.

OP-248
 Temporal Kinetics of 18F-DOPA in Medullary Thyroid Carcinoma: The Added Value of Dynamic PET

G. Bianciardi¹, E. Fortunati², E. Tabacchi², I. Brusa², D. Dall'Olio³, M. Assenza⁴, E. Greco¹, C. M. P. Sgro¹, G. A. Fuso¹, L. Carrara¹, G. Cuzzani¹, L. Zanon⁵, L. Calderoni², S. Fanti^{1,2}, V. Ambrosini^{1,2};
¹Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Bologna, ITALY, ³Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, Bologna, ITALY, ⁴Professional Development and Implementation of Research in Health Professional Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Nuclear Medicine, AST Pesaro-Urbino, Pesaro, ITALY.

609

Sunday, October 5, 2025, 16:45 - 18:15

Room 133+134

e-Poster Presentations Session 4 - Physics Committee: Physics e-Poster Presentations Session

EPS-073
 Dynamic ¹⁸F-FDG PET/CT Imaging Combined with Machine Learning Models for Improved Classification of Solitary Pulmonary Lesions: A Series of Studies

Y. Luo, L. Huang, W. Ma, J. Liu;
 The Second Hospital of Lanzhou University (Second Clinical Medical College), lanzhou, CHINA.

EPS-074
 Effect of data-driven motion correction for respiratory movement on lesion detectability in PET-CT: a phantom study

M. de Winter¹, R. Gevers¹, J. Lavalaye¹, J. Habraken¹, M. Maspero²;
¹Sint Antonius Hospital, Nieuwegein, NETHERLANDS, ²University Medical Center Utrecht, Utrecht, NETHERLANDS.

EPS-075
 Linearity and Dynamic Range of Digital PET Systems for Myocardial Blood Flow Quantification

R. DeKemp¹, J. Huettges², J. Abele³, R. Hung³, M. Iwanochko⁴, M. Alwan⁵, M. Al Mallah⁵, S. Chih¹;
¹University of Ottawa Heart Institute, Ottawa, ON, CANADA, ²Cardiac Imaging Inc, Houston, TX, UNITED STATES OF AMERICA, ³University of Alberta Hospital, Edmonton, AB, CANADA, ⁴University Health Network, Toronto, ON, CANADA, ⁵Houston Methodist Hospital, Houston, TX, UNITED STATES OF AMERICA.

EPS-076
 ⁸²Rb Myocardial perfusion imaging - how high can you go?

C. López Martínez¹, H. McMeekin^{1,2}, M. Burniston¹, B. Sanghera¹;
¹Barts Health NHS Trust, London, UNITED KINGDOM, ²Hermes Medical Solutions, London, UNITED KINGDOM.

EPS-077
 Potential of Lean Body Mass-Adjusted FDG PET/CT Parameters to Predict Pathologic Findings in Overweight Endometrium Cancer Cases

F. Avci¹, A. Tunc¹, B. K. Erkek², A. A. Ozsaran³, G. Serin⁴, O. Zekioglu⁴, Z. Burak¹;
¹Ege University, Nuclear Medicine, Izmir, TÜRKIYE, ²Agri Training and Research Hospital, Nuclear Medicine, Izmir, TÜRKIYE, ³Ege University, Obstetrics and Gynecology, Izmir, TÜRKIYE, ⁴Ege University, Pathology, Izmir, TÜRKIYE.

EPS-078
 Optimization of Whole-Body Dynamic ⁶⁸Ga PET Acquisition Protocols Using a 32 cm Axial Field of View: A Phantom Study

Q. Maronnier, S. Brillouet, C. Lamesa, F. Courbon, O. Caselles;
 Oncopole Claudius Regaud, Toulouse, FRANCE.

EPS-079
 Optimisation of [¹⁸F]FDG dosage for quantitative whole-body PET: ensuring image quality anthropometric independency and EARL harmonisation

I. Baltabaev, A. Khalimon, A. Nikiforuk, B. Shvets, M. Khodzhibekova, G. Khamadeeva, D. Khodakova, T. Lazutina, I. Pylova, A. Leontev;
 P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EPS-080
 A Systematic Exploratory Study on SUV Harmonization for Long Axial PET/CT

Y. Li, X. Lu, H. Pang;
 Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EPS-081
 Validation of image-derived SUV estimates for ultra-low ¹⁸F-FDG PET imaging using a large axial field-of-view PET/CT system

C. Smith, G. J. C. Zwezerijnen, J. Heijmen, M. E. den Hollander, J. M. Zijlstra, C. Menke-van der Houven van Oordt, I. Bahce, M. Yaqub, R. Boellaard;
 Amsterdam UMC, Amsterdam, NETHERLANDS.

EPS-082
 Redefining Ultra-low Dose: Full-sensitivity LAFOV PET/CT for Paediatric Imaging

G. C. van den Oever, J. H. van Snick, K. P. Koopmans, E. H. J. G. Aarntzen, R. H. J. A. Slart, W. Noordzij, A. H. Brouwers, G. N. Stormezand, T. Velleman, A. W. J. M. Glaudemans, O. V. Ivashchenko;
 University Medical Center Groningen, Groningen, NETHERLANDS.

EPS-083

The effect of Dead Time Correction on the accuracy of brain PET imaging quantification

A. Issa¹, J. Scheins¹, L. Tellmann¹, C. Brambilla¹, P. Lohmann¹, H. Herzog¹, N. Shah^{1,2,3}, C. Lerche¹;

¹Institute of Neuroscience and Medicine 4, INM-4, Forschungszentrum Jülich GmbH, Jülich, GERMANY, ²Institute of Neuroscience and Medicine 11, INM-11, JARA, Forschungszentrum Jülich, Germany, Jülich, GERMANY, ³Department of Neurology, RWTH Aachen University, Aachen, Germany, Aachen, GERMANY.

EPS-084

Optimization of the imaging protocols for a SAFOV digital PET/CT

C. Steenhout, C. Bernard, D. Palmeri, L. Seidel, C. Lachapelle, S. Marchiori, A. Jadoul, C. Derwael, P. Lovinfosse, N. Withofs, R. Hustinx; CHU Liège, Liège, BELGIUM.

EPS-085

Evaluation of deep learning-based reconstruction models on non-TOF BGO PET/CT: Impact of acquisition times and BSREM penalization factors

S. Kvernby^{1,2}, A. Stenvall¹, E. Trägårdh^{2,3}, D. Minarik^{1,2}; ¹Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Sweden, Lund, SWEDEN, ²Department of Translational Medicine and Wallenberg Centre of Molecular Medicine, Lund University, Malmö, SWEDEN, ³Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, SWEDEN.

EPS-086

Performance Evaluation of Advanced PET Reconstruction Algorithms Using Phantom and Patient Datasets

P. Goorhoo, M. Qebetu, K. Banda, K. Legodi, C. Davis, L. Smith, S. Sibiya, A. Mdlophane, S. Mdanda, K. Mokoala, M. Sathekge, K. Ramonaheng; Nuclear Medicine Research Infrastructure (NuMeRI), Pretoria, SOUTH AFRICA.

EPS-087

Clinical Protocol Simulations and Phantom Validations for a dual-collimator 3D CZT Camera

R. Zananiri, Y. Odes, O. Ziv, A. Shtangel, N. Didi, B. Yuzefovich, J. Sachs, A. Efrati, H. Kosovezer, G. Rabin, A. Devir-Wolfman, J. Bouhnik; GE HeathCare, Haifa, ISRAEL.

EPS-088

Characterisation of Tungsten-Collimator Penetration in Cadmium Zinc Telluride-based Detectors for ¹²³I: A Monte Carlo Simulation Study

I. Ceric Andelius^{1,2}, P. Kalaitzidis¹, J. Oddstig^{1,2}, D. Roth³, M. Ljungberg³; ¹Radiation Physics, Department of Haematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, SWEDEN, ²Department of Translational Medicine and Wallenberg Centre of Molecular Medicine, Lund University, Malmö, SWEDEN, ³Medical Radiation Physics Lund, Lund University, Lund, Sweden, Lund, SWEDEN.

EPS-089

The effect of SPECT pulmonary ventilation/perfusion scintigraphy on the efficacy of pulmonary endarterectomy in treating chronic thromboembolic pulmonary hypertension

P. Han, R. Ma, W. Xie, H. Li, Q. Huang, Z. Zhai, L. Fu; China Japan Friendship Hospital, Beijing, CHINA.

EPS-090

Comparison of Three Diagnostic Strategies for Suspicion of Pulmonary Embolism: Planar Ventilation-Perfusion Scan (V/Q), Computed Tomography Pulmonary Angiography (CTPA), and Single Photon Emission Computed Tomography Ventilation-Perfusion Scan (SPECT V/Q): a multicenter, non-inferiority randomized controlled trial

R. Le Pennec¹, P. Le Roux¹, P. Robin¹, F. Couturaud¹, M. Righini², A. Trinh-Duc³, P. Roy⁴, E. Leung⁵, A. Helias⁶, L. Bertoletti⁷, C. Revel⁸, O. Sanchez⁹, J. Schmidt¹⁰, C. Moreau-Triby¹¹, D. Goetghebeur¹, H. Robert-Ebadi¹², M. Blondon¹², D. Momboisse³, P. Guillo¹, G. Le Gal⁵, P. Salaün¹; ¹Brest University Hospital, Brest, FRANCE, ²HUG, Genève, SWITZERLAND, ³Agen Hospital, Agen, FRANCE, ⁴Angers University Hospital, Angers, FRANCE, ⁵Ottawa Hospital, Ottawa, ON, CANADA, ⁶Toulon Hospital, Toulon, FRANCE, ⁷Saint Etienne University Hospital, Saint Etienne, FRANCE, ⁸Saint Denis La Reunion Hospital, Saint Denis La Reunion, FRANCE, ⁹APHP, Paris, FRANCE, ¹⁰Clermont Ferrand University Hospital, Clermont Ferrand, FRANCE, ¹¹Lyon University Hospital, Lyon, FRANCE, ¹²HUG, Genève, SWITZERLAND.

EPS-091

Optimizing Quantitative ¹⁷⁷Lu SPECT-CT: Effects of OSEM Parameters and Deadtime

R. Albergueiro^{1,2}, A. Carvalho¹, J. Santos²; ¹Unidade Local de Saúde do São João, Porto, PORTUGAL, ²IPO Porto Research Center, Porto, PORTUGAL.

EPS-092

Acquisition and Reconstruction Parameters for ³²P Imaging in a CZT Gamma Camera

P. Guardiola-Zaragoza¹, D. Sánchez-Artuñedo¹, I. Navales-Mateu², M. López-Arribas², D. Borrás-Sánchez², C. Gamez-Cenzano², M. Beltran-Vilagrasa¹; ¹Servei de Física i Protecció Radiològica. Hospital Universitari Vall d'Hebron, Barcelona, SPAIN, ²Servei de Medicina Nuclear. Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

EPS-093

Phantom-based characterisation of an ultra-fast and ultra-low-dose tomographic molecular breast imaging system

A. Cherlin¹, K. Erlandsson², N. Atkins¹, M. Exley¹, I. Baistow¹, K. Thielemans², B. Hutton²; ¹Kromek Ltd, Sedgfield, UNITED KINGDOM, ²Institute of Nuclear Medicine, University College London, London, UNITED KINGDOM.

610

Sunday, October 5, 2025, 16:45 - 18:15

Room 116

CTE 3 - Technologists Committee: Best Practice in Paediatric Inflammation & Infection Radionuclide Imaging - Heart, Bone and Joint, Kidney and Urinary Tract

OP-249

The [18F]FDG PET-CT in Inflammation of Unknown Origin Among Children

D. Albano; ASST Spedali Civili of Brescia, Università degli di studi of Brescia, Brescia, ITALY.

OP-250

Musculoskeletal Diseases – State-of-the-Art in Hybrid Imaging

B. Rodriguez-Alfonso; Nuclear Medicine Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, SPAIN.

OP-251

When the Kidneys Fail: The Urinary Tract Inflammation & Infection Molecular Diagnosis

R. Madru; Medical Physicist at Skane University Hospital, Department of Medical Radiation Physics, Lund, SWEDEN.

611

Sunday, October 5, 2025, 16:45 - 18:15

Room 111

Featured Session - Paediatrics Committee: Advances in Paediatric Molecular Imaging: Innovations in Oncology, Radiomics and Hybrid Technologies

OP-253

Invited Speaker

C. Olianti; ITALY.

OP-254

Impact of Interim ¹⁸F-FDG PET/CT Metabolic Parameters and Deauville Score on Outcomes of Pediatric Hodgkin Lymphoma

O. Kodaz¹, A. Pala¹, G. Kaya², B. Volkan Salanci¹, P. Ozgen Kiratli¹; ¹Hacettepe University Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Yozgat City Hospital Department of Nuclear Medicine, Yozgat, TÜRKIYE.

OP-255

The value of PET/MR in prognostic evaluation of nephroblastoma in children

Y. Xu; Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

OP-256

Early TreatmentResponse Assessment with ⁶⁸GaDOTANOC PET/CT: Superior Concordance with Clinical Outcome

N. Kundu, D. Khan, S. Sagar, A. Mahalik, A. Roy, A. K. Pandey, R. Kumar; AIIMS New Delhi, Delhi, INDIA.

OP-257

Comparative Analysis of Diagnostic Efficacy:[⁶⁸Ga] DOTATATE PET/CT Versus [¹²³I]MIBG Scintigraphy in Paediatric Neuroblastoma Detection

N. Güllaldi, A. Karacan; University of Health Sciences, Ankara Bilkent City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-258

The value of ¹⁸F-FDG PET/MR radiomic features in predicting WT1 and CTNNB1 mutations in nephroblastoma in children

Y. Xu; Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

OP-259

Incidental Detection of Non-Ossifying Fibroma in Pediatric Oncology: FDG PET/CT Features and Diagnostic Pitfalls

B. Arca¹, E. G. Isik¹, Z. Bayramoglu², K. Aslaner¹, Z. G. Ozkan¹, S. Kuyumcu¹; ¹Istanbul University, Istanbul Faculty of Medicine, Nuclear Medicine Department, Istanbul, TÜRKIYE, ²Istanbul University, Istanbul Faculty of Medicine, Radiology Department, Istanbul, TÜRKIYE.

OP-260

Gallium-68 labelled satoreotide trizoxetan in pediatric patient with neuroblastoma: biodistribution and radiation dosimetry results

L. Teles¹, R. van Rooij^{1,2}, M. van Noesel^{1,3}, A. Poot^{1,2}, N. Tolboom^{1,2}, A. Braat^{1,2,4}; ¹Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS, ²University Medical Center Utrecht / Wilhelmina Children's Hospital, Utrecht, NETHERLANDS, ³Division Imaging and Cancer, University Medical Center Utrecht, Utrecht, NETHERLANDS, ⁴Netherlands Cancer Institute, Utrecht, NETHERLANDS.

OP-261

Stable clinical metrics of metabolic activity in synthetic CT based pediatric PET during and following treatment from a LAFOV scanner

S. Honoré d'Este¹, M. E. Montgomery¹, F. L. Andersen^{1,2}, C. Schulze¹, E. S. Saxtoft¹, C. N. Ladefoged¹, K. F. Andersen¹; ¹Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Copenhagen, DENMARK, ²Department of Clinical Medicine, University of Copenhagen, Copenhagen, DENMARK.

OP-262

Potential for Shortening Acquisition Time or Administered Activity in Paediatric Bone Scans with a 360-Degree Digital SPECT/CT Camera

Z. Bar-Sever¹, S. Caduri¹, A. P. Steinmetz²; ¹Schneider Children's Medical Center of Israel, Petach Tikva, ISRAEL, ²Rabin Medical Center, Petach Tikva, ISRAEL.

701

Monday, October 6, 2025, 08:00 - 09:30

Auditorium

CME 5 - Thyroid Committee: Parathyroid Carcinoma: Rare but Complex

OP-263

Beyond the Surface: Advanced Ultrasonographic Detection and Characterization of Parathyroid Carcinoma

M. Tuncel; Hacettepe University, Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-264

From Detection to Decision: [99mTc]MIBI Scintigraphy in Parathyroid Cancer Mapping

A. Campenni; University of Messina, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Messina, ITALY.

OP-265

[18F]fluorocholine PET/CT(MR): A Molecular Beacon in Parathyroid Cancer Imaging

M. W. Huellner; University Hospital Zurich, Department of Nuclear Medicine, Zurich, SWITZERLAND.

OP-266

Decoding Parathyroid Malignancy: [18F]FDG and beyond

D. Deandreis; Gustave Roussy and Paris Saclay University, Nuclear Medicine and Endocrine Oncology, Paris, FRANCE.

702

Monday, October 6, 2025, 08:00 - 09:30

Room 112 (Arena)

Special Track 5 - Inflammation & Infection: Debate: WBC Scintigraphy Scan vs FDG PET/CT in Musculoskeletal Infections

OP-267

WBC Scintigraphy in Musculoskeletal Infections

C. Lauri; Sant'Andrea Hospital, "Sapienza" University of Rome, Department of Medical-Surgical Sciences and of Translational Medicine, Rome, ITALY.

OP-268

FDG-PET/CT in Musculoskeletal Infections

E. Arnon-Sheleg; Galilee Medical Center, Departments of Nuclear Medicine and Diagnostic Radiology, Nahariya, ISRAEL.

703

Monday, October 6, 2025, 08:00 - 09:30

Room 113

LIPS Session 5 - Dosimetry Committee: Statistical Analysis in Clinical Studies and Specifically in Dosimetry

OP-270

Statistics for Clinical Trials and Dosimetry Studies (Basics and Practice)

L. Strigari; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Medical Physics, Bologna, ITALY.

OP-271

Routine or Puzzling Concepts? Uncertainty, Bias, Accuracy and Others (Basics and Practice)

M. Brambilla; AOU Maggiore della Carità, Novara, Department of Medical Physics, Novara, ITALY.

OP-272

Correlations and Models (Basics and Practice)

O. Ivashchenko; University Medical Centre Groningen, Groningen, NETHERLANDS.

OP-273

How Statistical Methods Can Improve Dosimetry?

G. Glatting; Universitätsklinikum Ulm, Nuklearmedizin, Ulm, GERMANY.

704

Monday, October 6, 2025, 8:00 - 9:30

Room 114

M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Preclinical Therapy - Various Targets

P-274

Engineered Helper Lipid Extracellular Vesicles for Pulmonary siRNA Delivery: PET Imaging-Guided Therapy of Lung Metastasis

R. Guo, X. Lan, R. An, D. Jiang; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

OP-275

Preclinical Comparison of [¹⁶¹Tb]Tb-NM600 and [¹⁷⁷Lu]Lu-NM600 in a Murine Triple Negative Breast Cancer Model

Y. Medina Guevara, H. Comas Rojas, O. Bio Idrissou, L. Lambert, A. Pinchuk, L. E. Wehner, A. Carston, N. Clemons, J. Weichert, R. Hernandez; University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

OP-276

Radium-223-Loaded Radioactive Metal-Organic Framework Induces Alpha-Particle-Driven PANoptosis to Halt Cancer Progression

F. Yu¹, J. Zhang¹, K. Kabayama², K. Fukase², T. Watabe², Y. Feng³, K. Shi⁴; ¹Department of Nuclear Medicine, Shanghai Tenth People's Hospital and Institute of Nuclear Medicine, School of Medicine, Tongji University, Shanghai, CHINA, ²Institute for Radiation Sciences, Osaka University, Osaka, JAPAN, ³Department of Radiology, Duke University Medical Center, Durham, NC, UNITED STATES OF AMERICA, ⁴Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND.

OP-277

Conjugation and Radiolabelling of anti-EphA3 Antibody [²²⁵Ac]Ac-macropa-tzPEG₄Sq-chIIIA4 and Preclinical Evaluation in a Murine Glioblastoma Model

C. Wichmann¹, K. Morgan², L. Osellame¹, Z. Cao¹, N. Guo¹, H. Gan¹, I. Burvenich¹, P. Donnelly², A. Scott¹; ¹Olivia Newton-John Cancer Research Institute, Heidelberg, AUSTRALIA, ²University of Melbourne, Parkville, AUSTRALIA.

OP-278

Preclinical Assessment of ¹⁷⁷Lu- and ¹⁶¹Tb-Labeled DZ-HX3 Cyanine Probes for Theranostic Targeting of Solid Tumors

W. Wang¹, M. Huang¹, Y. Wang², R. Wang¹, Y. Zhang³, R. Tian¹;

¹Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA, ²Department of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Sichuan University, Chengdu, CHINA, ³Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA.

OP-279

Simultaneous Alpha- and Beta-Particle Digital Autoradiography for Evaluating Co-Therapy and Theranostic Differential Activity Uptake Distributions: Initial Results in Pre-Clinical Studies of Co-Injected Ac-225 with Lu-177 and with Diagnostic PET Tracers

B. W. Miller^{1,2}, S. S. Rinne³, N. Aguirre⁴, B. Vaughn⁵, A. Wacker⁶, A. Le Roux⁴, J. Kelly⁶, S. M. Cheal⁶; ¹The University of Arizona, Tucson, AZ, UNITED STATES OF AMERICA, ²QScint Imaging Solutions, LLC, Tucson, AZ, UNITED STATES OF AMERICA, ³Uppsala University, Uppsala, SWEDEN, ⁴Memorial Sloan Cancer Center, New York, NY, UNITED STATES OF AMERICA, ⁵Convergent Therapeutics, Cambridge, MA, UNITED STATES OF AMERICA, ⁶Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA.

OP-280

Targeted Alpha Therapy (TAT) in AML: CD38 as a Promising Alternative to CD33

M. Sorin¹, S. Gouard¹, S. Marionneau-Lambot^{1,2}, C. Maingueneau¹, A. Morgenstern³, F. Bruchertseifer³, M. Chérel^{1,4}, F. Haddad^{5,6}, M. Allard¹, J. Gaschet¹; ¹Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes, FRANCE, ²Nantes University Hospital, Nantes, FRANCE, ³European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, GERMANY, ⁴ICO-René Gauducheau Cancer Center, Saint-Herblain, FRANCE, ⁵GIP ARRONAX, Saint-Herblain, FRANCE, ⁶Nantes Université, IMT Atlantique, CNRS-IN2P3, SUBATECH, Nantes, FRANCE.

OP-281

The dose-response effects of ²²⁵Ac-Labeled MOF regulates endoplasmic reticulum stress to induce antitumor immunity

F. Yu¹, X. Luan¹, T. Watabe², Y. Feng³, K. Shi⁴, K. Kabayama², K. Fukase²; ¹Department of Nuclear Medicine, Shanghai Tenth People's Hospital and Institute of Nuclear Medicine, School of Medicine, Tongji University, Shanghai, CHINA, ²Institute for Radiation Sciences, Osaka University, Osaka, JAPAN, ³Department of Radiology, Duke University Medical Center, Durham, NC, UNITED STATES OF AMERICA, ⁴Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND.

OP-282

¹⁹¹Pt-labeled agents targeting tumor DNA in vivo: compound design and biological evaluation for targeted Auger electron therapy

H. Obata¹, A. B. Tsuji¹, Y. Feng², M. R. Zalutsky², M. R. Zhang¹; ¹National Institutes for Quantum and Radiological Science and Technology, Chiba, JAPAN, ²Duke University Medical Center, Durham, NC, UNITED STATES OF AMERICA.

705

Monday, October 6, 2025, 8:00 - 9:30

Room 211

Cutting Edge Science Track - TROP Session - Physics Committee: PET/CT & PET/MR

OP-283

Evaluation of MRgTOF-BSREM PET Reconstruction for Accurate T Classification in Oral Cancer

M. Nogami^{1,2}, J. Inoue Inukai³, F. Zeng³, N. Sugiyama³, M. G. Spangler-Bickell⁴, T. Kurimoto⁵, K. Kubo¹, Y. Kiyono², T. Murakami^{3,1}; ¹Department of Radiology, Kobe University Hospital, Kobe, JAPAN, ²Biomedical Imaging Research Center, University of Fukui, Fukui, JAPAN, ³Department of Radiology, Kobe University Graduate School of Medicine, Kobe, JAPAN, ⁴GE HealthCare, Waukesha, WI, UNITED STATES OF AMERICA, ⁵GE HealthCare, Hino, JAPAN.

OP-284

BrainPET-7T: an Ultra-high filed MRI compatible PET insert for neuroscience

C. Lerche¹, D. Niekaemper¹, J. Scheins¹, L. Tellmann¹, C. Régio Brambilla², C. Choi¹, E. Farrher¹, J. Felder^{1,3}, D. Arutinov⁴, R. Heil⁴, W. Silex⁴, S. van Waasen⁴, D. Grunwald⁵, M. Lennartz⁵, T. Meurer⁵, G. Natour^{5,6}, B. Weissler^{7,8}, F. Mueller⁷, D. Schug^{7,8}, E. Gegenmantele⁸, H. Radermacher⁷, O. Mühlens⁸, M. Lang⁹, P. Gebhardt¹⁰, J. Lefaucheur¹¹, Z. Chen¹², G. Egan¹², V. Schulz^{7,8}, J. Shah^{1,13,14}; ¹Institute of Neuroscience and Medicine 4, Forschungszentrum Jülich GmbH, Juelich, GERMANY, ²Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine 4, Jülich, GERMANY, ³Affinity Imaging GmbH, Jülich, GERMANY, ⁴Integrated Computing Architectures - Peter Grünberg Institute 4, Forschungszentrum Jülich GmbH, Juelich, GERMANY, ⁵Institute of Technology and Engineering, Forschungszentrum Jülich GmbH, Juelich, GERMANY, ⁶Mechanical Engineering, Rheinisch-Westfälische Technische Hochschule, Aachen, GERMANY, ⁷Institute of Imaging & Computer Vision, Rheinisch-Westfälische Technische Hochschule, Aachen, GERMANY, ⁸Hyperion Hybrid Imaging Systems GmbH, Aachen, GERMANY, ⁹Institute of Neuroscience and Medicine 5, Forschungszentrum Jülich GmbH, Juelich, GERMANY, ¹⁰Institute of Experimental Molecular Imaging, Rheinisch-Westfälische Technische Hochschule, Aachen, GERMANY, ¹¹Inviscan Imaging Systems SA, Strasbourg, FRANCE, ¹²Monash Biomedical Imaging, Monash University, Clayton, AUSTRALIA, ¹³Department of Neurology, Rheinisch-Westfälische Technische Hochschule, Aachen, GERMANY, ¹⁴Affinity Imaging GmbH, Juelich, GERMANY.

OP-285
Impact of MR-Guided TOF-BSREM Reconstruction on Visual Interpretation in [¹⁸F]Flutemetamol PET/MR
*J. Inoue Inukai¹, M. Nogami^{2,3}, F. Zeng², K. Kubo², T. Kurimoto⁴, F. Kotasidis^{5,6}, M. Spangler-Bickell⁶, M. W. Huellner⁵, T. Murakami^{1,2};
¹Department of Radiology, Kobe University Graduate School of Medicine, Kobe, JAPAN, ²Department of Radiology, Kobe University Hospital, Kobe, JAPAN, ³Division of Medical Imaging, Biomedical Imaging Research Center, University of Fukui, Fukui, JAPAN, ⁴GE Healthcare, Hino, JAPAN, ⁵Department of Nuclear Medicine, University Hospital Zurich and University of Zurich, Zurich, SWITZERLAND, ⁶GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA.*

OP-286
New Discoveries in Systemic Amyloidosis: A Network of Brain and Organ Relationships Based on ¹¹C-PiB PET/MRI
S. Wei, W. Ruan, Z. Zhou, D. Zheng, Y. Lv, Z. Dai, Y. Gai, X. Lan, C. Qin;
 Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, CHINA.

OP-287
Posterior Putamen Vulnerability in Parkinson's Disease: Multimodal ¹⁸F-FPCIT PET/MRI Reveals Iron-Mediated Nigrostriatal Degeneration and Microstructural Decoupling
H. Lin¹, Y. Wei², Y. Zhu¹, Z. Lin², Y. Yang³, C. Zuo¹;
¹Department of Nuclear Medicine / PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ²United Imaging Healthcare Co., Ltd., Shanghai, CHINA, ³Beijing United Imaging Healthcare Co., Ltd., Beijing, CHINA.

OP-288
Impact of Continuous Bed Motion on Image Quality and Quantification with a LAFOV PET/CT: A Comparative Study
F. Schmidt^{1,2}, W. Lan¹, P. M. Linder¹, E. Calderón¹, C. la Fougère^{1,3};
¹Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, GERMANY, ²Werner Siemens Imaging Center, Dep Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, GERMANY, ³Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, GERMANY.

OP-289
Less Is More: Tailored Low-Dose [¹⁸F]FDG PET/CT Imaging in Pregnant Patients Using LAFOV Technology
I. S. Deurloo^{1,2}, M. M. Steemers-de Boer³, J. H. van Snick², K. P. Koopmans², R. H. J. A. Slart², W. Noordzij², A. H. Brouwers², G. N. Stormezand², T. Velleman², E. H. J. G. Aarntzen², B. J. de Wit - van der Veen³, W. V. Vogel³, S. M. Jansen³, A. J. A. T. Braat^{3,4}, A. W. J. M. Glaudemans², O. V. Ivashchenko²;
¹Isala, Zwolle, NETHERLANDS, ²University of Groningen, University Medical Centre Groningen, Groningen, NETHERLANDS, ³Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ⁴University Medical Centre Utrecht, Utrecht, NETHERLANDS.

OP-290
²¹²Pb PSMA imaging by pair production PET confirms localisation of alpha emissions within tumour lesions

M. Griffiths¹, L. Campbell¹, M. Latter¹, D. Wyld¹, E. OMahoney², I. Holmes², L. Katchel², S. Baker², A. Hansen², M. Baronet³, S. Rose³, A. Karmann³, D. Pattison¹;
¹Royal Brisbane and Women's Hospital, Brisbane, AUSTRALIA, ²Princess Alexandra Hospital, Brisbane, AUSTRALIA, ³AdvanCell, Sydney, AUSTRALIA.

OP-291
A PET/CT Phantom Study on the Potential Overcorrection of Lesion Activity in Cortical Bone like Structures and a Potential Solution
J. Ni, A. Haslauer, S. Nekolla;
 Department of Nuclear Medicine, TUM Klinikum Rechts der Isar, Technical University Munich, School of Medicine & Health, Munich, GERMANY.

706
Clinical Oncology Track - TROP Session - Oncology & Theranostics Committee: Imaging Melanoma and New Targets

OP-292
The MELATEP study: Diagnostic performance of [18F]FDG-PET/CT follow-up for patients on adjuvant immunotherapy for melanoma in real-life setting
A. Bauduer, V. Sibaud, C. Pages, F. Courbon, M. Terroir;
 Oncopole, Toulouse, FRANCE.

OP-293
DYNAMO: Dynamic Total Body FDG PET/CT and Kinetic Modeling for Early Lesion-Level Response Assessment in Metastatic Melanoma Undergoing Immunotherapy - Preliminary Results from a Prospective Study
A. Di Giorgio¹, D. Dall'Olio², I. Brusa³, P. Marchese⁴, G. Siepe⁵, M. Assenza⁶, A. Zappacosta³, C. Nanni³, B. Melotti⁴, G. Castellani^{2,7}, S. Fantì^{1,3}, A. Farolfi³;
¹Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITALY, ³Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁶Professional Development and Implementation of Research in Health Professions Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁷IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-294
Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [¹⁸F]FDG PET/CT study
C. Sachpekidis¹, D. Machiraju², C. Ziener¹, L. Edenbrandt³, J. C. Hassel⁴, A. Dimitrakopoulou-Strauss¹;
¹German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ²National Center for Tumor Diseases (NCT), Heidelberg, GERMANY, ³Sahlgrenska University Hospital, Gothenburg, Gothenburg, SWEDEN, ⁴National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, GERMANY.

OP-295
Pseudoprogression Rates in the Dutch Melanoma Population suggest Opportunities for Cost-Effective Use of [¹⁸F]FDG PET/CT during Therapy with Immune Checkpoint Inhibitors
S. van Mossel^{1,2}, D. Vriens³, D. Kersbergen¹, M. Bloem⁴, E. Kapiteijn¹, H. Koffijberg², S. Saing², L. De Geus-Oei^{1,2,5};
¹Leiden University Medical Center, Leiden, NETHERLANDS, ²University of Twente, Enschede, NETHERLANDS, ³Radboud University Medical Center, Nijmegen, NETHERLANDS, ⁴Dutch Institute for Clinical Auditing, Leiden, NETHERLANDS, ⁵Delft University of Technology, Delft, NETHERLANDS.

OP-296
Comparison of melanin-targeted [¹⁸F]DMPY2 and [¹⁸F]FDG PET/CT in Advanced Melanoma Patients
Y. Yang, M. Zhou, J. Su, X. Chen, S. Hu;
 Xiangya Hospital, Central South University, Changsha, CHINA.

OP-297
[⁶⁸Ga]Ga-DPI-4452 PET/CT for Staging of Patients with Clear Cell Renal Cell Carcinoma (ccRCC)
A. Küper¹, D. Kersting¹, K. Pabst¹, M. Nader¹, C. Darr², L. Umutlu³, U. Krafft², V. Grünwald², B. Hadaschik², K. Herrmann¹, W. Fendler¹;
¹Department of Nuclear Medicine, University Hospital Essen, GERMANY, ²Department of Urology, University Hospital Essen, GERMANY, ³Department of Radiology, University Hospital Essen, GERMANY.

OP-298
First-in-Human Phase I Study of [⁶⁸Ga]Ga-OncoCAIX: Preliminary Results on Safety, Dosimetry, Pharmacokinetics, and Diagnostic Performance
F. Gelardi¹, M. Sollini^{2,1}, C. Pini^{2,1}, L. Antunovic¹, A. Maielli¹, R. Petrelli¹, G. Bonfitto¹, A. Tudda¹, M. Minotti¹, J. Mock³, S. Cazzamalli³, S. Oehler³, M. Müller³, D. Neri³, A. Alessi⁴, P. Erba^{5,6}, A. Chiti^{2,1};
¹IRCCS Ospedale San Raffaele, Milan, ITALY, ²Università Vita-Salute San Raffaele, Milan, ITALY, ³Philochem AG, Otelfingen, SWITZERLAND, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, ITALY, ⁵Università degli Studi di Milano-Bicocca, Milan, ITALY, ⁶ASST Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, ITALY.

OP-299
The impact of ⁶⁸Ga-Pentixafor PET/CT imaging with solid tumours, a comparison with ¹⁸F-FDG: a prospective cross-sectional study
B. Hadebe-Chonco¹, L. Harry¹, N. Ndlovu¹, M. Patel¹, L. Gabela¹, S. Masikane¹, V. Pillay¹, T. Nxasana¹, T. Mkhize¹, M. Msimang², M. Sathekge³, M. Vorster¹;
¹University of KwaZulu Natal, Nuclear Medicine Department, Durban, SOUTH AFRICA, ²University of KwaZulu Natal, Anatomical Pathology Department, Durban, SOUTH AFRICA, ³Department of Nuclear Medicine, University of Pretoria, Pretoria, SOUTH AFRICA.

OP-300
Prospective Head-to-Head Comparison of ¹⁸F-FDG PET/CT and ¹⁸F-FAPI-42 PET/CT for Assessing Inguinal Lymph Node Metastases in Penile Squamous Cell Carcinoma
X. Tong¹, W. Ouyang¹, W. Hou¹, C. Zhou¹, H. Fu¹, J. Liu¹, Q. Wang¹, Z. Liu², K. Cao¹, K. Yao¹, X. Li³, L. Wang¹, M. Zhao¹;
¹Third Xiangya Hospital of Central South University, Changsha, Hunan, CHINA, ²The Affiliated Cancer Hospital of Xiangya School of Medical, Changsha, Hunan, CHINA, ³Medical University of Vienna, Vienna, Austria, AUSTRIA.

707
Monday, October 6, 2025, 8:00 - 9:30
Room 212

TROP Session - Neuroimaging Committee: Innovations and Methodologies in Nuclear Neuroimaging

OP-301
First-in-human study of a ¹⁸F-labeled PET tracer for glutamate AMPA receptors, [¹⁸F]K-40
S. Ichijo¹, Y. Kimura², T. Arisawa¹, M. Hatano¹, W. Nakajima¹, T. Miyazaki¹, T. Eiro¹, Y. Takada¹, R. Iai¹, A. Sano¹, M. Sonoda¹, Y. Takayama¹, T. Takahashi¹;
¹Yokohama City University, Yokohama, JAPAN, ²Kindai University, Osaka, JAPAN.

OP-302
Quantitative Detection of Limbic-predominant Age-related TDP-43 Encephalopathy (LATE) Using Brain FDG PET: An IAEA Multinational Neuroimaging Consortium
T. Thientunyakit¹, J. Arbizu², M. Garcia-Granero³, D. Cross⁴, A. Damián⁵, J. Warwick⁶, J. Jamsek⁷, J. Reimand⁸, M. Tripathi⁹, M. Trost¹, N. Sultana¹⁰, O. Pellet¹, D. Paez¹, S. Minoshima⁴;
¹Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, THAILAND, ²Clinica Universidad de Navarra, Pamplona, SPAIN, ³Consultoria Estadística Marta Garcia-Granero, Pamplona, SPAIN, ⁴The University of Utah, Salt Lake City, UT, UNITED STATES OF AMERICA, ⁵Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, URUGUAY, ⁶Stellenbosch University, Stellenbosch, SOUTH AFRICA, ⁷University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ⁸North Estonia Medical Centre, Tallinn, ESTONIA, ⁹All India Institute of Medical Sciences, New Delhi, INDIA, ¹⁰NINMAS, Bangladesh Atomic Energy Commission (BAEC), Dhaka, BANGLADESH, ¹¹The International Atomic Energy Agency, Vienna, AUSTRIA.

OP-303
Variations in Glucose Metabolism Covariance Pattern Linked to Aβ Status in Subjective Cognitive Decline
R. Devi¹, M. Daamen^{1,2}, E. Duezel^{3,4,5}, M. Essler⁶, F. C. Gaertner⁶, J. Hellmann^{7,8,9}, F. Jessen^{1,10,11}, C. Laske^{12,13,14}, O. Peters^{7,8,9}, J. Priller^{7,15,16}, A. Spottke^{1,17}, S. Teipel^{18,19}, N. Upadhyay^{1,2}, M. Wagner^{1,20}, H. Boecker^{1,2};
¹German Center for Neurodegenerative Diseases (DZNE), Bonn, GERMANY, ²Clinical Functional Imaging Lab, Department of Nuclear Medicine, University Hospital Bonn, Bonn, GERMANY, ³German Center for Neurodegenerative Diseases (DZNE), Magdeburg, GERMANY, ⁴Insitute of Cognitive Neurology and Dementia Research (IKND), Magdeburg, GERMANY, ⁵Department for Psychiatry and Psychotherapy, University Hospital Magdeburg, Magdeburg, GERMANY, ⁶Department of Nuclear Medicine, University Hospital Bonn, Bonn, GERMANY, ⁷German Center for Neurodegenerative Diseases (DZNE), Berlin, GERMANY, ⁸Department of Psychiatry and Neurosciences, Charité Universitätsmedizin Berlin, Berlin, GERMANY, ⁹Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin, Berlin, GERMANY, ¹⁰Department of Psychiatry, University of Cologne, Cologne, GERMANY, ¹¹Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, GERMANY, ¹²German Center for Neurodegenerative Diseases (DZNE), Tübingen, GERMANY, ¹³Section for Dementia Research, Hertie Institute for Clinical Brain Research,

Tübingen, GERMANY, ¹⁴Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, GERMANY, ¹⁵Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, GERMANY, ¹⁶University of Edinburgh and UK DRI, Edinburg, UNITED KINGDOM, ¹⁷Department of Neurology, University Hospital Bonn, Bonn, GERMANY, ¹⁸German Center for Neurodegenerative Diseases (DZNE), Rostock, GERMANY, ¹⁹Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, GERMANY, ²⁰Department of Old Age Psychiatry and Cognitive Disorders, University Hospital Bonn, Bonn, GERMANY.

OP-304
The interaction among Amyloid, tau and FDG metabolism in Alzheimer's disease using PET-based Braak staging
G. Huang¹, Y. Zhou¹, H. Shao¹, J. Hao², L. Qi², J. Liu¹, C. Zhang¹;
¹Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ²United Imaging Healthcare, Shanghai, CHINA.

OP-305
Glymphatic system dysfunction is strongly linked to neurodegeneration and serves as a bridge between ATN biomarkers and cognitive decline in sex-dependent in Alzheimer's disease
J. Wang;
 Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, CHINA.

OP-306
Amyloid PET/CT could not replace tau PET/CT for Alzheimer's disease in terms of disease staging and predicting outcome: a large cohort single-institutional study
S. Chen, Y. Leung, K. Wu, Y. Wong, S. Cheung, Y. Yip, K. Cheng, C. Ho;
 Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

OP-307
The role of metabolism first or amyloid first approach in the assessment of patients with early cognitive impairment due to Alzheimer's disease
A. Damian¹, M. Trošt², J. Jamsek³, T. Thientunyakit⁴, M. Garcia Granero⁵, J. Warwick⁶, J. Reimand⁷, M. Perovnik², N. Sultana⁸, O. Pellet⁹, F. Mariani¹⁰, D. Cross¹¹, M. Tripathi¹², D. Paez⁹, J. Arbizu¹³, S. Minoshima¹¹;
¹Uruguayan Centre of Molecular Imaging (CUDIM), Montevideo, URUGUAY, ²University Medical Centre, Ljubljana, SLOVENIA, ³UMC Ljubljana, Ljubljana, SLOVENIA, ⁴Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, THAILAND, ⁵Consultoria Estadística Marta Garcia-Granero, Pamplona, SPAIN, ⁶Stellenbosch University, Stellenbosch, SOUTH AFRICA, ⁷North Estonia Medical Centre, Tallinn, ESTONIA, ⁸NINMAS, Bangladesh Atomic Energy Commission (BAEC), Dhaka, BANGLADESH, ⁹International Atomic Energy Agency, Vienna, AUSTRIA, ¹⁰Departamento de Neuropsicología, Hospital de Clínicas, Universidad de la República (UdelaR), Montevideo, URUGUAY, ¹¹The University of Utah, Salt Lake City, UT, UNITED STATES OF AMERICA, ¹²All India Institute of Medical Sciences, New Delhi, INDIA, ¹³Clinica Universidad de Navarra, Pamplona, SPAIN.

OP-308
Multiorgan Metabolic Dysregulation in Alzheimer's Disease: Total-body PET/CT Reveals Systemic Network Interactions with Amyloid Burden
R. Xu¹, Y. Duan², L. Gao², Y. Chen¹, H. Han¹, Z. Cheng², Z. Xie^{1,3}.
¹Institute of Medical Technology, Peking University Health Science Center, Peking University, Beijing, CHINA, ²Department of Nuclear Medicine, The First Affiliated Hospital of Shandong First Medical University Shandong Provincial Qianfoshan Hospital, Jinan, CHINA, ³National Biomedical Imaging Center, Peking University, Beijing, CHINA.

OP-309
PET imaging of βAmyloid Load Across the Spectrum of Dementia with Lewy Bodies
M. Yoshita¹, S. Tsuji², K. Yokoyama²;
¹NHO Hokuriku National Hospital, Nanto, JAPAN, ²Public Central Hospital of Matto Ishikawa, Hakusan, JAPAN.

708
Monday, October 6, 2025, 08:00 - 09:30
Room 115
Joint Symposium 3 - Oncology & Theranostics Committee / EORTC: Oncological Response Criteria for PET: Beyond RECIST, EORTC & PERCIST

OP-310
The Importance of Molecular Imaging Response Criteria: Rationale and Overview of the Landscape
E. Lopci; IRCCS–Humanitas Research Hospital, Nuclear Medicine, Milan, ITALY.

OP-311
Overview of PET Response Criteria in Haematological Malignancies (Lymphoma & Multiple Myeloma)
C. Nanni; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-312
Risk and Response Assessment in Prostate Cancer Using PSMA-PET
W. Fendler; Universitätsklinikum Essen, Klinik für Nuklearmedizin, Essen, GERMANY.

OP-313
How to Define Response for Somatostatin Receptor PET?
C. Deroose; UZ Leuven, Nuclear Medicine, Leuven, BELGIUM.

709
Monday, October 6, 2025, 8:00 - 9:30
Room 133+134

e-Poster Presentations Session 5 - Cardiovascular Committee: Cardiovascular e-Poster Presentations Session

EPS-094
Prediction value of cingulate gyrus activity by brain FDG PET for sudden cardiac death in patients with HFrEF
Y. Zhao¹, M. Yun¹, Z. Shi¹, Y. Ba², X. Zhang¹;
¹Laboratory for Molecular Imaging, Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA, ²Department of Nuclear Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, CHINA.

EPS-095
Serial FDG PET analysis for detection of cardiotoxicity of breast cancer chemotherapy
Y. Izoe¹, M. Nagao², H. Tsukada², S. Watanabe², Y. Maekawa², A. Yamamoto², Y. Satoh³, H. Saya¹, S. Akashi-Tanaka², S. Sakai²;
¹Fujita Health University, Toyoake, JAPAN, ²Tokyo Women's Medical University, Shinjuku-ku, JAPAN, ³Fujita Medical Innovation Center Tokyo, Ota-ku, JAPAN.

EPS-096
Left ventricular volumes and ejection fraction by [¹³N]-NH³ positron emission tomography are dependent on the reconstruction method: A head-to-head comparison with cardiovascular magnetic resonance
S. Kvernby^{1,2}, J. Oddstig^{1,2}, F. Hedeer³, S. Akil Engblom³;
¹Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Sweden, Lund, SWEDEN, ²Department of Translational Medicine and Wallenberg Centre of Molecular Medicine, Lund University, Malmö, SWEDEN, ³Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, SWEDEN.

EPS-097
Clinical Validation of Automated Convolutional Neural Network Screening of Incidental Cardiac Uptake on Bone Scintigraphy
V. Uusitalo, H. Halme, T. Ahokas, E. Hippeläinen;
 Helsinki University Hospital, Helsinki, FINLAND.

EPS-098
Graph Theory Analysis of Brain Functional and Metabolic Network Alterations in Heart Failure Patients: a simultaneous PET/MR study
C. Zheng¹, R. Qin¹, N. Li², J. Lu¹;
¹Xuanwu Hospital, Capital Medical University, Beijing, CHINA, ²Beijing United Imaging Research Institute of Intelligent Imaging, Beijing, CHINA.

EPS-099
Impact of CT-free Attenuation Correction on Left Ventricular Ejection Fraction and Volumes obtained from a dedicated Cardiac CZT SPECT Camera
V. Roelants¹, M. Hesse², F. Dupont², N. Laajimi², A. Oulad Bouchetta², R. Lhomme²;

¹Cliniques Universitaires Saint-Luc, Brussels, BELGIUM, ²Cliniques Universitaires Saint-Luc - Université Catholique de Louvain, Brussels, BELGIUM.

EPS-100
FAPI SPECT/CT to Evaluate Fibrosis Burden of Right Ventricular in CTEPH: Correlation with Echocardiographic Strain Parameters and Response to BPA
K. Wang, X. Li, S. Song, W. Fang, L. Wang, C. Yan;
 Chinese Academy of Medical Sciences & Peking Union Medical College, Fuwai Hospital, Beijing, CHINA.

EPS-101
Detection of myocardial metabolic abnormalities by ¹⁸F-FDG and preliminary mechanism analysis in mice with Anthracycline cardiotoxicity: A corresponding ¹⁸F-FDG PET/MRI observation
T. Yuan¹, X. Chen¹, M. Wei¹, X. Lin¹, H. Zhu¹, Z. Yang¹, X. Wang²;
¹Peking University Cancer Hospital & Institute, Beijing, CHINA, ²Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Beijing, CHINA.

EPS-102
First total-body dynamic imaging and kinetic modeling of ¹⁸F-flurpiridaz quantifying perfusion and mitochondrial complex I distribution in healthy volunteers
H. Song^{1,2,3}, J. Zhao^{1,2,3}, Z. Xiang^{1,2,3}, Z. Qin^{1,2,3}, Y. Wang⁴, P. Wu^{1,2,3}, S. Li^{1,2,3};
¹Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA, ²Shanxi Key Laboratory of Molecular Imaging, Shanxi Medical University, Taiyuan, CHINA, ³Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Taiyuan, CHINA, ⁴United Imaging Healthcare, Shanghai, CHINA.

EPS-103
Prognostic Value of Stress Myocardial Perfusion Entropy (MPE) in Patients with Normal Single-Photon Emission-Computed Tomography (SPECT) Myocardial Perfusion Imaging
L. Djaileb¹, N. De Leiris¹, M. Desvignes², D. Fagret¹, C. Ghezzi³, G. Barone-Rochette¹, L. Riou³;
¹University Grenoble Alpes, Grenoble, FRANCE, ²Gipsa-Lab, University Grenoble Alpes, Grenoble, FRANCE, ³Univ. Grenoble Alpes, INSERM, LRB, Grenoble, FRANCE.

EPS-104
Incidence of Cardiotoxicity Assessed with CZT-ERNA in Patients Undergoing Medical Cancer Therapy: A 12-year real-word experience
J. E. Larsson, M. Ø. Nielsen, B. Zerahn;
 Department of Nuclear Medicine, Copenhagen University Hospital – Herlev, Copenhagen, DENMARK.

EPS-105
Clinical Outcomes and Management Following Abnormal SPECT Myocardial Perfusion Imaging
B. Miles, K. Atieh, K. Mason, U. Oza;
 Baylor University Medical Center, Dallas, TX, UNITED STATES OF AMERICA.

EPS-106
Potential link between left ventricular mechanical dyssynchrony (LVMD) and coronary microvascular dysfunction (CMD) in suspected coronary arteries disease (CAD) patients: a preliminary study based on CZT-SPECT

H. Zhang¹, F. Caobelli², K. Shi², F. Yu¹;
¹Tongji University School of Medicine,shanghai Tenth people’s hospital, Shanghai, CHINA, ²Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

EPS-107
Functional Evaluation of Cardiac Cell Membrane Transporter P-Glycoprotein in healthy volunteers with [¹⁸F]MC225-PET imaging- a feasibility study
W. Liu¹, J. Somsen¹, G. S. d. Souza¹, P. Mossel², A. Bartels³, R. Slart¹, G. Luurtsema¹;
¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Leiden University Medical Center, Leiden, NETHERLANDS, ³Ommelander Ziekenhuis Groep, Scheemda, NETHERLANDS.

EPS-108
Diagnostic Performance of NaI(Tl) SPECT Myocardial Blood Flow Quantification versus Relative MPI in Detecting Hemodynamically Significant Stenosis: A Prospective Study Using ICA with Wire-Based FFR as Reference
R. Sun¹, Z. Zhang, K. Han, X. Wang, L. Wang, W. Fang;
Chinese Academy of Medical Sciences Fuwai Hospital, Beijing, CHINA.

EPS-109
Pre-administration of caffeine anhydrous has the potency to suppress myocardial [¹⁸F]-FDG uptake: a feasibility study
C. P. W. Cox¹, Q. G. de Lussanet de la Sablonière, T. Mulders, L. H. Graven, F. A. Verburg, T. Brabander;
Erasmus MC, Rotterdam, NETHERLANDS.

EPS-110
Agreement of ⁶⁸Ga-DOTANOC PET/CT with ¹⁸F-FDG PET/CT and Cardiac MR in sarcoid patients with suspected cardiac involvement
R. Solanki¹, A. Sood, B. Mittal;
Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA.

EPS-112
The relationship between myocardial blood flow assessed by dynamic CZT-SPECT and the radiomics features of coronary artery calcification in NOCAD patients
K. Zavadovsky¹, A. Maltseva, I. Taskaev, A. Dasheeva, A. Mochula;
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EPS-113
Early Detection of Anthracycline Combined with Immune Checkpoint Inhibitor Therapy-Related Cardiotoxicity Using [¹⁸F]FDG PET MRI
Y. Cai¹, T. Yuan², X. Xu³, Y. Sun⁴, X. Chen⁵, h. zhu³, T. Wu¹, Z. Yang³, X. Wang¹;
¹Department of Nuclear Medicine, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking

Union Medical College,, Beijing, CHINA, ²Department of Nuclear Medicine, Peking University First Hospital,, Beijing, CHINA, ³Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Peking University, Beijing, CHINA, ⁴Department of Pathology, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, ⁵Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital, Beijing, CHINA.

EPS-114
Low myocardial flow reserve would predict all-cause mortality, cardiovascular mortality, and non-cardiovascular mortality in end stage kidney disease patients
S. Ohshima¹;
Kaikoukai Nagoya Kyoritsu Hospital, Nagoya, JAPAN.

710
Monday, October 6, 2025, 8:00 - 9:30
Room 116
Technologists’ Track Oral Presentations 2 - Technologists Committee: Advanced Practice and Novel Solutions

OP-314
Filling A Void: An altered teaching method for Nuclear Medicine Technology in Australia
M. Scalzo¹, K. Metzger¹, T. Pearson², J. Barlow³;
¹RMIT University, Melbourne, AUSTRALIA, ²Royal Brisbane and Women’s Hospital, Brisbane, AUSTRALIA, ³Queensland X-ray, Brisbane, AUSTRALIA.

OP-315
Revisiting SeHCAT: A Familiar Tool with Renewed Clinical Significance in Nuclear Medicine
M. Ryser¹, S. Figueiredo, J. O. Prior, P. Ferreira, M. Nicod-Lalonde;
CHUV, Lausanne, SWITZERLAND.

OP-316
Correlating Subjective Evaluations in Equine Nuclear Scintigraphy with Radiomic Profiles, Serum Osteocalcin and C-Terminal Telo peptides of Type I Collagen
P. Tually¹, J. Meadows¹, S. Tagore¹, G. Currie²;
¹TeleMedVET, Perth, Western Australia, AUSTRALIA, ²Charles Sturt University, Wagga Wagga, AUSTRALIA.

OP-317
Relationship of point-of-care β-hydroxybutyrate measurements with myocardial glucose uptake: an observational study.
S. Bourouis¹, C. Derneden, Q. Shagera, F. Jamar, O. Gheysens, V. Depoortere;
Cliniques universitaires Saint-Luc, Bruxelles, BELGIUM.

OP-318
Design and Fabrication of Spherical Inserts using Stereolithography for 10 L Imaging Validation Phantom

N. Salkica¹, M. Jusufbegović², A. Beganović³, A. Skopljak-Beganović³, S. Hadžimusić¹, E. Tinjak⁴;
¹Clinic of Nuclear Medicine, Sarajevo, BOSNIA AND HERZEGOVINA, ²Clinic of Radiology, Sarajevo, BOSNIA AND HERZEGOVINA, ³Department for Medical Physics and Radiation Protection, Sarajevo, BOSNIA AND HERZEGOVINA, ⁴Clinic of Oncology, Sarajevo, BOSNIA AND HERZEGOVINA.

OP-319
Evaluating the Effectiveness of Virtual Reality as a distraction tool in Pediatric Scanning Procedures - To Enhance Image Quality and Reducing Anesthesia use
N. Svendsen¹, V. Setterberg;
Rigshospitalet, Copenhagen, DENMARK.

OP-320
Preclinical PET Imaging of B7-H3 Expression Using Affibody Molecules Labelled with Positron-Emitting Gallium-68
M. Oroujeni¹, V. Tolmachev¹, E. A. Bezverkhniaia¹, E. Papalanis¹, A. Mujahid Bin Muhammad¹, A. Verabyova¹, E. Gunneriusson², S. Klint², E. Ryer², M. Carlqvist², W. Kazmierczak², A. Orlova¹, F. Y. Frejd²;
¹Uppsala University, Uppsala, SWEDEN, ²Affibody AB, Stockholm, SWEDEN.

OP-321
Using AI to assess PRRT response in ¹⁷⁷Lu-DOTATATE post-treatment scans: creation of a Python-based tool to automate inter-cycle comparison
F. Montanini¹, E. M. Abenavoli², V. Briganti², M. Nerattini³, A. Lastrucci⁴, C. Galeotti¹, R. Ricci⁴, R. Sciagrà^{2,3}, V. Berti^{2,3};
¹Nuclear Medicine Unit, Department of Health and Rehabilitation Technical Professions, Careggi University Hospital, Florence, ITALY, ²Nuclear Medicine Unit, Department of Diagnostic Services, Careggi University Hospital, Florence, ITALY, ³Department of Experimental and Clinical Biomedical Sciences ‘Mario Serio’, University of Florence, Florence, ITALY, ⁴Department of Health and Rehabilitation Technical Professions, Careggi University Hospital, Florence, ITALY.

OP-322
Development of a Dynamic Flow Phantom for Routine Calibration and Quality Control in [⁸²Rb] RbCl PET imaging.
S. Mallem¹, M. Bernardini²;
¹INSERM - U970 PARCC, Paris, FRANCE, ²Hôpital Européen Georges Pompidou AP-HP, Paris, FRANCE.

711
Monday, October 6, 2025, 8:00 - 9:30
Room 111
Theranostics Track - Oncology & Theranostics Committee: Prostate and Novel Targets

OP-323
[¹⁷⁷Lu]Lu-PSMA-617 SPECT/CT as an Early Response Biomarker for Prediction of Progression Free and Overall Survival in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Enzalutamide and [¹⁷⁷Lu]Lu-PSMA-617 within the ENZA-p Trial (ANZUP 1901)

N. Ayati^{1,2}, N. Papa³, S. Subramaniam^{4,5}, M. Crumbaker^{1,3,6}, E. Askari⁷, R. Alipour^{8,9}, A. Irvani¹⁰, S. Khan¹, S. Yadav¹¹, M. Eiber¹², R. Francis^{13,14}, A. Nguyen¹, M. Hofman^{8,9}, S. Sandhu^{8,9}, T. Hioki¹, J. Oorschodt¹⁵, K. Devitt¹, K. Willowson^{16,17}, S. Sharma¹, A. Stancu¹⁸, S. Chauvie¹⁹, P. Wilson²⁰, M. Stockler⁴, I. Davis^{21,22}, L. Emmett^{1,2,3};
¹St Vincent’s Hospital, Sydney, AUSTRALIA, ²St Vincent’s Clinical School, University of New South Wales, Sydney, AUSTRALIA, ³Garvan Institute of Medical Research, Sydney, AUSTRALIA, ⁴NHMRC Clinical Trials Centre, University of Sydney, Sydney, AUSTRALIA, ⁵Department of Medical Oncology, Bankstown-Lidcombe Hospital, Sydney, AUSTRALIA, ⁶Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent’s Hospital, Sydney, AUSTRALIA, ⁷Nuclear Medicine Research Centre, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ⁸Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC); Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ⁹Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, AUSTRALIA, ¹⁰Department of Radiology, University of Washington, Seattle, WA, UNITED STATES OF AMERICA, ¹¹Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, UNITED STATES OF AMERICA, ¹²Department of Nuclear Medicine, Rechts der Isar Medical Center, Technical University of Munich, Munich, GERMANY, ¹³Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, AUSTRALIA, ¹⁴Medical School, University of Western Australia, Perth, AUSTRALIA, ¹⁵Eindhoven University of Technology, Eindhoven, NETHERLANDS, ¹⁶Royal North Shore Hospital, St. Leonards, Sydney, AUSTRALIA, ¹⁷Institute of Medical Physics, School of Physics, University of Sydney, Camperdown, Sydney, AUSTRALIA, ¹⁸Dixit Srl, Torino, ITALY, ¹⁹Division of Medical Physics, ‘Santa Croce e Carle’ Hospital, Cuneo, ITALY, ²⁰MIM Software, A GE HealthCare Company, Cleveland, OH, UNITED STATES OF AMERICA, ²¹Monash University Eastern Health Clinical School, Melbourne, AUSTRALIA, ²²Eastern Health, Melbourne, AUSTRALIA.

OP-324
Impact of PET-Guided Versus Conventional Imaging-Guided Metastasis-Directed Therapy on Clinical Outcomes in Oligometastatic Castration Resistant Prostate Cancer (omCRPC): A Secondary Analysis of the PRECISE-MDT Study
F. Lanfranchi¹, D. Albano², F. Linguanti³, L. Urso⁴, A. Rizzo⁵, D. Dubois¹, F. Dondi², E. M. Abenavoli⁶, L. Vaggelli⁶, N. Ortolan⁴, F. Garrou⁷, S. Grimaldi⁷, P. Ghedini⁸, A. Iudicello⁸, G. Rovera⁷, D. Vita¹, M. Salgarello⁹, M. Racca⁵, M. Bartolomei⁴, S. Panareo⁸, F. Bertagna², S. Morbelli⁷, G. Sambuceti¹, L. Belgioia¹, M. Bauckneht¹;
¹IRCCS Ospedale Policlinico San Martino, Genova, ITALY, ²Nuclear Medicine, ASST Spedali Civili di Brescia, Brescia, ITALY, ³Nuclear Medicine, Ospedale San Donato, Arezzo, ITALY, ⁴Nuclear Medicine, University Hospital of Ferrara, Ferrara, ITALY, ⁵Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, Torino, ITALY, ⁶Nuclear Medicine, Careggi University Hospital, Firenze, ITALY, ⁷Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, Torino, ITALY, ⁸Nuclear Medicine, University Hospital of Modena, Modena, ITALY, ⁹Nuclear Medicine, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, ITALY.

OP-325
Assessment of PARPi-uptake in metastatic castration resistant prostate cancer patients using [¹⁸F]PARPi- and [⁶⁸Ga]PSMA PET/CT
H. Einspieler, H. Ofner, M. Ozenil, C. P. Spielvogel, I. K. Langrate, M. R. Hassler, L. Nics, K. Bammingner, P. A. T. Baltzer, S. F. Shariat, M. Hacker, G. Kramer, S. Rasul;
 Medical University of Vienna, Vienna, AUSTRIA.

OP-326
Diagnostic Performance, Safety, and Pharmacokinetics of [⁶⁸Ga]Ga-OncoACP3 in Prostate Cancer - Preliminary Results from a Prospective Phase I Clinical Trial
*C. Pini*¹, F. Gelardi¹, M. Sollini^{1,2}, L. Antunovic², R. Di Donato², G. R. Bonfitto², A. Piaï³, R. Petrelli³, M. Minotti², J. Mock⁴, S. Cazzamalli⁴, S. Oehler⁴, A. Ciamarone⁴, F. Migliorini⁴, D. Neri⁴, M. Kirienko⁵, P. A. Erba^{6,7}, A. Chiti^{1,2};
¹Vita-Salute San Raffaele University, Milan, ITALY, ²Department of Nuclear Medicine, IRCCS Ospedale San Raffaele, Milan, ITALY, ³Medical Physics Department, IRCCS Ospedale San Raffaele, Milan, ITALY, ⁴Philochem AG, Otelfingen, SWITZERLAND, ⁵Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, ITALY, ⁶School of Medicine and Surgery, University of Milano-Bicocca, Milan, ITALY, ⁷Nuclear Medicine Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, ITALY.

OP-327
Theranostic targeting of the prostatic acid phosphatase (ACP3) with [⁶⁸Ga]Ga-OncoACP3-DOTA and [¹⁷⁷Lu]Lu-OncoACP3-DOTA in prostate cancer patients
P. Backhaus^{1,2}, K. E. Seifert^{2,3}, S. Cazzamalli⁴, S. Oehler⁴, F. Migliorini⁴, A. Ciamarone⁴, T. Georgiev⁴, J. Mock⁴, M. Bögemann³, H. Breyholz¹, D. Ventura^{1,2}, F. Landau^{1,2}, F. Büther^{1,2}, E. Puca⁴, D. Neri⁴, K. Rahbar¹, A. J. Schrader³, M. Schäfers^{1,2};
¹Department of Nuclear Medicine, West German Cancer Center, University Hospital Münster, Münster, GERMANY, ²European Institute for Molecular Imaging, University of Münster, Münster, GERMANY, ³Department of Urology, Werst German Cancer Center, University Hospital Münster, Münster, GERMANY, ⁴Philochem AG, R&D department, Otelfingen, SWITZERLAND.

OP-328
FAPSTera: Comparison of [¹⁸F]DCFPyL and [¹⁸F]FAPI-74 PET/CT imaging in metastatic prostate cancer
*H. Minn*¹, A. Hyväkkä¹, M. Sundvall¹, V. Sivonen¹, K. Mattila¹, M. Anttinen², O. Ettala², M. Högerman², A. Kirjavainen³, O. Eskola³, S. Forsback³, V. Saunavaara⁴, M. Seppänen⁵, S. Malaspina⁵;
¹Department of Oncology and FICAN West Cancer Centre, University of Turku and Turku University Hospital, Turku, FINLAND, ²Department of Urology, University of Turku and Turku University Hospital, Turku, FINLAND, ³Radiopharmaceutical Chemistry, Turku PET Centre, University of Turku, Turku, FINLAND, ⁴Department of Medical Physics and Turku PET Centre, Turku University Hospital, Turku, FINLAND, ⁵Department of Nuclear Medicine and Turku PET Centre, University of Turku and Turku University Hospital, Turku, FINLAND.

OP-329
Impact of Radiotherapy on Overall Survival in Prostate Cancer Patients with Biochemical Recurrence Staged by PROMISE Criteria Using PSMA-PET

*C. Civan*¹, M. J. Karpinski^{1,2}, S. Hoberück³, K. Herrmann¹, K. Rahbar², M. Bögemann⁴, L. Nikoukar², M. Schäfers², M. Miederer⁵, T. Hölscher³, S. Rasul⁶, C. H. Pfob⁷, K. Goffin⁸, A. Gafita⁹, J. Hüsing¹⁰, J. Calais¹¹, M. S. Hofman¹², T. A. Hope¹³, T. Soeterik¹⁴, A. D. Giorgio¹⁵, L. M. Unterrainer¹⁶, A. Holzgreve¹⁶, G. T. Sheikh¹⁶, I. Rauscher¹⁷, M. Eiber¹⁷, B. A. Hadaschik¹⁸, M. Stuschke¹⁹, W. P. Fendler¹, N. Guberina¹⁹, PROMISE Registry Group;
¹Department of Nuclear Medicine, DTK and NCT University Hospital Essen, Essen, GERMANY, ²Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY, ³Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, GERMANY, ⁴Department of Urology, University Hospital Münster, Münster, GERMANY, ⁵Department of Translational Imaging in Oncology, National Center for Tumour Diseases (NCT/UCC) Dresden: Faculty of Medicine and University Hospital Carl Gustav Carus, University of Technology Dresden, Dresden, GERMANY, ⁶Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University Vienna, Vienna, AUSTRIA, ⁷Department of Nuclear Medicine, University of Augsburg, Augsburg, GERMANY, ⁸Department of Nuclear medicine, University Hospitals Leuven, KU Leuven, Leuven, BELGIUM, ⁹Johns Hopkins University School of Medicine, The Russell H. Morgan Department of Radiology, Baltimore, MD, UNITED STATES OF AMERICA, ¹⁰Cancer Registry North-Rhine Westphalia, Bochum, GERMANY, ¹¹Ahmanson Translational Theranostics Division, David Geffen School of Medicine at UCLA,, Los Angeles, CA, UNITED STATES OF AMERICA, ¹²Sir Peter MacCallum Department of Oncology and Department of Medicine, University of Melbourne, Melbourne, AUSTRALIA, ¹³Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, UNITED STATES OF AMERICA, ¹⁴Department of Urology, St Antonius Ziekenhuis Nieuwegein/Utrecht,, Utrecht, NETHERLANDS, ¹⁵Department of Nuclear Medicine, Alma Mater Studiorum, University of Bologna, Bologna, ITALY, ¹⁶Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany, Munich, GERMANY, ¹⁷Department of Nuclear Medicine, School of Medicine and Health, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany, Munich, GERMANY, ¹⁸Department of Urology, University Hospital Essen, Essen, Germany, Essen, GERMANY, ¹⁹Department of Radiotherapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY.

OP-330
Kinetic Profiling of [⁶⁸Ga]Ga-PSMA-11 Using Total-Body PET in Suspected Prostate Cancer: Preliminary Results from the Prospective FUPERMAN Study
*A. Farolfi*¹, I. Brusa¹, D. Dall’Olio², C. M. P. Sgro³, L. Bianchi⁴, R. Mei¹, C. Nanni¹, P. Castellucci¹, S. Fanti¹;
¹Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ²Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, ITALY, ³Nuclear Medicine, Alma Mater Studiorum - University of Bologna, Bologna, ITALY, ⁴Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-331
¹⁷⁷Lu-PSMA-1 applied to ccRCC
A. Giraudet, A. Vinceneux, A. Sanchez-Lajusticia, G. Garin, J. Badel, D. Perol, A. Bidaux, C. Cropet, C. Trolliet, D. Kryza;
 Centre Léon Bérard, Lyon, FRANCE.

801
Monday, October 6, 2025, 09:45 - 11:15
Auditorium
CME 6 - Oncology & Theranostics Committee: PET in mCRPC: Toward Multiparametric Multitracer Biomarkers

OP-332
Evaluating mCRPC with PSMA PET: Strengths and Pitfalls
I. Burger; Kantonsspital Baden, Nuclear Medicine, Baden, SWITZERLAND.
OP-333
Multi-Tracer PET/CT for the Characterisation and Prognostication of mCRPC: the 3TMPO Study
Jean-M. Beauregard; CHU de Quebec, Université Laval, Quebec City, Quebec, CANADA.

OP-334
Standardised Assessment: Promise V2 and Beyond
W. Fendler; Universitätsklinikum Essen, Klinik für Nuklearmedizin, Essen, GERMANY.

OP-335
Multimodal Imaging in mCRPC: A Game Changer
N. Tunariu; The Institute of Cancer Research, Division of Radiotherapy and Imaging, Sutton, UNITED KINGDOM.

802
Monday, October 6, 2025, 09:45 - 11:15
Room 112 (Arena)
Special Track 6 - Cardiovascular Committee: Challenge the Expert: Myocardial Perfusion Imaging : Should I Stay with SPECT or Go with PET?

OP-336
I Should Definitely Stay with SPECT for Myocardial Perfusion Imaging
M. Bailly; CHU Orléans, Department of Nuclear Medicine, Orléans, FRANCE.
OP-337
I Should Definitely Move to PET for Myocardial Perfusion Imaging
P. Arumugam; Manchester University, Department of Nuclear Medicine, Manchester, UNITED KINGDOM.

803
Monday, October 6, 2025, 09:45 - 11:15
Room 113
LIPS Session 6 - Radiation Protection Committee: What Would You Do If...? Radiation Protection Issues in Special Cases of Everyday Practices

OP-338
After an Imaging Procedure, It Is Realised that the Patient Is Pregnant. What Would You Do?
I. Schatka; Department of Nuclear Medicine, Charité-Universitätsmedizin , Berlin, GERMANY.

OP-339
A Breast-feeding Patient Needs a NM Scan or NM Treatment. What Would You Do?
S. Leide Svegborn; Department of Medical Radiation Physics, Skåne University Hospital, Lund University, Lund, SWEDEN.

OP-340
A Patient Treated with Lu-177, I-131 or Ra-223 Needs to Be Transferred to an Intensive Care Unit or Any Other Department of the Hospital. What Would You Do?
J. Kurth; University Medical Center Rostock, Department of Nuclear Medicine, Rostock, GERMANY.

OP-341
How Do You Report SUV in PET in Case of an Extravasation?
J. van der Pol; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, NETHERLANDS.

OP-342
A patient Who Has Recently Undergone a Nuclear Medicine Procedure Sets Off an Alarm at an Airport Security Scanner. What Would You Do?
A. Stenvall; Radiation Physics, Skåne University Hospital, Lund, SWEDEN.

804
Monday, October 6, 2025, 9:45 - 11:15
Room 114

M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Optimising Radiolabeling and Quality Control: The Key for Clinical Translation

OP-343
Optimization and Scale-Up of ¹⁷⁷Lu Radiolabeling of PSMA-ALB-56 for Automated Patient Dose Preparation
C. Fersing^{1,2}, J. Torchio¹, S. Renaud¹, L. Rubira¹, J. Vanney¹;
¹Montpellier Cancer Institute, Nuclear Medicine Unit, Montpellier, FRANCE, ²IBMM, Univ Montpellier, CNRS, ENSCM, Montpellier, FRANCE.

OP-344
Fully compliant automated cassette-based sterility testing of radiopharmaceuticals on miniAllinOne
*T. Vergote*¹, C. Vriamont¹, P. Novelli¹, F. De Meeus d’Argenteuil¹, K. Van Butsele¹, G. Zeiske², M. Nousch²;
¹Trasis, Ans, BELGIUM, ²CUP Contract Labs, Radeberg, GERMANY.

OP-345
²²⁵Ac-radiopharmaceuticals and Their Daughters - HPLC-Based Liquid Scintillation Detection for Routine Characterization

G. Claude, M. Balzer, W. Brenner, S. Spreckelmeyer;
Charité – Universitätsmedizin Berlin, Klinik für
Nuklearmedizin, Berlin, GERMANY.

OP-346
Nitrosoarenes for ¹⁸F-labeling - insights into substrate scope

M. Laube¹, S. Roscales², J. Pietzsch^{1,3}, A. G. Csáky²;
¹Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY, ²Instituto Pluridisciplinar, Universidad Complutense de Madrid, Madrid, SPAIN, ³Faculty of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, Dresden, GERMANY.

OP-347
PYTA is the new DOTA - A versatile chelator for targeted radionuclide therapy

M. Cheveau^{1,2}, M. Moreau², A. Grohmann¹, S. Robert¹, M. Mendes-Arnaud¹, D. Vivier², A. Cochet^{2,3}, B. Collin^{2,3}, F. Boschetti¹, S. Poty², F. Denat²;
¹Chematech-MDT, Dijon, FRANCE, ²ICMUB, UMR 6302, CNRS, Université Bourgogne Europe, Dijon, FRANCE, ³Centre Régional De Lutte Contre Le Cancer Georges François Leclerc, Dijon, FRANCE.

OP-348
Chelating [²²⁷Th]Th⁴⁺ For Peptide Receptor Radionuclide Therapy Of Neuroendocrine Tumours

L. Wharton¹, S. W. McNeil^{1,2}, H. Meeres^{1,2}, D. Zhang^{1,2}, A. Ingham³, H. Merkens⁴, M. Osooly⁵, C. Rodríguez-Rodríguez^{6,7,8}, F. Bénard^{4,9}, H. Yang^{1,2,10};
¹TRIUMF, Vancouver, BC, CANADA, ²Department of Chemistry, University of British Columbia, Vancouver, BC, CANADA, ³Memorial Sloan Kettering Cancer Center, New York City, NY, UNITED STATES OF AMERICA, ⁴British Columbia Cancer Research Centre, Vancouver, BC, CANADA, ⁵Alpha 9 Oncology, Vancouver, BC, CANADA, ⁶Centre for Comparative Medicine, Vancouver, BC, CANADA, ⁷Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, CANADA, ⁸Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA, ⁹Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, ¹⁰Department of Chemistry, Simon Fraser University, Vancouver, BC, CANADA.

OP-349
Impact of formulation buffers on the radiolysis and stability of RHN001-Tx (¹⁸⁸Re-PSMA)

A. Mdlophane^{1,2}, S. Mdanda^{1,2}, S. M. Sibiya^{1,2}, M. Qebetu^{1,2}, K. Ramonaheng^{1,2}, M. M. Sathekge^{1,2,3}, F. L. Giesel⁴, J. Cardinale⁴;
¹Nuclear Medicine Research Infrastructure, Pretoria, SOUTH AFRICA, ²University of Pretoria, Pretoria, SOUTH AFRICA, ³Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA, ⁴Medical Faculty and University Hospital Duesseldorf, Duesseldorf, GERMANY.

OP-350
3p-C-DEPA_{-TFP}-PEG₄ as an effective bifunctional chelator for radiolabelling ¹⁶¹Tb and ²²⁵Ac for theranostic applications

J. Pougoue Ketchemen¹, S. Ahenkorah², E. Nwangele¹, F. Njotu¹, D. Fon¹, M. Khosravifarsani¹, K. Bato¹, M. Ooms³, C. Van Laere³, S. Leekens⁴, F. Cleeren⁴, H. Fonge¹;
¹Université Laval, Quebec, QC, CANADA, ²University of Iowa Health Care, Iowa, IA, UNITED STATES OF AMERICA, ³Belgian Nuclear Research Center (SCK CEN), Mol, BELGIUM, ⁴University of Leuven, Leuven, BELGIUM.

OP-351
Bischelate Strategy for a “Pseudo-Theranostic Pair” (PET and RIT): Synthesis and in vivo Evaluation of the First Site-Specific DFO/DOTAGA Immunoconjugate

D. Vivier¹, M. Grah Kple¹, J. Ariztia¹, M. Moreau¹, M. Claron¹, A. Laouafa¹, A. Kownacka², C. Petitot², J. Simonet², R. Ruffin², A. Oudot², B. Collin², F. Denat¹;
¹Université Bourgogne Europe, CNRS, ICMUB UMR 6302, Dijon, FRANCE, ²Centre Georges François Leclerc, IMATHERA, BioSanD – UMS INSERM 58, Dijon, FRANCE.

805

Monday, October 6, 2025, 9:45 - 11:15
Room 211

Cutting Edge Science Track - TROP Session - AI Committee: Disease Characterisation and Prediction Models

OP-352
Reactive Evaluation - A Novel Alternative to Transfer Learning to Handle Multi-Centric Variations in Prostate Cancer Cohorts

L. Papp¹, S. Wail², D. Haberl¹, L. Dolezel², M. Hacker¹, R. A. Bundschuh³, C. Lapa⁴, R. Laudicella⁵, I. Burger⁶, W. Drexler¹;
¹Medical University of Vienna, Vienna, AUSTRIA, ²Telix Pharmaceuticals, Melbourne, AUSTRALIA, ³Universitätsklinikum Carl Gustav Carus Dresden, Dresden, GERMANY, ⁴Universitaetsklinikum Augsburg, Augsburg, GERMANY, ⁵Università di Messina, Messina, SWITZERLAND, ⁶Kantonspital Baden, Baden, SWITZERLAND.

OP-353
PSMA PET radiomics in risk stratification of prostate cancer; A machine learning approach

K. Mathiazhagan, K. B. Chandra, R. Kumar, C. D. Patel, A. Seth, S. Kaushal, G. Priyanka;
All India Institute of Medical Sciences, Delhi, INDIA.

OP-354
Training Classical Neural Networks with Quantum Learning to Improve Cancer Prediction Models

L. Papp¹, S. Moradi¹, D. Haberl¹, C. Spielvogel¹, Z. Ritter², A. Boukhari³, M. Hatt³, W. Drexler¹;
¹Medical University of Vienna, Vienna, AUSTRIA, ²Medical University of Pécs, Pécs, HUNGARY, ³University of Brest, LaTIM, INSERN, Brest, FRANCE.

OP-355
Time-activity Curves Learning for Differentiating Benign and Malignant Lung Lesions with Dynamic [¹⁸F]FDG-PET

T. Sun¹, Z. Yao¹, Y. Wang², Y. Wu³, Y. Liang², M. Wang³;
¹Chinese Acedemy of Sciences, Shenzhen, CHINA, ²Shenzhen Cancer Hospital, Shenzhen, CHINA, ³Henan Provincial People's Hospital, Zhengzhou, CHINA.

OP-356
Machine Learning-Based Prediction of Radiochemotherapy Response in NSCLC Using ¹⁸F-FDG PET/CT

R. Da-ano¹, O. Tankyevych², Y. Mtazaoui², C. Cheze Le Rest², D. Visvikis¹;
¹INSERM - DR GRAND OUEST/ LaTIM U1101, Brest, FRANCE, ²Nuclear Medicine, University of Poitiers, Poitiers, FRANCE.

OP-357
Dual-Attention Deep Learning Framework for Non-Invasive Histological Subtyping of Lung Cancer Using ¹⁸F-FDG PET/CT Imaging

Y. Jia¹, X. Zhu², M. Hacker¹, X. Li¹, Y. Wu², S. Xue¹;
¹Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, AUSTRIA, ²Department of Nuclear Medicine, Peking University Cancer Hospital Inner Mongolia Hospital/Cancer Hospital Affiliated to Inner Mongolia Medical University, Hohhot, CHINA.

OP-358
Evaluating tumour heterogeneity and therapy response with AI-assisted longitudinal analysis of FDG- and PSMA-PET/CT

L. Förner^{1,2}, K. Tehlan^{1,2}, E. Gastreich de Llanes¹, J. Enke¹, Z. Reinke¹, K. Hildebrand¹, P. Hoffmann¹, M. Trepel¹, R. Claus¹, C. Lapa¹, T. Wendler^{1,2}, LF and KT are first authors with equal contribution;
¹University Hospital Augsburg, Augsburg, GERMANY, ²Technical University of Munich, Munich, GERMANY.

OP-359
AI-Assisted Detection of Prostate Cancer Lesions on 18F-Flutufolastat PET/CT: Agreement with Expert Readers.

P. Blanc-Durand¹, C. Besnier¹, A. Dujardin², R. Penny³, E. Itti¹;
¹CHU Henri Mondor, Créteil, FRANCE, ²PAIRE, Paris, FRANCE, ³Blue Earth Diagnostics, Oxford, UNITED KINGDOM.

806

Monday, October 6, 2025, 9:45 - 11:15
Room 117

Clinical Oncology Track - TROP Session - Oncology & Theranostics Committee: NET Imaging

OP-361
A phase I/II study of [⁶¹Cu]Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET Trial

G. Nicolas¹, A. Chirindel¹, F. Kaul¹, L. McDougall¹, A. Johayem², A. Llamazares², M. Baier³, N. Schubert³, F. De Rose³, B. Pais³, L. Jaafar-Thiel³, M. Alejandro Lafont¹, A. Bauman¹, M. Fani¹, D. Wild¹;
¹Department Theragnostics, University Hospital Basel, Basel, SWITZERLAND, ²Department of nuclear Medicine, University Hospital Zurich, Zürich, SWITZERLAND, ³Nuclidium AG, Basel, SWITZERLAND.

OP-362
Head-to-head comparison of [¹⁸F]AIF-NOTA-TATE and [⁶⁸Ga]Ga-DOTA-TATE PET/CT in Patients with Neuroendocrine Tumors: a prospective study

H. Liu, G. Ma, H. Wen, X. Zhang, R. Wang, J. Zhang;
Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, Beijing, CHINA.

OP-363
Intra-individual Comparison of 68Ga-DOTA-TOC PET/CT and 18F-SiTATE PET/CT: Frequency of Pitfalls in patients with neuroendocrine tumors (G1-G2)

K. Hansen, J. Q. Petzold, M. C. M. Gammel, A. Richter, W. A. Weber, M. Eiber, I. Rauscher, S. Notohamiprodjo;
TUM Klinikum Rechts der Isar, Munich, GERMANY.

OP-364
High versus Low Specific Activity in the Biodistribution of [¹⁸F]SiTATE: A Matched-pair Analysis of clinical PET Data

J. Petzold¹, S. Notohamiprodjo¹, A. Richter¹, A. Wurzer¹, P. Bösl¹, S. Fischer¹, S. Lindner², J. Allmann¹, W. Weber¹, M. Eiber¹, I. Rauscher¹;
¹TUM University Hospital, Munich, GERMANY, ²LMU University Hospital, Munich, GERMANY.

OP-365
First histological ex vivo validation of the novel [¹⁸F]SiTATE SSTR PET tracer

N. Trautwein¹, S. Mattern², M. Hinterleitner³, G. Reischl⁴, R. Schirrmacher⁵, V. Steger⁶, S. Nadalin⁷, K. Nikolaou⁸, J. Schwenck¹, S. Singer⁹, C. la Fougère¹;
¹Nuclearmedizin Tuebingen, Tübingen, GERMANY, ²Pathology Tuebingen, Tübingen, GERMANY, ³Internal Medicine VIII Tuebingen, Tübingen, GERMANY, ⁴Preclinical imaging and radiopharmacy Tuebingen, Tübingen, GERMANY, ⁵Medical Isotope and Cyclotron Facility, Alberta, AB, CANADA, ⁶Department of Thoracic and Cardiovascular Surgery Tuebingen, Tübingen, GERMANY, ⁷Department of General, Visceral and Transplant Surgery Tuebingen, Tübingen, GERMANY, ⁸Department of Diagnostic and Interventional Radiology Tuebingen, Tübingen, GERMANY, ⁹Patology Tuebingen, Tübingen, GERMANY.

OP-366
Retrospective Evaluation of [¹⁸F]AIF-NOTA-Octreotide PET/CT in 288 Patients Referred for SSTR PET/CT

H. Leupe¹, S. De Buyst¹, J. Dekervel¹, F. Cleeren², C. Dooms¹, K. Goffin¹, S. Jentjens¹, L. Boeckxstaens¹, F. Van Herpe¹, E. Van Cutsem¹, P. Clement¹, G. Rasschaert¹, G. Bormans², C. Verslype¹, C. Deroose¹;
¹UZ Leuven, Leuven, BELGIUM, ²KU Leuven, Leuven, BELGIUM.

OP-367
[⁶⁸Ga]Ga-FAPI PET/MR Imaging for Predicting Invasive Potential in Pituitary Neuroendocrine Tumors

Y. Xi¹, J. Li², X. Wang², Y. Lu², W. Sun¹, X. Zhang¹, W. Hai¹, B. Li¹, S. Lin²;
¹Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, CHINA, ²Department of Neurosurgery, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, CHINA.

OP-368
Validation of PET Response Evaluation Criteria in Neuroendocrine Tumors (PERCIN) in an Independent Cohort.

A. Chaban¹, L. Unterrainer², R. Werner², A. Holzgreve², L. Bode³, W. Weber¹, G. Sheikh²;
¹Klinik und Poliklinik für Nuklearmedizin, Klinikum Rechts der Isar, Technische Universität München, München, GERMANY, ²Klinik und Poliklinik für Nuklearmedizin, LMU Klinikum München, München, GERMANY, ³Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA, New York, NY, UNITED STATES OF AMERICA.

United Imaging Intelligence Imaging Technology Research Institute, Beijing, CHINA, ³United Imaging Healthcare, Shanghai, CHINA.

EPS-119

Multi-site, prospective trial of FET-PET In Glioblastoma (FIG) Study (TROG 18.06):Results of central review of FET-PET biologic target volume delineation for radiation planning.

A. Scott¹, R. Francis², S. Lee¹, E. Lau³, E. Thomas², A. Moore⁴, D. Pattison⁵, T. Akhurst⁶, E. Hsiao⁷, G. Schembri⁷, P. Lin⁸, I. Kirkwood⁹, D. Krishna¹⁰, S. Ngai¹¹, S. Beuzeville¹², D. Wong¹³, N. Barry¹⁴, M. Ebert², H. Gan¹, S. Ng¹, M. Pinkham¹¹, D. Bailey⁷, E. Koh¹⁵;

¹ONJCRI and Austin Health, Heidelberg, AUSTRALIA, ²Sir Charles Gairdiner Hospital, Perth, AUSTRALIA, ³Austin Health, Heidelberg, AUSTRALIA, ⁴TROG, Newcastle, AUSTRALIA, ⁵Royal Brisbane and Womens Hospital, Brisbane, AUSTRALIA, ⁶Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ⁷Royal North Shore Hospital, St Leonards, AUSTRALIA, ⁸Liverpool Hospital, Sydney, AUSTRALIA, ⁹Royal Adelaide Hospital, Adelaide, AUSTRALIA, ¹⁰Canberra Hospital, Canberra, AUSTRALIA, ¹¹Princess Alexandra Hospital, Brisbane, AUSTRALIA, ¹²St George Hospital, Sydney, AUSTRALIA, ¹³Wesley Hospital, Brisbane, AUSTRALIA, ¹⁴University of Western Australia, Perth, AUSTRALIA, ¹⁵Liverpool Hospital, Liverpool, AUSTRALIA.

EPS-120

Metabolic activity of proton radiation therapy related effects in gliomas measured with [18F]FET PET imaging

K. Madsen¹, A. Muhic^{2,3}, J. Skjøth-Rasmussen⁴, J. Carlsen⁵, D. Scheie⁶, I. Law¹, O. Henriksen¹;

¹Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital Rigshospitalet, Copenhagen, DENMARK, ²Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, DENMARK, ³Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, DENMARK, ⁴Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Copenhagen, DENMARK, ⁵Department of Radiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, DENMARK, ⁶Department of Pathology, Copenhagen University Hospital Rigshospitalet, Copenhagen, DENMARK.

EPS-121

[18F]FDOPA PET/MRI in Brain Metastases: Effect of Immunotherapy in Detecting Tumor Relapse

M. Suárez-Piñera¹, C. Cases Pellise², C. Salomón³, N. Vilariño Quintela⁴, R. Velasco Fargas⁵, M. Pudis¹, L. Rodríguez-Bel¹, B. Hervás Sanz¹, M. Cortés-Romera¹;

¹Hospital Universitario de Bellvitge. (Nuclear-Medicine Department), Barcelona, SPAIN, ²Department of Nuclear Medicine. Hospital Universitario Virgen del Rocío, Sevilla, SPAIN, ³Department of Nuclear Medicine. Hospital Universitario Son Espases, Palma. Islas Baleares, SPAIN, ⁴Medical Oncology Department, Catalan Insitute of Oncology, L' Hospitalet, Barcelona, SPAIN, ⁵Department of Neurology, Institut Català d'Oncologia (ICO)-Hospital Universitari de Bellvitge, Barcelona, SPAIN.

EPS-122

Analytic processing of dynamic ¹⁸F-FET PET Time Activity Curves in patients affected by different grades of gliomas.

C. Pettinato¹, L. Savio², A. Castello³, L. Florimonte³, G. Zuccotti⁴, F. Buffoni³, C. Canzi¹, A. Barantani¹, M. Schiavini³, E. Galli³, M. Arnaboldi³, M. Campoleoni¹, M. Castellani³;

¹Health Physics - Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, ITALY, ²Department of Physics - University od Milan, Milan, ITALY, ³Nuclear Medicine - Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, ITALY, ⁴Nuclear Medicine - Regional Hospital U. Parini, Aosta, ITALY.

EPS-123

Noninvasive Assessment of IDH Mutation Status and WHO Grade in Untreated Prospective Glioma Patient Cohort using Integrated ¹⁸F-FET PET/MR

B. Yu¹, W. Zhou¹, M. Li¹, Z. Lin², Y. Wei², X. Chen², Y. Yang³, T. Hua¹;

¹Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ²United Imaging Healthcare Co., Ltd., Shanghai, Shanghai, CHINA, ³Beijing United Imaging Healthcare Co., Ltd., Beijing, Beijing, CHINA.

EPS-124

MRI radiomic analyses to predict the clinical utility of additional [¹⁸F]FET PET imaging in glioblastoma patients

L. Kaiser¹, A. J. Zounek¹, E. Istrefi¹, J. Isakaj¹, E. Barci¹, J. Reis², R. Forbrig², B. Wiestler³, K. J. Müller¹, L. von Baumgarten⁴, M. J. Mair^{1,5}, S. Ziegler^{6,1}, N. L. Albert¹;

¹Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ²Institute of Neuroradiology, LMU University Hospital, LMU Munich, Munich, GERMANY, ³Department of Neuroradiology, Klinikum Rechts der Isar, Technical University of Munich, Munich, GERMANY, ⁴Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, GERMANY, ⁵Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, AUSTRIA, ⁶Department of Nuclear Medicine, Hannover Medical School (MHH), Hannover, GERMANY.

EPS-125

Can radiomics from conventional MRI forecast [¹⁸F] FET PET positivity in patients with suspected low-grade gliomas?

L. Kaiser¹, A. J. Zounek¹, E. Istrefi¹, J. Isakaj¹, E. Barci¹, J. Reis², R. Forbrig², B. Wiestler³, K. J. Müller⁴, L. von Baumgarten⁵, M. J. Mair^{1,6}, S. Ziegler^{7,1}, N. L. Albert¹;

¹Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ²Institute of Neuroradiology, LMU University Hospital, LMU Munich, Munich, GERMANY, ³Department of Neuroradiology, Klinikum Rechts der Isar, Technical University of Munich, Munich, GERMANY, ⁴Department of Neurology, LMU University Hospital, LMU Munich, Munich, GERMANY, ⁵Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, GERMANY, ⁶Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, AUSTRIA, ⁷Department of Nuclear Medicine, Hannover Medical School (MHH), Hannover, GERMANY.

EPS-126

SSTR-PET Characteristics of Meningiomas: a Retrospective Comparison of Gallium-68- and Fluorine-18-labelled Tracers

L. Degryse¹, L. Teles², S. De Vleeschouwer¹, L. Boeckxstaens¹, S. Jentjens³, W. Deckers¹, G. Schramm¹, M. Lambrecht¹, J. Daisne⁴, K. Van Laere¹, P. Clement¹, K. Goffin¹, C. M. Deroose¹;

¹University Hospitals Leuven, Leuven, BELGIUM, ²Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS, ³Maastricht University Medical Center, Maastricht, NETHERLANDS, ⁴ZAS, Antwerp, BELGIUM.

EPS-127

Calibration of 3D ring-design SPECT/CT system to ENC-DAT database

T. Noponen, H. Suoraniemi, A. Rissanen, M. Seppänen; Turku University Hospital, Turku, FINLAND.

EPS-128

Clinical Impact of Dual-Biomarker PE2I-PET in the Differential Diagnosis of Parkinsonian Syndrome: A Retrospective Study

T. Crnic Bojkovic¹, L. Falk¹, L. Appel¹, C. Widström¹, D. Nyholm², J. Sörensen¹, T. Danfors¹, M. Lubberink¹, M. Jonasson¹;

¹Department of Surgical Sciences, Molecular Imaging and Medical Physics, Uppsala University, Uppsala, SWEDEN, ²Department of Medical Sciences, Neurology, Uppsala University, Uppsala, SWEDEN.

EPS-130

A Head-to-head Comparison of ¹⁸F-DPA714 PET and ¹⁸F-FDG PET in the diagnosis of Autoimmune Encephalitis

M. Zhang¹, H. Meng², S. Chen², H. Wang¹, B. Li¹;

¹Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ²Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

EPS-131

In search of the optimal pseudo-reference region for the quantification of synaptic density using Positron Emission Tomography imaging with [¹¹C]UCB-J in Alzheimer's Disease

I. Arino¹, A. Dubois¹, P. Testard², M. Tonietto³, G. Klein³, C. Clerget¹, P. Gervais¹, A. Pinon¹, B. Zinnhardt³, I. Gerlach¹, M. Ly-Le Moal³, A. Petiet⁴, T. Lebouvier⁵, D. Wallon⁶, G. Dorothee², M. Potier⁸, A. Kas⁹, M. Sarazin^{2,1}, M. Bottlaender¹, J. Lagarde^{1,2};

¹Université Paris-Saclay, BioMaps, CEA, Inserm Service Hospitalier Frédéric Joliot, Orsay, FRANCE, ²Service de Neurologie de la Mémoire et de Langage, GHU Paris Psychiatrie et Neurosciences, 75014 Paris, FRANCE, ³Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center, Basel, SWITZERLAND, ⁴Institut Roche, 92100 Boulogne-Billancourt, FRANCE, ⁵Univ Lille, Inserm U1172, Lille, France ; CHU de Lille, DISTALZ, F-59000 Lille, FRANCE, ⁶Normandie Univ, UNIROUEN, Inserm U1245; CHU Rouen, Department of Neurology and CNR-MAJ, F 76000 Rouen, FRANCE, ⁷Sorbonne Université, Inserm ; Centre de Recherche Saint-Antoine, CRSA, Immune System and Neuroinflammation Laboratory, Hôpital Saint-Antoine, Paris, FRANCE, ⁸Paris Brain Institute (ICM), Centre National de la Recherche Scientifique (CNRS) UMR 7225, INSERM U1127, Hôpital de la Pitié-Salpêtrière, Sorbonne Université, Paris, FRANCE, ⁹Service de médecine nucléaire, Hôpital Pitié-Salpêtrière, 75013 Paris, FRANCE.

EPS-132

¹⁸F-SynVesT-1 PET Imaging Reveals Synaptic Density Abnormalities and Brain Network Alterations in Tinnitus Patients: A Pilot Study

J. Zhong, S. Hu; Xiangya Hospital,Central South University, Changsha, CHINA.

EPS-133

Evidence for brain glial activity in chronic migraine patients: A [¹¹C] PBR28 PET/MR study

Y. Chang, R. Wang; Chinese PLA General Hospital, Beijing, CHINA.

EPS-134

Simplified Quantification of Brain Estrogen Receptors with Fluoroestradiol PET: Evidence Supporting a 30-60 Minute Window for SUVR Calculation

M. Nerattini¹, V. Berti¹, D. C. Matthews², S. Williams³, C. Andy³, F. Fauci³, C. Boneu³, T. Ajila³, S. Pahlajani³, M. Battista³, R. Andrews², A. Pupi¹, R. Diaz Brinton⁴, J. P. Dyke³, L. Mosconi³;

¹University of Florence, Florence, ITALY, ²ADM Diagnostics, Northbrook, IL, UNITED STATES OF AMERICA, ³Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA, ⁴University of Arizona, Tucson, AZ, UNITED STATES OF AMERICA.

EPS-135

Precision Diagnostics in Neurodegeneration via AI-Augmented PET/MRI Fusion of ASL, DTI, and PET

J. Strobel¹, J. Kassubek², G. Grön³, A. J. Beer⁴, M. Beer⁵, H. Müller¹, N. Sollmann¹;

¹Department of Nuclear Medicine and Department of Diagnostic and Interventional Radiology, University Hospital Ulm, Ulm, GERMANY, ²Department of Neurology, University Hospital Ulm, Ulm, GERMANY, ³Department of Psychiatry and Psychotherapy III, University Hospital Ulm, Ulm, GERMANY, ⁴Department of Nuclear Medicine, University Hospital Ulm, Ulm, GERMANY, ⁵Department of Diagnostic and Interventional Radiology, University Hospital Ulm, Ulm, GERMANY.

810

Monday, October 6, 2025, 09:45 - 11:15

Room 116

CTE 4 - Technologists Committee: Breathing Knowledge – the New Approaches of PET-CT Lung Scanning

OP-388

The Impact of PET/CT in Patients with Lung Cancer

R. Mei; Nuclear Medicine, IRCCS Policlinico S.Orsola Malpighi, Bologna, ITALY.

OP-389

The Role of the Technologists in PET/CT Lung Imaging: Techniques and Patient Care

S. Valente; Hospital Lusíadas Lisboa, Nuclear Medicine, Lisbon, PORTUGAL.

OP-390

A Step into the Future: Perspectives for Lung Cancer in Nuclear Medicine

H. Hautzel; University Hospital Essen, Nuclear Medicine, Essen, GERMANY.

811

Monday, October 6, 2025, 09:45 - 11:15
Room 111

Special Symposium 3 - Dosimetry Committee:
Challenges in Dosimetry of Alpha-Emitters

OP-392
Need of Validated Primary and Secondary Standards to Calibrate Alpha Emitters in Radionuclide Calibrators
A. Denis-Bacelar; National Physical Laboratory (NPL), London, UNITED KINGDOM.

OP-393
Feasibility of SPECT–Based Dosimetry of Alpha Emitters
J. Gustafsson; Lund University, Medical Radiation Physics, Lund, SWEDEN.

OP-394
How to Address Daughters’ Redistribution in Dosimetry of Alpha Emitters
A. Delker; Ludwig-Maximilians-Universität, Munich, GERMANY.

OP-395
Small Scale Dosimetry and Microdosimetry to Better Understand Treatment Outcomes
P. Mínguez Gabiña; Gurutzeta/Cruces University Hospital, Department of Medical Physics, Barakaldo, SPAIN.

901

Monday, October 6, 2025, 11:30 - 13:00
Auditorium

Plenary 3: Referring Patients to Nuclear
Medicine: When, How and Mainly Why?

OP-396
Never without Nuclear Medicine in Prostate Cancer, is Kidney Cancer Next in Line?
S. Muselaers; Radboudumc, Nijmegen, NETHERLANDS

OP-397
New Targets in Kidney Cancer
L. Lindenberg; National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, UNITED STATES OF AMERICA.

OP-398
Nuclear Medicine Is Routine in Lung Cancer and Optional in the Majority of Breast Cancers
A. Gennari; University of Piemonte Orientale, Department of Oncology, Maggiore University Hospital, Novara, ITALY.

OP-399a
New Frontiers in Breast Cancer Molecular Imaging
G. Ulaner; Hoag Family Cancer Institute, Irvine, UNITED STATES OF AMERICA.

OP-399b
Nuclear Medicine has Revolutionised the Alzheimer’s Disease Landscape, is Parkinson’s

Disease the Next?
D. Ferreira Padilla; Karolinska Institute, Solna, SWEDEN.

OP-399c
Parkinson’s Disease Can Only Be Understood with Molecular Imaging
G. Hoeglinger; LMU Klinikum, Munich, GERMANY.

1001

Monday, October 6, 2025, 15:00 - 16:30
Auditorium

CME 7 - Oncology & Theranostics Committee:
Targeted Radionuclide Therapy Accross
Various SST Expressing Tumor Models: a new
Framework for Rethinking

OP-400
The “mild” tumour model (midgut/PPGL/ G1-G2 meningioma/typical lung carcinoids)
V. Ambrosini; Alma Mater Studiorum, University of Bologna, Bologna, Italy; Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-401
The “aggressive” tumour model (heavily treated GEP-NET/atypical lung carcinoids)
D. Taïeb; Marseille University Hospitals, APHM/AMU, Departement of Nuclear Medicine, Marseille, FRANCE.

OP-402
The “highly aggressive” tumour model (SCLC-LCLC/ G3 GEP-NET/G3 meningioma/Merckel)
M. Mileva; Institut Jules Bordet, Brussels, BELGIUM.

OP-403
When passing the baton to alpha?
E. Deshayes; Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, FRANCE.

1002

Monday, October 6, 2025, 15:00 - 16:30
Room 112 (Arena)

Special Track 7: Award Session: EANM Sanjiv
Sam Gambhir Award - Compete and Win!

1003

Monday, October 6, 2025, 15:00 - 16:30
Room 113

LIPS Session 7 - Cardiovascular Committee:
What to look at in the Heart and in Vessels on
Oncological PET Images

OP-407
What to Look for On Low-Dose CT
M. Badarna; Rambam Healthcare campus, Nuclear medicine, Haifa, ISRAEL.

OP-408
What to Look for in the Heart on FDG-PET
N. Mikail; APHP Paris Centre, Nuclear Medicine, Paris, FRANCE.

OP-409
What to Look for in the Vessels on FDG-PET
J. Bucerius; Graz University Hospital, Nuclear Medicine Department, Graz, AUSTRIA.

OP-410
What to Look for with Tracers Other than FDG
A. Kjær; University of Copenhagen, Copenhagen, DENMARK.

1004

Monday, October 6, 2025, 15:00 - 16:30
Room 114

M2M Track - TROP Session -
Radiopharmaceutical Sciences + Translational
Molecular Imaging & Therapy Committee:
Innovations in Translational Oncology

OP-411
Preclinical Evaluation of 3B031: A Novel FAP-Targeting Peptide Radioligand with High Tumor Retention and Promising Tumor-to-Kidney Ratio
W. XU, J. Zhang; PepLib, Metuchen, NJ, UNITED STATES OF AMERICA.

OP-412
mRNA Display-enabled De Novo Discovery of Covalent Macrocyclic Peptide Radiotracers Targeting Fibroblast Activation Protein
X. Cui¹, P. Liu¹, Y. Yang², Y. Yin², Z. Liu^{1,3}; ¹Changping Lab, Beijing, CHINA, ²Shandong University, Qingdao, CHINA, ³Peking University, Beijing, CHINA.

OP-413
Development of ¹⁶¹Tb Radioimmunotherapy for the Treatment of T-cell Lymphomas
E. Rioja Blanco^{1,2}, Y. Banz³, C. Schlapbach⁴, U. Novak⁵, T. Chiorazzo¹, N. Bertschi⁴, P. Bernhardt^{6,7}, P. Grundler¹, N. van der Meulen^{1,8}, M. Grzmil¹, R. Schibli^{1,2}, M. Behe¹; ¹Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen PSI, SWITZERLAND, ²Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, SWITZERLAND, ³Institute of Tissue Medicine and Pathology, University of Bern, Bern, SWITZERLAND, ⁴Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND, ⁵Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND, ⁶Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN, ⁷Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, SWEDEN, ⁸Laboratory of Radiochemistry, PSI Center for Nuclear Engineering and Sciences, Villigen PSI, SWITZERLAND.

OP-414
Tb, or Not Tb - Exploring Terbium-161 for CD44v6-Targeted Radionuclide Therapy
A. Gustafsson¹, S. S. Rinne¹, T. Xu¹, K. Bratteby^{2,3}, A. Lundgren Mortensen^{1,2}, P. Bernhardt^{4,5}, M. Nestor¹; ¹Uppsala University, Uppsala, SWEDEN, ²Karolinska Institutet, Stockholm, SWEDEN, ³Karolinska University Hospital, Stockholm, SWEDEN, ⁴University of Gothenburg, Gothenburg, SWEDEN, ⁵Sahlgrenska University Hospital, Gothenburg, SWEDEN.

OP-415
A feasibility study of SmartCC platform for a two-step pretargeted radioimmunotherapy (PRIT): taking GD2-expressing neuroblastoma as an example
Z. Qiao, H. Qi, Y. Yang, C. Wei, T. Xu; SmartNuclide Biotech, Suzhou, CHINA.

OP-416
Novel SSTR2 RPT agent RYZ401 demonstrates significant improvement in Biodistribution and Efficacy compared to DOTATATE
T. Lo, T. Chung, L. Nyiranshuti, N. Bakes, S. Richardson, S. Richardson, A. Noncovich, A. Hudson, P. Napier, N. Smith, A. Bhat; RayzeBio, a subsidiary of Bristol-Myers Squibb, San Diego, CA, UNITED STATES OF AMERICA.

OP-417
Tumor-stroma dynamics define FAP optimum imaging and therapeutic windows in the management of glioblastoma
A. Bilinska¹, N. Kumar¹, E. Menéndez¹, T. Läppchen¹, F. Rösch², A. Rominger¹, E. Gourni¹; ¹Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND, ²Department of Chemistry—TRIGA site, Johannes Gutenberg University of Mainz, Mainz, GERMANY.

OP-418
Novel CAIX-Targeted Radiotracer for Precision PEC/CT Imaging of Renal Cell Carcinoma
S. Cheng¹, X. Niu², Y. Zhang¹, X. Lan¹, P. Teng², D. Jiang¹; ¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²College of Pharmaceutical Sciences, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, CHINA.

OP-419
Nectin-4 targeted PET imaging of advanced urothelial carcinoma: tracer development and preclinical evaluation
X. Long, X. Nian, Y. Zhang, R. An, D. Jiang; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

1005

Monday, October 6, 2025, 15:00 - 16:30
Room 211

Cutting Edge Science Track - TROP Session -
Dosimetry Committee: Personalised Dosimetry
and Predictive Modeling

OP-420
**Predictive Dosimetry in PSMA-targeted
Radiopharmaceutical Therapies Guided by
Physiologically-Based Pharmacokinetic (PBPk)
Modeling and Artificial Intelligence**
H. Abdollahi¹, A. Rahmim, J. Fowler, C. Uribe;
BC Cancer Agency, Vancouver, BC, CANADA.

OP-421
**Optimization of ¹⁷⁷Lu-PSMA Dosimetry Imaging
Schedules using Physiologically-Based
Pharmacokinetic (PBPk) Modeling**
J. Fowler^{1,2}, M. Sabouri^{1,2}, A. Rahmim^{1,2}, C. Uribe^{1,2};
¹BC Cancer Research Institute, Vancouver, BC, CANADA,
²University of British Columbia, Vancouver, BC, CANADA.

OP-422
**Progress Update on Personalized Single-Timepoint
Kidney Dosimetry in ¹⁷⁷Lu-DOTATATE PRRT Using
Deep Learning-Based Segmentation: A Multi-Center
Study**
M. Reymann¹, L. Bönsel¹, S. M. Montenegro¹, D. L. Bailey², A.
H. Vija³;
¹Siemens Healthineers AG, Forchheim, GERMANY, ²Royal
North Shore Hospital, Sydney, AUSTRALIA, ³Siemens Medical
Solutions USA, Inc., Hoffman Estates, IL, UNITED STATES OF
AMERICA.

OP-423
**Towards Personalised Dosimetry: Predicting
Radiological Response in Neuroendocrine Tumours
Treated with [¹⁷⁷Lu]Lu-DOTATATE Using Cyclic
Changes and Absorbed Dose**
M. Macsuka¹, B. Driscoll², I. W. T. Yeung³, J. Publicover⁴,
U. Metser⁵, R. Juergens⁶, S. D. Myrehaug⁷, D. Laidley⁸, R. K.
Wong⁹, D. R. McGowan¹, K. A. Vallis¹;
¹Department of Oncology, University of Oxford, Oxford,
UNITED KINGDOM, ²Radiation Medicine Program, Princess
Margaret Cancer Centre, University Health Network,
Toronto, ON, CANADA, ³Southlake Regional Health
Centre, Newmarket, ON, CANADA, ⁴University Health
Network, Toronto, ON, CANADA, ⁵Joint Department of
Medical Imaging, University Health Network, Toronto,
ON, CANADA, ⁶Division of Medical Oncology, Juravinski
Cancer Centre, Hamilton, ON, CANADA, ⁷Department of
Radiation Oncology, Odette Cancer Centre, Sunnybrook
Health Sciences Centre, University of Toronto, Toronto,
ON, CANADA, ⁸University of Western Ontario, London, ON,
CANADA.

OP-424
**Systematic Comparison of Reported PRRT Tumour
Dose-Response Relationships in an Independent
Cohort; Pilot Results for Tumour Absorbed Dose**
M. Kvassheim^{1,2}, H. Ramsvik¹, T. Husevåg¹, J. Blakkisrud¹, C.
Stokke^{1,3};
¹Department of Physics and Computational Radiology,
Division of Radiology and Nuclear Medicine, Oslo University

Hospital, Oslo, NORWAY, ²Institute of Clinical Medicine,
University of Oslo, Oslo, NORWAY, ³Department of Physics,
University of Oslo, Oslo, NORWAY.

OP-425
**RADIO-MARKER Study: Biomarker identification of
radionuclide therapy-induced radiation responses**
J. Nonnekens¹, N. Becx¹, P. Morvay², T. de Wolf¹, P. Davies²,
G. Tamborino¹, R. Brandt¹, G. O'Brain², T. Heredia Genestar¹,
M. Konijnenberg¹, H. Hofland¹, C. Badie², L. Cruz Garcia²;
¹Erasmus MC, Rotterdam, NETHERLANDS, ²UK Health
Security Agency, Chilton, UNITED KINGDOM.

OP-426
**Comparison of radiation-induced DNA damage in
PBMCs and absorbed dose to the blood between
two therapy cycles with [¹⁷⁷Lu]Lu-PSMA-617**
N. Zindler¹, H. Scherthan², S. Schumann¹, P. E. Hartrampf¹, I.
Strobel¹, M. Lassmann¹, U. Eberlein¹;
¹University Hospital Würzburg, Würzburg, GERMANY,
²Bundeswehr Institute of Radiobiology affiliated to the
University of Ulm, Munich, GERMANY.

OP-427
**Potential for home-based blood sampling for
estimating maximum tolerated activity for [131I]-
Nal dosimetry-patients**
S. Synnes Lindseth¹, L. T. G. Mikalsen¹, A. Tulipan^{2,3}, E.
Hernes², C. Stokke^{1,4};
¹Department of Physics and Computational Radiology,
Division of Radiology and Nuclear Medicine, Oslo University
Hospital, Oslo, NORWAY, ²Department of Nuclear Medicine,
Division of Radiology and Nuclear Medicine, Oslo University
Hospital, Oslo, NORWAY, ³Department of Radiology, Nuclear
medicine/PET-centre, Haukeland University Hospital,
Bergen, NORWAY, ⁴Department of Physics, University of
Oslo, Oslo, NORWAY.

OP-428
**Long-Term Renal Safety of Personalized [¹⁷⁷Lu]Lu-
DOTA-TATE PRRT: Evidence from the NCT02754297
trial Supporting Absorbed Doses Beyond
Conventional Limits**
S. Kurkowska¹, P. L. Esquinas², A. Rahmim¹, X. Hou²,
F. A. Buteau³, A. Beaulieu³, G. April³, F. Arsenault³, J. M.
Beauregard³, C. Uribe²;
¹BC Cancer Research Institute, Vancouver, BC, CANADA,
²BC Cancer, Vancouver, BC, CANADA, ³CHU de Québec –
Université Laval, Quebec City, QC, CANADA.

1006

Monday, October 6, 2025, 15:00 - 16:30
Room 117

Clinical Oncology Track - TROP Session -
Oncology & Theranostics Committee: NET and
PRRT

OP-429
**Dosimetry of [¹⁷⁷Lu]Lu-edotreotide in patients
with grade 1 or grade 2 gastroenteropancreatic
neuroendocrine tumours: Results from the
COMPETE Phase 3 trial**
E. Deshayes¹, A. M. García-Burrillo², H. Amthauer³, C.
Ansquer⁴, R. García-Carbonero⁵, A. Teulé Vega⁶, H. J.
Verberne⁷, J. B. Cwikla⁸, R. Srirajskanthan⁹, A. Buck¹⁰, C.
M. Grana¹¹, R. P. Baum¹², L. O. Dierickx¹³, M. Michael¹⁴, J.

Strosberg¹⁵, L. De Mestier¹⁶, M. Pavel¹⁷, P. Jimenez-Fonseca¹⁸,
A. Kollár¹⁹, B. Viglianti²⁰, A. Kluge²¹, P. Ritt²², C. Lachachi²³;
¹SFMN, Montpellier Cedex 5, FRANCE, ²Vall d'Hebron
University Hospital, Barcelona, SPAIN, ³Charité –
Universitätsmedizin Berlin, Corporate Member of Freie
Universität Berlin and Humboldt-Universität zu Berlin,
Berlin, GERMANY, ⁴Centre Hospitalier Universitaire de
Nantes, Nantes, FRANCE, ⁵Hospital Universitario 12 de
Octubre, Imas12, UCM, Madrid, SPAIN, ⁶Institut Català
d'Oncologia, Barcelona, SPAIN, ⁷Amsterdam UMC,
Amsterdam, NETHERLANDS, ⁸Diagnostic and Therapeutic
Center – Gammed, Warsaw, POLAND, ⁹King's College
Hospital, London, UNITED KINGDOM, ¹⁰Universitätsklinikum
Würzburg, Würzburg, GERMANY, ¹¹IRCCS European Institute
of Oncology Milano, Milano, ITALY, ¹²Curanosticum
Wiesbaden-Frankfurt, Wiesbaden, GERMANY, ¹³Institut
Universitaire du Cancer Toulouse Oncopole, Toulouse,
FRANCE, ¹⁴Peter MacCallum Cancer Centre, University
of Melbourne, Melbourne, AUSTRALIA, ¹⁵Moffitt Cancer
Center, Tampa, FL, UNITED STATES OF AMERICA, ¹⁶Beaujon
Hospital, Clichy, FRANCE, ¹⁷Universitätsklinikum Erlangen,
Erlangen, GERMANY, ¹⁸Hospital Universitario Central de
Asturias, Oviedo, SPAIN, ¹⁹Universitätsspital Bern, Bern,
SWITZERLAND, ²⁰University of Michigan Medical Center,
Ann Arbor, MI, UNITED STATES OF AMERICA, ²¹ABX-CRO
advanced pharmaceutical services Forschungsgesellschaft
mbH, Dresden, GERMANY, ²²ITM Oncologics GmbH,
Garching, GERMANY, ²³Edouard Herriot Hospital, Lyon,
FRANCE.

OP-430
**A decade of Peptide Receptor Radionuclide Therapy
with ¹⁷⁷Lu-DOTATATE: Results from the Spanish
SEPTRALU Registry**
M. Mitjavila Casanovas¹, V. Pubu², P. Bello³, A. García
Burillo⁴, M. Castellón⁵, L. García Cañamaque⁶, A. Piñeiro⁷, M.
Velasco⁸, M. Nevaes⁹, R. Valverde¹⁰, A. Padilla¹¹, B. Llana¹²,
Z. Nogareda², A. Custodio¹³, J. Hernando⁴, D. Balaguer¹⁴, J.
Arbizu¹⁵, M. Tabuenca¹⁶, D. Gomez Sanchez¹⁷, M. Orduña¹⁸,
J. Ardila¹⁹, P. Jimenez-Fonseca¹², A. Carmona-Bayonas²⁰;
¹Hospital Universitario Puerta de Hierro Majadahonda,
Madrid, SPAIN, ²Complejo Hospitalario Universitario de
Santiago, Santiago de Compostela, SPAIN, ³Hospital
Universitario La Fe, Valencia, SPAIN, ⁴Hospital Universitario
Vall d'Hebron, Barcelona, SPAIN, ⁵Hospital Universitario
Virgen de la Arrixaca, Murcia, SPAIN, ⁶Hospitales H.M.
Sanchinarro, Madrid, SPAIN, ⁷Hospital Universitario Virgen
de las Nieves, Granada, SPAIN, ⁸Hospital Universitario
de la Santa Creu i Sant Pau, Barcelona, SPAIN, ⁹Hospital
Universitario de Burgos, Burgos, SPAIN, ¹⁰Hospital
Universitario de Cruces Cruces, Bilbao, SPAIN, ¹¹Hospital
General Universitario de Ciudad Real, Ciudad Real, SPAIN,
¹²Hospital Universitario Central de Asturias, Oviedo, SPAIN,
¹³Hospital Universitario La Paz, Madrid, SPAIN, ¹⁴Hospital
Universitario Doctor Pesset, Valencia, SPAIN, ¹⁵Clínica
Universidad de Navarra, Pamplona, SPAIN, ¹⁶Hospital
Universitario 12 de Octubre, Madrid, SPAIN, ¹⁷Hospital
Universitario de Navarra, Pamplona, SPAIN, ¹⁸Hospital
Universitario Ramón y Cajal, Madrid, SPAIN, ¹⁹Hospital
Universitario Gregorio Marañón, Madrid, SPAIN, ²⁰Hospital
General Universitario Morales Meseguer, Murcia, SPAIN.

OP-431
**Safety and Efficacy of ¹⁷⁷Lu-LNC1010 in Advanced
SSTR-Positive Neuroendocrine Tumors: A Single-
Center, Single-Arm, Phase II Study**
W. Guo¹, Y. Chen¹, H. Fu¹, L. Zhao¹, J. Zhang², X. Chen², H.
Chen¹;
¹The first affiliated hospital of Xiamen University, Xiamen
City, CHINA, ²Yong Loo Lin School of Medicine, National
University of Singapore, Singapore, SINGAPORE.

OP-432
**Radiolabeled Somatostatin Receptor (SSTR)
Antagonist versus Agonist for Peptide Receptor
Radionuclide Therapy in Patients with SSTR positive
Neuroendocrine Tumors - a retrospective Basket
study**
A. Mushaweh¹, C. Eigler¹, L. McDougall¹, A. Bauman¹, E.
Christ², P. Bernhardt³, G. Nicolas¹, M. Fani¹, D. Wild¹;
¹Department Theragnostics, University Hospital of Basel,
Basel, SWITZERLAND, ²Department of Endocrinology,
Diabetology and Metabolism, University Hospital of Basel,
Basel, SWITZERLAND, ³Department of Medical Radiation
Sciences, Institute of Clinical Sciences, Sahlgrenska
Academy at University of Gothenburg, Gothenburg,
SWEDEN.

OP-433
**Safety Profile of [¹⁷⁷Lu]Lu-DOTATATE: A
Disproportionality Analysis of Adverse Events from
the WHO Global Pharmacovigilance Database**
J. Vigne, T. Ladrrière, B. Chrétien, A. Bignon-Bretagne, K.
Bouhier-Leporrier, C. Dolladille;
University Hospital of Caen, Caen, FRANCE.

OP-434
**Impact of ¹⁸F-FDG PET in Patients with Advanced
Metastatic Neuroendocrine Tumors Undergoing
Rechallenge PRRT: Final Results from a Multicenter
WARMTH Study**
G. Santo¹, M. Rodrigues¹, D. Paez², L. Kabasakal³, K.
Kairemo⁴, C. Grana⁵, R. Baum⁶, G. di Santo¹, I. J. Virgolini¹;
¹Department of Nuclear Medicine, Innsbruck Medical
University, Innsbruck, AUSTRIA, ²Nuclear Medicine and
Diagnostic Imaging Section, Division of Human Health,
International Atomic Energy Agency, Vienna, AUSTRIA,
³Department of Nuclear Medicine, Faculty of Medicine,
Yeditepe University School of Medicine, İstanbul, TÜRKIYE,
⁴Nuclear Medicine & Theragnostics, Docrates Cancer Center,
Helsinki, FINLAND, ⁵Radiometabolic Therapy Unit, IRCCS IEO
European Institute of Oncology, Milan, ITALY, ⁶Theranostics
Centre for Molecular Radiotherapy and Precision Oncology,
Zentralklinik,, Bad Berka, GERMANY.

OP-435
**[¹⁷⁷Lu]Lu-DOTA-LM3 for PRRT in Metastatic NET:
Dosimetry, Response and Safety**
T. Speicher, A. Schaefer-Schuler, M. Mavrommatis, M. B.
Bastian, A. Blickle, S. Maus, M. Bartholomä, C. Burgard, F.
Rosar, S. Ezziddin;
Nuclear Medicine, Saarland University Hospital, Homburg,
GERMANY.

OP-436
**Novel FAP-Targeted Radiopharmaceutical Therapy
with ¹⁷⁷Lu/⁹⁰Y/²²⁵Ac-3BP-3940 in Patients with
Pancreatic Ductal Adenocarcinoma (PDAC)**
J. Zhang¹, J. Li¹, A. Eismant², L. Greifenstein², A. Klega², C.
Landvogt², C. Mueller², T. Zhao¹, O. Klein³, B. Jaeschke², R. P.
Baum²;
¹National University of Singapore, Singapore, SINGAPORE,
²Center for Advanced Radiomolecular Precision Oncology,
Wiesbaden, GERMANY, ³Helios DKD Klinik, Wiesbaden,
GERMANY.

OP-437
**Changes in Brain Glucose Metabolism Induced by
Long-Acting Somatostatin Analogues Therapy in
Patients with Neuroendocrine Tumors: a ¹⁸F-FDG
PET Study**

A. Martini¹, F. De Lauro², G. Bianciardi³, S. Fanti⁴, S. Lastoria², S. Sestini¹;

¹Unit of Nuclear Medicine, Department of Diagnostic Imaging, N.O.P. - S. Stefano, U.S.L. Toscana Centro, Prato, ITALY, ²Nuclear Medicine Unit, Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”, Naples, ITALY, ³Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ⁴Nuclear Medicine, Alma Mater Studiorum University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

1007

Monday, October 6, 2025, 15:00 - 16:30
Room 212

TROP Session - Neuroimaging Committee: Tau PET Imaging

OP-438
Spatial match and mismatch of tau pathology and hypometabolism at individual level

C. Boccalini¹, D. E. Peretti¹, A. Mendes¹, M. Scheffler², N. Ashton³, H. Zetterberg³, K. Blennow³, G. B. Frisoni¹, V. Garibotto¹;

¹University of Geneva, Geneva, SWITZERLAND, ²Geneva University Hospitals, Geneva, SWITZERLAND, ³University of Gothenburg, Gothenburg, SWEDEN.

OP-439
Mapping Clinical and Tau Trajectories in Alzheimer’s Disease: Prognostic and Monitoring Utility of 18F-Florzolotau Tau-PET in a Real-Word Memory Clinic Cohort

J. Lu¹, J. Wang², H. Zhang¹, J. Wu², Y. Yang¹, M. Wang³, X. Ma², W. Bao¹, Z. Xiao², H. Lin¹, X. Zhou², Z. Ju¹, S. Yan², F. Jiao¹, X. Liang², Y. Liu¹, L. Zheng², M. Li¹, J. Ge¹, D. Ding^{2,4,5}, T. Yen⁶, Y. Guan^{1,4,5}, C. Zuo^{1,4,5}, Q. Zhao^{2,4,5}, the Shanghai Memory Study (SMS);

¹Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ²Department and Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA, ³Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, CHINA, ⁴National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, CHINA, ⁵National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, CHINA, ⁶APRINOIA Therapeutics Co. Ltd, Suzhou, CHINA.

OP-440
Tau-PET imaging of advanced primary age-related tauopathy mimicking early-stage AD

M. Grothe¹, A. Moscoso², M. A. Labrador-Espinosa², J. Silva-Rodríguez¹, F. Heeman², A. Costoya-Sánchez³, V. Camacho⁴, M. van Essen⁵, I. Mainta⁶, A. Perissinotti⁷, O. Rodríguez-Fonseca⁸, F. Ribaldí⁸, M. D. Devos⁹, M. J. Pontecorvo⁹, G. B. Frisoni⁶, V. Garibotto⁶, M. Schöll¹;

¹CIEN Foundation, Madrid, SPAIN, ²University of Gothenburg, Gothenburg, SWEDEN, ³University of Santiago de Compostela, Santiago de Compostela, SPAIN, ⁴Universitat Autònoma de Barcelona, Barcelona, SPAIN, ⁵Sahlgrenska University Hospital, Gothenburg, SWEDEN, ⁶Geneva University Hospitals, Geneva, SWITZERLAND, ⁷Hospital Clínic Barcelona, Barcelona, SPAIN, ⁸Lucus Augusti University Hospital, Lugo, SPAIN, ⁹Avid Radiopharmaceuticals, Philadelphia, PA, UNITED STATES OF AMERICA.

OP-441
Inhibitory and Promotive Effects of Amyloid-β on Tau Growth: A Stage-dependent Analysis in Alzheimer’s Disease

T. Zhang, B. Nie, B. Shan;
Institute of High Energy Physics, CAS, Beijing, CHINA.

OP-442
Correlation between Tau PET imaging and fluid biomarkers in individuals with Down syndrome

P. Stefaneli Mormandi¹, V. Camacho¹, L. Vaqué-Alcázar^{2,3}, M. Calls-Calahorra¹, Y. Delisau¹, B. Serrallonga¹, I. Barroeta^{2,4}, D. Alcolea^{2,5}, M. Carmona-Iragui^{4,2,5}, J. Fortea^{2,4,5}, A. Fernández-León¹, S. Asadurova¹, M. Velasco-Nuño¹, A. Flotats-Giralt¹;

¹Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ²Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ³Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SPAIN, ⁴Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, SPAIN, ⁵Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, SPAIN.

OP-443
Comparability of [¹⁸F]-FDG and Early-Phase amyloid and tau PET in detecting LATE Pattern in in amnesic mild cognitive impairment

G. Mathoux¹, C. Boccalini², D. E. Peretti², M. Scheffler¹, G. B. Frisoni¹, V. Garibotto¹;

¹Hôpitaux Universitaires de Genève, Genève, SWITZERLAND, ²Geneva University, Genève, SWITZERLAND.

OP-444
Neuropathological Tau Deposition Mediates the Relationship Between Glymphatic dysfunction and Hippocampal Neurodegeneration in Patients with Mild Cognitive Impairment

X. Xu¹, B. Zhang², W. Zhang², J. Chen²;

¹Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, CHINA, ²Department of Radiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China, Nanjing, CHINA.

OP-445
Amyloid and tau changes in preclinical autosomal dominant Alzheimer’s disease mutation carriers: a dual-tracer PET/MRI qualitative and quantitative analysis

L. Fu¹, Z. Zhou², J. Gao¹, Q. Wang³, Q. Wang³;

¹Department of Nuclear Medicine, China-Japan Friendship Hospital, Beijing, CHINA, ²Department of Neurology, China-Japan Friendship Hospital, Beijing, CHINA, ³Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, CHINA.

OP-446
Could [¹⁸F]PI-2620 be used as a biomarker for progressive supranuclear palsy?

A. Bronte^{1,2}, E. Prieto¹, G. Martí-Andrés³, D. Pigg⁴, F. Mínguez¹, F. Pareja¹, G. Quincoces¹, M. Erro³, J. Arbizu¹;

¹Clínica Universidad de Navarra, Pamplona, SPAIN, ²Hospital Universitario de Son Espases, Palma, SPAIN,

³Hospital Universitario de Navarra, Pamplona, SPAIN, ⁴Siemens Medical Solutions USA, Knoxville, TN, UNITED STATES OF AMERICA.

1008

Monday, October 6, 2025, 15:00 - 16:30
Room 115

Joint Symposium 4 - AI Committee / EFOMP: Trustful AI in the Clinic

OP-447
Ethical AI and the EU AI Act
S. Zipponi; , Milan, ITALY.

OP-448
Explainable AI for NM
M. Hatt; INSERM, LaTIM, UMR 1101, Brest, FRANCE.

OP-449
Trustworthy image processing with AI

O. Diaz; Dept of Mathematics and Computer Science, University of Barcelona, Barcelona, SPAIN.

1009

Monday, October 6, 2025, 15:00 - 16:30
Room 133+134

e-Poster Presentations Session 7 - Radiopharmaceutical Sciences Committee: Radiopharmacy e-Poster Presentations Session Radiochemistry and Quality Control

EPS-136
A Novel Substance P Derivative Labeled With Ga68 and Lu177 as Candidates for diagnosis and Therapy of Glioblastoma Tumor

J. Abedi¹, s. Mozaffari¹, H. Khoshhosn¹, R. Nami¹, N. Soltani¹, M. Mehraziz², M. Mokhtari¹;

¹Pars Isotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Trauma and Injury Research Center, Iran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EPS-137
Streamlining [¹⁸F]F-JK-PSMA-7 production: A GMP-compliant alternative to HPLC purification using solid-phase extraction

E. Cazzola, C. Favaretto, L. Pennacchio, J. Amico, D. Peruzzi, N. Bergamaschi, P. Bovone, M. Malachini, G. Gorgoni; Ospedale Sacro Cuore, Negrar, ITALY.

EPS-138
Quality control of Actinium-225: Francium-221 to be or not to be?

D. Abou^{1,2}, M. Toro-Gonzalez¹, L. Wheelless¹, L. Van Epern¹, M. Hommen¹, V. Tangadanchu¹, C. Hawkins¹, T. Drum¹, D. Devries¹;

¹Northstar Medical Radioisotopes LLC., Beloit, WI, UNITED STATES OF AMERICA, ²Washington University School of Medicine, Mallinckrodt Institute of Radiology, St. Louis, MO, UNITED STATES OF AMERICA.

EPS-139
Direct Alpha Spectroscopy for Detection of ²²⁵Ac Radio-pharmaceuticals in Cancer Cells

M. Farasat¹, B. Saeedi Saghez¹, L. Wharton¹, S. Shapiro², C. Vinnick³, M. Daignault³, M. Kostashuk⁴, N. Pranjatno³, M. Weiman¹, C. Andreou³, H. Yang¹, P. Kunz¹;

¹TRIUMF, Vancouver, BC, CANADA, ²University of British Columbia, Vancouver, BC, CANADA, ³Simon Fraser University, Burnaby, BC, CANADA, ⁴McMaster University, Hamilton, ON, CANADA.

EPS-140
Development and Optimization of [68Ga]68Ga-DOTA-EMP-100 for Non-invasive PET Imaging and Targeted Radioligand Therapy of c-MET Overactivation in Cancer

S. Migliari¹, C. Portal², A. Gibson², A. Gagliardi¹, A. Guercio¹, M. Scarlattei¹, G. Baldari¹, L. Ruffini¹;

¹Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY, ²Edinburgh Molecular Imaging Ltd., Edinburgh, UNITED KINGDOM.

EPS-141
Development of CYP11B2 selective pyridinylbenzimidazole derivatives for pathological analysis of primary aldosteronism

Y. Yagi¹, H. Kimura², R. Fuseda³, T. Murakami⁴, M. Omokawa⁵, S. Kise⁶, M. Sone⁷, H. Yasui³, N. Inagaki⁴, H. Saji⁸;

¹Kyoto University of Medical Science, Nantan, JAPAN, ²Agency for Health, Safety and Environment, Kyoto University, Kyoto, JAPAN, ³Kyoto Pharmaceutical University, Kyoto, JAPAN, ⁴Kyoto University Hospital, Kyoto, JAPAN, ⁵Okayama University, Okayama, JAPAN, ⁶Kanazawa University, Kanazawa, JAPAN, ⁷St. Marianna University School of Medicine, Kawasaki, JAPAN, ⁸Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, JAPAN.

EPS-142
La-[^{18/19}F]fluoride Complexes: a novel addition to the radiofluorination family.

R. Faizova¹, S. Gruber², L. Mu³, M. Schottelius¹, M. Behe⁴;

¹Lausanne University Hospital, Lausanne, SWITZERLAND, ²ETH Zurich, Zurich, SWITZERLAND, ³ETH Zurich, Zürich, SWITZERLAND, ⁴Paul Scherrer Institute, Villigen, SWITZERLAND.

EPS-143
Radiochemistry and Evaluation of Novel Selective α-Synuclein Fibrils tracers for Parkinson’s Disease

N. Mortazavi Golsfedi¹, B. Uzegbunam², M. Luster¹, D. Librizzi^{1,3}, B. Hooshyar Yousefi^{1,4};

¹Department of Nuclear Medicine, School of Medicine, Philipps University Marburg, Marburg, GERMANY, ²Department of Nuclear Medicine, Technical University of Munich, and Isotope Technologies Munich (ITM), Munich, GERMANY, ³Department of Nuclear Medicine, University Hospital OWL, Evangelisches Klinikum Bethel, Bielefeld, GERMANY, ⁴Preclinical Imaging Core Facility, Center for Tumor Biology and Immunology (ZTI), Philipps University Marburg, Marburg, GERMANY.

EPS-144
CADD-Guided Optimization and Synthesis of Novel CD13-Targeting PET Probes for Precision Management of Prostate Cancer

T. Liying, Z. Ming, H. Shou;
Xiangya Hospital, Central South University, Hunan Province, CHINA.

EPS-145
Developing covalent radiotracers for detection of neurodegenerative proteinopathies

P. Liu¹, Z. Liu^{1,2};
¹Changping Labrotary, Beijing, CHINA, ²Peking University, Beijing, CHINA.

EPS-146
Tetrazine Ligation Meets αvβ6 Integrin-Targeted PET Imaging: Radiosynthesis and Preclinical Evaluation of ¹⁸F-Flutrahexin

M. Martin¹, V. Morath², F. Reissig³, U. M. Battisti^{1,4}, N. Holzleitner^{2,5}, S. Stangl^{2,5}, V. Shalgunov^{1,6}, A. T. I. Jensen¹, J. Notni³, S. Kossatz^{2,5}, M. M. Herth^{1,4,6};
¹TetraKit Technologies ApS, Copenhagen, DENMARK, ²Department of Nuclear Medicine, TUM University Hospital, School of Medicine and Health, Technical University Munich, Munich, GERMANY, ³TRIMT GmbH, Radeberg, GERMANY, ⁴University of Copenhagen, Department of Drug Design and Pharmacology Faculty of Health and Medical Sciences, Copenhagen, DENMARK, ⁵Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, Technical University, Munich, GERMANY, ⁶Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen, DENMARK.

EPS-147
Synthesis and Evaluation of a High Affinity and Long-time Retention CXCR4-Targeted Probe

X. Yu, M. Zhang, G. Li, W. Yang, J. Wang, F. Kang;
Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, CHINA.

EPS-148
Chelator-free gallium-68 labeling of Nanoclays for in vivo tracking

N. Liu;
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EPS-149
Production of ⁶⁴Cu with hybrid target

D. Szikra¹, V. Forgács¹, M. Fodor², Z. Szücs²;
¹University of Debrecen, Division of Nuclear Medicine, Medical Imaging Department, Debrecen, HUNGARY, ²Radiochemical Laboratory, HUN-REN Institute for Nuclear Research, Debrecen, HUNGARY.

EPS-150
Method for producing medical ⁹⁰Y via radionuclide generator: improving quality and efficiency

A. Baimukhanova^{1,2}, G. Magomedov^{2,3}, V. Pokalchuk³, E. Magomedbekov³, D. Karaivanov², D. Filosofov²;
¹Institute of Nuclear Physics of the Republic of Kazakhstan, Almaty, KAZAKHSTAN, ²Joint Institute for Nuclear Research, Dubna, RUSSIAN FEDERATION, ³D. I. Mendeleev Russian University of Chemical Technology, Moscow, RUSSIAN FEDERATION.

EPS-151
Development of novel nanobody-based ⁶⁸Ga and ¹³¹I radiotracers for detecting MUC16 expression in vivo

J. Han, Y. He;
Fudan University, Shanghai, CHINA.

EPS-152
Discovery of a novel [¹⁸F]-labeled phenylalanine derivative PET tracer for preclinical tumor imaging

Y. Xie, Y. Wang, H. Zhou, M. Hu, W. Chen;
West China Hospital, Sichuan University, Chengdu, CHINA.

EPS-153
Radiolabeling of Gold Nanoconstructs with Particle-Emitting Radioisotopes

A. Apostolopoulou¹, E. A. Salvanou¹, D. E. Bajwa¹, C. Liolios¹, S. Xanthopoulos¹, F. Denat², G. Laurent³, R. Bazzi³, S. Roux³, P. Bouziotis¹;
¹National Center for Scientific Research "Demokritos", Athens, GREECE, ²Institut de Chimie Moléculaire de l'Université de Bourgogne, Dijon, FRANCE, ³Université Marie et Louis Pasteur, CNRS, Chrono-environnement, Besançon, FRANCE.

EPS-154
Development of a cGMP-compliant automated synthesis of the radiotherapeutic [¹⁷⁷Lu]Lu-ABY-271: Enabling reliable radiolabelling for a first-in-human phase I study

S. Omer¹, M. Ferrat¹, E. Jussing¹, N. Molina², T. Tegnebratt², J. Garousi², H. Alfredéen¹, J. Ödling³, L. Bremer³, H. Bönisch³, S. Wood³, F. Y. Frejd³, M. M. Moein², T. A. Tran¹;
¹Karolinska Institutet, Solna, SWEDEN, ²Karolinska University Hospital, Solna, SWEDEN, ³Affibody AB, Solna, SWEDEN.

EPS-155
Photocatalyzed nucleophilic ¹⁸F-deoxyfluorination of highly electron-rich catechol derivatives for [¹⁸F] FDOPA synthesis

W. Chen, M. Hu, Y. Wang, C. Zheng;
West China Hospital, Sichuan University, Chengdu, CHINA.

EPS-156
Routine Radiolabeling of FAP Peptide 3BP-3940 with Y-90, Lu-177, and Ac-225 for FAP-Targeted Radiopharmaceutical Therapy (FTRT): Production and Performance Data from 5 Years and 90+ Clinical Batches

L. Greifenstein, S. Stephan, C. Mueller, C. Landvogt, R. P. Baum;
Curanosticum MVZ GmbH, Wiesbaden, GERMANY.

e-Poster Presentation Sessions

1010

Monday, October 6, 2025, 15:00 - 16:30

Room 116

Technologists' e-Poster Presentations Session - Technologists Committee: Techs' e-Posters

TEPS-001
Extravasations in Nuclear Medicine: Mechanisms, Consequences and Dosimetry

C. Sobral, A. Rodrigues Teixeira, M. Nicod Lalonde, J. Prior, S. Medici;
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SWITZERLAND.

TEPS-002
A Novel ⁶⁷Ga-Labeled CXCR4-Targeted Tracer: Radiolabeling Performance, Stability, and In Vivo Evaluation in Atherosclerotic Models

S. Chen, M. Chen, C. Chen, C. Hsia, M. Weng, Y. Chang, W. Chen;
National Atomic Research Institute, Taoyuan, TAIWAN.

TEPS-003
Injection Method Alters Diagnostic Confidence and Quantitative Metrics in [¹⁸F]Fluorocholine PET/CT for Parathyroid Adenomas

M. Rode, H. Reilev Møller, P. Abadi, H. Juel Nissen;
University Hospital of Southern Denmark, Vejle, DENMARK.

TEPS-004
Optimizing the Use of a Single Radiopharmaceutical Production for Increased Throughput of Patients with Primary Hyperparathyroidism in [¹⁸F] Fluorocholine-PET Without Compromising Image Quality

M. Matkovic¹, F. Hedeer¹, A. Stenvall², J. Oddstig³, U. Bitzén¹;
¹Department of Clinical Physiology and Nuclear Medicine, Lund, SWEDEN, ²Radiation Physics, Department of Haematology, Oncology and Radiation Physics, Skåne, SWEDEN.

TEPS-005
Clinical Utility of Lacrimal Scintigraphy in the Management of Epiphora

L. Crook, R. Sajjan, B. Sathyamurthi, S. Muthu;
Department of Nuclear Medicine, Manchester Foundation Trust, Manchester, UNITED KINGDOM.

TEPS-006
How to Ensure Sustainability and Research Governance in Nuclear Medicine? A UK Single-Site Experience.

D. Ribeiro, M. Ratola, Z. Kingsmell;
King's College Hospital NHS Foundation Trust, London, UNITED KINGDOM.

TEPS-007
Biodistribution of BMMSC-Derived Exosomes for Alzheimer's Disease

M. Wang, C. Ho, C. Chan, K. Cheng, H. Yu, C. Kuo, C. Yang, S. Liu;
National Atomic Research Institute, Taoyuan, TAIWAN.

TEPS-008
Development and validation of a 3D-printed phantom for PET texture analysis

K. Honda¹, K. Okuda¹, H. Yamamoto², R. Mori¹, S. Hosokawa¹, Y. Takahashi¹;
¹Guraduate School of Health Sciences, Hirosaki University, Aomori, JAPAN, ²Hirosaki University Hospital, Aomori, JAPAN.

TEPS-009
Implementing a safe workflow for intra-operative PET/CT imaging of surgical specimen

F. Verschure, B. Lambert, V. Vergucht, N. Dhont, B. De Paepe, V. Piens, M. Colle, B. Gevaert, L. Meiresonne;
Maria Middelaes, Gent, BELGIUM.

TEPS-010
Evaluation of a reduced dose 123I-ioflupane in patients examined with SPECT for clinically uncertain parkinsonism

G. Abell¹, S. Skauge¹, T. Keil¹, S. Øen¹, A. Karlberg^{1,2};
¹Department of Radiology and Nuclear Medicine, St. Olavs hospital, Trondheim University Hospital, Trondheim, NORWAY, ²Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, NORWAY.

TEPS-011
Pharmacokinetics and Dosimetry of ¹⁷⁷Lu-DOTATATE in Patients with Advanced well-differentiated,

gastroenteropancreatic neuroendocrine tumours: results from a Sub-study of the phase 3 XT-XTR008-3-01 trial

H. Zhou¹, A. Yin², R. Wang¹;
¹Chinese PLA general hospital, Beijing, CHINA, ²Beijing Sinotau Intl. Pharmaceutical Technology Co., Ltd., Beijing, CHINA.

TEPS-012
Split renal function in living kidney donors derived from ^{99m}Tc-DTPA vs ^{99m}Tc-DMSA: a preliminary evaluation

N. Laajimi, A. Bouzidi, S. Bourouis, F. Dupont, N. Kanaan, R. Lhommel, F. Jamar, O. Gheysens, V. Depoortere;
Cliniques Universitaires Saint-Luc, Bruxelles, BELGIUM.

TEPS-013
The Impact of PET/MRI Imaging and Tumor Markers on the Diagnosis of Prostate Cancer

M. Nürnberger¹, S. Djouraev², M. Hacker¹, R. Agha Mohammadi Sareshgi², S. Rasul¹;
¹Universitätsklinikum AKH Wien, Wien, AUSTRIA, ²FH Campus Wien, Wien, AUSTRIA.

TEPS-014
Cardiac Stress Testing: Is it time for NMTs to take the lead? - St. Barts Centre

A. Tsvetanova;
Barts Health NHS Trust, London, UNITED KINGDOM.

TEPS-015
Analysis of Image Artifacts in TOF-PET/CT - Impact of Defective Block Detectors on Image Quality

J. Teng^{1,2}, S. Djouraev¹, R. A. M. Sareshgi¹, I. Rausch²;
¹FH Campus Wien, Vienna, AUSTRIA, ²Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA.

TEPS-016
Using the Monte Carlo Code RayXpert to Solve Radiation Protection Issues in Six Brachytherapy Rooms

J. Hemptinne, I. Duarte, C. Dossat, N. Chatry;
TRAD Tests & Radiations, Labège, FRANCE.

TEPS-017
The updated capabilities for Registered Nuclear Medicine Technologist practice in Australia

T. Pearson, C. Miller, A. Reinhard;
Medical Radiation Practice Board of Australia, Melbourne, AUSTRALIA.

TEPS-018
Comparison of Two Synthesis Methods for ⁶⁸Ga PSMA-11

G. Walker, K. Allen;
IDX Group Lake Imaging, Ballarat, AUSTRALIA.

TEPS-019
Preclinical Biodistribution Study of [⁶⁸Ga]Ga-FAPI-46 in a Breast Cancer Mouse Model

H. Hassan¹, M. F. Othman², W. H. B. Wan Kamal³, N. N. Jafperi², S. Mohamad³, A. S. Sued³, S. A. Muhamad³, H. R. Abdul Razak⁴, M. H. Zakaria⁵;
¹Centre for Diagnostic Nuclear Imaging, Serdang, Selangor, MALAYSIA, ²Universiti Teknologi MARA, Bandar Puncak Alam, MALAYSIA, ³Malaysian Nuclear Agency, Kajang, MALAYSIA, ⁴University of Exeter, Exeter, UNITED KINGDOM, ⁵Universiti Putra Malaysia, Serdang, MALAYSIA.

TEPS-020
Utility of Tc-99m HMDP SPECT with synthetic planar images and SUV ratio for the diagnosis of cardiac amyloidosis
Y. Miyazaki¹, M. Nogami^{1,2}, Y. Izawa³, H. Hashimura⁴, K. Kubo¹, A. Kusaka¹, T. Murakami^{1,4};
¹Department of Radiology, Kobe University Hospital, Kobe, JAPAN, ²Biomedical Imaging Research Center, University of Fukui, Fukui, JAPAN, ³Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, JAPAN, ⁴Department of Radiology, Kobe University Graduate School of Medicine, Kobe, JAPAN.

TEPS-021
First clinical results for the unique TB-PET IMAS with TOF and DOI capabilities
A. González¹, D. Sanchez², S. Jimenez-Serrano¹, A. Anreus¹, E. Y. Ulin-Briseño¹, A. Gonzalez-Montoro¹, M. Freire¹, J. Alamo³, J. Barbera³, A. Rios⁴, J. M. Benlloch¹, B. Martinez Sanchis⁵, A. S. Canoves Llombart⁵, I. Torres Espallardo⁵;
¹Consejo Superior de Investigaciones Científicas, CSIC-i3M, Valencia, SPAIN, ²Oncovision, SA, Valencia, SPAIN, ³Oncovision SA, Valencia, SPAIN, ⁴Full Body Insight, Valencia, SPAIN, ⁵Hospital Universitario y Politécnico La Fe, Valencia, SPAIN.

1011
Monday, October 6, 2025, 15:00 - 16:30
Room 111
EANM Journals - Scientific Writing in 2025

OP-450a
LLM: Do and Do Not
L. Papp; Medical University of Vienna, Vienna, AUSTRIA.
OP-450b
How to Prepare and Share Your Data
R. Ni; University Zurich, Zurich, SWITZERLAND.
OP-450c
How to Write a Great Paper without LLMs
M. Andrade; Grand Hôpital de Charleroi, Charleroi, BELGIUM.

1101
Monday, October 6, 2025, 16:45 - 18:15
Auditorium
CME 8 - Radiopharmaceutical Committee - Radiotheranostics 2.0: The Power of Emerging Radioisotopes in Translating Imaging into Personalised Radiotherapy

OP-450d
Most Promising Radionuclides for Immediate Clinical Impact
K. Herrmann; Herrmann, University Hospital Essen, Essen, GERMANY.
OP-450e
Radiometals for Imaging and Radioligand Therapy

M. Ma; King's College London, Department of Imaging Chemistry, London, UNITED KINGDOM.
OP-450f
Terbium-based Theranostic Pairs
C. Favaretto; IRCCS Ospedale Sacro Cuore Don Calabria, Department of Radiopharmacy, Verona, ITALY.
OP-450g
Bringing Theranostics to the Clinic: Main Clinical Issues
A. Iagaru; Stanford University Medical Center, Department of Nuclear Medicine, Stanford, UNITED STATES OF AMERICA.

1102
Monday, October 6, 2025, 16:45 - 18:15
Room 112 (Arena)
Special Track 8 - Neuroimaging Committee - Round Table: Tau PET Imaging: Ready for Clinical Use?

OP-450h
Availability and Standardization of Tau-PET Procedures: What Is Needed in the Field?
R. Smith; Lund University, Clinical Memory Research, Department of Clinical Sciences, Lund, SWEDEN.
OP-450i
Visual Reading of T+ and T- Cases. Already Available to Routine Settings?
G. Mathoux; University Hospitals, Division of Nuclear Medicine and Molecular Imaging, Geneva, SWITZERLAND.
OP-450j
Staging of Tau Pathology with Tau-PET. Can We Already Provide this in Molecular Imaging Reports?
E. Doering; University Hospital Cologne, Department of Nuclear Medicine, Cologne, GERMANY.
OP-450k
Harmonisation of Tau PET Imaging Read-Outs. Is Unified Reading and Quantification for Different Tracers already Available?
M. Vermeiren; Amsterdam UMC – Alzheimer Center & Department of Radiology & Nuclear Medicine, Amsterdam, NETHERLANDS.

1103
Monday, October 6, 2025, 16:45 - 18:15
Room 113
LIPS Session 8 - Physics Comittee - Getting Imaging Right with Protocol Optimisation

OP-450l
Image Optimisation in SPECT
J. Tran-Gia; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY.
OP-450m
Image Optimisation in PET

I. Armstrong; Nuclear Medicine, Manchester University NHS Foundation Trust, Oxford Road, Mancheser, UNITED KINGDOM.
OP-450n
Getting the Best Out of Your Data with Optimised Image Processing
I. Buvat; PSL University, Inserm, LITO U1288, Orsay, FRANCE.

1104
Monday, October 6, 2025, 16:45 - 18:15
Room 114
M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Preclinical Neuroimaging

OP-451
Assessment of Reactive Astrocytes Across the Alzheimer's Disease Spectrum and Post-Treatment of Nrf2-Targeted Therapy via ¹⁸F-SMBT-1 Imaging in 3xTg-AD mice
S. Guo¹, F. Wei¹, S. Liang¹, Y. Ma¹, Q. Huang², C. Fu³, W. Cheng¹, Y. Yin¹;
¹Department of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ²PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ³Institute for Developmental and Regenerative Cardiovascular Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.
OP-452
PARP Inhibition Alleviates Neuroinflammation in a Rat Model of Multiple Sclerosis: Insights from a PET Study
G. Li, M. Kominia, S. Blok, C. Kwizera, I. F. Antunes, B. T. Cornelissen, E. F. J. d. Vries;
 Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.

OP-453
Multitracer PET Imaging Reveals Region-Specific BBB Dysfunction in a Mouse Model of Anxiety/Depression
E. N'Diaye¹, C. Corvo¹, S. Goutal¹, S. Leterrier¹, S. Amargier-Barrial¹, M. Goislard¹, S. Cisternino², D. J. David³, N. Tournier¹;
¹Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Service Hospitalier Frédéric Joliot, 4 place du général Leclerc, Orsay 91401, FRANCE, ²Université Paris Cité, Inserm UMRS 1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Paris, FRANCE, ³Université Paris-Saclay, Centre de recherche en Epidémiologie et Santé des Populations (CESP-Inserm), UMR 1018, Team Moods, Orsay 91400, FRANCE.

OP-454
Contribution of CXCR4-Targeted PET Imaging in the Non-Invasive Evaluation of Radiation-Induced Brain Injury

J. Pei, S. Wang, K. Zhao, X. Zhao, J. Yu, J. Liu;
 Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CHINA.
OP-455
PET Imaging of the Mouse Brain During Running
X. Yu¹, H. Liu², Q. Qiao², W. Zhu², D. Liang², H. Zhao², J. Tao², W. Ma², Q. Peng²;
¹Huazhong University of Science and Technology, Wuhan, CHINA, ²Shenzhen Bay Laboratory, Shenzhen, CHINA.

OP-456
Longitudinal SV2A Expression Increase and Profound Desynchronization is Accompanied by Reactive Astrogliosis and Precedes Neurodegeneration in a Mouse Model of Taupathy: A Multi-Tracer Imaging Study
Y. Li¹, G. Palumbo¹, S. Lindner¹, F. J. Gildehaus¹, A. Zatcepin^{1,2}, R. Werner¹, M. Brendel^{1,2,3}, L. H. Kunze^{1,2};
¹Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, ²German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY, ³Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.

OP-457
[¹⁸F]SDM-18: A high-affinity SV2A PET tracer for spinal cord imaging
P. W. Tan¹, T. Balayeva¹, N. H. Martin¹, Z. Chao², S. F. Nejati¹, T. Toyonaga¹, D. Holden¹, M. Kapinos¹, M. Zheng¹, K. Wilcox³, S. Finnema³, R. Carson¹, Y. Huang¹, Z. Cai¹;
¹School of Medicine, Yale University, New Haven, CT, UNITED STATES OF AMERICA, ²Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, UNITED STATES OF AMERICA, ³AbbVie R&D Discovery Research Neuroscience - Translational Imaging Dept., Chicago, IL, UNITED STATES OF AMERICA.

OP-458
Discovery and Preclinical Characterization of PET Tracers for Imaging Alpha-Synuclein Aggregates in the Human Brain
M. Mugnaini¹, S. Vukelic¹, G. Fink¹, M. Voorbach², Y. Zhuang², S. Benninghoff¹, S. Seifarth¹, A. Grill¹, S. M. Spohr¹, W. Amberg¹, C. Petrunaro¹, S. Vaidyanathan², A. Reed², D. Sunnemark³, H. Jongsma Wallin³, J. Wang², B. Chen², D. Wooten², M. B. Skaddan², T. Dellovalle⁴, M. Cik¹, R. Comley², F. Pohlki¹, S. J. Finnema², S. Barghorn¹;
¹AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, GERMANY, ²AbbVie Inc., North Chicago, IL, UNITED STATES OF AMERICA, ³Offspring Biosciences AB, Södertälje, SWEDEN, ⁴AbbVie Cambridge Research Centre, Cambridge, MA, UNITED STATES OF AMERICA.

OP-459
Comparison of Optimized PET Tracer [¹⁸F]FS9 with its Predecessor [¹⁸F]FS3 for α-Synuclein Fibrils Imaging
B. Hooshyar Yousefi^{1,2}, B. Uzuogunam^{3,4}, S. Bagheri^{1,2}, N. Mortazavi¹, W. Paslawski², P. Svenningsson⁵, R. Zou⁶, A. K. Rosenau⁷, M. T. Henrich⁷, F. Geibl⁷, H. Agren⁶, W. Oertel⁷, W. Weber³, M. Luster¹, T. Arzberger⁸, D. Librizzi⁹;
¹Nuclear Medicine Department, Philipps University of Marburg, Marburg, GERMANY, ²Core Facility Molecular Imaging, Center for Tumor Biology and Immunology, Philipps University Marburg, Marburg, GERMANY, ³Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY, ⁴ITM, Munich, GERMANY, ⁵Department of Clinical Neuroscience, Karolinska

Institutet,, Stockholm, SWEDEN, ⁶Department of Physics and Astronomy, Uppsala University, Uppsala, SWEDEN, ⁷Department of Neurology, Philipps University of Marburg, Marburg, GERMANY, ⁸Neurobiobank Munich, Ludwig-Maximilians-University Hospital of Munich, Munich, GERMANY, ⁹Nuclear Medicine Department, University Hospital OWL, Evangelical Clinic Bethel, Bielefeld, GERMANY.

1105

Monday, October 6, 2025, 16:45 - 18:15
 Room 211

Cutting Edge Science Track - TROP Session - AI Committee: AI for Report Generation and Patient Prognostication

OP-460
 Bone2Report: Automated Bone Scintigraphy Reporting with Clinically-Inspired Vision-Language Reasoning

X. Wu^{1,2}, X. Xie^{1,2}, S. Huang³, H. Zheng^{1,2}, N. Zhang^{1,2}, D. Liang^{1,2}, Y. Liang^{3,4}, Z. Hu^{1,2}; ¹Research Center for Medical AI, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, CHINA, ²Key Laboratory of Biomedical Imaging Science and System, Chinese Academy of Sciences, State Key Laboratory of Biomedical Imaging Science and System, Shenzhen 518055, Shenzhen, CHINA, ³National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, CHINA, ⁴National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.

OP-461
 Deep Multimodal Visual Question Answering System for Prognostication of PSMA-RPT Outcomes Using PSMA-directed Imaging and Clinical Data

M. Kassar¹, J. Hu², I. Rauscher¹, C. V. Gomes², T. Wendler³, S. Ziegler⁴, A. Afshar-Oromieh², A. Rominger², N. Navab¹, M. Eiber¹, K. Shi², R. Seifert²; ¹Technische Universität München, München, GERMANY, ²University Hospital Bern, Bern, SWITZERLAND, ³University Hospital Augsburg, Augsburg, GERMANY, ⁴LMU University Hospital, München, GERMANY.

OP-462
 Integrated PET/CT Multimodal Automated Report Generation for Lung Cancer Diagnosis

X. Xie^{1,2}, H. Wang^{1,2}, E. Liu³, N. Zhang^{1,2}, H. Zheng^{1,2}, D. Liang^{1,2}, X. Yao^{4,5}, S. Cong^{4,5}, L. Jiang³, Z. Hu^{1,2}; ¹Research Center for Medical AI, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China, Shenzhen, CHINA, ²Key Laboratory of Biomedical Imaging Science and System, Chinese Academy of Sciences, State Key Laboratory of Biomedical Imaging Science and System, Shenzhen, China, Shenzhen, CHINA, ³PET Center, Department of Nuclear Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, Guangzhou, CHINA, ⁴College of Intelligent Science and Engineering, Harbin Engineering University, Harbin 150001, China, Harbin, CHINA, ⁵Qingdao Innovation and Development Center, Harbin Engineering University, Qingdao, 266000, China, Qingdao, CHINA.

OP-463
 LymRadar: Lymphoma Risk Assessment through Multimodal Data-based Artificial Intelligence Analysis

Y. Fu^{1,2}, X. Huang^{3,4}, R. Guo^{3,4}, S. Li⁵, F. Wang⁶, Y. Zhou⁷, C. Jiang⁸, Z. Gao⁹, X. Li⁷, J. Tian^{1,2,10}, W. Mu^{1,2}, B. Li^{3,4}; ¹School of Engineering Medicine, Beihang University, Beijing, CHINA, ²Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology of the People's Republic of China, Beijing, CHINA, ³Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ⁴Institute for Medical Imaging Technology, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, CHINA, ⁵Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CHINA, ⁶PET Center, Department of Nuclear Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, CHINA, ⁷Department of Nuclear Medicine, Qilu Hospital of Shandong University, Jinan, CHINA, ⁸Department of Nuclear Medicine, West China Hospital, Sichuan University, Sichuan, CHINA, ⁹School of Biological Science and Medical Engineering, Beihang University, Beijing, CHINA, ¹⁰CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, CHINA.

OP-464
 Large-Scale Analysis of Melanoma Recurrence-Free Survival and Predictors Using AI-Driven Data Extraction from non-English Clinical Reports

C. Hinge, C. N. Ladefoged, F. L. Andersen, K. Korsholm; Copenhagen University Hospital, Rigshospitalet, Copenhagen, DENMARK.

OP-465
 Device-independent Artificial Intelligence Approach for Fast Bone Scintigraphy

V. Menezes¹, A. A. S. Oliveira¹, A. J. S. Filho¹, A. F. Morais¹, M. E. Flaminio¹, F. A. Mourato¹, T. I. Ren², A. Vigário³, C. Queiroz⁴, M. Machado⁵; ¹Hospital das Clínicas da UFPE, Recife, BRAZIL, ²Univerisade Federal de Pernambuco, Recife, BRAZIL, ³ND Núcleo Diagnóstico Maringá, Maringá, BRAZIL, ⁴Hospital Universitário Professor Alberto Antunes, Maceió, BRAZIL, ⁵Hospital Universitário Professor Edgard Santos - HUPES, Salvador, BRAZIL.

OP-466
 Automated PET/CT Report Generation Using Lesion-Aware Segmentation and a LoRA-Fine-Tuned Qwen Large Language Model

S. Xue¹, K. Chen², Y. Jia¹, K. Wu³, X. Hu⁴, M. Hacker¹, Y. Cai⁵, H. Yi², X. Li¹; ¹Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, AUSTRIA, ²Department of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, CHINA, ³ByteDance, Beijing, CHINA, ⁴Technical University of Munich, Munich, GERMANY, ⁵Postgraduate training base Allianceof Wenzhou Medical University (ZheJiang Cancer Hospital), Wenzhou, CHINA.

OP-467
 Q Amyloid: building an open-access platform for automated amyloid-beta quantification

F. Piva¹, B. Marin¹, C. Da Villa¹, L. Maccioni¹, M. Moretto^{1,2}, L. Lorenzini³, M. Veronese¹; ¹Department of Information Engineering, University of Padova, Padova, ITALY, ²Department of Neuroimaging, King's College London, London, UNITED KINGDOM, ³Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, NETHERLANDS.

OP-468
 Improving the referral process to bone scintigraphy by multi-modal detection of at-risk populations for cardiac amyloidosis using machine learning

C. Spielvogel¹, D. Kersting², D. Haberl¹, J. Yu¹, J. Hennenberg¹, K. Kluge¹, J. Ning¹, K. Kumpf¹, M. Koefler¹, F. Hofer¹, T. Traub-Weidinger¹, C. Hengstenberg¹, M. Hacker¹, R. Calabretta¹, C. Nitsche¹; ¹Medical University of Vienna, Vienna, AUSTRIA, ²University of Duisburg-Essen, Essen, GERMANY.

1106

Monday, October 6, 2025, 16:45 - 18:15
 Room 117

Clinical Oncology Track - TROP Session - Oncology & Theranostics Committee: Gastrointestinal Tumor Imaging

OP-469
 Clinical Translation of⁶⁸Ga-aGPC3-scFv ImmunoPET for Precision Diagnosis and Staging of Newly Diagnosed Hepatocellular Carcinoma

M. Li¹, W. Hu¹, X. Zhang¹, X. Cai², D. Jiang¹, X. Lan¹; ¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology ; Hubei Key Laboratory of Molecular Imaging, Wuhan 430022, China, Wuhan, CHINA, ²Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

OP-470
 [⁶⁸Ga]Ga-FAPI-46 PET/CT Enhances Preoperative Assessment of Peritoneal Metastases - Updated Interim Analysis of prospective FAPeCa trial

A. Arçay Öztürk, G. Liberale, L. Polastro, A. Veron Sanchez, A. Deleu, P. Kristanto, Z. Wimana, L. Taraji, P. Flamen; Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (UL), Brussels, BELGIUM.

OP-471
 The Analysis of Biodistribution and Tumor Uptake of [¹⁸F]AIF-FAPI-74 in Patients with Soft Tissue Sarcoma and Gastro-Intestinal Tumors compared with [¹⁸F] FDG in a prospective, exploratory study

E. Novruzov¹, F. L. Giesel¹, E. Mamlin¹, T. Watabe², J. Cardinale¹, Y. Mori¹, N. Schupps¹, C. Pinto³, C. Soza-Ried⁴, R. Fernandez⁵, H. Amaral¹, V. Kramer¹, L. Badinez⁶; ¹University Hospital Düsseldorf, Düsseldorf, GERMANY, ²Institute for Radiation Sciences, Osaka, JAPAN, ³Departamento Anatomia Patologica, Hospital Sotero del Rio, Santiago, CHILE, ⁴Center for Nuclear Medicine and PET/CT Positronmed, Santiago, CHILE, ⁵Center for Nuclear Medicine and PET/CT Positronmed, Santiago, CHILE, ⁶Instituto Radiooncológico Santiago INRAD, Santiago, CHILE.

OP-472
 Role of 68Ga-FAPI-46 PET/CT in the evaluation gastrointestinal tract tumors: comparison with ¹⁸F-FDG PET/CT

M. Komarova¹, A. Pronin¹, V. Sinityn², E. Davydova¹, A. Martinovich¹, I. Nazarenko¹, V. Solomyany¹; ¹N.N. Blokhin National Medical Research Center of Oncology, Moscow, RUSSIAN FEDERATION, ²Lomonosov Moscow State University, Moscow, RUSSIAN FEDERATION.

OP-473
 Diagnostic accuracy of 68Ga-FAPI-46 PET/CT vs. ¹⁸F-FDG PET/CT in patients with liver tumors

M. Komarova¹, A. Pronin¹, A. Martinovich¹, O. Ryzhova¹, V. Solomyany¹, I. Amosova¹, V. Sinityn²; ¹N.N. Blokhin National Medical Research Center of Oncology, Moscow, RUSSIAN FEDERATION, ²Lomonosov Moscow State University, Moscow, RUSSIAN FEDERATION.

OP-474
 Dynamic [68Ga]Ga-FAPI-46 LAFOV PET/CT in pancreatic cancer- preliminary results

M. Krarup¹, R. Aleksyniene¹, C. P. Hansen², J. Madsen¹, F. L. Andersen¹, K. Korsholm¹, J. M. Hall¹, I. Chen³, B. M. Fischer⁴, A. Loft¹; ¹Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, DENMARK, ²Department of Surgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, DENMARK, ³Department of Oncology, Herlev Hospital, Herlev, DENMARK, ⁴Copenhagen University Hospital, Rigshospitalet, Copenhagen, DENMARK.

OP-476
 The Role of [⁶⁸Ga]Ga-FAPi PET/CT in Evaluating Treatment Response in Gastrointestinal System Malignancies

G. Beydagi¹, K. Akcay¹, A. Gormez², L. Kabasakal¹, N. Alan-Selcuk¹; ¹Yeditepe University, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²Yeditepe University, Department of Radiology, Istanbul, TÜRKIYE.

OP-477
 A Clinical-Radiomics Integrated Model Based on Baseline ¹⁸F-FDG PET/CT Predicts Survival Outcomes in Hepatocellular Carcinoma Patients Receiving PD-1 Inhibitor Combined with Lenvatinib as Preoperative Conversion Therapy

J. Zhang¹, G. Wang², J. Cui¹, C. Li¹, Y. Han¹, Y. Pan¹, B. Xu¹; ¹Department of Nuclear Medicine, The First Medical Center of Chinese PLA General Hospital, Beijing, CHINA, ²Nuclear Medicine Department, Beijing Friendship Hospital, Affiliated to Capital Medical University, Beijing, CHINA.

1107

Monday, October 6, 2025, 16:45 - 18:15
 Room 212

TROP Session - Thyroid Committee: The Pivotal Role of Nuclear Medicine Imaging to Localise Parathyroid Lesion

OP-478
 Evaluation of the Performance of [¹⁸F]fluorocholine PET/CT for the Preoperative Localization of

Parathyroid Adenoma in Patients with Primary Hyperparathyroidism and Negative [^{99m}Tc]Tc-MIBI SPECT/CT: Our experience

E. Pérez de los Ríos, O. Ajuria Illarramendi, A. Martínez Lorca, T. Navarro Martínez, P. Azpeitia Hernández, M. Gutiérrez Guerrero, U. Vera Schmülling, I. Hernández Pérez, P. Paredes Rodríguez, M. Ottino, M. Orduña Díez; Hospital Universitario Ramón y Cajal, Madrid, SPAIN.

OP-479
Development of a set of predictors for a machine learning model that will be able to predict ¹⁸F-fluorocholine PET/CT findings in patients with primary hyperparathyroidism based on a medical record

N. Pantic¹, B. Radovic^{1,2}, L. Grujicic¹, M. Kotur¹, K. Petrovic¹, J. Malicevic Crevar¹, J. Zivanovic¹, A. Novkovic¹, O. Radivojevic¹, A. Ivanovski¹, A. Jovanovic¹, M. Veljkovic^{1,3}, I. Grozdic Milojevic^{1,3}, D. Sobic Saranovic^{1,3}, V. Artiko^{1,3}, S. Odalovic^{1,3}; ¹Center for Nuclear Medicine with PET, University Clinical Center of Serbia, Belgrade, SERBIA, ²Faculty of Medicine, University of Pristina with temporary headquarters in Kosovska Mitrovica, Kosovska Mitrovica, SERBIA, ³Faculty of Medicine, University of Belgrade, Belgrade, SERBIA.

OP-480
Protocol Optimization in 3T PET/MRI for Primary Hyperparathyroidism: Comparative Analysis of MRI Sequences and [18F]Fluorocholine Uptake.

V. Carrero-Vásquez, A. Villamayor Hernández, J. Díaz-Moreno, M. Cortés Romera, B. Hervás-Sanz, M. Zamorano-Rivas, A. Bagan-Trejo, C. Martínez-Ramos, M. Pudis, I. Sanchez-Rodriguez; Nuclear Medicine, Bellvitge University Hospital, Barcelona, SPAIN.

OP-481
Clinical application and semiquantitative analysis of ¹⁸F-FCH PET/CT in the pre-surgical localization of primary hyperparathyroidism.

E. Campaña Díaz¹, P. García-Talavera San Miguel¹, F. Gómez-Camínero López¹, J. Álvarez Pérez¹, C. Montes Fuentes¹, J. Badell Martínez¹, E. Martin Gallardo², S. Rama Alonso¹, A. Peñaherrera Cepeda¹, J. Villanueva Curto¹, F. Caltagirone¹, B. Santos García¹, M. Tamayo Alonso¹, M. Martín Gómez¹; ¹University Hospital of Salamanca, Salamanca, SPAIN, ²UCIII y UComillas, Madrid, SPAIN.

OP-482
Incremental benefit of integrated 18-fluorocholine PET and 4DCT in preoperative parathyroid adenoma localization over either modality alone

D. Malik, D. Thakrani, J. Gupta, M. Koley, N. Rana, A. Uppal, P. Thakral, I. B. Sen; Fortis Memorial research institute (FMRI), Gurugram, INDIA.

OP-483
[¹⁸F]Fluorocholine PET/CT in the Diagnosis of Hyperparathyroidism: Comparison with Other Preoperative Localization Methods and correlation with biochemical markers

N. Calviño, A. García-Burillo, D. Sanchez-Artuñedo, A. Palomar-Muñoz, R. Vilallonga-Puy, M. Díez Castro, M. Rubio Alvarez, J. Echeverri-Díaz, M. Marusso Fizzani, Ó. Hernandez Cristancho, L. Marconi Porcel, L. Nunes Lemos, C. Gámez-Cenzano; Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, Barcelona, SPAIN.

OP-484
Real-World Diagnostic Performance of 99mTc-SestaMIBI Scintigraphy and Fluorocholine PET/CT in Primary Hyperparathyroidism: A Comparative Analysis from Two Italian Centers

I. Gotuzzo¹, F. Garrou¹, L. Airò Farulla², S. Vadalà³, F. Lattuada¹, F. Del Gaudio¹, E. Bressan³, M. Carrara¹, A. Rossini⁴, S. Ippolito⁴, S. Cassibba⁴, C. Rossetti², P. A. Erba³; ¹Nuclear Medicine Unit - ASST Papa Giovanni XXIII Hospital, Bergamo, ITALY, ²Nuclear Medicine Unit - ASST Grande Ospedale Metropolitano Niguarda, Milano, ITALY, ³School of Medicine and Surgery, University of Milano-Bicocca, Milano, ITALY, ⁴Endocrinology Unit - ASST Papa Giovanni XXIII Hospital, Bergamo, ITALY.

OP-485
Impact of critical appraisal of parathyroid SPECT-CT requests: an opportunity to improve efficacy and safety.

I. Lopez Villar¹, M. Vinuesa Sebastian², J. Alonso Farto³, R. Jover Díaz¹, D. Tamayo Carabaño¹, J. Díaz Melguizo⁴, G. Torralbo Caballero⁵, A. Planas Roca⁶, F. Sebastian Valles⁷, J. Muñoz de Nova⁸; ¹Department of Nuclear Medicine, La Princesa University Hospital, Madrid, SPAIN, ²Clinical Quality Coordinator, La Princesa University Hospital, Madrid, SPAIN, ³Department of Nuclear Medicine, Gregorio Marañón University Hospital, Madrid, SPAIN, ⁴Medical Director, La Princesa University Hospital, Madrid, SPAIN, ⁵Medical Director, La Princesa University Hospital, Madrid, SPAIN, ⁶Associate Medical Director, La Princesa University Hospital, Madrid, SPAIN, ⁷Department of Endocrinology, La Princesa University Hospital, Madrid, SPAIN, ⁸Department of Surgery, La Princesa University Hospital, Madrid, SPAIN.

OP-486
Preoperative Localization in Primary Hyperparathyroidism with Combined 4DCT-MIBI SPECT/CT

K. Y. Li¹, S. K. Wu¹, C. Tang¹, H. K. Wong¹, H. M. Leung², W. H. Luk¹; ¹Department of Interventional and Diagnostic Radiology, Kowloon West Cluster Hospitals, Hong Kong, HONG KONG, ²Faculty of Medicine, The University of Hong Kong, Hong Kong, HONG KONG.

1108

Monday, October 6, 2025, 16:45 - 18:15

Room 115

Joint Symposium 5 - Oncology & Theranostics Committee / EAU: Advances in Renal Cancer Research

OP-488
New Tracers in Renal Cancer

K. Goffin; UZ Leuven, Leuven, BELGIUM.

OP-489
Girentuximab Imaging in Renal Cancer

S. Muselaers; Radboud University Medical Center, Department of Urology, Nijmegen, NETHERLANDS.

OP-490
Immunotherapy for Renal Cancer

E. Castro; Hospital Universitario 12 de Octubre, Department of Medical Oncology, Madrid, SPAIN.

1109

Monday, October 6, 2025, 16:45 - 18:15

Room 133+134

e-Poster Presentations Session 8 - Oncology & Theranostics Committee: Cancer Imaging and Therapy

EPS-157
Two-step pretargeted radioimmunotherapy of GPA33-expressing colorectal cancer with optimized self-assembling and disassembling bispecific fusion protein tetramer (SmartCC)

Z. Qiao, Y. Yang, Q. Liu, Y. Liu, T. Hu, C. Wei, T. Xu; SmartNuclide Biotech, Suzhou, CHINA.

EPS-158
A Hapten-Based Background-Free Reporter System for Longitudinal PET Imaging of CAR-T Cells

B. Wang¹, W. Niu², Y. Zhang², J. Li¹, H. Wu¹, Z. Xiao¹, P. Lei², Y. He¹; ¹Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA, ²Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, CHINA.

EPS-159
First clinical experience with the bicyclic peptide radiotracer [⁶⁸Ga]Ga-BCY25286 for PET/CT imaging of MT1-MMP in lung, urothelial and head and neck cancer

A. Eder^{1,2}, C. Wielenberg¹, M. A. Omrane^{1,2}, C. A. Jilg¹, C. F. Waller¹, M. Mix¹, C. Schell¹, B. Passlick¹, M. Eder^{1,2}, P. T. Meyer^{1,2}, M. T. Freitag^{1,2}; ¹University Medical Center, Freiburg, GERMANY, ²German Cancer Consortium, Freiburg, GERMANY.

EPS-160
Multi-Organ Metabolic Profiling with ¹⁸F-FDG PET/CT Predicts Pathological Response to Neoadjuvant Immunotherapy in Resectable NSCLC

J. Li, Q. Ma, Y. Tang, S. Hu; Xiangya Hospital, Central South University, Changsha, CHINA.

EPS-162
Prognostic Value of Preoperative [¹⁸F]FDG PET/CT in Malignant Pleural Mesothelioma: Correlation with Surgical Resectability and Survival Outcomes

J. Hong, K. Kimura, V. Ludwig, A. Salavati, A. Nguyen, L. Theus, A. Holzgreve, M. Allen-Auerbach, J. Czernin, R. B. Cameron, J. Calais; University of California, Los Angeles (UCLA), Los Angeles, CA, UNITED STATES OF AMERICA.

EPS-163
Preliminary Clinical Studyon the Safety and Antitumor Activity of¹⁷⁷Lu-Catelase in Soft Tissue Sarcoma

X. Guo, Z. Tan, J. Liu, H. Zhu, J. Liu, Z. Yang; Beijing Cancer Hospital, Beijing, CHINA.

EPS-164
Superior performance of ⁶⁸Ga-Pentixafor PET/CT on detecting lymphoma lesions: comparison with ¹⁸F-FDG PET/CT

H. Liu, Y. Wang, Z. Xiao, Y. Huang, Y. He; Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA.

EPS-165
Head-to-head comparison of mpMRI, PSMA and GRPR PET/CT for local staging of primary prostate cancer: results from a prospective, single-arm, phase II multimodal imaging trial

Y. Li, Y. Tang, S. Hu; Xiangya Hospital, Central South University, Changsha, CHINA.

EPS-166
Benfo-Oxythiamine as a Radiosensitizer in PSMA-Targeted Radioligand Therapy for Treatment-Refractory Prostate Cancer - Analysis of Clinical Outcome Data

C. Kramer, R. P. Baum; Curanosticum Wiesbaden-Frankfurt MVZ GmbH, Wiesbaden, GERMANY.

EPS-167
Comparison of [⁶⁸Ga]Ga-DOTA-FAPI-04and [¹⁸F]FDG PET/CT in the Evaluation of Ovarian Cancer

J. Wang, Y. Li, H. Pang; The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EPS-168
Dual-Tracer FAPI and FDG PET/CT Enhances Prediction of Pathological Response and Survival in Neoadjuvant Immunochemoradiotherapy for Esophageal Squamous Cell Carcinoma

J. Dai¹, H. WANG², R. Tian²; ¹West China Hospital, Chengdu, CHINA, ²West China Hospital, Sichuan University, Chengdu, CHINA.

EPS-169
Comparison of [^{99m}Tc]Tc-FAPI SPECT/CT and [¹⁸F]FDG PET/CT as Predictive Biomarkers for Immunotherapy Response in Gastrointestinal Cancer

Y. Zhang, W. Chen; Department of Nuclear Medicine, Fuzhou University Affiliated Provincial Hospital, Fuzhou, CHINA.

EPS-170
Preoperative Noninvasive ¹⁸F-FDG PET/CT-Based Nomogram For Predicting HER2 Expression in Gastric Adenocarcinoma

S. Yang, X. Shao, X. Zhang; Department of Nuclear Medicine, the Third Affiliated Hospital of Soochow University, Changzhou, CHINA.

EPS-171
Trop2-Targeted PET/CT for Diagnosis and Patient Stratification in Breast Cancer Toward Trop2-Directed Antibody-Drug Conjugate Therapy

L. Zhao, H. Chen; The First Affiliated Hospital of Xiamen University, Xiamen, CHINA.

EPS-172
The prognostic value of PET/MR in children with hepatoblastoma

Y. Xu; Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EPS-173
 Head-to-head Comparison of [¹⁸F]MFBG and [¹⁸F] FDG PET in Neuroblastoma

P. Wang¹, S. Yu¹, J. Mao², X. Su¹;
¹The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, CHINA, ²The Children's Hospital Zhejiang University School of Medicine, Hangzhou, CHINA.

EPS-174
 A Predictive Model Based on Lymph Node-to-Primary Tumor SUV Ratio Accurately Classifies Neck Nodal Malignancy Risk and Guides Neck Dissection in Head and Neck Squamous Cell Carcinoma Patients

S. Chan¹, S. Chi²;
¹Hualien Tzu Chi Hospital, Hualien, TAIWAN, ²Tzu Chi University, Hualien, TAIWAN.

EPS-175
 A Novel Prognostic Scoring System Integrating [¹⁸F]PFPN PET Metrics and Clinical Parameters for Mucosal Melanoma Survival Stratification

Z. Lin^{1,2}, C. Tang^{1,2}, Y. Feng^{1,3,4}, W. Ruan^{1,3,4}, F. Hu^{1,3,4}, Y. Gai^{1,3,4}, X. Zhang^{1,3,4}, X. Lan^{1,3,4};
¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²First School of Clinical Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ³Hubei Key Laboratory of Molecular Imaging, Wuhan, CHINA, ⁴Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, CHINA.

EPS-176
 Comparison of [¹⁸F]AIF-NOTA-FAPI-04 PET/CT and [¹⁸F]FDG PET/CT for diagnosing lymph node metastasis in malignant tumors

W. Zhou, J. Dai, K. Zheng, X. Peng, Y. Zhang, C. Jiang, J. Yang, H. Ye;
 The Affiliated Cancer Hospital of Xiangya School of Medicine/Hunan Cancer Hospital, Changsha, CHINA.

EPS-177
 Complementary role of ¹¹C-acetate to ⁶⁸Ga-FAPI-46 in tumor imaging with negative/indeterminate ¹⁸F-FDG findings

I. Ho^{1,2}, S. Chen², Y. Wong², K. Wu², S. Cheung², Y. Yip², K. Cheng², J. Kung¹, C. Ho²;
¹Queen Elizabeth Hospital, Hong Kong, HONG KONG, ²Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

1110

Monday, October 6, 2025, 16:45 - 18:15
 Room 116

CTE 5 - Technologists Committee: Dynamic Cardiovascular Hybrid Imaging

OP-491
 Digital Evolution and Hybrid Scanners: The Future of Cardiovascular Imaging in Nuclear Medicine.

S. Nekolla; Nuklearmedizinische Klinik und Poliklinik Klinikum rechts der Isar der Technischen Universität München, Munich, GERMANY.

OP-492
 Clinical implementation of Hybrid Digital Technology in Nuclear Medicine Cardiovascular Imaging

C. Nappi; Department of Advanced Biomedical Sciences Federico II University, Naples, ITALY.

OP-493
 Meeting Clinical Needs – The Technologist’s Perspective on Delivering Optimal Results

L. Langhoff Lund; Bispebjerg og Frederiksberg Hospital, Department of Physiology and Nuclear Medicine, Copenhagen, DENMARK.

1111

Monday, October 6, 2025, 16:45 - 18:15
 Room 111

Featured Session - Cardiovascular Committee: Innovation in Myocardial Perfusion in SPECT

OP-495
 Invited Speaker

A. Manrique;
 CHU de Caen, Caen, FRANCE.

OP-496
 CT-free attenuation correction for cardiac-dedicated CZT SPECT: update of the CASCTEC study

M. Hesse, F. Dupont, N. Laajimi, A. Oulad Bouchetta, R. Lhommel, V. Roelants;
 Cliniques Universitaires Saint-Luc, Brussels, BELGIUM.

OP-497
 Multimodal Approaches to Coronary Arteries: Myocardial Perfusion Imaging, Coronary CT Angiography, Calcium Score, MESA Risk Score and Coronary Age

A. Dursun¹, N. A. Dizdar¹, Y. Aktürk², F. Başyigit³, E. Tatır⁴, Ö. Özmen⁴;
¹Ankara Etlik City Hospital, Nuclear Medicine Clinic, Ankara, TÜRKIYE, ²Ankara Etlik City Hospital, Radiology Clinic, Ankara, TÜRKIYE, ³Ankara Etlik City Hospital, Cardiology Clinic, Ankara, TÜRKIYE, ⁴Health Sciences University, Ankara Etlik City Hospital, Nuclear Medicine Clinic, Ankara, TÜRKIYE.

OP-498
 Diagnostic value of pericoronary fat attenuation index (FAI) in predicting abnormal myocardial perfusion in INOCA patients: a comparative study of CCTA and CZT-SPECT

H. Zhang¹, F. Caobelli², K. Shi², R. Ji¹, M. Fei³, F. Yu¹;
¹Tongji University School of Medicine, Shanghai Tenth People's Hospital, Shanghai, CHINA, ²Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND, ³Tongji university School of Medicine, Shanghai Pulmonary Hospital, Shanghai, CHINA.

OP-499
 Assessment of myocardial perfusion Sestamibi CZT-SPECT reconstructed using deep-learning-based virtual attenuation correction maps with correlation to results from Rubidium-PET and coronary angiography

T. Sprauel¹, L. Imbert^{1,2}, K. Doyeux³, M. Perrin¹, M. Claudin¹, V. Roch¹, M. Doyen², N. Roth⁴, Y. Lamash⁴, R. Chequer^{3,5}, F. Rouzet^{3,5}, F. Hyafil^{6,7}, P. Marie^{1,2};

¹Université de Lorraine, Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, Nancy, FRANCE, ²Université de Lorraine, IADI, INSERM U1254, Nancy, FRANCE, ³Department of Nuclear Medicine, Bichat university Hospital, Assistance Publique-Hopitaux de Paris (AP-HP), Paris, FRANCE, ⁴Spectrum Dynamics Medical, Caesarea, ISRAEL, ⁵Université Paris Cité, INSERM U 1148, Paris, FRANCE, ⁶Department of Nuclear Medicine, DMU IMAGINA, European Hospital Georges-Pompidou, Assistance Publique-Hopitaux de Paris (AP-HP), Paris, FRANCE, ⁷INSERM U 970, University Paris-City, Paris, FRANCE.

OP-500
 Diagnostic Validation of a Novel Deep Learning Attenuation Correction Software for Stress MPI using a Dedicated CZT Cardiac Camera. A comparison with Fractional Flow Reserve acquired during Invasive Coronary Angiography in Patients with Suspected CAD

A. Manrique¹, M. Esnault¹, R. Baavour², N. Coudrais¹, N. Roth², D. Agostini¹;
¹CHU de Caen, Caen, FRANCE, ²Spectrum Dynamics, Cesarea, ISRAEL.

OP-501
 Coronary Flow Reserve Evaluation with a Novel Multi-pinhole Collimator on Triple-Na-I-detector SPECT/CT in Coronary Artery Disease: A Pilot Study

A. Ogum¹, S. Barna^{2,3}, Z. Szoboszlai², A. K. Krizsan⁴, J. Renaud⁵, T. Mitchell⁶, Á. Budai², G. Ország², C. Csikos^{1,3}, I. Gara^{2,3};
¹Gyula Petrányi Doctoral School of Allergy and Clinical Immunology, Debrecen, HUNGARY, ²Scanomed Ltd, Debrecen, HUNGARY, ³University of Debrecen, Faculty of Medicine, Medical Imaging Department, Division of Nuclear Medicine, Debrecen, HUNGARY, ⁴Mediso Ltd., Budapest, HUNGARY, ⁵INVIA Medical Imaging Solutions, Ann Arbor, MI, UNITED STATES OF AMERICA.

OP-502
 The fesibility of CZT-SPECT in the assessment of coronary microvascular dysfunction (CMD) in INOCA patients: a comparative study with Coronary Agnio-IMR

H. Zhang¹, F. Caobelli², K. Shi², F. Yu³, K. Wang¹, M. Fei⁴;
¹Tongji University School of Medicine, Shanghai Tenth People's Hospital, Shanghai, CHINA, ²Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bren, SWITZERLAND, ³Tongji University School of Medicine, Shanghai Tenth people's Hospital, Shanghai, CHINA, ⁴Tongji University School of Medicine, Shanghai Pulmonary Hospital, Shanghai, CHINA.

OP-503
 A new parameter - increasing ratio derived from SPECT: validation by PET- myocardial flow reserve

A. Inoue, M. Nagao, A. Yamamoto, A. Sakai, R. Nakao, M. Watanabe, J. Yamaguchi, S. Sakai;
 Tokyo Women's Medical University Hospital, Tokyo, JAPAN.

1201

Tuesday, October 7, 2025, 08:00 - 09:30
 Auditorium

CME 9 - Oncology & Theranostics + Neuroimaging Committee: RLT Applications in Neuro-Oncology

OP-504
 Targets in CNS tumors

J. Kunikowska; Medical University of Warsaw, Department of Nuclear Medicine, Warsaw, POLAND.

OP-505
 RLT in gliomas

N. Tolboom; UMC Utrecht, Department of Nuclear Medicine, Utrecht, NETHERLANDS.

OP-506
 RLT in meningiomas

N. Albert; LMU University Hospital, Department of Nuclear Medicine, Munich, GERMANY.

OP-507
 RLT in brain metastases

M. Preusser; Medical University of Vienna, Division of Oncology Department of Medicine I, Vienna, AUSTRIA.

1202

Tuesday, October 7, 2025, 08:00 - 09:30
 Room 112 (Arena)

Special Track 9 - Physics Committee: Debate: Quantitative Imaging: What’s the Point? (Focus on Kinetic Modeling)

OP-508
 Pro Kinetic Modeling

R. Boellaard; VU University Medical Center, Amsterdam, NETHERLANDS.

OP-509
 Contra Kinetic Modeling

L. Kumar Shiyam Sundar; LMU University Hospital, Munich, GERMANY.

1203

Tuesday, October 7, 2025, 08:00 - 09:30
 Room 113

LIPS Session 9 - Oncology & Theranostics Committee: Pitfalls in PSMA-Based RLT: Case-Based Review

OP-511
 Pitfalls in Patient Selection

M. Bauckneht; IRCCS Ospedale Policlinico San Martino, University of Genova, Genoa, ITALY.

OP-512

Pitfalls in Response Assessment

A. Gafita; Nuclear Medicine and Molecular Imaging Division, The Johns Hopkins Hospital, Johns Hopkins School of Medicine, Baltimore, UNITED STATES OF AMERICA.

OP-513

Pitfalls in Dosimetry and Radiation Protection

J. Brosch-Lenz; Institute of Nuclear Medicine, Glen Burnie, Maryland, UNITED STATES OF AMERICA.

1204

Tuesday, October 7, 2025, 8:00 - 9:30

Room 114

M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Combination Therapy - Shaping the Future of TRT

OP-515

Radiobiology and Synergistic Approaches in [¹²³I] CC1 Radionuclide Therapy

N. Delgado Mayenco¹, L. Hernandez Cano¹, E. Diekstra¹, S. Unnikrishnan¹, F. Amoroso¹, H. Kramer¹, G. Alachouzos², W. Szymanski³, I. F. Antunes¹, E. F. J. de Vries¹, B. Cornelissen¹; ¹University Medical Center Groningen, University of Groningen, Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS, ²University of Groningen, Centre for Systems Chemistry, Stratingh Institute for Chemistry, Faculty for Science and Engineering, Groningen, Groningen, NETHERLANDS, ³University Medical Center Groningen, University of Groningen, Department of Radiology, Medical Imaging Center, Groningen, NETHERLANDS.

OP-516

Synergistic Anti-Tumour Effects of ²²⁵Ac-DOTA-Girentuximab Combined with DNA Damage Response Inhibitors in CAIX-Positive Renal Cancer

Z. Cao^{1,2,3}, C. Wichmann^{1,2,3}, A. Ivashkevich⁴, A. Zimmermann⁵, C. Sirrenberg⁵, H. Dahmen⁵, L. Osellame^{1,2}, N. Guo¹, F. Scott^{1,2}, M. Wheatcroft⁴, A. Scott^{1,2,3}; ¹Olivia Newton-John Cancer Research Institute, Heidelberg, AUSTRALIA, ²School of Cancer Medicine, La Trobe University, Bundoora, AUSTRALIA, ³Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, AUSTRALIA, ⁴Telix Pharmaceuticals, Melbourne, AUSTRALIA, ⁵Merck Healthcare KGaA, Darmstadt, GERMANY.

OP-517

Radiation Induced Senescence Limits Radiopharmaceutical Therapy Efficacy in Murine Models of GU Cancers

M. Lindsey, M. Bio Idrissou, H. Comas-Rojas, A. Adeniyi, A. Pinchuk, L. Lambert-Lepesevich, N. Clemons, E. Santos, O. Kwon, G. Iyer, B. Bednarz, R. Hernandez; University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

OP-518

Targeted Radionuclide Therapy of Prostate Cancer using a ¹⁷⁷Lu- and ⁴⁷Sc-labeled Gastrin-Releasing Peptide Receptor Antagonist. Evaluation as Monotherapy and in Combination with Everolimus

N. Kumar¹, A. Bilinska¹, E. Menéndez¹, T. Läppchen¹, E. S. Moon², M. Zoltowska³, D. Pawlak³, I. Cieszykowska³, R. Mikolajczak³, F. Rösch², A. Rominger¹, E. Gourni¹; ¹Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND, ²Department of Chemistry-TRIGA site, Johannes Gutenberg University of Mainz, Mainz, GERMANY, ³Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, POLAND.

OP-519

Combining CD44v6-Targeted Radionuclide Therapy with Chemotherapy for Treatment of Pancreatic Ductal Adenocarcinoma

A. Gustafsson¹, H. Svedberg¹, S. S. Rinne¹, A. Lundgren Mortensen^{1,2}, M. Nestor¹; ¹Uppsala University, Uppsala, SWEDEN, ²Karolinska Institutet, Stockholm, SWEDEN.

OP-520

New combination therapies to improve [¹⁷⁷Lu]Lu-PSMA treatment in prostate cancer cells.

F. Amoroso^{1,2}, E. O'Neil², L. Hernandez Cano¹, B. T. Cornelissen^{1,2}; ¹Dept. of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS, ²Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM.

OP-521

Combining CAIX-targeted radionuclide therapy with immune checkpoint inhibitors: which inhibitor and when?

S. Kleinendorst¹, E. Oosterwijk¹, M. Konijnenberg¹, S. Wenker¹, K. Twumasi-Boateng², M. Wheatcroft², S. Heskamp¹; ¹RadboudUMC, Nijmegen, NETHERLANDS, ²Telix Pharmaceuticals Limited, Melbourne, AUSTRALIA.

OP-522

Fractionated versus single-dose PSMA-targeted radioligand therapy as adjuvant therapy in a murine model for oral squamous cell carcinoma treated with immune checkpoint inhibitors

M. Henrotte^{1,2,3}, D. Creytens^{1,2,3}, F. De Vos², B. Descamps^{2,3}, L. Devisscher^{2,3}, G. Holtappels², W. J. A. Huvenne^{1,2,3}, K. Kersemans^{1,3}, A. Meskens^{2,3}, S. Neyt^{2,3}, S. Rottey^{1,2,3}, M. Saerens^{1,2,3}, C. Vanhove^{2,3}, T. Vermassen^{1,2,3}, J. M. Debacker^{2,4,5}; ¹Ghent University Hospital, Ghent, BELGIUM, ²Ghent University, Ghent, BELGIUM, ³Cancer Research Institute Ghent (CRIG), Ghent, BELGIUM, ⁴Vrije Universiteit Brussel (VUB), Molecular Imaging and Therapy Research Group (MITH), Brussels, BELGIUM, ⁵Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, BELGIUM.

OP-523

PD-1 blockade enhances therapeutic effects of ¹⁷⁷Lu-DOTA-MSA in colorectal cancer CEA-transgenic mice

T. Mohajershojai¹, E. Bengtsson¹, I. Vallin², D. Spangler², M. Melssen², P. J. Yazaki³, M. Nestor²; ¹Karolinska Institute, Stockholm, SWEDEN, ²Uppsala University, Uppsala, SWEDEN, ³Beckman Research Institute, Duarte, CA, UNITED STATES OF AMERICA.

1205

Tuesday, October 7, 2025, 8:00 - 9:30

Room 211

Cutting Edge Science Track - TROP Session - AI Committee: AI Techniques for Patient Classification

OP-524

Decision support for early treatment adaptation, a case study for NSCLC: RTEP7-IFCT 14.02

Z. Mesbah^{1,2,3}, R. Modzelewski^{1,3}, P. Le Roux¹, G. Zalcman^{4,5}, P. Giraud⁶, P. Vera^{1,7}, S. Thureau^{1,7}; ¹Henri Becquerel Cancer Center, Rouen, FRANCE, ²Siemens Healthineers, Courbevoie, FRANCE, ³AIMS-QuantIF, Rouen, FRANCE, ⁴Bichat Claude Bernard Hospital, Paris, FRANCE, ⁵Francoophone Intergroup of Thoracic Oncology, Paris, FRANCE, ⁶European Hospital Georges Pompidou, Paris, FRANCE, ⁷AIMS-QuantIF, Paris, FRANCE.

OP-525

Systemic Metabolic Signatures of Lung Cancer: A Machine Learning Approach Using Whole-Body Dynamic [¹⁸F]FDG-PET

S. Castaneda Vega^{1,2}, V. Agrawa^{3,2}, M. Weissinger^{1,4}, M. Stettler², V. Groos⁵, A. Assmann⁵, S. von Beschwitz¹, B. Pichler^{2,6}, S. Bauer^{7,8}, C. la Fougère^{1,9,10}; ¹Department of Nuclear Medicine and Clinical Molecular Imaging, Tübingen, GERMANY, ²Werner Siemens Imaging Center, Tübingen, GERMANY, ³Max Planck Institute for Intelligent Systems, Tübingen, GERMANY, ⁴Department of Diagnostic and Interventional Radiology, Tübingen, GERMANY, ⁵University of Tübingen, Tübingen, GERMANY, ⁶IFIT-Cluster of Excellence, Tübingen, GERMANY, ⁷Helmholtz AI, München, GERMANY, ⁸Technical University, München, GERMANY, ⁹IFIT-Cluster of Excellence, Tübingen, GERMANY, ¹⁰German Cancer Consortium (DKTK), Tübingen, GERMANY.

OP-526

Transfer Learning and External Validation of a ResNet-Based Deep Learning Model for Deauville Score Classification with [¹⁸F]FDG-PET-CT: A Retrospective Analysis

M. Dubrocaq¹, A. Mezher¹, T. Guiot², A. Gjukaj¹, O. Debeir³, P. Flamen², E. Woff²; ¹Université Libre de Bruxelles, Brussels, BELGIUM, ²Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Department of Nuclear Medicine, Brussels, BELGIUM, ³Université libre de Bruxelles (ULB), Ecole polytechnique de Bruxelles, Brussels, BELGIUM.

OP-527

Performance of an automatic tool for breast cancer staging with [¹⁸F]FDG PET/CT

C. Constantino^{1,2}, C. Oliveira¹, F. P. Oliveira¹, S. Vinga², D. C. Costa¹; ¹Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, PORTUGAL, ²INESC-ID, Instituto Superior Tecnico, University of Lisbon, Lisbon, PORTUGAL.

OP-528

AI-based Prediction of Myocardium Viability Using [⁸²Rb] PET/CT

A. Chevalley^{1,2}, G. Bonnet², M. Amirian^{1,2}, V. Andrearczyk^{1,2}, S. Bors², R. Klein³, R. DeKemp⁴, E. Moulton⁵, J. O. Prior², M. Jreige², C. H. Kaman², A. Depeursinge^{1,2}; ¹Institute of Informatics, HES-SO Valais-Wallis, Sierre,

SWITZERLAND, ²Department of Nuclear Medicine and Molecular Imaging, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SWITZERLAND, ³Division of Nuclear Medicine and Molecular Imaging, University of Ottawa, Ottawa, ON, CANADA, ⁴Division of Cardiology, University of Ottawa Heart Institute,, Ottawa, ON, CANADA, ⁵Jubilant DraxImage Inc., Kirkland, QC, CANADA.

OP-529

Integration of Spatial Analysis and Deep Learning for Enhanced Tumour Classification in Total-Body PET/CT Imaging: A Preliminary Study

D. Han¹, S. Wai²; ¹Telix Pharmaceuticals, Sydney, AUSTRALIA, ²Telix Pharmaceuticals, Melbourne, AUSTRALIA.

OP-530

Wasserstein Distance as a Metric for Molecular Connectivity Analysis in Amyotrophic Lateral Sclerosis

C. Tang¹, J. De Vocht^{2,3}, K. Van Laere^{1,4}, P. Van Damme^{2,3}, M. Koole¹; ¹Nuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven, BELGIUM, ²Laboratory for Neurobiology (VIB-KU Leuven), Department of Neurosciences, KU Leuven, Leuven, BELGIUM, ³Neurology, University Hospitals Leuven, Leuven, BELGIUM, ⁴Department of Nuclear Medicine, University Hospitals UZ Leuven, Leuven, BELGIUM.

OP-531

Detecting The Epileptogenic Zone Using Attention U-Net Model in FDG PET Images: Integration of Deep Learning Techniques to PET Imaging

M. Bodur¹, L. Uslu-Besli¹, O. E. Sahin¹, K. Saglam¹, A. Sarikas², O. Demir², C. Ozkara³, H. B. Sayman¹; ¹Istanbul University-Cerrahpasa, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²Marmara University, Department of Computer Engineering, Istanbul, TÜRKIYE, ³Istanbul University-Cerrahpasa, Department of Neurology, Istanbul, TÜRKIYE.

OP-532

Stratified Evaluation of Deep Learning Models by Age and Cognition Level for Amyloid Positivity Prediction in [¹⁸F]FDG PET

S. Seo¹, M. So¹, S. Lee¹, Y. Yoon¹, D. Seo¹, D. Kim², H. Han², S. Kang¹, D. Kim³, M. Yun¹; ¹Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, ²Yonsei University, Seoul, KOREA, REPUBLIC OF, ³Hallym University College of Medicine, Anyang, KOREA, REPUBLIC OF.

1206

Tuesday, October 7, 2025, 8:00 - 9:30

Room 117

Clinical Oncology Track - TROP Session - Oncology & Theranostics Committee: Protate Cancer Therapy: Dosimetry, SPECT/CT, AI

OP-533

Validation of the collapsed-cone superposition for whole-body patient-specific dosimetry in [¹⁷⁷Lu] Lu-PSMA-617 radionuclide therapy

A. Terro¹, S. Perret¹, A. Dumouchel^{1,2}, D. Tonnelet², A. Edet-Sanson^{1,2}, P. Vera^{1,2}, P. Decazes^{1,2}, A. Dieudonné^{1,2};

¹QuantIF-AIMS, Rouen University, Rouen, FRANCE, ²Nuclear Medicine Department, Henri Becquerel Center, Rouen, FRANCE.

OP-534
The tumour sink effect on healthy tissues dosimetry in ¹⁷⁷Lu-PSMA-I&T radiopharmaceutical therapy
A. Zamanian¹, F. A. Buteau², G. Apri², F. Arsenault², A. Beaulieu², F. Pouliot³, J. M. Beauregard¹;
¹Department of Radiology and Nuclear Medicine, Université Laval, Quebec City, QC, CANADA, ²Department of Medical Imaging, CHU de Québec - Université Laval, Quebec City, QC, CANADA, ³Urology Division, Department of Surgery, Université Laval, Quebec City, QC, CANADA.

OP-536
Prognostic value of ⁶⁸Ga-PSMA PET radiomics in metastatic castration-resistant prostate cancer treated with ¹⁷⁷Lu-PSMA radioligant therapy
L. Edouard¹, L. Ferrer², L. Papillon², Y. Godbert¹, M. Meyer¹, V. Préga-Renaud¹, C. Subreville³, N. Anizan⁴, M. Cabart⁵, D. Teyssonneau⁵, G. Roubaud⁵, T. Colin², P. Schwartz¹;
¹Nuclear Medicine Department, Institut Bergonié, Bordeaux, FRANCE, ²Sophia Genetics, Pessac, FRANCE, ³Department of Pharmacy, Institut Bergonié, Bordeaux, FRANCE, ⁴Department of Physics, Institut Bergonié, Bordeaux, FRANCE, ⁵Oncology Department, Institut Bergonié, Bordeaux, FRANCE.

OP-537
Early Progression Prediction with RECIP 1.0 on Routine Post-Therapy ¹⁷⁷Lu-PSMA SPECT/CT
M. Kassas¹, L. Devriendt², T. Guiot³, M. Manley¹, C. Marin³, R. Danieli³, L. Taraji¹, I. Karfis¹, E. Woff¹, P. Flamen¹, C. Artigas¹;
¹Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Nuclear Medicine Department, Brussels, BELGIUM, ²Faculté de Médecine, Université Libre de Bruxelles, Brussels, BELGIUM, ³Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Medical Physics Department, Brussels, BELGIUM.

OP-538
Comparison of PET Response Criteria in mCRPC Patients Treated with [¹⁷⁷Lu]PSMA
T. Tellj¹, V. Grünwald², B. Hadaschik³, C. Kesch³, L. Umutlu⁴, K. Herrmann¹, W. P. Fendler¹;
¹Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY, ²Department of Urology, University Hospital Essen, Essen, Germany, Essen, GERMANY, ³Department of Urology, University Hospital Essen, Essen, GERMANY, ⁴Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, GERMANY.

OP-539
SPECT to PET image translation with a conditional Generative Adversarial Network (GAN) improves assessment of ¹⁷⁷Lu-PSMA post therapy scans
T. Otani, F. Moradi, H. Song, G. Davidzon, A. Iagaru;
Stanford Healthcare, Stanford, CA, UNITED STATES OF AMERICA.

OP-540
Post-Therapy Planar ¹⁷⁷Lu-PSMA Imaging: Lesion-to-Parotid Ratio Predicts Early PSA Response
H. Pekedis, E. M. Kaya, A. S. Yilmaz, G. Yilmaz, B. Esen Akkas;
Basaksehir Çam ve Sakura City Hospital Nuclear Medicine Department, Istanbul, TÜRKIYE.

OP-541
Balancing efficacy and nephrotoxicity in Lu-177 PSMA I&T therapy: clinical and imaging determinants of significant eGFR decline, an Asian cohort
D. Lim¹, C. Tang¹, W. Chua¹, A. Tong¹, A. Wong², Y. Khor¹, W. Tham¹, W. Lam¹, S. Thang¹;
¹Singapore General Hospital, Department of Nuclear Medicine and Molecular Imaging, Singapore, SINGAPORE, ²National University Cancer Institute, Singapore, SINGAPORE.

1207
Tuesday, October 7, 2025, 8:00 - 9:30
Room 212
TROP Session - Thyroid Committee: Current and Future Perspective of Nuclear Medicine Imaging in Endocrinological Disorders

OP-542
18F-FET PET : a potential new tool for localizing ACTH-producing pituitary adenomas in patients with newly diagnosed Cushing's disease
L. Al Mansour, C. Merino, S. Solomon, S. Chaib, C. Sergeant, M. Janier, E. Jouanneau, G. Raverot, A. Flaus;
Hospices Civils de Lyon, Lyon, FRANCE.

OP-543
Diagnostic Value of FDG PET/CT Quantitative Parameters in Differentiating Adrenal Masses: Our Clinical Experience
G. Deniz¹, E. Isik¹, D. Arslan¹, S. Erturk², D. Has Simsek¹, Y. Sanli¹;
¹Istanbul University, Istanbul Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²Istanbul University, Istanbul Faculty of Medicine, Department of Radiology, Istanbul, TÜRKIYE.

OP-544
⁶⁸Ga-Pentixafor PET/CT versus Adrenal Venous Sampling for Surgical Decision-Making in Primary Aldosteronism
W. Zhengjie, Z. Xiaoyang, L. Junyang, L. Jia, Z. Rui, L. Mengdan, P. Hua;
The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

OP-545
Development and validation of a dual-time ⁶⁸Ga-Pentixafor PET/CT-based radiomic nomogram for subtyping diagnosis of primary aldosteronism
R. Zuo¹, L. Xu¹, T. Xu², S. Liu¹, Z. Wang¹, W. Li¹, Y. Chen², H. Pang¹;
¹The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA, ²Affiliated Hospital of Southwest Medical University, Luzhou, CHINA.

OP-546
Evaluation of AI¹⁸F-NOTA-Pentixafor PET/CT in Subtyping and Surgical Guidance in Primary Aldosteronism Patients: A Prospective Phase II Study
X. Yan¹, G. Zheng², M. Liu¹, Y. Zhang¹, Y. Xie¹, L. Huo¹;
¹Department of Nuclear Medicine, Peking Union Medical

College Hospital, Chinese Academy of Medical Sciences, Beijing, CHINA, ²Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, CHINA.

OP-547
The value of chemokine receptor type 4 targeted PET imaging in treatment management for primary aldosteronism compared to adrenal venous sampling
N. Lu, Z. Xiao, D. Xing, D. Zeng, Y. He;
Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA.

OP-548
Organ-Specific Alterations in Physiological FDG Uptake in Diabetic Patients: A Retrospective PET/CT Study Using Japanese Cancer Screening Cohort
H. Wakabayashi¹, Z. Chen¹, S. Gutschmayer², D. Ferrara², M. Pires², S. Takeda³, J. Taki³, S. Kinuya¹, L. Shiyam Sundar^{2,4}, T. Beyer²;
¹Kanazawa University, Kanazawa, JAPAN, ²Quantitative Imaging Medical Physics (QIMP) Team, Medical University of Vienna, Vienna, AUSTRIA, ³PET Center, Kanazawa Advanced Medical Center, Kanazawa, JAPAN, ⁴DIGIT-X Lab, Department of Radiology, LMU Munich, Munich, GERMANY.

OP-549
Detection of pancreatic β-cells in individuals with type 1 and type 2 diabetes and obesity, via the PET tracer [68Ga]Ga-NODAGA-Exendin-4
S. Migliari¹, M. Scarlattei¹, A. Gagliardi¹, A. Guercio¹, G. Baldari¹, R. Aldigeri², V. Spigoni², F. Fantuzzi², G. Cinquegrani², E. Balestrieri², A. Dei Cas², R. Bonadonna², L. Ruffini¹;
¹Nuclear Medicine Division, Azienda Ospedaliero-Universitaria di Parma, Parma, ITALY, ²Laboratory of Endocrinology, Diabetes and Metabolic Disease, Department of Medicine and Surgery, Azienda Ospedaliero-Universitaria di Parma, Parma, ITALY.

OP-550
Triple-Tracer Imaging in Metastatic High-Grade Neuroendocrine Neoplasms: A Preliminary Observational Study
P. HJ¹, K. G. Kallur², S. S P¹, D. Kumar³, P. Wadhwa³;
¹Aster Hospital, Banglore, INDIA, ²HCG Cancer Center, Banglore, INDIA, ³United Imaging Healthcare, Delhi, INDIA.

1208
Tuesday, October 7, 2025, 8:00 - 9:30
Room 115
TROP Session - Cardiovascular Committee: Cardiovascular Infection and Inflammation: Evidence and Novelty

OP-551
Digital FDG PET/CT as First-Line Diagnostic Modality for Cranial Giant Cell Arteritis
A. Roy^{1,2,3}, J. Alberini^{4,5}, R. H. J. A. Slart^{6,7}, M. Samson^{4,5}, J. Makhzoum^{8,9}, M. A. Stein², L. Berkson^{3,2}, É. Rousseau^{10,11}, N. Dendukuri², P. H. Nienhuis^{6,7}, N. van der Geest^{6,7}, C. Pineau^{1,2}, P. Liang^{10,11}, G. Abikhzer^{3,2};
¹McGill University Healthcare Center, Montréal, QC, CANADA, ²McGill University, Montréal, QC, CANADA, ³Jewish General Hospital, Montréal, QC, CANADA, ⁴François Mitterrand University Hospital, Dijon, FRANCE, ⁵Université

Bourgogne Franche-Comté, Dijon, FRANCE, ⁶University Medical Center Groningen, Groningen, NETHERLANDS, ⁷University of Groningen, Groningen, NETHERLANDS, ⁸Hôpital du Sacré-Cœur de Montréal, Montréal, QC, CANADA, ⁹Université de Montréal, Montréal, QC, CANADA, ¹⁰University of Sherbrooke, Montréal, QC, CANADA, ¹¹Centre hospitalier de l'Université de Sherbrooke, Sherbrooke, QC, CANADA.

OP-552
FDG PET-CT in suspected giant cell arteritis: visual analysis has superior diagnostic accuracy compared to semiquantitative image analysis. The VASCAI study.
F. Caobelli, R. Friedli, N. Gözlügöl, S. Bucher, P. Seitz, F. Lötscher, M. Gilgen, P. Stähli, F. Helfenstein, Y. Döring, G. Hamvas, M. Schindewolf, A. Rominger, B. Maurer, L. Christ, L. Seitz;
Inselspital Bern, Bern, SWITZERLAND.

OP-553
[¹⁸F]FDG-PET/CT in giant cell arteritis: assessing temporal and vertebral artery involvement with and without corticosteroid treatment, and the potential diagnostic value of adding quantitative analysis
M. Calls Calahorro¹, M. Velasco-Nuño¹, H. Codés Mendez², P. Moya Alvarado², A. Barros³, A. Fernández-León¹, P. Stefaneli¹, B. Serrallonga¹, Y. Delisau¹, S. Castejón¹, G. Guzmán¹, V. Camacho¹, A. Flotats¹;
¹Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ²Rheumatology and Systemic Autoimmune Diseases Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ³Cardiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

OP-554
Value addition of [Ga-68] fapi pet/ct in enhancing the detection of the inflammatory disease activity in patients suspected of takayasu arteritis- a pilot study
R. Maurya, M. Ora, S. Gambhir, M. Rai, R. Mehra;
Sanjay Gandhi post graduate institute of medical sciences, Lucknow, INDIA.

OP-555
¹⁸F-FDG PET/CT value in the diagnosis evaluation of patients with polyarteritis nodosa
N. Martinage, J. Guyot, G. Delaby, D. Huglo, E. Ledoult, C. Baillet;
Centre Hospitalier Universitaire de Lille, Lille, FRANCE.

OP-556
Diagnostic Value of Splenic and Bone Marrow Metabolic Uptake on ¹⁸F-FDG PET/CT in Patients with Suspected Infective Endocarditis
S. Capitanio¹, A. Franchini¹, A. Spataro¹, L. Virdone², L. Airò Farulla¹, A. Scarale¹, G. Cabrini¹, E. Gay¹, C. Rossetti¹;
¹Nuclear Medicine Unit, Dipartimento Ematologia, Oncologia e Medicina Molecolare, ASST Niguarda Hospital, Milan, ITALY, ²School of Medicine and Surgery, University of Milan-Bicocca, Monza, ITALY.

OP-557
Metabolic Signatures of Smoking-Induced Immune Suppression and Vascular Inflammation: Insights from ¹⁸F-FDG PET/CT
E. Panagiotidis¹, G. Angelidis¹, A. Paschal², T. Kalathas², A. Pipintakou², I. Tsougos¹, V. Valotasios¹, V. Chatzipavlidou², P. Georgoulas¹;
¹University Hospital, Larisa, GREECE, ²Theageneio Cancer Center, Thessaloniki, GREECE.

OP-558
Hybrid [18F]FDG-PET/MRI in Inflammatory Cardiac Disease: One Scan, Complete Insight

G. Argalia¹, M. Fogante², G. Biscontin¹, A. Palucci¹, C. Romagnolo¹, C. Cottignoli¹, P. Esposto Pirani², C. Ventura², N. Schicchi³, G. Argalia², F. M. Fringuelli¹;
¹Nuclear Medicine, Department of Radiological Sciences, University Hospital of Marche, Ancona, ITALY, ²Maternal-Child-Senological-Cardiological Radiology and Outpatient Ultrasound, Department of Radiological Sciences, University Hospital of Marche, Ancona, ITALY, ³Cardiovascular Radiological Diagnostics, Department of Radiological Sciences, University Hospital of Marche, Ancona, ITALY.

OP-559
FDG PET/CT in Inflammatory Myopathies: Bridging Biochemistry and Imaging Clues

A. S Babu, R. Karna, M. G. Umar, A. Mahalik, K. Bangkim Chandra, R. Kumar;
All India Institute of Medical Sciences, Delhi, INDIA.

1209
Tuesday, October 7, 2025, 8:00 - 9:30
Room 133+134

e-Poster Presentations Session 9 - Dosimetry Committee: Advances in Clinical and Preclinical Dosimetry

EPS-178
Scenario based uncertainty estimation of radionuclide therapy dose
F. Kähler;
RaySearch Laboratories, Stockholm, SWEDEN.

EPS-179
A Unified MeshBased Modelling Framework for Age and AnatomySpecific Skeletal Dosimetry
R. Dawson¹, C. Choi¹, Y. Wang¹, B. Shin¹, J. Tran-Gia², M. Salas-Ramirez², A. Theisen², M. Laßmann², W. E. Bolch¹;
¹J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, UNITED STATES OF AMERICA, ²Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY.

EPS-180
Increasing Precision in Image-Based Bone Marrow Absorbed Dose Estimations following [¹⁷⁷Lu]Lu-DOTATATE Treatment
K. Smits¹, F. Westerbergh¹, J. Hemmingsson¹, M. van Essen², J. Svensson³, A. Theisen⁴, J. Tran-Gia⁴, T. Rydén⁵, P. Bernhardt⁵;
¹Institute of Clinical Sciences, Gothenburg, SWEDEN, ²Institute of Medicine, Gothenburg, SWEDEN, ³Department of Oncology, Gothenburg, SWEDEN, ⁴Department of Nuclear Medicine, Wurzburg, GERMANY, ⁵Department of Medical Physics and Biomedical Engineering, Gothenburg, SWEDEN.

EPS-181
Semi-automated small-volume sampling for quantitative SPECT/CT-based renal dosimetry in ¹⁷⁷Lu radiopharmaceutical therapy: comparison with whole-kidney segmentation

J. M. Beauregard¹, A. S. Demers¹, F. A. Buteau¹, G. April¹, F. Arsenault¹, A. Beaulieu¹, C. F. Uribe²;
¹Department of Medical Imaging, CHU de Québec - Université Laval, Quebec City, QC, CANADA, ²BC Cancer Research, Vancouver, BC, CANADA.

EPS-182
DBS sampling as a method for dosimetry in Lu-PSMA therapy.
K. Doornhof, I. Bumanjal, M. Konijnenberg, S. Koolen;
Erasmus MC, Rotterdam, NETHERLANDS.

EPS-183
Assessing the Impact of Multi-Cycle Data Integration on the Accuracy of Single-Time-Point Dosimetry: A Non-linear Mixed-Effect Modeling Evaluation
I. Budiansah¹, D. Hardiansyah¹, S. M. B. Peters², S. Ardjo Pawiro¹, B. Prive^{2,3}, J. Nagarajah^{2,4}, M. W. Konijnenberg^{2,3}, A. J. Beer⁵, G. Glatting⁵;
¹Universitas Indonesia, Depok, INDONESIA, ²Radboud University Medical Centre, Nijmegen, NETHERLANDS, ³Erasmus Medical Centre, Rotterdam, NETHERLANDS, ⁴Röntgeninstitut Düsseldorf, Düsseldorf, GERMANY, ⁵Ulm University, Ulm, GERMANY.

EPS-184
Dosimetry-guided treatment planning for ¹⁷⁷Lu-labelled PSMA therapy based on a diagnostic ⁶⁸Ga-labelled PSMA PET/CT
E. Yousefzadeh-Nowshahr^{1,2}, L. D. Jiménez-Franco³, V. Vasic¹, A. Theisen⁴, J. Tran-Gia⁴, P. Hartrampf⁴, A. J. Beer², M. Lassmann⁴, G. Glatting^{1,2};
¹Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY, ²Department of Nuclear Medicine, University Hospital Ulm, Ulm, GERMANY, ³ESQlabs GmbH, Saterland, GERMANY, ⁴Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY.

EPS-185
Digital twins for PET data based prediction of absorbed dose in mice after [¹⁷⁷Lu]Lu-PSMA10.1 infusion
G. Costa^{1,2}, E. Yousefzadeh-Nowshahr^{2,1}, V. Vasic¹, B. Sun³, L. Nagel³, A. Wurzer³, F. Schilling³, A. Beer², W. Weber³, S. Kossatz³, G. Glatting^{1,2};
¹Univesität Ulm, Ulm, GERMANY, ²Uniklinik Ulm, Ulm, GERMANY, ³Technische Universität München, Munich, GERMANY.

EPS-186
Diagnostic ⁶⁸Ga-PSMA-11 PET/CT image-based dosimetry: a better estimate of ¹⁷⁷Lu-PSMA-617 therapy absorbed dose than PET uptake metrics
N. Payan^{1,2}, C. Drouet¹, A. Jougl¹, A. Cochet^{1,2}, J. M. Vrigneaud^{1,2};
¹Centre Georges-François Leclerc, Dijon, FRANCE, ²ICMUB UMR CNRS 6302, Université Bourgogne-Europe, Dijon, FRANCE.

EPS-187
More Bang For Your Becquerel: A Novel Approach to “Dosing” in ¹⁷⁷Lu-PSMA Radioligand Therapy
N. Scott, B. Fongenie, D. Stevens;
Blue Earth Therapeutics, Oxford, UNITED KINGDOM.

EPS-189
Tumour Dosimetry - It’s a Gray Area: Analysing the Importance of Lesion-Level Dosimetry Methods in ¹⁷⁷Lu-PSMA Targeted Therapy
B. Fongenie, D. Stevens, N. Scott;
Blue Earth Therapeutics, Oxford, UNITED KINGDOM.

EPS-190
Intraindividual tumor dosimetry of monomer [⁹⁰Y] Y-FAPI-46 vs dimer [⁹⁰Y]Y-DOTAGA-Glu-(FAPI)2 FAP radioligand therapy of advanced stage solid tumors
P. Fragoso Costa¹, W. Jentzen¹, K. Pabst¹, I. Mavroeidi², H. Lanza fame¹, R. Hamacher², J. Siveke², S. Bauer², F. Rösch³, J. Kurth⁴, M. Heuschkel⁴, K. Herrmann¹, D. Kersting¹, W. Fendler¹;
¹Clinic for Nuclear Medicine, University Hospital Essen, University Duisburg-Essen, Essen, GERMANY, ²Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ³Department of Chemistry—TRIGA Site, Johannes Gutenberg-University Mainz, Germany, Frankfurt, GERMANY, ⁴Department of Nuclear Medicine, Rostock University Medical Center, Essen, GERMANY.

EPS-191
Stability, Biodistribution, and Patient Dosimetry of [¹⁷⁷Lu]Lu-FAP-2286 Radionuclide Therapy
K. Akçay, T. Toklu, G. Beydagi, H. Adigüzel, B. Caner, L. Kabasakal, N. Alan;
Yeditepe University, İstanbul, TÜRKIYE.

EPS-192
Absorbed Dose Estimate of Neoadjuvant ¹⁷⁷Lu-PSMA-l&T Therapy Prior to Oligometastasis Directed SBRT in Patients with Hormone Sensitive Oligorecurrent Prostate Cancer:Preliminary analysis from the Randomized Phase 2 LUNAR Trial (NCT05496959)
Z. Ellis¹, C. Meyer¹, M. Lauria¹, K. Kimura¹, V. Ludwig¹, L. M. Unterrainer^{1,2}, A. Farolfi^{1,3}, D. Sennung¹, K. Masri¹, L. F. Valle¹, M. L. Steinberg¹, C. Felix¹, R. Alano¹, K. Adame¹, A. Daley¹, J. Czernin¹, M. Dahlbom¹, A. U. Kishan¹, J. Calais¹;
¹University of California - Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ²Ludwig-Maximilians University, Munchen, GERMANY, ³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EPS-193
Therapeutic potential of DOTAGA.Glu.(FAPI)₂ and DO3A.Glu.(FAPI)₂ with human dosimetry extrapolation for ¹⁷⁷-lutetium and ¹⁶¹-terbium
A. Bilinska¹, N. Kumar¹, S. Gnesin², T. Läppchen¹, E. Menéndez¹, M. Martin³, F. Rösch³, A. Rominger¹, E. Gourni¹;
¹Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, SWITZERLAND, ²Institute of Radiation Physics, Lausanne University Hospital, Lausanne, SWITZERLAND, ³Department of Chemistry—TRIGA site, Johannes Gutenberg-University Mainz, Mainz, GERMANY.

EPS-194
Development of ²⁰⁶Bi as a SPECT Imaging Radiotracer to Annotate the in vivo Biodistribution of Bismuth Daughters
L. Wehner, E. Aluicio-Sarduy, A. O. Adeniyi, L. Batley, B. Bednarz, J. W. Engle, R. Hernandez;
University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

EPS-195
Exploiting PARP Trapping to Enhance the DNA-Targeting Efficiency of [¹²⁵I]CC1
L. Hernandez Cano¹, N. Delgado Mayenco¹, H. Kramer¹, E. Diekstra¹, F. Amoroso¹, G. Alachouzos², W. Szymanski^{2,3,4}, M. van Vugt⁵, B. Cornelissen¹;
¹Department of Nuclear Medicine and Molecular Imaging Department, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, ²Stratingh Institute for Chemistry, Faculty for Science and Engineering, University of Groningen, Groningen, NETHERLANDS, ³Department of Radiology, Medical Imaging Centre, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, ⁴Department of Medical Chemistry, Photopharmacology and Imaging, University of Groningen, Groningen, NETHERLANDS, ⁵Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, Groningen, NETHERLANDS.

EPS-196
Exploring combinatory treatments to enhance targeted α- and β-radionuclide therapy in prostate cancer
M. Sabatella, P. Engbers, T. Heredia-Genestar, A. Gebara Garcia de Lima, E. Hooijman, E. de Blois, J. Nonnekens;
Erasmus MC, Rotterdam, NETHERLANDS.

EPS-197
Relative Biological Effectiveness (RBE) of ²²⁵Ac-PSMA-l&T in-vitro treatment and its dependence on cellular incubation time
P. Hawarihewa¹, M. Rumiantcev¹, H. Scherthan², R. Oos¹, M. Zacherl¹, F. Lindheimer¹, G. Böning¹, R. A. Werner^{1,3}, S. Ziegler⁴, M. Brendel^{1,5,6}, A. Delker¹;
¹LMU University Hospital, Munich, GERMANY, ²Bundeswehr Institute of Radiobiology affiliated to the Univ. of Ulm, Munich, GERMANY, ³Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Sciences, Division of Nuclear Medicine and Molecular Imaging, Baltimore, MD, UNITED STATES OF AMERICA, ⁴Department of Nuclear Medicine, Hannover Medical School (MHH), Hannover, GERMANY, ⁵SyNergy, University of Munich, Munich, GERMANY, ⁶DZNE - German Center for Neurodegenerative Diseases, Munich, GERMANY.

EPS-198
Development of a simulated preclinical database for 3D AI-based dosimetry prediction based on 2D nuclear imaging
G. Savvidis¹, V. Paneta¹, V. Eleftheriadis¹, V. Lagaki¹, D. Anestis¹, S. Sarpaki¹, T. Karamelas¹, L. Fysikopoulos¹, G. Loudos¹, P. Papadimitroulas^{1,2};
¹BIOEMTECH, Athens, GREECE, ²Medical Informatics Laboratory, School of Medicine, University of Thessaly, Larissa, GREECE.

1210

Tuesday, October 7, 2025, 08:00 - 09:30
Room 116

CTE 6 -Technologists Committee: Fibroblast-Activated: the 68Ga-FAPI in Different Types of Cancer

OP-560
Fibroblast Activation Protein – The Science Behind 68Ga-FAPI Imaging

K. Pabst; University Hospital of Essen, Dept. of Nuclear Medicine, Essen, GERMANY.

OP-561
How to Perform FAPI PET?

M. Bentestuen; University Hospital of Aalborg, Dept. of Nuclear Medicine, Aalborg, DENMARK.

OP-562
68Ga-FAPI Imaging – Practical Considerations for Technologists
B. Emmerson; Peter MacCallum Cancer Center, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Melbourne, AUSTRALIA.

1211

Tuesday, October 7, 2025, 08:00 - 09:30
Room 111

EU Policy Symposium 1 - Policy & Regulatory Affairs Council: From Policy to Patients: Building Readiness for Nuclear Medicine Innovation in Europe

OP-564a
SIMPLERAD Legacy: Regulatory Lessons

M. Lassmann; University of Wurzburg, Würzburg, GERMANY.

OP-564b
Carrying the Torch: PRISMA Vision

S. Kaijaluoto; Finnish Radiation and Nuclear Safety Authority, Vantaa, FINLAND.

OP-565
Anticipating the Wave: How Many Patients, How Soon?

U. Holzwarth; Joint Research Centre - European Commission, Ispra, ITALY.

OP-566
Growing the capacity of healthcare systems for Radioligand Therapy

K. Goffin; KU Leuven, Leuven, BELGIUM.

OP-567
Right Patient, Right Time: Streamlining Access to Innovation

Anne-L. Giraudet; Centre Léon Bérard, Lyon, FRANCE.

1301

Tuesday, October 7, 2025, 09:45 - 11:15
Auditorium

CME 10 - AI Committee: AI as Accelerator for NM Research

OP-568
Virtual Clinical Trials and AI-supported Clinical Trials Design

P. Arsela; Fondazione IRCCS Istituto Nazionale Tumori di Milano, AI-ON-Lab and Medical Oncology Department, Milan, ITALY.

OP-569
AI for Radiopharmaceuticals’ Development

D. Jiang; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Nuclear Medicine, Wuhan, CHINA.

OP-570
AI for Quantitative Imaging

D. Visvikis; Inserm, LaTIM, Brest, FRANCE.

OP-571
Digital Twins and Computational Nuclear Oncology, Where Do We Stand?

L. Cavinato; Politecnico di Milano, Department of Mathematics, Milan, ITALY.

1302

Tuesday, October 7, 2025, 09:45 - 11:15
Room 112 (Arena)

Special Track 10 - Oncology & Theranostics Committee: Round Table: Residents for Residents

OP-572
Basic Knowledge on the Oncological EANM Procedural Guidelines

S. Wallenius; Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

OP-573
Knowledge on the Clinical Application of EANM Oncological Guidelines

A. Piñeiro-Donís; Nuclear Medicine Service at the Virgen de las Nieves University Hospital, Granada, SPAIN.

OP-574a
Image-based Cases: FDG in Oncology

Alessia L. Daverio; Gustave-Roussy, Nuclear Medicine, Paris, FRANCE.

OP-574b
Image-based Cases: non- FDG in Oncology

G. Bianciardi; Alma Mater Studiorum, University of Bologna, Bologna, ITALY.

1303

Tuesday, October 7, 2025, 09:45 - 11:15
Room 113

LIPS Session 10 - Paediatrics Committee: Update on Paediatric GI Nuclear Studies

OP-575
Gastrointestinal Reflux and Gastric Emptying

Z. Bar-Sever; Nuclear Medicine Institute at Schneider Children's Tel Aviv University, Tel Aviv, ISRAEL.

OP-577
GI Transit Studies in Paediatrics
Role of Hepatobiliary Imaging in Neonatal Hepatitis

A. Brink; Nuclear Medicine and Diagnostic Imaging Section, IAEA, Vienna, AUSTRIA.

1304

Tuesday, October 7, 2025, 9:45 - 11:15
Room 114

M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Improving Radionuclide Production for Tracer Development

OP-579
Small cyclotron production of n.c.a. ¹⁰³Pd from Rh targets for targeted radionuclide therapy

M. Salek¹, K. S. Pedersen², C. Deville², A. C. Boggiano¹, J. C. Mixdorf¹, T. E. Barnhart¹, M. Jensen², J. W. Engle^{1,3}; ¹The University of Wisconsin – Madison, Department of Medical Physics, Madison, WI, UNITED STATES OF AMERICA, ²Hevesy Laboratory, Technical University of Denmark, Roskilde, DENMARK, ³The University of Wisconsin – Madison, Department of Radiology, Madison, WI, UNITED STATES OF AMERICA.

OP-580
Production of alpha emitters Ac-225, Bi-213, Pb-212, and Th-227 from Th-232 spallation at TRIUMF

H. Yang^{1,2,3}, Q. Miao¹, B. McNeil^{1,2}, L. Wharton¹, S. W. McNeil^{1,3}, H. Meeres^{1,3}, C. Ramogida^{1,2}, P. Schaffer^{1,2,3}, C. Hoehr¹; ¹TRIUMF, Vancouver, BC, CANADA, ²Simon Fraser University, Burnaby, BC, CANADA, ³The University of British Columbia, Vancouver, BC, CANADA.

OP-581
Optimal energy interval for the cyclotron production of ⁶⁸Ga using solid targets

M. Avila-Rodriguez, A. Zarate-Morales, A. Flores-Moreno; Facultad De Medicina, Universidad Nacional Autónoma De México, Ciudad De México, MEXICO.

OP-582
Production of high-purity ²¹²Pb from natural ²³²Th for alpha radionuclide therapy

R. Wang, Z. Liu; Changping Laboratory, Beijing, CHINA.

OP-583
Cyclotron Production of ¹³⁵La from enriched ¹³⁵BaCO₃ targets.

E. Aluicio-Sarduy, A. P. Olson, J. C. Mixdorf, T. E. Barnhart, J. W. Engle; University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

Aim/Introduction: ¹³⁵La (t_{1/2}=19.93h, 98.1% EC) is an attractive radionuclide for targeted Auger therapy due to its unique decay characteristics and chemical properties resembling those of commonly used therapeutic radiometals [1,2]. However, high production yields and radionuclidic purity are essential for its potential use in preclinical and clinical settings. Our goal is to develop a scalable, automatable, and cost-efficient production method of ¹³⁵La from isotopically enriched ¹³⁵Ba targets. **Materials and Methods:** Enriched ¹³⁵BaCO₃ (94.9%) was irradiated with 13MeV protons using a GE PETtrace cyclotron at 10µA. Lanthanum-135 was isolated by single column extraction chromatography using N,N,N',N'-tetrakis-2-ethylhexyldiglycolamide functionalized (branched-DGA) resin. Final product radionuclidic and elemental purity were verified by HPGe gamma spectrometry and microwave plasma-atomic emission spectroscopy (MP-AES), respectively. Apparent molar activity (AMA) was quantified by complexation of the purified ¹³⁵La with DOTA and macropa. The target material was recycled by precipitation/decantation using a saturated (NH₄)₂CO₃ solution. **Results:** Lanthanum-135 was produced with a physical yield of 50 ± 5 MBq/µAh (EoB-corrected) from ~150 mg/cm² ¹³⁵BaCO₃ targets. After target dissolution, the resin's differential affinity for Ba²⁺ and La³⁺ ions at different nitric acid concentrations was leveraged to selectively load La³⁺ from the 3M HNO₃ (25 mL) target dissolution. Subsequent rinsing with decreasing HNO₃ concentrations (15 mL 3M HNO₃ and 3 mL 0.5M HNO₃) eluted trace metal impurities. Lanthanum(3+) was eluted in a small volume of 0.1M HCl (0.3 - 0.5 mL) with a radiochemical yield of 96.7 ± 0.5%. MP-AES analysis (n=4) established 0.65 ± 0.51 ppm (Ba), 0.16 ± 0.11 ppm (Zn), and 0.03 ± 0.03 ppm (Cu) of the only detectable impurities in the purified ¹³⁵La solution. AMA was 11 ± 4 GBq/µmol DOTA and 35 ± 7 Gbq/µmol macropa (n=4). The enriched target material was recovered with a run-to-run efficiency of 98.1 ± 1.4 % (n=4). **Conclusion:** We developed and characterized a method for cost-effective production of radiopharmaceutical-quality ¹³⁵La, facilitating its potential preclinical/clinical use. A similar strategy can also be followed to produce the positron-emitting radioisotope ¹³²La. **References:** 1- Aluicio-Sarduy E, et al., 2019, doi:10.1038/s41598-019-47137-0 2- Aluicio-Sarduy E, et al., 2020, doi: 10.1002/chem.201905202.

OP-584
Multi Copper and Gallium Radioisotopes Production by Irradiation of ZnO Target via Medical Cyclotron

F. Porto¹, G. Speltri¹, S. Cisternino², C. Favaretto³, N. Bergamaschi², D. Peruzzi³, J. Amico³, P. Bovone³, G. Gorgoni³, A. Boschi¹, R. Tassinari¹, L. Marvelli¹, R. Napolitano¹, A. Nioiretini¹, L. Uccelli¹, L. Mou², G. Piteo⁴, A. Kotliarenko², L. De Dominicis², G. Pupillo², J. Esposito², E. Cazzola², P. Martini¹; ¹University of Ferrara, Ferrara, ITALY, ²National Institute for Nuclear Physics, Legnaro, ITALY, ³IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, ITALY, ⁴University of Padova, Padova, ITALY.

OP-585
Production of ²²⁵Ac for Targeted Alpha Therapy Using an Electron Linear Accelerator: Improving Radiolabeling Quality Comparable to ²²⁹Th Generator-Produced ²²⁵Ac

M. Maeda¹, Y. Ueno¹, K. Nishida¹, Y. Kani¹, M. Yoshimoto², H. Fujii², A. Inaki², H. Kikunaga³, T. Yokokita³, S. Kashiwagi³, K.

Shirasaki^{4,5};
¹Hitachi Ltd., Research & Development Group, Hitachi, JAPAN, ²National Cancer Center, Exploratory Oncology Research & Clinical Trial Center, Kashiwa, JAPAN, ³Research Center for Accelerator and Radioisotope Science, Tohoku University, Sendai, JAPAN, ⁴Institute for Materials Research, Tohoku University, Sendai, JAPAN, ⁵Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, Toyonaka, JAPAN.

OP-586
Resin Based Extraction of ⁴⁵Ti⁴⁺ for Radiopharmaceutical Applications
M. DeLuca¹, E. Aluicio-Sarduy¹, T. E. Barnhart¹, J. C. Mixdorf¹, P. N. Tran², A. Marlin³, E. Boros², J. W. Engle¹;
¹University of Wisconsin - Department of Medical Physics, Madison, WI, UNITED STATES OF AMERICA, ²University of Wisconsin - Department of Chemistry, Madison, WI, UNITED STATES OF AMERICA, ³PSL University - Chimie ParisTech, Paris, FRANCE.

OP-587
Purifying radionuclides using microfluidic chips: towards the automated liquid-liquid extraction of Ac-225
R. de Kruijff¹, S. Trapp, A. Santoso, E. Paulssen;
Delft University of Technology, Delft, NETHERLANDS.

1305
Tuesday, October 7, 2025, 9:45 - 11:15
Room 211

Cutting Edge Science Track - TROP Session - Dosimetry Committee: Quantification and Innovation in Dosimetry

OP-588
Comparison between semi-automated vertebral segmentation and manual bone marrow sampling for quantitative SPECT/CT-based bone marrow dosimetry in ¹⁷⁷Lu radiopharmaceutical therapy
V. Forget¹, S. Hammouda¹, F. A. Buteau², G. April², F. Arsenault², A. Beaulieu², J. M. Beaugregard¹;
¹Department of Radiology and Nuclear Medicine, Université Laval, Quebec City, QC, CANADA, ²Department of Medical Imaging, CHU de Québec - Université Laval, Quebec City, QC, CANADA.

OP-589
A semi-automatic model for correcting adjacent-organ cross-talk in bone marrow dosimetry after [¹⁷⁷Lu]Lu-DOTATATE treatment
K. Smits¹, J. Hemmingsson¹, T. Rydén², A. Theisen³, M. van Essen⁴, J. Svensson⁵, A. Hallqvist⁵, J. Tran-Gia³, P. Bernhardt²;
¹Institute of Clinical Sciences, Gothenburg, SWEDEN, ²Department of Medicial Physics and Biomedical Engineering, Gothenburg, SWEDEN, ³Department of Nuclear Medicine, Wurzburg, GERMANY, ⁴Institute of Medicine, Gothenburg, SWEDEN, ⁵Department of Oncology, Gothenburg, SWEDEN.

OP-590
Main sources of uncertainty affecting vertebral activity quantification in SPECT/CT imaging after [¹⁷⁷Lu]Lu-DOTATATE therapy using a physical phantom and patient simulations

A. Theisen¹, J. Leube¹, L. Pieper¹, M. Laßmann¹, K. Smits², J. Hemmingsson², P. Bernhardt², M. Salas-Ramirez¹, J. Tran-Gia¹;
¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Sahlgrenska Academy, Gothenburg, SWEDEN.

OP-591
Proof of concept for in vivo organ dosimetry with a tissue-equivalent 3D-printed heart
R. Ringler¹, A. Poellmann¹, N. Zeiss-Carstens¹, D. Hellwig², D. Schmidt²;
¹Technical University of applied sciences Amberg-Weiden, Weiden, GERMANY, ²University Hospital Regensburg, Department of Nuclear Medicine, Regensburg, GERMANY.

OP-592
Nephron-Level Dosimetry of¹⁶¹Tb- and ¹⁷⁷Lu-DOTA-TATE Reveals Greater Absorbed Dose Heterogeneity from ¹⁶¹Tb in Murine Renal Substructures
M. Andersson^{1,2}, T. Opsomer³, N. Reynaert², H. Levillain², C. Saldarriaga Vargas¹;
¹Dosimetry Research for Targeted Radionuclide Therapy – Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, ²Medical Physics Department, Institut Jules Bordet – Université Libre de Bruxelles, Brussels, BELGIUM, ³Nuclear Medical Applications – Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM.

OP-593
Time-dependent biodistribution and dosimetry of radiolabelled FAP-targeting single-domain antibody 4AH29 in Göttingen minipigs
N. Dumauthioz¹, L. Navarro¹, M. Berdal¹, S. Nagachinta¹, J. Eersels¹, V. Gaspariunaite¹, A. R. Pombo Antunes¹, T. Jørgensen², L. Kellemann Kristensen², T. Starostka², D. Mantzilas¹, T. Lahoutte¹, M. D’Huyvetter¹;
¹Precirix, Brussels, BELGIUM, ²Minerva Imaging, Oelstykke, DENMARK.

OP-594
Feasibility study of ²²⁵Ac-PSMA-CY313 dosimetry in mCRPC patients using SPECT
S. Li¹, Y. Shi¹, Z. Li², Y. Xu³, Y. Zhou³, J. Liu², Y. Wu²;
¹Department of Nuclear Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, CHINA, ²C-Ray Pharmaceuticals (Chengdu) Co. Ltd., Chengdu, CHINA, ³United Imaging Healthcare Technology Group Co., Ltd, Shanghai, CHINA.

OP-595
Radiation Dosimetry of¹⁵O-water Based on Dynamic Large Axial Field of View PET
M. Lubberink¹, A. Åhlström¹, T. Maaniitty², T. Tolvanen², J. Knuuti²;
¹Uppsala University, Uppsala, SWEDEN, ²Turku PET Centre, Turku University and Turku University Hospital, Turku, FINLAND.

OP-596
Biodistribution and dosimetry for a ¹¹C labelled PARP1 inhibitor
A. Törnblom¹, C. He¹, M. Bolin¹, A. Tzortzakakis¹, J. Fernebro¹, C. Li¹, S. Fridsten², R. Altena¹, R. Axelsson¹, J. Siikanen¹, C. Hindorf¹;
¹Karolinska Institutet, Stockholm, SWEDEN, ²Karolinska University Hospital, Stockholm, SWEDEN.

1306
Tuesday, October 7, 2025, 9:45 - 11:15
Room 117

Theranostics Track - TROP Session - Oncology & Theranostics Committee: Prostate Cancer Therapy in HSPC and CRPC

OP-597
PROQUIRE-I: Results of the phase I dose- escalation study combining [¹⁷⁷Lu]Lu-PSMA-617 and EBRT in curative intent treatment of N1 prostate cancer
D. Hoogenkamp¹, L. G. Zuur¹, E. C. A. van der Sar², M. G. E. H. Lam², J. R. N. van der Voort-van Zyp², P. J. van Leeuwen¹, B. J. de Wit - van der Veen¹, D. M. V. de Vries-Huizing¹, J. J. M. A. Hendriks¹, A. J. A. T. Braat^{1,2}, W. V. Vogel¹;
¹Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ²University Medical Centre Utrecht, Utrecht, NETHERLANDS.

OP-598
Lutetium-177-PSMA-617 in Oligometastatic Hormone Sensitive Prostate Cancer (BULLSEYE trial)
B. Privé¹, W. Noordzij², C. Muselaers¹, I. De Jong², I. Van Oort¹, M. Janssen¹, M. Van Rijk¹, W. Van Gemert³, M. De Groot¹, N. Mehra¹, W. Gerritsen¹, M. Jonker¹, E. Alevroudis⁴, S. Van der Gaag⁵, J. Koppes⁵, J. Sedelaar¹, A. Vis⁵, A. Vrachimis⁴, D. Oprea-Lager⁵, J. Nagarajah¹;
¹Radboudumc, Nijmegen, NETHERLANDS, ²UMC Groningen, Groningen, NETHERLANDS, ³Canisius Wilhelmina Hospital, Nijmegen, NETHERLANDS, ⁴German Oncology Center, Limassol, CYPRUS, ⁵Amsterdam UMC, Amsterdam, NETHERLANDS.

OP-599
PEACE 6 Poor-responders: A randomized phase III trial evaluating the efficacy and safety of ¹⁷⁷Lu-PSMA-617 in addition to Standard of Care (SoC) versus SoC alone in de novo metastatic hormone-sensitive prostate cancer (mHSPC)
D. Deandreis¹, G. Gravis², S. Foulon³, F. Tantom⁴, C. Leger⁴, F. Courbon³, L. Turpin⁶, A. Giraudet⁷, K. Fizazi¹;
¹Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, FRANCE, ²Institut Paoli Calmette, Marseille, FRANCE, ³Gustave Roussy, Villejuif, FRANCE, ⁴Unicancer, Kremlin Bicetre, FRANCE, ⁵UIC Oncopole, Toulouse, FRANCE, ⁶Hopital Foche, Suresnes, FRANCE, ⁷CLCC Leon Berard, Lyon, FRANCE.

OP-600
Prognostic Impact of Homologous Recombination Repair and Mismatch Repair Gene Alterations in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Prostate-Specific Membrane Antigen-directed Radioligand Therapy
A. Antic Nikolic¹, S. Xue², S. Wen², J. Baessler¹, M. Hacker², X. Li², C. Lapal¹;
¹Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY, ²Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Vienna, AUSTRIA.

OP-601
Safety and efficacy of ¹⁷⁷Lu-PSMA-I&T for RLT in mCRPC - a prospective multicenter Swiss Registry study
A. Chirindel¹, G. Nicolas¹, M. Tissier², M. del Sol Pérez Lago³, F. Forrer⁴, A. Afshar-Oromieh⁵, S. Beintner-Skawran⁶, A. Bauman⁷, F. Melpomeni⁷, E. Nitzsche⁸, N. Schaefer², D. Wild¹;

¹University Hospital of Basel, Department of Theranostics, Nuclear Medicine, Basel, SWITZERLAND, ²CHUV, Department of Nuclear Medicine, Lausanne, SWITZERLAND, ³Luzerner Kantonsspital, Department of Nuclear Medicine, Lucerne, SWITZERLAND, ⁴Kantonsspital St. Gallen, Department of Nuclear Medicine, St. Gallen, SWITZERLAND, ⁵Inselspital, Department of Nuclear Medicine, Bern, SWITZERLAND, ⁶University Hospital Zurich, Department of Nuclear Medicine, University of Zurich, Zurich, SWITZERLAND, ⁷University Hospital of Basel, Department of Theranostics, Radiopharmaceutical Chemistry, Basel, SWITZERLAND, ⁸Kantonsspital Aarau, Department of Nuclear Medicine, Aarau, SWITZERLAND.

OP-602
Retreatment with [¹⁷⁷Lu]Lu-PSMA-617 in mCRPC patients treated under the French Early access program
D. Taieb¹, P. Robin², P. Barthelemy³, C. Peltier⁴, S. Chêne⁵, A. Douillet⁵, F. Somme³;
¹APHM-AMU, Marseille, FRANCE, ²Université de Brest, Inserm, UMR 1304, GETBO, CHU Brest, Brest, FRANCE, ³Institut de cancérologie Strasbourg Europe, Strasbourg, FRANCE, ⁴ICTA PM, Dijon, FRANCE, ⁵Novartis, Rueil-Malmaison, FRANCE.

OP-603
Final analysis of patients treated with [¹⁷⁷Lu] Lu-PSMA-617 in early access program in metastatic castration-resistant prostate cancer (mCRPC) in France
C. Bailly¹, P. Olivier², L. Vija³, A. Giraudet⁴, V. Massard⁵, G. Roubaud⁶, S. Girault⁷, S. Abadie-Lacourtoisie⁷, C. Viala¹, A. Flechon⁸, S. Chêne⁸, Y. Godbert⁶;
¹Centre Hospitalier Universitaire, Nantes, FRANCE, ²Centre hospitalier régional et universitaire, Vandoeuvre-lès-Nancy, FRANCE, ³Institut Universitaire du Cancer de Toulouse, Toulouse, FRANCE, ⁴Centre Léon Bérard, Lyon, FRANCE, ⁵Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, FRANCE, ⁶Institut Bergonié, Bordeaux, FRANCE, ⁷Institut de cancérologie de l'Ouest Paul Papin, Angers, FRANCE, ⁸Novartis, Rueil-Malmaison, FRANCE.

OP-604
Fracture risk and treatments at progression in EORTC-1333 PEACE-3 study evaluating the addition of Radium 223 in metastatic castration-resistant prostate cancer starting enzalutamide
A. Rodriguez Vida¹, B. Tomba², A. Choudhury³, F. Saad⁴, E. Gallardo⁵, A. Soares⁶, Y. Lorient⁷, R. McDermott⁸, C. Poncet⁹, C. Corneel⁹, B. Fournier⁹, F. Lecouvet², S. Gillesen¹⁰;
¹Hospital del Mar, Barcelona, SPAIN, ²Cliniques universitaires Saint Luc, Brussels, BELGIUM, ³The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, ⁴Centre hospitalier de l'Université de Montréal, Montréal, QC, CANADA, ⁵Parc Tauli Hospital Universitari, Sabadell, SPAIN, ⁶Hospital Israelita Albert Einstein, Sao Paulo, BRAZIL, ⁷Institut Gustave Roussy, Paris, FRANCE, ⁸Tallaght University Hospital, Dublin, IRELAND, ⁹European Organisation of Research and Treatment of Cancer, Brussels, BELGIUM, ¹⁰Oncology Institute of Southern Switzerland, EOC, Bellinzona, SWITZERLAND.

OP-605
Efficacy of Lutetium-177 [¹⁷⁷Lu]Lu-PSMA radioligand therapy re-treatment beyond six cycles in patients with metastatic castration-resistant prostate cancer.
J. Weindler¹, E. Medhurst¹, N. Papa¹, L. Kostos², B. Emmerson¹, A. A. Azad², M. S. Hofman¹, J. P. Buteau¹;
¹Prostate Cancer Theranostics and Imaging Centre of

Excellence (ProstIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ²Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

1307

Tuesday, October 7, 2025, 9:45 - 11:15
 Room 212

TROP Session - Neuroimaging Committee: Neuro-Oncology

OP-606

Checkpoint inhibitor therapy is associated with elevated false-positive findings in amino acid PET imaging of brain metastases

A. Chaban¹, L. Baumgart², C. Delbridge³, D. Bernhardt⁴, B. Wiestler⁵, A. Aftahy², V. Schneller⁶, B. Meyer², W. Weber¹, H. Meyer⁷, J. Gempt², I. Yakushev¹; ¹Klinik und Poliklinik für Nuklearmedizin, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY, ²Klinik und Poliklinik für Neurochirurgie, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY, ³Institut für Allgemeine Pathologie und Pathologische Anatomie, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY, ⁴Klinik und Poliklinik für RadioOnkologie und Strahlentherapie, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY, ⁵Neur-Kopf-Zentrum, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY, ⁶Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY, ⁷University Medical Center Hamburg - Eppendorf, Hamburg, GERMANY.

OP-607

Diagnostic Accuracy and Optimal Thresholding of [¹⁸F]fluoroethyl-L-tyrosine PET to Detect Tumor Tissue in Patients with Glioblastoma

E. Van de Giessen¹, J. L. Ebenau, T. Koopman, F. Barkhof, P. Wesseling, J. C. Reijneveld, W. P. Vandertop, P. C. de Witt Hamer, P. J. Pouwels, R. Boellaard, M. M. Yaqub, N. Verburg; Amsterdam UMC, Amsterdam, NETHERLANDS.

OP-608

Preoperative Delineation of Tumor Boundaries in Adult High-Grade Glioma Using Integrated ¹⁸F-FET PET/MR Imaging

Q. Han¹, J. Liu², T. Li¹, X. Su³, E. Li³, Y. Yang³, X. Guo², W. Ma², Y. Wang², X. Cheng¹, L. Huo¹; ¹Nuclear Medicine Department, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, CHINA, ²Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, ³Beijing United Imaging Healthcare Co., Ltd, Beijing, CHINA.

OP-609

Prognostic stratification of IDH-mutant gliomas based on amino acid PET parameters at diagnosis

M. Mair^{1,2}, J. Werner^{2,3}, J. Weller⁴, E. Barci¹, S. Katzendobler⁴, J. Isakaj¹, L. Berchtold^{2,5}, T. Aras¹, R. Stürzl¹, J. Reis⁶, J. Hennenberg⁷, H. C. Pühr², T. Schabhüttl^{1,2}, B. Kiesel⁸, G. Widhalm⁸, A. Wöhrer⁹, T. Nakuz¹⁰, M. Hacker¹⁰, J. Furtner^{7,11}, P. N. Harter^{12,13,14}, L. von Baumgarten^{4,13,15}, A. S. Berghoff², N.

Thon^{4,16}, M. Preusser², N. L. Albert^{1,13,14}; ¹Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ²Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, AUSTRIA, ³Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, GERMANY, ⁴Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, GERMANY, ⁵Institute of Medical Statistics, Center for Medical Data Science, Medical University of Vienna, Vienna, AUSTRIA, ⁶Institute of Neuroradiology, LMU University Hospital, LMU Munich, Munich, GERMANY, ⁷Division of Neuroradiology and Musculoskeletal Radiology, Department of Radiology and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, ⁸Department of Neurosurgery, Medical University of Vienna, Vienna, AUSTRIA, ⁹Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, AUSTRIA, ¹⁰Division of Nuclear Medicine, Department of Radiology and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, ¹¹Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Faculty of Medicine and Dentistry, Danube Private University, Krems, AUSTRIA, ¹²Center of Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Munich, GERMANY, ¹³Bavarian Cancer Research Center (BZKF), Partner Site Munich, Munich, GERMANY, ¹⁴German Cancer Consortium (DKTK), Partner Site Munich, Munich, GERMANY, ¹⁵Department of Neurology, LMU University Hospital, LMU Munich, Munich, GERMANY, ¹⁶Department of Neurosurgery, Knappschaft University Hospital Bochum, Bochum, GERMANY.

OP-610

Measurable disease for response assessment in IDH-mutant glioma - a comparison of MRI-based (RANO 2.0) versus PET-based (PET RANO 1.0) assessment

E. Barci¹, J. Reis², M. J. Mair³, J. Isakaj¹, K. J. Müller⁴, L. Kaiser¹, M. Preusser², P. Harter⁵, L. von Baumgarten⁶, N. Thon⁷, R. Forbrig², N. L. Albert¹; ¹Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY, ²Institute of Neuroradiology, LMU University Hospital, LMU Munich, Munich, GERMANY, ³Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, AUSTRIA, ⁴Department of Neurology, LMU University Hospital, LMU Munich, Munich, GERMANY, ⁵Center for Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Munich, GERMANY, ⁶Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, GERMANY, ⁷Department of Neurosurgery, University Hospital of the Ruhr-University of Bochum, Bochum, GERMANY.

OP-611

External validation of an Automated Model of Extraction of Brain Amino Acid PET parameters: application to ¹⁸F-FDOPA PET imaging

T. Zaragori¹, L. Rozenblum², G. Rovera^{3,4}, G. Stien⁵, A. Zinsz⁵, S. D. Morbelli^{3,4}, A. Kas², A. Verger⁵; ¹CIC-IT 1433, Inserm, CHRU Nancy, Université de Lorraine, Nancy, FRANCE, ²Department of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, FRANCE, ³Nuclear Medicine Unit, A.O.U. Città Della Salute e della Scienza Di Torino, University of Turin, Turin, ITALY, ⁴Department of Medical Sciences, University of Turin, Turin, ITALY, ⁵Department of Nuclear Medicine, CHRU Nancy, Université de Lorraine, Nancy, FRANCE.

OP-612

Metabolic tumor volume (MTV) reflects the presence of seizure better than target-to-background-ratio (TBR) in patients with gliomas: a [18F]Fluorodopa (F-DOPA) PET study

G. Garelli^{1,2}, M. Zotta², F. Bruno³, E. Pronello³, A. Pellerino³, A. Lesca², G. Rovera^{1,2}, R. Rudà³, S. Morbelli^{1,2}; ¹Department of Medical Sciences, University of Turin, Turin, ITALY, ²Nuclear Medicine Unit, AOU Città della Salute e della Scienza di Torino, Turin, ITALY, ³Division of Neuro-Oncology, Department of Neuroscience "Rita Levi Montalcini", AOU Città della Salute e della Scienza di Torino and University of Turin, Turin, ITALY.

OP-613

Role of 68Ga-DOTATOC PET/CT in Assessing Treatment Response in Re-Irradiated Recurrent Meningiomas: A Volumetric and Molecular Perspective

L. Picori¹, D. Donner¹, S. Agostini¹, D. Scartoni¹, D. Amelio¹, F. Chierichetti¹, P. Feraco²; ¹Ospedale Santa Chiara, Trento, ITALY, ²University of Trento, Trento, ITALY.

OP-614

[¹⁷⁷Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data

C. Boursier¹, T. Zaragori, N. Garabedian, M. Blonski, T. Obara, L. Taillandier, L. Imbert, A. Verger; CHRU Nancy, Vandoeuvre-les-Nancy, FRANCE.

1308

Tuesday, October 7, 2025, 09:45 - 11:15
 Room 115

Joint Symposium 6 - Translational Molecular Imaging & Therapy + Radiopharmaceutical Sciences Committee / ESTRO: Radiobiological Aspects of PRRT

OP-615

How Does TRT Differ from Conventional External Radiotherapy: Generalities

M. Cremonesi¹; European Institute of Oncology, IRCCS, Milan, ITALY.

OP-616

Absorbed Dose Rate, Dose Heterogeneity and their Impact on (Local and Systemic) Biological Effects

Z. Morris¹; Human Oncology Department, University of Wisconsin-Madison, UNITED STATES OF AMERICA

OP-617

The Interplay between DNA Damage, DNA Damage/Replication Stress Response, and Immunomodulation

K. Harrington¹; The Institute of Cancer Research, Chelsea, UNITED KINGDOM.

1309

Tuesday, October 7, 2025, 9:45 - 11:15
 Room 133+134

e-Poster Presentations Session 10 - Paediatrics Committee: Paediatrics e-Poster Presentations Session

EPS-199

Evaluating Concordance in SIOOPEN Scoring 1231 MIBG scintigraphy among Nuclear Medicine Physicians

H. Noamen¹, M. Borsali, L. Agrigoroaie, Y. Cras, K. Trabelsi, A. Daverio, D. Deandreis, C. Garcia; Gustave Roussy Cancer Campus, Villejuif, FRANCE.

EPS-200

Artificial Intelligence-assisted Fast Silent PET/ MRI for Diagnostic and Therapeutic Assessment in Pediatric Diseases

T. Cai¹, H. Jun¹, C. Zhou², Y. Bai¹, Y. Zhang¹, L. Jiang³, Y. Hu², Z. Lin⁴, Y. Yang⁵, Y. Wei⁴, Z. Zhang⁴, W. Fan², W. Lu³, J. Hu¹, B. Li¹; ¹Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ²Sun Yat-sen University Cancer Center, Guangzhou, CHINA, ³Department of Pediatrics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CHINA, ⁴United Imaging Healthcare Co., Ltd., Shanghai, CHINA, ⁵Beijing United Imaging Healthcare Co., Ltd., Beijing, CHINA.

EPS-201

^{99m}Tc labelled heat denatured red cell scintigraphy in suspected right isomerism

K. Chan¹, T. Tong, L. Cheung, Y. Hui, W. Ho; Queen Mary Hospital, Hong Kong, HONG KONG.

EPS-202

Validation of a Pediatric Dose Calculator, L_PDC v2025.04.1, for SPECT and PET Radiopharmaceuticals

M. Buaki Sogo¹, L. Nunes-Lemos², L. Rubio Álvarez², A. Palomar-Muñoz², Ó. Hernández-Cristancho², J. Suils-Ramón², F. Dellepiane-Clarke², A. García-Burillo², C. Gámez-Cenzano²; ¹Unidad de Radiofarmacia, Hospital Universitario Vall D'Hebrón, Barcelona, SPAIN, ²Servicio de Medicina Nuclear, Hospital Universitario de Vall D'Hebrón, Barcelona, SPAIN.

EPS-203

The impact of F-18 FDG PET/CT on the management of complicated Tuberculosis in children

C. Burger¹, D. Smith-Tsibolane, C. le Roux, A. Doruyter, P. Goussard; Stellenbosch University, Cape Town, SOUTH AFRICA.

EPS-204

The Role Of Tc-99m Sestamibi Myocardial Perfusion Scintigraphy On Patient Management In Pediatric Kawasaki Patients With Giant Coronary Aneurysm

H. Kapucu¹, B. Esen Akkas, M. Kaya, K. Toplutas; University of Health Sciences Cam Sakura City Hospital, Istanbul, TÜRKIYE.

EPS-205

Persistent FDG-PET Uptake After First-Line Therapy in Paediatric Lymphoma and Risk of Progression: a Monocentric Retrospective Analysis

F. Serani¹, E. Carraro², D. Cecchin¹, C. Giraudo³, M. Pillon², P. Zucchetta¹;
¹Nuclear Medicine Unit, Department of Medicine DIMED, University-Hospital of Padova, Padua, ITALY, ²Oncohematology Unit, Department of Woman and Child Health, University of Padova School of Medicine, Padua, ITALY, ³Unit of Advanced Clinical and Translational Imaging, Department of Cardiac, Thoracic, Vascular Sciences and Public Health-DCTV, University of Padova, Padua, ITALY.

EPS-206
Use of semiquantitative parameters on baseline Tc99m mebrofenin hepatobiliary scintigraphy for predicting post Kasai outcome in ExtraHepatic Biliary Atresia- a retrospective analysis
N. Kundu, V. Singh, A. Mahalik, A. Roy, K. Jain, J. Choudhary, J. Krishna, R. Kumar;
 AIIMS New Delhi, Delhi, INDIA.

EPS-207
Meckel's Diverticulum in Paediatric Patients. Diagnostic Performance of [^{99m}Tc]Tc- pertechnetate Scintigraphy. A Retrospective Study.
A. Guerra, C. Salomon, E. Durand, M. Vivar, A. Puig, M. Gimenez, C. Peña;
 Servicio de Medicina Nuclear, Hospital Universitari Son Espases, Palma, SPAIN.

EPS-208
Role of SSTR PET-CT in paediatric neuroblastoma patients-A promising one stop shop modality.
D. Halanaik, S. Kumar, H. Goyal, P. Srinivasan, S. Keerthivasagam;
 Jawaharlal Institute of postgraduate medical education and Research, Puducherry, INDIA.

EPS-209
Comparative diagnostic performance of 68GaDOTANOC PET/CT versus 131IImIBG SPECT/CT in newly diagnosed pediatric neuroblastoma- a prospective single centre study.
N. Kundu, D. Khan, S. Sagar, S. Bakhshi, R. Seth, S. Agarwala, A. K. Pandey, R. Kumar;
 AIIMS New Delhi, Delhi, INDIA.

EPS-210
Meckel's Scan Revisited
J. Lanctôt-Bédard, R. Lambert, S. Turpin;
 CHU Sainte-Justine, Montréal, QC, CANADA.

EPS-211
Scintigraphic Localization of Intestinal Bleeding in a Pediatric Patient with High-Grade B-cell Lymphoma: A Life-Saving Intervention
L. Nunes Lemos, L. Rubio-Álvarez, A. Cardozo-Saavedra, O. Hernández-Cristancho, A. Palomar-Muñoz, I. Navales-Mateu, M. de Bonilla Candau, A. García-Burillo, C. Gámez-Cenzano;
 Nuclear Medicine Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, SPAIN.

EPS-212
Contribution of FDG PET-CT to Risk Stratification and Treatment Response in Pediatric Hodgkin Lymphoma
A. Khelifa, F. Koudri, A. Talbi, M. Lamali, L. Chelghoum, L. Belabas, S. Benzerdjeb, D. Tahmi, S. Brahmi, S. Rahabi, D. Mouas, A. Taibi, S. E. Bouyoucef, A. Amimour;
 Bab El Oued Hospital, Algiers, ALGERIA.

EPS-213
AI based automatic measurement of split renal function in [¹⁸F]PSMA-1007 PET/CT
K. Valind^{1,2}, J. Ulén³, A. Gålne^{1,2}, J. Jögi^{1,2}, D. Minarik^{1,4}, E. Trägårdh^{1,2};
¹Department of Translational Medicine, Wallenberg Centre for Molecular Medicine, Lund University, Malmö, SWEDEN, ²Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund and Malmö, SWEDEN, ³Eigenvision AB, Lund, SWEDEN, ⁴Department of Radiation Physics, Skåne University Hospital, Lund and Malmö, SWEDEN.

EPS-214
Relationship Between Prostatic FDG Uptake, Prostatic Calcifications, and Symptom Scores of NIH-CPSI and IPSS in male patients undergoing health checkups
J. Lee, G. Lee, J. Choi, H. Son;
 Dankook University Hospital, Cheonan, KOREA, REPUBLIC OF.

EPS-215
Assessment of Tumor Response to Neoadjuvant Hormone Therapy in Prostate Cancer Using F-18 PSMA-1007 PET: A Feasibility Study
S. Cho¹, H. Han², S. Lee³, M. Jung⁴, Y. Oh⁵, M. Yun³;
¹Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, ²Department of Artificial Intelligence, Yonsei University, Seoul, KOREA, REPUBLIC OF, ³Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, ⁴Department of Pathology, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, ⁵Department of Radiology, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EPS-216
¹⁸F-FDG PET/CT in diagnosis, staging and management of pediatric patients with Langerhans histiocytosis
P. Grecu-Bodnariuc¹, M. Gutu^{1,2};
¹"Sfântul Ioan cel Nou" County Hospital of Emergency, Suceava, ROMANIA, ²"Stefan cel Mare" University, Faculty of Medicine, Suceava, ROMANIA.

EPS-217
SIOPEN Semiquantitative Score Adapted to 68GaDOTANOC PET/CT: A Superior DiseaseBurden Biomarker
N. Kundu, D. Khan, S. Sagar, R. Kumar, A. K. Pandey, S. Bakhshi, R. Seth, S. Agarwala;
 AIIMS New Delhi, Delhi, INDIA.

EPS-218
Correlation of [¹⁸F]FDG PET/CT Metabolic Activity with Clinical Presentations and Outcomes in Children Diagnosed with Langerhans Cell Histiocytosis
E. Aslan, N. Gülaldi;
 University of Health Sciences, Department of Nuclear Medicine, Ankara Bilkent City Hospital, Ankara, TÜRKIYE.

EPS-219
Mean Parenchymal Transit Time measurement on Tc-99m EC Diuretic renography can help differentiate obstructed from non-obstructed kidneys and help monitor response post-pyeloplasty.
N. Gupta, M. Ponnusamy, K. G, P. Mathiyazhagan;
 JIPMER, Pondicherry, INDIA.

1310
Tuesday, October 7, 2025, 9:45 - 11:15
Room 116

Technologists' Track Oral Presentations 3 - Technologists Committee: Interdisciplinary Nuclear Medicine Workforce Sustainability and Training

OP-619
Technologist perspective in practice change and mitigations during the installation of two Total Body PET scanners in a busy department
S. Pereira^{1,2}, G. Testanera^{1,2}, G. Cook^{1,2}, J. John^{1,2}, S. Chicklore^{1,2}, G. Krokos^{1,2}, S. Giles^{1,2};
¹King's College London, London, UNITED KINGDOM, ²Guy's and St Thomas' Hospital NHS Foundation Trust, London, UNITED KINGDOM.

OP-620
Exploring curriculum considerations to prepare future radiographers for an AI-assisted healthcare environment: a scoping review
C. Kammies¹, E. Archer², P. Engel-Hills³, M. Volschenk²;
¹University of Johannesburg, Johannesburg, SOUTH AFRICA, ²Stellenbosch University, Cape Town, SOUTH AFRICA, ³Cape Peninsula University of Technology, Cape Town, SOUTH AFRICA.

OP-621
A national collaborative initiative for knowledge sharing among nuclear medicine staff
C. Holm¹, M. Hylle², T. Kirk Lehnkov³;
¹Odense University Hospital, Odense C, DENMARK, ²Aalborg University Hospital, Aalborg, DENMARK, ³Copenhagen University Hospital, Copenhagen, DENMARK.

OP-622
Developing Interdisciplinary VR-Education on Scanxiety: A Technologists Perspective
C. Van Den Haak¹, A. J. Nijkerk², J. J. Pool², E. W. Elings², J. C. Houting², J. A. Adam²;
¹Amsterdam UMC, Amsterdam, NETHERLANDS, ²Amsterdam UMC and University of Amsterdam, Amsterdam, NETHERLANDS.

OP-623
From Doctors to Technologists: Operational Efficiency following role reassignment in sentinel node procedures
A. Moura, C. Rodrigues;
 Imperial College NHS Healthcare Trust, London, UNITED KINGDOM.

OP-624
More Than Just Teaching: The Hidden Impact of the London Nuclear Medicine Practice Educators
H. Chandler^{1,2}, C. Rodrigues^{1,3};
¹London Imaging Academy/University College Hospitals London, London, UNITED KINGDOM, ²London Northwest University Healthcare NHS Trust, London, UNITED KINGDOM, ³Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

OP-625
The Role of Technologists in the TOTEM Study: Operational Challenges and Fostering a Research Culture in a 2 LAFOV PET Scanner Department
G. Testanera, S. Lam, S. Pereira, J. Joemon, S. L. Giles, G. Cook, S. Gould, P. K. Marsden, L. Agoro;
 King College London, London, UNITED KINGDOM.

OP-626
Embedded Student Program - Delivering a sustainable workforce pipeline to address a critical Nuclear Medicine Scientist shortage across Queensland, Australia.
T. Pearson¹, S. Daniel¹, L. McBride², E. Gacitua²;
¹Metro North Hospital & Health Service, Brisbane, AUSTRALIA, ²Office of the Chief Allied Health Officer, Brisbane, AUSTRALIA.

OP-627
Enhancing Nuclear Medicine Services Through a Hybrid, Collaborative Workforce: Integrating Technologists and Radiographers
M. Casanova Martins, N. Hopson;
 Swansea Bay University Health Board, Swansea, UNITED KINGDOM.

1311
Tuesday, October 7, 2025, 9:45 - 11:15
Room 111

TROP Session - Case Report Session 1: Case-based Learning in Theranostics

OP-628
Molecular Response Assessment of combined intravesical Radio-Ligand-Therapy (iRLT) and systemic chemotherapy of Muscle Invasive Bladder Cancer patients by liquid biopsy testing from urine - the RadioMolecularIncubator Experience within the Bladder BRIDGister
R. Wirtz¹, E. Storz², M. von Brandenstein², F. Friedersdorff³, D. Barski⁴, T. Otto⁴, J. Graff⁵, M. Waldner⁵, E. Veltrup¹, P. Gehle¹, R. Hake⁶, S. Eidt⁶, C. Rieger², T. Ecke⁷, A. Heidenreich², L. Greifenstein⁸, R. P. Baum⁸;
¹STRATIFYER Molecular Pathology GmbH, Köln, GERMANY, ²Dpt. of Urology, University Clinic Cologne, Köln, GERMANY, ³Dpt. of Urology, Charité - Universitätsmedizin Berlin, Berlin, GERMANY, ⁴Dpt. of Urology, Rheinlandklinikum, Neuss, GERMANY, ⁵Dpt. of Urology St. Elisabeth Hospital,, Köln, GERMANY, ⁶Institute of Pathology at the St. Elisabeth Hospital, Köln, GERMANY, ⁷Dpt. of Urology, HELIOS Klinik Bad Saarow, Berlin, GERMANY, ⁸CURANOSTICUM Wiesbaden-Frankfurt, Wiesbaden, GERMANY.

OP-629
Role of Post-Therapy SPECT/CT in Detecting Pseudoprogression during Lu-177 PSMA Radioligand Therapy: A Case Report
K. Resuello, W. Lim, P. Fernando;
 St. Luke's Medical Center - Global City, Taguig, PHILIPPINES.

OP-630
Non-Invasive Management of an Asymptomatic Lu-177-PSMA-617 Extravasation: A Case Report with Scintigraphic and Dosimetric Evaluation

Y. Cras, M. Borsali, P. Lacassagne, L. Ferreol, D. Deandreis, C. García;
Gustave Roussy, Villejuif, FRANCE.

OP-631
Validation of SPECT-based dosimetry in 177Lu-DOTATATE peptide receptor radionuclide therapy: ex-vivo confirmation after liver transplantation
C. Avigo¹, F. Bonutti², L. Barresi¹, S. Peric¹, V. Cherchi², U. Baccarani^{2,3}, E. Scarpa², A. Mangogna², G. Fanetti¹, E. Borsatti¹, A. Drigo¹;
¹Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, ITALY, ²University Hospital, Udine, ITALY, ³University of Udine, Udine, ITALY.

OP-632
From Diagnosis to Treatment: A Multimodal Journey in Metastatic PanNET: A Case Report
R. Marao, D. Barbosa, D. Silva, N. Vasconcelos, I. Próspero, J. Ferro, L. Violante, S. Fontão de Castro, R. Ferreira, I. Lucena Sampaio;
Instituto Português Oncologia do Porto Francisco Gentil, Porto, PORTUGAL.

OP-633
Taming the Insulinoma: A Case of Glycaemic Recovery with [¹⁷⁷Lu]Lu-DOTATATE
D. Carvalho, S. Barata, S. Paiva, I. Casimiro, J. Silva, L. Lemos, M. Monteiro, P. Lapa, G. Costa;
ULS Coimbra - HUC, Coimbra, PORTUGAL.

OP-634
Ramsay-Hunt Syndrome and Encephalitis following [¹⁷⁷Lu]Lu-DOTA-TATE: a case report
F. Silva-Ribeiro, B. Martins, F. P. Branco, V. C. Sousa;
Unidade Local de Saúde de Loures / Odivelas, Lisbon, PORTUGAL.

OP-635
TARE Application for Bridging Liver Transplantation in Unresectable Embryonal Rhabdomyosarcoma of Biliary Tract Origin in a Toddler
N. Güldi, V. Çayhan;
University of Health Sciences, Ankara Bilkent City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-636
When Fire Meets Fuel: Thyrotoxic Crisis Following Radioactive Iodine Therapy for an Autonomous Thyroid Nodule
S. Ramos Barata¹, S. Paiva¹, J. Silva¹, D. Carvalho¹, I. Casimiro¹, A. Albuquerque¹, G. Costa^{1,2};
¹Hospitais da Universidade de Coimbra - ULS Coimbra, Coimbra, PORTUGAL, ²Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

1401
Tuesday, October 7, 2025, 11:30 - 13:00
Auditorium

Plenary 4: Quo vadis Nuclear Medicine 2040: Who Wins? Team Red or Team Green?

Topic 1: Theranostics Involving Radionuclides Will (not) Represent a Major Pillar of Cancer Therapy

Topic 2: Ai Will Complement Nuclear Medicine Physicians / AI Will Replace Nuclear Medicine Physicians

Topic 3: Nuclear Medicine as a Specialty Will Remain Independent / Nuclear Medicine as a Specialty Will Be Taken Over by Radiology and Radiation Oncology

1501
Tuesday, October 7, 2025, 15:00 - 16:30
Auditorium

CME 11 - Translational Molecular Imaging & Therapy Committee: A Comprehensive Approach to Preclinical Dosimetry

OP-641
The Power of Preclinical Dosimetry for Personalised Treatment Radio-Immunotherapy Studies
O. Kochebina; Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), F-91401, Paris, FRANCE.

OP-642
Interaction of Radiation Dosimetry and DNA Repair to Build a Mathematical Model for Radiopharmaceutical Therapy Treatment Planning
K. Shi; Department of Nuclear Medicine, University of Bern, Bern, SWITZERLAND.

OP-643
Small Scale Dosimetry Models for Normal Organs, Dose Effect Limits in Mice, Relevant for Human?
C. Saldarriaga Vargas; Belgian Nuclear Research Centre, Mol, BELGIUM.

OP-644
Preclinical Dosimetry Experience, Ready for Clinical Application?
M. Konijnenberg; Erasmus MC, Rotterdam, NETHERLANDS.

1502
Tuesday, October 7, 2025, 15:00 - 16:30
Auditorium

Special Track 11 - Oncology & Theranostics Committee: Debate: Lymphoma Evaluation: Do We Need to Go Beyond the Deauville Score?

OP-645
How to Interpret PET/CT in Lymphoma in Daily Routine and Clinical Trials
C. Kobe; University of Cologne, Department for Nuclear Medicine, Cologne, GERMANY.

OP-646
Challenger Team Nantes
R. Metz; Nantes University Hospital, Nantes, FRANCE.

OP-647a
Challenger Team Nantes
C. François; Nantes University Hospital, Nantes, FRANCE.

OP-647b
Challenger Team Nantes
R. Bardy; Nantes University Hospital, Nantes, FRANCE.

OP-647c
Challenger Team Cologne
D. Ufton; University of Cologne, Department for Nuclear Medicine, Cologne, GERMANY.

OP-647d
Challenger Team Cologne
N. Große Hokamp; University of Cologne, Department for Diagnostic Radiology, Cologne, GERMANY.

1503
Tuesday, October 7, 2025, 15:00 - 16:30
Auditorium

LIPS Session 11 - Neuroimaging Committee: Crazy Enough to do Molecular Imaging in Psychiatric Disorders?

OP-648
The Current Need of Biomarkers in Psychiatry
G. Knudsen; Rigshospitalet – Neurocentret, Copenhagen, DENMARK.

OP-649
The Current Use of PET/SPECT Imaging in Psychiatry
F. Fraioli; University College London, Institute of Nuclear Medicine, London, UNITED KINGDOM.

OP-650
Perspectives for News Paradigm of Acquisition
R. Lanzenberger; Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, AUSTRIA.

OP-651
Perspectives for New Targets and New Indication
J. Booi; Amsterdam UMC, department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

1504
Tuesday, October 7, 2025, 15:00 - 16:30
Room 114

M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Peptides for All Taste

OP-652
Preclinical studies of structurally optimized ⁶⁴Cu- and ⁶⁸Ga-labeled bicyclic peptides for improved imaging of nectin-4-positive tumors
T. Krönke, J. Trommer, M. Ullrich, M. Laube, R. Löser, K. Kopka, S. Stadlbauer, J. Pietzsch, R. Wodtke;

Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, GERMANY.

OP-653
Development of a Novel ⁶⁸Ga-Labelled Lasso Peptide Radiotracer for EphA2: Advancements in Prostate Cancer Imaging and Beyond
X. Cui, Z. Liu;
Changping Laboratory, Beijing, CHINA.

OP-654
Preclinical Evaluation of 3B010: A Novel GPC3-Targeting Peptide Radioligand with High Tumor Retention and Remarkable Tumor-to-Kidney Ratio
W. XU, J. Zhang;
PepLib, Metuchen, NJ, UNITED STATES OF AMERICA.

OP-655
Dimerization and ¹⁷⁷Lu-labeling of HER2-receptor Targeting Peptide
S. GUPTA^{1,2}, M. Kumar², K. Repaka³, A. Kengar¹, D. Satpati^{2,4};
¹KET's V. G. Vaze College, Mumbai University, Mumbai, INDIA, ²Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, INDIA, ³Board of Radiation and Isotope Technology, Mumbai, INDIA, ⁴Homi Bhabha National Institute, Mumbai, INDIA.

OP-656
Preclinical Evaluation of [¹⁶¹Tb]Tb-DPI-4452 for CAIX-Targeted Radionuclide Therapy in Pancreatic Cancer
C. Van Laere^{1,2}, C. Segers², A. Coolkens², M. Dewilde¹, F. Cleeren¹, M. Ooms²;
¹KU Leuven, Leuven, BELGIUM, ²SCK CEN, Mol, BELGIUM.

OP-657
Substantially Higher Treatment Efficacy of ¹⁶¹Tb-Labelled GRPR Antagonists over ¹⁷⁷Lu-Labelled GRPR Antagonists in PC3 Tumour-Bearing mice
T. Günther¹, A. S. Moses¹, E. H. Günther¹, M. R. Landry¹, S. Ramaekers², M. Van de Voorde², M. Ooms², B. Ponsard³, C. Beinat¹;
¹Molecular Imaging Program at Stanford (MIPS), Department of Radiology, School of Medicine, Stanford University, Palo Alto, CA, UNITED STATES OF AMERICA, ²Nuclear Medical Applications, Belgian Nuclear Research Centre, Mol, BELGIUM, ³BR2 Reactor, Belgian Nuclear Research Centre, Mol, BELGIUM.

OP-658
Improved Tumour Targeting and Efficacy with Comparable Daughter Redistribution of ²²⁵Ac-SSO110 versus ²²⁵Ac-DOTA-TATE in a Preclinical SCLC Model
P. Desai, M. Huber, M. Ruediger, G. Gericke, A. Jaekel;
Ariceum Therapeutics GmbH, Berlin, GERMANY.

OP-659
Preclinical evaluation of GRPR-antagonist PK3 as a candidate for targeted alpha therapy with Ac-225
P. Kanellopoulos¹, A. Lebedev², E. Papalannis³, K. Obeid¹, E. A. Bezverkhniaia¹, C. Byrne², T. Pack², V. Tolmachev³, A. Orlova¹, S. V. Selivanova²;
¹Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN, ²Canadian Nuclear Laboratories, Chalk River, ON, CANADA, ³Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN.

OP-660
ImmunoPET Imaging of TIM3 Expression in the Tumor Microenvironment Using [68Ga]-Labelled Cyclic Peptide Tracers: From Bench to Bedside

J. Hou, S. Hu;
Xiangya Hospital, Central South University, Changsha, CHINA.

1505

Tuesday, October 7, 2025, 15:00 - 16:30
Room 211

Cutting Edge Science Track - TROP Session - Physics Committee: Instrumentation, QC & Standardisation

OP-661
Performance evaluation for a dual-collimator 3D CZT Camera

R. Zananiri, A. Devir-Wolfman, M. Wilk, O. Ziv, J. Bouhnik; GE HeathCare, Haifa, ISRAEL.

OP-662
Performance Evaluations in ¹⁶¹Tb SPECT Imaging: Sensitivity, Septal Penetration, and Dead-Time Effects

F. Westerbergh¹, L. McDougall², P. Ritt³, J. G. Fricke², N. P. van der Meulen^{4,5}, C. Müller^{6,5}, R. Schibli^{5,6}, D. Wild², P. Bernhardt^{1,7};
¹Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN, ²Division of Nuclear Medicine, University Hospital Basel, Basel, SWITZERLAND, ³Chair for Clinical Nuclear Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GERMANY, ⁴Laboratory of Radiochemistry, PSI Center for Nuclear Engineering and Sciences, Villigen-PSI, Villigen, SWITZERLAND, ⁵Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Villigen, SWITZERLAND, ⁶Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, SWITZERLAND, ⁷Department of Medical Physics and Biomedical Engineering (MFT), Sahlgrenska University Hospital, Gothenburg, SWEDEN.

OP-663
Final results of the first in human validation of a DROP-IN β-probe during robotic PSMA-guided Surgery: insights and perspectives

F. Collamati¹, F. Ceci², G. Musi², R. Mirabelli³, S. Morganti¹, F. Mattana⁴, S. Luzzago⁴, F. Nicolanti³, F. W. B. van Leeuwen⁵, M. N. van Oosterom⁶, R. Faccini⁷;
¹INFN Rome, Rome, ITALY, ²IEO Milan, Milan, ITALY, ³Università Sapienza Roma, Rome, ITALY, ⁴IEO Milan, Rome, ITALY, ⁵Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS, ⁶Interventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden, NETHERLANDS, ⁷Università Sapienza Roma, Rome, ITALY.

OP-664
An investigation of noise in standardised NEMA image quality phantoms used in multi-centre trials

S. Jin, G. Krokos, A. Harman, D. M. L. Lilburn, S. Barrington, P. K. Marsden;
King's College London, London, UNITED KINGDOM.

OP-665
Optimising Diagnostic CT in PET/CT: Balancing Dose and Image Fidelity with a Catphan® 600 Phantom

V. Menezes^{1,2}, C. Gomes³, P. Bergamo³, R. Machado², T. Chang², A. Duarte²;
¹Hospital das Clinicas da UFPE, Recife, BRAZIL, ²Memorial Star Red D'or, Recife, BRAZIL, ³RADTEC, RECIFE, BRAZIL.

OP-666
Advantages of Minimally Invasive MIBI-Radioguided Parathyroidectomy.

C. Villaprado, I. Blanco, A. Barrera, K. Sanabria, E. Goñi, F. Lozada, P. Boya, M. Ribelles, L. Paruta, A. Rosero, M. Garcia, E. Anda, N. Cruz, P. Salvador;
Hospital Universitario de Navarra, Pamplona, SPAIN.

OP-667
Quantifying the Contribution of Residual ⁶⁸Ga in ¹⁸F Imaging - the First Step to a 'One Stop Shop'?

N. Davis¹, H. Natarajan^{1,2}, B. F. Holman¹;
¹Royal Free London NHS Foundation Trust, London, UNITED KINGDOM, ²King's College London, London, UNITED KINGDOM.

OP-668
Addressing brain PET harmonization challenges in clinical settings: joint estimation of true activity and effective image resolution using paired T1W MRI

L. Fu, S. Yang, L. Yin;
Department of Nuclear Medicine, China-Japan Friendship Hospital, Beijing, CHINA.

OP-669
From multicenter variability to harmonized synthetic phantoms: a national DAT SPECT study within the National Virtual Institutes for Parkinson's and Dementia (IVNPD & IVND)

M. Inglese¹, S. P. Caminiti², G. Pol³, C. Bianchi³, S. Parabolici³, S. Mazzaglia⁴, M. Bagnalasta⁵, L. Tagliabue⁴, A. Chiti⁶, M. Castellani⁷, S. Raffa⁸, P. Calza⁹, L. Evangelista¹⁰, D. Di Giuda¹¹, M. Bonacina¹², D. D'Ambrosio¹³, D. Arnaldi¹⁴, E. M. Valente², F. Tagliavini¹⁵, S. D. Morbelli¹⁶, N. Toschi^{11,17};
¹Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, ITALY, ²Department of Brain and Behavioral Sciences, University of Pavia, Pavia, ITALY, ³Medical Physics Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, ITALY, ⁴ASST Santi Paolo e Carlo, Milan, ITALY, ⁵Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, ITALY, ⁶Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ⁷Nuclear Medicine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, ITALY, ⁸Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ⁹Istituti Clinici Scientifici Maugeri IRCCS, Gattico-Veruno, Piedmont, ITALY, ¹⁰Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY, ¹¹Institute of Nuclear Medicine, Fondazione Policlinico Universitario "A. Gemelli" Università Cattolica del Sacro Cuore, Rome, ITALY, ¹²Nuclear Medicine Department, Fondazione Poliambulanza, Brescia, ITALY, ¹³Physics Unit, Istituti Clinici Scientifici Maugeri SpA SB IRCCS, Pavia, ITALY, ¹⁴Clinical Neurology IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ¹⁵Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, ITALY, ¹⁶IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ¹⁷A.A. Martinos Center for Biomedical Imaging and Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA.

1506

Tuesday, October 7, 2025, 15:00 - 16:30
Room 117

Theranostics Track - TROP Session - Oncology & Theranostics Committee: Prostate Cancer Therapy: New Tracer

OP-670
A First-in-human, Phase 1 Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, and Anti-tumor Activity of [²²⁵Ac]Ac-FL-020, an Anti-PSMA Radioconjugate in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

S. Ngai¹, G. Cardaci², A. Singh², A. Iagaru³, C. Artigas⁴, K. Goffin⁵, R. Villanueva Vázquez⁶, K. Herrmann⁷, C. S. Kramer⁸, A. Robert⁸, K. Schumacher⁸, S. Heeger⁸, D. Barton⁹, A. Hansen¹;
¹Princess Alexandra Hospital, Brisbane, AUSTRALIA, ²GenesisCare Australia. St John of God Hospital Murdoch, Murdoch, AUSTRALIA, ³Stanford University, Stanford, CA, UNITED STATES OF AMERICA, ⁴Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, BELGIUM, ⁵Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, ⁶ICO Hospitalet, l'Hospitalet de Llobregat, Barcelona, SPAIN, ⁷University Hospital Essen, Essen, GERMANY, ⁸Full-Life Technologies GmbH, Heidelberg, GERMANY, ⁹Full-Life Technologies U.S. Inc., Dover, DE, UNITED STATES OF AMERICA.

OP-671
Evaluation of the safety and efficacy of ²²⁵Ac-PSMA-CY313 in metastatic castration-resistant prostate cancer: preliminary results

S. Li¹, Y. Shi¹, J. Liu², Z. Li², Y. Wu²;
¹Department of Nuclear Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, CHINA, ²C-Ray Pharmaceuticals (Chengdu) Co. Ltd., Chengdu, CHINA.

OP-672
First-in-Human Study of a Novel PSMA-Targeted Radiotherapeutic Agent: Safety, Preliminary Efficacy, and Dosimetry of [¹⁷⁷Lu]Lu-PSMA-XT in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Y. Liu^{1,2}, H. Wang¹, X. Zhang¹, W. Zhao³, R. Wang¹, B. Xu¹, J. Zhang¹;
¹Chinese PLA General Hospital, Beijing, CHINA, ²Chinese PLA Medical School, Beijing, CHINA, ³Sinotau Pharmaceutical Group, Beijing, CHINA.

OP-673
Head-to-Head dosimetry, safety and preliminary early response evaluation of [¹⁶¹Tb]Tb-SibuDAB versus [¹⁷⁷Lu]Lu-PSMA-I&T in patients with mCRPC: PROGNOSTICS Phase Ia

A. Chirindel¹, G. Nicolas¹, F. Westerbergh², L. McDougall¹, D. Schmid³, S. Geistlich³, A. Bauman⁴, A. Fokkema⁴, N. Aceto⁵, P. Bernhardt^{2,6}, N. van der Meulen^{2,3}, C. Müller^{3,8}, R. Schibli^{3,8}, D. Wild¹;
¹Department Theranostics, Nuclear Medicine, University Hospital Basel, Basel, SWITZERLAND, ²Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN, ³PSI Center for Life Sciences,

Villigen-PSI, SWITZERLAND, ⁴Department Theranostics, Radiopharmacy, University Hospital, Basel, SWITZERLAND, ⁵Department of Biology, Institute for Molecular Health Sciences, ETH Zurich, Zurich, SWITZERLAND, ⁶Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, SWEDEN, ⁷PSI Center for Nuclear Engineering and Sciences, Villigen-PSI, SWITZERLAND, ⁸Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, SWITZERLAND.

OP-674
ProstACT Global: A phase 3 study of Lutetium (Lu177) rosopatamab tetraxetan plus standard of care vs standard of care alone in patients with metastatic castration-resistant prostate cancer
J. Roetman¹, S. Tagawa², N. Agarwal³, D. Cade¹, O. Sartor⁴;
¹Telix Pharmaceuticals, Melbourne, AUSTRALIA, ²Weill Cornell, New York, NY, UNITED STATES OF AMERICA, ³Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, UNITED STATES OF AMERICA, ⁴Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA.

OP-675
SatisfACtion Trial-in-Progress: A Phase 1/2 Study of [²²⁵Ac]Ac-PSMA-R2 in Patients with Metastatic Hormone-Sensitive Prostate Cancer or Metastatic Castration-Resistant Prostate Cancer

H. Mahammedi¹, F. Kraeber Bodéré², L. Emmett³, C. Rousseau⁴, A. Vinceneux⁵, C. Drouet⁶, J. Wehbe⁷, Y. Qing⁸, L. Pinto⁸, P. Olivier⁹;
¹Centre Jean Perrin UMR INSERM 1240 Imost, Clermont-Ferrand, FRANCE, ²Centre Hospitalier Universitaire de Nantes, Département de Médecine Nucléaire, Nantes, FRANCE, ³Department of Theranostics and Nuclear Medicine, Garvan Institute of Medical Research, St Vincent's Hospital, Sydney, AUSTRALIA, ⁴Institut de Cancérologie de l'Ouest, Département de Médecine Nucléaire, Saint Herblain, FRANCE, ⁵Centre Léon Bérard, Lyon, FRANCE, ⁶Centre Georges-François Leclerc, Département de Médecine Nucléaire, Dijon, FRANCE, ⁷Novartis Pharma AG, Basel, SWITZERLAND, ⁸Novartis Pharma, East Hanover, NJ, UNITED STATES OF AMERICA, ⁹Centre Hospitalier Régional Universitaire de Nancy, Département de Médecine Nucléaire, Nancy, FRANCE.

OP-676
Adaptive Design and Dose Optimization in a Phase Ib/Ia Dose Escalation and Expansion Study of ²¹²Pb-ADVC001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC): TheraPb - Phase I/II Study

A. Hansen¹, A. Karmann², D. Pattison³, S. Ngai¹, L. Katchell¹, L. Campbell³, A. Soderholm², M. Griffiths³, E. O'Mahoney¹, J. Brady³, S. Rose², M. Baronet², M. Crumbaker², T. Kryza², S. Puttick², K. Kuan², N. Dhantravan³, I. Holmes¹, S. Baker¹, P. Santoro², L. Skingley², W. Tieu², C. Gan³, J. Goh³, D. Wyld³;
¹Princess Alexandra Hospital, Brisbane, AUSTRALIA, ²AdvanCell Pty Ltd, Sydney, AUSTRALIA, ³Royal Brisbane and Women's Hospital, Brisbane, AUSTRALIA.

OP-677
Dose escalation study for targeted radionuclide therapy with [¹⁶¹Tb]Tb-SibuDAB in mCRPC - PROGNOSTICS Phase Ib study

A. Chirindel¹, G. Nicolas¹, F. Westerbergh², L. McDougall¹, D. Schmid³, S. Geistlich³, A. Bauman¹, A. Fokkema⁴, N. Aceto⁴, P. Bernhardt^{2,5}, N. van der Meulen^{6,3}, C. Müller^{3,7}, R. Schibli^{3,7}, D. Wild¹;
¹Department Theranostics, Nuclear Medicine, University Hospital Basel, Basel, SWITZERLAND, ²Department of Medical Radiation Sciences, Institute of Clinical Sciences,

Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN, ³PSI Center for Life Sciences, Villigen-PSI, SWITZERLAND, ⁴Department of Biology, Institute for Molecular Health Sciences, ETH Zurich, Zurich, SWITZERLAND, ⁵Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, SWEDEN, ⁶PSI Center for Nuclear Engineering and Sciences, Villigen-PSI, SWITZERLAND, ⁷Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, SWITZERLAND.

OP-678
Dosimetry and Dose-escalation Study of a Novel Long-Acting Radiopharmaceutical [¹⁷⁷Lu]Lu-LNC1011 inMetastatic Castration-Resistant Prostate Cancer Patients
J. Wang¹, R. Wang¹, J. Xiang¹, X. Chen², Z. Zhu¹, J. Zhang²; ¹Peking Union Medical College Hospital, Beijing, CHINA, ²National University of Singapore, Singapore, SINGAPORE.

1507
 Tuesday, October 7, 2025, 15:00 - 16:30
 Room 212

TROP Session - Cardiovascular Committee: Myocardial Perfusion on PET: Where Are We Going?

OP-679
Safer3: A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel F-18-labelled Myocardial perfusion tracer, F-18-SYN2
J. Knuuti¹, M. H. Al-Mallah², P. J. Slomka³, P. Soman⁴, T. M. Bateman⁵, P. Chareonthaitawee⁶, M. Dziuk⁷, J. Bi⁸, S. Krajewski⁹, A. Einstein¹⁰, R. R. S. Packard¹¹, W. Kula¹², L. Steczek⁹, K. Gotowicz⁹, P. Kozanecki⁹, J. Wlostowska⁹, C. Kozanecki⁹; ¹Turku University Hospital, Turku, FINLAND, ²Heart and Vascular Center, Houston, TX, UNITED STATES OF AMERICA, ³Cedars Sinai Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA, ⁴University of Pittsburgh Medical Center, Pittsburg, PA, UNITED STATES OF AMERICA, ⁵6)Mid America Heart Institute and the Saint Luke's Health System, Kansas City, MO, UNITED STATES OF AMERICA, ⁶Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA, ⁷Military Institute of Medicine - National Research Institute, Warsaw, POLAND, ⁸10)National Medical Institute of the Ministry of Interior and Administration, Warsaw, POLAND, ⁹Research and Development Centre, Synektik SA, Warsaw, POLAND, ¹⁰Columbia University Irving Medical Center, New York, NY, UNITED STATES OF AMERICA, ¹¹University of California, Los Angeles, CA, UNITED STATES OF AMERICA, ¹²Axcellant, Warsaw, POLAND.

OP-680
Diagnostic Approach to Microvascular Dysfunction in INOCA: Simultaneous Dual-Perfusion Imaging with ¹³N-Ammonia and Gadolinium Using an Integrated PET-MR Scanner
R. Wen, X. Wang; The First Affiliated Hospital of University of Science and Technology of China, Hefei, CHINA.

OP-681
Simultaneous ¹³N-Ammonia and Gadolinium-Based First-Pass Myocardial Perfusion Using Integrated PET-MRI Imaging: A Comparative Evaluation of Diagnostic Accuracy in Coronary Microvascular Dysfunction
R. Wen, X. Wang; The First Affiliated Hospital of University of Science and Technology of China, Hefei, CHINA.

OP-682
Native T1 Mapping versus Coronary Flow Reserve for Coronary Microvascular Dysfunction in INOCA: PET-MRI Validation
R. Wen, X. Wang; The First Affiliated Hospital of University of Science and Technology of China, Hefei, CHINA.

OP-683
Association between Coronary Microvascular Dysfunction and Diabetic Microvascular complications in Type 2 Diabetes Mellitus: A ¹³N-Ammonia PET study
J. Ilangovan, H. Singh, A. Rastogi, A. Sood, B. Mittal; PGIMER, Chandigarh, INDIA.

OP-684
Prognostic value of coronary flow capacity by 82Rb PET in a large cohort of patients with suspected and known coronary artery disease
E. Zampella¹, R. Assante¹, T. Mannarino¹, A. D'Antonio¹, M. Panico², P. Buongiorno¹, V. Cantoni¹, R. Green¹, A. Cuocolo¹, W. Acampa¹; ¹University Federico II, Naples, ITALY, ²3Institute of Biostructure and Bioimaging, CNR, Naples, ITALY.

OP-685
Improved cardiac⁸²Rb-PET functional imaging with 16-gates protocol using a LAFOV PET system
N. Gözlügöl, H. Sari, F. Aghapour Zangeneh, A. Rominger, F. Caobelli; Inselspital Bern University Hospital, Bern, SWITZERLAND.

OP-686
Reduction of acquisition time in [¹⁵O]H₂O-myocardial perfusion imaging
K. Thøgersen, M. Nowak Lonsdale, M. Krakauer; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital – Bispebjerg and Frederiksberg, Copenhagen, DENMARK.

OP-687
Reproducibility of splenic blood flow and splenic switch-off in ¹⁵O-water positron emission tomography myocardial perfusion imaging
J. Jou¹, J. Nordström², J. Sörensen³, M. Lubberink³, T. Kero³; ¹Department of Medical Sciences, Clinical Physiology, Uppsala University, Uppsala, SWEDEN, ²Center for Research and Development Uppsala/Gävleborg Country, Gävle, SWEDEN, ³Molecular Imaging and Medical Physics, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN.

1508
 Tuesday, October 7, 2025, 15:00 - 16:30
 Room 115

Joint Symposium 7 - Inflammation & Infection Committee / EUSEM: The Role of Nuclear Medicine Imaging in Intensive Care Unit (ICU) Patients

OP-688
Infection and Inflammation in ICU Patients
H. Bracht; Department of Anesthesiology, Intensive Care, Emergency Medicine, Transfusion Medicine, and Pain Therapy, University Hospital of Bielefeld, Campus Bielefeld-Bethel, Bielefeld, GERMANY.

OP-689
Patient Preparation, Transport Logistics and Safety
J. Pillay; Department of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS.

OP-690
Diagnostic Performance of FDG PET/CT in ICU Patients
E. Romano Gargarella; Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, ITALY.

1509
 Tuesday, October 7, 2025, 15:00 - 16:30
 Room 133+134

e-Poster Presentations Session 11 - AI Committee: AI e-Poster Presentations Session

EPS-220
SuPro-MPI: Deep Learning-based Supine-to-Prone Transformation of ^{99m}Tc-MIBI SPECT MPI
G. Hajianfar¹, P. Mohammadi Kazaj², Y. Salimi¹, S. Bagheri³, Z. Mansouri¹, A. Aghaee⁴, M. Mogharrabi⁵, M. Ghodsirad⁶, A. Khorasanchi⁷, E. Askari⁸, M. Sehat⁹, F. Shirdel¹, A. Sanaat¹, I. Shiri², H. Zaidi¹; ¹Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Genève, SWITZERLAND, ²Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND, ³Department of Nuclear Medicine, Children Medical Center, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Department of Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ⁵Nuclear Medicine department, 5 Azar Hospital, Golestan University of Medical Sciences, Gorgan, IRAN, ISLAMIC REPUBLIC OF, ⁶Department of Nuclear Medicine, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁷Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ⁸Comprehensive Cancer Center, Hashemi Rafsanjani Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EPS-221
Evaluation of histo-image based Fast PET reconstruction method in whole-body 82-Rubidium blood-flow studies with a LAFOV PET scanner
I. Brovedani^{1,2}, M. Morini^{1,2}, M. Millardet^{3,4}, M. De Francisci², Y. Zheng³, D. Bharkhada³, M. Conti³, L. Mercolli¹, M. Castellaro², M. Veronese^{2,5}, A. Rominger¹, F. Caobelli¹, H. Sari^{1,6}; ¹Department of Nuclear Medicine, Bern University Hospital, Bern, SWITZERLAND, ²Department of Information Engineering, University of Padova, Padua, ITALY, ³Siemens Medical Solutions, USA Inc., Knoxville, TN, UNITED STATES OF AMERICA, ⁴Department of Radiology, University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, ⁵Department of Neuroimaging, Kings College London, London, UNITED KINGDOM, ⁶Siemens Healthineers International AG, Zurich, SWITZERLAND.

EPS-222
Feasibility Study of Deep Learning-Based Low-Dose PET and Accelerated MR Imaging in PET/MR
Y. Xu; Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EPS-223
MIPET: A Fast Localized Machine Learning Approach for Probabilistic PET Image Reconstruction Using Informed Priors - Application to Phantom data
T. M. Hansen¹, N. L. Christensen², M. H. Vendelbo^{3,2}; ¹Department of Geoscience, Aarhus University, Aarhus, DENMARK, ²Department of Nuclear Medicine & PET, Aarhus university Hospital, Aarhus, DENMARK, ³Department of Biomedicine, Aarhus University, Aarhus, DENMARK.

EPS-224
Assessment of Deep Learning Attenuation Correction for Myocardial Perfusion Scintigraphy on a Dedicated Cardiac CZT-SPECT Camera: Comparison with [⁸²Rb] PET-CT
M. Westerman¹, P. Bharadwaj¹, G. Keramida¹, L. Munemo², K. Wechalekar¹, L. Hossen¹; ¹Royal Brompton Hospital, London, UNITED KINGDOM, ²Auckland City Hospital, Auckland, NEW ZEALAND.

EPS-225
Feasibility Study of Deep Learning-Based Low-Dose PET and CT Imaging in PET/CT
Y. Xu; Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EPS-226
Cross-Modal Synthesis of Tau-PET Images from Amyloid-PET Scans Using Deep Learning
Y. Hu¹, D. E. Peretti², V. Garibotto¹, A. Sanaat¹, H. Zaidi¹; ¹Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, SWITZERLAND, ²Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND.

EPS-227
Deep Learning Model for Denoising and Positron Range Correction for Clinical Gallium-68 PET/CT Scanning
P. Gavrilidis^{1,2,3}, R. Wiert¹, F. M. Mottaghy^{1,4}, M. Koole³; ¹Maastricht UMC+, Maastricht, NETHERLANDS, ²Maastricht

University, Maastricht, NETHERLANDS, ³KU Leuven, Leuven, BELGIUM, ⁴RWTH Aachen University Hospital, Aachen, GERMANY.

EPS-228
Image quality and lung nodule detectability in LAFOV PET: quantitative and qualitative evaluation
A. Spataro, A. Franchini, S. Capitanio, A. Scarale, L. Airo' Farulla, G. Cabrini, E. Gay, C. Rossetti; Nuclear Medicine Unit, Dipartimento Ematologia, Oncologia e Medicina Molecolare, ASST Niguarda, Milan, ITALY.

EPS-229
Study of Different Partial Volume Correction Methods in Tau PET Imaging for Alzheimer's Disease
A. Rohmah¹, K. Lin², I. Hsiao^{1,2}; ¹Chang Gung University, Taoyuan, TAIWAN, ²Department of Nuclear Medicine, Chang Gung Memorial Hospital, Taoyuan, TAIWAN.

EPS-230
Independent external validation of NSCLC Pro Score, a clinico-radiomic predictive signature of survival for NSCLC patients treated with immunotherapy.
R. Abgral^{1,2}, D. Bourhis^{1,2}, V. Bourbonne³, K. Amrane⁴, C. Le Meur³, M. Geier^{5,2}, R. Floch¹, K. Kerleguer¹, P. Salaün^{1,2}, C. Nioche⁶, I. Buvat⁶, F. Orlhac⁶; ¹Molecular Imaging and Radiotheranostic Department, University Hospital of Brest, Brest, FRANCE, ²UMR 1304 Inserm GETBO, Brest, FRANCE, ³Radiotherapy Department, University Hospital of Brest, Brest, FRANCE, ⁴Oncology Department, Regional Hospital of Morlaix, Morlaix, FRANCE, ⁵Thoracic Oncology Department, University Hospital of Brest, Brest, FRANCE, ⁶Institut Curie, Université PSL, Inserm, U1288, LITO, Orsay, FRANCE.

EPS-231
Refining Prognostic Models in Metastatic Breast Cancer Patients Using Whole-Body Radiomic Features
J. Auriac¹, N. Hovhannisyan-Baghdasarian¹, C. Nioche¹, R. Seban^{1,2}, N. Jehanno^{1,2}, M. Luporsi¹, F. Bidard³, I. Buvat¹, F. Orlhac¹; ¹Institut Curie, Université Paris-Saclay, Inserm LITO U1288, Orsay, FRANCE, ²Institut Curie, Department of Nuclear Medicine, Paris-St-Cloud, FRANCE, ³Institut Curie, Department of Medical Oncology, Paris-St-Cloud, FRANCE.

EPS-232
[¹¹C]PIB Uptake in Lateral Ventricles is Associated with Neuroinflammation: A PET Imaging Study in Down Syndrome and Normal Aging
D. Mantovani, L. C. Oliveira, O. V. Forlenza, C. A. Buchpiguel, D. de Paula Faria; University of São Paulo, São Paulo, BRAZIL.

EPS-233
Metabolic Brain Network and "Imaging-Protein" Association Analysis of Cognitive Function Recovery in Aging Rats Based on STT3A/ALG5
Z. Yang¹, L. Chen¹, K. Pandya², T. Wang¹, B. Nie³, B. Shan³, Q. Liu⁴, T. Wang⁵, S. H. Bossmann⁶, K. Shi², G. Zhu¹; ¹Department of Nuclear Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, CHINA, ²Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND, ³Beijing Engineering Research Center of Radiographic Techniques and Equipment, Institute of High Energy Physics, Beijing,

CHINA, ⁴Department of Library, First Affiliated Hospital of Kunming Medical University, Kunming, CHINA, ⁵Institute of Neurological Disease, Translational Neuroscience Center, West China Hospital, Chengdu, CHINA, ⁶The University of Kansas Medical Center, Department of Cancer Biology, Kansas city, KS, UNITED STATES OF AMERICA.

EPS-234
Novel approach for simultaneous quantitative parametric imaging in Large Axial field-of-view PET
H. Iida¹, N. Ono², H. Merisaari¹, A. E. Latva-Rasku¹, J. Tuisku¹, N. Tuomola¹, N. Tuomola¹, R. Siekkinen¹, V. Saunavaara¹, J. Knuuti¹, L. Nummenmaa¹, K. Virtanen¹, P. Nuutila¹; ¹Turku PET Centre, Turku University Hospital and University of Turku, Turku, JAPAN, ²Nara Institute of Information Science and Technology, Ikoma, FINLAND.

EPS-235
AI-Based 3D Diffusion Model Enables High-Fidelity, Quantitatively Accurate Ultra-Low-Dose Whole-Body PET Imaging
V. Menezes¹, M. Machado², C. Queiroz³, B. Anjos⁴, E. Almeida⁴, A. Oliveira¹, M. Flamini¹, F. Mourato¹, T. Ren⁵; ¹Hospitals Das Clinicas Da UFPE, Recife, BRAZIL, ²Hospital Universitário Professor Edgard Santos - HUPES, Salvador, BRAZIL, ³Hospital Universitário Professor Alberto Antunes, Maceió, BRAZIL, ⁴Nuclearis, Recife, BRAZIL, ⁵Univerisade Federal de Pernambuco, Recife, BRAZIL.

EPS-236
Improving the Generalization of PET Image-Enhancing Deep Learning Algorithms Through Domain Randomization. A Monte Carlo Study.
J. Poveda^{1,2}, J. Gómez², F. López³, G. Webber⁴, M. Dassanayake⁴, B. Pan⁴, A. Reader⁴, P. Aguiar¹, J. Silva³; ¹Universidad Santiago de Compostela, Santiago de Compostela, SPAIN, ²Qubiotech Health Intelligence, A Coruña, SPAIN, ³Reina Sofía Alzheimer Centre, CIEN Foundation, Madrid, SPAIN, ⁴King's College London, London, UNITED KINGDOM.

EPS-237
AI denoising enhances centiloid analysis in count-poor amyloid brain PET/CT scans
K. Knesaurek; Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

EPS-238
Partial Volume Correction Enables Feasible Kinetic Analysis of Brain Tumours on Short Axial Field-of-View PET Scanners: A Preliminary Study
A. Lazar¹, P. Scifo², A. Chiti^{1,2}; ¹Vita-Salute San Raffaele University, Milan, ITALY, ²Department of Nuclear Medicine, IRCCS San Raffaele Hospital, Milan, ITALY.

EPS-239
Partial Volume Correction Improves Kinetic Modelling in Dynamic [¹⁸F]FET PET: A Simulation-Based Validation Study
S. Raju^{1,2}, T. Schmidt¹, A. J. Zounek¹, Y. Beqqali², E. Barci¹, E. Istrefi¹, J. Isakaj¹, N. L. Albert¹, S. Ziegler^{3,1}, L. Kaiser¹; ¹Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ²Department of Physics, Technical University of Munich, Munich, GERMANY, ³Department of Nuclear Medicine, Hannover Medical School (MHH), Hannover, GERMANY.

EPS-240
Patient-specific reinforcement learning for planar-based 3D SPECT imaging synthesis
A. Lopez Montes¹, R. Seifert¹, A. Delker², G. Boening², J. Wang¹, A. Afshar-Oromieh¹, A. Rominger¹, K. Shi¹; ¹University of Bern, Bern, SWITZERLAND, ²Ludwig-Maximilians-Universität in Munich, Munich, GERMANY.

EPS-241
Integration of Deep Learning and Radiomics for Predicting the Histological Classification of Peripheral Neuroblastic Tumor Base on ¹⁸F-FDG PET/CT Imaging
Z. Zhou; Capital Medical University, Beijing Friendship Hospital, Beijing, CHINA.

1510
 Tuesday, October 7, 2025, 15:00 - 16:30
 Room 116

CTE 7 - Technologists Committee - Hybrid Imaging in Differentiated Thyroid Cancer (DTC) Diagnosis and Treatment

OP-691a
Differentiated Thyroid Cancer Diagnosis and Treatment - The Current and Future Challenges
R. Czepczyński; Dept. of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Poznan, POLAND.

OP-691b
Clinical Impact of Radioiodine Hybrid Imaging in the Management Of DTC Patients
A. Campenni; Unit of Nuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University Hospital of Messina, Messina, ITALY.

OP-691c
Nuclear Medicine in Thyroid Cancer Diagnosis – An Overview
C. Nielsen; Nuclear Medicine educator, Gurnick Academy of Medical Arts, Concord, California, UNITED STATES OF AMERICA.

1511
 Tuesday, October 7, 2025, 15:00 - 16:30
 Room 111

EU Policy Symposium 2

OP-691d
Setting the Stage: The Future of HTA in Nuclear Medicine
N. Withofs; Liège University Hospital, Liège, BELGIUM.

OP-691e
The EU Regulation on Health Technology Assessment (HTAR) Applying from January 2025
J. Spony; Policy officer, European Commission, Directorate-General for Health and Food Safety, Unit C2 Health Technology Assessment, BELGIUM.

OP-691f
The Impact of EU HTAR on National HTA Bodies: The Case of Belgium
M. Neyt; Belgian Health Care Knowledge Centre, BELGIUM.

OP-691g
Patient-Centred Perspectives: Implications for Radioligand Therapy in Light of the New EU HTAR
E. Briers; Patient Representative, Europa Uomo, BELGIUM.

OP-691h
Positioning Imaging in the HTA Process
M. Beck; European Society of Radiology, SWITZERLAND.

1601
 Tuesday, October 7, 2025, 16:45 - 18:15
 Auditorium

CME 12 - Oncology & Theranostics Committee - Improving Breast Cancer Care: Highlights from Focus Meeting 6: Staging

OP-691i
Loco-Regional (T&N) Staging with Imaging
T. van Nijmegen; Maastricht University Medical Center+, Department of Radiology and Nuclear Medicine, Maastricht, NETHERLANDS.

OP-691j
Systemic (M) Staging with Imaging
S. Carrilho Vaz; Champalimaud Clinical Center, Nuclear Medicine-Radiopharmacology, Lisbon, PORTUGAL.

OP-691k
Expectations Towards Emerging New PET Tracers
P. Backhaus; Hospital Münster, Department of Nuclear Medicine, Münster, GERMANY.

OP-691l
Nuclear Medicine Toolkit - The Answers the Oncologist Is Looking for in Clinical Practice
A. Gennari; University of Piemonte Orientale, Department of Oncology, Maggiore University Hospital, Novara, ITALY.

1602
 Tuesday, October 7, 2025, 16:45 - 18:15
 Room 112 (Arena)

Special Track 12 - Dosimetry Committee - Round Table: Unlocking the Potential: Can Total Body PET Revolutionise Dosimetry?

OP-691m
Y-90 SIRT and Conventional PET Imaging – Technical Challenges and Quantitative Potential
S. Gnesin; Lausanne University Hospital and University of Lausanne, Institute of Radiation Physics, Lausanne, SWITZERLAND.

OP-691n
Total-Body PET for Y-90 SIRT – New Opportunities for Pre- and Post-Therapy Dosimetry
R. Abgral; CHU of Brest, Nuclear Medicine Department, Brest, FRANCE.

OP-691o
Future of Y-90-based Therapies: FAPI, CXCR4 and I-124 Dosimetry with TB-PET
P. Fragoso Costa; University Hospital Essen, Nuclear Medicine, Essen, GERMANY.

OP-691p
Kinetic Modelling with TB-PET – Towards Quantitative Therapy Guidance
C. Tsoumpas; Medical Center Groningen, Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS.

OP-691q
Young Perspective on Dosimetry with Total-Body PET – The New Normal?
P. Lindner; University Hospital Tuebingen, Nuclear Medicine and Molecular Imaging, Tuebingen, GERMANY.

1603
Tuesday, October 7, 2025, 16:45 - 18:15
Room 113

LIPS Session 12 - Inflammation & Infection Committee - Interpretation of FDG PET/CT in Common Infectious-Inflammatory Diseases

OP-691r
FDG PET Pattern Recognition in the Main Inflammatory and Infectious Diseases
G. Treglia; Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Division of Nuclear Medicine, Bellinzona, SWITZERLAND.

OP-691s
Visual vs Semiquantitative Assessment in Cardiovascular Infections
L. Leccisotti; Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Nuclear Medicine, Rome, ITALY.

OP-691t
Pitfalls of FDG PET/CT in Inflammation and Infection in Adults
R. Slart; University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS.

OP-691u
Pitfalls of FDG PET/CT in Inflammation and Infection in Paediatrics
M. Øbro Fosbøl; Copenhagen University Hospital, Rigshospitalet Hospital/Institute, Department of Clinical Physiology and Nuclear Medicine, Copenhagen, DENMARK.

1604
Tuesday, October 7, 2025, 16:45 - 18:15
Room 114

M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Imaging of Non-oncological Targets

OP-692
Stabilin-2 receptorspecific radioligand ¹⁸FS2P for atherosclerotic plaque PET imaging
D. Adili, D. Zhang, Z. Li, X. Su;
First Affiliated Hospital of Zhejiang University, School of Medicine, Zhejiang University, Hangzhou, CHINA.

OP-693
Superiority of αvβ6 Integrin-Targeted 68 Ga-Trivehexin over ¹⁸F-FDG in Diagnosis and Therapeutic Efficacy Monitoring of Idiopathic Pulmonary Fibrosis: A Translational Study from Bench to Bedside
J. Li, H. Wu, Y. He;
Zhongnan Hospital of Wuhan Universiry, Wuhan, CHINA.

OP-694
Neuropilin-1-Targeted PET Imaging for early detection of pulmonary fibrosis activity: comparison with the ¹⁸F-FDG and ⁶⁸Ga-FAPI-04 PET approach
F. Qiu, J. Li, S. Song;
Fudan University Shanghai Cancer Center, Shanghai, CHINA.

OP-695
Development and Validation of ¹⁸F-Labeled Pirfenidone Analogs as Potential p38-Targeted Ligands for Pulmonary Fibrosis Imaging
X. Wang, J. Wang, M. Niu, F. Kang, J. Wang;
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

OP-696
Development of Novel Radiotracer for Accurate Assessing Functional Liver Reserve via PET Imaging
*L. Feng*¹, Y. Xu², H. Yang¹, X. Lan¹, D. Jiang¹;
¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science, Wuhan, CHINA, ²Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science, Wuhan, CHINA.

OP-697
Tracking monocyte kinetics in healthy volunteers and patients with inflammatory arthritis
*N. Farahi*¹, A. Y. K. C. Ng¹, J. Hutton¹, D. Gillett², F. Sunzini³, R. Hohne³, A. Ade-Ojo², V. Lotz⁴, A. Tate³, M. Arnott³, N. Basu³, J. Brock³, A. McGucken³, N. G. Shenker⁵, E. R. Chilvers⁶, J. Cavanagh³, C. Summers¹;
¹University of Cambridge, Cambridge, UNITED KINGDOM, ²Cambridge University Hospitals NHS Foundation Trust, Cambridge, UNITED KINGDOM, ³University of Glasgow, Glasgow, UNITED KINGDOM, ⁴Royal Papworth Hospital NHS Foundation Trust, Cambridge, UNITED KINGDOM, ⁵Cambridge University Hospitals NHS Foundation Trust and Department of Medicine, University of Cambridge, Cambridge, UNITED KINGDOM, ⁶Imperial College, London, UNITED KINGDOM.

OP-699
The Preclinical Study of [¹⁸F]AV45 and [¹⁸F]DPA714 PET as Potential Imaging Biomarkers for Hashimoto's Thyroiditis-Associated Cognitive Impairment
Y. Zhang, G. Zhu;
First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, CHINA.

OP-700
Dual-Radiolabeling Strategy for In Vivo Tracking of Mycoplasma pneumoniae and Pulmonary Surfactant Biodistribution Using microSPECT/CT Imaging
*F. Hendy Pérez-Aranda*¹, A. Fernández-Gonzalez¹, I. Rodríguez-Arce², O. Cañadas^{3,4}, M. Collantes^{5,6,7}, G. Gómez-Montesino^{3,4}, F. Pareja^{1,6}, G. Quincoces^{1,6}, R. Ramos-Membrive⁸, L. Serrano^{2,9,10}, J. Pérez-Gil^{3,4}, I. Peñuelas^{1,6,7};
¹Radiopharmacy Unit. Nuclear Medicine Department. Clínica Universidad de Navarra, Pamplona, SPAIN, ²Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, SPAIN, ³Department of Biochemistry and Molecular Biology, Faculty of Biological Sciences, Complutense University, Madrid, SPAIN, ⁴Research Institute “Hospital Doce de Octubre (imas12)”, Madrid, SPAIN, ⁵Nuclear Medicine Department. Clínica Universidad de Navarra, Pamplona, SPAIN, ⁶Navarra Institute for Health Research (IdISNA), Pamplona, SPAIN, ⁷Translational Molecular Imaging Unit (UNIMTRA). Nuclear Medicine Department. Clínica Universidad de Navarra, Pamplona, SPAIN, ⁸Radiopharmacy Unit. Nuclear Medicine Department. Clínica Universidad de Navarra, Madrid, SPAIN, Madrid, SPAIN, ⁹Universitat Pompeu Fabra (UPF), Barcelona, SPAIN, ¹⁰ICREA, Barcelona, SPAIN.

1605
Tuesday, October 7, 2025, 16:45 - 18:15
Room 211

Cutting Edge Science Track - TROP Session - Radiation Protection Committee: Radiation Exposure and Protection

OP-701
Dosimetry of Radiation Exposure to Patients, Caregivers, and Medical Staff Following Lu-177 PSMA Therapy
*M. Chiang*¹, P. Chuang², C. Lu³;
¹Taipei Medical University Hospital, Taipei, TAIWAN, ²National Taiwan University Hospital Cancer Center, Taipei, TAIWAN, ³National Taiwan University Hospital, Taipei, TAIWAN.

OP-702
Extremity exposure due to handling of ¹⁷⁷Lu - results of a multi-center pilot study
*E. Aalbersberg*¹, A. McCann², N. Cherbuin³, J. Dabin⁴, S. Haruz-Waschitz⁵, H. Datz⁶, R. Wierst⁷, A. Zorz⁸, T. Kráčmerová⁹, L. Albinia¹⁰, M. Hakulinen¹¹, M. Ferrari¹², R. Kollaard¹³;
¹Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ²St. Vincent's University Hospital, Dublin, IRELAND, ³Lausanne University Hospital, Lausanne, SWITZERLAND, ⁴Belgian Nuclear Research Center, Mol, BELGIUM, ⁵Shamir Medical Center, Be'er Ya'akov, ISRAEL, ⁶Soreq Nuclear Research Center, Yavne, ISRAEL, ⁷Maastricht University Medical Center, Maastricht, NETHERLANDS, ⁸Veneto Institute of Oncology IOV – IRCCS, Padua, ITALY, ⁹Motol University Hospital, Prague, CZECH REPUBLIC, ¹⁰University of Lodz, Lodz, POLAND, ¹¹Kuopio University Hospital, Kuopio, FINLAND, ¹²Istituto Europeo di Oncologia, Milan, ITALY, ¹³NRG PALLAS, Arnhem, NETHERLANDS.

OP-703
Radiation Safety with ²¹²Pb-Based Therapeutics from Clinical Experience with ²¹²Pb-ADVC001 (TheraPb): Dose to Staff and Members of the Public
*E. O'Mahoney*¹, M. Griffiths², S. Ngai¹, D. Pattison², A. Hansen¹, D. Wyld², I. Holmes¹, L. Katchel¹, S. Baker¹, H. Biggs¹, L. Campbell², M. Baronet³, M. Crumbaker³, P. Santoro³, S. Rose³, A. Karmann³;
¹Princess Alexandra Hospital, Brisbane, AUSTRALIA, ²Royal Brisbane and Women's Hospital, Brisbane, AUSTRALIA, ³AdvanCell Pty Ltd, Sydney, AUSTRALIA.

OP-704
Addressing Radiation Safety Concerns for Alpha-Emitter Astatine-211
*S. Palm*¹, E. Leidermark¹, H. Jensen², T. Bäck¹;
¹University of Gothenburg, Gothenburg, SWEDEN, ²Copenhagen University Hospital, Copenhagen, DENMARK.

OP-705
Evaluation of Custom Shielding Made From Epoxy Resin to Reduce Doses to the Hand When Dispensing ⁹⁰Y Resin Microspheres
A. Smout, E. Bolt, M. Pryor, J. Scuffham;
Royal Surrey County Hospital, Guildford, UNITED KINGDOM.

OP-706
Preliminary Assessment of ⁸⁹Zr-Girentuximab Excretion and Radiation Protection in ccRCC patients undergoing PET/CT imaging
*A. Piai*¹, G. Colelli^{2,1}, A. Loria¹, D. Tosoni^{2,1}, B. Bordigoni^{3,1}, L. Antunovic¹, F. Gelardi^{4,1}, A. Chiti^{4,1}, A. del Vecchio¹;
¹IRCCS Ospedale San Raffaele, Milan, ITALY, ²University of Milan, Milan, ITALY, ³University of Padua, Milan, ITALY, ⁴Vita-Salute University, Milan, ITALY.

OP-707
The UK perspective on establishing adult national diagnostic reference levels for nuclear medicine and PET
L. Fraser, A. Powell, N. Parkar, M. Richardson;
UK Health Security Agency, Didcot, UNITED KINGDOM.

OP-708
Building a European Network for Quality and Safety of Medical Ionizing Radiation Applications: Outcomes from the PRISMA SAMIRA EU4Health Project
*S. Annunziata*¹, E. Solfaroli², J. Liukkonen³, T. Jørgensen⁴, C. Munoz⁵, L. Boudewijns⁶, T. Larose⁷, I. Kralik⁸, A. Sundlov⁹, M. Do Carmo Lopes¹⁰, K. Breddam¹¹, S. Geza¹², C. Franciosi¹, A. Capotosti¹, C. Rosenbaum⁶, A. Rosi², on behalf of the SAMIRA-PRISMA EU4Health Consortium;
¹Gemelli, Rome, ITALY, ²ISS, Rome, ITALY, ³STUK, Helsinki, FINLAND, ⁴DSA, Oslo, NORWAY, ⁵ICO, Barcelona, SPAIN, ⁶RIVM, Bilthoven, NETHERLANDS, ⁷Helsedirektoratet, Oslo, NORWAY, ⁸Children Hospital, Zagreb, CROATIA, ⁹Swedish Medical Products Agency, Goteborg, SWEDEN, ¹⁰IPO, Coimbra, PORTUGAL, ¹¹DHA, Copenhagen, DENMARK, ¹²NNGYK, Budapest, HUNGARY.

1606

Tuesday, October 7, 2025, 16:45 - 18:15
Room 117

Clinical Oncology Track - TROP Session -
Oncology & Theranostics Committee: Imaging
Prostate Cancer: Prediction and Outcome

OP-709

Additive Value of [⁶⁸Ga]Ga-RM26 PET/CT to [⁶⁸Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study

Y. Tang¹, Y. Li¹, L. Xiao¹, J. Yang¹, M. Zhou¹, K. Shi², S. Hu¹;
¹Xiangya Hospital Central South University, Changsha, CHINA, ²Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, BERN, SWITZERLAND.

OP-710

Association of Genomic Classifier Scores with PSMA PET/CT in Patients with High-Risk Prostate Cancer: First-Year Results from the Phase 2/3 THUNDER trial (NCT06282588)

F. Kleiburg^{1,2,3}, P. Dirix³, V. Fonteyne⁴, S. Bral⁵, B. De Troyer⁶, B. Sautois⁷, M. Lamande⁷, N. Liefhooghe⁸, G. Grisay⁹, S. Meersschout¹⁰, A. Vandermeulen¹¹, N. Jullian¹², L. Staelens¹³, M. Johnson¹⁴, E. Kelly¹⁴, F. Poelaert¹⁵, M. Strijbos¹⁵, J. Verschueren¹⁵, K. Goffin¹⁶, N. Withofs⁷, P. Ost³;
¹Leiden University Medical Centre, Leiden, NETHERLANDS, ²University of Twente, Enschede, NETHERLANDS, ³Iridium Network, Antwerp, BELGIUM, ⁴Ghent University Hospital, Ghent, BELGIUM, ⁵AZORG, Aalst, BELGIUM, ⁶VITAZ, Sint-Niklaas, BELGIUM, ⁷Centre Hospitalier Universitaire de Liège, Liège, BELGIUM, ⁸AZ Groeninge, Kortrijk, BELGIUM, ⁹Centres Hospitaliers Universitaires HELORA, La Louvière, BELGIUM, ¹⁰AZ Sint-Jan, Bruges, BELGIUM, ¹¹Cliniques Universitaires Saint-Luc, Brussels, BELGIUM, ¹²Institut Jules Bordet, Brussels, BELGIUM, ¹³AZ Delta, Roeselare, BELGIUM, ¹⁴Veracyte Inc, San Diego, CA, UNITED STATES OF AMERICA, ¹⁵ZAS, Antwerp, BELGIUM, ¹⁶UZ Leuven, Leuven, BELGIUM.

OP-711

Initial Staging 68Ga-PSMA PET/CT Predicts Overall Survival in Unfavorable Intermediate and High-Risk Prostate Cancer: An IAEA Multicenter Study

J. Cerci¹, S. Fanti², E. EstradaLobato³, J. Kunikowska⁴, O. Garcia⁵, F. Novruzov⁶, R. Kumar⁷, A. Al-Ibraheem⁸, M. Haidar⁹, M. Nasir¹⁰, O. Kucuk¹¹, U. Elboga¹², F. Redondo Moneda¹³;
¹Quanta - Diagnóstico e Terapia, Curitiba, BRAZIL, ²IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Division of Human Health, International Atomic Energy Agency, Vienna, AUSTRIA, ⁴Nuclear Medicine Department, Medical University of Warsaw, Warsaw, POLAND, ⁵Instituto Nacional de Cancerologia, Tlalpan, MEXICO, ⁶Nuclear Medicine Department, National Centre of Oncology, Baku, AZERBAIJAN, ⁷All India Institute of Medical Sciences, New Delhi, INDIA, ⁸King Hussein Cancer Center, Amman, JORDAN, ⁹American University of Beirut Medical Center, Beirut, LEBANON, ¹⁰Institute Kanser Negara, Putrajaya, MALAYSIA, ¹¹Ankara University, Ankara, TÜRKIYE, ¹²University of Gaziantep, Gaziantep, TÜRKIYE, ¹³Complejo Asistencial Sotero del Río, Santiago Clínica Andes Salud, Puerto Montt, CHILE.

OP-712

The additivevalue of ⁶⁸Ga-RM26 to ⁶⁸Ga-PSMA-617PET/CT in the early prediction of biochemical failure in prostate cancer: results from a prospective, single-arm, phase IImultimodal imaging trial

J. Yang, Y. Tang, Y. Li, L. Xiao, S. Hu;
Xiangya hospital, Changsha, CHINA.

OP-713

Prognostic value of basline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease

F. Kleiburg^{1,2}, L. Heijmen¹, A. Witteveen², K. van Duuren¹, P. Zuidgeest¹, F. Smit³, L. de Geus-Oei^{1,2,4}, T. van der Hulle¹;
¹Leiden University Medical Centre, Leiden, NETHERLANDS, ²University of Twente, Enschede, NETHERLANDS, ³Alrijne Hospital, Leiderdorp, NETHERLANDS, ⁴Delft University of Technology, Delft, NETHERLANDS.

OP-714

Preoperative Imaging Biomarkers of Aggressive Prostate Cancer: Assessing the role of PSMA PET/CT and mpMRI with Whole-Mount Histopathology Gold Standard

I. Sonni, D. Hyeong Seok Kim, A. Ter-Pogosyan, S. Satonkiatngam, K. Kimura, T. Grogan, N. Barroso, P. Ahuja, J. Calais, J. Czernin, R. Reiter, A. Sisk, S. S. Raman;
University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA.

OP-715

Optimization of the PRIMARY Score in Ga-68 PSMA PET/CT: A New Approach to Active Surveillance Decision

D. Sahin, H. Uslu, S. Güngör, S. Yaşar Belek, Ö. Doğan Yıldız, B. Canitez, H. Kösem;
İstanbul Medeniyet University Göztepe Prof. Dr. Süleyman Yalçın City Hospital, İstanbul, TÜRKIYE.

OP-716

The Diagnostic Utility of PSMA PET with Real-Time PSMA-PET Fusion - Target Biopsy in MRI-Negative or Equivocal Prostate Cancer: Results from the FUPERMAN Study

C. Sgro¹, L. Bianchi², P. Castellucci³, R. Mei³, E. Greco¹, M. Presutti², F. Rome², M. Droghetti², R. Schiavina², E. Brunocilla², C. Gaudiano⁴, B. Corcioni⁴, S. Fanti^{3,1}, A. Farolfi³;
¹Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Division of Urology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Department of Radiology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-717

[⁶⁸Ga]Ga-PSMA-617 PET/CT and [⁶⁸Ga]Ga-NT PET/CT for Prostate Cancer Imaging: A Comparative Study and First Attempt of a Molecular Imaging Probe Targeting NTSR1 in Humans

Y. Tang¹, Y. Li¹, L. Xiao¹, J. Yang¹, K. Shi², S. Hu¹;
¹Xiangya Hospital Central South University, Changsha, CHINA, ²Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

1607

Tuesday, October 7, 2025, 16:45 - 18:15
Room 212

TROP Session - Neuroimaging Committee:
Neurology: Psychiatry, Epilepsy, Inflammation
and Others

OP-718

Short antidepressant response and brain amyloid load in non-demented older adults with depression - The first part of ASAP Study

M. Santiago-Ribeiro¹, T. Desmidt¹, J. Vercouillie², F. Lejeune³, N. Arlicot¹, V. Gissot¹, A. Dupont¹, W. El-Hage¹, A. Caille¹, V. Camus¹, ASAP group;
¹CHRU, Tours, FRANCE, ²Université de Tours, Tours, FRANCE, ³CHU, Rennes, FRANCE.

OP-719

Altered AMPA receptors density associated with ketamine response in treatment-resistant depression: PET study using [¹¹C]K-2.

W. Nakajima¹, M. Hatano¹, Y. Ohtani², H. Tani², S. Tsuchimoto³, Y. Fujimoto¹, T. Eiro¹, S. Ichijo¹, K. Nakano¹, T. Arisawa⁴, Y. Takada¹, K. Kimura¹, H. Abe¹, T. Miyazaki^{1,5}, A. Sano¹, K. Nomoto-Takahashi², T. Yatomi^{1,2}, K. Yonezawa², S. Tomiyama², N. Naga^{2,6}, K. Kusudo², S. Honda², S. Moriyama², S. Nakajima², Y. Kimura⁷, H. Uchida², T. Takahashi^{1,8};
¹Department of Physiology, Yokohama City University School of medicine, Yokohama, JAPAN, ²Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, JAPAN, ³Division of Neural Dynamics, Department of System Neuroscience, National Institute for Physiological Sciences, Okazaki, JAPAN, ⁴Radioisotope Research Center, Yokohama City University Graduate School of Medicine, Yokohama, JAPAN, ⁵Center for Promotion of Research and Industry-Academic Collaboration, Yokohama, JAPAN, ⁶Department of Psychiatry, Minami-Hanno Hospital, Tokyo, JAPAN, ⁷Faculty of Informatics, Cyber Informatics Research Institute, Kindai University, Higashi-Osaka, JAPAN, ⁸The International Research Center for Neurointelligence, Institutes for Advanced Study, University of Tokyo, Tokyo, JAPAN.

OP-720

Seasonal DAT availability in Major Depressive Disorder: a ¹²³I-FP-CIT study.

D. Pizzuto¹, A. M. D'Onofrio², S. Annunziata¹, F. Cavallo³, F. Cocciolillo³, G. Sani², G. Camardese², D. Di Giuda³;
¹Nuclear Medicine Unit, GSTeP Radiopharmacy, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY, ²Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, Rome, ITALY, ³Nuclear Medicine Unit, Department of Radiology and Radiotherapy, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY.

OP-721

Striatal network desynchronization in schizophrenia: initial insights from FDOPA-PET imaging

Y. Mayr^{1,2}, J. Schulz³, M. Thalhammer³, M. Veronese^{4,5}, C. Sorg³, F. Brandl⁶, I. Yakushev^{1,2};
¹Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY, ²Graduate School of Systemic Neurosciences GSN-LMU, Munich, GERMANY, ³Institute for Neuroradiology, Technical University of

Munich, Munich, GERMANY, ⁴Department of Information Engineering, Padova University, Padova, ITALY, ⁵Department of Neuroimaging, King's College London, London, UNITED KINGDOM, ⁶Department of Psychiatry, Technical University of Munich, Munich, GERMANY.

OP-722

Post Covid-19 cerebral perfusion in patients complaining of recent memory loss: a dual-timepoint study

S. Lopes de Souza¹, L. C. Melo², H. F. Carvalho³, K. Ruzzon², A. O. Blackman⁴, B. M. Oliveira⁵, S. K. A. Lima¹, A. C. J. Sousa⁶;
¹Universidade Federal do Rio de Janeiro / School of Medicine / Radiology Department, Rio de Janeiro, BRAZIL, ²IRB Medicina Nuclear, Brasília, BRAZIL, ³Universidade Católica de Brasília, Brasília, BRAZIL, ⁴Centro Universitário de Brasília, Brasília, BRAZIL, ⁵Centro Universitário do Planalto Central Aparecido dos Santos, Brasília, BRAZIL, ⁶Clinica da Memoria Brasilia, Brasilia, BRAZIL.

OP-723

Neurodegenerative Protein Load Correlates with Cognitive Decline in Temporal Lobe Epilepsy: A Multimodal PET Imaging Study

Y. Tang¹, L. Xiao¹, M. Zhou¹, J. Yang¹, K. Shi², S. Hu¹;
¹Xiangya Hospital Central South University, Changsha, CHINA, ²Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, SWITZERLAND.

OP-724

The correlation between the efficacy of levetiracetam in the treatment of temporal lobe epilepsy and PET metabolic brain networks

H. Zhang, J. Liu;
The second hospital&clinical medical school. Lanzhou University, Lanzhou, CHINA.

OP-725

Functional correlates of cognitive impairment and mood alterations in Multiple Sclerosis: an early perfusion PET study

L. Sofia¹, M. Donegani², S. Raffa², A. Donniaquio³, L. Argenti³, L. Roccatagliata¹, A. Chincarini⁴, G. Novi², A. Laroni³, G. Sambuceti¹, M. Bauckneht¹, A. Uccelli³, M. Inglese³, M. Pardini³, S. Morbelli²;
¹Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY, ²IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ³Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINO-GMI), University of Genoa, Genoa, ITALY, ⁴National Institute of Nuclear Physics (INFN), Genoa, ITALY, ⁵Department of Medical Sciences, University of Turin, Turin, ITALY.

OP-726

O-15-water PET in cochlear-implant users reveals different strategies for speech processing in the central nervous system depending on background noise and speech comprehension

M. Voskamp^{1,2}, S. Hansen^{3,4}, D. Merz¹, F. Bengel¹, T. Lenarz^{2,5}, A. Büchner^{2,5}, T. Ross¹, P. Sandmann^{3,4,6}, G. Berding^{1,2};
¹Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY, ²Cluster of Excellence "Hearing4all", Hannover, GERMANY, ³Department of Otorhinolaryngology at Evangelisches Krankenhaus Oldenburg, Oldenburg, GERMANY, ⁴Cluster of Excellence "Hearing4all", Oldenburg, GERMANY, ⁵Department of Otorhinolaryngology, Hannover Medical School, Hannover, GERMANY, ⁶Research Center Neurosensory Science, University of Oldenburg, Oldenburg, GERMANY.

1608

Tuesday, October 7, 2025, 16:45 - 18:15
 Room 115

TROP Session - Cardiovascular Committee:
 Metabolism,Fibrosis and Innervation: The Basis
 of Cardiomyopathies

OP-727

First-in-human study of a novel cardiac sympathetic
 neuronal PET imaging agent: [¹⁸F]FPMBBG

M. Ju, W. Ren, L. Wang, W. Fang;
 Fuwai Hospital, Public Union Medical College, Beijing,
 CHINA.

OP-728

Ga-68 labelled Affibody molecule based
 radiopharmaceutical targeting platelet derived
 growth factor receptor beta detects active fibrosis
 in patients with myocardial infarction.

I. Velikyan^{1,2}, K. Grinnemo², V. Flodin², S. James³, U.
 Thelander², O. Korsgren⁴, O. Eriksson^{1,5};
¹Science for Life Laboratory, Department of Medicinal
 Chemistry, Uppsala University, Uppsala, SWEDEN,
²Department of Surgical Sciences, Uppsala University,
 Uppsala, SWEDEN, ³Department of Medical Sciences,
 Uppsala University, Uppsala, SWEDEN, ⁴Department of
 Immunology, Genetics and Pathology, Uppsala University,
 Uppsala, SWEDEN, ⁵Antaros Tracer AB, Uppsala, SWEDEN.

OP-729

Differential prediction of heart failure death and
 arrhythmic events using a practical multivariable
 model with ¹²³I-MIBG Imaging

K. Nakajima¹, T. Doi², T. Nakata³, T. Nakahashi⁴, H. Tada¹, H.
 Wakabayashi¹, H. J. Verberne⁵;
¹Kanazawa University, Kanazawa, JAPAN, ²Teine Keijinkai
 Hospital, Sapporo, JAPAN, ³Hokodate-Goryoukaku
 Hospital, Hakodate, JAPAN, ⁴Takaoka Municipal Hospital,
 Takaoka, JAPAN, ⁵University of Amsterdam, Amsterdam,
 NETHERLANDS.

OP-730

Systemic Metabolic Coordination Index (SMCI): A
 Graph-Based Biomarker of Whole-Body Metabolic
 Integrity from FDG PET

X. Li¹, Z. Shi², M. Hacker¹, X. Zhang², X. Li¹, S. Xue¹;
¹Division of Nuclear Medicine, Department of Biomedical
 Imaging and Image-guided Therapy, Vienna General
 Hospital, Medical University of Vienna, Vienna, AUSTRIA,
²Department of Nuclear Medicine, Molecular Imaging Lab,
 Beijing Anzhen Hospital, Capital Medical University, Beijing,
 CHINA.

OP-731

Mapping Immune-Metabolic Dysregulation in HFrEF
 Using Whole-Body PET and Inter-Organ Network
 Analysis

X. Li¹, Z. Shi², M. Hacker¹, X. Zhang², S. Xue¹, X. Li¹;
¹Division of Nuclear Medicine, Department of Biomedical
 Imaging and Image-guided Therapy, Vienna General
 Hospital, Medical University of Vienna, Vienna, AUSTRIA,
²Department of Nuclear Medicine, Molecular Imaging Lab,
 Beijing Anzhen Hospital, Capital Medical University, Beijing,
 CHINA.

OP-732

Characteristics of myocardial imaging at ¹⁸F-FAPI-74
 PET/CT and potential value in predicting left
 ventricular reverse remodeling in non-ischemic
 dilated cardiomyopathy

W. Liu^{1,2,3}, L. Li^{1,2,3}, Q. Wu^{1,3}, J. Song⁴, S. Li^{1,2,3};
¹Department of Nuclear Medicine, First Hospital of Shanxi
 Medical University, Shanxi Medical University, Taiyuan,
 Shanxi, CHINA, ²Shanxi Key Laboratory of Molecular
 Imaging, Shanxi Medical University, Taiyuan, Shanxi,
 CHINA, ³Collaborative Innovation Center for Molecular
 Imaging of Precision Medicine Shanxi Medical University,
 Taiyuan, Shanxi, CHINA, ⁴Academy of Medical Sciences,
 Shanxi Medical University, Taiyuan, Shanxi, CHINA.

OP-733

Evaluation of Myocardial Fibrosis and Wall Motion
 Abnormality with ⁶⁸Ga-FAPI PET/MR in Coronary
 Heart Disease

R. Luo¹, Z. Zhao¹, C. Zhang¹, R. Li¹, Q. Meng¹, Y. Ni¹, R. Yang¹,
 X. Chen¹, L. Xie², M. Zhang², F. Wang¹;
¹Nanjing First Hospital, Nanjing Medical University, Nanjing,
 CHINA, ²3.Department of Advanced Nuclear Medicine
 Sciences, Institute for Quantum Medical Science, National
 Institutes for Quantum Science and Technology, Chiba,
 JAPAN.

OP-734

[⁶⁸Ga]FAPI: A New Game-Changer in Cardiac
 Inflammation? Early Findings from a Prospective
 Study of [⁶⁸Ga]FAPI PET/CT Diagnostic Performance
 Compared to [¹⁸F]FDG PET/CT in Suspected Cardiac
 Sarcoidosis

A. Safarian^{1,2}, H. Malek¹, M. Beheshti², S. Almasi³, M.
 Chehrara¹, N. Yaghoobi¹;
¹Department of Nuclear Medicine, Rajaie Cardiovascular
 Medical and Research Center, Rajaie Cardiovascular
 Institute, Iran University of Medical Sciences, Tehran, IRAN,
 ISLAMIC REPUBLIC OF, ²Division of Molecular Imaging and
 Theranostics, Department of Nuclear Medicine, University
 Hospital, Paracelsus Medical University, Salzburg, AUSTRIA,
³Department of Rheumatology, Firoozgar Hospital, Iran
 University of Medical Sciences, Tehran, IRAN, ISLAMIC
 REPUBLIC OF.

OP-735

Downregulation of myocardial expression of
 glucagon-like peptide-1 receptor with aging and
 obesity showing on⁶⁸Ga-exendin-4 PET/CT

H. Zhang¹, Q. Pan², S. Liu¹, J. Feng¹, Y. Luo¹;
¹Department of Nuclear Medicine, Chinese Academy
 of Medical Sciences and Peking Union Medical College
 Hospital; State Key Laboratory of Common Mechanism
 Research for Major Diseases, Beijing, CHINA, ²Department
 of Nuclear Medicine, Chinese Academy of Medical Sciences
 and Peking Union Medical College Hospital, Beijing, CHINA.

1609

Tuesday, October 7, 2025, 16:45 - 18:15
 Room 133+134

e-Poster Presentations Session 12 - Thyroid
 Committee: Diagnostic and Therapeutic
 Approach in Patients with Endocrinological
 Disorders

EPS-242

Prognostic Value of Al¹⁸F-NOTA-Pentixafor PET/CT
 for Surgical Outcomes in Primary Aldosteronism: A
 Prospective Study

X. Yan¹, G. Zheng², M. Liu¹, Y. Zhang¹, Y. Xie¹, L. Huo¹;
¹Department of Nuclear Medicine, Peking Union Medical
 College Hospital, Chinese Academy of Medical Sciences,
 Beijing, CHINA, ²Department of Urology, Peking Union
 Medical College Hospital, Chinese Academy of Medical
 Sciences, Beijing, CHINA.

EPS-243

The value of ⁶⁸Ga-Pentixafor PET/MR-based
 Radiomics in Differentiating Functional
 Adrenocortical Adenomas

X. Chen¹, R. Zhang¹, J. Song¹, C. Liu¹, Q. Ji², Y. Hu³, J. Zhao¹,
 Y. Xing¹;
¹Department of Nuclear Medicine, Shanghai General
 Hospital, Shanghai Jiao Tong University School of Medicine,
 Shanghai, CHINA, ²United Imaging Healthcare Advanced
 Technology Research Institute Co., Ltd., Shanghai, CHINA,
³United Imaging Healthcare, Shanghai, CHINA.

EPS-245

The Role of [¹¹C]metomidate PET in Predicting
 Post-treatment Outcomes in Patients with Primary
 Aldosteronism: A Meta-Analysis

P. Chuang¹, J. S. Chueh², J. Huang², T. Hong¹, V. Wu², Y. Lin²,
 P. Kuo³, C. Lu¹;
¹National Taiwan University Cancer Center, Taipei, TAIWAN,
²National Taiwan University Hospital, Taipei, TAIWAN,
³National Taiwan University, Taipei, TAIWAN.

EPS-246

Efficacy, Tolerability, and Resensitizing Effects of
 Dabrafenib-Trametinib in Advanced Thyroid Cancer:
 A Retrospective Monocentric Real-World Study

C. Fersing¹, E. Noudeau¹, J. Toucheboeuf¹, M. Vinches³, F.
 Leenhardt⁴;
¹Montpellier Cancer Institute, Nuclear Medicine unit,
 Montpellier, FRANCE, ²Montpellier Cancer Research Institute
 (IRCM), INSERM U1194, Montpellier, FRANCE, ³Montpellier
 Cancer Institute, Medical Oncology department,
 Montpellier, FRANCE, ⁴Montpellier Cancer Institute,
 Pharmacy unit, Montpellier, FRANCE.

EPS-247

Indeterminate Thyroid Nodules: Can [18F]F-FDG
 PET/CT and Radiomic Influence Patients’ Treatment
 Strategies?

G. Cuzzani¹, E. Fortunati², M. Santoro³, E. Greco¹, E.
 Tabacchi², L. Calderoni², L. Zannoni⁴, C. Malizia², F. Serani⁵,
 C. M. P. Sgro¹, G. Bianciardi¹, G. A. Fuso¹, L. Carrara¹, S.
 Damiani⁶, L. Strigari³, S. Fanti^{1,2};
¹Nuclear medicine, Alma Mater Studiorum University
 of Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS
 Azienda Ospedaliero-Universitaria di Bologna, Bologna,
 ITALY, ³Department of Medical Physics, IRCCS Azienda
 Ospedaliero-Universitaria di Bologna, Bologna, ITALY,
⁴Nuclear Medicine, AST Pesaro-Urbino, ITALY, ⁵Nuclear
 Medicine Unit, Department of Medicine, DIMED, University-
 Hospital of Padova, ITALY, ⁶Pathology Unit, IRCCS Azienda
 Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EPS-248

Exploration of Lu-177-DOTATATE PRRT for treatment
 of radioiodine-refractory follicular thyroid
 carcinoma

L. Widjaja¹, S. C. Kunte¹, V. U. Wenter¹, A. Holzgreve¹, G. T.
 Sheikh¹, F. J. Gildehaus¹, S. Lindner¹, R. Schirmmacher², C.

Spitzweg³, C. J. Auernhammer³, R. A. Werner¹, M. J. Zacherl¹;
¹Department of Nuclear Medicine, LMU University Hospital,
 Munich, GERMANY, ²Department of Oncology, Division
 of Oncological Imaging, University of Alberta, Edmonton,
 AB, CANADA, ³Department of Internal Medicine IV, LMU
 University Hospital, Munich, GERMANY.

EPS-249

Multicenter study of Spanish metabolic therapy
 units. Usefulness of protective therapy during
 hospital admission in preventing late side effects of
 131I in thyroid carcinoma patients

J. Villa-Palacios¹, M. Negre², A. Piñeiro-Donis¹, L. Cagua
 Ruiz¹, E. Domínguez-Polanco¹, L. Menendez-Muros³, T.
 Aroui-Luquin¹, M. Muros de Fuentes¹;
¹Hospital Universitario Virgen de las Nieves, Granada, SPAIN,
²Hospital Universitario de Girona Doctor Josep Trueta,
 Girona, SPAIN, ³Hospital Universitario Clínico San Cecilio,
 Granada, SPAIN.

EPS-250

Analysis of Clinical and Imaging Factors Predicting
 Treatment Outcomes of Radioiodine Therapy for
 Pulmonary Metastasis in Thyroid Carcinoma

L. Hashimoto^{1,2}, S. Watanabe^{1,3}, K. Hirata^{1,3}, J. Takenaka^{1,3,4},
 R. Kimura^{3,5}, N. Wakabayashi^{1,5}, H. Koga^{1,3}, K. Kudo^{3,5};
¹Department of Nuclear Medicine, Hokkaido University
 Hospital, Sapporo, JAPAN, ²Department of Diagnostic
 Radiology, Sapporo City General Hospital, Sapporo,
 JAPAN, ³Department of Diagnostic Imaging, Graduate
 School of Medicine, Hokkaido University, Sapporo,
 JAPAN, ⁴Comprehensive Heart Failure Center, University
 Clinic Würzburg, Würzburg, GERMANY, ⁵Department
 of Diagnostic and Interventional Radiology, Hokkaido
 University Hospital, Sapporo, JAPAN.

EPS-251

Redifferentiation and Radioiodine Therapy of
 Thyroid Cancer After the Use of Signaling Pathway
 Inhibitors: A Systematic Review and Meta-Analysis

F. Mourato^{1,2}, D. O. S. Ramos³, S. Brandão^{4,5}, M. Mariuss⁶, M.
 C. Fagundes⁷, G. B. Torri⁸, S. Altmayer⁹, L. G. Schmitt¹⁰;
¹Hospital das Clínicas da UFPE - EBSERH, Recife, BRAZIL,
²Universidade de Pernambuco (UPE), Recife, BRAZIL,
³Hospital das Clínicas da Faculdade de Medicina da
 Universidade de São Paulo (HCFMUSP), São Paulo, BRAZIL,
⁴Hospital das Clínicas da UFPE, Recife, BRAZIL, ⁵Havard
 Medical School, Boston, MA, UNITED STATES OF AMERICA,
⁶Hospital Israelita Albert Einstein - Interventional Radiology
 Department, São Paulo, BRAZIL, ⁷Hospital Alemão Oswaldo
 Cruz - Imaging Diagnostic Center, São Paulo, BRAZIL,
⁸Hospital Universitário de Santa Maria, Santa Maria,
 BRAZIL, ⁹Stanford University School of Medicine, Stanford,
 CA, UNITED STATES OF AMERICA, ¹⁰University of Texas
 Southwestern Medical Center, Dallas, TX, UNITED STATES OF
 AMERICA.

EPS-253

The Clinical Impact of 131I-iodine Whole Body
 Scintigraphy Following 131I-iodine Therapy of
 Thyroid Cancer

J. Kjems¹, M. Hofmann¹, B. Zerahn¹, B. Kristensen¹, C.
 Maare², L. Jensen¹;
¹Department of Nuclear Medicine, Herlev Hospital, Herlev,
 DENMARK, ²Department of Oncology, Herlev Hospital,
 Herlev, DENMARK.

EPS-254

The role of Tc99m-Sestamibi scintigraphy in the diagnostic algorithm of thyroid nodules classified as Bethesda III/IV

K. Papadopoulou, N. Papadopoulos, A. Kriari, E. Giannoula, P. Exadaktylou, E. Papanastasiou, A. Tsangaridi, P. Charalambous, G. Giakoumettis, E. Gkatzouli, A. Doumas, I. Iakovou;
2nd Laboratory of Nuclear Medicine, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, GREECE.

EPS-255

Estimation of Effective Half-Life and Evaluation of Treatment Response in ¹³¹I Therapy for Thyroid Cancer

Y. Iizuka¹, R. Nakashima¹, R. Aizawa¹, M. Kajisako², M. Shioji², K. Mitsumoto², K. Itagaki², S. Kawase², T. Mizowaki¹;
¹Kyoto University Graduate School of Medicine, Kyoto, JAPAN, ²Kyoto University Hospital, Kyoto, JAPAN.

EPS-256

Evaluation of the Efficacy of Lu-177 DOTATATE Therapy in Radioactive Iodine-Refractory Thyroid Cancer

A. Kibar¹, K. Saglam¹, A. Nazari², O. E. Sahin¹, S. Asa¹, L. Uslu-Besli¹, S. Sager¹, K. Sonmezoglu¹, H. B. Sayman¹;
¹Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²Tekirdag City Hospital, Department of Nuclear Medicine, Tekirdag, TÜRKIYE.

EPS-257

The efficacy of radioiodine therapy in patients with non-toxic multinodular goiter with large cold nodule

S. Abdelrazek, I. Sulima, P. Szumowski, J. Mysliwiec;
Medical University of Białystok, Białystok, POLAND.

EPS-258

Utility of somatostatin receptor imaging in differentiated thyroid cancer with elevated thyroglobulin and negative 131I whole body scan

L. Barberan Corral¹, A. Calatayud Cubes¹, M. Proaño Fierro², M. Rashki¹, J. Nogueiras Alonso³, V. Pubul Nuñez¹;
¹Hospital Clínico Universitario de Santiago, Santiago de Compostela, SPAIN, ²Complejo Hospitalario Universitario de Pontevedra, Pontevedra, SPAIN, ³Hospital Meixoeiro, Vigo, SPAIN.

EPS-259

The Clinical Application of ⁶⁸Ga-FAPI PET/MR in Thyroid Eye Disease

Y. Zhou^{1,2,3}, Y. Hou^{1,2,3}, X. Xia^{1,2,3};
¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²Hubei Province Key Laboratory of Molecular Imaging, Wuhan, CHINA, ³Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, CHINA.

EPS-260

Impact of Perinodal Infiltration on Recurrence in Papillary Thyroid Cancer

U. Turan¹, A. Cinar¹, K. Okuyucu², N. Aydinbelge Dizdar¹, A. Erol¹, B. Bedi Alpay¹, P. Akkus Gunduz¹, M. Ozkara³, D. Cayir⁴, E. Alagoz², S. Ince²;
¹Gulhane Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²University of Health Sciences, Gulhane Medical Faculty, Department of Nuclear Medicine, Ankara, TÜRKIYE, ³Gulhane Training and

Research Hospital, Department of General Surgery, Ankara, TÜRKIYE, ⁴University of Health Sciences, Etlik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EPS-261

Therapeutic ¹³¹I Dose for Hyperthyroidism Treatment of Unifocal Autonomy in Compliance with Council Directive 2013/59/Euratom Optimization Principle

C. Canzi, V. Longari, L. Florimonte, A. Castello, R. Leo, M. Castellani;
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ITALY.

EPS-262

Redifferentiation therapy in Radioactive iodine refractory thyroid cancer: post therapy response and clinical outcomes

K. Kulkarni¹, K. Manglani², A. Bendre³, A. Bendre²;
¹Medstar Medical Group Radiology, Medstar Washington Hospital Center, DC, UNITED STATES OF AMERICA, ²Medstar Washington Hospital Center, Washington, DC, UNITED STATES OF AMERICA, ³Medstar Health Research Institute, Medstar Washington Hospital Center, DC, UNITED STATES OF AMERICA.

EPS-263

Redifferentiation Therapy in Refractory Differentiated Thyroid Cancer with Progression. Initial Experience

C. Paniagua Correa, R. Vegara Fernández, G. Guijarro de Armas, L. Castillejos Rodríguez, M. Tagliatori Nogueira, S. Pérez Quirós, A. Herrero Muñoz, M. de la Rubia Marcos, A. Ortega Valle, D. Rodriguez Oviedo, C. Galindo Fernández, K. Guichay Duran, J. Sánchez Calderón, P. García Alonso;
Hospital De Getafe, Madrid, SPAIN.

1611

Tuesday, October 7, 2025, 16:45 - 18:15

Room 111

TROP Session - Case Report Session 2: Case-based Learning in Nuclear Medicine Beyond Oncology

OP-740

¹⁸F-DPA-714 versus ¹⁸F-FDG PET for localizing the epileptogenic zone in drug-resistant epilepsy: a case report

L. Xiao, L. Feng, Y. Tang, S. Hu;
Xiangya Hospital Central South University, Changsha, CHINA.

OP-741

Impact of Venlafaxine on ¹²³I-FP-CIT Imaging: A Case Series

M. El-Sayed, J. Dias;
Queen Elizabeth Hospital Birmingham, Birmingham, UNITED KINGDOM.

OP-742

Managing Pediatric Multisystem Langerhans Cell Histiocytosis: A 5-Year Follow-Up with Serial [18F] FDG-PET/CT Metabolic Imaging

D. Barbosa, H. Duarte, D. Silva, N. Vasconcelos, R. Marão, I. Sampaio;
IPO, Porto, PORTUGAL.

OP-743

“68 Ga-CRH (Corticotropin Releasing Hormone) PET/CT: Transforming Cushing Syndrome Diagnosis”

V. Jain¹, M. L. Narayan¹, K. Shridharan¹, J. Shukla², R. Kumar², B. Mittal²;
¹All India institute of Medical Sciences, Rishikesh, Rishikesh, INDIA, ²PGIMER, Chandigarh, Chandigarh, INDIA.

OP-744

Role of 99mTc-Ethambutol SPECT/CT in Resolving Diagnostic Dilemma in a Case of Chronic Vertebral Lesions

A. Roy, N. A. Damle, A. Mahalik, N. Kundu, S. Sikdar;
AIIMS New Delhi, New Delhi, INDIA.

OP-745

A Non-invasive PET ¹⁸F-FTHA Imaging Strategy for Observing Lymphatic Flow Patterns

D. Lee, R. Laforest, K. D. Harrison, M. L. Nickels, R. J. Gropler, G. J. Randolph;
Washington University School of Medicine in Saint Louis, Saint Louis, MO, UNITED STATES OF AMERICA.

OP-746

Too Subtle to Miss? The Diagnostic Value of V/Q SPECT in Low-Risk CTEPH

C. Küçüker¹, G. Kaya², E. B. Kaya³, P. Özgen Kiratli¹;
¹Hacettepe University, Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Republic of Türkiye, Ministry of Health, Yozgat State Hospital, Department of Nuclear Medicine, Yozgat, TÜRKIYE, ³Hacettepe University, Faculty of Medicine, Department of Cardiology, Ankara, TÜRKIYE.

OP-747

Prospective pilot study to evaluate Ga-68 FAPI for the early detection of hepatic fibroblast activation in patients with primary sclerosing cholangitis (PSC)

M. Nejabat¹, E. Halilbasic², M. Trauner², A. Ba-Ssalamah³, S. Rasul¹, B. Mozayani⁴, T. Nakuz¹, C. Philippe⁵, R. Calabretta¹, S. Poetter-Lang³, M. Hacker¹;
¹1.Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, ²2.Division of Gastroenterology and Hepatology, Department of Internal Medicine III., Vienna, AUSTRIA, ³3.Division of General and Pediatric radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, ⁴4.Department of Clinical Pathology, Medical University of Vienna, Vienna, AUSTRIA, ⁵Radiopharmaceutical Sciences, Coordinator Joint Medicinal Radiochemistry Facility, Vienna, AUSTRIA.

OP-748

Unexpected Skeletal Uptake on ⁶⁸Ga-Trivehexin PET/CT in a Case of Renal Osteodystrophy

S. Kar, V. R. Lele, N. Shaikh;
Jaslok Hospital and Research Centre, Mumbai, INDIA.

1701

Wednesday, October 8, 2025, 08:00 - 09:30

Auditorium

CME 13 - Dosimetry Committee: Challenges in Red Bone Marrow Dosimetry

OP-749

Introduction to red marrow dosimetry
P. Bernhardt; Sahlgrenska University Hospital, Radiaton Physics, Gothenburg, SWEDEN.

OP-750

Small-scale dosimetry
P. Minguez Gabina; Unidad de Radiofísica y Protección radiológica. Gurutzeta/Cruces University Hospital, Medical Physics, Barakaldo, SPAIN.

OP-751

Image-based versus blood-based dosimetry
J. Tran-Gia; University Hospital Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY.

OP-752

Absorbed dose-toxicity correlations
M. Cremonesi; European Institute of Oncology, IRCCS, Milan, ITALY.

1702

Wednesday, October 8, 2025, 08:00 - 09:30

Room 112 (Arena)

Special Track 13 - Women Empowerment Initiative + Young Professional Council: Challenge the Expert: Current Challenges in Career and in Leadership for the Future Generations

OP-753

Building Resilient Careers When Intelligence Isn’t Just Human
S. Massalha; Rambam Health Care Campus, Haifa, ISRAEL.

OP-754

Voices, Visions, and the Next-Gen Leaders in Nuclear Medicine
T. Van den Wyngaert; Antwerp University Hospital (UZA), Antwerp, BELGIUM.

OP-755a

Challengers’ Team
P. Soeiro; Centro Hospitalar Universitário de São João, Department of Nuclear Medicine, Porto, PORTUGAL.

OP-755b

Challengers’ Team
O. Ivaschenko; Medical Physicist in Radiology and Nuclear Medicine, University Medical Center, Groningen, NETHERLANDS.

OP-755c

Challengers' Team

M. de Almeida Coelho; University Hospital Essen, Nuclear Medicine, Essen, GERMANY.

OP-755d

Challengers' Team

E. Mamis; CERN, Geneva, SWITZERLAND.

OP-755e

Challengers' Team

G. Gariglio; Medical University of Innsbruck, Innsbruck, AUSTRIA.

OP-755f

Challengers' Team

M. Calls Calahorro; Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

1703

Wednesday, October 8, 2025, 08:00 - 09:30

Room 113

LIPS Session 13 - Oncology & Theranostics
Committee: Structured PET Reporting in
Oncology

OP-756

Hematologic Cancer: Are We Beyond Deauville?

C. Nanni; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-757

Standardised Neuroendocrine Tumour Assessment:
When and How?

F. Grawe; DKFZ, Heidelberg, GERMANY.

OP-758

Do We Need Standardised PET Reports for Prostate
Cancer?

F. Ceci; Istituto Europeo di Oncologia (IEO), Milan, ITALY.

OP-759

Standardised Reporting in Solid Tumors

S. Carrilho Vaz; Champalimaud Clinical Center, Nuclear Medicine-Radiopharmacology, Lisbon, PORTUGAL.

1704

Wednesday, October 8, 2025, 8:00 - 9:30

Room 114

M2M Track - TROP Session -
Radiopharmaceutical Sciences + Translational
Molecular Imaging & Therapy Committee:
Antibodies and Co.

OP-760

First-In-Human PET Imaging of Two Novel Antibody
Fragments in Patients with Solid Tumors - a Phase 0
Nuclear Imaging Basket Trial (VARTUTRACE)

N. C. van Dijk^{1,2}, A. F. S. Verhaar^{1,3}, Y. F. Janssen^{1,3}, M. Brom¹, T. Gustavsson^{4,5}, R. Dagil^{4,5}, S. Choudhary^{4,5}, E. E. Vidal-

Calvo⁴, D. Waagmeester⁶, D. J. Vugts⁶, T. G. Theander^{4,5}, H. H. Boersma^{2,7}, A. Salanti^{4,5}, A. W. J. M. Glaudemans², G. M. van Dam¹;

¹TRACER Europe B.V., Groningen, NETHERLANDS, ²Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen (UMCG), Groningen, NETHERLANDS, ³Department of Surgery, University of Groningen, University Medical Center Groningen (UMCG), Groningen, NETHERLANDS, ⁴Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, DENMARK, ⁵Var2pharmaceuticals ApS, Frederiksberg, DENMARK, ⁶Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, NETHERLANDS, ⁷Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen (UMCG), Groningen, NETHERLANDS.

OP-761

Theranostic Application of Radiolabeled HER2-
Targeting Single-Domain Antibodies (RAD202) in
Preclinical Setting

B. Altunay¹, A. Florea¹, A. Vogg¹, L. Schäfer¹, A. Morgenroth¹, L. K. Meszaros², S. Lütje¹, F. M. Mottaghy^{1,3};
¹Uniklinik RWTH Aachen, Aachen, GERMANY, ²Radiopharm Theranostics Ltd, Victoria, AUSTRALIA, ³Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, NETHERLANDS.

OP-762

Therapeutic potential of first-in-class claudin
18.2-targeted radiolabeled nanobody [¹⁷⁷Lu]Lu-
DOTA-SNA014 in gastric cancer

Y. Wang¹, M. Zheng¹, Q. Liu¹, H. Mou¹, S. Ge¹, B. Zhang¹, C. Wei², S. Qin¹, T. Xu², L. Miao¹;
¹First Affiliated Hospital of Soochow University, Suzhou, CHINA, ²Smart-Nuclide Biotech, Suzhou, CHINA.

OP-763

FL802, a B7-H3-targeting nanobody radioligand
precursor, developed using UniRDC™ discovery
platform

X. Wang, M. Jheng, P. Li, D. Li, Y. Xie, B. Guo, R. Hu, F. Liu;
Full-Life Technologies Limited, Shanghai, CHINA.

OP-764

Head-to-head comparison of ABD-fused Affibody
Molecule labelled with Lu-177 and Tb-161

Y. Liu¹, I. Zelepukin¹, A. Orlova¹, M. Konijnenberg², F. Y. Frejd³, V. Tolmachev¹;
¹Uppsala University, Uppsala, SWEDEN, ²Erasmus MC, Rotterdam, NETHERLANDS, ³Affibody AB, Solna, SWEDEN.

OP-765

Radiolabeled engineered HER2 antibodies for
cancer theranostics

X. Chen, X. Wen, B. Li, X. Wu, J. Zhang;
National University of Singapore, Singapore, SINGAPORE.

OP-766

Affibody-masked cetuximab prodrug for protease-
dependent tumor targeting: a novel strategy to
enhance specificity and minimize toxicity in EGFR-
directed therapies

A. Bitzios¹, A. Mestre Borrás², H. Mehari², I. Zelepukin¹, M. Ud-Din¹, T. Xu¹, S. Li¹, S. StåhP, J. Löfblom², A. Orlova¹, V.

Tolmachev¹, A. Vorobyeva¹;

¹Uppsala Universitet, Uppsala, SWEDEN, ²KTH Universitet, Stockholm, SWEDEN.

OP-767

Immunomodulation of the tumour
microenvironment by 225Ac-hGirentuximab in a
syngeneic murine tumor mode

R. LADJOHOUNLOU¹, W. J. Jin¹, P. Clark¹, M. Bio Idrissou¹, B. Bednarz¹, R. Hernandez¹, M. P. Wheatcroft², K. Twumasi-Boateng², Z. S. Morris¹;
¹University of Wisconsin School of Medicine and Public Health, Madison, WI, UNITED STATES OF AMERICA, ²Telix Pharmaceuticals Limited, Melbourne, AUSTRALIA.

OP-768

Therapeutic Superiority of ¹³¹I-aGPC3-scFv in
Hepatocellular Carcinoma: Biodistribution and
Efficacy

W. Hu, M. Li, Z. Lin, X. Zhang, X. Cai, D. Jiang, X. Lan;
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science, Wuhan, CHINA.

1705

Wednesday, October 8, 2025, 8:00 - 9:30

Room 211

Cutting Edge Science Track - TROP Session - AI
Committee: Kinetic Modeling and Parametric
Imaging

OP-769

Kinetic Model Selection for Motion-Compensated
Whole-Body PET Imaging

J. Rosenskjold Madsen^{1,2}, A. H. Dias¹, L. C. Gormsen^{1,2}, A. B. Rodell³, D. Pigg⁴, J. Schaefferkoetter⁴, O. L. Munk^{1,2};
¹Department of Nuclear Medicine & PET, Aarhus University Hospital, Aarhus, DENMARK, ²Department of Clinical Medicine, Aarhus University, Aarhus, DENMARK, ³Siemens Healthcare A/S, Aarhus, DENMARK, ⁴Siemens Medical Solutions USA, Knoxville, TN, UNITED STATES OF AMERICA.

OP-770

Improving AI-Generated Parametric Image
Estimation with Accurate AI-Assisted Input Function
Modelling in Dynamic PET

K. Tehlan^{1,2}, V. Langer³, A. Rominger⁴, K. Shi⁴, T. Wendler^{1,2}, KT and VL are first authors with equal contribution;
¹University Hospital Augsburg, Augsburg, GERMANY, ²Technical University of Munich, Munich, GERMANY, ³University of Augsburg, Augsburg, GERMANY, ⁴Inselspital, Bern, SWITZERLAND.

OP-771

Whole-Body Perfusion Imaging Using Dynamic ⁸²Rb
PET with a Long Axial Field-of-View Scanner

M. Morini^{1,2}, I. Brovedani^{1,2}, M. De Francisci², M. Castellaro², L. Mercolli¹, M. Veronese^{2,3}, A. Rominger¹, F. Caobelli¹, H. Sari^{1,4};
¹Department of Nuclear Medicine, Bern University Hospital, University of Bern, Bern, SWITZERLAND, ²Department of Information Engineering, University of Padova, Padova, ITALY, ³Department of Neuroimaging, Kings College London, London, UNITED KINGDOM, ⁴Siemens Healthineers International AG, Zurich, SWITZERLAND.

OP-772

Improvement of quantitative accuracy of ultra-
short-duration parametric imaging with a long axial
field-of-view PET/CT system

Q. Ye, H. Zeng, G. Liang, E. Revilla, Y. Lu;
United Imaging Healthcare, Shanghai, CHINA.

OP-773

Evaluation of Image-Derived Input Function
Methods for Non-Invasive Kinetic Modelling of
[18F]-Fluorodeprenyl-D2 in Alzheimer's Disease

T. Schmidt^{1,2}, A. J. Zounek¹, T. Saller³, S. Lindner¹, B. Kugelmann¹, Y. Beqqali¹, A. Zatcepin^{1,4}, S. Raju¹, L. Tagnin¹, G. N. Bischof⁶, S. Ziegler^{7,1}, M. Brendel^{1,4,8}, L. Kaiser¹;
¹Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ²Department of Physics, Ludwig Maximilians University, Munich, GERMANY, ³Department of Anaesthesiology, LMU University Hospital, LMU Munich, Munich, GERMANY, ⁴German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY, ⁵Multimodal Neuroimaging Group, Department of Nuclear Medicine, University Hospital Cologne, Cologne, GERMANY, ⁶Life Molecular Imaging GmbH, Berlin, GERMANY, ⁷Department of Nuclear Medicine, Hannover Medical School (MHH), Hannover, GERMANY, ⁸Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.

OP-774

Parametric analysis of dynamic long axial field-of-
view ¹⁸F-FDG PET/CT studies

C. Smith, G. J. C. Zwezerijnen, M. E. den Hollander, H. N. J. M. Greuter, N. R. Gerards, J. Zijlstra, C. Menke-van der Houven van Oordt, I. Bahce, M. Yaqub, R. Boellaard;
Amsterdam UMC, Amsterdam, NETHERLANDS.

OP-775

Assessment of IDIF Quantification in PET Using 3D
Printed Vessel Phantoms

Y. Beqqali^{1,2}, A. Zounek¹, S. Raju^{1,2}, T. Schmidt¹, N. Albert¹, S. Ziegler^{1,3}, L. Kaiser¹;
¹Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ²Department of Physics, Technical University of Munich, Munich, GERMANY, ³Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY.

OP-776

Differential Binding Kinetics of [¹⁸F]F-PSMA-1007
and [⁶⁸Ga]Ga-PSMA-11: Real-Time Analysis with
Potential Impact on PSMA-PET Imaging Protocols

E. Dighero¹, M. Riondato², P. Fossa^{3,4}, P. Pelucchi⁴, B. Casini³, P. D'Ursi⁴, M. Ghelardoni², S. Losacco², L. Sofia², F. Vitale², S. Carta², S. Chiesa², C. Marini⁵, G. Sambuceti⁶, M. Bauckneht⁶;
¹Department of Experimental Medicine (DIMES), University of Genoa, Genoa, ITALY, ²Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ³Department of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Genoa, ITALY, ⁴Institute for Biomedical Technologies, National Research Council, Segrate, ITALY, ⁵Institute of Molecular Biomimaging and Physiology, National Research Council, Milan, ITALY, ⁶Department of Health Sciences, University of Genoa, Genoa, ITALY.

OP-777
Explainable AI Enhances Lung Cancer Diagnosis Using Metabolic and Perfusion Features from Dynamic¹⁸F-FDG PET/CT
T. Sun¹, Z. Yao¹, Y. Wang², Y. Wu³, M. Wang³, Y. Liang²;
¹Chinese Academy of Sciences, Shenzhen, CHINA,
²Shenzhen Cancer Hospital, Shenzhen, CHINA, ³Henan Provincial People's Hospital, Zhengzhou, CHINA.

1706

Wednesday, October 8, 2025, 8:00 - 9:30
 Room 117

Clinical Oncology Track - TROP Session
 - Oncology & Theranostics Committee:
 Theranostic and New Therapies

OP-778
Phase II study to evaluate safety, tolerability, and preliminary efficacy of carrier-added 4-L-[¹³¹I]iodo-phenylalanine (¹³¹I-IPA) in patients with recurrent GBM concomitantly to 2nd line re-irradiation
J. Pichler¹, I. Höllmüller¹, J. Dierneder², R. Pichler³, O. Osipova³, S. Wimmer⁴, J. Feichtinger⁵, S. Weis⁶, A. Leibetseder⁷;
¹Department of Internal Medicine and Neurooncology Kepler University Hospital Neuromed Campus, Linz, AUSTRIA, ²Department of Nuclear Medicine and Endocrinology, Ordensklinikum Linz Barmherzige Schwestern, Linz, AUSTRIA, ³Department of Neuronuclear Medicine, Kepler University Hospital, Neuromed Campus, Linz, AUSTRIA, ⁴Department of Neuroradiology, Kepler University Hospital, Neuromed Campus, Linz, AUSTRIA, ⁵Department of Radiation Oncology, Ordensklinikum Linz Barmherzige Schwestern, Linz, AUSTRIA, ⁶Division of Neuropathology, Department of Pathology and Molecular Pathology, Neuromed Campus, Linz, AUSTRIA, ⁷Department of Neurology, Neuromed Campus, Kepler University Hospital, Johannes Kepler University Linz, Linz, AUSTRIA.

OP-779
Safety of Radioligand Therapy with [177Lu]Lu-FAPI-Dimer with Dose Escalation in a Clinical Setting
J. Urena Pochi¹, J. Kurth¹, B. Krause¹, H. Lanzafame², M. Jokschi¹, B. Bothe¹, G. Alsasser³, W. Fendler², K. Herrmann², M. Heuschkel¹;
¹Department of Nuclear Medicine, Rostock University Medical Center, Rostock, GERMANY, ²Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY, ³Department of General, Thoracic, Vascular and Transplantation Surgery, University of Rostock, Rostock, GERMANY.

OP-780
SANTANA-225: A multicentre, open-label, Phase I/II study investigating the safety, tolerability, and preliminary efficacy of 225Ac-SSO110 in participants with extensive stage small cell lung cancer (ES-SCLC) or Merkel cell carcinoma (MCC) receiving Standard of Care (SoC)
E. Zan¹, J. Fleck², G. Gericke², K. Herrmann³;
¹Cleveland Clinic, Cleveland, OH, UNITED STATES OF AMERICA, ²Ariceum International AG, Basel, SWITZERLAND, ³Universitätsklinikum Essen, Essen, GERMANY.

OP-781
Clinicopathological Features Predict Outcomes in Patients with End-Stage Metastatic Cancers Treated with ¹⁷⁷Lu-LNC1004
H. Fu¹, J. Huang¹, W. Guo¹, J. Zhang², X. Chen², H. Chen¹;
¹The First Affiliated Hospital of Xiamen University, Xiamen, CHINA, ²Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.

OP-782
Deep Learning Model for Automatic Tumour Segmentation and Margin Status Prediction in Micro-PET-CT Images of Breast Lumpectomy Specimens
L. Maris^{1,2}, M. Göker³, K. De Man⁴, B. Van den Broeck⁴, S. Van Hoecke⁵, K. Van de Vijver^{6,7}, C. Vanhove^{1,8}, V. Keereman^{1,2};
¹Department of Electronics and Information Systems, MEDISIP, Ghent University, Ghent, BELGIUM, ²XEOS Medical, Ghent, BELGIUM, ³Department of Gynaecology, Ghent University Hospital, Ghent, BELGIUM, ⁴Department of Medical Imaging, Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM, ⁵Internet Technology and Data Science Lab (IDLab), Ghent University-Imec, Ghent, BELGIUM, ⁶Department of Pathology, Ghent University Hospital, Ghent, BELGIUM, ⁷Department of Diagnostic Sciences and CRIG, Ghent University, Ghent, BELGIUM, ⁸CORE ARTH INFINITY, Ghent University, Ghent, BELGIUM.

OP-783
Unlocking the predictive potential of preoperative SPECT/CT roadmaps for signal intensities during cervical cancer sentinel node surgery
G. Pisano^{1,2}, N. van Ruremonde², F. H. P. van Velden³, P. Dibbets-Schneider³, J. J. Beltman⁴, L. S. Nooij⁴, M. N. van Oosterom², F. W. B. van Leeuwen², D. D. D. Rietbergen^{3,2};
¹Nuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY, ²Interventional Molecular Imaging Laboratory, Leiden University Medical Centre, Leiden, NETHERLANDS, ³Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS, ⁴Department of Gynecology, Leiden University Medical Center, Leiden, NETHERLANDS.

OP-784
Integrated Multidisciplinary Workflow for ROLL of PET/CTPositive Lesions: Technical Feasibility and Clinical Impact
M. Zapardiel¹, L. León Ramírez, C. Wakfie Corieh, C. González Roiz, J. Armijo Astrain, M. Leyva Vásquez Caicedo, S. Ochagavia Cámara, C. Sánchez del Pueblo, M. Vaillant López, A. Berardinelli Isea, M. Romero Porras, M. Cornide Carrallo, M. Cabrera Martin;
H. U. Clínico San Carlos, Madrid, SPAIN.

OP-785
Radioguided Occult Lesion Localisation (ROLL) for Intraoperative Detection of Parathyroid Adenomas: A Preliminary Single-Centre Experience
L. León Ramírez¹, C. González Roiz², T. Díaz Vico³, I. Grao Torrente³, A. García Muñoz Nájara³, A. Hermosín Peña³, M. Durán Poveda³;
¹Hospital clínico san carlos, Madrid, SPAIN, ²Hospital Puerta del Sur, Madrid, SPAIN, ³Hospital Universitario Rey Juan Carlos, Madrid, SPAIN.

OP-786
Accuracy of PSMA-PET/CT, mpMRI and ex vivo specimen PET/CT for molecular guidance of nerve sparing

P. Fragoso Costa¹, T. Kah², W. Fendler¹, H. Reis³, J. Köllermann³, C. Kesch², L. Püllen², U. Krafft², J. Kleesiek⁴, D. Kersting¹, M. Ingenwerth⁵, B. Hadaschik², K. Herrmann¹, F. Barbato¹, C. Darr²;
¹Clinic for Nuclear Medicine, University Hospital Essen, University Duisburg-Essen, Essen, GERMANY, ²Department of Urology, University Hospital Essen, University Duisburg-Essen, Essen, GERMANY, ³Institute of Pathology, University Hospital Frankfurt, Frankfurt, GERMANY, ⁴Institute of Artificial Intelligence in Medicine, University Hospital Essen, University Duisburg-Essen, Essen, GERMANY, ⁵Institute of Pathology, University Hospital Essen, University Duisburg-Essen, Essen, GERMANY.

1707

Wednesday, October 8, 2025, 8:00 - 9:30
 Room 212

TROP Session - Cardiovascular Committee:
 Atherosclerosis Burden, from Plaque to Perfusion

OP-787
First-in-Human Phase I/IIa Study of [^{99m}Tc]Tc-cAbVCAM1-5: Safety, Dosimetry, and Biodistribution in Healthy Volunteers and Asymptomatic Patients Prior to Carotid Endarterectomy
L. Djaileb¹, J. Leenhardt², R. Spear³, N. De Leiris², G. Reboulet², M. Faure³, A. Paris³, L. Dumas², C. Ghezzi², G. Vanzetto², D. Fagret², G. Barone-Rochette², A. Broisat²;
¹University Grenoble Alpes,LRB, Grenoble, FRANCE, ²University Grenoble Alpes,LRB, Grenoble, FRANCE, ³University Grenoble Alpes, Grenoble, FRANCE.

OP-788
Carotid Calcified Inflammatory Plaques and Cardiocerebrovascular Events: A ⁶⁸Ga-DOTA-TOC PET/CT study in an oncological setting
X. Shao^{1,2}, C. Bregenz², J. Wang², Y. Chen², A. Rominger², K. Shi², F. Caobelli²;
¹the Third Affiliated Hospital of Soochow University, Changzhou, CHINA, ²Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

OP-789
Increase of 18F-rhPSMA-7 uptake in atherosclerotic plaques is associated with higher cardiovascular risk in patients with prostatic cancer.
S. Notohamiprodjo¹, B. Haller², I. Rauscher¹, M. Eiber¹, W. Weber¹, M. Krönke²;
¹Technical University of Munich, TUM School of Medicine and Health, TUM University Hospital, Department of Nuclear Medicine, Munich, GERMANY, ²Technical University of Munich, TUM School of Medicine and Health, TUM University Hospital, Department of Biostatistics and Clinical Epidemiology, Munich, GERMANY, ³Die Radiologie, Munich, GERMANY.

OP-790
[⁶⁸Ga]FAPI PET molecular imaging in atherosclerosis compared with [¹⁸F]FDG
R. Calabretta¹, E. Atli, B. Geist, D. Muin, E. Kretschmer-Chott, C. Spielvogel, S. Schmitl, X. Li, P. Binder, M. Hacker;
Medical University of Vienna, Vienna, AUSTRIA.

OP-791
Impact of Hemoglobin Concentration on Quantitative Cardiac Perfusion Measurements
P. Svanström¹, T. Kero, J. Sigfridsson, K. M. Eggers, N. Johnston, A. Brandt, H. J. Harms, M. Lubberink, J. Sörensen;
Uppsala University, Uppsala, SWEDEN.

OP-792
Model-Free Perfusion Quantification for Dynamic Total-body ¹⁸F-FDG PET Reveals Remote Blood Flow Alterations in Coronary Artery Disease
T. Sun¹, Y. Wu², M. Wang²;
¹Chinese Academy of Sciences, Shenzhen Insitute of Advanced Technology, Shenzhen, CHINA, ²Henan Provincial People's Hospital, Zhengzhou, CHINA.

OP-793
Respiratory Motion and Attenuation Corrections Improve Prognostic Value of Myocardial Perfusion Imaging in Patients With Ischemia and Nonobstructive Coronary Arteries
C. Chen¹, C. Ko;
National Taiwan University Hospital, Taipei, TAIWAN.

OP-794
Stenosis degree and plaque burden differ between the major epicardial coronary arteries supplying ischemic myocardial territories
T. Kero¹, J. Knuuti², S. Bär², J. J. Bax³, A. Saraste², T. Maaniitty²;
¹Uppsala University, Department of Surgical Sciences/ Nuclear Medicine & PET, Uppsala, SWEDEN, ²University of Turku, Turku, FINLAND, ³Leiden University Medical Center, Leiden, NETHERLANDS.

OP-795
Impact of quantitative CCTA-derived atherosclerotic plaque features on myocardial blood flow assessed by dynamic CZT-SPECT in NOCAD patients
K. Zavadovsky¹, A. Maltseva, R. Dorzhieva, K. Kopeva, A. Dasheeva, A. Mochula, E. Grakova;
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

1708

Wednesday, October 8, 2025, 8:00 - 9:30
 Room 115

TROP Session - Case Report Session 3: Case-based Learning PET in Oncology

OP-796
Anti-CD8α PET uptake patterns before and during Immune Checkpoint Inhibitor therapy related to irAEs
E. Peeters¹, E. A. J. van Genugten¹, M. R. Ferris², K. A. Margolin³, C. M. L. van Herpen¹, S. Heskamp¹, H. Westdorp¹, E. H. J. G. Aarntzen^{1,4};
¹Radboudumc, Nijmegen, NETHERLANDS, ²ImaginAb, Inglewood, CA, UNITED STATES OF AMERICA, ³Saint John's Cancer Institute, Santa Monica, CA, UNITED STATES OF AMERICA, ⁴University medical center Groningen, Groningen, NETHERLANDS.

OP-797
Unveiling the diagnostic potential of ¹⁸F-FDG PET/CT in evaluation of post-transplant disorders.

B. Mittal, K. Preet, P. Singh, N. Agrawal, R. Kumar, H. Singh; Postgraduate Institute of Medical Education & Research, Chandigarh, INDIA.

OP-798
An Example of Higher Accuracy of [68Ga]Ga-FAPI-46 PET/CT in Staging Lymph Nodes Metastases Compared to [18F]F-FDG PET/CT in a Head and Neck Cancer Patient

E. Fortunati¹, I. Brusa¹, G. Cuzzani², A. Farolfi¹, E. Tabacchi¹, L. Calderoni¹, D. Dall'Olio³, M. Assenza⁴, C. Nanni¹, P. Castellucci¹, R. Mei¹, M. Fermi⁵, G. Siepe⁶, S. Fanti^{1,2}; ¹Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY; ²Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY; ³Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITALY; ⁴Professional Development and Implementation of Research in Health Professional Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY; ⁵Department of Otorhinolaryngology-Head and Neck Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY; ⁶Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-799
Seeing beyond ⁶⁸Ga DOTANOC and ¹⁸F FDG PET/CT : ⁶⁸Ga FAPI only uptake in a rare metastatic well differentiated grade I pancreatic neuroendocrine tumor

C. Singareddy, A. Baa, S. Kankara, M. Bukelo; St.Johns's Medical college Hospital, Bengaluru, INDIA.

OP-800
Lack of FES Avidity in FDG-Positive ER-Positive Breast Cancer: A Case Indicating Non-Functional Estrogen Receptors in a Treatment-Naive Patient
A. Mahalik, N. Kundu, A. Roy, K. Jain, M. Tripathi, R. Kumar; All India Institute of Medical Sciences, New Delhi, INDIA.

OP-801
Detection of Insulinoma Using 68Ga-NODAGA-Exendin-4 PET/CT: A Report of Two Cases
A. Guercio¹, T. Graziani¹, M. Scarlattei¹, S. Migliari¹, C. Cidda¹, G. Baldari¹, V. Cervati¹, A. Gagliardi¹, A. Dei Cas², R. Bonadonna³, L. Ruffini¹; ¹Nuclear Medicine Division, University Hospital of Parma, Parma, ITALY; ²Laboratory of Endocrinology, Diabetes and Metabolic Diseases, Department of Medicine and Surgery, University of Parma, Parma, ITALY; ³Endocrinology Division, Diabetes and Metabolic Diseases, Department of Medicine and Surgery, University of Verona, Verona, ITALY.

OP-802
A Weighty Problem: GLP-1 Agonists and the Altered Images of FDG PET-CT
P. Strouhal, A. Meadows, A. McGovern; Alliance Medical Ltd, Warwick, UNITED KINGDOM.

OP-803
Efficacy of short acting and ultra-short acting insulin in improving image quality of ¹⁸F-FDG PET in diabetic cancer patients.
S. Saeed¹, M. Nadeem², S. Hanan³, M. Younis⁴, S. Saeed⁵; ¹Punjab Institute of Cardiology, Lahore, PAKISTAN, ²AI Nasar Lab & Diagnostic Center, Lahore, PAKISTAN, ³NUR

International University, Lahore, PAKISTAN, ⁴Doctors Hospital and Medical Center, Lahore, PAKISTAN, ⁵Fatima Memorial College of Medicine and Dentistry, Lahore, PAKISTAN.

OP-804
Multimodality Imaging in the Assessment of Liver-Directed Therapy Response in Prostate Cancer: A Case Demonstrating False Positive PSMA Uptake
Y. Eryilmaz, O. Kodaz, G. Kaya, B. Volkan Salanci, M. Tuncel; Hacettepe University Medical School Department of Nuclear Medicine, Ankara, TÜRKIYE.

1709
Wednesday, October 8, 2025, 8:00 - 9:30
Room 133+134
e-Poster Presentations Session 13 - Bone & Joint Committee: Bone & Joint e-Poster Presentations Session

EPS-264
Head-to-head comparison of bone scintigraphy metastasis detection provided by a high-speed whole-body 360° CZT-SPECT and a currently recommended Anger camera protocol
A. Bahloul, M. Perrin, A. Verger, S. Ouguirti, V. Roch, P. Marie, L. Imbert; CHU de Nancy, Vandoeuvre Les Nancy, FRANCE.

EPS-265
Potential of 68Ga-FAPI-46 PET/CT in patients with primary bone and soft tissue sarcoma: head-to-head comparison with ¹⁸F-FDG PET/CT
E. Davydova¹, M. Komarova¹, A. Chaban², A. Pronin¹, A. Martinovich¹, O. Ryzhova¹, I. Amosova¹; ¹N.N Blokhin National Medical Research Center of Oncology of the Russian Ministry of Health, Moscow, RUSSIAN FEDERATION, ²Klinikum Rechts der Isar, Technical University of Munich, Munich, GERMANY.

EPS-266
Baseline Bone Marrow Scintigraphy as Predictive Marker of Outcomes in mCRPC Patients Treated with Radium-223 Dichloride
Q. Shagera, O. Gheysens, E. Jonard, E. Seront, B. Tombal, F. Jamar; Cliniques universitaires Saint-Luc, UClouvain, Brussels, BELGIUM.

EPS-267
Unspecific Bone Uptake on PSMA PET/CT in Prostate Cancer: Distinguishing Early Metastases from Benign Findings
N. Vasconcelos, D. Barbosa, D. Silva, R. Marão, J. Teixeira, I. Lucena Sampaio; Instituto Português de Oncologia, Porto, PORTUGAL.

EPS-268
Targeting SSTR2 in Monitoring Skeletal Stem Cells and Osteosarcoma via [¹⁸F]-Octreotide PET-CT
Z. Li, X. Su; First Affiliated Hospital of Zhejiang University, School of Medicine, Zhejiang University, Hangzhou, CHINA.

EPS-269
Use of ¹⁸F-FDG PET-CT in pediatric Rhabdomyosarcoma:can progression be predicted?
S. Iaria¹, C. Caldarella², L. Leccisotti^{1,2}; ¹Università Cattolica del Sacro Cuore, Rome, ITALY, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY.

EPS-270
Diagnostic Potential of ⁶⁸Ga-FAPI-46 PET/CT in the Evaluation of Metastatic Soft Tissue Sarcomas: A Comparative Analysis with ¹⁸F-FDG PET/CT
S. Shamim, Y. Khandelwal, B. Jain, S. Rastogi; AIIMS New Delhi, Delhi, INDIA.

EPS-271
⁶⁸Ga-FAPI-PET/CT leads to changes in clinical management of patients with malignant and benign peripheral nerve sheath tumors
A. Spektor¹, A. Waldschütz¹, M. Fried^{2,3}, D. Kalasauskas^{4,5}, M. Schreckenberger¹, M. Röhrich¹; ¹Department of Nuclear Medicine, University Center Mainz, Mainz, GERMANY, ²University Center for Oncology, University Medical Center Mainz, Mainz, GERMANY, ³Clinic and Polyclinic for Internal Medicine III, University Center Mainz, Mainz, GERMANY, ⁴Department of Neurosurgery, University Center Mainz, Mainz, GERMANY, ⁵Department of Neurosurgery, University Hospital LMU Munich, Munich, GERMANY.

EPS-272
PET/CT Core + PeritumoralRing Radiomics for Histotype Classification of Pediatric Sarcomas
N. Quartuccio¹, F. Fiz², E. M. Abenavoli³, C. Olianti³, A. Tondo⁴, A. Tamburini⁴, I. Bertacca⁴, C. Manzitti⁵, V. Livellara⁵, A. Garaventa⁵, P. D'Angelo⁶, F. Dondi⁷, M. Conte⁸, V. Frantellizzi⁸, S. Ialuna¹, V. Berti⁹, A. Piccardo², A. Cistaro¹⁰; ¹Nuclear Medicine Unit, Ospedali Riuniti Villa Sofia-Cervello, Palermo, ITALY, ²Nuclear Medicine Unit, Galliera Hospital, Genoa, ITALY, ³Nuclear Medicine Unit, Careggi University Hospital, Florence, ITALY, ⁴Paediatric Oncoematology IRCC A. Meyer, Florence, ITALY, ⁵Oncology Unit, IRCCS Istituto Giannina Gaslini, Genoa, ITALY, ⁶Pediatric Hematology and Oncology Unit, ARNAS "Civico, Di Cristina and Benfratelli" Hospitals, Palermo, ITALY, ⁷Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, Brescia, ITALY, ⁸Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza, Rome, ITALY, ⁹Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, ITALY, ¹⁰Nuclear Medicine Department, Salus Alliance Medical, Genoa, ITALY.

EPS-273
Diagnostic Utility of Bone Scintigraphy in Pediatric Acute Osteomyelitis
K. Guichay Duran, M. Tagliatori Nogueira, C. Galindo Fernández, D. Rodríguez Oviedo, J. Sanchez Calderón, M. Castillejos Rodríguez, A. Herrero Muñoz, C. Paniagua Correa, A. Ortega Valle, M. Álvarez Moreno, M. García Alonso, M. De la Rubia Marcos; Department of Nuclear Medicine, Getafe University Hospital, Madrid, SPAIN.

EPS-274
Quantitative Bone SPECT/CT in Hand and Wrist Osteoarthritis Imaging and Management

M. Soltanolkotabi, G. Safazadeh, G. J. Stoddard, M. K. Mills, A. Wang, S. Minoshima; University of Utah, Salt Lake City, UT, UNITED STATES OF AMERICA.

EPS-275
Contribution of ^{99m}Tc-SPECT/CT to Magnetic Resonance Imaging Inpainful Foot Pathologypainful Foot Pathology
C. Gonzalez Roiz¹, L. León-Ramírez², P. Recarte Ortega¹, G. Orlandini¹, M. Ollarves Carrero¹, M. Alvarez¹, L. García Cañamaque¹; ¹Hospital Puerta del Sur, Móstoles, Madrid, SPAIN, ²Hospital Clínico San Carlos, Madrid, SPAIN.

EPS-276
Clinical Decision-Making Using [¹⁸F]NaF PET/CT Imaging in Non-Unions
N. D. van Rijsewijk, M. Wouthuyzen-Bakker, J. H. van Snick, J. van Sluis, K. ten Duis, A. W. J. M. Glaudemans, F. F. A. Ijpma; University Medical Center Groningen, Groningen, NETHERLANDS.

EPS-277
Beyond the Bone Scan: FDG PET/CT as a Decisive Tool in Differentiating PJI from Aseptic Loosening
J. Choudhary, A. Mahalik, N. Kundu, S. Singh, V. Singh, J. Krishna P, K. Jain, S. Shamim, R. Kumar; All india institute of medical sciences, New Delhi, INDIA.

EPS-278
Integrating Whole-Body Bone SPECT and AI-Synthetic CT in the Evaluation of Non-Oncologic Disorders
M. Einieh¹, S. Barna^{2,3}, Á. Budai², G. Ország², C. Csikos³, I. Garai^{2,3}; ¹University of Debrecen, Faculty of Medicine, Debrecen, HUNGARY, ²Scanomed Ltd., Debrecen, HUNGARY, ³University of Debrecen, Faculty of Medicine, Medical Imaging Department, Division of Nuclear Medicine, Debrecen, HUNGARY.

EPS-279
Composite 3-phase bone scan and FDG-PET in suspected infections post open reduction and hardware fixation of fractures
I. El Bez, R. Tulbah, S. Alhazza, R. Alsalah, K. Ibrahim, F. Algmlas, M. Alharbi; AAML, Riyad, SAUDI ARABIA.

EPS-280
Assessment of Noise Reduction Deep Learning Reconstruction Algorithm for Bone Scan: A pilot study
J. Hagerman¹, I. Ceric Andelius²; ¹Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, SWEDEN, ²Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, SWEDEN.

Pretoria, SOUTH AFRICA, ³Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY, ⁴Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Duesseldorf, GERMANY, ⁵Department of Radiation Oncology, University of Pretoria, Pretoria, SOUTH AFRICA, ⁶Telix Pharmaceuticals Limited, Melbourne, AUSTRALIA.

1801

Wednesday, October 8, 2025, 09:45 - 11:15
 Auditorium

CME 14 - Bone & Joint Committee: NM Sports, it's in the Game

OP-826
 J. Bliss; London Bridge Orthopaedics, London, UNITED KINGDOM.

OP-827
 M. De Jonge; St. Antonius Ziekenhuis, Amsterdam, NETHERLANDS.

OP-828
 T. Van Den Wyngaert; University of Antwerp and Antwerp University Hospital, Antwerp, BELGIUM.

OP-829
 R. Dhawan; Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

1802

Wednesday, October 8, 2025, 09:45 - 11:15
 Room 112 (Arena)

Special Track 14 - Translational Molecular Imaging & Therapy Committee: Challenge the Expert: How can Lessons from Radiobiology be Applied to the Design of Clinical Trials?

OP-830
 The Radiobiologists View
 J. Nonnekens; Erasmus Medical Center, Departments of Molecular Genetics and Radiology & Nuclear Medicine, Rotterdam, NETHERLANDS.

OP-831
 The Physicians View
 E. Deshayes; University hospital, Montpellier, Department of Nuclear Medicine, Montpellier, FRANCE.

OP-832a
 Challengers' Team
 S. Kleinendorst; Radboud University Medical Center, Department of Medical Imaging, Nijmegen, NETHERLANDS.

OP-832b
 Challengers' Team
 H. Koch; University Hospital Lausanne, Lausanne, SWITZERLAND.

OP-832c
 Challengers' Team
 S. Schumann; University Hospital Würzburg, Würzburg, GERMANY.

OP-832d
 Challengers' Team
 W. Delbart; University Hospital Brussels, Institute Jules Bordet, Brussels, BELGIUM.

1803

Wednesday, October 8, 2025, 09:45 - 11:15
 Room 113

LIPS Session 14 - Neuroimaging Committee: PET Response Assessment in Neurooncology

OP-833
 PET RANO Criteria in Gliomas
 N. Albert; LMU University Hospital, Department of Nuclear Medicine, Munich, GERMANY.

OP-834
 Meningiomas
 N. Tolboom; UMC Utrecht, Department of Nuclear Medicine, Utrecht, NETHERLANDS.

OP-835
 Brain Metastases
 A. Verger; CHRU Nancy, Vandoeuvre les Nancy, FRANCE.

OP-836
 CNS Lymphomas
 L. Rozenblum; Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, FRANCE.

1804

Wednesday, October 8, 2025, 9:45 - 11:15
 Room 114

M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Advances in Preclinical Cardiovascular Imaging

OP-837
 Inflammation Imaging via CD206-Targeted ⁶⁸Ga-NOTA-UNO in the Mouse Myocardial Infarction Model
 D. Zheng; Y. Lv, Z. Zhou, S. Wei, Z. Lin, Z. Wu, Y. Deng, X. Lv, X. Song, C. Qin, X. Lan; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

OP-838
 Synergistic effects of dapagliflozin and low salt diet evaluated by multi-nuclear ¹⁸F-FDG PET-MRI (²³Na/¹H) in radiation-induced heart failure with preserved ejection fraction (HFpEF)
 H. Rida¹, M. Guetlin^{1,2}, C. Simard¹, M. Naveau³, S. Allouche⁴, L. Coulbault¹, P. Dupont¹, A. Lebrun¹, M. Joubert^{1,2}, A.

Manrique^{1,5};
 ¹Cyceron UR4650 PSIR, Université Caen Normandie, Caen, FRANCE, ²Diabetology, CHU de Caen, Caen, FRANCE, ³UAR3408/US50 Cyceron, CNRS, INSERM, Université Caen Normandie, Caen, FRANCE, ⁴Biochimie, CHU de Caen, Caen, FRANCE, ⁵Nuclear Medicine, CHU de Caen, Caen, FRANCE.

OP-839
 Longitudinal Multimodal Imaging Elucidates Temporal Metabolic Reprogramming and Mitochondrial-Microvascular Dysfunction in Diet-Induced HFpEF

J. Zhao^{1,2,3}, Z. Xiang^{1,2,3}, Q. Wang^{1,2,3}, R. Shen^{1,2,3}, Y. Wen^{1,2,3}, X. Liu^{1,2,3}, P. Wu^{1,2,3}, Z. Wu^{1,2,3}, S. Li^{1,2,3};
 ¹Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA, ²Shanxi Key Laboratory of Molecular Imaging, Shanxi Medical University, Taiyuan, CHINA, ³Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Taiyuan, CHINA.

OP-840
 In vitro functional assessment of cardiac membrane transporter P-glycoprotein with [¹⁸F]MC225 by using μ-engineered heart tissues
 W. Liu¹, M. Dannenberg², R. Slart¹, V. Schwach², G. Luurtsema¹;
 ¹University Medical Center Groningen, Groningen, NETHERLANDS, ²University of Twente, Enschede, NETHERLANDS.

OP-841
 Spatiotemporal TSPO Dynamics Predict Ventricular Remodeling in Pressure Overload: Early Inflammation to Late Mitochondrial Dysfunction
 Z. Xiang^{1,2,3}, L. Gao⁴, X. Liu^{1,2,3}, H. Song^{1,2,3}, Z. Qin^{1,2,3}, P. Wu^{1,2,3}, Z. Wu^{1,2,3}, S. Li^{1,2,3};
 ¹Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA, ²Shanxi Key Laboratory of Molecular Imaging, Shanxi Medical University, Taiyuan, CHINA, ³Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Taiyuan, CHINA, ⁴Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, and the Department of Physiology, School of Basic Medicine, Shanxi Medical University, Taiyuan, CHINA.

OP-842
 Assessment of cerebral blood flow in extracorporeal cardiopulmonary resuscitation in a pig model of prolonged cardiac arrest: a [¹⁵O]water PET study
 R. Berti¹, J. C. Fostitsch¹, B. A. Bretthauer², S. Brixius², L. Blum³, C. Scherer², J. Dinkelaker⁴, J. Haberstroh⁴, H. J. Busch³, C. Benk², G. Trummer², F. Beyersdorf², M. Mix¹, P. T. Meyer¹, J. S. Pooth³;
 ¹Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine – University of Freiburg, Freiburg, GERMANY, ²Department of Cardiovascular Surgery, Medical Center – University of Freiburg, Faculty of Medicine – University of Freiburg, Freiburg, GERMANY, ³Department of Emergency Medicine, Medical Center – University of Freiburg, Faculty of Medicine – University of Freiburg, Freiburg, GERMANY, ⁴Department of Experimental Surgery, Center for Experimental Models and Transgenic Service, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, GERMANY.

OP-843
 Dual-tracer PET/CT Reveals the Spatiotemporal Evolution Patternof Fibro-inflammatory InteractionsAfter Myocardial Infarction: A Longitudinal Rodent Study
 Y. Hong, J. Song, L. Li;
 First Hospital of Shanxi Medical University, Taiyuan, CHINA.

OP-844
 The dynamic process of cardiac fibroblast activation after myocardial infarction
 L. Wang¹, S. Huang², F. Shan¹, X. Ye², J. Lou¹, X. Liu¹;
 ¹Shanghai Pudong Hospital, Fudan University, Shanghai, CHINA, ²Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CHINA.

OP-845
 Preparation of a Novel P2X7 Targeted Nanobody Molecular Probe [¹⁸F]F-1c81 and micro PET Imaging Study of Atherosclerotic Plaque
 B. Hu, T. Mou, M. Yun, Y. Wang, X. Xu, Y. Tian, X. Zhang;
 Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.

1805

Wednesday, October 8, 2025, 9:45 - 11:15
 Room 211

TROP Session - Paediatrics Committee: Emerging Roles of Molecular Imaging in Paediatric Oncology, Neurology and Transplant Medicine

OP-846
 ¹⁸F-FDG PET Radiomics as a Prognostic Tool in Pediatric Ewing Sarcoma
 B. Soydas Turan¹, C. Küçüker², B. Volkan Salancı², P. Ozgen Kiratli²;
 ¹Kastamonu Training and Research Hospital, Department of Nuclear Medicine, Kastamonu, TÜRKIYE, ²Hacettepe University, Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-847
 Prognostic Value of Baseline ¹⁸F-FDG PET/CT Metabolic Parameters for Pediatric Nasopharyngeal Carcinoma Patients
 A. Pala, O. Kodaz, P. Özgen Kiratlı, B. Volkan Salancı;
 Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-848
 Utility of 18F-fluorodeoxyglucose positron emission tomography in presurgical evaluation of paediatric patients with Drug Resistant Epilepsy - A Concordance Analysis between PET/MRI and EEG
 A. Meena, A. Subramanyam, H. Singh, R. Kumar, B. Mittal;
 Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, INDIA.

OP-849
Extracranial Disease Burden in Paediatric Tuberculous Meningitis Characterised on F-18 FDG PET-CT
B. Berndorfler¹, J. M. Warwick¹, J. A. Seddon^{2,3}, C. Bekker³, R. S. Solomons¹, R. Van Toorn¹, A. G. G. Doruyster^{1,4};
¹Stellenbosch University, Cape Town, SOUTH AFRICA, ²Imperial College London, London, UNITED KINGDOM, ³Desmond Tutu TB Centre, Stellenbosch University, Cape Town, SOUTH AFRICA, ⁴NuMeRi Node for Infection Imaging, Stellenbosch University, Cape Town, SOUTH AFRICA.

OP-850
Prognostic Value of Quantitative Interim PET in Pediatric High-Grade Non-Hodgkin Lymphomas: Toward More Predictable Outcomes
G. Kaya¹, O. Kodaz², B. Volkan Salanci², B. Aydin³, P. Özgen Kiratlı²;
¹Republic of Türkiye, Ministry of Health, Yozgat City Hospital, Dept. of Nuclear Medicine, Yozgat, TÜRKIYE, ²Hacettepe University, Faculty of Medicine, Nuclear Medicine Dept., Ankara, TÜRKIYE, ³Hacettepe University, Faculty of Medicine, Paediatric Oncology Dept., Ankara, TÜRKIYE.

OP-851
Using radiomics based on 2-[¹⁸F]FDG PET/CT and machine learning methods to predict the WHO/ISUP grade of clear cell renal cell carcinoma
Y. Han¹, J. Zhang¹, Y. Pan², J. Cui¹, C. Li², Y. Wang³, G. Wang⁴, B. Xu²;
¹Graduate School, Chinese PLA General Hospital, Beijing, CHINA, ²Chinese PLA General Hospital, Beijing, CHINA, ³GE Healthcare China, Shanghai, CHINA, ⁴Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, CHINA.

OP-852
Dynamic 3D 12-headed CZT-detector ring SPECT/CT renal transplant MAG3 renography: a phantom and clinical implementation study
A. van de Burgt¹, Q. de Lussanet de la Sabloniere, M. Segbers, F. A. Verburg, A. A. Harteveld;
Erasmus MC, Rotterdam, NETHERLANDS.

OP-853
Comparison of [18F]F-FAPI and [18F]F-FDG PET/CT for Prediction of Treatment Response in Patients with Lupus Nephritis
M. Zhao¹, C. Zhou¹, X. Yi², X. Zhang²;
¹Third Xiangya Hospital of Central South University, Changsha, CHINA, ²Xiangya Hospital of Central South University, Changsha, CHINA.

OP-854
Diagnostic utility of renogram and SPECT-CT in the management of kidney transplant complications
A. Suazo Montero, J. Gómez Hidalgo, M. García Aragón, R. Zambrano Infantino, B. Jaramillo López, N. Álvarez Mena, F. Sebastián Palacid, C. Gamazo Laherrán, R. Ruano Pérez;
Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

1806
Wednesday, October 8, 2025, 9:45 - 11:15
Room 117
Clinical Oncology Track - TROP Session - Oncology & Theranostics Committee: Prostate Cancer Staging and Restaging

OP-855
Adaptive, MRI-Guided ¹⁶⁶Ho-TARE with Intra-Procedural Voxel-Based Dosimetry: First Results from EMERITUS-2
M. W. M. van Wijk¹, J. Roosen¹, M. J. Arntz¹, M. J. R. Janssen¹, E. T. T. J. Tjwa², J. F. W. Nijsen¹;
¹Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, NETHERLANDS.

OP-856
Gemcitabine/Cisplatin Plus Transarterial Radioembolization versus Transarterial Radioembolization Alone for Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Study
N. Coskun¹, A. Karacan¹, C. Sin², E. M. Kaya², G. Beydagi³, M. Ozdemir¹, T. Guzelbey², M. Topcuoglu³, A. Ozdemir¹, M. A. N. Sendur¹, M. Akdogan¹, M. Kaya², N. Alan Selcuk³, B. Esen Akkas², E. Cingi Ozdemir¹;
¹Bilkent City Hospital, Ankara, TÜRKIYE, ²Cam & Sakura City Hospital, Istanbul, TÜRKIYE, ³Yeditepe University, Istanbul, TÜRKIYE.

OP-857
Association of Tumor Response According to mRECIST and LI-RADS-TRA 2024 Criteria With Overall Survival After Yttrium-90 Transarterial Radioembolization in Hepatocellular Carcinoma: A Comparative Retrospective Analysis
E. Kaya¹, B. Akkas¹, T. Güzelbey², C. Erdim², M. Arslan², C. Şin¹, H. B. Kapucu¹, M. Kaya¹;
¹Basaksehir Cam and Sakura City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²Basaksehir Cam and Sakura City Hospital, Department of Radiology, Istanbul, TÜRKIYE.

OP-858
Exploring Radiomic and Dosiomic Features as Novel Predictors of Response to Yttrium-90 Radioembolization in Liver Cancer
A. Capotosti¹, R. Moretti¹, I. Moretti^{1,2}, M. Costa³, S. Cuttone³, L. Zagaria¹, L. Leccisotti¹, M. Calcagni^{1,2}, A. Posa¹, R. Iezzi^{1,2}, M. De Spirito^{1,2}, L. Indovina^{1,2}, L. Placidi¹;
¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ²Università Cattolica del Sacro Cuore, Rome, ITALY, ³Tecnologie Avanzate TA S.r.l, Turin, ITALY.

OP-859
Correlation of Voxel-Based Dosimetric Parameters With Progression-Free Survival and Overall Survival After Yttrium-90 Glass Microsphere Radioembolisation in Hepatocellular Carcinoma
H. Kapucu, E. Kaya, A. Dere, C. Sin, B. Esen Akkas, M. Kaya, K. Toplutas;
University of Health Sciences Cam Sakura City Hospital, Istanbul, TÜRKIYE.

OP-860
FAP-Targeted radiopeptide therapy (FRT) using ¹⁷⁷Lu-, ⁹⁰Y- and ²²⁵Ac-labelled 3BP-3940 in a large cohort of 105 patients
J. Zhang¹, T. Zhao¹, V. Jakobsson¹, L. Greifenstein², A. Eismant², A. Mishra², A. Klega², C. Landvogt², C. Mueller², D. Benz-Zils², O. Klein³, B. Jaeschke³, E. Perrone⁴, R. P. Baum²;
¹National University of Singapore, Singapore, SINGAPORE, ²DKD HELIOS Klinik, Wiesbaden, GERMANY, ³International Centers for Precision Oncology (ICPO), Wiesbaden, GERMANY, ⁴Università Cattolica del Sacro Cuore, Rome, ITALY.

OP-861
Dosimetric Correlation and Clinical Efficacy of ¹⁸⁸Re-N-DEDIC lipiodol Transarterial Radionuclide Therapy (TART) in Inoperable Hepatocellular Carcinoma: A Prospective Study
N. Kumar¹, S. Shamim¹, P. Gupta¹, G. Arora¹, S. Gamanagatti¹, D. Shalimar¹, V. Chirayil², S. Subramanian², M. B. Mallia², P. Thakral³, I. B. Sen³;
¹All India Institute of Medical Sciences, New Delhi, INDIA, ²BARC, Mumbai, INDIA, ³FMRI, Gurgaon, Haryana, INDIA.

OP-862
Targeting the Tumor Stroma: Safety and Efficacy of 3BP-3940-Based FAP Radiopharmaceutical Therapy in Advanced Metastatic Colorectal Cancer
J. Zhang¹, T. Zhao¹, A. Eismant², L. Greifenstein², J. Li¹, A. Klega², C. Landvogt², C. Mueller², R. P. Baum²;
¹National University of Singapore, Singapore, SINGAPORE, ²Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY.

OP-863
Efficacy of Intra-arterial [¹⁷⁷Lu]Lu-DOTATATE Monotherapy for Treatment-refractory Meningioma
A. El Ghalbouni^{1,2}, T. J. Snijders², A. Amerein³, N. Tolboom¹, M. Patt³, C. Maurer⁴, I. C. van der Schaaf¹, C. Lapa³, A. J. A. T. Braat¹;
¹Department of Radiology and Nuclear Medicine, UMC Utrecht, Utrecht, NETHERLANDS, ²Department of Neurology and Neurosurgery, Brain Center, UMC Utrecht, Utrecht, NETHERLANDS, ³Department of Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY, ⁴Department of Diagnostic and Interventional Neuroradiology, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY.

1807
Wednesday, October 8, 2025, 9:45 - 11:15
Room 212

TROP Session - Inflammation & Infection Committee: Infection/inflammation Under the Lens: Innovations in Nuclear Medicine Imaging

OP-864
Ventilation/Perfusion SPECT/CT in Patients with Long COVID Syndrome: A Multicenter Observational Study
P. Bonnefoy¹, P. Pascal², Q. Ceyrat³, S. Burg⁴, M. Razzouk-Cadet⁵, C. Moreau Triby⁶, I. Biancheri Mounicq⁷, J. Bourre⁸, P. Salaun⁹, P. Le Roux⁸;
¹CHU Saint-Etienne, Saint Etienne, FRANCE, ²CHU Toulouse Rangueil, Toulouse, FRANCE, ³Centre d'imagerie

Fonctionnelle, Bordeaux, FRANCE, ⁴GCS Médecine nucléaire, Ajaccio, FRANCE, ⁵CHU de Nice, Nice, FRANCE, ⁶CHU de Lyon, Lyon, FRANCE, ⁷CH Angoulême, Angoulême, FRANCE, ⁸CH Chambéry, Chambéry, FRANCE, ⁹CHU Brest, Médecine Nucléaire, GETBO, UMR1304, Brest, FRANCE.

OP-865
[¹⁸F]F-FDG PET/CT in IgG4-Related Disease: Phenotypic Classification and Clinical Correlations in a Cohort of 65 Patients
A. Bagán-Trejo¹, M. Pudis¹, X. Solanich², C. A. Tapias¹, G. Rocamora-Blanch², F. Climent³, M. Zamorano-Rivas¹, S. Maymó-Garrido⁴, C. García-Alcober⁴, M. Cortés-Romera¹;
¹Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Internal Medicine Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN, ³Pathology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ⁴Radiopharmacy Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

OP-866
Diagnostic value of labelled leukocyte scintigraphy in patients with low-grade periprosthetic joint infection
L. Lezaic¹, S. Roskar², R. Mihalic², V. Levasic¹, R. Trebse²;
¹University Medical Centre Ljubljana, Division of Nuclear Medicine, Ljubljana, SLOVENIA, ²Valdoltra Orthopaedic Hospital, Ankaran, SLOVENIA.

OP-867
Dynamic [¹⁸F]FDG PET/CT imaging in fracture-related infections to distinguish infection from inflammation
N. D. van Rijsewijk, M. Wouthuyzen-Bakker, J. H. van Snick, J. van Sluis, R. H. J. A. Slart, A. W. J. M. Glaudemans, F. F. A. Ijpma;
University Medical Center Groningen, Groningen, NETHERLANDS.

OP-868
Development and External Validation of Metabolic Tumor Volume Measures at Baseline [18F]FDG-PET/CT to Predict Treatment Failure and Relapse-Free Survival in Antibiotic-Naïve Patients with Pyogenic Spondylodiscitis
F. Lanfranchi^{1,2}, D. Albano^{3,4}, C. Delucchi², S. Maggio², V. Iannaccone², P. Furtuna^{3,4}, D. Dubois^{1,2}, F. Bertagna^{3,4}, G. Sambuceti^{1,2}, M. Bauckneht^{1,2};
¹Nuclear Medicine, Department of Health Sciences (DISSAL), University of Genoa, Genova, ITALY, ²IRCCS Ospedale Policlinico San Martino, Genova, ITALY, ³Nuclear Medicine, ASST Spedali Civili, Brescia, ITALY, ⁴University of Brescia, Brescia, ITALY.

OP-869
Added Value of FDG-PET Imaging in Patients with Spondylodiscitis
L. Reichel¹, R. Liang², S. Hirsch², B. Meyer², W. Weber¹, A. Jörger², S. Notohamiprodjo¹;
¹Department of Nuclear Medicine, TUM University Hospital, Munich, GERMANY, ²Department of Neurosurgery, TUM University Hospital, Munich, GERMANY.

OP-870
Identification of chronic musculoskeletal pain generators with [18F]FDG PET-MRI
J. Mostert¹, E. H. G. Oei¹, M. Ananta¹, G. S. R. Muradin¹, F. J. M. P. Huygen¹, C. C. de Vos¹, P. K. Bos¹, S. Biswal², R. A. van der

Heijden^{1,2};
¹Erasmus Medical Center, Rotterdam, NETHERLANDS,
²University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

OP-871
Clinical Utility of FDG PET/CT in the Management of Bloodstream Infections: Interim Results from A Single-Center Study

A. Karellis¹, G. Abikhzer^{1,2}, B. Bilodeau-Harnois^{1,2}, A. Roy^{1,2}, K. Weiss^{1,2};
¹Jewish General Hospital, Montréal, QC, CANADA, ²McGill University, Montréal, QC, CANADA.

OP-872
Diagnostic Utility of [¹⁸F]-FDG PET/CT in Guiding Biopsy Sites in Pyrexia of Unknown Origin; Site Concordance, Yield and ROC-Based Suvmax Threshold for Differentiating Between Benign and Malignant Etiology

K. Vengadesan, N. A. Damle, G. B. Priyanka, C. Ganapathy, M. Tripathi, C. Bal, M. Soneja, N. Nischal, P. Sethi, S. Jain, A. Singh, B. Prakash, R. Yadav;
All India Institute of Medical Sciences, New Delhi, INDIA.

1808

Wednesday, October 8, 2025, 09:45 - 11:15
Room 115

Joint Symposium 8 - Cardiovascular Committee / EACVI - Controversies in the Evaluation of Coronary Artery Disease

OP-872a
Risk Stratification: CT First!

M. Dweck; University of Edinburgh, Cardiology, Edinburgh, UNITED KINGDOM.

OP-872b
Risk stratification: MPI Get Me Out of Trouble!

M. Lyngby Lassen; The Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, DENMARK.

OP-872c
Guiding Patient Management: Look at the Anatomy with CT!

J. Geers; University Hospital Brussels, Department of Cardiology, Brussels, BELGIUM.

OP-872d
Guiding Patient Management: Surfing on the Flow with MPI!

C. Nappi; Department of Advanced Biomedical Sciences Federico II University, Naples, ITALY.

1809

Wednesday, October 8, 2025, 9:45 - 11:15
Room 133+134

e-Poster Presentations Session 14 - Radiation Protection Committee: Radiation Protection e-Poster Presentations Session

EPS-285

A radiation Life Cycle Assessment for TAT-isotopes
G. de With¹, M. Hakulinen², R. Kollaard¹, G. Sandker¹, A. Sarnelli³, E. Winters¹, SECURE partners of T4.2;
¹NRG PALLAS, Arnhem, NETHERLANDS, ²Kuopio University Hospital, Kuopio, FINLAND, ³IRST, Meldola, ITALY.

EPS-286

Targeted alpha therapy in clinical practice: a radiation protection assessment before implementation

A. Sarnelli¹, E. Mezzenga¹, R. Kollaard², E. Winters², G. De With², R. Mikolajczak³;
¹Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, ITALY, ²NRG|PALLAS, Petten, NETHERLANDS, ³Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, POLAND.

EPS-287

Radiation protection efficacy of a new device for the infusion of radiopharmaceuticals labeled with ¹⁷⁷Lu

M. Marengo¹, A. Zorz¹, L. M. Colombo Gomez¹, F. De Monte¹, M. Paiusco¹, L. Pompignoli²;
¹Veneto Institute of Oncology IOV – IRCCS, Padua, ITALY, ²Tema Sinergie, Faenza, ITALY.

EPS-288

Assessment of Early Excretion and Radiation Protection Considerations in ¹⁷⁷Lu-PSMA Therapy

F. Zagari¹, L. Vetrone², A. Farolfi², E. Lodi-Rizzini³, A. Golemi², S. Civollani¹, M. Maccagnani¹, L. Strigari¹, S. Fanti²;
¹Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Radiation Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EPS-289

Assessment of Patient Emitted Radiation and Caregiver Exposure Following ¹⁷⁷Lu-PSMA Therapy

P. Sheikhzadeh¹, S. Farzanehfar¹, M. Abbasi¹, Z. Bayat², M. Abdolmaleki³, F. Koosha³, N. Kasraie⁴;
¹Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Science and Research Branch, Islamic Azad University, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴UT Southwestern Medical Center, Dallas, TX, UNITED STATES OF AMERICA.

EPS-290

Nephroprotective effects of metformin in patients undergoing radioligand therapy

S. Kunte¹, M. Wu¹, L. Hempel¹, A. Holzgreve¹, M. Scheifele¹, T. Siegmund², J. Ells¹, F. J. Gildehaus¹, G. Böning¹, M. Unterrainer¹, L. M. Unterrainer¹, R. A. Werner¹, A. Delker¹, Z. Ells¹;
¹Department of Nuclear Medicine, LMU University

Hospital, Munich, GERMANY, ²Division for Endocrinology, Diabetology and Metabolism, Isar Clinic Munich, Munich, GERMANY.

EPS-291

(V)Are skin doses real? - experimental verification of estimated skin dose calculations.

K. Tallat-Szczotka¹, P. Begley², P. Colley², O. Harris³, K. Barrie², J. Poole-Jones²;
¹Barts Health NHS Trust, London, UNITED KINGDOM, ²University Hospitals Sussex NHS Foundation Trust, Brighton, UNITED KINGDOM.

EPS-292

A new model for Needlestick dosimetry using the measured activity profile of a needlestick with depth in tissue and VARSKIN+v1.3

W. Thomson, H. Benderz;
Midland Metropolitan University Hospital, Birmingham, UNITED KINGDOM.

EPS-293

Using VARSKIN+v1.3 with values of basal layer depth distribution to give accurate estimates of skin doses to the face, wrist, back-of-hand, arms/legs and trunk from contamination with alpha emitters Ra223, Pb212, Ac215, At211 and Th207

W. Thomson;
Midland Metropolitan University Hospital, Birmingham, UNITED KINGDOM.

EPS-294

Limits of detection of internal radiation exposure via DSB focus analysis in PBMcs

I. Strobel¹, H. Scherthan², K. Blaurock¹, S. Schumann¹, J. Müller², A. K. Buck¹, M. Port², M. Lassmann¹, U. Eberlein¹;
¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.

EPS-295

In-Silico Modeling of Radiation-Induced DNA Damage Complexity and Repair Kinetics after Mixed α-/β-Irradiation Using Geant4-DNA and MEDRAS

M. Salas Ramirez¹, I. Strobel¹, H. Scherthan², M. Lassmann¹, U. Eberlein¹;
¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Bundeswehr Institute of Radiobiology Affiliated to the University of Ulm, Munich, GERMANY.

EPS-296

Fetal radiation exposure from iodine-131 imaging during an unsuspected pregnancy

F. Simeonov¹, J. Vassileva¹, R. Ristova¹, A. Zagorska²;
¹National Centre of Radiobiology and Radiation Protection, Sofia, BULGARIA, ²Nuclear Medicine Department, Acibadem City Clinic Tokuda University Hospital, Sofia, BULGARIA.

EPS-297

Radiological protection measures in diagnostic techniques: results of a survey in Catalonia

D. Sánchez-Artuñedo¹, G. Reyes-Llompart², T. Canela-i-Col³, M. Fierro Alanís⁴, L. Prats-Cabaces⁵, M. Manel⁶, M. Milà López²;
¹Hospital Universitari Vall d'Hebron, Barcelona, SPAIN, ²Servei de Física Mèdica i Protecció Radiològica. Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, SPAIN, ³Servei de Medicina Nuclear. Hospital Universitari Vall

d'Hebron, Barcelona, SPAIN, ⁴Servei de Medicina Nuclear. Hospital Universitari Joan XXIII, Tarragona, SPAIN, ⁵Servei de Física Mèdica. Institut Català d'Oncologia, HU Germans Trias i Pujol, Badalona, SPAIN, ⁶Institut de diagnòstic per la Imatge. Serveis Corporatius, Barcelona, SPAIN, ⁷Hospital Universitari Joan XXII, Tarragona, SPAIN.

EPS-298

Considering the different biodistributions of ¹⁸F radiopharmaceuticals is crucial in calculating effective dose to public and caregivers

A. De Maggi¹, E. Murru¹, E. Roberto¹, M. Lio¹, A. Lanza², E. Bergalla², F. Bergesio¹, S. Chauvie¹;
¹Medical Physics Divisions of Santa Croce e Carle Hospital (Cuneo), Cuneo, ITALY, ²Univeristy of Turin, Turin, ITALY.

EPS-299

Belgian paediatric Diagnostic Reference Levels for whole-body and brain ¹⁸F-FDG PET/CT

T. Assoignon¹, M. Hesse², F. Dupont², F. Jamar²;
¹UCLouvain, Woluwe-Saint-Lambert, BELGIUM, ²Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, BELGIUM.

EPS-300

Establishing DRLs in [¹⁸F]FDG PET-CT: A Digital-Analog Comparison

A. Carvalho¹, R. Albergueiro¹, J. Vale², L. Cunha², C. Souto²;
¹ULS São João, Porto, PORTUGAL, ²Atrys, Porto, PORTUGAL.

EPS-301

Radiation dose reduction for low-dose CT in hybrid imaging with three generations of iterative reconstruction and varying denoising strengths

N. Bebbington¹, R. H. Kappel², J. W. Aunsborg², P. C. Holdgaard²;
¹Siemens Healthcare A/S, Ballerup, DENMARK, ²Lillebaelt Hospital-University Hospital of Southern Denmark, Vejle, DENMARK.

EPS-302

Estimation of infant gonad dose from urine contamination following Tc-99m MAG3 renal scintigraphy

T. Ball, A. Maenhout, N. A. Kapse, J. J. Phillips;
Chelsea and Westminster Hospital NHS Foundation Trust, London, UNITED KINGDOM.

EPS-303

Impact of Ionizing Radiation on Children whose Mothers Underwent Pulmonary Perfusion Scintigraphy with Technetium-99m Macroaggregated Albumin

P. Guijarro-Caba, J. Díaz-Alarcón;
Hospital Universitario de Jaén, Jaén, SPAIN.

EPS-304

Development of Lightweight, Flexible, and Lead-Free Epoxy-Based Composites for Gamma Radiation Shielding in Nuclear Medicine

F. Moradi¹, P. Sheikhzadeh¹, H. Mohammad Hosseini², A. Sajedi³;
¹Department of Nuclear Medicine, IKHC, Tehran University of Medical Sciences, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Iran polymer and petrochemical institute, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Composite Materials Laboratory, Faculty of Mechanical Engineering, Amirkabir University of Technology, Tehran Polytechnic, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EPS-305

Development of the first national event learning system in the UK

A. Powell, L. Fraser, U. Findlay, Y. Kinsella, N. Kirk; UK Health Security Agency, Oxford, UNITED KINGDOM.

1811

Wednesday, October 8, 2025, 9:45 - 11:15

Room 111

TROP Session - Oncology & Theranostics Committee: Radioembolisation and Novel Therapies

OP-873

Ga-PSMA-11 PET/CT in unfavourable intermediate and high-risk prostate cancer staging reduces unnecessaryprostatectomy: a prospective, an IAEA international multicentre study.

J. Cerci¹, S. Fanti², E. Estrada Lobato³, J. Kunikowska⁴, O. Garcia⁵, F. Novruzov⁶, R. Kumar⁷, A. Al-Ibraheem⁸, M. Haidar⁹, M. Nasir¹⁰, O. Kucuk¹¹, U. Elboga¹², F. Redondo Moneda¹³; ¹Quanta - Diagnóstico e Terapia, Curitiba, BRAZIL, ²IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Division of Human Health, International Atomic Energy Agency, Viena, AUSTRIA, ⁴Nuclear Medicine Department, Medical University of Warsaw, Warsaw, POLAND, ⁵Instituto Nacional de Cancerologia, Mexico, MEXICO, ⁶Nuclear Medicine Department, National Centre of Oncology, Baku, AZERBAIJAN, ⁷All India Institute of Medical Sciences, New Delhi, INDIA, ⁸King Hussein Cancer Center, Amman, JORDAN, ⁹American University of Beirut Medical Center, Beirut, LEBANON, ¹⁰Institute Kanser Negara, Putrajaya, Malaysia, MALAYSIA, ¹¹Ankara University, Ankara, TÜRKIYE, ¹²University of Gaziantep,, Gaziantep, TÜRKIYE, ¹³Complejo Asistencial Sotero del Río, Santiago Clínica Andes Salud,, Puerto Montt, CHILE.

OP-874

Interobserver and Intraobserver Agreement for Equivocal Lesions in Ga-68 PSMA PET/CT According to PSMA-RADS 2.0 Criteria

K. Niftaliyeva¹, S. Kesim², N. Filizoglu², Z. Balaban Genc¹, S. Özgüven¹, F. Çağlıyan¹, T. Öneş¹, F. Dede¹, H. Turoğlu¹, T. Erdil¹; ¹Marmara University Pendik Training and Research Hospital, Istanbul, TÜRKIYE, ²Kartal Dr. Lutfi Kırdar City Hospital, Istanbul, Turkey, Istanbul, TÜRKIYE.

OP-875

Preliminary Results from a Phase II Clinical Trial of Fully Integrated [¹⁸F]-PSMA PET/MRI for Diagnosing Clinically Significant Prostate Cancer

S. Ghezzi¹, A. Samanes Gajate¹, G. Brembilla², A. Stabile³, T. Russo², S. Capoferri⁴, G. Cristel², G. Gandaglia³, C. Bezzi¹, P. Mapelli¹, A. Briganti^{3,4}, F. De Cobelli^{2,4}, F. Montorsi^{3,4}, A. Chiti^{1,4}, P. Scifo¹, M. Picchio^{1,4}; ¹Nuclear Medicine Department, IRCCS San Raffaele, Milan, ITALY, ²Radiology Department, IRCCS San Raffaele, Milan, ITALY, ³Urology Department, IRCCS San Raffaele, Milan, ITALY, ⁴Vita-Salute San Raffaele University, Milan, ITALY.

OP-876

Quantitative Imaging Parameters Improve the Accuracy of PSMA PET/CT for the Local Staging of Primary Prostate Cancer

M. Donswijk¹, R. H. Ettema², M. Wondergem³, Z. Cheung¹, H. G. van der Poel¹, D. E. Oprea-Lager⁴, A. N. Vis²; ¹Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ²Amsterdam UMC - Locatie VUMC, Amsterdam, NETHERLANDS, ³Noordwest Ziekenhuisgroep, Alkmaar, NETHERLANDS, ⁴Radboud University Medical Center, Nijmegen, NETHERLANDS.

OP-877

Primary Staging of Intermediate- and High-Risk Prostate Cancer Patients using[¹⁸F]PSMA-1007-PET/CT and Na[¹⁸F]F-PET/CT: a Comparison of Diagnostic Accuracy, Stage, and Patient Management.

K. Buch-Olsen^{1,2}, M. H. Vilstrup³, S. Hansen^{1,2}, M. H. Poulsen³, P. C. Holdgaard⁴, K. E. A. Zieger⁴, S. S. Madsen³, J. T. Asmussen¹, J. Holm^{1,2}, K. T. Pedersen¹, S. Hess^{1,2}, O. Gerke^{1,2}, M. G. Hildebrandt^{1,2}; ¹Odense University Hospital, Odense, DENMARK, ²University of Southern Denmark, Odense, DENMARK, ³Esbjerg and Grindsted Hospitals, University of Southern Denmark, Esbjerg, DENMARK, ⁴Lillebaelt Hospital - University Hospital of Southern Denmark, Vejle, DENMARK.

OP-878

Incremental value of multiparametric F18 PSMA PET CT in comparison to conventional F18 PSMA PET CT in the diagnosis of prostate cancer

D. Malik, J. Gupta, N. Rana, M. Koley, D. Thakrani, A. Uppal, P. Thakral, I. B. Sen; Fortis Memorial research institute (FMRI), Gurugram, INDIA.

OP-879

Sensitivity of distinct segmentation thresholds to different PET-reconstruction algorithms in volumetric PSMA-PET assessment

D. Ufton, J. Heilingner, K. S. Roth, M. Schmidt, A. Drzezga, C. Kobe; University Hospital of Cologne, Department of Nuclear Medicine, Cologne, GERMANY.

OP-880

Towards Biopsy-Sparing Prostate Cancer Diagnosis:45%SUVmax-Based Radiomics with AdaBoost for Pathological Feature Prediction

C. Jianbo^{1,2,3}, G. Wang⁴, X. Meng¹, Y. Han^{1,2}, J. Zhang^{1,2}, Y. Liu^{1,2}, B. Xu¹; ¹Chinese PLA General Hospital, Beijing, CHINA, ²Graduate School, Chinese PLA General Hospital, Beijing, CHINA, ³Nuclear Medicine Department, The 983rd Hospital of the Joint Logistic Support Force, TianJin, CHINA, ⁴Beijing Friendship Hospital, Affiliated to Capital Medical University, Beijing, CHINA.

OP-881

A comparative analysis of normal organ biodistribution and tumor uptake pattern of novel RHN001-Dx (^{99m}Tc-PSMA) in correlation with tumor burden and its implications for theranostic use

S. Martlbauer¹, E. Mamlin¹, E. Novruzov¹, K. Mattes-György¹, Y. Mori¹, E. Winter², J. Cardinale¹, U. Haberkorn², C. Kratochwiß¹, F. L. Giesel¹; ¹Department of Nuclear Medicine, Medical Faculty and University Hospital Dusseldorf, Heinrich-Heine-University

Dusseldorf, Dusseldorf, GERMANY, ²Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY.

1901

Wednesday, October 8, 2025, 11:25 - 11:45

Auditorium

Closing Ceremony

OP-882

Closing Ceremony

V. Garibotto; Geneva University and Geneva University Hospitals, Geneva, SWITZERLAND.

e-Posters

EP-01

e-Poster Area

A: Preclinical and Translational Studies -> A1 Medical Preclinical -> A11 In Vitro Studies

EP-0001

Conversion of¹⁸F to³H-based autoradiography for PET tracer quantification

A. Van Eetveldt¹, F. Elvas¹, L. Liu², J. A. Bard³, D. Bertoglio¹, S. Staelens¹; ¹University of Antwerp, Wilrijk, BELGIUM, ²CHDI foundation, Los Angeles, CA, UNITED STATES OF AMERICA.

EP-0002

Evaluation of purinergic P2X7 receptor level in Alzheimer's disease patients

R. Ni¹, C. Maschio¹, O. Moreno², J. Wang³, U. Maheshwari⁴, A. Keller⁴, A. Rominger³, U. Konietzko¹, A. Nordberg⁵, D. Razansky¹, C. Hock¹, J. Llop², R. Nitsch¹; ¹University of Zurich, Zurich, SWITZERLAND, ²CIC biomaGUNE, San Sebastián, SPAIN, ³Inselspital, Bern, SWITZERLAND, ⁴University Hospital Zurich, Zurich, SWITZERLAND, ⁵Karolinska Institutet, Stockholm, SWEDEN.

EP-0003

First Steps Towards Developing a Dual-Targeted Radionuclide Theranostic Strategy Combining PSMA- and GRPR-Targeting radiopharmaceuticals for Prostate Cancer Management.

L. Bokhout, J. de Swart, S. U. Dalm; Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS.

EP-0004

Enhanced Glioblastoma Targeting and Therapeutic Efficacy with⁶⁴Cu-NOTA-TP-c(RGDfK)

A. Mirzaei, S. Samia Ait-Mohand, P. Mercy Ignatius, É. Rousseau, B. Guérin; Department of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, CANADA.

EP-0005

Novel Dynamic Cardiac Phantom for Comparison of Cardiac Volumes and LVEF Between CZT-ERNA and PET-MPI

M. Nielsen^{1,2}, R. Wozniak¹, T. C. Hansen¹, L. L. Duchstein¹, J. D. Hermansen³, S. Hvidsten⁴, L. T. Jensen^{1,2}, B. Zerahn¹; ¹Dept. of Nuclear Medicine, Copenhagen University Hospital – Herlev and Gentofte, Herlev, DENMARK, ²Dept. of Clinical Medicine, University of Copenhagen, Copenhagen, DENMARK, ³Medical Technology Dept., Køge Hospital, Køge, DENMARK, ⁴Dept. of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

EP-0007

Radiolabelled alginate nanoparticles - developing a peptide targeting radiotherapeutic approach to cancer treatment

M. Dornish¹, J. Dahle², S. Al-Haidar³, K. H. Ferning³; ¹Blue Wave Therapeutics AS, Sandvika, NORWAY, ²Department of Oncology Akershus University Hospital, Nordbyhagen, NORWAY, ³Minerva Imaging ApS, Ølstykke, DENMARK.

EP-0008

The effectiveness of targeted lead-212 alpha therapy and EBRT in neuroendocrine spheroids

K. Grayson¹, P. M. D. Gape¹, M. Patel¹, M. Riiabova¹, L. Wagner², M. K. Schultz², G. Stasiuk¹, S. Y. A. Terry¹; ¹King's College London, London, UNITED KINGDOM, ²DKFZ German Cancer Research Center, Heidelberg, GERMANY, ³Perspective Therapeutics, Coralville, IA, UNITED STATES OF AMERICA.

EP-0009

Preclinical Evaluation of NK-1R-Targeting Molecule in Epithelial Cancer Cell Lines.

T. Xu¹, S. Chopra¹, U. Yngve^{2,3}, Z. Wang¹, H. Yushchyshyna¹, P. Jha¹, U. Rosenström², M. Nestor¹; ¹Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, Uppsala, SWEDEN, ²Department of Medicinal Chemistry, Preparative Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN, ³Science for Life Laboratory (SciLifeLab), Drug Discovery and Development platform, Uppsala, SWEDEN.

EP-0010

Exploring [¹⁸F]FAPI-74 as a diagnostic tool in vulvar cancer: in vitro evaluation and preliminary results

A. Florit^{1,2}, M. Ruggiero³, S. Fragomeni⁴, A. Piermattei⁵, T. Pasciuto^{6,7}, A. Federico⁴, E. Martinelli⁸, F. Alcaro⁴, G. Zannoni^{5,9}, L. Alici¹⁰, L. de Geus-Oei^{1,11,12}, S. Annunziata², F. H. P. van Velden¹¹, A. Fagotti^{4,8}, V. Rufin^{2,13}, C. Nero^{4,8}, G. Garganese^{4,8}, A. Collarino²; ¹Biomedical Photonic Imaging Group, University of Twente, Enschede, NETHERLANDS, ²Nuclear Medicine Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY, ³PET/CT Centre, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY, ⁴Gynaecologic Oncology Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY, ⁵Anatomical Pathology Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY, ⁶Research Core Facility Data Collection G-STeP, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY, ⁷Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, ITALY, ⁸Section of Obstetrics

and Gynaecology, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, ITALY, ⁹Section of Pathology, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, ITALY, ¹⁰Magnetic Detection & Imaging Group, University of Twente, Enschede, NETHERLANDS, ¹¹Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS, ¹²Department of Radiation Science and Technology, Delft University of Technology, Delft, NETHERLANDS, ¹³Section of Nuclear Medicine, University Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, ITALY.

EP-0011
Is radiolabelling a PARP inhibitor with a radiometal via a DOTA chelator a viable strategy for PARP-targeted radionuclide therapy (TRT)?
A. Kurniawan¹, Z. Ming¹, M. Boëtius², W. Szymanski², S. Blok¹, P. Elsinga¹, I. Antunes¹, E. de Vries¹, B. Cornelissen¹; ¹Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, ²Department of Medicinal Chemistry, Photopharmacology and Imaging, Groningen Research Institute of Pharmacy, Faculty of Science and Engineering, University of Groningen (RUG), Groningen, NETHERLANDS.

EP-0012
DNA damage in thyroid cancer patients treated with radioactive iodine
S. Kagodora, M. Vangu; University of Witwatersrand, Johannesburg, SOUTH AFRICA.

EP-0013
In vitro evaluation of [¹⁸F]SYN2 effect on mouse myoblast and human cardiomyocyte cell lines.
K. Gotowicz^{1,2}, K. Archacka³, A. Ostaszewska³, M. Zimowska³, S. Krajewski¹, J. Włostowska¹, C. Kozanecki¹; ¹Synektik S.A. Research and Development Center, Warsaw, POLAND, ²University of Warsaw, Faculty of Chemistry, Warsaw, POLAND, ³University of Warsaw, Faculty of Biology, Warsaw, POLAND.

EP-0014
Targeting the Tumor Microenvironment via Fibroblast Activation Protein (FAP): A 3D Co-Culture Model for FAP-Targeted Alpha Therapy in Prostate Cancer
S. Kvarsvik Kristiansen¹, N. Dernjani², A. Juzeniene¹; ¹Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, NORWAY, ²Department of Molecular Biology, Norwegian University of Life Science, Ås, Norway, Oslo, NORWAY.

EP-0015
Quantitative Analysis of KiSS-1R Cell Surface Expression in Triple-Negative Breast Cancer Using Dye-Conjugated Kisspeptins
L. Kovacs, H. Taş, U. Bauder-Wüst, M. Schäfer, M. Benesova-Schäfer; German Cancer Research Center (DKFZ), Heidelberg, GERMANY.

EP-0016
Beyond PSMA Targeting: What Truly Drives the Radiotoxicity of the Alpha-Emitting [²¹²Pb]Pb-AB001?

R. Liukaityte¹, V. Stenberg^{2,1}, S. Kvarsvik Kristiansen¹, A. Kleinauskas^{3,1}, A. Juzeniene^{1,3}; ¹Oslo University Hospital, Oslo, NORWAY, ²ARTBIO AS, Oslo, NORWAY, ³University of Oslo, Oslo, NORWAY.

EP-0017
Treatment efficacy and DNA damage induced by [¹⁶¹Tb]Tb-PSMA I&T vs [¹⁷⁷Lu]Lu-PSMA I&T in prostate cancer cell lines
M. Kirienko, E. Jachetti, R. Sulsenti, C. Cucchi, C. Beretta, A. Bogni, C. Pascali; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, ITALY.

EP-02
e-Poster Area
A: Preclinical and Translational Studies -> A1 Medical Preclinical -> A12 Preclinical Cardiology and Neurology

EP-0018
Assessment of early-phase [¹⁸F]Florbetaben images as a proxy for brain metabolism in mouse models of Alzheimer's disease
R. Gröger¹, A. Englert¹, M. Lalia¹, L. de Weerd², M. Rovere², C. Haass², S. Tahirovic², R. Werner¹, M. Brendel¹, J. Gnörich¹; ¹Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY, ²German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY.

EP-0019
Adjustment for Perfusion Masks Hypermetabolism in FDG-PET imaging of Aging Rodents
M. Lalia¹, S. Wagner¹, J. Thevis¹, L. Bartos¹, L. Kunze¹, S. Roemer-Cassiano², N. Franzmeier³, S. Tahirovic⁴, R. Werner¹, M. Brendel^{1,4,5}, J. Gnörich^{1,4}; ¹Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY, ²Department of Neurology, LMU University Hospital, Munich, GERMANY, ³Institute for Stroke and Dementia Research, LMU University Hospital, Munich, GERMANY, ⁴German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY, ⁵Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.

EP-0020
Metabolic Kinetics Study of a Novel TDP-43 Targeted Molecular Probe
Y. Kong¹, B. He¹, J. Xu¹, A. Xu¹, C. Yang², D. Ng², W. Lam², Z. Zhang¹, Y. Guan¹; ¹Huashan Hospital, Fudan University, Shanghai, CHINA, ²Singapore General Hospital, Singapore, SINGAPORE.

EP-0021
Multimodal Assessment of Isoproterenol-Induced Cardiac Injury in a Mouse Model of Type 2 Myocardial Infarction
K. Vandoorne¹, C. Zeltser Dekel¹, T. Yoganathan¹, N. Kalish-Achrai¹, N. Hajj¹, M. Berihu¹, B. Tavitian², S. Karni-Ashkenazi¹; ¹Technion - Israel Institute of Technology, Haifa, ISRAEL, ²Université Paris Cité, Inserm, Paris, FRANCE.

EP-0022
Pioglitazone Mitigates Immunotherapy-Induced Neuroinflammation in an Alzheimer's Disease Mouse Model: Longitudinal TSPO- and Aβ-PET Study
A. Zatcepin^{1,2}, K. Wind-Mark^{1,2}, G. Palumbo¹, L. Kunze¹, M. Willem³, F. Gildehaus¹, S. Lindner¹, L. M. Bartos¹, G. Biechele¹, R. Werner¹, N. L. Albert^{1,4,5}, S. I. Ziegler^{1,6}, M. Brendel^{1,2,7}; ¹Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ²German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY, ³Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, LMU Munich, Munich, GERMANY, ⁴German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ⁵Bavarian Cancer Research Center (BZKF), Erlangen, GERMANY, ⁶Department of Nuclear Medicine, Hannover Medical School (MHH), Hannover, GERMANY, ⁷Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.

EP-0023
First Longitudinal Characterization of Aluminum-Induced Neuroinflammation in the Rat Hippocampus Using TSPO-PET Imaging
Z. Xiang^{1,2,3}, J. Zhang^{4,5}, Y. Zhang^{1,2,3}, S. Wang^{4,5}, Z. Qin^{1,2,3}, H. Wang^{1,2,3}, Q. Niu⁵, S. Li^{1,2,3}; ¹Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA, ²Shanxi Key Laboratory of Molecular Imaging, Shanxi Medical University, Taiyuan, CHINA, ³Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Taiyuan, CHINA, ⁴Key Laboratory of Coal Environmental Pathogenicity and Prevention, Ministry of Education, Shanxi Medical University, Taiyuan, CHINA, ⁵Department of Labor Health, School of Public Health, Shanxi Medical University, Taiyuan, CHINA.

EP-0024
Combining Dopamine Transporter and Amyloid PET Tracer: A Preclinical Study on Dual-Target Imaging
B.-N. Park¹, Y.-S. An²; ¹Ajou University Hospital, Suwon, Gyeonggi-Do, KOREA, REPUBLIC OF, ²Ajou University Hospital, Suwon, KOREA, REPUBLIC OF.

EP-0025
Fibroblast-Specific Txndc5 Deletion Attenuates Myocardial Fibroblast Activation Following Acute Myocardial Infarction as Demonstrated by ¹⁸F-FAPI-74 PET/CT
K.-Y. Ko¹, C.-J. Liu², T.-Y. Lee², C.-H. Chiu², K.-C. Yang³, M.-F. Cheng²; ¹National Taiwan University Cancer Center, Taipei, TAIWAN, ²National Taiwan University Hospital, Taipei, TAIWAN, ³National Taiwan University College of Medicine, Taipei, TAIWAN.

EP-0026
Application of ¹⁸F-D₂-LW223 in the rat model of ischemic stroke
Liao¹, Z. Wang², W. Li², H. Pang²; ¹Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-0027
Partial volume characterization in mouse cardiac PET imaging using 3D-printed radioactive partition-less left ventricular phantoms

O. Sarhini, J.-F. Beaudoin, T. Galarneau, R. Lecomte; Université de Sherbrooke, Sherbrooke, QC, CANADA.

EP-0028
Evaluation of cardiotoxicity induced by doxorubicin using a FABP3-selective tracer, [¹⁸F]LUF
J. Toyohara¹, T. Komoda², T. Tago¹, M. Ito², H. Yoshino²; ¹Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi-ku, Tokyo, JAPAN, ²Shiratori Pharmaceuticals Co., Ltd., Narashino, Chiba, JAPAN.

EP-03
e-Poster Area
A: Preclinical and Translational Studies -> A1 Medical Preclinical -> A13 Preclinical Oncology

EP-0029
In Vitro evaluation of a ⁶⁴Cu-labeled PSMA-terpyridine conjugate as a potential radiotheranostic agent for prostate cancer
H. Talebian, S. Ait-Mohand, P. Mercy Ignatius Arokia Doss, L. Sanche, B. Guerin; ¹Université de Sherbrooke, Sherbrooke, QC, CANADA.

EP-0030
Dual-locked targeted alpha-emitter enhanced tumor immunotherapy via Diels-Alder reaction-based self-immolative molecular cage strategy
F. Yu¹, M. Yang¹, Y. Feng², K. Shi³, T. Watabe⁴, K. Kabayama⁴, K. Fukase⁴; ¹Department of Nuclear Medicine, Shanghai Tenth People's Hospital and Institute of Nuclear Medicine, School of Medicine, Tongji University, Shanghai, CHINA, ²Department of Radiology, Duke University Medical Center, Durham, NC, UNITED STATES OF AMERICA, ³Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND, ⁴Institute for Radiation Sciences, Osaka University, Osaka, JAPAN.

EP-0031
Camouflaged Membrane-Bridged Radionuclide/Mn Single Atom Enzymes Target Lipid Metabolism Disruption to Evoke Antitumor Immunity
M. Yang¹, F. Yu¹, K. Shi², T. Watabe³, K. Kabayama³, K. Fukase³, Y. Feng⁴; ¹Department of Nuclear Medicine, Shanghai Tenth People's Hospital and Institute of Nuclear Medicine, School of Medicine, Tongji University, Shanghai, CHINA, ²Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND, ³Institute for Radiation Sciences, Osaka University, Osaka, JAPAN, ⁴Department of Radiology, Duke University Medical Center, Durham, NC, UNITED STATES OF AMERICA.

EP-0032
Metabolic stability-dependent targeting of NTS₁ R-tumors in mice, as exemplified by [^{99m}Tc]Tc-DT1 and its branched versions [^{99m}Tc]Tc-DT10 and [¹¹¹In]In-DT14D
P. Kanellopoulos¹, T. Maina-Nock¹, B. A. Nock¹, E. P. Krenning²; ¹Molecular Radiopharmacy, INRaSTES, NCSR Demokritos, 15341 Athens, GREECE, ²Cyclotron Rotterdam BV, Erasmus MC, 3015 CE Rotterdam, NETHERLANDS.

EP-0034

The application of crown chelator in Ac-225 and Tb-161 PRRT

H. Yang^{1,2,3}, L. Wharton¹, S. W. McNeil^{1,2}, C. Zhang⁴, A. Ingham¹, C. Rodríguez-Rodríguez², H. Merkens^{4,2}, M. Van de Voorde⁵, M. Ooms⁵, F. Bénard^{4,2};
¹TRIUMF, Vancouver, BC, CANADA, ²The University of British Columbia, Vancouver, BC, CANADA, ³Simon Fraser University, Burnaby, BC, CANADA, ⁴BC Cancer, Vancouver, BC, CANADA, ⁵SCK CEN, Mol, BELGIUM.

EP-0035

Development of FL-261 as a theranostic RDC vector for the diagnosis and treatment of c-MET overexpression cancers

J. Yang, G. Jiang, J. Xia, J. Zhang, F. Liu;
 Full-Life Technologies, Shanghai, CHINA.

EP-0036

Breaking New Frontiers in In Vivo Molecular Imaging: Multiplex Cancer Fingerprinting on MRI using 3-[¹⁹F]FDGal

D. Cohen, B. Subramani, L. Saad, M. Fisler, L. Avram, T. Harris, H. Allouche-Arnon, A. Bar-Shir;
 Weizmann Institute of Science, Rehovot, ISRAEL.

EP-0037

Multimodal Imaging for Response Assessment to Combined anti-PD-L1/anti-CTLA-4 Immunotherapy in a Murine Melanoma Model: A Comparative Evaluation of [¹⁸F]FDG-PET/CT, MRI and CEUS

M. J. Antons¹, F. Herr¹, M. M. Heimer¹, H. Hirner-Eppeneder¹, R. Oos², G. Palumbo², J. Stueckl¹, S. Kloiber¹, A. Cimic¹, L. V. Blume¹, S. Lindner², D. Clevert¹, M. Brendel^{2,3}, J. Ricke¹, R. A. Werner^{2,4}, C. C. Cyran¹;
¹Department of Radiology, LMU University Hospital, LMU Munich, Munich, GERMANY, ²Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ³Munich Cluster for Systems Neurology (SyNergy), University of Munich, Munich, GERMANY, ⁴The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

EP-0038

Preclinical Comparison of 68 Ga-DOTA-LM3 and 68Ga-DOTATATE for SSTR2-Targeted Imaging in C6 Glioma Model

M. Pirdadeh¹, M. Nasiri², R. Nami¹, S. Mazidi Sharaf Abadi¹, A. Gravand¹, R. Salehi¹, M. Ghapanvari¹, M. Samizadeh¹, H. Vosoughi³, E. Jafari⁴, M. Dehghani¹, S. Jamalabadi¹, M. Kashani¹, M. Safari¹, A. Abolhosseini Shahrnoy¹;
¹Pars Isotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Cellular and Molecular Biology, School of Biology, Damghan University, Damghan, IRAN, ISLAMIC REPUBLIC OF, ³Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Bushehr University of Medical Science, Bushehr, IRAN, ISLAMIC REPUBLIC OF.

EP-0039

Multi - dimensional Transcriptomic Integration Identifies Molecular Markers for Predicting Radioactive Iodine - Refractory Thyroid Cancer Progression and Novel Targeted Therapies

J. Quan, G. Zhu;
 First Affiliated Hospital of Kunming Medical University, Kunming, CHINA.

EP-0041

Understanding the Impact of Lung Cancer Cell-of-Origin and the Immune Cell Composition on Tumour Metabolic Heterogeneity with RadioFlow

I. Caldera-Quevedo¹, C. Vranka^{1,2}, D. Solovyev¹, G. Brown¹, F. Edgar¹, R. Bielik¹, D. Y. Lewis¹;
¹Cancer Research UK Scotland Insititute, Glasgow, UNITED KINGDOM, ²Medical University of Vienna, Vienna, AUSTRIA.

EP-0042

Investigation of Innovative ⁶⁸Ga-Labeled σ₂ Receptor-Targeted Proliferation Probes

X. Cai, Y. Jiajun, Y. Kangxia, Y. Weidong, K. Fei, W. Jing;
 Air Force Medical University, Xi'an, CHINA.

EP-0043

Synergistic Antitumor Efficacy of Bimiralisib (PQR309) Combined with ¹⁷⁷Lu-PSMA-617 Radionuclide Therapy in PSMA-Expressing Tumors

Q. Wu^{1,2,3}, X. Yao^{1,2,3}, X. Duan^{1,2,3}, R. P. Baum⁴, T. Zhao^{1,2,3}, J. Zhang^{1,2,3};
¹Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, ²Theranostics Center of Excellence (TCE), Yong Loo Lin School of Medicine, National University of Singapore, 11 Biopolis Way, Helios, Singapore 138667, Singapore, Singapore, SINGAPORE, ³Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, ⁴Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY.

EP-0044

Biodistribution of the novel CXCR4-directed PET tracer [⁶⁸Ga]Ga-NOTA-R54 in Patient-Derived Xenograft models of lung cancer

I. Alberico¹, M. Gentili¹, M. Pitzalis¹, G. Bertolini¹, F. Facchinetti¹, C. Cucchi¹, F. Rizzo¹, C. Beretta¹, M. Kirienko¹, C. Chiesa¹, M. Maccauro¹, S. Di Maro², S. Scala³, A. Bogni¹, C. Pascali¹, L. Roz¹;
¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, ITALY, ²University of Campania "Luigi Vanvitelli", Caserta, ITALY, ³Istituto Nazionale per lo Studio e la Cura dei Tumori-IRCCS-Fondazione "G. Pascale", Naples, ITALY.

EP-0045

High resolution autoradiography based imaging visualizes chemotherapy induced metabolic suppression in colorectal cancer organoids

Z. Jiang, K. Draganic, G. Egger, H. Marcus, E. Patronas;
 Medical University of Vienna, Vienna, AUSTRIA.

EP-0046

Low-dose Fibronectin-targeted Gd-based contrast agent Enables Early and Accurate Assessment of Chemotherapy Response in Pancreatic Cancer

W. Zhang¹, Y. Du²;
¹Peking University People's Hospital, Beijing, CHINA, ²Institute of Automation, Chinese Academy of Sciences, Beijing, CHINA.

EP-0047

Image-derived Blood Normalization for TREM2 PET Imaging in Glioblastoma Mice Enhances Sensitivity during Monitoring of Immunomodulation

M. Haertel¹, R. Schaefer¹, L. H. Kunze¹, K. Schlepckow², M. Willem², C. Haass^{2,3,4}, G. Palumbo¹, J. W. Lewcock⁵, K. M. Monroe⁵, R. A. Werner¹, N. L. Albert^{1,6,7}, L. von Baumgarten^{8,9},

L. M. Bartos¹, S. Lindner^{1,4}, M. Brendel^{1,2,4};
¹Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ²German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY, ³Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig Maximilians University, Munich, GERMANY, ⁴Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY, ⁵Denali Therapeutics, Inc., South San Francisco, CA, UNITED STATES OF AMERICA, ⁶German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ⁷Bavarian Cancer Research Center (BZKF), Erlangen, GERMANY, ⁸German Cancer Consortium (DKTK), Partner Site Munich, Munich, GERMANY, ⁹Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, GERMANY.

EP-0049

Use of blocking agent re-distributes alpha-emitter astatine-211, in free form, after targeted alpha therapy

T. Bäck¹, E. Aneheim², H. Jensen³, S. Palm¹;
¹Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, ²Sahlgrenska University Hospital, Gothenburg, SWEDEN, ³Copenhagen University Hospital, Copenhagen, DENMARK.

EP-0050

Preclinical Evaluation of a Novel PSMA-Targeted Nanobody Radiopharmaceutical [¹⁷⁷Lu]Lu-Ab0362-H0202 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

B. Li, X. Wu, Y. Gao;
 Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People's Hospital; Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, CHINA.

EP-0051

Effects of adding Arg and Arg-Arg to the linker of GRPR antagonist tracer, [⁶⁸Ga]Ga-TacsBOMB5, on its invitro/ vivo capability

S. Pathania¹, L. Wang¹, C. Chen², P. Ng², W. Lau², F. Radnia³, F. Bénard², K. Lin¹;
¹University of British Columbia, Vancouver, BC, CANADA, ²BC Cancer Research Institute, Vancouver, BC, CANADA, ³UBC, Vancouver, BC, CANADA.

EP-0052

Noninvasive PET imaging of Trop2 expression in bladder cancer using ⁶⁴Cu-labeled anti-Trop2 antibody-drug conjugate (Trodelvly)

L. Kang¹, W. Huang¹, Q. Yang¹, W. Cai²;
¹Dept. of Nuclear Medicine, Peking University First Hospital, Beijing, CHINA, ²University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-0053

First-in-Primate PET Imaging of a BCMA-Targeted ImmunoPET Probe for Multiple Myeloma

L. Kang, T. Wang, Q. Yang, X. Sun, Y. Lei, L. Song;
 Dept. of Nuclear Medicine, Peking University First Hospital, Beijing, CHINA.

EP-0054

Preclinical evaluation of ⁶⁸Ga-labeled PD-L1 nanobody for PET imaging of pharmacokinetics in gastric cancer

L. Kang, Q. Yang, T. Wang, X. Sun, L. Song, W. Huang;
 Dept. of Nuclear Medicine, Peking University First Hospital, Beijing, CHINA.

EP-0055

Multimodal PET Imaging Monitors Tumor Cell Vaccine Combined with Immunoadjuvant Therapy for Colorectal Cancer

N. Wei, M. Hu, Y. Long, P. Yuan, Y. Gai, X. Lan;
 Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0056

Evaluation of a Novel Long-acting FAPI in HEK-293-FAP Solid Tumor Model

L.-C. Chen, W.-L. Lo;
 National Atomic Research Institute, Taoyuan City, TAIWAN.

EP-0057

Validating CD44v6 as targeted for molecular radiotherapy of gastric cancer

S. Rinne, Z. Wang, M. Nestor;
 Uppsala University, Uppsala, SWEDEN.

EP-0058

Preclinical evaluation of [¹⁶¹Tb]Tb-pypa-p-Phe-trastuzumab in SKOV3-tumor-bearing mice

M. Ligeour, I. R. Astiazarán-Rascón, L. Li, H. Merkens, P. Ng, W. Lau, M. Jaraquemada-Peldez, F. Bénard;
 BC Cancer, Vancouver, BC, CANADA.

EP-04

e-Poster Area

A: Preclinical and Translational Studies -> A1 Medical Preclinical -> A14 Preclinical Therapy

EP-0059

Predictors of Iodine-131 Therapy Outcomes in Obese Thyroid Cancer Patients

Y. Zhou^{1,2,3}, Y. Hou^{1,2,3}, X. Xia^{1,2,3};
¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²Hubei Province Key Laboratory of Molecular Imaging, Wuhan, CHINA, ³Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, CHINA.

EP-0060

Multifunctional Biomimetic Nanocarriers Orchestrated by Radionuclide Click Chemistry for Synergistic and Precision Tumor Intervention

R. Wu^{1,2,3}, Z. Gao^{1,2,3}, X. Xia^{1,2,3};
¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²Hubei Province Key Laboratory of Molecular Imaging, Wuhan, CHINA, ³Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, CHINA.

EP-0061

[¹⁶¹Tb]Tb-DOTA-PSMA I&T Exerts Antitumour Effects and Induces Immune Activation in 2D and 3D Prostate Cancer Coculture Models

Z. Ming, A. Kurniawan, C. Wu, I. Farina Antunes, E. F. J. de Vries, B. Cornelissen;
 UMCG, Groningen, NETHERLANDS.

EP-0062

Multi-tracer PET monitoring of an immunomodulatory therapy in 4R tauopathy: Evaluating a novel drug's impact on glial function and protein pathology

T. Bathe^{1,2}, S. Salomasova¹, M. Lalia¹, G. Palumbo¹, R. Oos¹, E. Joseph¹, R. Schaefer¹, R. A. Werner¹, M. Brendel^{1,2,3}, L. H. Kunze^{1,4};

¹LMU Hospital - Department of Nuclear Medicine, Munich, GERMANY, ²Graduate School of Systemic Neurosciences (GSN), Munich, GERMANY, ³Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY, ⁴German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY.

EP-0064

Assessment of [225Ac]Ac-DOTATATE for targeted radioligand therapy in neuroblastoma

M. Nestor¹, H. Berglund¹, S. Rinne¹, S. Chopra¹, H. Alfredeen², T. Bergström¹, F. J. Swartling¹, A. Kristian³, T. Tran², J. Stenman⁴;

¹Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, Uppsala, SWEDEN, ²Department of Oncology and Pathology, Karolinska Institutet, Stockholm, SWEDEN, ³Biomedical Research, Novartis Pharma AG, Basel, SWITZERLAND, ⁴Department of Women's and Children's Health, Karolinska Institutet, Stockholm, SWEDEN.

EP-0065

Preclinical In Vivo Imaging of ²²⁵Ac Daughters in Oncology Models

T. Karampelas, M. Rouchota, E. Lambidis, C. Arapatzi, A. Zacharioudaki; BIOEMTECH, Athens, GREECE.

EP-0066

Clinical-Grade Production and Quality Control of ²²⁵Ac-FAP2286 for First-in-Human Application

H. khoshhosn¹, M. Davarpanah¹, S. Banihashemian², A. Abolhoseini¹, M. Nasiri³, R. Nami¹, M. Kandi Dayeni¹, M. Mohebalil¹, M. Kashani¹, J. Abedi¹; ¹Pars Isotope company, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Cellular and Molecular Biology, School of Biology, Damghan University, Damghan, IRAN, ISLAMIC REPUBLIC OF.

EP-0067

Theranostic application of ⁸⁹Zr/¹⁷⁷Lu-labeled anti-RANKL monoclonal antibody in multiple myeloma tumor models

H. Yan¹, R. Zhang¹, X. Wang¹, Z. Huang¹, C. Xu¹, Z. Li¹, P. Chen², J. Li¹, M. Dong¹; ¹Department of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, CHINA, ²Department of Pharmacy, Peking University Shenzhen Hospital, Shenzhen, CHINA.

EP-0068

161[Tb]Tb-DOTATATE as a novel approach to SSTR2-targeted neuroblastoma therapy

S. Chopra¹, T. Xu¹, H. Berglund¹, R. Selvaraju², M. Nestor¹; ¹Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, Uppsala, SWEDEN, ²Department of Medicinal Chemistry, Preclinical PET-MRI Platform, Uppsala University, Uppsala, Sweden, Uppsala, SWEDEN.

EP-0069

Preclinical development of [¹⁶¹Tb]Tb-DOTA-HYNIC-panPSMA and comparison with [¹⁷⁷Lu]Lu-DOTA-HYNIC-panPSMA, [¹⁶¹Tb]Tb-DOTA-J591 and [¹⁷⁷Lu]Lu-DOTA-J591

J. Roetman¹, C. Morgat², L. Ali², S. Bodin², E. Hindie²; ¹Telix Pharmaceuticals, Melbourne, AUSTRALIA, ²University Hospital of Bordeaux, Bordeaux, FRANCE.

EP-0070

DNA Damage Repair Inhibition boots Radiopharmaceutical Therapy for Triple Negative Breast Cancer

Y. Medina Guevara, H. Comas Rojas, O. Bio Idrissou, O. Kwon, L. Lambert, A. Pinchuk, L. Wehner, A. Carston, N. Clemons, B. Bednarz, J. Weichert, R. Hernandez; University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-0071

¹⁷⁷Lu-Microspheres as Biocompatible Micro-Seed Implants for Loco-regional Radiation Ablation in Breast Cancer: A Preclinical Proof-of-Concept

S. Chopra, A. Aggarwal, K. Kaur, S. R. Shovan, A. Kumar, A. Bal, A. S. Oinam, B. R. Mittal, J. Shukla; Postgraduate Institute of Medical Education and Research, Chandigarh, INDIA.

EP-0072

Preclinical Evaluation of ¹⁶¹Tb-BPAMD: A Bone-Targeting Radiopharmaceutical with High Affinity and Stability

A. Vukadinovic, D. Stankovic, M. Mirkovic, D. Jankovic, P. Sitarica, M. Maric, M. Peric, S. Vranjes-Djuric, M. Radovic; University of Belgrade, Vinca Institute of Nuclear Sciences, Belgrade, SERBIA.

EP-0073

Dimeric CCK2R Radiotheranostic Tracers Synergize with mTOR Inhibition for Enhanced Tumor Therapy

L. Bian; Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EP-0074

Experimental radionuclide therapy using [¹⁷⁷Lu]Lu-AU-SAR-M1 in GRPR-positive xenograft models

K. Obeid¹, P. Kanellopoulos¹, E. Bezverkhniaia¹, Y. Liu², M. W. Konijnenberg³, B. A. Nock⁴, T. Maina⁴, V. Tolmachev¹, A. Orlova¹; ¹Uppsala University, Uppsala, SWEDEN, ²Uppsala Univeristy, Uppsala, SWEDEN, ³Erasmus MC, Rotterdam, NETHERLANDS, ⁴NCSR Demokritos, Athens, GREECE.

EP-0075

Granzyme B PET Imaging Enhances Belzutifan and KL201 Combination Therapy Using a Tumor Cell Membrane Nano-Loading Platform for Renal Cell Carcinoma

Y. Hou^{1,2,3}, X. Xia^{1,2,3}; ¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²Hubei Province Key Laboratory of Molecular Imaging, Wuhan, CHINA, ³Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, CHINA.

EP-0077

PET imaging of integrin $\alpha_v\beta_8$ upregulation as an early prognostic marker for radiotherapy response

A. Litvinenko¹, A. Sesink¹, L. Wendlinger¹, D. Repáraz², H. Koch¹, D. Viertl¹, F. Herrera¹, J. Notni³, M. Schottelius¹; ¹CHUV, Lausanne, SWITZERLAND, ²Unibe, Bern, SWITZERLAND, ³Trimt, Radeberg, GERMANY.

EP-0078

Enhancing Triple-Negative Breast Cancer Radiotherapy via EZH2-Targeted Nanoplatfrom and Synergistic Radionuclide Therapy

R. Wu^{1,2,3}, Y. Hou^{1,2,3}, Z. Gao^{1,2,3}, X. Xia^{1,2,3}; ¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²Hubei Province Key Laboratory of Molecular Imaging, Wuhan, CHINA, ³Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, CHINA.

EP-0079

Synergistic suppression of anaplastic thyroid carcinoma via targeted co-delivery of integrin $\alpha_v\beta_3$ siRNA and ¹³¹I using iRGD-modified exosomes

R. Zhang¹, W. Zhang², N. Li¹, S. Wang¹, Q. Jia¹, J. Tan¹; ¹Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, CHINA, ²Department of Nuclear Medicine, West China Hospital, Chengdu, CHINA.

EP-0080

Does the PSMA ligand, PSMA-11, prevent ¹⁷⁷Lu-PSMA-617 uptake into human non-tumour cells and enhance the cytotoxic effect of ¹⁷⁷Lu-PSMA-617 in human prostate cancer cells?

Y. Zhao, A. Alfteimi, A. Helm, M. Jueptner, U. Luetzen, M. Zuhayra; Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of Schleswig-Holstein, Kiel, GERMANY.

EP-0081

Theranostic PET Imaging and Radioimmunotherapy (RIT) of Head and Neck Squamous Cell Carcinoma (HNSCC) Patient-Derived Xenografts (PDX) in NRG mice with Anti-Epidermal Growth Factor Receptor (EGFR) [⁶⁴Cu]Cu- and [¹⁷⁷Lu]Lu-DOTA-Panitumumab-F(ab')₂

C. Chan¹, M. Khosravifarsani¹, A. Ku¹, J. Meens¹, L. Ailles¹, S. Bratman¹, R. Reilly^{1,2}; ¹Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, Toronto, ON, CANADA, ²Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA.

EP-05

e-Poster Are

A: Preclinical and Translational Studies -> A1 Medical Preclinical -> A15 Preclinical Dosimetry and Radiobiology

EP-0082

Dual-Line Approach: Radiosensitisation in Prostate Cancer Cell Lines with histone deacetylase inhibitors and Ac-225, Lu-177 and X-ray Radiation

T. Wallner, R. Runge, K. Tietze, K. Wetzig, R. A. Bundschuh, J. Kotzerke; Universitätsklinikum Carl Gustav Carus, Dresden, GERMANY.

EP-0083

Towards Monte-Carlo Based Preclinical Personalized Dosimetry for Targeted Radioligand-Immunotherapy

O. Kochebina, C. Comtat, A. Grindel, C. Truillet; BioMaps Laboratory, Service Hospitalier Frédéric Joliot, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Université Paris-Saclay, Orsay, FRANCE.

EP-0084

Optimisation and calibration for pre-clinical SPECT imaging of Pb-212 for targeted alpha therapy

P. Gape¹, A. Jones¹, A. Drews¹, G. Stasiuk¹, L. Livieratos¹, M. K. Schultz², S. Y. A. Terry¹; ¹King's College London, London, UNITED KINGDOM, ²Perspective Therapeutics, Coralville, IA, UNITED STATES OF AMERICA.

EP-06

e-Poster Area

A: Preclinical and Translational Studies -> A1 Medical Preclinical -> A16 New Radiopharmaceuticals - SPECT

EP-0085

Clinical feasibility of ^{99m}Tc-CTR-FAPI SPECT/CT imaging in lung cancer: a prospective head-to-head comparison with ¹⁸F-FDG PET/CT

S. Li^{1,2}, Z. Li³, M. Xu⁴, P. Yang¹, H. Xu¹, C. Van De Wiele², Z. Liu⁵, Y. Wu¹; ¹Peking University Cancer Hospital Inner Mongolia Hospital/Cancer Hospital Affiliated to Inner Mongolia Medical University, Hohhot, CHINA, ²Gent University, Gent, BELGIUM, ³Peking University Cancer Hospital, Beijing, CHINA, ⁴Changping Laboratory, Beijing, CHINA, ⁵Peking University, Beijing, CHINA.

EP-0086

iPSMA-BN: A novel theranostic dual target molecule, assessing two prostate cancer clinical scenarios: metastatic hormone-sensitive and metastatic hormone-resistant. Asociations with genomic alterations in DNA damage repair genes

S. Gonzalez Rueda¹, F. Garcia Perez¹, A. Calderon Avila², G. Ferro Flores³, Q. Pitalua Cortes¹, E. Gomez Argumosa¹, I. Soldevilla Gallardo¹; ¹National Cancer Institute of Mexico, Tlalpan, Mexico City, MEXICO, ²UMAE IMSS CMN SXXI Especialidades, Cuahutemoc, Ciudad de México, MEXICO, ³National Institute of Nuclear Research, Toluca, Mexico City, MEXICO.

EP-0087

eSOMA-FAP-02, a Dual SSTR2 and FAP-Targeted Heterodimer for Neuroendocrine Tumors

Y. Seimille, D. Chapeau, A. Piet, L. Li, C. de Ridder, D. Stuurman, P. Paraiso, H. Ma; Erasmus MC, Rotterdam, NETHERLANDS.

EP-0088

LDLR as a glioblastoma gateway: 203Pb-labeled peptide for targeted glioblastoma SPECT imaging

I. Tworowska¹, L. Flores¹, C. Malicet², R. Zielinski³, P. Davis¹, P. Lecorche², J. Temsamani², E. Delpassand¹;
¹RadioMedix Inc., Houston, TX, UNITED STATES OF AMERICA,
²Vect-Horus, Marseille Cedex 15, FRANCE, ³MDAnderson, Houston, TX, UNITED STATES OF AMERICA.

EP-0089
The position of HYNIC chelator and the molecular design of the DARPIn-based G3 constructs influence the biodistribution of an imaging tracer for detection of HER2-expressing tumors

V. Tolmachev¹, R. Varvashenya², A. Prach², E. Plotnikov², M. Tretyakova², D. Eskova², V. Bodenko², G. Yanovich², A. Schulga³, E. Konovalova³, M. Belousov^{4,5}, V. Chernov⁵, S. Deyev³, M. Larkina²;
¹Department of Immunology, Genetics and Pathology (IGP), Uppsala University, Uppsala, SWEDEN, ²Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, ³Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, RUSSIAN FEDERATION, ⁴Siberian State Medical University, Tomak, RUSSIAN FEDERATION, ⁵Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EP-07

e-Poster Are

**A: Preclinical and Translational Studies
-> A1 Medical Preclinical -> A17 New Radiopharmaceuticals - PET**

EP-0090
Optimization of the N-terminus of neurotensin analogs for PET imaging of solid malignancies
S. Kaur^{1,2}, S. Mair¹, W. Lau¹, J. Zeisler¹, F. Benard^{1,2}, K. Lin^{1,2}, J. Lau^{1,2};
¹BC Cancer Research Institute, Vancouver, BC, CANADA, ²The University of British Columbia, Vancouver, BC, CANADA.

EP-0091
Evaluation of two Nastorazepide derived ⁶⁸Ga-labelled radiotracers for imaging of CCK2R expressing tumors.
M. Asti¹, M. Verona², S. Rubagotti¹, T. Zavvar³, E. von Guggenberg³, P. C. Capponi¹, M. Tosato^{4,1}, F. Mastrotto², G. Marzaro⁵;
¹AUSL-IRCCS, Reggio Emilia, ITALY, ²University of Padua, Padua, ITALY, ³Medical University of Innsbruck, Innsbruck, AUSTRIA, ⁴Simon Fraser University, Burnaby, BC, CANADA, ⁵University of Verona, Verona, ITALY.

EP-0092
Innovative Peptides for the Diagnosis and Treatmend of HER2-Positive Breast Cancer
F. Alves da Silva¹, D. Gushiken Junior, E. Bernardes, P. Spencer;
Instituto de Pesquisas Energéticas e Nucleares (IPEN/CNEN), São Paulo, BRAZIL.

EP-0093
Development of fluorine-18 analogs of metoclopramide for P-gP PET imaging at the blood-brain barrier
S. Huvelle^{1,2}, P. Deniel³, B. Hosten^{3,4}, S. Chasseigneaux⁴, N. Tournier¹, L. Breuil^{4,5}, F. Caillé¹;
¹Laboratoire d'Imagerie Biomédicale Multimodale

(BIOMAPS), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Orsay, FRANCE, ²Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, FRANCE, ³Service Pharmacie, Assistance Publique - Hôpitaux Paris, Hôpital Saint-Louis, Paris, FRANCE, ⁴Inserm UMR-S 1144, Faculté de Pharmacie de Paris, Université Paris-Cité, Paris, FRANCE, ⁵Service Pharmacie, Assistance Publique - Hôpitaux Paris, Hôpital Cochin, Paris, FRANCE.

EP-0095
Precise monitoring of acquired drug resistance in melanoma by ACC-targeted PET imaging
J. Ye, J. Wang;
Xijing Hospital, Xi'an, CHINA.

EP-0096
Comparative Study of Thiol-Reactive Linkers for the Design of Stable Radioimmunoconjugates
J. Ariztia¹, M. Leroux¹, M. Moreau¹, C. Bernhard¹, P. Bellaye², A. Cochet^{2,1}, A. Daoust³, D. Vivier¹, F. Denat¹;
¹Université Bourgogne Europe, ICMUB UMR CNRS 6302, Dijon, FRANCE, ²Centre Georges François Leclerc, IMATHERA, BioSanD, Dijon, FRANCE, ³Oncodesign Precision Medicine, Dijon, FRANCE.

EP-0097
Biodistribution of Two Novel FAP - targeting Radiopharmaceuticals in Solid Tumors and Their Comparison with ⁶⁸Ga - FAPI - 46: a Pilot Study
X. Mu¹, Y. Lu¹, Z. Chen², J. Li¹, L. Zhang¹, W. Chong¹, J. Li¹, W. Fu¹, X. Li³;
¹Department of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, CHINA, ²GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, PET Center, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical Universit, Guangzhou, CHINA, ³Department of Chemistry, State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hongkong, CHINA.

EP-0098
Preclinical Evaluation of ⁶⁸Ga-labelled Cyclic Peptide for Neupilin-1-Targeted PET Imaging in Pan-tumors
F. Qiu, S. Song, J. Li;
Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EP-0099
Development and Evaluation of a Novel Peptide-Based Radiotracer for Netrin-1 Non-invasivei Imaging in Tumor
J. Wang, L. Feng, L. Zhang, H. Yang, X. Lan, W. Cao, D. Jiang;
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0100
Evaluation of ¹¹C-SAM Radiotracers for Prostate Cancer Imaging: In Vivo and Ex Vivo Comparison of Scalemic and Enantiopure Forms
M. Bentura¹, F. Zoppolo¹, L. Reyes¹, A. Paolino¹, G. Falasco¹, L. Urrutia¹, D. Umplierrez², G. Irazoqui², S. Rodriguez², E. Savio¹;
¹Departamento de Radiofarmacia, Centro Uruguayo

de Imagenología Molecular, Montevideo, URUGUAY, ²Departamento de Biociencias, Facultad de Química, UdelAR, Montevideo, URUGUAY.

EP-0101
Selective Probes for PET Imaging of Tumor-Associated Cathepsins
O. Cini¹, M. M. M. Santos¹, F. Elvas², R. Moreira¹;
¹Research Institute for Medicines (iMed.Ulisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, PORTUGAL, ²Molecular Imaging and Radiology, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, BELGIUM.

EP-0102
Cu-64/Cu-67-Labeled TCOs as Promising Agents for Theranostic Pretargeting Applications
Q. Yu, K. Adhikari, T. Van den Wyngaert, F. Elvas;
University of Antwerp, Molecular Imaging and Radiology (MIRA), Wilrijk, BELGIUM.

EP-0103
Preclinical evaluation of [¹¹C]Onalespib for Heat Shock Protein 90 (HSP90) cancer imaging
L. Le Saux¹, V. Narykina^{1,2,3}, R. Cools¹, N. Van Winnendael^{1,4}, G. Bormans¹;
¹Laboratory for Radiopharmaceutical Research, Department of Pharmacy and Pharmacological Sciences, KU Leuven, Leuven, BELGIUM, ²Switch Laboratory, VIB Center for Brain and Disease Research, Herestraat 49, 3000, Leuven, BELGIUM, ³Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Herestraat 49, 3000, Leuven, BELGIUM, ⁴Nuclear Medical Applications, Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM.

EP-0105
Preclinical evaluation of ⁶⁸Ga-DOTA-NEI as a radiotracer for neutrophil elastase
J. Wang, F. Kang, J. Wang;
The First Affiliated Hospital of Air Force Military Medical University, Xi'an, CHINA.

EP-0106
Pretargeted PET imaging of tumors using a DZ-1-TCO and ⁶⁸Ga-tetrazine system: synthesis, optimization, and in vivo evaluation
M. Huang¹, W. Wang¹, Y. Wang², R. Wang¹, Y. Zhang³, R. Tian¹;
¹The Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Chengdu, CHINA, ²Department of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Sichuan University, Chengdu, China, Chengdu, CHINA, ³Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States, CA, UNITED STATES OF AMERICA.

EP-0107
ImmunoPET Imaging of TROP2 Expression in Lung Cancer with scFv Tracers
Z. Wu, Z. Lin, Y. Feng, D. Zheng, X. Zhang, R. An, Y. Zhang, J. Zhu, D. Jiang, X. Lan;
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0108
Development of ¹¹C/¹⁸F PET radioligands selective for LRRK2
K. Jia¹, R. Arakawa¹, A. Forsberg Morén¹, T. Jensen², M. Hentzer², C. Jones², M. Jorgensen², B. Bang-Andersen², A. Varrone¹, C. Halldin¹, S. Nag¹;
¹Karolinska Institutet, Stockholm, SWEDEN, ²H. Lundbeck, Valby, DENMARK.

EP-0109
Development of a ⁶⁸Ga-Radiolabeled Fluorescent Dye for Potential Multimodal PET Imaging of Aneurysmal Subarachnoid Hemorrhage
L. Schäfer¹, J. W. Gerhards¹, D. Kang¹, U. Lindauer², B. Altunay¹, S. Lütje¹, F. M. Mottaghy^{1,3}, T. Schmidt², A. T. J. Vogg¹;
¹Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, GERMANY, ²Translational Neurosurgery and Neurobiology, Department of Neurosurgery, RWTH Aachen University Hospital, Aachen, GERMANY, ³Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, 6229 ER Maastricht, NETHERLANDS.

EP-0110
Mesoporous Silica Nanoparticles Labeled with Zirconium-89 for Long-Term In Vivo Tracking of Cells via PET Imaging
M. Xu, Z. Liu;
Changping Laboratory, Beijing, CHINA.

EP-0111
Development of ¹⁸F-Labeled Deuterated Tropane Derivatives with High Metabolic Stability for PET Imaging of the Dopamine Transporter
Z. Chen, J. Hong, Y. Fang, C. Liu, J. Kang, J. Zuo, J. Li;
NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA.

EP-0112
A study on radiolabeling methods for novel tau tracer lead compounds discovered using a big data/ AI-based drug development platform
K. Kangbin¹, H.-C. Song^{1,2};
¹Chonnam National University Hospital, Gwangju, KOREA, REPUBLIC OF, ²Chonnam National University Medical School, Gwangju, KOREA, REPUBLIC OF.

EP-0113
Synthesis of [¹¹C]PF-07799933 and evaluation of its whole-body distribution in NHP using PET
S. Nag¹, Z. Jia¹, M. Tóth¹, Y. Khani¹, A. Varrone¹, L. Chen², J. Wong², B. Baer², J. Gaudino², K. Maresca², C. Halldin¹;
¹Karolinska Institutet, Stockholm, SWEDEN, ²Pfizer Inc., Worldwide Research & Development, Cambridge, MA, UNITED STATES OF AMERICA.

EP-0114
ImmunoPET tracer based on antibody fragments radiolabeled with ⁸⁹Zr for detecting the α1 subunit of the GABA-A receptors in the brain.
Á. García de Lucas^{1,2,3}, L. Kovacs^{4,2}, B. Todorov⁵, L. Nissilä⁴, B. Salinas Rodríguez^{1,3,6}, U. Lamminmäki², F. López-Picón^{7,2}, A. Airaksinen^{4,2};
¹Universidad Carlos III de Madrid, Madrid, SPAIN, ²University of Turku, Turku, FINLAND, ³Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, SPAIN, ⁴Turku PET Centre, Turku, FINLAND, ⁵University of Sofia,

Sofia, BULGARIA, ⁶Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, SPAIN, ⁷Turku PET Centre, Turku, FINLAND.

EP-0115
Development of a novel PET radiotracer for targeting HER2-expressing tumors
A. Coliva¹, M. Maspero², S. Di Benedetto³, R. Ferrisi³, C. Papotto⁴, S. Valtorta², R. Moresco⁴, C. Dallanocce³, A. Chiti^{5,6}; ¹Nuclear Medicine Department, IRCCS San Raffaele, Milan, ITALY, ²Institute of Bioimaging and Complex Biological Systems, National Research Council (IBSBC-CNR), Milan, ITALY, ³Department of Pharmaceutical Sciences, University of Milan, Milan, ITALY, ⁴Department of Surgical Sciences, University of Milano-Bicocca, Milan, ITALY, ⁵Vita-Salute San Raffaele University, Milan, Italy, ⁶IRCCS San Raffaele, Milan, ITALY.

EP-0116
Synthesis of [¹¹C]BIIB135, a Tyrosine Kinase (BTK) Inhibitor evaluated in NHP using PET
P. Datta¹, A. Forsberg Morén¹, Y. Khani Meynaq¹, M. Kaliszczak², B. Cook², A. Varrone¹, C. Halldin¹, S. Nag¹; ¹Karolinska Institutet, Stockholm, SWEDEN, ²Biogen Inc, 225 Binney street, Cambridge, MA 02142, MA, UNITED STATES OF AMERICA.

EP-0117
Development and evaluation of [⁶⁸Ga]LAYp: A novel PET probe for tumor-associated enzyme targeting
W. Hongyong, H. Wu, Y. Liu, J. Wu, P. Zou; Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, CHINA.

EP-0118
Synthesis and in vitro/in vivo Evaluation of the Synaptic Vesicle Protein SV2C PET Radioligands: ¹⁸F-UCB-F, ¹¹C-SV2C-1, and ¹¹C-SV2C-2
S. Nag¹, A. F. Morén¹, V. Sousa¹, R. Zou², P. Datta¹, J. Mercier³, Y. Khani Meynaq¹, H. Ågren², C. Halldin¹, A. Varrone¹; ¹Karolinska Institutet, Stockholm, SWEDEN, ²Uppsala University, Uppsala, SWEDEN, ³UCB Biopharma, Braine l'Alleud, BELGIUM.

EP-0119
Research on Dynamic Monitoring and Quantitative Assessment of Liver Function in Liver Injury Based on [⁶⁸Ga]Ga-DTPA-EOB PET Imaging
Y. Fan¹, W. Hai¹, Q. Qu¹, B. Cai², X. Xiang², Y. Shen³, B. Li¹, J. Hu¹; ¹Department of Nuclear Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ²Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ³Research Center for Experimental Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

EP-0120
Effects of replacing the ether linkage of a benzo[h] quinoline-based fibroblast activation protein-targeted tracer, [⁶⁸Ga]Ga-SB03178, with an N-methyl linkage on its FAP-targeting capability
S. Jozi, C.-C. Chen, H. Merkens, P. Ng, W. Lau, F. Bédard, K.-S. Lin; BC Cancer Research Institute, Vancouver, BC, CANADA.

EP-0121
Preclinical Evaluation of MT1-MMP-Targeting Bicyclic Peptides for Radiotheranostic Applications
M. Sulewska¹, A. Regupathy², L.-C. Domogalla³, N. Steinacker³, J. Johanna Lahdenranta⁴, B. Blakeman², F. Wood², P. Meyer³, P. Huxley², M. Eder¹, G. Mudd², A.-C. Eder³; ¹German Cancer Consortium (DKTK) / University Medical Center Freiburg, Freiburg, GERMANY, ²BicycleTx Limited, Cambridge, UNITED KINGDOM, ³University Medical Center Freiburg, Freiburg, GERMANY, ⁴Bicycle Therapeutics, Cambridge, MA, UNITED STATES OF AMERICA.

EP-0122
Comparison of 3rd generation β-Amyloid PET radiotracers with PiB and FBB in mouse models of Alzheimer’s Disease
S. Bagheri¹, B. Uzegbunam², M. Luster¹, D. Librizzi^{1,3}, B. Yousefi^{1,4}; ¹Department of Nuclear Medicine, School of Medicine, Philipps University Marburg, Marburg, GERMANY, ²Department of Nuclear Medicine, Technical University of Munich, and Isotope Technologies Munich (ITM), Munich, GERMANY, ³Department of Nuclear Medicine, University Hospital OWL, Evangelical Hospital Bethel, Bielefeld, GERMANY, ⁴Preclinical Imaging Core Facility, Center for Tumor Biology and Immunology (ZTI), Philipps University Marburg, Marburg, GERMANY.

EP-0123
FAPI-DyeMER: a Novel Dual-Modality Agent for Image-Guided Cancer Surgery
G. Gariglio¹, C. Rangger¹, K. Bendová², Z. Nový², M. Petřík², C. Decristoforo¹; ¹Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA, ²Institute of Molecular and Translational Medicine, Palacky University, Olomouc, CZECH REPUBLIC.

EP-08

e-Poster Area

A: Preclinical and Translational Studies -> A1 Medical Preclinical -> A18 New Radiopharmaceuticals - Therapy

EP-0124
C. Lu, M. Zhou, P. Liu, S. Hu; Xiangya Hospital, Central South University, Changsha, CHINA.

EP-0125
Optimization of theMolar Dose of Dimeric FAP-Targeted Radioligandsfor TherapeuticApplications
L. Li, H. Ma, D. Stuurman, C. d. Ridder, A. Piet, Y. Seimбилle; Erasmus Medical Central, Rotterdam, NETHERLANDS.

EP-0127
In-Vivo Evaluation of a Novel Fibroblast Activation Protein (FAP) Inhibitor as a Targeted Therapeutic Agent in Oncology
M. Rezaeianpour^{1,2}, M. Mosayebnia², A. Gravand¹, R. Nami¹, M. Ghapanvari¹, S. Mazidi¹, M. Dehghani¹; ¹PARS ISOTOPE Co., Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Pharmaceutical Chemistry and

Radiopharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0128
Preliminary theranostic candidates for Glioblastoma tumors based on Substance P derivatives.
S. Mozaffari¹, J. Abedi¹, H. A. Khoshhosn¹, N. Soltani¹, A. Tavakoli¹, Y. H. Tavakoli¹, M. Davarpanah¹, S. M. Mazidi¹, R. Nami¹, F. Johari Daha², M. Erfani²; ¹PARS ISOTOPE Co., Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Nuclear Science and Technology Research Institute (NSTRI), Atomic Energy Organization of Iran (AEOI), Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0129
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of ⁶⁸Ga-NRT6020 Injection and ¹⁷⁷Lu-NRT6020 Injection in FAP-positive Participants with Advanced Solid Tumors
X. Zhang, X. Li, Q. Liu, J. Liu, X. Xu, Q. Kong, Y. Wu, C. Huang, S. Cao, J. Cai; Chengdu New Radiomedicine Technology Co. LTD., Chengdu, CHINA.

EP-0130
Carbonic Anhydrase IX-Targeting for Radioimmunotherapy in Triple-Negative Breast Cancer
A. Ivashkevich¹, A. Elz^{2,3}, V. Liapis^{2,3,4}, M. P. Wheatcroft¹, M. P. Brown^{2,4,3}, A. H. Staudacher^{2,1,3}; ¹Telix Pharmaceuticals Ltd Pty, Melbourne, AUSTRALIA, ²Central Adelaide Local Health Network, Adelaide, AUSTRALIA, ³Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, AUSTRALIA, ⁴Adelaide Medical School, The University of Adelaide, Adelaide, AUSTRALIA.

EP-0131
Fibroblast Activation Protein (FAP)-Targeted Theranostic Application of [¹⁶¹Tb]Tb-FAPI-04: Radiolabelling, Qualilty Control and Scintigraphic Imaging in Wistar Rats
C. Sezgin¹, E. Uygur², B. Ozel³, R. Celik³, G. Gumuser⁴, F. Z. Biber Muftuler³, Y. Parlak⁴; ¹Manisa City Hospital, Manisa, TÜRKIYE, ²Manisa Celal Bayar University, Biomedical Device Technologies, Manisa, TÜRKIYE, ³Ege University, Izmir, TÜRKIYE, ⁴Manisa Celal Bayar University, Manisa, TÜRKIYE.

EP-09

e-Poster Area

A: Preclinical and Translational Studies -> A1 Medical Preclinical -> A19 New Biological Targets and Ligands

EP-0132
Development and characterisation of peptide-based agents targeting HER2 receptor for breast cancer radiotheranostics
L. Wagner¹, M. Amghar¹, U. Bauder-Wüst¹, Y. Remde², M. Schäfer², M. Benešová-Schäfer¹; ¹Research Group Translational Radiotheranostics, German Cancer Research Center, Heidelberg, GERMANY, ²Service Unit for Radiopharmaceuticals and Preclinical Studies, German Cancer Research Center, Heidelberg, GERMANY.

EP-0133
Preclinical Evaluation of Novel ⁶⁸Ga/¹⁷⁷Lu-labeled Minigastrin Analogs as CCK2R targeted radiotheranostics
X. Chen, H. Yang, X. Wen, Z. Qiao, X. Wu, J. Zhang; National University of Singapore, Singapore, SINGAPORE.

EP-0134
Development and primary evaluation of[^{99m}Tc]Tc(CO)₃-(H₂O)-Erlotinib as a potential radiopharmaceutical for molecular imaging in triple negative breast cancer
A. Rey¹, J. Afonso¹, D. Gamenara², G. Carrau², M. Tejería¹; ¹Area Radioquímica, Facultad de Química, Udelar, Montevideo, URUGUAY, ²Departamento de Química Orgánica, Facultad de Química, Udelar, Montevideo, URUGUAY.

EP-0135
SPAAC-Enhanced Puromycin Linker optimizes cDNA-Dispaly for Targeted Peptide Selection
S. Schneider^{1,2,3}, M. Boll^{1,2}, M. Eder^{1,2}, A. Eder^{1,2}; ¹Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg and Freiburg, GERMANY, ²Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY, ³Faculty of Biology, University of Freiburg, Freiburg, GERMANY.

EP-0136
Development and characterisation of a novel peptide-based tracer targeting proteoglycans overexpressed in triple-negative breast cancer
J. D. Campeiro¹, C. Morgat², S. U. Dalm¹; ¹Erasmus University Medical Centre, Rotterdam, NETHERLANDS, ²University Hospital of Bordeaux, Bordeaux, FRANCE.

EP-0137
Optimization of an Affibody molecule construct for PDGFRb-targeted theranostics
H. Mallapura¹, A. Abouzayed^{1,2}, H. Olsson³, M. Xiong¹, O. Korsgren⁴, J. Löfblom³, M. Wagner², O. Eriksson^{1,2}; ¹Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN, ²Antaros Tracer AB, Uppsala, SWEDEN, ³Department of Protein Science, Division of Protein Engineering, KTH Royal Institute of Technology, Stockholm, SWEDEN, ⁴Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN.

EP-0138
Comparative Biodistribution and Stability Assessment of [⁶⁸Ga]Ga-labeled Kisspeptins: Implications for Design of KiSS-1R Targeting Radioligands
H. Taş¹, M. Schäfer², U. Bauder-Wüst¹, Z. Nový³, M. Petřík³, M. Benešová-Schäfer¹; ¹DKFZ (Research Group Translational Radiotheranostics), Heidelberg, GERMANY, ²DKFZ (Service Unit for Radiopharmaceuticals and Preclinical Studies), Heidelberg, GERMANY, ³Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University (UPOL) and University Hospital Olomouc, Olomouc, CZECH REPUBLIC.

EP-0139
Basic Comparative Study of ⁶⁴Cu²⁺ complexes with tripodal amine ligands using the extrahepatic bile duct carcinoma cell line TFK-1
M. Shinada^{1,2}, M. Takahashi^{1,2}, C. Igarashi², H. Matsumoto², F. Hihara², T. Tachibana^{2,1}, M. Oikawa², H. Suzuki², M.-R. Zhang², T. Higashi², H. Kurihara³, Y. Yoshii², Y. Doi¹;
¹TOHO University, Funabashi, JAPAN, ²Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, JAPAN, ³Kanagawa Cancer Center, Yokohama, JAPAN.

EP-0140
Technetium-99m radiolabeling of HYIGSR peptide for in vivo and ex vivo assessment as a biomarker in breast cancer
F. Ferreira Mendonça¹, M. Tejeria², P. Decuadra², M. Zeni², A. Rey², S. Nogueira³, J. Mejia³, M. Barboza³, L. Fuscaldi¹, L. Malavolta¹;
¹Faculty of Medical Sciences of Santa Casa de São Paulo, São Paulo, BRAZIL, ²Faculty of Chemistry at the University of the Republic, Montevideo, URUGUAY, ³Hospital Israelita Albert Einstein, São Paulo, BRAZIL.

EP-0141
[¹⁸F]4-(3-(4-(4-fluorophenyl)piperidine-1-carbonyl)phenoxy)benzamide, a promising PET agent to investigate PARP10
M. Riondato^{1,2}, G. Destro³, M. Nemati³, J. Martinelli², F. Vitale¹, S. Morbelli⁴, G. Sambuceti², E. Terreno³;
¹IRCCS Policlinic Hospital of Genoa, Genoa, ITALY, ²Dept. Health Sciences, University of Genoa, Genoa, ITALY, ³University of Torino, Department of Molecular Biotechnology and Health Sciences, Turin, ITALY, ⁴University of Torino, Department of Medical Sciences, Turin, ITALY.

EP-10
e-Poster Area
A: Preclinical and Translational Studies -> A1 Medical Preclinical -> A20 Radiopharmacokinetics and Drug Development

EP-0143
First-in-Monkey SPECT Imaging of ¹³¹I-Labeled Aging Targeted Extracellular Vesicles
K. Yu, J. Ye, F. Kang, J. Wang;
The First Affiliated Hospital of Air Force Medical University, Shaanxi, Xi'an, CHINA.

EP-0144
Clinical Pharmacology and Dose Optimization Considerations applied to Radioligand Therapies (RLTs)
A. Manon¹, D. Imbs¹, D. Heller², H. Stephens², M. Trame²;
¹Certara, Paris, FRANCE, ²Certara, Radnor, PA, UNITED STATES OF AMERICA.

EP-0145
Dynamic Total Body PET imaging unfolds [11C]-choline kinetics and dosimetry
G. Fuso¹, I. Brusa², M. Santoro², D. Dall'Olio³, F. Zagni², M. Assenza², E. Fortunati², E. Tabacchi², A. Farolfi², R. Mei², C. Nanni², P. Castellucci², L. Calderoni², L. Strigari², G. Castellani³, S. Fanti^{1,2};

¹Policlinico Sant'Orsola-Malpighi, University of Bologna, Bologna, ITALY, ²IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³University of Bologna, Bologna, ITALY.

EP-0146
Design of Heterodimeric Radiopharmaceuticals Targeting FAP and SSTR2 Receptors Using Theoretical Affinity Profiling and Biodistribution Correlation
A. Abolhosseini Shahrnoy¹, M. Pirdadeh¹, M. Safari¹, M. Dehghani¹, Z. Karimi¹, R. Salehi-Moratab¹, M. Nasir², R. Nami¹, S. Mazidi¹;
¹PARS ISOTOPE Company, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Cellular and Molecular Biology, School of Biology, Damghan University, Damghan, IRAN, ISLAMIC REPUBLIC OF.

EP-0147
Decoding Fluorine-18 PET Tracers: Integrated Pharmacokinetics and Molecular Design
V. Trusova, U. Malovytsia, P. Kuznietsov, I. Yakymenko, G. Gorbenko;
V.N. Karazin Kharkiv National University, Kharkiv, UKRAINE.

EP-0148
Preclinical evaluation of radiolabelled desferrioxamine-B analogues for imaging bacterial infections
M. Petrik^{1,2,3}, B. Neuzilova¹, K. Hrabakova¹, K. Krasulova¹, K. Dvorakova Bendova¹, R. Maradan^{4,5,6}, J. Kronberger^{4,5,6}, I. Feiner^{4,7}, X. Guarrochena^{4,5}, T. Mindt^{4,6,8};
¹Institute of Molecular and Translational Medicine, Palacky University, Olomouc, CZECH REPUBLIC, ²Czech Advanced Technology and Research Institute, Palacky University, Olomouc, CZECH REPUBLIC, ³Institute of Molecular and Translational Medicine, University Hospital, Olomouc, CZECH REPUBLIC, ⁴Bioorganic Radiochemistry, Institute of Inorganic Chemistry, University of Vienna, Vienna, AUSTRIA, ⁵Vienna Doctoral School in Chemistry, University of Vienna, Vienna, AUSTRIA, ⁶Joint Applied Medicinal Radiochemistry Facility, University of Vienna and Medical University of Vienna, Vienna, AUSTRIA, ⁷Ludwig Boltzmann Institute Applied Diagnostic, AKH Wien c/o Sekretariat Nuklearmedizin, Vienna, AUSTRIA, ⁸Department of Biomedical Imaging and Image Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.

EP-0149
Pharmacokinetics study of FT-FAPI, a novel multi-nuclide label-able FAP targeting tracer, in mice
X. Wang, J. Ye, F. Kang, J. Wang;
The First Affiliated Hospital of Air Force Medical University, Xi'an, CHINA.

EP-0151
Using Modeling and Simulation to Assess the Impact of the Pharmacokinetics and Biodistribution on the Absorbed and Biologically Effective Dose for Radioligand Therapies
H. Stephens, D.-C. Imbs, M. N. Trame, A. Manon;
Certara, Radnor, PA, UNITED STATES OF AMERICA.

EP-11
e-Poster Area
A: Preclinical and Translational Studies -> A1 Medical Preclinical -> A21 Other Preclinical and Translational

EP-0152
Single-cell RNA Sequencing Reveals Immune and Vascular Remodelling in Graves' Disease: Implications for Molecular Imaging and Targeted Therapy
S. Yang^{1,2}, G. Zhu¹;
¹Department of Nuclear Medicine, the First Affiliated Hospital of Kunming Medical University, Kunming City, Yunnan Province, CHINA, ²Department of Nuclear Medicine, Yuxi People's Hospital of Yunnan Province/Department of Nuclear Medicine, the Sixth Affiliated Hospital of Kunming Medical University, Yuxi City, Yunnan Province, CHINA.

EP-0153
Impact of Isotope, Molar Activity, and Ligand Mass on the Biodistribution Profile of 212Pb-based Radioligand Therapies
F. Liu, A. Prior, M. E. Monterosso, D. Boucher, S. Shakti, A. Horsfall, H. Green, S. Kumar, J. Koehbach, R. Huebner, K. Kuan, W. Tieu, S. Rose, A. Karmann, S. Puttick, G. Li, T. Kryza;
AdvanCell Pty Ltd, Brisbane, AUSTRALIA.

EP-0154
Meeting Upcoming Clinical and Diagnostic Needs in oncological Imaging: A Structured Reporting System for Fibroblast-Activation-Protein-Targeted Imaging: FAP-RADS Version 1.0
E. Novruzov¹, G. Sheikh², E. Mamlins¹, A. Holzgreve², Y. Mori¹, S. Ledderose², F. Klauschen², M. Gorin³, M. G. Pomper⁴, K. Herrmann⁵, S. P. Rowe⁶, R. A. Werner², F. L. Giesel¹;
¹University Hospital Düsseldorf, Düsseldorf, GERMANY, ²University Hospital München LMU, Munich, GERMANY, ³Milton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA, ⁴Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, UNITED STATES OF AMERICA, ⁵University Hospital Essen, Essen, GERMANY, ⁶Department of Radiology, University of North Carolina, Chapel Hill, NC, UNITED STATES OF AMERICA.

EP-0155
Design and in vivo evaluation of a novel NIR-II/PET dual-modality probe
D. Fan¹, L. Ai¹, K. Zhou²;
¹Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, CHINA, ²Center for Advanced Materials Research & Faculty of Arts and Sciences, Beijing Normal University, Zhuhai, CHINA.

EP-0156
Toward Bacterial Vectors for Targeted Atherosclerosis Therapy: microSPECT/CT Biodistribution Studies of [¹¹¹In]In-Oxine-Labeled Mycoplasma pneumoniae in a murine model of Atheroma.
F. Pareja del Rio^{1,2}, A. Fernández-González^{1,2}, A. Hendy-Pérez^{1,2}, J. Escola Gil^{3,4}, N. Rotllan Vila^{3,4}, I. Rodríguez-Arce⁵, M. Collantes^{1,2,6}, G. Quincoces^{1,2}, I. Peñuelas^{1,2,6};
¹Radiopharmacy Unit. Nuclear Medicine Department. Clínica Universidad de Navarra, Pamplona, SPAIN, ²Navarra

Institute for Health Research (IdISNA), Pamplona, SPAIN, ³Institut de Recerca de l' Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ⁴CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, SPAIN, ⁵Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, SPAIN, ⁶Translational Molecular Imaging Unit (UNIMTRA). Nuclear Medicine Department. Clínica Universidad de Navarra, Pamplona, SPAIN.

EP-0157
Neurofunctional changes over time after administration of Ibogaine and Noribogaine in Rats Assessed by [¹⁸F]FDG PET Imaging
M. Bentura¹, L. Reyes¹, A. Paolino¹, G. Falasco¹, L. Urrutia¹, B. Gonzalez², J. Mesa², F. Arredondo¹, I. Carrera², E. Savio¹;
¹Departamento de Radiofarmacia, Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, URUGUAY, ²Departamento de Química Orgánica, Facultad de Química, Udelar, Montevideo, URUGUAY.

EP-0158
Preclinical evaluation and first-in-human study of [68Ga]Ga/[177Lu]Lu-JH120061, novel CXCR4-targeting radiopharmaceuticals
J. Zang¹, G. Wang¹, J. Zhan², E. Wang², J. He², H. Yu², W. Miao¹;
¹The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, CHINA, ²Bivision Pharmaceuticals, Inc., Shanghai, CHINA.

EP-0159
Intraoperative visualisation of tumor margins using FITC glucose as fluorescent probe
A. Aggarwal¹, A. Sharma², S. Chopra¹, S. Pandey¹, D. Attri¹, A. Semwal¹, I. Laoriya¹, A. Aggarwal¹, B. R. Mittal¹, A. Bal¹, J. Shukla¹;
¹Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA, ²Amity University, Mohali, INDIA.

EP-0160
Evaluating 4-bed µPET/CT Imaging Performance using Mouse Phantoms.
I. Martin¹, E. Jamieson¹, N. Colpo¹, J. Jeffry², B. Cox², F. Bénard¹, P. L. Esquinas¹, C. Uribe-Munoz¹;
¹BC Cancer Research Centre, Vancouver, BC, CANADA, ²Phantec LLC, Madison, WI, UNITED STATES OF AMERICA.

EP-0161
Adjusting Relative Biological Effectiveness for Tumor Microdosimetric Heterogeneity in Radiopharmaceutical Therapy: A Theoretical Analysis
J. Hong¹, S. Bae^{2,3}, H. Choi^{2,3,4}, M. Ryhiner¹, V. Morath⁵, S. Kossatz^{2,6}, R. Seifert¹, W. Weber^{5,7}, A. Rominger¹, K. Shi¹;
¹Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND, ²Institute of Radiation Medicine, Medical Research Center, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF, ³Portrai, Inc., 78-18, Dongsulla-gil, Jongno-gu, Seoul, KOREA, REPUBLIC OF, ⁴Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF, ⁵Department of Nuclear Medicine, TUM University Hospital, School of Medicine, Technical University of Munich, Munich, GERMANY, ⁶Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, Technical University Munich, Munich, GERMANY, ⁷Bavarian Cancer Research Center (BZKF), TUM University Hospital, Munich, GERMANY.

EP-0162
 Dosimetry-enabled Internal Hematopoietic Acute Radiation Syndrome Model Using the ⁸⁶Y/⁹⁰Y Isotopic Pair

L. Wehner, O. Kwon, A. O. Adeniyi, H. Comas Rojas, M. Bio Idrissou, E. Aluicio-Sarduy, J. W. Engle, B. Bednarz, R. Hernandez; University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-0163
 [¹⁸F]-Pentixafor CXCR4-Targeted PET/CT for Osteogenesis Evaluation and Fracture Healing Monitoring

Z. Li, D. Zhang, X. Su; First Affiliated Hospital of Zhejiang University, School of Medicine, Zhejiang University, Hangzhou, CHINA.

EP-0164
 Supramolecular Chemistry Enables Radiolabelling of Antibodies under Mild Conditions

V. Goncalves¹, R. Vizier¹, M. Moreau¹, J. Faivre¹, M. Carrière¹, M. Cheveau^{1,2}, S. Poty¹, F. Denat¹, M. Boswinkel³, S. van Lith³; ¹Université Bourgogne Europe, Dijon, FRANCE, ²CheMatech, Dijon, FRANCE, ³Radboud UMC, Nijmegen, NETHERLANDS.

EP-0165
 Uridine-Based PET/NIRF Dual-Modality Imaging for Precision Tumor Diagnosis and Surgery

L. Bian; Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EP-0166
 From Rats to Humans: Dosimetry Extrapolation Challenges and Opportunities for ¹⁷⁷Lu-FAPI-46 Therapy in Fibrosing Mediastinitis

L. Song¹, X. Chen^{2,3}, J. Li², Z. Wu¹; ¹First Hospital of Shanxi Medical University, Taiyuan, CHINA, ²China Institute for Radiation Protection, Taiyuan, CHINA, ³Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CHINA.

EP-0167
 Irisin as a Novel Therapeutic Agent for Glioblastoma: Targeting Ferroptosis via Specific Tumor Binding and AAV-Mediated Overexpression

C. Chuang¹, F. Huang¹, C. Huang²; ¹National Taiwan University, Taipei City, TAIWAN, ²Chang Gung Memorial Hospital, Taoyuan City, TAIWAN.

EP-0168
 Disrupted Synchronization of Organ Translocator Protein (TSPO) Expression in Glioblastoma Mice: Exploiting Total-Body TSPO-PET

G. Müller¹, A. Zatcepin^{1,2}, L. Bartos¹, L. Hörmann¹, J. Thevis¹, L. Wesser¹, G. Palumbo¹, R. Oos¹, K. Wind-Mark¹, R. Werner^{1,3}, S. Ziegler^{1,4}, M. Brendel^{1,2,5};

¹Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ²German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY, ³Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA, ⁴Department of Nuclear Medicine, Hannover Medical School (MHH), Hannover, GERMANY, ⁵Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.

EP-0169
 Computational Design of Chelators for Actinium-225 and Its Decay Daughters: Toward Optimized Alpha-Emitter Theranostics

D. Lee¹, J. Kim², K. Kang³, J. Yoo³, W. Lee², M. K. Schultz⁴; ¹Department of Physics and Chemistry, Korea Military Academy, Seoul, KOREA, REPUBLIC OF, ²Department of Chemical and Biological Engineering, Seoul National University, Seoul, KOREA, REPUBLIC OF, ³Chemical, Biological, Radiological Defense Research Institute, Seoul, KOREA, REPUBLIC OF, ⁴Perspective Therapeutics, Inc., Coralville, IA, UNITED STATES OF AMERICA.

EP-0170
 Dimorphism of whole body Crayfish by [¹⁸F]FDG uptake

A. Avendaño-Estrada^{1,2}, K. Mendoza-Ángeles¹, J. Hernandez-Falcón¹, M. Ávila-Rodríguez^{1,2}; ¹School of Medicine, UNAM, Mexico, MEXICO, ²Centro de Investigación sobre el Envejecimiento, Centro de Investigación y de Estudios Avanzados Sede Sur, Mexico City, MEXICO.

EP-0171
 PET-Based Assessment of Tumour Heterogeneous Uptake in Response to Doxorubicin/Andiroba Oil Nanoemulsion Therapy in a 4T1 Murine Breast Cancer Model

M. B. Silveira¹, S. E. M. Miranda¹, A. L. P. Magalhães², A. E. M. M. Oliveira², J. O. Silva², A. L. B. Barros²; ¹Center for the Development of Nuclear Technology (CDTN/CNEN), Belo Horizonte, BRAZIL, ²Federal University of Minas Gerais (UFMG), Belo Horizonte, BRAZIL.

EP-12

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B11 Central Nervous System

EP-0172
 Glioma and brain blood flow quantification using dynamic [¹⁸F]FET PET/CT and Tikhonov model-free deconvolution

C. Engkebølle¹, U. Lindberg², O. M. Henriksen¹, K. Madsen³, T. L. Andersen¹, T. Urup⁴, R. Rasmussen⁵, H. B. W. Larsson², **I. Law**¹;

¹Department of Clinical Physiology & Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, DENMARK, ²Functional Imaging Unit, Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Glostrup, DENMARK, ³Department of Clinical Physiology & Nuclear Medicine, Rigshospitalet, Copenhagen, DENMARK, ⁴Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, DENMARK, ⁵Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Copenhagen, DENMARK.

EP-0173
 Features of PET/CT with fluoroethyltyrosine interpretation after proton radiation therapy of patients with IDH wildtype glioblastoma

E. Gromova, N. Kataev, D. Susin, Nikolay Vorobyov, Marina Linnik, Natalia Berezina; LDC MIBS, Saint-Petersburg, RUSSIAN FEDERATION.

EP-0174
 Integrated ¹⁸F-FET PET/MR-Based Multi-parametric Imaging for Predicting IDH Mutation and MGMT Promoter Methylation in Adult Gliomas

Q. Han¹, J. Liu², T. Li¹, E. Li³, Z. Lin⁴, Y. Yang³, X. Guo², Y. Wang², H. Xing², W. Ma², Y. Wang², X. Cheng¹, L. Huo¹; ¹Nuclear Medicine Department, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, CHINA, ²Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, ³Beijing United Imaging Healthcare Co., Ltd, Beijing, CHINA, ⁴United Imaging Healthcare Group Co., Ltd, Shanghai, CHINA.

EP-0175
 Prognostic role of [¹⁸F]FET PET/CT: integrating metabolic and molecular data in the management of gliomas

A. Castello¹, G. A. Zuccotti², G. Lopez³, G. Fiore⁴, M. Schiavini¹, E. Galli¹, M. Arnaboldi¹, F. Buffoni¹, C. Pettinato⁵, L. Savio⁶, M. Locatelli⁴, M. Caroli⁷, M. Castellani¹, L. Florimonte¹; ¹Department of Nuclear Medicine, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, ITALY, ²Unit of Nuclear Medicine, Aosta Regional Hospital, Aosta, Italy, Aosta, ITALY, ³Division of Pathology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, ITALY, ⁴Unit of Neurosurgery, IRCCS Ca' Granda Foundation Ospedale Maggiore Policlinico, Milan, ITALY, ⁵Medical Physics Unit, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, ITALY, ⁶Department of Physics "Aldo Pontremoli", University of Milan, Milan, ITALY, ⁷Unit of Neurosurgery, IRCCS Ca' Granda Foundation Ospedale Maggiore Policlinico, Milan, ITALY.

EP-0176
 Improved AI Reporting of Amyloid PET with Location-Based Centiloids

B. Schemmer; Katholisches Klinikum Bochum, Bochum, GERMANY.

EP-0177
 Ga-68 PSMA-11 PET/CT in High-Grade Glioma Recurrence: Imaging, Prognosis, and Theranostic Implications

V. Arunachalam Ragupathi, N. Damle, M. Tripathi, S. Shamim, V. Tandon, K. Hareesh, S. Bharati, A. Kumar, S. Gupta, A. Singhal, S. Rastogi, A. Mohan; All India Institute of Medical Sciences, Delhi, INDIA.

EP-0178
 Amino Acid PET/CT in Assessing EGFR Gene Expression in CNS Gliomas

N. Vikhrova¹, D. Kalaeva^{1,2}, S. Drozd¹, O. Kalennik¹, G. Pavlova^{1,3}, I. Pronin¹; ¹National Medical Research Center for Neurosurgery named after N.N. Burdenko, Moscow, RUSSIAN FEDERATION, ²National Research Nuclear University MEPhI, Moscow, RUSSIAN FEDERATION, ³Institute of Higher Nervous Activity and Neurophysiology, Moscow, RUSSIAN FEDERATION.

EP-0179
 Amino-acid PET imaging to monitor mIDH inhibitors treatments in patients with refractory IDH-mutant gliomas

G. Stien¹, T. Obara^{2,3}, M. Blonski^{2,3}, L. Taillandier^{2,3}, A. Verger^{1,4,5}; ¹Department of Nuclear Medicine, CHRU of Nancy, Nancy, FRANCE, ²Department of Neurology, Neurooncology Unit, CHRU Nancy, Nancy, FRANCE, ³Centre de Recherche en Automatique de Nancy CRAN, UMR 7039, Université de Lorraine, CNRS, Nancy, FRANCE, ⁴IADI, U1254, Inserm, Université de Lorraine, Nancy, FRANCE, ⁵Nancyclotep Imaging Platform, Université de Lorraine, Nancy, FRANCE.

EP-0180
 Mult-Pinhole SPECT/CT in Meningioma Imaging: A New Diagnostic Perspective

G. Sipka¹, K. Apro¹, A. Dobí, K. Hideghety², M. Balazsfi³, P. Barzo³, M. Szolikova⁴, L. Pavics¹, Z. Besenyi¹; ¹University of Szeged, Department of Nuclear Medicine, Szeged, HUNGARY, ²University of Szeged, Department of Oncotherapy, Szeged, HUNGARY, ³University of Szeged, Department of Neurosurgery, Szeged, HUNGARY, ⁴Mediso Medical Imaging Ltd., Budapest, HUNGARY.

EP-0181
 Utility of Dynamic [⁶⁸Ga]Ga-PSMA PET/CT in post-surgical high-grade gliomas: An insight on preliminary Analysis

M. Usmani, K. al Riyami, S. Hashmi, A. Jain, S. Kheruka, V. Jayakrishnan, A. al busaidi, Z. Al-Mandhari; Sultan Qaboos Comprehensive Cancer Care and Research Center (SQCCRC), University Medical City, Muscat, OMAN.

EP-0182
 Meningioma Risk Stratification: Association Between Molecular-Morphologic Score and Somatostatin Receptor Expression on PET Imaging.

A. Chaban¹, O. Kertels², C. Ertelt-Delbridge³, D. Bernhardt⁴, F. Schmidt-Graf⁵, B. Wiesler², C. Negwer⁶, I. Yakushev¹; ¹Klinik und Poliklinik für Nuklearmedizin, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY, ²Institut für Diagnostische und Interventionelle Neuroradiologie, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY, ³Institut für Allgemeine Pathologie und Pathologische Anatomie, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY, ⁴Klinik und Poliklinik für RadioOnkologie und Strahlentherapie, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY, ⁵Klinik und Poliklinik für Neurologie, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY, ⁶Klinik und Poliklinik für Neurochirurgie, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY.

EP-0183
 Positron emission tomography (PET) use in neuro-oncology among European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) sites

M. Mair^{1,2}, P. Lohmann^{3,4}, N. Galdiks^{5,3}, M. Belting^{6,7}, P. Branda^{8,9}, M. P. G. Broen¹⁰, F. Ciccone¹¹, J. Daisne¹², F. Ducray^{13,14}, F. Ehret^{15,16}, J. Furtner¹⁷, A. S. Jakola^{18,19}, M. Niyazi²⁰, A. Pellerino²¹, M. Rasschaert²², E. Razis²³, F. Sahm²⁴, M. Smits^{25,26}, N. Tolboom²⁷, A. Verger²⁸, E. Le Rhun²⁹, G. Minniti^{30,31}, M. Weller³², M. Preusser², N. L. Albert¹; ¹Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ²Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, AUSTRIA, ³Institute of Neuroscience and Medicine

(INM-3, INM-4), Research Center Juelich, Juelich, GERMANY, ⁴Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, GERMANY, ⁵Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, GERMANY, ⁶Division of Oncology, Department of Clinical Sciences, Lund University, Lund, SWEDEN, ⁷Department of Hematology, Oncology and Radiophysics, Skåne University Hospital, Lund, SWEDEN, ⁸Department of Oncology, Oslo University Hospital, Oslo, NORWAY, ⁹Institute for Clinical Medicine, University of Oslo, Oslo, NORWAY, ¹⁰Department of Neurology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, NETHERLANDS, ¹¹Nuclear Medicine Unit, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, ITALY, ¹²Department of Radiation Oncology, Iridium Cancer Network, Wilrijk (Antwerp), BELGIUM, ¹³Department of Neurooncology, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, FRANCE, ¹⁴Université Claude Bernard Lyon 1, Villeurbanne, FRANCE, ¹⁵Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology, Berlin, GERMANY, ¹⁶German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité – Universitätsmedizin Berlin, Berlin, GERMANY, ¹⁷Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Faculty of Medicine and Dentistry, Danube Private University, Krems, AUSTRIA, ¹⁸Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, SWEDEN, ¹⁹Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, Gothenburg, SWEDEN, ²⁰Department of Radiation Oncology, University Hospital Tuebingen, Tuebingen, GERMANY, ²¹Division of Neuro-Oncology, Department of Neuroscience "Rita Levi Montalcini", University and City of Health and Science Hospital, Torino, ITALY, ²²Department of Medical Oncology, University Hospital Antwerp, Edegem, BELGIUM, ²³Third Department of Medical Oncology, Hygeia Hospital, Athens, GREECE, ²⁴Department of Neuropathology, Institute of Pathology, Clinical Cooperation Unit Neuropathology, Ruprecht-Karls University Heidelberg, and German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ²⁵Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, NETHERLANDS, ²⁶Brain Tumour Centre, Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS, ²⁷Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, NETHERLANDS, ²⁸Department of Nuclear Medicine & Nancyclotep Imaging Platform, CHRU Nancy and IADI INSERM, UMR 1254, Université de Lorraine, Nancy, FRANCE, ²⁹Department of Medical Oncology and Hematology, Brain Tumor Center, University Hospital and University of Zurich, Zurich, SWITZERLAND, ³⁰Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, ITALY, ³¹IRCCS Neuromed, Pozzilli (IS), ITALY, ³²Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, SWITZERLAND.

EP-0184
Diagnostic accuracy of FET-PET/CT for the differential diagnosis of recurrent brain metastases versus radionecrosis
N. Testart Dardel, N. Schilliger, K. Auf Der Springe, M. Nicod-Lalonde, N. Schaefer, J. Prior, M. Jreige; CHUV, Lausanne, SWITZERLAND.

EP-13
 e-Poster Area
 B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B12 Head and Neck

EP-0186
⁶⁸Ga-FAPI-04 PET/CT For Predicting Pathological Response of Cervical Lymph Node Metastases to Neoadjuvant Chemoimmunotherapy in Locally Advanced Oral Squamous Cell Carcinoma
Y. Jiang¹, Z. Yu², Y. Sun³, L. Wang³, J. Jia², Y. He¹; ¹Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA, ²Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan, CHINA, ³Department of Pathology, School and Hospital of Stomatology, Wuhan University, Wuhan, CHINA.

EP-0187
Predictive value of ⁶⁸Ga-FAPI-04 PET/CT for assessing pathologic response to neoadjuvant chemoimmunotherapy in locally advanced resectable oral squamous cell carcinoma
Y. Jiang¹, J. Jia², Z. Yu², Y. Sun³, Y. Tian¹, Y. He¹; ¹Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA, ²Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan, CHINA, ³Department of Pathology, School and Hospital of Stomatology, Wuhan University, Wuhan, CHINA.

EP-0188
Imaging-Detected Lymph Node Metastases (iLNM) and Extranodal Extension (iENE) as Prognostic Factors in HPV-Related Oropharyngeal Squamous Cell Carcinoma: FDG-PET/CT and Node-RADS-Based Evaluation
S. Tsukamoto, S. Koyasu, C. Suzuki, K. Nakatani, Y. Kishimoto, Y. Nakamoto; Kyoto University Hospital, Kyoto, JAPAN.

EP-0189
¹⁸F-PSMA and ¹⁸F-FDG PET/CT in Head and Neck Squamous Cell Carcinoma: A comparative Analysis
V. Heringer, H. S. V. Sousa, L. T. Macedo, N. A. A. Silveira, S. Kuba, C. S. P. Lima, C. D. Ramos; UNICAMP, Campinas, BRAZIL.

EP-0190
Prognostic Assessment in Nasopharyngeal Carcinoma Patients without distant metastases: Development and Validation of a Multidimensional Prognostic Nomogram integrating ¹⁸F-FDG PET/CT Parameters, Inflammation Markers, and Clinical Characteristics
Y. Lv^{1,2,3}, D. Zheng^{1,2,3}, R. Wang⁴, Z. Zhou^{1,2,3}, Z. Dai^{1,2,3}, S. Wei^{1,2,3}, Z. Gao^{1,2,3}, X. Lan^{1,2,3}, C. Qin^{1,2,3}; ¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²Hubei Key Laboratory of Molecular Imaging, Wuhan, CHINA, ³Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, CHINA, ⁴Department of Radiology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0191
"Ultra-Low-Dose ¹⁸F-FDG PET With Ultra-Low-Dose CT" Based Radiomic Features And Machine Learning In Non-Invasive Characterization Of Suspicious Lung Lesions
P. Singh, T. Singhal, S. K. Gupta, R. Kumar, N. Singh, H. Singh, B. R. Mittal; PGIMER, Chandigarh, INDIA.

EP-0192
Prognostic Value of Pre-Treatment F-18 FDG PET/CT Volumetric Parameters in Patients Diagnosed with Laryngeal Squamous Cell Carcinoma
I. Ak Sivrikoz¹, E. Ilhan¹, M. F. Acikalin², S. Aslan¹, I. Uslu Biner¹; ¹ESOGU School of Medicine Department of Nuclear Medicine, Eskisehir, TÜRKIYE, ²ESOGU School of Medicine Department of Pathology, Eskisehir, TÜRKIYE.

EP-0194
Prognostic Utility of ¹⁸F-FDG PET/MRI with Intravoxel Incoherent Motion Imaging in Nasopharyngeal Carcinoma
S.-C. Chan¹, S.-H. Ng², C.-H. Yeh²; ¹Hualien Tzu Chi Hospital, Hualien, Taiwan, ²Linkou Chang Gung Memorial Hospital, Taoyuan, TAIWAN.

EP-0195
C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [¹⁸F]FDG PET/CT
S. Serfling¹, Y. Zhi², P. E. Hartrampf¹, H. Takahiro¹, A. Kübler³, A. K. Buck¹, R. A. Werner⁴, S. Hartmann³; ¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, University Hospital Würzburg, Würzburg, GERMANY, ³Department of Oral and Maxillofacial Plastic Surgery of the University Hospital Würzburg, Würzburg, GERMANY, ⁴Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY.

EP-0196
Prognostic value of volumetric ¹⁸F-FDG PET in head and neck cancer
A. Doma^{1,2}, T. Škerl¹, A. Studen^{3,4}, P. Strojan^{1,2}; ¹Oncology institute, Ljubljana, SLOVENIA, ²Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA, ³Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, SLOVENIA, ⁴Experimental Particle Physics Department, Jožef Stefan Institute, Ljubljana, SLOVENIA.

EP-0197
Comparison of the Diagnostic Value of FDG PET/ MRI and MRI Imaging in Nodal Staging of Laryngeal Cancer and Predictive Parameters of Lymph Node Metastasis
E. Erbil Capci, U. Aydos, S. Gülbahar Ateş, E. Balcı, M. Yılmaz, M. Uçar, L. Atay; Gazi University Faculty of Medicine, Ankara, TÜRKIYE.

EP-0198
Habitat-Based Radiomic Features from ¹⁸F-FDG PET/ MR for Recurrence Prediction in Head and Neck Oral Carcinoma

W. Zhou¹, C. Jiang¹, J. Yang¹, X. Peng¹, K. Zheng¹, Y. Guo², H. Ye¹; ¹Department of PET-CT Center, The Affiliated Cancer Hospital of Xiangya School of Medicine/Hunan Cancer Hospital, Central South University, Changsha, CHINA, ²Shenzhen United Imaging Healthcare Co., Ltd., Shenzhen, CHINA.

EP-0199
[¹⁸F]FDG PET/CT in Post-Treatment Assessment of Head and Neck Cancer: Exploring the Diagnostic Role of SUVmax and Uptake Pattern
D. Silva, I. Miguel, D. Barbosa, N. Vasconcelos, R. Marão, P. Silva, J. Ferro, S. Fontão de Castro, L. Violante, J. Teixeira, A. Soares, H. Duarte, I. Lucena Sampaio; Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PORTUGAL

EP-0200
Machine learning for the prediction of synchronous second primary tumours in head and neck cancer assessed by ¹⁸F-FDG PET/CT
F. Gomez-Caminero Lopez¹, E. Campaña Diaz¹, S. Rama Alonso¹, J. Cañadas Salazar¹, F. Caltagirone Rodriguez¹, L. Diaz Gonzalez¹, J. Villanueva Curto¹, J. Badell Martinez¹, M. Sanchez Barba², P. Garcia-Talavera San Miguel¹; ¹Nuclear Medicine. University Health Complex of Salamanca, Salamanca, SPAIN, ²Department of Statistics, University of Salamanca, Salamanca, SPAIN.

EP-14
 e-Poster Area
 B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B13 Breast

EP-0201
Leveraging ¹⁸F-FDG PET/CT to investigate the biology of circulating cell-free tumor DNA (ctDNA): an exploratory study in metastatic breast cancer (MBC) patients
M. de Oliveira Taveira¹, L. Cabel¹, J. Das¹, J. Teysir¹, C. White¹, Y. Chen¹, P. Razavi¹, R. Yeh²; ¹Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, ²Mount Sinai Health System, New York, NY, UNITED STATES OF AMERICA.

EP-0202
Predictive value of 18F-FES PET/CT on the efficacy of late rechallenge of hormone therapy in metastatic breast cancer
M. Masse, C. Bailleux, J.-M. Ferrero, A. Creisson, O. Humbert; Centre Antoine Lacassagne, Nice, FRANCE.

EP-0203
The Potential Of 18F-Fluorocholine Computed Tomography (18F-FCH PET CT) As Predictor For Breast Cancer Immunophenotyping And Genetic Profiling Heterogenicity.
M. Zakaria¹, S. Shaharuddin², S. Abdullah Suhaimi³, F. Ahmad Saad¹; ¹Universiti Putra Malaysia, Serdang, MALAYSIA, ²Universiti Pertahanan Nasional Malaysia, Kuala Lumpur, MALAYSIA, ³Universiti Kebangsaan Malaysia, Cheras, MALAYSIA.

EP-0204
 MAMMI PET-based Habitat-radiomics for Measuring Intratumoral-heterogeneity and Predicting Neoadjuvant Chemotherapy Response in HER2-positive Breast Cancer

C. Ren;
 Shanghai Proton and Heavy Ion Center, Shanghai, CHINA.

EP-0205
 ¹⁸F-fluoroestradiol (¹⁸F-FES) PET/CT guided first-line treatment for HR+/HER2- metastatic breast cancer patients: experience from real-world

C. Liu¹, Y. Xie², Y. Chen², S. Song¹, B. Wang², Z. Yang¹;
¹Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, CHINA, ²Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EP-0206
 The prognostic significance of [¹⁸F]FDG PET/CT in triple-negative breast cancer: results of the TRINE-PET trial

L. Urso¹, S. Panareo², A. Iudicello^{3,2}, D. Albano⁴, S. Taralli⁵, A. Mazzeletti⁶, A. Annovazzi⁷, L. Fantini⁸, M. L. Mangia⁹, L. Sofia¹⁰, L. Setti¹¹, G. Cassarino¹², D. Aricò¹³, S. Ialuna¹⁴, A. Miceli¹⁵, E. Rizza¹⁶, C. Ferrari¹⁷, A. Marongiu¹⁸, F. Garrou¹⁹, P. Reccia²⁰, A. Arnone²¹, C. Colombo²², A. M. Maffione²³, D. Donner²⁴, L. Evangelista²⁵;
¹University of Ferrara, Ferrara, ITALY, ²University-Hospital of Modena, Modena, ITALY, ³University-Hospital of Ferrara, Ferrara, ITALY, ⁴University of Brescia, Brescia, ITALY, ⁵Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Rome, ITALY, ⁶Fondazione Poliambulanza Istituto Ospedaliero, Brescia, ITALY, ⁷irccs Istituto Nazionale Tumori Regina Elena, Rome, ITALY, ⁸IRCCS IRST “Dino Amadori, Meldola, ITALY, ⁹University of Turin, Turin, ITALY, ¹⁰University of Genoa, Genoa, ITALY, ¹¹Humanitas Gavazzeni, Bergamo, ITALY, ¹²Ospedale GPII, Ragusa, ITALY, ¹³Humanitas Istituto Clinico Catanese, Catania, ITALY, ¹⁴Osp. Riuniti Villa Sofia Cervello, Palermo, ITALY, ¹⁵AOU SS. Antonio e Biagio.e c. Arrigo, Alessandria, ITALY, ¹⁶Vito Fazzi Hospital, Lecce, ITALY, ¹⁷University Aldo Moro, Bari, ITALY, ¹⁸University of Sassari, Sassari, ITALY, ¹⁹A.O.U. Maggiore della Carità, Novara, ITALY, ²⁰IOV, Padua, ITALY, ²¹Arcispedale S. Maria Nuova, Reggio Emilia, ITALY, ²²Fondazione IRCCS Ca’ Granda, Milan, ITALY, ²³Santa Maria della Misericordia Hospital, Rovigo, ITALY, ²⁴Santa Chiara Hospital, Trento, ITALY, ²⁵Department of Biomedicine, Humanitas University, Pieve Emanuele, Milan, ITALY.

EP-0207
 Visualising HER2 Heterogeneity in Advanced Breast Cancer using [⁶⁸Ga]Ga-ABY-025 PET - a SingleCentre Polish Experience

G. Kramer-Marek^{1,2}, A. Kastelik-Hryniewiecka², M. Kubezko², I. Gorczewska², A. d’Amico², J. Feldwisch³, F. Y. Frejd^{3,4}, K. Daszewska², M. Jarzab²;
¹The Institute of Cancer Research, London, UNITED KINGDOM, ²Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, POLAND, ³Affibody AB, Solna, SWEDEN, ⁴Uppsala University, Uppsala, SWEDEN.

EP-0208
 Prognostic Value of Molecular Imaging TNM System for [¹⁸F]FES PET/CT in Estrogen Receptor-Positive Breast Cancer: A Single-Center Retrospective Study

K. Kimura¹, M. Jafarvand Giglou², S. Alkassis³, V. Ludwig¹, A. Holzgreve¹, I. Sonni^{1,4}, J. Czernin¹, B. Aditya³, J. Calais¹;
¹Department of Molecular and Medical Pharmacology Ahmanson Translational Theranostics Division, David

Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, ²Department of Radiological Sciences, University of California Irvine School of Medicine, Irvine, CA, UNITED STATES OF AMERICA, ³Department of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, ⁴Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES OF AMERICA.

EP-0209
 [⁶⁸Ga]Ga-NOTA-T4 PET/CT Imaging of Trop2 Expression in Patients with Metastatic Breast Cancer

L. Yao¹, Z. Chu², Y. Wu¹, D. Jiang¹, Y. Gu³, Q. Ge⁴, Y. Guan¹, W. Wei⁵, F. Xie¹;
¹Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ²Department of Oncology, Huashan Hospital, Fudan University, Shanghai, CHINA, ³Central Research Institute United Imaging Healthcare Group Co, Ltd, Shanghai, CHINA, ⁴Central Research Institute United Imaging Healthcare Group Co, Ltd, Shanghai, CHINA, ⁵Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA.

EP-0210
 The Predictive Role of Pre-Treatment PET/CT-Derived Quantitative Parameters in Disease Progression of Triple-Negative Breast Cancer

N. Ünsal¹, S. Karabulut¹, A. Aksu², G. Capa Kaya¹;
¹Dokuz Eylul University Medical Faculty Hospital, Department of Nuclear Medicine, Izmir, TÜRKIYE, ²Izmir Katip Celebi University Medical Faculty Hospital, Department of Nuclear Medicine, Izmir, TÜRKIYE.

EP-0211
 Accuracy of [⁶⁸Ga]Ga-FAPI PET/CT in Evaluating Axillary Lymph Node Status After Neoadjuvant Therapy in Clinically Node-Positive Breast Cancer Patients

Y. Fan¹, J. Hu¹, C. Hu², S. Zhu², Y. Lu², Y. Peng¹, Q. Hu¹, P. Ju¹, B. Li¹, Y. Yuan³, K. Shen², X. Chen²;
¹Department of Nuclear Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ²Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ³Department of Radiology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

EP-0212
 Trop2-targeted [18F]AIF-RESCA-T4 Immuno-PET/CT in Breast Cancers: Evaluation Across Different Molecular Subtypes

W. Jia, G. Huang, J. Liu, W. Wei;
 Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA.

EP-0213
 Response Assessment with ¹⁸F-FDG PET/CT in Tripple Negative Breast Cancer Patients Undergoing Combined Immunochemotherapy: A Retrospective Analysis

E. Popova¹, Z. Zhelyazkova², S. Sergieva¹, R. Krasteva²;
¹Acibadem City Clinic Tokuda Hospital, Sofia, BULGARIA, ²Unihospital, Panagyurishte, BULGARIA.

EP-0214
 Influence of Plasma Estradiol Levels on ¹⁸F-FES Uptake in ER-Positive Breast Cancer

K. Miyake¹, Y. Shimizu¹, M. Kawashima¹, S. Yuge², Y. Kitano¹, S. Yasumura¹, Y. Kitai³, T. Oishi³, K. Itagaki³, M. Kataoka¹, N. Masuda¹, K. Nakatani¹, Y. Nakamoto¹;
¹Kyoto University Graduate School of Medicine, Kyoto, JAPAN, ²Tenri Hospital, Nara, JAPAN, ³Kyoto University Hospital, Kyoto, JAPAN.

EP-0215
 Toward ‘Less is More’: ⁶⁸Ga-FAPI PET/CT Optimizes Axillary Management in Invasive Breast Cancer

J. Li, W. Mu, Y. Tang, K. Zhang, S. Hu;
 Xiangya Hospital, Central South University, Changsha, CHINA.

EP-0216
 Radiological indicators of peritumoural and whole-breast vascularity and their association with [¹⁸F]-FMISO PET/MRI parameters of hypoxia and vascular function in breast cancer

R. Manavaki¹, J. C. Carmona-Bozo¹, S. Carriero¹, N. Stranzl¹, J. L. Miller², C. Brodie², C. Caracò¹, M. J. Graves¹, A. J. Patterson¹, T. D. Fryer¹, E. Provenzano³, F. J. Gilbert¹;
¹University of Cambridge, Cambridge, UNITED KINGDOM, ²Cancer Research UK - Cambridge Institute, Cambridge, UNITED KINGDOM, ³Cambridge University Hospitals NHS Foundation Trust, Cambridge, UNITED KINGDOM.

EP-0217
 [18F]FDG and [68Ga]FAPI PET/CT for lesion detection and characterization in Triple Negative Breast Cancer patients

N. Hovhannisyan-Baghdasarian¹, L. Champion², N. Jehanno³, R.-D. Seban², H. Tissot³, J. Fouque⁴, F. Coussy⁵, D. Bello Roufai⁵, D. Loirat⁶, S. Rafie⁷, F.-C. Bidard⁵, F. Mechta-Grigoriou⁷, I. Buvat¹;
¹Institut Curie, Inserm, Orsay, FRANCE, ²Dpt of Nuclear Medicine, Institut Curie, Saint Cloud, FRANCE, ³Dpt of Nuclear Medicine, Institut Curie, Paris, FRANCE, ⁴Dpt of Pharmacy, Institut Curie, Saint-Cloud, FRANCE, ⁵Dpt of Medical Oncology, Institut Curie, Saint-Cloud, FRANCE, ⁶Dpt of Medical Oncology, Institut Curie, Paris, FRANCE, ⁷Unité Chimie Biologie des Cancers, Institut Curie, Inserm, CNRS, Paris, FRANCE.

EP-15
 e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B14 Lung (including Mesothelioma)

EP-0218
 Exploring Brain Metabolic and Functional Changes in Solitary Pulmonary Lesions: A ¹⁸F-FDG PET/MR Study Comparing Malignant and Benign Cohorts

N. Meng¹, Q. Ji², J. Pan¹, Q. Chen¹, Y. Yang³, Z. Wang², M. Wang¹;
¹Henan Provincial People’s Hospital, Zhengzhou, CHINA, ²United Imaging Healthcare Advanced Technology Research Institute Co., Ltd., Shanghai, CHINA, ³United Imaging Healthcare Co., Ltd., Beijing, CHINA.

EP-0219
 Long-Axial-Field-Of-View PET/CT in Deep-Inspiration-Breath-Hold for radiation therapy planning of mediastinal lymphoma

S. Honoré d’Este¹, O. E. Wagner¹, P. A. Andersen², D. Dejanovic¹, A. Loft¹, M. G. Askløf¹, E. Albrecht-Beste^{1,3}, I. R. Vogelius^{2,3}, L. Specht^{2,3}, F. L. Andersen^{1,3};
¹Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Copenhagen, DENMARK, ²Department of Oncology, Copenhagen University Hospital, Copenhagen, DENMARK, ³Department of Clinical Medicine, University of Copenhagen, Copenhagen, DENMARK.

EP-0220
 Multicenter Evalution of Predictive Clinical and Radiological markers for Pathological Complete Response and Major Pathological Response in NSCLC Patients Undergoing Neoadjuvant Chemoimmunotherapy

M. Zhang¹, M. Yan², Z. Zhang¹;
¹Department of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Lung Cancer, Tianjin, CHINA, ²Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Lung Cancer Center, 30, Tianjin, CHINA.

EP-0221
 Performance pulmonary nodules detection using Deep Learning motion correction techniques in ¹⁸-FDG PET/CT protocols.

M. Giménez Aranda^{1,2}, E. Marino^{1,3}, G. Peña¹;
¹FUESMEN (Fundación Escuela de Medicina Nuclear), Mendoza, ARGENTINA, ²Universidad de Mendoza, Mendoza, ARGENTINA, ³CNEA (Comisión Nacional de Energía Atómica), Buenos Aires, ARGENTINA.

EP-0222
 Correlation of PD-L1 Expression with PET/CT Metabolic Parameters in Non-Small Cell Lung Cancer

A. Erdem Karaoglu¹, A. Cinar¹, O. Sutcuoglu², N. Aydinbelge Dizdar¹, O. Ozmen^{1,3};
¹Ankara Etlik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Ankara Etlik City Hospital, Department of Medical Oncology, Ankara, TÜRKIYE, ³University of Health Sciences, Ankara, TÜRKIYE.

EP-0223
 Comparative Performance of ¹⁸F-FDG and ¹⁸F-PSMA PET/CT in Lung Cancer: Adenocarcinoma versus Squamous Cell Carcinoma

N. Silveira, M. W. P. Júnior, M. S. Takahashi, S. Kuba, B. J. Amorim, M. d. L. Lima, C. A. Souza, C. S. P. Lima, C. D. Ramos;
 UNICAMP, Campinas, BRAZIL.

EP-0224
 The Relationship Between Metabolic Parameters Derived from ¹⁸F-FDG PET/CT Images and Systemic Inflammatory Response with Disease Stage and Survival in Primary Staging of Small Cell Lung Cancer

K. Seker, Z. Hasbek;
 Sivas Cumhuriyet University, Faculty Of Medicine, Department of Nuclear Medicine, Sivas, TÜRKIYE.

EP-0225

Relationship of staging FDG PET/CT parameters with clinicopathological data and mortality in non-small cell lung cancer patients

B. Yilmaztekin, G. Yilmaztekin, B. B. Demirel, G. Vural; Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TÜRKIYE.

EP-0226

Impact of a Breath Hold Protocol in PET/CT on Thoracic Lesion Delineation

T. Lima¹, C. Gomes¹, F. Tabotta², A. Leimgruber²; ¹Lucerne University Teaching and Research Hospitals, Lucerne, SWITZERLAND, ²Genolier Clinic, Swiss Medical Network, Genolier, SWITZERLAND.

EP-0227

Comparison of Hypothetical [68Ga]Ga-FAPI-46 PET/CT-derived and [18F]F-FDG PET/CT-derived Treatment Plan in a Suspected/Confirmed Lung Cancer Cohort Addressed to Surgery by Conventional Staging, Within a Monocentric Prospective Trial

G. Cuzzani¹, E. Fortunati², L. Zanoni³, C. Nanni², C. Malizia², M. Assenza⁴, L. Vetrone², F. Lodi², V. S. Cabitza², I. Brusa², S. Emiliani², F. Giunchi², A. De Giovanni², F. Antonacci², M. Ferrari², F. Natali², T. Galasso², G. P. Bandelli², P. Candoli², A. D'errico⁵, S. Civollani⁶, P. Solli⁶, S. Fanti^{1,2}; ¹Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Nuclear Medicine, AST Pesaro-Urbino, ITALY, ⁴Professional Development and Implementation of Research in Health Professional Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Pathology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁶Division of Thoracic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁷Interventional Pulmonology Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁸Department of Medical Physics, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0228

Mapping the Spread: Prognostic Relevance of Dmax in Metastatic Small Cell Lung Cancer

A. Us¹, A. Aksu¹, K. Kucuker¹, Z. Guc², A. Alacacioglu², B. Turgut¹; ¹Izmir Katip Celebi University Faculty of Medicine, Department of Nuclear Medicine, Izmir, TÜRKIYE, ²Izmir Katip Celebi University Faculty of Medicine, Department of Oncology, Izmir, TÜRKIYE.

EP-0229

Prediction of PD-L1 Status and Tumor Subtype Characterization in Non-Small Cell Lung Cancer Using Abbreviated [¹⁸F]FDG Dynamic Imaging Protocols with Long Axial Field-of-View PET/CT

E. Calderón Ochoa, J. A. Benecke, W. Lan, F. P. Schmidt, H. Dittmann, C. la Fougère; Department of Nuclear Medicine and Molecular Imaging, University Hospital of Tübingen, Tübingen, GERMANY.

EP-0230

Focal [18F]-FDG Uptake in the Heart: A Favourable Sign in Lung Cancer Patients at Risk of Cachexia?

E. Abenavoli¹, M. Pepponi¹, T. Beyer², D. Ferrara², A. Frille³, S. Gruenert⁴, M. Hacker⁴, S. Hesse⁵, L. Hofmann⁵, O. Sabri⁵, L. Shiyam Sunda², J. Yu², R. Sciagra¹;

¹Nuclear Medicine Unit, Florence, ITALY, ²QIMP Team, Medical University of Vienna, Vienna, AUSTRIA, ³Department of Respiratory Medicine, Leipzig University, Leipzig, GERMANY, ⁴Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, ⁵Department of Nuclear Medicine, Leipzig University, Leipzig, GERMANY.

EP-0231

Enhanced Diagnostic Efficacy of Deep-Inspiration Breath-Hold Total-Body ¹⁸F-FDG PET/CT for Pulmonary Lesions: A Comparative Study

X. Zhou; Peking University Cancer Hospital, Beijing, CHINA.

EP-0232

Association Between Ventilasion/Perfusion Scan Outcomes and Novel MAPH Score in Patients with Suspected Acute Pulmonary Embolism

A. Dursun¹, N. A. Dizdar¹, E. Tatci², G. İnal¹, A. Çınar¹, Ö. Özmen²; ¹Ankara Etlik City Hospital, Departmant of Nuclear Medicine Clinic, Ankara, TÜRKIYE, ²Health Sciences University, Ankara Etlik City Hospital, Nuclear Medicine Clinic, Ankara, TÜRKIYE.

EP-0233

Tumor Dissemination (Dmax) derived from ¹⁸F-FDG PET/CT as a Predictor of Response to Immunotherapy in Patients With Non-small Cell Lung Cancer

S. Pellegrino¹, A. Volpicelli¹, A. Russo², M. Iernia², F. Salomone², A. Servetto², R. Bianco², R. Fonti¹, S. Del Vecchio¹; ¹Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, ²Department of Clinical Medicine and Surgery, University Federico II, Naples, ITALY.

EP-0234

Artificial intelligence prognostic predictive algorithms in advanced lung cancer using pre-therapy ¹⁸F-FDG PET-CT metabolic parameters. The role of MTV in the model performance. Preliminary results.

D. Donner¹, F. Rignanese², V. Vultaggio³, M. Moroni⁴, M. Datres⁵, M. Pozzi⁶, M. Chierici⁴, G. Jurman⁴, O. Caffo⁷, L. Bazan⁸, L. Picori¹, S. Agostini⁹, C. C. Quattrocchi¹⁰, A. G. Morganti¹¹, F. Chierichetti¹; ¹Dep. Nuclear Medicine, Dipartimento Radiologie, APSS, Trento, ITALY, ²Data Science for Health Unit FBK (Fondazione Bruno Kessler), Trento, ITALY, ³Dep. Nuclear Medicine, ARNAS Civico, Palermo, ITALY, ⁴Data Science for Health Unit FBK (Fondazione Bruno Kessler), Trento, ITALY, ⁵Data Science for Health Unit FBK (Fondazione Bruno Kessler); Dept of Math University of Trento, Trento, ITALY, ⁶CIBIO (Cellular Computational and Integrative Biology) University of Trento, Trento, ITALY, ⁷Dipartimento Oncologia medica, APSS, Trento, ITALY, ⁸Sant'Anna School of Advanced Studies, University od Pisa, Pisa, ITALY, ⁹Dep. Nuclear Medicine Radiopharmacy, Dipartimento Radiologie, APSS, Trento, ITALY, ¹⁰CISMED University of Trento, Dipartimento Radiologie, APSS, Trento, ITALY, ¹¹DIMEC, University of Bologna; Radiation Oncology Department; IRCCS Azienda Ospedaliero-Universitaria of Bologna, Bologna, ITALY.

EP-0235

Diagnostic role of [¹⁸F]FDG PET/CT in Pulmonary Hamartomas: Retrospective Analysis

M. Marques, C. Loewenthal; Hospital da Luz Lisboa, Lisbon, PORTUGAL.

EP-0236

The Evaluation of Nivolumab Treatment and Survival Efficacy with Metabolic Parameters in Patients with Non-Small Cell Lung Cancer

N. Aydin¹, G. Mutevelizade¹, B. C. Bozdemir¹, N. Kolkiran², A. P. Erdogan², E. Sayit Bilgin¹; ¹Manisa Celal Bayar University Faculty of Medicine Department of Nuclear Medicine, Manisa, TÜRKIYE, ²Manisa Celal Bayar University Faculty of Medicine Division of Medical Oncology, Manisa, TÜRKIYE.

EP-0237

Refining Prognostic Assessment in Small Cell Lung Cancer: Development and Validation of Multiparametric Models Integrating ¹⁸F-FDG PET/CT Dissemination Characteristic

Y. Liu, X. Zhou, X. Meng, X. Kong, Y. Cui, Y. Liu, Y. Yao, J. Zhu, N. Li; Peking University Cancer Hospital, Beijing, CHINA.

EP-0238

Early prediction of tumor response to carbon-ion radiotherapy via ¹⁸F-FMISO PET/CT in locally advanced non-small-cell lung cancer patients

C. Ren; Shanghai Proton and Heavy Ion Center, Shanghai, CHINA.

EP-0239

Kinetic modeling and parametric imaging of ¹³N-NH₃ in treatment-naïve lung cancer using total-body

H. Yuan¹, F. Wang¹, T. Sun², L. Jiang¹; ¹Guangdong Provincial People's Hospital, Guangzhou, CHINA, ²Lauterbur Research Center for Biomedical Imaging,Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, CHINA.

EP-0240

Evaluating the Use of Metabolic Tumor Volume (MTV) During Follow-Up in NSCLC Patients Treated with Immunotherapy

O. Ekmekcioglu¹, S. Halil², A. I. Yasin²; ¹Nuclear Medicine Dept., University of Health Sciences, Sisli Hamidiye Etfal Education and Research Hospital, Istanbul, TÜRKIYE, ²Medical Oncology Dept., University of Health Sciences, Sisli Hamidiye Etfal Education and Research Hospital, Istanbul, TÜRKIYE.

EP-0241

Head-to-head Comparison of Peptide- and Nanobody-based Radiotracers for Detecting PD-L1 expression in Non-Small Cell Lung Cancer

Y. Wu¹, H. Wang¹, Y. Gu², D. Xu¹, F. Xie¹; ¹Huashan Hospital,Fudan University, Shanghai, CHINA, ²Central Research Institute, United Imaging Healthcare Group Co, Shanghai, CHINA.

EP-0242

Assessing Time-Dependent SUV Changes in small and medium Pulmonary Nodules: Diagnostic Implications of Dual-Time-Point 18F FDG PET/CT

N. Kapsoritakis¹, F. Tsitoura², O. Bourogianni¹, G. Barmparis², G. Tsironis², A. Bertsiyas³, N. Tzanakis⁴, S. Koukouraki¹; ¹Nuclear Medicine Department, Medical School University of Crete, Heraklion, Crete, GREECE, ²Department of Physics, Univercity of Crete, Heraklion, Crete, GREECE, ³Rheumatology Department, Medical School University of

Crete, Heraklion, Crete, GREECE, ⁴Department of respiratory Medicine, University Hospital, Heraklion, Crete, Greece and School of Medicine, Heraklion, Crete, GREECE.

EP-0243

Comparison of SUV, MTV and TLG volumetric changes in early and delayed FDG PET/CT: A prospective analysis for optimized pulmonary nodule evaluation.

N. Kapsoritakis¹, F. Tsitoura², G. Barmparis², O. Bourogianni¹, G. Tsironis², A. Bertsiyas³, N. Tzanakis⁴, S. Koukouraki¹; ¹Nuclear Medicine Department, Medical School University of Crete, Heraklion, Crete, GREECE, ²Department of Physics, Medical School, University of Crete, Heraklion, Crete, GREECE, ³Department of Rheumatology, Medical School, University of Crete, Heraklion, Crete, GREECE, ⁴Department of Respiratory, Medical School, University of Crete, Heraklion, Crete, GREECE.

EP-0244

Diagnostic Performance of 18F-PSMA PET/CT in detecting early and very early Biochemical Recurrence of Prostate Cancer: Insights from an 8-Month Single-Center Experience

N. Kapsoritakis¹, O. Bourogianni¹, I. Skamagkas², G. Georgiadis², C. Mamoulakis², S. Koukouraki¹; ¹Nuclear Medicine Department, Medical School University of Crete, Heraklion, Crete, GREECE, ²Department of Urology, University Hospital of Crete, Heraklion, Crete, GREECE.

EP-0245

Is M1c1 a Distinct Prognostic Entity? Survival Impact of Single-Organ Extrathoracic Metastasis in the Proposed TNM-9 Lung-Cancer Classification

D. Nak¹, O. Bülbül¹, B. Demir², M. H. Baltacioğlu³; ¹Recep Tayyip Erdoğan University Training and Research Hospital, Rize, TÜRKIYE, ²Mehmet Akif Inan Training and Research Hospital, Şanlıurfa, TÜRKIYE, ³Trabzon University Faculty of Medicine Trabzon Kanuni Research and Training Hospital, Trabzon, TÜRKIYE.

EP-0246

Can F-18 FDG PET/CT Metabolic Parameters Predict STAS in Non-Small Cell Lung Cancer Patients?

B. Kocabeyoglu, R. H. Tokac, A. Akgun; Ege University Nuclear Medicine Department, Izmir, TÜRKIYE.

EP-0247

Predicting PD-L1 expression status in NSCLC using radiomic analysis of FDG-PET/CT images

F. Kiss, I. Járó, K. Szigeti, T. Györke; Semmelweis University, Budapest, HUNGARY.

EP-0248

Baseline PET/MR Imaging for Lung Cancer Patients with Immunotherapy: A Correlation and Prognostic Study of IVIM, CTRW Diffusion and PET Metabolic Parameters

Y. Jiang¹, S. Xie¹, C. Zhou¹, C. Sun², Y. Guo³, Y. Wu¹, W. Fan¹; ¹Sun Yat-sen University Cancer Center, Guangzhou, CHINA, ²United Imaging Healthcare Group Co., Ltd, Shanghai, CHINA, ³Shenzhen United Imaging Healthcare Co., Ltd., Shenzhen, CHINA.

EP-0249

¹⁸F-FAPI PET/CT Imaging in Pneumoconiosis:a new tool for early diagnosis and guiding treatment of pulmonary fibrosis

C. Liu, S. Li;
First hospital of shanxi medical university, Taiyuan, CHINA.

EP-0250

Comparative Evaluation of 68-Gallium-Fibroblast Activation Protein Inhibitor (FAPI) PET/CT and 18-F-Fluorodeoxyglucose (FDG) PET/CT in Non-Small Cell Lung Cancer: Insights from an Expanded Cohort

S. Sathoo, D. Halanaik, R. Manju, S. Pradeep;
Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, INDIA.

EP-0251

Prognostic Value of Cerebral Metabolic Activity in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients

J. Auria¹, G. Lemoudda¹, N. Hovhannisyan-Baghdasarian¹, M. Pires², L. K. Shiyam Sundar³, P. Salamoun-Feghali⁴, R.-D. Seban^{1,5}, N. Jehanno^{1,5}, C. Nioche¹, M. Luporsi¹, T. Beyer², N. Girard⁴, I. Buvat¹, F. Orlhac¹;

¹Institut Curie, Université Paris-Saclay, Inserm LITO U1288, Orsay, FRANCE, ²Quantitative Imaging and Medical Physics (QIMP) Team, Medical University of Vienna, Vienna, AUSTRIA, ³DIGIT-X Lab, Department of Radiology, LMU University Hospital, Munich, GERMANY, ⁴Institut Curie, Institut du Thorax Curie-Montsouris, Paris, FRANCE, ⁵Institut Curie, Department of Nuclear Medicine, Paris-St-Cloud, FRANCE.

EP-0252

Spatial radiomics features derived from SUVmax location in resectable NSCLC are associated with tumor aggressiveness

Z. Jiang, D. Haberl, C. P. Spielvogel, J. Yu, K. Lukas, H. Marcus;
Medical University of Vienna, Vienna, AUSTRIA.

EP-0253

Performance of [18F] FDG PET/CT versus FAPI PET/CT for lung cancer assessment

M. Komarova, N. Meshcheryakova, I. Nazarenko, O. Ryzhova, A. Pronin, V. Solomyany;
N.N. Blokhin National Medical Research Center of Oncology, Moscow, RUSSIAN FEDERATION.

EP-0254

Towards Personalised Lung Cancer Screening: A Prospective Multicentre Study Integrating LDCT, [¹⁸F]FDG-PET/CT and AI-Driven Risk Stratification

F. Gelardi¹, P. Muriana¹, L. Antunovic¹, M. Sollini^{2,1}, D. Palumbo¹, R. Ferrara^{2,1}, R. Petrelli¹, R. Di Donato¹, R. Cuocolo³, P. Veltri⁴, P. Soda⁵, G. Veronesi^{2,1}, A. Chiti^{2,1};
¹IRCCS Ospedale San Raffaele, Milan, ITALY, ²Università Vita-Salute San Raffaele, Milan, ITALY, ³Università di Salerno, Baronissi (SA), ITALY, ⁴DIMES, Università della Calabria, Rende (CS), ITALY, ⁵Università Campus Bio-Medico di Roma, Rome, ITALY.

EP-16

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B15 Gastro-Intestinal (including Liver and Non-Endocrine Pancreas)

EP-0255

Early tumor response following transarterial radioembolization (TARE): preliminary data from 30 patients with primary and secondary liver tumors

A. Moretti, A. Vizzuso, M. Renzulli, E. Giampalma, E. Del Giudice, D. Tirotta, R. Galassi, G. Pontone, F. Di Mauro, F. Matteucci;
Ospedale Morgagni Forli, Forli, ITALY.

EP-0256

Fibroblast activation protein-targeted PET/CT with ¹⁸F-Fibroblast activation protein inhibitor-74 for evaluating the staging and guiding clinical management of gastrointestinal cancers: comparison with contrast-enhanced CT

L. Ma¹, Z. Quan¹, H. Chen², F. Kang¹, J. Wang¹;
¹Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, CHINA, ²The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, CHINA.

EP-0258

Multicentre Study Comparing [⁶⁸Ga] FAPI-04 PET/CT and [¹⁸F]FDG PET/CT for Staging Gastrointestinal Tumours

P. Hji¹, H. Nagaraj^{2,3}, K. G. Kallur^{4,3}, S. S P¹, M. Saini², P. Saini², R. Krishnappa³, P. G. Ramachandra³, D. Kumar⁵, P. Wadhwa⁵;
¹Aster Hospital, Banglore, INDIA, ²The Nairobi West Hospital, Nairobi, KENYA, ³HCG CCK Cancer Centre, Nairobi, KENYA, ⁴HCG Cancer Center, Banglore, INDIA, ⁵United Imaging Healthcare, Delhi, INDIA.

EP-0259

Evaluating Protein-Losing Enteropathy Using 99mTc-MDP Scintigraphy: A Non-Invasive Diagnostic Approach

K. Vidhya¹, S. K. Jha², P. Palanivel³, S. L S⁴, R. Mishra⁵, V. K. Dhingra¹;
¹AIIMS, Rishikesh, Rishikesh, INDIA, ²Ranchi Cancer Hospital and Research Centre, Ranchi, INDIA, ³American Oncology Institute, Coimbatore, INDIA, ⁴AIIMS, Delhi, Delhi, INDIA, ⁵Hope and Heal Cancer Hospital, Siliguri, INDIA.

EP-0260

Timing is Everything: Unmasking Pancreatic Cancer with Multiple-Time-Point [⁶⁸Ga]Ga-FAPI-46 PET Imaging

P. Rasinski^{1,2}, T. Nilsson^{1,2}, A. Gebremariam², M. Holstensson^{1,2}, E. Sparrelid^{1,3}, M. Löhr^{1,3}, T. Tran^{2,4}, R. Axelsson^{2,5};
¹Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, SWEDEN, ²Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, SWEDEN, ³Department of Upper Gastrointestinal Diseases, Karolinska University Hospital, Stockholm, SWEDEN, ⁴Department of Oncology-Pathology, Karolinska Institutet, Stockholm, SWEDEN, ⁵Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, SWEDEN.

EP-0261

Prognostic Value of Preoperative Staging ¹⁸F-FDG PET/MRI Findings in Surgically Resected Gastric Cancer Patients

R. Kalkan, S. Gülbahar Ateş, U. Aydos, Ü. Ö. Akdemir, L. Ö. Atay;
Gazi University Faculty of Medicine, Ankara, TÜRKIYE.

EP-0262

Head-to-Head Comparison of ¹⁸F-FDG and ¹⁸F-PSMA PET/CT in Hepatocellular Carcinoma

G. Picciola Bordoni, M. E. S. Takahashi, F. F. Zarpelão, N. A. A. Silveira, V. C. C. R. Heringer, S. Kuba, N. Tobar, S. Q. Brunetto, C. A. de Souza, J. B. C. Carvalho, C. Dario Ramos;
Universidade Estadual de Campinas UNICAMP, Campinas, BRAZIL.

EP-0263

Dual-energy CT imaging for the evaluation of tumour response to Phosphorus-32 microparticles injection: preliminary results.

V. Landoni, L. Chiacchiararelli, M. Pressello, G. Regine, A. Sbrozzi Vanni, C. Garufi, G. Ventroni;
San Camillo Forlanini Hospital, Rome, ITALY.

EP-0264

Gastric Emptying Scintigraphy Using a High-Caloric Liquid Meal - Single Center Experience

I. Sisko Markos^{1,2}, I. Blazekovic^{1,2}, M. Romic^{1,2}, M. Bosak Butkovic^{1,2}, D. Filipan¹, T. Jukic¹;
¹UHC Sestre Milosrdnice, Zagreb, Zagreb, CROATIA, ²Croatian Catholic University, School of Medicine, Zagreb, CROATIA.

EP-0265

Predictive Value of 99mTc-Mebrofenin Hepatobiliary Scintigraphy in Evaluating Liver Function and Volumetry Pre- and Post-Radioembolization in Hepatocellular Carcinoma (HCC) Patients

S. Shamim, M. Meena, G. Arora, P. Gb, P. Gupta, N. Kumar;
AIIMS New Delhi, Delhi, INDIA.

EP-0266

Diagnostic Performance of [68Ga]-FAPI-46 PET/CT in Suspected Recurrence in Signet Ring Cell Colorectal Cancers (SRCC)

S. Mahambre^{1,2}, I. Dev^{1,2}, A. Agrawal^{1,2}, N. Purandare^{1,2}, S. Shah^{1,2}, A. Puranik^{1,2}, S. Choudhury^{1,2}, S. Ghosh^{1,2}, M. Venkatachalam^{1,2}, V. Rangarajan^{1,2};
¹Tata Memorial Hospital, Mumbai, INDIA, ²Homi Bhabha National University, Mumbai, INDIA.

EP-0267

A single center prospective study to evaluate clinical utility of Gallium 68- FAPI in poorly cohesive carcinoma of stomach

M. Gupta¹, S. Singh², S. Goel³, S. Goyal³, V. Talwar³, V. Goyal³, S. Swamy M S³, G. Gupta⁴, A. Pathak¹, P. Sarathi Choudhury¹;
¹Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA, ²Department of GI Oncosurgery, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA, ³Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA, ⁴Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA.

EP-0268

¹⁸F-PSMA-1007 PET/CT in Hepatocellular Carcinoma (HCC): Determining the Ideal Acquisition Window

C. Vallone^{1,2}, P. Rossi³, P. Guglielmo^{2,4}, J. Jandric³, M. Rodari³, K. Marzo³, M. Marengo³, M. Olivieri⁵, L. Evangelista^{2,3};
¹Department of Advanced Biomedical Sciences, University of Napoli, Napoli, ITALY, ²Department of Bioscience, Humanitas University, Pieve Emanuele (MI), ITALY, ³Nuclear Medicine Unit, IRCCS Humanitas Cancer Center, Rozzano (MI), ITALY, ⁴Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, ITALY, ⁵Physic Unit, IRCCS Humanitas Cancer Center, Italy, Rozzano (MI), ITALY.

EP-0269

Assessing the Value of Short-Duration Dynamic [¹⁸F]FDG PET on LAFOV Scanners in Hepatocellular Carcinoma

S. Capitanio¹, A. Lazar², A. Franchini¹, A. Spataro¹, G. Muti³, L. Airo' Farulla¹, A. Scarale¹, G. Cabrini¹, E. Gay¹, C. Pettinato⁴, A. Chiti⁵, C. Rossetti¹;
¹Nuclear Medicine Unit, Dipartimento Ematologia, Oncologia e Medicina Molecolare, ASST Niguarda Hospital, Milan, ITALY, ²Vita-Salute San Raffaele University, Milan, ITALY, ³Department of Physics, ASST Niguarda Hospital, Milan, ITALY, ⁴Medical Physics Unit, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, ITALY, ⁵Vita-Salute San Raffaele University, Nuclear Medicine Unit, IRCCS San Raffaele Hospital, Milan, ITALY.

EP-0270

Kinetic Modeling of PSMA Uptake in Hepatocellular Carcinoma with LAFOV PET/CT: Correlation with Histopathological Features

L. Vetrone¹, E. Proserpi², E. Proserpi², D. Malvi³, A. Degiovanni³, F. Vasuri⁴, I. Brusa¹, S. Emiliani¹, D. Dall'Olio⁵, M. Ravaoli², M. Cescon², S. Fanti^{1,6}, A. Farolfi¹;
¹Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ²Department of Hepatobiliary Surgery and Liver Transplant, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Department of Medical and Surgical Sciences (DIMEC), Bologna University, Bologna, ITALY, ⁵Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITALY, ⁶Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY.

EP-0271

Normal patterns of pancreatic uptake on 68Ga-DOTATATE PETCT

A. Hassan, A. W. Alessi, E. Wahab, S. J. Hughes;
Queen Elizabeth Hospital Birmingham, Birmingham, UNITED KINGDOM.

EP-0272

Evaluation of the Effectiveness of 68Ga-Trivehexin (Integrin αvβ6) PET/CT in Staging and Restaging of Pancreatic Adenocarcinoma: Preliminary Findings

A. Ozturk¹, Ö. F. Şahin¹, Z. Tosunoğlu¹, T. F. Çermik², G. Alçın¹, E. Akgün¹, M. M. Sevinç³, Ç. Usul Afşar⁴, E. Arslan¹;
¹Istanbul Training and Research Hospital Nuclear Medicine Department, Istanbul, TÜRKIYE, ²Acibadem Maslak Hospital, Nuclear Medicine Department, Istanbul, TÜRKIYE, ³Istanbul Training and Research Hospital General Surgery Department, Istanbul, TÜRKIYE, ⁴Istanbul Training and Research Hospital Medical Oncology Department, Istanbul, TÜRKIYE.

EP-0273

Association Between PET/CT-Derived PCI and Survival in Peritoneal Carcinomatosis: A Retrospective Analysis

S. Demirtas Senlik¹, A. Cinar¹, C. Engur Uyanik¹, O. Sutcuoglu², O. Ozmen¹;
¹Ankara Etlik City Hospital, Ankara, TÜRKIYE, ²Gazi University Hospital, Ankara, TÜRKIYE.

EP-0274

Trans-arterial radioemoembolization for treatment of large hepatocellular carcinoma, a single center experience

A. Alsugair;
King Faisal Specilaist Hospital And Research Center, Riyadh, SAUDI ARABIA.

EP-0275

Characterizing PDAC and Pancreatitis: Insights from [⁶⁸Ga]Ga-FAPI-46 Kinetic Modeling

T. Nilsson^{1,2}, P. Rasinski^{1,2}, E. Sparrelid^{2,3}, M. Löhr^{2,3}, T. Tran^{1,4}, M. Lubberink⁵, R. Axelsson^{1,6}, M. Holstenson^{1,2};
¹Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, SWEDEN, ²Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, SWEDEN, ³Department of Upper Gastrointestinal Diseases, Karolinska University Hospital, Stockholm, SWEDEN, ⁴Department of Oncology-Pathology, Karolinska Institutet, Stockholm, SWEDEN, ⁵Uppsala University, Department of Surgical Sciences Molecular Imaging and medical physics, Uppsala, SWEDEN, ⁶Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, SWEDEN.

EP-0276

Usefulness of [¹⁸F]FAPI-04 and [¹⁸F]FDG PET/CT for the detection of peritoneal carcinomatosis: a comparative study

C. Jiang, H. Ye, W. Zhou, K. Zheng, Y. Zhang, J. Dai, X. Peng, J. Yang, H. He, X. Hu;
Department of PET-CT Center, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CHINA.

EP-0277

Comparison of 68Ga-FAPI PET and ¹⁸F-FDG PET Findings in the Pre-Treatment Evaluation of Transarterial Radioembolization (TARE)

K. Saglam, O. Sahin, M. Bodur, A. Kibar, L. Kabasakal;
Istanbul University-Cerrahpasa, Istanbul, TÜRKIYE.

EP-0278

Clinical evaluation of a unified data-driven respiratory motion correction technique in ¹⁸F-FDG PET/CT imaging of upper abdominal lesions: a real-world study

T. Han¹, Y. Wang², Z. Quan¹, J. Wang¹, F. Kang¹;
¹Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA, ²United Imaging Healthcare, Shanghai, CHINA.

EP-0279

The value of ¹⁸F-FDG PET/MR radiomic features in predicting CTNNB1 mutations in pediatric hepatoblastoma

Y. Xu;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0280

Machine lerning-driven characterization of lymph node metastasis and 10-year overall survival in extrahepatic cholangiocarcinoma using ¹⁸F-FDG PET/CT

J. Ning^{1,2}, C. Li¹, H. Yang¹, X. Luan¹, R. Xue¹, Y. Wang³, J. Tian¹, M. Hacker⁴, L. Kenner², B. Xu¹;
¹Department of Nuclear Medicine, First Medical Center of Chinese PLA General Hospital, Beijing, CHINA, ²Christian Doppler Lab for Applied Metabolomics, Vienna, AUSTRIA, ³GE Healthcare China, Shanghai, CHINA, ⁴Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

EP-0281

Prognostic value of lymph node-to-primary tumor standardized uptake value ratio in esophageal cancer patients who underwent surgery

C.-S. Tseng, S.-C. Chan;
Hualien Tzu Chi Hospital, Hualien, TAIWAN.

EP-0282

Contribution of ⁶⁸Ga-FAPI PET/CT to ¹⁸F-FDG PET/CT in the Initial Staging and Restaging of Gastric Cancer:

M. Y. Kiran¹, L. D. Ercan², S. Kuyumcu¹, C. Ertekin², Z. G. Ozkan¹, D. Has Simsek¹, E. G. İsik¹, Y. Sanli¹;
¹Istanbul University, Istanbul Medical Faculty, Departmant of Nuclear Medicine, Istanbul, TÜRKIYE ²Istanbul University, Istanbul Medical Faculty, Departmant of General Surgery, Istanbul, TÜRKIYE.

EP-0283

Diagnostic Performance of ⁶⁸Ga-FAPI PET/CT in Liver Fibrosis Staging: Correlation with Transient Elastography, APRI, and FIB-4

S. Kar, V. R. Lele, A. S. Nagral, N. Shaikh;
Jaslok Hopsital and Research Centre, Mumbai, INDIA.

EP-0284

Before and After CCRT ¹⁸F-FDG PET/CT Derived Parameters for Prognosis of Esophageal Cancer Patients underwent Trimodality Treatment

M. Chiang¹, P.-J. Chuang², J.-Y. Huang³;
¹Taipei Medical University Hospital, Taipei, TAIWAN, ²National Taiwan University Hospital Cancer Center, Taipei, TAIWAN, ³National Taiwan University Hospital, Taipei, TAIWAN.

EP-0285

⁶⁸Ga-PSMA PET/CT in Inoperable/Heavily Pretreated Pancreatic Adenocarcinoma: A Pilot study on Imaging, Prognostic and Theranostic Potential

G. B. Priyanka, N. A. Damle, A. N. Singh, K. Kuradia, S. Mishra, S. J. Bharati, R. Yadav, C. Ganapathy, A. Choudhary, M. Aishwarya;
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0286

¹⁸F-FDG and ⁶⁸Ga-FAPI PET/CT in evaluation of esophageal cancer

M. Komarova¹, V. Sinitsyn¹, E. Davydova¹, A. Chaban², A. Martinovich³;
¹Lomonosov Moscow State University, Moscow, RUSSIAN FEDERATION, ²Rechts der isar, technische Universität Munchen, Munich, GERMANY, ³N.N. Blokhin Russian Cancer Research Center, Moscow, RUSSIAN FEDERATION.

EP-0287

Comparison of 68Ga-FAPI and FDG PET/CT in the Detection of Peritoneal Carcinomatosis, Staging and Restaging in Patients with Gastrointestinal Cancer

H. Pala, M. Tuncel, E. Karabulut, S. Yalçın, N. Akkapulu, T. Erol, C. Sökmensüer, Ö. Uğur;
Hacettepe University, Ankara, TÜRKIYE.

EP-0288

Optimization of gastric emptying scan times

K. Velasquez, I. Garrido, P. Meneses, M. Grajeda, C. Pradere, M. Estrella, R. Jimeno, M. Mijtavila;
Hospital Puerta de Hierro, Majadahonda, SPAIN.

EP-17

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B16 Neuroendocrine (Pancreatic and Others)

EP-0289

Diagnostic Contribution of [⁶⁸Ga]Ga-ABY-025 PET in HER2-Positive Breast Cancer: Beyond [¹⁸F]FDG PET

A. Alhuseinalkhudhur^{1,2}, H. Lindman¹, F. Y. Frejd^{1,3}, P. Liss⁴, J. Feldwisch³, T. Sundin⁵, V. Iyer², M. Lubberink², I. Velikyan², J. Sörensen²;
¹Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, ²Department of Surgical Sciences, Molecular imaging and medical physics, Uppsala University, Uppsala, SWEDEN, ³Affibody AB, Solna, SWEDEN, ⁴Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, SWEDEN, ⁵Clinical Research and Development Unit, Uppsala University Hospital, Uppsala, SWEDEN.

EP-0290

Enhanced Probabilistic Analysis of Breast Cancer FDG-PET Images Using Probabilistic Machine Learning Techniques

N. Christensen¹, M. H. Vendelbo¹, T. M. Hansen²;
¹Aarhus University Hospital, Aarhus N, DENMARK, ²Aarhus University, Aarhus C, DENMARK.

EP-0291

Correlation of Primary Lesion FDG PET/CT Texture Features with Prognosis and Histopathological Data in Luminal A Type Breast Cancer

M. Genç¹, K. Şeker², Z. Hasbek², B. Yücel³, M. Yılmaz⁴;
¹Sivas Numune Hospital Department of Nuclear Medicine, Sivas, TÜRKIYE, ²Sivas Cumhuriyet University Faculty of Medicine Department of Nuclear Medicine, Sivas, TÜRKIYE, ³Sivas Cumhuriyet University Faculty of Medicine Department of Radiation Oncology, Sivas, TÜRKIYE, ⁴Sivas Cumhuriyet University Faculty of Medicine Department of Medical Oncology, Sivas, TÜRKIYE.

EP-0292

PET-positive extra-axillary lymph nodes in high-risk primary breast cancer: a retrospective study of location, treatment planning, and follow-up

A. L. Rudbeck¹, N. M. Jakobsen², M. G. Hildebrandt², M. Vogsen³;
¹Department of Clinical Research, University of Southern Denmark, Odense, DENMARK, ²Department of Nuclear

Medicine, Odense University Hospital, Odense, DENMARK, ³Department of Oncology, Odense University Hospital, Odense, DENMARK.

EP-0293

Integrating 18FDG-PET/CT Biomarkers and Tumor Biology in Breast Cancer Prognosis

N. Fatima^{1,2}, M. Zaman²;
¹Dow University Health Sciences, Karachi, PAKISTAN, ²Aga Khan University Hospital, Karachi, PAKISTAN.

EP-0294

Prognostiv Value of F-18 FDG PET/CT-Derived TLG and Radiomics Features in Breast Cancer Patients

F. Görtan¹, M. Karta², A. Karta²;
¹Turkish Ministry of Heath, Ankara Bilkent City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Elazığ Fethi Sekin City Hospital, Department of Nuclear Medicine, Elazığ, TÜRKIYE.

EP-0295

Contribution of 68Ga-DOTA-cyclo (RGDfK) [Integrin αvβ3 Inhibitor] PET/CT Imaging in Staging and Restaging of Breast Cancer: Preliminary Findings

Z. Tosunoglu, Ö. F. Şahin, A. E. Öztürk, G. Alçın, E. Akgün, E. Arslan;
Istanbul Training and Research Hospital, Nuclear Medicine Clinic, Istanbul, TÜRKIYE.

EP-0296

Novel spatial PET parameters NHOC and NHOP Predict Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer

O. Vezir¹, A. Aksu¹, Z. Guc², K. Kucuker¹, A. Alacacioglu², B. Turgut¹;
¹Izmir Katip Celebi University Faculty of Medicine, Department of Nuclear Medicine, Izmir, TÜRKIYE, ²Izmir Katip Celebi University Faculty of Medicine, Department of Oncology, Izmir, TÜRKIYE.

EP-0297

From single-cell to whole-body imaging of the expression of Fibroblast Activation Protein in Triple Negative Breast Cancer patients

N. Hovhannisyan-Baghdasarian¹, Y. Kieffer², V. Selvarasa², L. Champion³, N. Jehanno⁴, R. Seban³, H. Tissot⁴, J. Fouque⁵, F. Coussy⁶, D. Bello Roufar⁶, D. Loirat⁷, S. Rafie², A. Cernat⁸, L. Djerroudi⁸, J. Sauge⁸, A. Vincent-Salomon⁸, F. Bidard⁶, F. Mechta-Grigoriou², I. Buvat¹;
¹Institut Curie, Inserm, Orsay, FRANCE, ²Unité Chimie Biologie des Cancers, Institut Curie, PSL University, Inserm, CNRS, Paris, FRANCE, ³Dpt of Nuclear Medicine, Institut Curie, Saint-Cloud, FRANCE, ⁴Dpt of Nuclear Medicine, Institut Curie, Paris, FRANCE, ⁵Dpt of Pharmacy, Institut Curie, Saint-Cloud, FRANCE, ⁶Dpt of Medical Oncology, Institut Curie, Saint-Cloud, FRANCE, ⁷Dpt of Medical Oncology, Institut Curie, Paris, FRANCE, ⁸Department of Diagnostic and Theranostic Medicine, Institut Curie, PSL University, Paris, FRANCE.

EP-0298

A study to evaluate the heterogeneity of estrogenreceptor (ER) expression in breast cancer using ¹⁸F Fluoroestradiol (FES) and ¹⁸F FDG PET/CT

A. Mahalik, N. Kundu, A. Roy, M. Tripathi, R. Kumar;
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0299

Outperforming FDG? Evaluating the Diagnostic Superiority of ⁶⁸Ga-FAPI-46 PET/CT in Breast Cancer Staging

S. Patel, P. Sundaram, P. Subramanyam; Amrita Institute of Medical Sciences & Research Center, Kochi, INDIA.

EP-0300

Diagnostic Performance of ⁶⁸Ga-FAPI-46 PET/CT in Metastatic Breast Cancer: A Prospective Comparative Pilot Study

Y. Khandelwal, B. Jain, P. Baberwal, S. Rastogi, S. Shamim; AIIMS, New Delhi, INDIA.

EP-0301

Prospective Evaluation of ⁶⁸Ga-FAPi PET/CT Imaging to guide ¹⁷⁷Lu-FAPi therapy in patients with metastatic Breast Cancer (mBC)

N. Kumar, S. Shamim, G. Arora, A. Batra; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0302

[¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT in patients with triple-negative breast cancer: a head-to-head comparative assessment study

T. Lazutina, A. Khalimon, S. Urtaev, A. Lokhova, M. Khodzhibekova, D. Khodakova, G. Khamadeeva, I. Pylova, A. Leontev; P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EP-0303

Evaluation of Treatment Response Using Post-¹³¹I-MIBG Scintigraphy in Patients with unresectable or metastatic PPGL: Correlation with Prognosis and Clinical Factors

J. Takenaka^{1,2,3}, S. Watanabe^{1,2,4}, T. Abe⁵, S. Takeuchi^{6,7}, K. Hirata^{1,2,8}, R. Kimura^{1,9}, H. Ishii^{1,2}, N. Wakabayashi^{1,2}, M. Majigsuren^{1,10}, K. Kudo^{1,8,9}.

¹Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN, ²Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, JAPAN, ³Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, GERMANY, ⁴Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Sapporo, JAPAN, ⁵Department of Renal and Genitourinary surgery, Hokkaido University Graduate School of Medicine, Sapporo, JAPAN, ⁶Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN, ⁷Center of Neuroendocrine Neoplasms, Hokkaido University Hospital, Sapporo, JAPAN, ⁸Medical AI Research and Development Center, Hokkaido University Hospital, Sapporo, JAPAN, ⁹Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, JAPAN, ¹⁰Department of Radiology, Diagnostic Imaging Center, Second State Central Hospital, Ulaanbaatar, MONGOLIA.

EP-0304

Progression and characterization of intracardiac metastases from gastroenteropancreatic neuroendocrine tumors.

I. Scalia¹, A. F. Yang², F. E. Abdelfattah¹, O. H. Ibrahim¹, J. M. Farina¹, R. Arsanjani¹, C. Ayoub¹, M. Yang¹; ¹Mayo Clinic Arizona, Phoenix, AZ, UNITED STATES OF AMERICA, ²Wayne State Medical School, Detroit, MI, UNITED STATES OF AMERICA.

EP-0305

Pancreatic Metastases in Small Intestinal Neuroendocrine Tumors: An Underestimated Occurrence?

Q. Wang¹, A. Rinke², F. Eilsberger¹, M. Luster¹, B. Hooshyar Yousefi¹, D. Librizzi^{1,3}; ¹Department of Nuclear Medicine, University Hospital Marburg, Philipps University of Marburg, Marburg, GERMANY, ²Department of Internal Medicine, Division of Gastroenterology and Endocrinology, University Hospital Marburg, Philipps University Marburg, Marburg, GERMANY, ³Department of Nuclear Medicine, University Hospital OWL, Evangelical Hospital Bethel, Bielefeld, GERMANY.

EP-0306

DOTATOC PET Response Under MKI in Advanced Neuroendocrine Tumors: Good or Bad News?

G. Rovera¹, I. Pavaluta¹, M. Longo¹, H. Noamen¹, Y. Menu², J. Hadoux³, L. Lamartina³, M. Faron⁴, S. Moog³, M. Ducreux⁵, E. Baudin³, D. Deandreis¹; ¹Nuclear Medicine Department, Gustave Roussy, University Paris Saclay, Villejuif, FRANCE, ²Department of Radiology, Gustave Roussy, University Paris Saclay, Villejuif, FRANCE, ³Department of Imaging, Endocrine Oncology Unit, Gustave Roussy, University Paris Saclay, Villejuif, FRANCE, ⁴Sarcoma Unit, Gustave Roussy Cancer Campus, Villejuif, FRANCE, ⁵Service d'Oncologie digestive, Institut Gustave Roussy, Villejuif, FRANCE.

EP-0307

Prognostic Value of [⁶⁸Ga]Ga-SSA PET/CT After [¹⁷⁷Lu]Lu-DOTATATE Therapy in Neuroendocrine Tumours

A. Bagán-Trejo¹, J. L. Vercher-Conejero¹, J. J. Martín-Marcuarta¹, G. Reynés-Llompart², M. Tormo-Ratera¹, J. C. Ruffinelli³, D. Rodríguez-Puig⁴, C. García-Alcober⁴, B. Hervás-Sanz¹, D. J. Tamayo-Ossa¹, M. Cortés-Romera¹; ¹Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Medical Physics and Radiation Protection Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN, ³Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN, ⁴Radiopharmacy Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EP-0308

Peptide receptor radionuclide therapy (PRRT) in high-grade neuroendocrine neoplasms: a systematic review and metanalysis

E. Zampella, F. Volpe, L. Piscopo, V. Gaudieri, c. Nappi, V. Cantoni, R. Green, E. Caiazza, A. Cuocolo, M. Klain; University Federico II, Naples, ITALY.

EP-0309

Optimal scan time for [¹⁸F]SiTATE PET/CT imaging of patients with neuroendocrine tumors

R. Ebner, F. Herr, M. Zacherl, F. Eckenweber, K. Klimek, J. Ricke, C. C. Cyran, R. A. Werner, G. T. Sheikh; University Hospital LMU Munich, Munich, GERMANY.

EP-0310

[⁶⁸Ga]68Ga-DOTANOC LAFOV PET/CT in NET: are HYPER and OSEM semiquantitative parameters comparable?

G. Bianciardi¹, E. Fortunati², M. Di Franco¹, C. Malizia², M. Assenza³, D. Campana⁴, E. Andriani⁴, E. Tabacchi², V. Allegri², S. Fanti^{1,2}, V. Ambrosini^{1,2}; ¹Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna,

ITALY, ³Professional Development and Implementation of Research in Health Professional Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Department of Medical and Surgical Sciences (DIMEC), Medical Oncology Unit, Alma Mater Studiorum-University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0311

Preliminary experience on the use of [⁶⁸Ga]68Ga-DOTANOC LAFOV PET/CT in NET patients

G. Bianciardi¹, E. Fortunati², M. Di Franco¹, C. Malizia², M. Assenza³, D. Campana⁴, E. Andriani⁴, V. Allegri², E. Tabacchi², S. Fanti^{1,2}, V. Ambrosini^{1,2}; ¹Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Professional Development and Implementation of Research in Health Professional Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Department of Medical and Surgical Sciences (DIMEC), Medical Oncology Unit, Alma Mater Studiorum-University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0312

Functional vs. morphological imaging in Well-Differentiated Neuroendocrine Tumors: how ⁶⁸Ga-DOTATOC PET/CT can influence treatment decision-making

C. Battisti¹, C. Ferrari¹, A. Pisani¹, D. Candido¹, E. Lauricella², M. Bacalim², D. Rubini³, M. Cives², G. Rubini¹; ¹Nuclear Medicine Unit, DIM, University "Aldo Moro", Bari, ITALY, ²University of Bari Aldo Moro, Interdisciplinary Department of Medicine, Bari, ITALY, ³Radiotherapy, Precision Medicine Department, University of Campania "Luigi Vanvitelli", Naples, ITALY.

EP-0313

Molecular Mechanisms of SSTR2-Mediated Regulation of Glucose Metabolism in Neuroendocrine Neoplasms

L. Hao; Central South University, Changsha, Hunan, CHINA.

EP-0314

Neuroendocrine carcinoma and NET grade 3: uptake of ¹⁸FDG and ⁶⁸DOTATOC in lesions in relation to SSTR2 expression and survival

D. Truong, Z. Ankers, A. Stenman, D. Granberg, J. Zedenius, C. C. Juhlin, A. Kistner; Karolinska Institute, Stockholm, SWEDEN.

EP-0315

Compare the diagnostic value of [¹⁸F]AIF-NOTA octreotide ([¹⁸F]-OC) PET/CT and enhanced CT for suspected pheochromocytoma/paraganglioma (PPGL)

L. Huang, J. Liu, Z. Cui, W. Ma, Y. Li; The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, CHINA.

EP-0316

Diagnostic accuracy of [^{99m}Tc]Tc-HYNIC-TOC SPECT/CT in patients with pheochromocytomas and paragangliomas:a single-center experience

B. Li, J. Zhang, X. Wu, Y. Gao; Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear

Medicine, Henan Provincial People's Hospital; Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, CHINA.

EP-0317

Comparison of Iodine-123 Metaiodobenzylguanidine scintigraphy with SPECT/CT and Fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide PET/CT in the Follow-Up of Neuroblastoma

Y. Liu¹, S. Li², J. Liu², B. Sang¹, Y. Xu², J. Yang², X. Sun¹; ¹Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CHINA, ²Beijing Friendship Hospital, Capital Medical University, Beijing, CHINA.

EP-0318

Prognostic Impact of Discordant Lesions on [¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI-04 PET/CT compared to Histological FAP expression in Neuroendocrine Neoplasms

T. Jedamzik¹, A. Kosmala¹, S. Kircher², M. Heinrich¹, W. Schlötelburg¹, A. Buck¹, A. Meining^{3,4}, R. A. Werner^{3,5,6}, A. Weich^{3,4}, K. Michalski¹; ¹Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, GERMANY, ²Institute of Pathology, University of Wuerzburg, Wuerzburg, GERMANY, ³NET-Zentrum Würzburg, European Neuroendocrine Tumor Society Center of Excellence (ENETS CoE), University Hospital Wuerzburg, Wuerzburg, GERMANY, ⁴Internal Medicine II, University Hospital Wuerzburg, Wuerzburg, GERMANY, ⁵Department of Nuclear Medicine, LMU Hospital, Ludwig-Maximilians-University of Munich, Munich, GERMANY, ⁶Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Sciences, Baltimore, MD, UNITED STATES OF AMERICA.

EP-0319

Comparison of FDOPA PET/CT and MRI for the diagnosis and follow-up of pheochromocytomas and paragangliomas

L. Rodríguez Díaz, C. Vigil Díaz, A. Álvarez Alonso, S. Menéndez Sánchez, M. Domínguez Grande, M. Fernández Llana, S. Naranjo Sancho, A. Álvarez Amigo, J. Guzmán de la Cerda, N. Martín Fernández, V. Pascual Pascual, F. Gonzalez García; Central University Hospital of Asturias (HUCA), Oviedo, SPAIN.

EP-0320

Accelerating Lu-177 SPECT Imaging Post Radioligand Therapy Using Deep Learning-Enhanced Projection Interpolation

A. Sitek¹, S. Plotka², J. Prządło³, H. Sabet¹, P. Heidari¹, J. B. Cwikła^{3,4}; ¹Massachusetts General Hospital and Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA, ²University of Warsaw, Warsaw, POLAND, ³University of Warmia and Mazury in Olsztyn, Olsztyn, POLAND, ⁴Diagnostic and Therapy Center Gammed, Warsaw, POLAND.

EP-0321

The Role of Ga-68 DOTA-TATE PET/CT in the Differential Diagnosis of Pheochromocytoma and Adrenal Adenoma

F. Demir¹, H. Yıldız¹, S. Karaçavuş¹, C. Güneş¹, S. A. Salt², E. Gündoğan³; ¹Department of Nuclear Medicine, Kayseri City Training and Research Hospital, Kayseri, TÜRKIYE, ²Department of Endocrinology, Kayseri City Training and Research Hospital,

Kayseri, TÜRKIYE ³Department of Gastroenterology Surgery , Kayseri City Training and Research Hospital, Kayseri, TÜRKIYE.

EP-0322
 Long-axial field-of-view dynamic ⁶⁴Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms

E. Carlsen^{1,2,3}, C. B. Johnbeck^{1,2,3}, M. Loft^{1,2,3}, T. L. Andersen^{1,3,4}, A. Kjaer^{1,2,3};

¹Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital – Rigshospitalet, Copenhagen, DENMARK, ²Cluster for Molecular Imaging, Copenhagen University Hospital – Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, DENMARK, ³ENETS Neuroendocrine Tumor Center of Excellence, Copenhagen University Hospital – Rigshospitalet, Copenhagen, DENMARK, ⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK.

EP-0323
 Comparison of physiological uptake by semiquantitative analysis of [⁶⁸Ga]Ga-DOTA-TATE PET/CT performed on digital and analog cameras

K. Bienkowski, K. Pełka, J. Kunikowska; Medical University of Warsaw, Warsaw, POLAND.

EP-0324
 NETPET vs. Krenning score: Redifining Eligibility for PRRT through Dual PET Imaging in Neuroendocrine Tumors

A. Matamala-Bezmalinović¹, M. Velasco-Nuño², M. Calls-Calahorro², P. Stefaneli², B. Serrallonga², Y. Delisau², S. Castejón², S. Asadurova², J. Duch², D. Paez², B. Martín³, V. Camacho², A. Flotats²;

¹Nuclear Medicine Department, Hospital Clínico Universidad de Chile, Santiago, CHILE, ²Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ³Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

EP-0325
 The utility of [¹⁸F]FET PET in the clinical management of PitNET: a preliminary descriptive analysis

V. De Meulenaere¹, B. Lapauw², F. Dewaele³, T. Van Zele⁴, E. Genbrugge¹, D. Van Weehaeghe¹;

¹Department of Radiology and Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM, ²Department of Endocrinology, Ghent University Hospital, Ghent, BELGIUM, ³Department of Neurosurgery, Ghent University Hospital, Ghent, BELGIUM, ⁴Department Otorhinolaryngology, University Hospital Ghent, Ghent, BELGIUM.

EP-0326
 AI-based Quantitative Volumetric [⁶⁸Ga]Ga-DOTATOC PET/CT Image Analysis in Predicting Response to Peptide Receptor Radionuclide Therapy and Disease Outcome

S. Manoochehry¹, F. Sharifian¹, S. Mirshahvalad¹, W. Hitzl², N. Capobianco³, B. Spottiswoode⁴, G. Schweighofer-Zwinkl¹, C. Pirich¹, M. Beheshti¹;

¹Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, AUSTRIA, ²Biostatistics and Publication of Clinical Trial Studies, Research and Innovation Management (RIM), Paracelsus Medical University, Salzburg, AUSTRIA, ³Siemens

Healthineers AG, Erlangen, GERMANY, ⁴Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

EP-0327
 Head-to-head comparison between AI¹⁸F-NOTA-LM3 and ⁶⁸Ga-DOTA-TATE PET/CT in patients with metastatic pheochromocytomas and paragangliomas

Y. Zhang, M. Liu, Y. Cai, X. Yan, C. Ren, Z. Huang, M. Wang, A. Tong, L. Huo, H. Jing; Peking Union Medical College Hospital, Beijing, CHINA.

EP-0328
 Diagnostic, Therapeutic, and Economic Impact of the Protocolized Use of ⁶⁸Ga-DOTATOC PET/CT in Patients with Neuroendocrine Tumors (IMDOTA-TNE Study).

M. Cruz Montijano¹, J. A. Bonilla Plaza¹, L. Garcia Zoghby¹, J. Montalva Pastor¹, M. Meneses Navas¹, S. Guzman Ortiz¹, I. García Megías¹, J. Medina Martínez¹, A. Marco Martínez¹, M. Abradelo De Usera¹, J. Cano Cano², L. García Blasco³, C. Alonso López³, C. Ortiz Muñoz², C. Martínez Osorio², F. Pena Pardo², V. García Poblete², A. García Vicente¹;

¹Complejo Hospitalario de Toledo, Toledo, SPAIN, ²Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN, ³Complejo Hospitalario Universitario de Albacete, Albacete, SPAIN.

EP-0329
 Whole-Body Tumor Burden on ⁶⁸Ga-DOTATOC PET/CT: A Prognostic Key in Well-Differentiated Neuroendocrine Tumors

C. Battisti¹, C. Ferrari¹, A. Pisani¹, D. Candido¹, E. Lauricella², M. Bacalim², D. Rubini³, A. Nappi¹, M. Cives², G. Rubini¹;

¹Nuclear Medicine Unit, DIM, University “Aldo Moro”, Bari, ITALY, ²University of Bari Aldo Moro, Interdisciplinary Department of Medicine, Bari, ITALY, ³Radiotherapy, Precision Medicine Department, University of Campania “Luigi Vanvitelli”, Naples, ITALY.

EP-0330
 Utility of Ga-68 DOTA-RGD2 PET/CT in Grade 2 & 3 neuroendocrine tumours and comparison with Ga-68 DOTANOC PET/CT

K. Subramanian; Post Graduate Institue of Medical Education and Research, Chandigarh, INDIA.

EP-18

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B17 Colorectal

EP-0331
 Feasibility of an early-imaging ⁶⁸Ga-FAPI-PET/CT protocol in prone position for rectosigmoid and anal cancer

D. Ufton¹, J. Heilingner¹, H. Weis¹, T. Fischer¹, K. Schomäcker¹, C. Bruns², G. Dieplinger², H. Dapper³, E. Fokas³, C. Kobe¹, A. Drzezga¹, S. Ferdinandus³, K. S. Roth¹;

¹University Hospital of Cologne, Department of Nuclear Medicine, Cologne, GERMANY, ²University Hospital of Cologne, Department of Surgery, Cologne, GERMANY, ³University Hospital of Cologne, Department of Radiation Oncology, Cologne, GERMANY.

EP-0332
 Clinical Application Value of FAPI Imaging in Colorectal Cancer: A Retrospective Study

T. Fang; Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA.

EP-0333
 Variations in F-18-FMISO Physiological Uptake

M. Araz, & Mesci, E. D. Avci, C. Soydal, N. Ö. Kucuk; Ankara University, Ankara, TÜRKIYE.

EP-0334
 Cost-Effectiveness of [¹⁸F]FDG PET/CT in Follow-Up after Thermal Ablation in Patients with Colorectal Liver Metastases in the Dutch Healthcare Setting

S. van Mosse^{1,2}, O. Bijlstra¹, F. van Delft², B. Boekestijn¹, M. Burgmans¹, P. Hendriks¹, E. Kapiteijn¹, S. Mieog¹, E. Persijn van Meerten¹, D. Rietbergen¹, S. Shahbazi Feshtali¹, L. De Geus-Oei^{1,2,3}, H. Koffijberg²;

¹Leiden University Medical Center, Leiden, NETHERLANDS, ²University of Twente, Enschede, NETHERLANDS, ³Delft University of Technology, Delft, NETHERLANDS.

EP-0335
 The Value of Staging FDG PET/CT Parameters in Predicting Liver Operability and Survival in Liver Metastatic Rectal Cancer

T. Bilgücü, G. Uçmak, B. Demirel; Ankara Abdurrahman Yurtaslan Educational and Research Onkology Hospital, Ankara, TÜRKIYE.

EP-0336
 Prognostic Utility of Volumetric PET Parameters in Colorectal Liver Metastases: Identifying Optimal Segmentation Strategies for MTV and TLG

M. Badarna, Z. Keidar; Rambam Health care campus, Haifa, ISRAEL.

EP-0337
 Comparison of qualitative and quantitative metabolic variables in FDG PET/CT inrectal cancer patients who achieved complete and incomplete response after neoadjuvantchemoradiotherapy

K. Amaral, R. Moreira Siqueira, C. sa de Camargo, E. Etchebehere, M. CL Lima, A. O Santos, C. D. Ramos, B. Juarez Amorim; UNICAMP, Campinas, BRAZIL.

EP-0338
 Mechanistic Study on the Inhibition of Colorectal Cancer Tumor Progression in Nude Mice via CL316243 Activation of Brown Adipose Tissue Using ¹⁸F-FDG MicroPET/CT

J. Li, L. Zhang, X. Mu, W. Fu; Affiliated Hospital of Guilin Medical University, Guilin, CHINA.

EP-0339
 Assessment of the prognostic value of ¹⁸F-FDG PET-CT metabolic parameters in patients with rectal cancer

G. Cuesta Domingo¹, A. Ortega Candil¹, C. Rodríguez Rey¹, R. Cano Carrizal², P. Nespral Torres³, P. Daudén Oñate¹, M. Vaillant López¹, M. Zapardiel Martínez-Falero¹, C. Wakfie Corieh¹, M. Cabrera Martín¹;

¹Department of Nuclear Medicine, Hospital Clínico San Carlos, Madrid, SPAIN, ²Department of Cardiology,

Hospital Infanta Sofía, San Sebastián de los Reyes, SPAIN, ³Department of Nuclear Medicine, Hospital Universitario Puerta de Hierro, Madrid, SPAIN.

EP-0340
 Added predictive value of [18F-FDG]PET/CT over MRI in detecting nodal persistence after neoadjuvant therapy in rectal cancer

G. Cuesta Domingo¹, C. Rodríguez Rey¹, A. Ortega Candil¹, R. Cano Carrizal², P. Nespral Torres³, P. Daudén¹, M. Vaillant Lopez¹, M. Zapardiel Martínez-Falero¹, C. Wakfie Corieh¹, M. Cabrera Martín¹;

¹Department of Nuclear Medicine, Hospital Clínico San Carlos, Madrid, SPAIN, ²Department of Cardiology, Hospital Infanta Sofía, San Sebastián de los Reyes, SPAIN, ³Department of Nuclear Medicine, Hospital Universitario Puerta de Hierro, Madrid, SPAIN.

EP-0341
 Utility of ¹⁸F-FDG PET/CT in the staging of rectal carcinoma

G. Cuesta Domingo¹, A. Ortega Candil¹, C. Rodríguez Rey¹, R. Cano Carrizal², P. Nespral Torres³, M. Vaillant López¹, P. Daudén Oñate¹, P. Bascuñana Almarcha⁴, C. Wakfie Corieh¹, M. Cabrera Martín¹;

¹Department of Nuclear Medicine, Hospital Clínico San Carlos, Madrid, SPAIN, ²Department of Cardiology, Hospital Infanta Sofía, San Sebastián de los Reyes, SPAIN, ³Department of Nuclear Medicine, Hospital Universitario Puerta de Hierro, Madrid, SPAIN, ⁴IDISSC, Department of Nuclear Medicine, Hospital Clínico San Carlos, Madrid, SPAIN.

EP-0342
 Preliminary results of⁶⁸Ga-FAPI PET imaging in total neoadjuvant therapy of rectal cancer

S.-h. Chen, K.-C. Ho, R.-E. Hsieh, E.-L. Shen, C.-K. Liao, H.-C. Hsu, A.-H. Chen, J.-F. You, P.-S. Hsieh, Y.-J. Hsu, Y.-J. Chern, C.-C. Cheng, Y.-C. Lin; Chang Gung Memorial Hospital, Taoyuan County, TAIWAN.

EP-0343
 Association Between KRAS Mutation and Metabolic and Volumetric Parameters Measured from the Primary Tumor in Colorectal Cancer Using F-18 FDG PET/CT

E. Tunca¹, R. H. Tokac¹, U. Yazarbas¹, M. Sezak²; ¹Ege University Faculty of Medicine, Department of Nuclear Medicine, Izmir, TÜRKIYE, ²Ege University Faculty of Medicine, Department of Pathology, Izmir, TÜRKIYE.

EP-0344
 The Value of F18 FDG-PET/CT Parameters Measured at the Anastomosis Line for Predicting Local Recurrence in Operated Colorectal Cancer Patients

E. Tunca, R. Tokac, U. Yazarbas; Ege University Faculty of Medicine, Department of Nuclear Medicine, Izmir, TÜRKIYE.

EP-0345
 Preliminary comparison of 68Ga-FAPI-46 against 18F-FDG, 68Ga-DOTATATE and 68Ga-Pentixafor PET/CT/MR imaging in the assessment of various cancer types

H. Dadgar¹, M. Assadi², B. Al-balooshi³, A. Cimini⁴, M. Ricci⁵, H. Arabi⁶; ¹Nuclear Medicine and Molecular imaging research center, RAZAVI Hospital, Mashad, Iran, ISLAMIC REPUBLIC OF, ²The Persian Gulf Nuclear Medicine Research Center, Department of Molecular Imaging and Radionuclide Therapy (MIRT),

Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF, ³Dubai Nuclear medicine & Molecular imaging Center- Dubai Academic Health corporation- DAHC, UAE, Dubai, UNITED ARAB EMIRATES, ⁴Nuclear Medicine Unit, St. Salvatore Hospital, 67100 L'Aquila, ITALY, ⁵Nuclear Medicine Unit, Cardarelli Hospital, Campobasso, ITALY, ⁶Division of Nuclear Medicine and Molecular Imaging, Diagnostic Department, Geneva University Hospital, Geneva, SWITZERLAND.

EP-19

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B18a Prostate Staging

EP-0346

Evaluating the Diagnostic Value of Dual-Time F-18 PSMA-1007 PET/CT in Prostate Cancer

S. Tsai^{1,2}, Y. Pu³, J. Hong³, P. Chuang⁴, H. Wen⁵, P. Kuo⁶, C. Lu⁴;
¹Department of Nuclear Medicine, National Yang Ming Chiao Tung University Hospital, Yilan County, TAIWAN, ²School of Medicine, National Yang Ming Chiao Yung University, Taipei, TAIWAN, ³Department of Urology, National Taiwan University Hospital, Taipei, TAIWAN, ⁴Department of Nuclear Medicine, National Taiwan University Cancer Center, Taipei, TAIWAN, ⁵Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, TAIWAN, ⁶Department of Radiology, National Taiwan University College of Medicine, Taipei, TAIWAN.

EP-0347

Comparative Performance of PSMA PET PRIMARY Score and mpMRI PIRADS in Localizing Clinically Significant Prostate Cancer

S. Shekhar Singh¹, P. Wadhwa², R. Parwar¹, S. Tandon¹;
¹Globe Healthcare, Lucknow, INDIA, ²United Imaging Healthcare, Delhi, INDIA.

EP-0348

Beyond the Standard: Enhancing prostate bed and regional lymph node detection in Prostate Cancer patients with Early and Delayed Imaging in 68Ga-PSMA PET/CT

A. Aghaee¹, S. Soltani², Z. Bakhshi¹, K. Aryana¹, N. Norouzbegi¹, H. Dadgar¹;
¹Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ²Kidney Transplantation Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0349

Reconstruction of ¹⁸F-PSMA-1007 PET Scans Affects SUV-based Classification of Unspecific Bone Uptake

R. Poelarends, A. G. Tegelaar - Kuiper, J. D. van Dijk, B. N. Vendel, J. A. van Dalen;
Isala Hospital, Zwolle, NETHERLANDS.

EP-0350

The Power Duo: PSMA PET/CT and Focal Ablation in Prostate Cancer (PCa) Care

J. Jandric¹, V. Fasulo^{1,2}, P. Guglielmo², C. Vallone¹, M. Rodari¹, M. Lazzeri¹, N. Buffi^{1,3}, G. Lughezzani^{1,3}, L. Evangelista^{1,3};

¹IRCCS Humanitas Research Hospital, Rozzano, ITALY, ²Humanitas University, Pieve Emanuele, ITALY, ³Humanitas University, Pieve Emanuele, ITALY.

EP-0351

Triple-time point PSMA-PET imaging in primary staging of high-risk prostate cancer enabled by LAFOV PET/CT: potential clinical benefit?

E. Calderón Ochoa¹, L. S. Kiefer¹, M. Maas², C. P. Reinert³, H. Dittmann¹, I. Tsaur², J. Schwenck^{1,4,5}, C. la Fougère^{1,4};
¹Department of Nuclear Medicine and Molecular Imaging, University Hospital of Tübingen, Tübingen, GERMANY, ²Department of Urology, University Hospital of Tübingen, Tübingen, GERMANY, ³Department of Diagnostic and Interventional Radiology, University Hospital of Tübingen, Tübingen, GERMANY, ⁴Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, GERMANY, ⁵Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, Tübingen, GERMANY.

EP-0352

P(yl)rimary: SUV Validation of PRIMARY score 5 in ¹⁸F-DCFPyL PET/CT for staging of Prostate Cancer

E. O'Dwyer, V. Marulanda Corzo, A. Ricaurte Fajardo, D. D'Angelo, T. McClure, S. Huicochea Castellanos, J. R. Osborne;
Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA.

EP-0353

Prostate Cancer Detection with [99mTc]Tc-HYNIC-iPSMA SPECT: The Australian Experience.

P. Tually¹, J. Meadows¹, L. Groombridge¹, N. Lenzo¹, G. Currie²;
¹Spartan First Imaging, Kalgoorlie, AUSTRALIA, ²Charles Sturt University, Wagga Wagga, AUSTRALIA.

EP-0354

Correlation Between PRIMARY Scores in Ga-68 PSMA PET and Histological ISUP Grades in Prostate Cancer

C. Soydal, M. Cidemal, M. Araz, N. O. Kucuk;
Ankara University Medical Faculty, Ankara, TÜRKIYE.

EP-0355

Awareness of the High Rate of False Positive Ga-68 PSMA-11 Uptake in the Prostate Gland: Can PET/MRI Solve This Problem?

L. Uslu-Besli¹, B. Bakir², N. Urganci³, I. Gurses³, E. Karayel¹, H. Pehlivanoglu¹, S. Ozel-Yildiz⁴, C. Demirdag⁵, H. B. Sayman¹;
¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²Istanbul University, Istanbul Medical Faculty, Department of Radiology, Istanbul, TÜRKIYE, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Medical Pathology, Istanbul, TÜRKIYE, ⁴Istanbul University, Istanbul Medical Faculty, Department of Biostatistics, Istanbul, TÜRKIYE, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Urology, Istanbul, TÜRKIYE.

EP-0356

The Diagnostic and Risk Stratification Significance of ⁶⁸Ga-PSMA PET/MR-Derived Parameters for Prostate Cancer

Z. Dai, Y. Lv, W. Ruan, Y. Gai, X. Zhang, M. Li, X. Lan, C. Qin;
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0357

Diagnostic and Therapeutic Value of Dual-Tracer PET Imaging with ⁶⁸Ga-PSMA and ¹⁸F-FDG In Prostate Cancer

Y. Zhang¹, Y. Li¹, G. Fei¹, M. Su², Y. Ni¹;
¹Department of Radiology, Medical School, Southeast University, Nanjing, CHINA, ²Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0358

Is the D'Amico risk classification enough to define the indication of [18F]-DCFPyL PET/CT and promote therapeutic impact?

J. Bonilla Plaza¹, M. Amo Salas², I. García Megías¹, J. Montalvá Pastor¹, L. García Zoghby¹, M. Cruz Montijano¹, M. Meneses Navas¹, S. Guzman Ortiz¹, C. Lucas Lucas³, M. de Cabo Ripoll⁴, F. Leal Hernandez⁵, A. Salinas Sanchez⁶, V. Poblete García³, A. García Vicente¹;
¹Hospital Universitario de Toledo, Toledo, SPAIN, ²Universidad de Castilla la Mancha, Ciudad Real, SPAIN, ³Hospital General Universitario Ciudad Real, Ciudad Real, SPAIN, ⁴Hospital Virgen de la Luz, Cuenca, SPAIN, ⁵Hospital Universitario de Guadalajara, Guadalajara, SPAIN, ⁶Complejo Hospitalario Universitario de Albacete, Albacete, SPAIN.

EP-0359

Evaluation of the Relationship of the Risk Status of Prostate Cancer Patient with PSA Density, PSA Metabolic Density and 68Ga-PSMA PET/CT Parameters

G. Inal¹, N. Aydinbelge Dizdar¹, O. Duyar¹, O. Ozmen²;
¹Ankara Etlik City Hospital Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Department of Nuclear Medicine, Etlik City Hospital, University of Health Sciences, Etlik City Hospital Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-0360

Head-to-head comparison of ^{99m}Tc-PSMA-T4 SPECT and ⁶⁸Ga-PSMA PET studies

P. Cichocki¹, K. Stawski², R. Mikolajczak³, W. Wojdowska³, P. Garnuszek³, Z. Adamczewski¹;
¹Department of Nuclear Medicine, Medical University of Lodz, Lodz, POLAND, ²Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, POLAND, ³National Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock, POLAND.

EP-0361

Clinical Impact of Delayed Pelvic Imaging in PSMA PET/CT for Primary Prostate Cancer Staging and Management

G. Galnaitiene, G. Grigaityte, K. Snarskis, I. Balciunaite, G. Aleksa, D. Vajauskas;
Lithuanian University of Health Sciences, Kaunas, LITHUANIA.

EP-0362

Impact of [⁶⁸Ga]PSMA-PET/CT using PRIMARY and miPSMA Expression Scores on Clinical Decision-Making for ePLND in Staging of Intermediate-Risk Prostate Cancer patients

A. Safarian^{1,2}, F. Sziget³, T. Kiener¹, H. Griebner⁴, H. Nasrollahi¹, S. Hecht⁵, L. Lusuard⁴, C. Pirich¹, M. Beheshti¹;
¹Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, AUSTRIA, ²Rajaie Cardiovascular Medical and Research Center, Rajaie

Cardiovascular Institute, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Salzburg University of Applied Sciences, Radiation Technology degree program, Salzburg, AUSTRIA, ⁴Department of Urology, Paracelsus Medical University, Salzburg, AUSTRIA, ⁵Department of Radiology, Paracelsus Medical University, Salzburg, AUSTRIA.

EP-0363

PRIMARY Score: when radionuclide matters

P. Guglielmo^{1,2}, L. Muraglia³, R. Zanca¹, C. Vallone^{1,4}, J. Jandric³, D. Aricò⁵, N. Buffi^{1,6}, G. Lughezzani^{1,6}, L. Evangelista^{1,3};
¹Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY, ²Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, ITALY, ³Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY, ⁴Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY, ⁵Nuclear Medicine Unit, Humanitas Istituto Clinico Catanese, Misterbianco, Catania, ITALY, ⁶Urology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY.

EP-0364

Concordance and added diagnostic value of [¹⁸F] PIFLUFOLASTAT PET/CT to pelvic MRI in the diagnosis of prostate cancer (Pca).

A. Peñaherrera Cepeda, J. A. Badell Martínez, L. Díaz González, E. Casillas Sagrado, E. Campaña Díaz, P. García-Talavera San Miguel, J. G. Villanueva, S. Rama Alonso, B. Santos García, F. Caltagirone Gutierrez, P. Tamayo Alonso;
Complejo asistencial universitario de Salamanca, Salamanca, SPAIN.

EP-0365

The Influence of Pre-Imaging Prostate-Specific Therapy on PSMA Uptake and Outcomes

G. Galnaitiene, G. Grigaitytė, K. Snarskis, I. Balčiūnaitė, G. Aleksa, D. Vajauskas;
Lithuanian University of Health Sciences, Kaunas, LITHUANIA.

EP-0366

Investigation of the Correlation Between the Briganti 2012 Nomogram and Ga-68 PSMA PET/CT Parameters in Localized and Locally Advanced Prostate Cancer

R. Tokac¹, F. Avci¹, M. Dinclal², K. Ergun¹, A. Argon¹, U. Yazarbas¹;
¹Ege University, Izmir, TÜRKIYE, ²Kars Harakani State Hospital, Kars, TÜRKIYE.

EP-0367

PSMA SPECT and PET Imaging in the Staging of High Intermediate Risk to High-Risk Prostate Cancer - an institutional experience in a resource limited setting

S. More, M. Rivombo, K. Hlongwa;
University of Cape Town, Cape Town, SOUTH AFRICA.

EP-0368

Impact of Ga-68 PSMA PET/MRI on the Accuracy of MRI-derived Grading Systems for Predicting Extraprostatic Extension in Prostate Cancer

L. Uslu-Besli¹, S. Durmaz², B. Bakir³, I. Gurses⁴, S. Ozel-Yildiz⁵, C. Demirdag⁶, H. B. Sayman¹;
¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²Gaziosmanpasa Training and Research

Hospital, Department of Radiology, Istanbul, TÜRKIYE, ³Istanbul University, Istanbul Medical Faculty, Department of Radiology, Istanbul, TÜRKIYE, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Medical Pathology, Istanbul, TÜRKIYE, ⁵Istanbul University, Istanbul Medical Faculty, Department of Biostatistics, Istanbul, TÜRKIYE, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Urology, Istanbul, TÜRKIYE.

EP-0369
PSMA PET in Prostate Cancer Staging: Preliminary Radiomics Analysis and Machine Learning Model for Predicting PRIMARY and E-PSMA Scores
P. Alongi¹, V. Benfante², P. Purpura², C. Messina³, A. Comelli⁴; ¹University of Palermo, Department B.I.N.D., Palermo, ITALY, ²Advanced Diagnostic Imaging-INNOVA Project, Department of Radiological Sciences, A.R.N.A.S. Cívico Di Cristina e Benfratelli Hospitals, Palermo, ITALY, ³Oncology Unit, ARNAS Cívico, Palermo, ITALY, ⁴Ri.MED Foundation, Palermo, ITALY.

EP-0370
The Added Value of PSMA-PET to Nomograms in Identifying Optimal Candidates for Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer Patients
F. Lanfranchi^{1,2}, E. Checuccci³, E. Cisero⁴, A. Rizzo⁵, S. Scuderi⁶, F. Barletta⁶, D. Robusti⁶, C. Pini⁷, D. Amparore⁴, A. Sterrantino⁴, M. Ortenzi⁴, S. De Cillis⁴, S. De Luca⁴, P. Rescigno⁸, A. Signori¹, G. Sambuceti^{1,2}, C. Terrone^{2,9}, A. Chiti⁷, A. Briganti⁶, C. Fiori⁴, G. Gandaglia⁶, F. Porpiglia⁴, M. Bauckneht^{1,2}; ¹Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY, ²IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ³Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), ITALY, ⁴Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano (TO), ITALY, ⁵Department of Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, C, ITALY, ⁶Division of Oncology/Unit of Urology, Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milano, ITALY, ⁷IRCCS San Raffaele Hospital, Milano, ITALY, ⁸Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UNITED KINGDOM, ⁹Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genoa, Genoa, ITALY.

EP-0371
Smart risk-stratification: machine learning predicts LATITUDE high-risk prostate cancer at presentation using routine multimodal clinical data
B. Khangembam, S. Sharma, R. Wakankar, M. Kavin, S. Kaushal, C. J. Das, R. K. Sahoo, A. Seth, A. R. Chanu, C. Patel, R. Kumar; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0372
Optimizing metastatic work-up: machine learning predicts M1 disease in newly diagnosed prostate cancer using routine multimodal clinical data
B. Khangembam, S. Sharma, R. Wakankar, M. Kavin, A. R. Chanu, C. J. Das, S. Kaushal, R. K. Sahoo, A. Seth, C. Patel, R. Kumar; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0373
Machine learning can predict CHAARTED high-volume disease in treatment-naïve prostate cancer patients undergoing⁶⁸Ga-PSMA-11 PET/CT
S. Sharma, R. Wakankar, M. Kavin, S. Kaushal, C. J. Das, R. K. Sahoo, A. Seth, A. R. Chanu, B. Khangembam, C. Patel, R. Kumar; All Institutes of Medical Sciences, New Delhi, INDIA.

EP-0374
PET/CT for staging Intermediate-Risk Prostate Cancer in Routine Clinical Practice
D. Martínez Osorio¹, C. Lucas Lucas¹, J. Rodríguez Gómez¹, E. Noriega Álvarez², F. Pena Pardo¹, A. Padilla Bermejo¹, C. Ortiz Muñoz¹, M. Contreras Ameduri¹, J. Gatón Ramírez¹, F. López-Bermejo García¹, N. Almeida Romera¹, M. Talavera Rubio¹, V. Poblete García¹; ¹Hospital General Universitario Ciudad Real, Ciudad Real, SPAIN, ²Hospital Universitario de Guadalajara, Ciudad de Guadalajara, SPAIN.

EP-0375
PSMA-PET vs wbMRI Performance in Detecting Local and Nodal Disease in Patients with Newly Diagnosed Prostate Cancer
E. Greco¹, L. Bianchi², C. Gaudiano³, B. Corcioni³, C. M. P. Sgro¹, C. Mignogna⁴, B. Renzetti⁵, A. Cattabriga³, R. Schiavina^{2,4}, E. Brunocilla^{2,4}, C. Mosconi^{3,5}, R. Mei⁶, P. Castellucci⁶, S. Fantì^{6,1}, A. Farolfi⁶; ¹Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Division of Urology, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ⁵Department of Radiology, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ⁶Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0376
Role of PSMA PET/CT and mpMRI in Determining Focal Therapy Eligibility in Localized Prostate Cancer: Correlation with Histopathology
I. Sonni, Z. Mohammadigoldar, G. Furey, K. Kimura, A. Holzgreve, A. Chung, J. Calais, J. Czernin, W. Brisbane, A. B. Weiner, S. S. Raman; University of California, Los Angeles, CA, UNITED STATES OF AMERICA.

EP-0377
Predictive Value of Baseline PSMA-PET Parameters in Locally Advanced Prostate Cancer Patients Treated with Radical-Intent Radiotherapy and Androgen Deprivation Therapy: An Inverse Probability of Treatment Weighting Analysis
D. Dubois^{1,2}, F. Lanfranchi^{1,2}, D. Vita^{1,2}, S. Mastrogiovanni^{1,3}, L. Sofia^{1,2}, S. Raffa², M. I. Donegani², S. Chiola², C. Marini^{2,4}, G. Timon^{1,3}, G. Sambuceti^{1,2}, L. Belgioia^{1,3}, M. Bauckneht^{1,2}; ¹Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY, ²Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ³Radiotherapy, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ⁴Institute of Molecular Bioimaging and Physiology, National Research Council (CNR), Milan, ITALY.

EP-0378
PET/CT with [18F]-Piflufolastat in the initial staging of patients with intermediate-high risk prostate cancer: relationship of SUVmax and SUVmean values of prostatic target lesion with gleason scale, ISUP prognostic grades and PSA values at diagnosis.
J. Badell, A. C. Peñaherrera Cepeda, L. G. Díaz González, E. Casillas Sagrado, J. G. Villanueva Curto, E. Campaña Díaz, S. Rama Alonso, F. Caltagirone Gutierrez, P. García-Talavera San Miguel, F. Gomez-Caminero Lopez, P. Tamayo Alonso; Hospital Clínico Universitario de Salamanca, Salamanca, SPAIN.

EP-0379
Utility of the PRIMARY Score on [^{99m}Tc]Tc-PSMA SPECT/CT - an exploratory study aimed to optimise prostate cancer diagnosis
S. More¹, M. Rivombo¹, N. Jacobs¹, O. Kolade², K. Hlongwa¹; ¹University of Cape Town, Cape Town, SOUTH AFRICA, ²University College Hospital, Ibadan, NIGERIA.

EP-0380
Regional Experience on Tc99m-PSMA SPECT/CT in staging of Prostate Cancer in New Zealand: Correlation of pre-imaging PSA level with delayed 24-hour pelvic SPECT/CT findings.
E. Ling¹, N. Tag¹, S. Abubakar², P. Burns¹, R. M. Subramaniam¹; ¹Wellington Regional Hospital, Wellington, NEW ZEALAND, ²Auckland City Hospital, Auckland, NEW ZEALAND.

EP-0381
^{99m}Tc-PSMA SPECT/CT in the primary staging of prostate cancer - a retrospective analysis
O. Jonmarker^{1,2}, C. Samuelsson^{1,2}, L. Steffens², M. Sunderland², D. O'Keeffe^{2,3}, S. Gabrielson^{1,4,2}; ¹Karolinska Institutet, Stockholm, SWEDEN, ²Christchurch Hospital, Christchurch, NEW ZEALAND, ³University of Canterbury, Christchurch, NEW ZEALAND, ⁴University of Otago, Christchurch, NEW ZEALAND.

EP-0382
Impact of PET/MR-guided biopsy with ¹⁸F-PSMA in patients with suspected prostate cancer: a prospective single-center pilot study.
E. Ruiz Gavilanez¹, J. Garcia¹, A. Compte¹, N. Garrido¹, P. Bassa¹, L. Mont-Castro¹, L. Pinilla¹, J. Romero¹, J. Santabárbara¹, J. Vela¹, S. Romero¹, E. Riera¹, A. Sertsios², M. Galdeano², M. Figols², N. De la Torre², D. Coll²; ¹CETIR, Barcelona, SPAIN, ²Fundació Althaia, Manresa, SPAIN.

EP-0383
Automated Extraction of TNM Staging from PSMA PET/CT Reports Using AI
A. Ghujeh^{1,2}, A. Alrahim¹, M. Altinyay¹, M. Kharita^{1,3}, F. Alves⁴, H. Fayad^{1,3}; ¹Hamad Medical Corporation, Doha, QATAR, ²University of Coimbra, Coimbra, PORTUGAL, ³Weill Cornell Medicine-Qatar, Doha, QATAR, ⁴CIBIT/ICNAS, Institute for Nuclear Sciences Applied to Health, University of Coimbra, Coimbra, PORTUGAL.

EP-0384
Impact of ¹⁸F-PSMA PET/MRI Imaging on Prostate Cancer Patients Staging: Prognostic Imaging Biomarkers Associated with Tumor Aggressiveness.
L. Pinilla¹, A. Compte¹, N. Garrido¹, J. Vela², L. Mont-Castro¹, S. Ruiz¹, J. Garcia¹, J. Romero¹, J. Santabárbara¹, M. Soria¹, P.

Bassa¹, E. Riera¹, A. Sertsios³, M. Figols³, M. Galdeano³, N. De La Torre³, D. Coll³; ¹ASCIRES Cetir, Barcelona, SPAIN, ²Hospital Universitario de Canarias, Tenerife, SPAIN, ³Fundació Althaia, Manresa, SPAIN.

EP-0385
A retrospective clinical study evaluated the diagnostic performance of ¹⁸F-PSMA-137 PET/CT in men newly diagnosed with prostate cancer and those experiencing biochemical recurrence
X. Liao¹, J. Zhang¹, Y. Fan¹, N. Zhang²; ¹Department of Nuclear Medicine, Peking University First Hospital, Beijing, CHINA, ²Peking University – Yunnan Baiyao International Medical Research Center, Beijing, CHINA.

EP-0386
Hybrid ¹⁸F-PSMA PET/MR with Diffusion-Relaxation Correlation Spectroscopy Enhances Prostate Cancer Diagnosis and Risk Stratification
H. Chunyu¹, H. Tang², X. Wang³, X. Chen¹, Y. Zhang¹, Y. Wei⁴, Z. Lin⁴, Y. Yang⁵, J. Dai³, Y. Shao³, J. Hu¹, B. Li¹; ¹Department of Nuclear Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, CHINA, ²Department of Ultrasound, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Jiading North Campus, Shanghai, 200025, CHINA, ³Department of Urology, Ruijin Hospital Affiliated to the Medical College of Hainan Jiaotong University, shanghai, CHINA, ⁴United Imaging Healthcare Co., Ltd., shanghai, CHINA, ⁵Beijing United Imaging Healthcare Co., Ltd., Beijing, CHINA.

EP-0387
Value of Prostatic Tumor Volume and Prostatic tumor Uptake on 18F-DCFPyL PSMA-PET/CT as Predictors of Lymph Node and Metastatic Involvement in the Initial Staging of Intermediate-High Risk Prostate Cancer.
X. Guarnizo Poma, A. Gómez Grande, P. Zaragoza-Ballester, S. Angiolillo Grau, E. López Llobet, B. Manzarbeitia Arroba, M. Áviles Jurado, R. García Delgado, P. Sarandeses Fernández, R. Sopeña Sutil, M. Tabuenca Mateo; Hospital Universitario 12 Octubre, Madrid, SPAIN.

EP-0388
Role of Androgen Receptor Targeted Agents in high risk prostate cancer staging by PSMA PET/CT
M. Simo Perdigó, I. Navales Mateu, J. Echeverri Diaz, S. Asadurova, C. Franco Monterroso, A. Hernandez Fructuoso; Hospital Universitari vall Dhebron, Barcelona, SPAIN.

EP-0389
Stage Migration in Prostate Cancer: The Role of PSMA-PET in Identifying Oligometastatic Disease
F. Mattana¹, V. Dragonetti¹, F. Ceci¹, S. Luzzago², V. Kasivisvanathan³, S. Conlon⁴, P. Castellucci⁵, A. Farolfi⁵; ¹IEO European Institute of Oncology, Nuclear Medicine, Milan, ITALY, ²Department of Urology, IEO European Institute of Oncology IRCCS, Milan, ITALY, ³British Urology Researchers in Surgical Training (BURST) Research Collaborative, London, UNITED KINGDOM, ⁴Centre for Urology Imaging, Prostate, AI and Surgical Studies (COMPASS) Research Group, Division of Surgery and Interventional Sciences, University College London, London, UNITED KINGDOM, ⁵Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-20

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B18b Prostate BC Recurrence

EP-0390
The Potential Utility of PSMA PET/CT in Prostate Cancer Biochemical Failure - A Global Retrospective Cohort Study

B. Miles¹, Q. Oza², J. Mackey³, U. Oza¹;
¹Baylor University Medical Center, Dallas, TX, UNITED STATES OF AMERICA, ²Greenhill High School, Dallas, TX, UNITED STATES OF AMERICA, ³West Virginia University, Dallas, TX, UNITED STATES OF AMERICA.

EP-0391
Evaluation of ¹⁸F-JK-PSMA-7 PET/CT as new imaging tool for the detection of biochemically recurrent prostate cancer

M. Vanneste¹, W. Deckers¹, K. Serdons¹, K. Van Laere^{1,2}, K. Goffin^{1,2};
¹Department of Nuclear Medicine, University Hospitals Leuven, Leuven, BELGIUM, ²Nuclear Medicine & Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM.

EP-0392
Utility of ¹⁸F-PSMA-1007 combined protocol of pelvic pet/mri and whole body PET/CT in planning focal therapy (ire/hifu) in radiorecurrent prostate cancer

J. J. Robles¹, A. P. Caresia-Aroztegui², A. Abella-Serra³, J. J. Martín-Marcuartu¹, D. Durany-Lara⁴, P. Servian-Vives³, V. Vallejos-Arroyo³, A. Cervera-Araez⁵, L. Pons-Martinez⁶, M. Cortés-Romera¹;
¹Servicio de Medicina Nuclear. Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, SPAIN, ²Servicio de Medicina Nuclear. Hospital Germans Trias i Pujol, Badalona, SPAIN, ³Servicio de Urología. Hospital Germans Trias i Pujol, Badalona, SPAIN, ⁴Servicio de Radiología. Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, SPAIN, ⁵Servicio de Radiología. Hospital Germans Trias i Pujol, Badalona, SPAIN, ⁶Servicio de Anatomía Patológica. Hospital Germans Trias i Pujol, Badalona, SPAIN.

EP-0393
PSMA PET/CT for the detection of prostate cancer (PCa) biochemical recurrence (BCR) after primary radiation therapy (RT): is it time to review the Phoenix criteria?

C. Vallone^{1,2}, P. Guglielmo^{2,3}, C. Franzese^{2,4}, R. Lucchini⁴, R. Mazzola^{2,5}, J. Jandric⁶, M. Rodari⁶, G. Di Grigoli⁶, M. Marengo⁶, S. Del Vecchio¹, L. Evangelista^{2,6};
¹Department of Advanced Biomedical Sciences, University of Napoli, Napoli, ITALY, ²Department of Bioscience, Humanitas University, Pieve Emanuele, Pieve Emanuele (MI), ITALY, ³Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, ITALY, ⁴Radiation Oncology Unit, IRCCS Humanitas Cancer Center, Rozzano (MI), ITALY, ⁵Radiation Oncology Unit, Humanitas Gavazzeni, Bergamo, ITALY, ⁶Nuclear Medicine Unit, IRCCS Humanitas Cancer Center, Rozzano (MI), ITALY.

EP-0394
PROMISE V.2. Staging with a Novel ¹⁸F-Piflufolastat PET/CT Protocol for the Detection of Prostate Cancer Recurrence

M. Romero, M. Cornide Carvallo, M. Zapardiel Martinez-Falero, M. Vaillant Lopez, A. Berardinelli Isea, P. Daudén Onate, G. Cuesta Domingo, R. Couto Caro, M. Nieves Cabrera;
HCSC, Madrid, SPAIN.

EP-0395
Prognostic Value of Total Tumor Volume Derived from ¹⁸F-FSU-880 PSMA-PET Imaging in Prostate Cancer Patients

R. Nakamoto, Y. Shimizu, Y. Nakamoto;
Kyoto University Hospital, Kyoto, JAPAN.

EP-0396
VAULT: Value of Long-Axial Field-of-View Tomography in ⁶⁸GaGa-PSMA-11 PET/CT for the Management of Biochemical Recurrent Prostate Cancer

A. Di Giorgio¹, M. Di Franco¹, M. Rapa¹, F. Monastero¹, M. Assenza², L. Bianconi³, C. Nanni³, P. Castellucci³, A. Farolfi³, S. Fanti^{1,3};
¹Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Professional Development and Implementation of Research in Health Professions Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0397
[¹⁸F] DCFPYL PET/CT in Prostate Cancer Patients Candidates for Salvage Radiotherapy for Very Low Biochemical Recurrence ≤0.25 ng/mL after Radical Prostatectomy: Impact on Restaging and Therapeutic Strategy.

N. Alvarez Mena, J. Gómez Hidalgo, F. Sebastián Palacid, B. Pérez López, C. Riola Parada, R. Ruano Pérez;
Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EP-0398
A Comparative Analysis of PSMA-PET/CT and Whole-Body MRI for Staging and Restaging in Patients with Prostate Cancer

E. Greco¹, L. Bianchi², C. Gaudiano³, B. Corcioni³, C. M. P. Sgro¹, C. Mignogna⁴, B. Renzetti⁵, A. Cattabriga³, R. Schiavina^{2,4}, E. Brunocilla^{2,4}, C. Mosconi^{3,5}, R. Mei⁶, P. Castellucci⁶, S. Fanti^{6,1}, A. Farolfi⁶;
¹Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Division of Urology, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ⁵Department of Radiology, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ⁶Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0399
Prediction of Occult Lymph Node Metastasis Using PSMA PET/CT-Based Radiomic Model in Clinical N0 Prostate Cancer

T. Li;
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CHINA.

EP-0400
Development and validation of a Nomogram for predicting positive [^{99m}Tc]Tc-HYNIC-PSMA SPECT/CT in patients with biochemically recurrent prostate cancer after radical prostatectomy

B. Li, X. Wu, Y. Yu, Y. Gao;
Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People's Hospital; Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, CHINA.

EP-0401
Can Tumour Burden On PET/CT With [¹⁸F]DCFPyL Predict Progression In Patients With Prostate Cancer Recurrence After Radical Treatment?

L. García Zoghby¹, J. Bonilla Plaza¹, M. Cruz Montijano¹, M. Meneses Navas¹, S. Guzmán Ortiz¹, J. Moltavá Pastor¹, I. García Megías¹, M. Amo Salas², A. García Vicente¹;
¹Hospital General Universitario de Toledo, Toledo, SPAIN, ²Facultad de Medicina de la Universidad de Castilla-La Mancha, Ciudad Real, SPAIN.

EP-0402
Possibility of ¹⁸F-PSMA-1007 PET/CT in patients with biochemical recurrence of prostate cancer after radical prostatectomy

M. Komarova, A. Pronin, E. Davydova, O. Ryzhova, I. Amosova;
N.N Blokhin National Medical Research Center of Oncology of the Russian Ministry of Health, Moscow, RUSSIAN FEDERATION.

EP-0403
The impact of ¹⁸F-PSMA-PET/CT on clinical decision making in biochemically recurrent prostate cancer

C. A. Poulsen¹, K. M. Buch-Olsen^{1,2}, M. H. Vilstrup³, K. T. Pedersen¹, S. Hansen^{4,2}, M. H. A. Poulsen^{5,6}, P. C. Holdgaard⁷, O. Gerke^{1,2}, M. G. Hildebrandt^{1,2}, J. Holm^{1,2};
¹Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, ²Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, DENMARK, ³Department of Radiology and Nuclear Medicine, Esbjerg and Grindsted Hospital, University Hospital of Southern Denmark, Esbjerg, DENMARK, ⁴Department of Oncology, Odense University Hospital, Odense, DENMARK, ⁵Department of Urology, Esbjerg and Grindsted Hospital, University Hospital of Southern Denmark, Esbjerg, DENMARK, ⁶Department of Regional Health Research, University of Southern Denmark, Odense, DENMARK, ⁷Department of Nuclear Medicine, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, DENMARK.

EP-21

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B18c Prostate Other

EP-0404
Short-term androgen deprivation therapy, ⁶⁸Ga-PSMA-11 binding potential and MR apparent diffusion restriction coefficient in hormone-sensitive, prostate cancer patients

O. Jonmarker¹, A. Sanchez-Crespo^{1,2}, F. Jäderling^{1,3}, S. Carlsson^{1,2}, M. Olsson², C. Li^{1,4}, R. Axelsson^{1,2};

¹Karolinska Institutet, Stockholm, SWEDEN, ²Karolinska University Hospital, Stockholm, SWEDEN, ³Capio S:t Görans Hospital, Stockholm, SWEDEN, ⁴Södersjukhuset, Stockholm, SWEDEN.

EP-0405
Long axial field-of-view ⁶⁸Ga-PSMA PET-CT detects physiological uptake in nerve roots

L. Badawy¹, S. Datta¹, T. Wagner^{1,2};
¹Royal Free London NHS Foundation Trust, London, UNITED KINGDOM, ²Centre for Medical Imaging, Department of Imaging, University College London, London, UNITED KINGDOM.

EP-0406
Explorative analysis on the role of the PRIMARY Score in PSMA PET-guided re-irradiation for recurrent prostate cancer

P. Guglielmo^{1,2}, L. Di Cristina^{3,4}, C. Franzese^{1,3}, R. Mazzola^{4,5}, J. Jandric⁶, L. Setti⁷, L. Evangelista^{1,6};
¹Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY, ²Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, ITALY, ³Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY, ⁴Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, ITALY, ⁵Department of Radiotherapy, Humanitas Gavazzeni, Bergamo, ITALY, ⁶Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY.

EP-0407
Diagnostic Evaluation of Blood Biomarkers and Multiparametric ¹⁸F-PSMA-1007 PET/MR Imaging in Prostate Cancer

L. Wang¹, X. Su², Y. Yang², W. Wu¹;
¹Jilin Cancer Hospital, Changchun, CHINA, ²Beijing United Imaging Healthcare Co., Ltd., Beijing, CHINA.

EP-0408
Enhancing Patient Selection for PSMA Radioligand Therapy: The Role of Dual-Tracer Imaging Biomarkers in Optimizing Outcomes for mCRPC

S. Xue, H. Einspieler, S. Wen, M. Hacker, S. Rasul, X. Li;
Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, AUSTRIA.

EP-0409
Is Dual-Time-Point PSMA-PET/CT a Predictive Tool for Response to PSMA Radioligand Therapy?

A. Weissensee, A. D. Sidandy, N. Gözlügöl, R. Saiyed Alsheikh, F. Caobelli, R. Seifert, A. Rominger, A. Afshar-Oromieh;
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

EP-0410
The added value of MRI to AI¹⁸F-PSMA-BCH PET/CT in detection of clinically significant prostate cancer

J. Ma¹, C. Wang¹, M. Wang², C. Ren¹, Z. Huang¹, M. Liu², L. Huo¹;
¹Peking union medical college hospital, Beijing, CHINA, ²Beijing hospital, Beijing, CHINA.

EP-0411

5-Alpha Reductase Inhibitor Therapy Increases Benign Prostatic PSMA Uptake: Implications for Primary Prostate Cancer Imaging

M. Celli¹, R. Gunelli², F. Ferroni¹, M. Costantini², A. Prochowski Iamurri¹, L. Fantini¹, E. Fragalà², I. Marini¹, D. Bezzi³, V. Rossetti¹, M. Sansovini¹, S. Nicolini¹, E. Giunta¹, S. Bellia¹, V. Di Iorio¹, F. Foca¹, F. Matteucci¹, P. Caroli¹; ¹IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola (FC), ITALY, ²Morgagni Pierantoni Hospital, Romagna Local Health Service, Forlì (FC), ITALY, ³Bufalini Hospital, Romagna Local Health Service, Cesena (FC), ITALY.

EP-0412

MRI characterization of 18F-PSMA 1007 bone uptake on integrated/hybrid PET/MRI exam in prostate cancer patients.

J. Vela León¹, J. García², A. Compte², L. Pinilla², L. Mont-Castro², S. Ruiz², M. Soria², P. Bassa², E. Riera²; ¹Hospital Universitario de Canarias, Tenerife, SPAIN, ²ASCIRES CETIR BCN, Barcelona, SPAIN.

EP-0413

Feasibility of Single-Time-Point Dosimetry from Voxel-Wise TAC Estimation Following 177Lu-PSMA Therapy

M. Alhashim¹, E. Alwuhaib¹, N. Ibrahim¹, M. Alabedi¹, H. Dadgar², X. Hong³, M. Azimi⁴, S. Rezaei⁵, H. Arabi⁶; ¹King Fahad Specialist Hospital Dammam, Dammam, SAUDI ARABIA, ²Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ³School of Biomedical Engineering, Southern Medical University, Guangzhou, CHINA, ⁴Department of Medical Radiation Engineering, Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF, ⁶Division of Nuclear Medicine and Molecular Imaging, Diagnostic Department, Geneva University Hospital, Geneva, SWITZERLAND.

EP-0414

[68Ga]Ga-PSMA PET/CT response evaluation after metastasis- directed therapy (MDT) in Low Burden Metastatic Prostate Cancer

M. Usmani, K. al Riyami, A. Jain, A. Al Busaidi, N. Pervaiz, B. Mir Khan, Z. Al-Mandhari; Sultan Qaboos Comprehensive Cancer Care and Research Center (SQCCCRC), University Medical City, Muscat, OMAN.

EP-0415

Defining Patient Selection for Lutetium-177[177Lu] Lu-PSMA Radioligand Therapy: Evaluating the Probability of FDG PET/CT to Identify Discordant Disease according to PSMA PET/CT SUVmean?

J. Weindler, J. P. Buteau, N. Papa, M. S. Hofman; Prostate Cancer Theranostics and Imaging Centre of Excellence; Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

EP-0416

Intra-Individual Head-to-head Comparison of ¹⁸F-PSMA-1007 vs ⁶⁸Ga-PSMA-11 PET-CT in Assessment of Prostate Carcinoma. A PRostate Imaging with ¹⁸F-PSMA-1007 Study in Malaysia (PRISM-My).

M. Abdul Onny^{1,2}, M. Mohd Rohani³, T. Selvarajoo^{4,5}, M. Ahmad Fadzil¹, Z. Md Safee¹, N. Razali¹, M. Mahmood¹, M. Said¹, N. Yaacob¹, R. Abdul Rahman¹, N. Mat Ail¹, S. Sukar¹, M. Wakiran¹, M. Mat Jusoh⁶, S. Jamaludin⁴, N. Ali¹, S. Amir Hassan³, C. Ng⁵; ¹National Cancer Institute Malaysia, Putrajaya, MALAYSIA, ²University Medical Center Groningen, Groningen, NETHERLANDS, ³Hospital Kuala Lumpur, Kuala Lumpur, MALAYSIA, ⁴Advance Medical & Dental Institute, Universiti Sains Malaysia, Kepala Batas, MALAYSIA, ⁵Hospital Sultanah Aminah, Johor Bahru, MALAYSIA, ⁶Hospital Sultan Idris Shah, Serdang, MALAYSIA.

EP-0417

Low sensitivity of mpMRI and 18F-PSMA-1007 PET/CT in localization of Primary Prostate cancer

A. Loimaala¹, O. Kerro², T. Mirtti³, M. Paloranta⁴, T. Koivula⁵, A. Rannikko⁶; ¹Helsinki University Hospital, Diagnostic Center, Helsinki, FINLAND, ²Helsinki University Hospital, Urology, Stomac center, Helsinki, FINLAND, ³Helsinki University Hospital, Diagnostic Center, Pathology, Helsinki, FINLAND, ⁴Helsinki University, Helsinki, FINLAND, ⁵Helsinki University Hospital, Diagnostic Center, Nuclear medicine, Helsinki, FINLAND, ⁶Helsinki University Hospital, Stomac center, Urology, Helsinki, FINLAND.

EP-0418

Effect of different scan duration on image quality and quantification in long axial field-of-view PSMA-PET/CT

L. Airo’ Farulla, A. F. Scarale, G. Cabrini, S. Capitanio, A. Franchini, E. Gay, A. Spataro, K. Shyli, C. Rossetti; ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY.

EP-0419

PI-RADS scoring in long-axial-field-of-view PSMA-PET/CT: effects of scan duration on diagnostic confidence

L. Airo’ Farulla, A. F. Scarale, A. Spataro, E. Gay, A. Franchini, S. Capitanio, G. Cabrini, K. Shyli, C. Rossetti; ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY.

EP-0420

Clinical Impact of Repeated 18F-PSMA-1007 PET/CT in the Longitudinal Follow-Up of Prostate Cancer Patients in Sub-Saharan Africa

W. Olwit, K. Makhdomi, M. Mwanja, P. K. Loyal, J. Nyamari, S. Nguku; Aga Khan University Hospital Nairobi, Nairobi, KENYA.

EP-0421

Prognostic Utility of Dynamic PSMA PET/CT and Kinetic Modeling with LAFOV in Advanced Prostate Cancer

A. Di Giorgio¹, I. Brusa², D. Dall’Olio³, V. Mollica⁴, F. Massari^{3,4}, M. Rapa¹, M. Assenza⁵, P. Castellucci², S. Fanti^{1,2}, A. Farolfi²; ¹Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITALY, ⁴Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Professional Development and Implementation of Research in Health Professions Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0422

The Value of VolumeIntensity-Sum and Other Volumetric PET Parameters in Predicting Progression in Patients with Metastatic Prostate Cancer Receiving Lu-177 PSMA Therapy

N. Unsal¹, S. Karabulut¹, A. Aksu², G. Capa Kaya¹; ¹Dokuz Eylul University Medical Faculty Hospital, Izmir, TÜRKIYE, ²Izmir Katip Celebi University Medical Faculty Hospital, Departmant of Nuclear Medicine, Izmir, TÜRKIYE.

EP-0423

The role of Choline PET/CT in patients with recurrent prostate cancer and a negative PSMA-PET/CT

N. Gözlügül¹, H. Sari¹, A. Rominger¹, K. Strobel², A. Afshar-Oromieh¹; ¹Inselspital Bern University Hospital, Bern, SWITZERLAND, ²Cantonal Hospital Lucerne, Lucerne, SWITZERLAND.

EP-0424

Comparison of Early Response Assessment Using Post-Therapy Imaging After Lu-177 PSMA Therapy with Interim Ga-68 PSMA PET/CT

O. Sahin, T. Bodur, K. Saglam, R. L. Uslu, S. Asa, S. Sager, L. Kabasakal, K. Sönmezoglu, H. B. Sayman; Department of Nuclear Medicine, Istanbul University-Cerrahpasa, Faculty of Medicine, Istanbul, TÜRKIYE.

EP-0425

How different treatments performed in hormone-sensitive prostate cancer could influence PSMA-PET/CT findings in resistant phase

M. Cuzzocrea¹, S. Merler², M. Pedrani², G. Treglia^{1,3,4}, C. Iacovitti¹, C. Martinello¹, S. Gillesen^{2,3}, G. Paone^{1,3}; ¹Imaging Institute of Southern Switzerland (IIMS), Ente Ospedaliero Cantonale (EOC), Bellinzona, SWITZERLAND, ²Institute of Oncology of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, SWITZERLAND, ³Università della Svizzera Italiana (USI), Lugano, SWITZERLAND, ⁴University of Lausanne, Lausanne, SWITZERLAND.

EP-0426

Clinical and Imaging Parameters to Predict the Efficacy of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer

O. Kodaz, Y. Eryilmaz, M. Caglar, M. Tuncel; Hacettepe University Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-0427

The impact of scan duration on detection of unspecific findings on large axial field-of-view PSMA PET/CT studies in Prostate cancer patients

A. Scarale, L. S. Airò Farulla, A. Spataro, A. Franchini, S. Capitanio, G. Cabrini, E. Gay, K. Shyli, A. M. Lazar, C. Rossetti; ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY.

EP-0428

The Relationship Between Clinical Scoring and Ga-68 PSMA PET/CT Parameters in Predicting Biochemical Failure After Radical Prostatectomy

F. Avci¹, R. H. Tokac¹, M. Dincka², K. E. Ergün³, A. M. Argon¹, U. Yazarbas¹; ¹Ege University, Nuclear Medicine, Izmir, TÜRKIYE, ²Harakani Training Researh Hospital, Urology, Kars, TÜRKIYE, ³Ege University, Urology, Izmir, TÜRKIYE.

EP-0429

Prediction of 2-year overall survival in mCRPC patients by total tumor volume (TTV) under PROMISE risk stratification scheme in a single Asian center

T. Tsoi, S. Chen, K. Yip, Y. Yip, K. Wu, Y. Wong, S. Cheung, C. Ho; Hong Kong Sanatorium & Hospital, Hong Kong, CHINA.

EP-0430

Which Patients with Negative PSMA-PET Imaging Can Safely Avoid Biopsy for Prostate Cancer? A Novel Step Towards PSMA-based Biopsy-Free Strategy

Y. Li, Y. Tang, S. Hu; Xiangya Hospital, Central South University, Changsha, CHINA.

EP-0431

18F-PSMA 1007 PET/CT metrics as a biomarker for progression-free survival in Patients with Metastatic Prostate Cancer

S. Moustafa; Assiut university hospital, Assiut, EGYPT.

EP-0432

Comparative evaluation of SUV variability in reference tissues and tumor lesions for defining the PSMA-positivity threshold in PSMA-targeted radioligand therapy

A. Khalimon¹, A. Nikiforuk¹, A. Shakirova¹, A. Lokhova¹, V. Bagaturya¹, I. Baltabaev¹, M. Khodzhibekova¹, G. Khamadeeva¹, D. Khodakova¹, T. Lazutina¹, I. Pylova¹, A. Leontev¹, A. Pronin², E. Bezumova²; ¹P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION, ²N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EP-0433

The impact of patient hydration and forced diuresis on [¹⁸F]PSMA-1007 urinary bladder uptake in PET/CT imaging

A. Khalimon¹, A. Nikiforuk¹, M. Khodzhibekova¹, G. Khamadeeva¹, D. Khodakova¹, T. Lazutina¹, I. Pylova¹, A. Leontev¹, V. Bobrov¹, O. Mukhortova², I. Aslanidi²; ¹P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION, ²A.N. Bakulev National Medical Research Center for Cardiovascular Surgery of the Russian Ministry of Health, Moscow, RUSSIAN FEDERATION.

EP-0434

Identifying Genetics Biomarkers in Correlation to Pathological and PSMA-PET Characteristics in Prostate Cancer

L. Xin; Qilu Hospital, Shandong University, Jinan, CHINA.

EP-0435

¹⁸F-PSMA-137 PET/CT Imaging in Suspected Prostate Cancer: A Multicenter, Prospective Trial with Pathologic Confirmation

J. Yang¹, J. Zhang², W. Wan³, X. Yang⁴, W. Wang¹, H. Ma¹, Y. Xu¹, Z. Fu¹, X. Wang⁵, Y. Liu⁵, M. Wang⁶, F. Liu⁷, Y. Guo⁷, Y. Liu², X. Zhang², N. Zhang³; ¹Beijing Friendship Hospital, Capital Medical University/

Department of Nuclear Medicine, Beijing, CHINA, ²Chinese PLA General Hospital/Department of Nuclear Medicine, Beijing, CHINA, ³Yunnan Baiyao Group Co., Ltd., Kunming, CHINA, ⁴Peking University People's Hospital/Department of Nuclear Medicine, Beijing, CHINA, ⁵Cancer Hospital Chinese Academy of Medical Sciences/Department of Nuclear Medicines (PET-CT Center), Beijing, CHINA, ⁶Cancer Hospital Chinese Academy of Medical Sciences/Department of Urology, Beijing, CHINA, ⁷Beijing Hospital/Department of Nuclear Medicine, Beijing, CHINA.

EP-0436
 Defining Semiquantitative PSMA PET Thresholds for Clinically Significant Prostate Cancer: Interim Analysis of the BIOPSTAGE Study

M. Celli¹, R. Gunelli², F. Ferroni², M. Costantini², A. Rossi¹, L. Fantini¹, E. Fragalà², I. Marini¹, D. Bezzi³, V. Rossetti¹, I. Grassi¹, M. Sansovini¹, E. Giunta¹, S. Bellia¹, V. Di Iorio¹, F. Foca¹, F. Matteucci¹, P. Caroli¹; ¹IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola (FC), ITALY, ²Morgagni Pierantoni Hospital, Romagna Local Health Service, Forlì (FC), ITALY, ³Bufalini Hospital, Romagna Local Health Service, Cesena (FC), ITALY.

EP-0437
 Role of PET/MRI in Prostate Cancer: Indications and Potential Uses. Our Preliminary Experience

J. Díaz Moreno¹, J. Robles-Barba¹, J. Martín-Marcuarta¹, D. Durany-Lara², A. Bagán-Trejo¹, A. Caresia-Aroztegui³, N. Picola-Brau⁴, J. Suárez-Novó⁴, B. Hervás-Sanz¹, P. Servian-Vives⁵, A. Abella-Serra⁵, M. Cortés-Romera¹; ¹Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN, ²Radiology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN, ³Nuclear Medicine-PET (IDI) Department, Hospital German Trias, Badalona, SPAIN, ⁴Urology Department, Hospital Universitari de Bellvitge, Barcelona, SPAIN, ⁵Urology Department, Hospital German Trias i Pujol, Badalona, SPAIN.

EP-22

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B19 Thyroid

EP-0438
 Clinicopathologic Features and Prognostic Stratification of Thyroid Carcinoma with Antecedent Distant Metastasis: A Retrospective Analysis of 44 Consecutive Cases

Y. Wu, L. Zhang, J. Gui, H. Chen, J. Wang, X. Long, W. Cao; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, CHINA.

EP-0439
 Exploring Factors of Achieving Excellent Response in Intermediate- and High-Risk Patients with Differentiated Thyroid Cancer after therapy with 100mCi Iodine-131

J. Xin, F. Kang, W. Ma, J. Wang; Department of Nuclear Medicine, Xijing Hospital, FourthMilitary Medical University, Xi'an, CHINA.

EP-0440
 Evaluation of the clinical utility of [¹⁸F]FDG PET/CT in the detection of non-metastatic disease in differentiated thyroid cancer

M. Opalinska¹, K. Undas², M. Olesiński², M. Osowski², K. Kaczmarek², E. Chudyba², T. Gorczyński², A. Sowa-Staszczak¹, M. Buziak-Bereza¹, M. Trofimuk-Muldrner¹, A. Hubalewska-Dydejczyk¹; ¹Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND, ²The Student Scientific Group of Nuclear Medicine, Jagiellonian University Medical College, Krakow, POLAND.

EP-0441
 Quantitative Tc-99m MIBI SPECT/CT parameters can predict malignancy in indeterminate thyroid nodules-preliminary results

M. Araz, &. Mesci, E. D. Avci, C. Soydal, O. B. Aksu, E. Eraslan, C. Konca, M. F. Erdogan, N. Ö. Kucuk; Ankara University, Ankara, TÜRKIYE.

EP-0442
 Quantification of I-131 Thyroid Remnant Uptake in Patients with Thyroid Cancer

E. Amini¹, C. Kim², A. Al-Busaidi³, R. Klein⁴, W. Zeng⁴; ¹Ottawa Hospital Research Institute, Ottawa, ON, CANADA, ²University of Ottawa, Ottawa, ON, CANADA, ³Sultan Qaboos Comprehensive Cancer Care and Research Centre, Muscat, OMAN, ⁴The Ottawa Hospital, Ottawa, ON, CANADA.

EP-0443
 Focal FDG Uptake in the Thyroid Gland: A Clinical Dilemma in Primary Malignancy

M. Dasar, G. Koca, A. Özden, K. Demirel, A. Akbulut, M. Korkmaz; University of Health Sciences, Ankara Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-0444
 Early FDG-PET Post-RAI in Differentiated Thyroid Cancer: Detecting Disease with Sub-Standard Thyroglobulin Levels

E. Greco¹, E. Fortunati², L. Zanon³, C. M. P. Sgro¹, G. A. Fuso¹, G. Bianciardi¹, G. Cuzzani¹, L. Carrara¹, C. Malizia², A. Golemi², E. Lodi Rizzini⁴, L. Calderoni², E. Tabacchi², S. Fanti^{1,2}; ¹Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Nuclear Medicine, AST Pesaro-Urbino, Pesaro-Urbino, ITALY, ⁴Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0445
 Value of ¹⁸F-FCH PET/CT for Diagnosing and Differentiating Hyperplasia From Adenoma

M. Li, H. Pang; The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-0446
 Prognostic risk factors in patients with papillary thyroid microcarcinoma (PTMC) with excellent response (ER) one year after initial treatment.

A. Marongiu, S. Nuvoli, A. Falchi, S. Vargiu, A. Spanu, G. Madeddu; Unit of Nuclear Medicine, University of Sassari, Sassari, ITALY.

EP-0447
 ¹⁸F-FDG PET/CT Illuminating The Roadmap For Tracking Differentiated Thyroid Cancer

T. Dardouri¹, H. Boudriga¹, A. Ezzine¹, S. Mensi¹, J. Houas², M. Grassa², R. Sfar¹, K. Chatti¹; ¹Department of nuclear medecine of Sahloul hospital, Sousse, TUNISIA, ²Department of Otorhinolaryngology of Farhat Hached hospital, Sousse, TUNISIA.

EP-0448
 Loco-regional relapse and metastatic recurrence in BRAFV600E-mutated papillary thyroid carcinoma patients during more than five years of follow-up

T. Makazlieva¹, N. Manevska^{1,2}, S. Stojanoski¹, N. Bozinovska¹, A. Jankulovska¹, B. Stoilovska Rizova¹, A. Eftimov³, S. Kostadinova-Kunovska³, R. Jovanovic³; ¹Institut of pathophysiology and nuclear medicine, Medical faculty, University Ss Cyril and Methodius, Skopje, NORTH MACEDONIA, THE REPUBLIC OF, ²University Institute of positron emission tomography, Skopje, NORTH MACEDONIA, THE REPUBLIC OF, ³Institut of pathology, Medical faculty, University Ss Cyril and Methodius, Skopje, NORTH MACEDONIA, THE REPUBLIC OF.

EP-23

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B20 Gynaecological

EP-0449
 Efficacy of Ca-125 exchange rate and ¹⁸F-FDG Pet/Ct in predicting progression in ovarian cancer

Z. Mammadkhanli, F. Ustun; Trakya University, Edirne, TÜRKIYE.

EP-0450
 PET/CT-Guided Patient Selection for Secondary Cyto reduction in Recurrent Ovarian Cancer

C. Csikos¹, A. Varga¹, Z. Hascs², S. Molnár³, Z. T. Krasznai³, I. Garai^{1,2}; ¹Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY, ²Scanomed Ltd., Debrecen, HUNGARY, ³Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY.

EP-0451
 Prognostic Value of Metabolic Biomarkers in Locally Advanced Cervical Cancer: Is Survival Predictable?

Y. Eryilmaz, O. Kodaz, G. Kaya, P. Özgen Kiratlı; Hacettepe University Medical School Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-0452
 Correlation of metabolic parameters and dissemination of preoperative ¹⁸F-FDG-PET/CT in endometrial cancer and its prognostic value

C. Ortiz Muñoz¹, J. Rodríguez Gómez¹, E. Noriega Álvarez², F. Lopez-Bermejo García¹, D. Martínez Osorio¹, F. Pena Pardo¹, M. Talavera Rubio¹, V. Poblete García¹; ¹Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN, ²Hospital Universitario de Guadalajara, Guadalajara, SPAIN.

EP-0453
 [¹⁸F]F-FDG PET-CT Imaging in Ovarian Carcinoma Patients: IAEA Coordinated POCA Project Study from Azerbaijan

F. Novruzov¹, K. Huseynzade¹, E. Mehdi¹, N. Orujova², N. Aliyeva¹, G. Alibayli², D. Paez³, F. Giammarile^{4,5}, E. Estrada Lobato⁶, E. Mansurov⁷, M. Isayeva⁸, J. Aliyev⁹; ¹Department of Nuclear Medicine, The National Centre of Oncology, Baku, AZERBAIJAN, ²Department of Nuclear Medicine, The National Centre of Oncology, Baku, AZERBAIJAN, ³Head of the Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, Vienna, AUSTRIA, ⁴International Atomic Energy Agency, Vienna, AUSTRIA, ⁵Deapartment of Nuclear Medicine, Université de Lyon, Lyon, FRANCE, ⁶International Atomic Energy Agency, Division of Human Health, Vienna, AUSTRIA, ⁷Department of Medical Oncology, The National Centre of Oncology, Baku, AZERBAIJAN, ⁸Columbia University, New York, NY, UNITED STATES OF AMERICA, ⁹Department of General Surgery, The National Centre of Oncology, Baku, AZERBAIJAN.

EP-0454
 Development and validation of pretreatment ¹⁸F-FDG PET/CT and MRI radiomics deep learning signatures to predict progressionfree survival in locally advanced cervical cancer

J. Song, H. Yi; Zhejiang Cancer Hospital, Hangzhou, CHINA.

EP-0455
 Enhanced tumor PET imaging with self-assembled peptide probe [⁶⁸Ga]HGFYp-NOTA

H. Wu^{1,2}, Y. Liu¹, H. Wang¹, J. Wu¹, X. Li², P. Zou¹; ¹NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA, ²College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, CHINA.

EP-0456
 Enzyme-activated nanocarriers for efficient ⁶⁸Ga delivery and tumor targeting

P. Zou, H. Wu, Y. Liu, H. Wang, J. Wu; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA.

EP-0457
 ¹⁸F-FDG-PET/CT in cervical cancer - challenging clinical acknowledgment for more accurate staging and therapy tailoring: single-centre experience

L. Chavdarova¹, N. Piperkova-Slavova², E. Piperkova¹; ¹University Specialized Hospital for Active Treatment in Oncology “Prof. I. Chernozemsky”, Sofia, BULGARIA, ²Neoclinic, Sofia, BULGARIA.

EP-0458
 Value of ¹⁸F-FDG PET/CT in Uterine Metastases From Invasive Lobular Breast Carcinoma

C. Mas, M. Feriche, E. Espinosa, T. Rudolphi, S. Sanz; Hospital Clínico Universitario Virgen de la Victoria, Málaga, SPAIN.

EP-0459
 Dynamic F-18 fluorodeoxyglucose positron emission tomography with texture analysis for the differential diagnosis of ovarian masses

T. Shinya¹, A. Shinya², T. Matsushita¹, Y. Hiroshima¹, J. Hiraoka¹, Y. Otomi¹, B. Zayabat¹, H. Inui¹, T. Kagawa¹, R. Kinouchi¹, K. Yoshida¹, M. Nishimura³, T. Iwasa¹, M. Harada¹; ¹Tokushima University Hospital, Tokushima-city, JAPAN, ²Tokushima Red Cross Hospital, Komatsushima-city, JAPAN, ³Tokushima Prefectural Central Hospital, Tokushima-city, JAPAN.

EP-0460
Performance of 18F-FDG-PET/CT in Lymph Node Staging of Patients with Endometrial Cancer
J. Rodríguez Gomez¹, C. F. Ortiz Muñoz¹, E. Noriega Alvarez², F. J. Pena Pardo¹, M. P. Talavera Rubio¹, V. M. Poblete García¹; ¹Hospital General Univesitario Ciudad Real, Ciudad Real, SPAIN, ²Hospital Univesitario De Guadalajara, Guadalajara, SPAIN.

EP-24

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B21 Lymphoma

EP-0461
Radiomic analysis of baseline 18-F FDG PET/CT to build machine-learning models able to predict treatment response in primary mediastinal B-cell lymphoma: results of a bicentric experience
S. Adamantiadis¹, L. Urso¹, L. Manco², F. Esposito³, G. Scribano², L. De Marchi³, A. Venditti³, M. Postorino³, N. Urbano⁴, R. Gafà¹, A. Cuneo⁵, A. Chiaravalloti⁶, M. Bartolomei⁷, C. Cittanti¹, L. Filippi⁶; ¹Department of Translational Medicine, University of Ferrara, Ferrara, ITALY, ²Medical Physics Unit, University Hospital of Ferrara, Ferrara, ITALY, ³Hematology, Department of Biomedicine and Prevention, University of Roma Tor Vergata, Rome, ITALY, ⁴Nuclear Medicine Unit, Department of Oncohaematology, Fondazione PTV Policlinico Tor Vergata University Hospital, Rome, ITALY, ⁵Hematology Unit, University of Ferrara, Ferrara, ITALY, ⁶Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, ITALY, ⁷Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, ITALY.

EP-0462
Prognostic Impact Of Metabolic Tumour Volume On Survival In Patients With Diffuse Large B-Cell Lymphoma Treated With Chimeric Antigen Receptor T-Cell Therapy
L. Henrich Malizia¹, A. Gomez Lopez¹, F. Arraut Serrano¹, A. Garin Rodriguez¹, N. Etxabeguren Gallo¹, I. Cillero Etxebeste¹, B. Mendibil Esquisabel², I. Zeberio Etxetxipia², I. Olazabal Eizaguirre², V. Rodriguez Ortega¹, I. Sanchez Oscoz¹, S. Sanchez Eguiguren¹, I. Jauregui Larrea¹, G. Rodriguez Rodriguez¹, I. Leon Zubizarreta¹, A. Iztueta Iturbe¹, I. Lopez Sanchez¹, A. Roteta Unceta Barrenechea¹; ¹Hospital Universitario Donostia - Onkologikoa, San Sebastian, SPAIN, ²Hospital Universitario Donostia, San Sebastian, SPAIN.

EP-0463
Automated AI-based total Metabolic Tumor Volume in lymphoma- a RECOMIA-tool
M. Sadik¹, J. Mörk¹, J. Lopez Urdaneta¹, M. Lewold², M. Larsson³, O. Enqvist⁴, S. F. Barrington⁵, L. Edenbrandt¹, E.

Trägårdh²; ¹Medicine, Gothenburg, SWEDEN, ²Clinical Physiology and Nuclear Medicine, Malmö, SWEDEN, ³Eigenvision AB, Lund, SWEDEN, ⁴Electrical Engineering, Gothenburg, SWEDEN, ⁵Clinical PET Centre, London, UNITED KINGDOM.

EP-0464
The Value of F-18 FDG PET/CT Quantitative and Semi-Quantitative Parameters in Predicting Treatment Response and Prognosis in Hodgkin Lymphoma
S. Aksu¹, G. Uçmak¹, B. B. Demirel¹, M. S. Dal²; ¹Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Hematology, Ankara, TÜRKIYE.

EP-0465
Variability factors of hepatic SUVmax and SULmax in patients with FDG avid lymphoma during chemotherapy
H. Habchi¹, S. Mensi^{2,3}, B. Daoud⁴, K. Chatti^{3,5}; ¹Department of Biophysics and Medical Imaging, Higher Institute of Medical Technologies of Tunis, University of Tunis El Manar, Tunis, TUNISIA, ²Nuclear Medicine department, CHU Sahloul, Sousse, TUNISIA, ³Department of biophysics, School of medicine of Sousse, University of Sousse, Sousse, TUNISIA, ⁴University of Texas, MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA, ⁵School of Medicine of Monastir, University of Monastir, Monastir, TUNISIA.

EP-0466
Lymphoma Therapy Response Assessment with Low-Dose [¹⁸F]FDG Total-Body PET/CT
C. Mingels¹, F. Sen², K. J. Chung², H. Nalbant², Y. Abdelhafez², N. S. Esteghamat³, J. Tuscano³, A. Rominger¹, R. D. Badawi², B. Spencer², L. Nardo²; ¹Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND, ²Department of Radiology, University of California Davis, Sacramento, CA, UNITED STATES OF AMERICA, ³Department of Internal Medicine, University of California Davis, Sacramento, CA, UNITED STATES OF AMERICA.

EP-0467
A Radiomic and Semiquantitative PET Approach to Post-Treatment Mediastinal Residuals in cHL and PMBCL: From Classification to PrognosisSA Radiomic and Semiquantitative PET Approach to Post-Treatment Mediastinal Residuals in cHL and PMBCL: From Classification to Prognosis
E. Abenavoli¹, A. Lombardo², F. Mungai³, M. Palazzo⁴, L. Nassi⁴, B. Puccini⁴, B. Sordi⁴, R. Sciagrà¹, S. Valente¹, A. M. Vannucchi⁴, V. Berti¹; ¹Nuclear Medicine Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY, ²Nuclear Medicine Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY, ³Department of Radiology, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY, ⁴Division of Hematology, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY.

EP-0468
Inter-reader variability of FDG PET/CT measurements in lymphoma patients
E. Tragardh^{1,2}, M. Lewold^{1,2}, J. Lopez Urdaneta³, M. Larsson⁴, O. Enqvist^{4,5}, L. Edenbrandt³, S. F. Barrington⁶, M. Sadik³; ¹Skåne University Hospital, Malmo, SWEDEN, ²Lund

University, Malmö, SWEDEN, ³Sahlgrenska Academy at the University of Gothenburg, Gothenburg, SWEDEN, ⁴Eigenvision AB, Lund, SWEDEN, ⁵Chalmers University of Technology, Gothenburg, SWEDEN, ⁶School of Biomedical Engineering and Imaging Sciences Kings College, London, UNITED KINGDOM.

EP-0469
Correlation analysis of PET parameters and clinical characteristics in 91 patients with diffuse large B-cell lymphoma
S. Chen, W. Chen, Y. Zhang; Fuzhou University Affiliated Provincial Hospital, Fuzhou, CHINA.

EP-0470
The impact of increased sensitivity of LAFOV PET/CT on DS assessment in lymphoma patients: implication and perspectives
A. Franchini¹, C. Romano², S. Capitanio¹, A. Spataro¹, A. Scarale¹, L. Airo' Farulla¹, G. Cabrini¹, E. Gay¹, C. Rossetti¹; ¹Nuclear Medicine Unit, Dipartimento Ematologia, Oncologia e Medicina Molecolare, ASST GOM Niguarda, Milan, ITALY, ²S.C. Fisica Sanitaria, ASST GOM Niguarda, Milan, ITALY.

EP-0471
Effect on Deep-Learning Time-of-Flight (DL-ToF) image enhancement compared to non-Time-of-Flight (non-ToF) Positron Emission Tomography (PET) images on clinical outcome for response assessment in lymphoma.
C. Low, O. Adesanya, N. Rao, V. Leung, A. Vasiljevic, C. Lim, L. Rowley; University Hospital Coventry and Warwickshire NHS Trust, Coventry, UNITED KINGDOM.

EP-0472
Prognostic Role of Volumetric and Dissemination Parameters from ¹⁸F-FDG PET/CT in Follicular Lymphoma.
F. López-Bermejo García¹, M. Contreras Ameduri¹, J. Rodríguez Gómez¹, E. Noriega Álvarez², J. Gatón Ramírez¹, F. Pena Pardo¹, D. Martínez Osorio¹, M. Talavera Rubio¹, V. Poblete García¹; ¹Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN, ²Hospital Universitario de Guadalajara, Guadalajara, SPAIN.

EP-0473
Diagnostic value of Metabolic Tumor Volume (MTV) as a prognostic criterion in Follicular Lymphoma
Y. Sauchuk; Minsk Oncology Center, Minsk, BELARUS.

EP-0474
Concordance and Discordance Between FDG PET/CT and Bone Marrow Biopsy in Detecting Bone Marrow Involvement in Lymphoma: A Retrospective Analysis.
L. Goriparti¹, C. S¹, J. Krishna P¹, V. Goenka², D. Khan¹, S. Sagar¹, S. Sharma¹, B. S. Nayak¹, R. Karna¹, A. Dhiman¹, R. Kumar¹; ¹All India Institute of Medical Sciences, New Delhi, INDIA, ²All India Institute of Medical Sciences, Jodhpur, INDIA.

EP-0475
Texture Analysis of Lymph Nodes on Initial FDG PET/CT for Predicting Interim Deauville Scores after Chemotherapy in Newly Diagnosed Non-Hodgkin Lymphoma Patients

A. Kibar, K. Saglam, S. Asa, S. Sager, H. B. Sayman; Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-0476
Metabolic biomarkers assessed with ¹⁸F-FDG PET/CT in patients with diffuse large B-cell lymphoma, with and without BCL-2 and MYC expression
Y. Sánchez Vera, M. Olarte Casas; Unidad PET/CT /Unidad UNAM, Mexico, MEXICO.

EP-0477
Prognostic Value of ¹⁸F-FDG PET/CT in CAR T-Cell Therapy for Relapsed/Refractory Non-Hodgkin Lymphoma
S. Gavrilidis¹, N. Pianou¹, I. Tzannou², I. Baltadakis², P. Rontogianni¹; ¹Nuclear Medicine Department, Evangelismos Hospital, Athens, GREECE, ²Hematology Department – BMT Unit, Athens, GREECE.

EP-0478
Prognostic Role of Interim PET in Peripheral T-Cell Lymphoma
S. Pacella¹, F. Rossi¹, N. Rampi¹, E. Domingo Domenech², C. Martinez-Ramos³, D. Bonometti¹, F. Passamonti⁴, M. Castellani¹; ¹Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, ITALY, ²Institut Catala d'Oncologia, Hospital Duran i Reynals, IDIBELL, Hematology, Barcelona, SPAIN, ³Hospital Universitari de Bellvitge, IDI, Nuclear Medicine, Barcelona, SPAIN, ⁴Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano, Milan, ITALY.

EP-0479
The Effect of MTV Value Evaluated in Staging FDG-PET/CT on Survival and Prognosis in Diffuse Large B-Cell Lymphoma
A. Tuncç¹, E. N. Durmazer², N. Akad Soyer³, A. Gunes³, A. M. Argon¹; ¹Ege University Nuclear Medicine Department, Izmir, TÜRKIYE, ²Yuksekoa State Hospital, Hakkari, TÜRKIYE, ³Ege University Hematology Department, Izmir, TÜRKIYE.

EP-0480
Metabolic Tumor Heterogeneity-Based Scoring System Predicts Prognosis in Hodgkin Lymphoma
S. Bayram¹, E. M. Kaya¹, M. G. Tekin², M. Ayer³, M. Kaya¹, B. Esen Akkasç; ¹University of Health Sciences Basaksehir Cam and Sakura City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²University of Health Sciences, Tepecik Training and Research Hospital, Department of Haematology, Izmir, TÜRKIYE, ³University of Health Sciences Basaksehir Cam and Sakura City Hospital, Department of Haematology, Istanbul, TÜRKIYE.

EP-0481
Visual and quantitative assessment of interim ¹⁸F-fluorodeoxyglucose-positron emission tomography/computed tomography in children with Hodgkin lymphoma
M. Dunaykin¹, K. Chaurasiya¹, E. Kireeva¹, G. Shestopalov^{1,2}, M. Yadgarov^{1,3}, N. Myakova¹, Y. Likar¹; ¹Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, RUSSIAN FEDERATION, ²Russian Children's Clinical Hospital, branch of the Federal State Autonomous

Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University”; Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION, ³Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, RUSSIAN FEDERATION.

EP-0482
 Diagnostic accuracy of¹⁸F-FDG PET/CT in detecting bone marrow lesions in children with Hodgkin's lymphoma

M. Dunaykin¹, G. Shestopalov^{1,2}, M. Yadgarov^{1,3}, K. Chaurasiya¹, E. Kireeva¹, N. Myakova¹, Y. Likar¹; ¹Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, RUSSIAN FEDERATION, ²Russian Children's Clinical Hospital, branch of the Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University”; Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION, ³Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, RUSSIAN FEDERATION.

EP-0483
 Prognostic Value of Total Metabolic Tumor Volume derived from baseline ¹⁸F-FDG PET in Patients with Aggressive Non-Hodgkin Lymphoma

S. Hoberück¹, P. Nikulin², F. Hofheinz², J. Kotzerke¹, R. A. Bundschuh¹, U. Dührsen³, F. Kroschinsky⁴, A. Braune²; ¹Department of Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GERMANY, ²Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, GERMANY, ³Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ⁴Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GERMANY.

EP-0484
 ¹⁸F-FDG PET-Based Multidimentional Scoring System for Immune Adverse Events in PD-1 Inhibitor-Treated Refractory Hodgkin Lymphoma

Z. Wu, X. Zhang, Z. Lin, Y. Deng, Z. Lin, D. Zheng, R. An, Y. Zhang, X. Lan; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0485
 Early ¹⁸F-FDG PET/CT as a predictor of metabolic response in large B-cell lymphoma patients following CAR T-cell therapy

C. Sachpekidis¹, C. Neelsen¹, F. T. Kurz², P. Dreger³, M.-L. Schubert³, S. A. Klein⁴, A. KoppSchneider¹, H.-P. Schlemmer¹, A. Dimitrakopoulou-Strauss¹; ¹German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ²Geveva University Hospitals, Geneva, SWITZERLAND, ³University Hospital Heidelberg, Heidelberg, GERMANY, ⁴University Hospital Mannheim, Mannheim, GERMANY.

EP-0486
 Prognostic Value of Diffusely Increased F-18 FDG Uptake in the Reticuloendothelial System and CBC Score in Patients with Aggressive B-Cell Lymphoma

Ü. Aksu¹, S. Bayram¹, E. M. Kaya¹, M. Bayer², M. Kaya¹, B. E. Akkas¹; ¹Basaksehir Cam and Sakura City Hospital, Department of

Nuclear Medicine, Istanbul, TÜRKIYE, ²Basaksehir Cam and Sakura City Hospital, Department of Hematology, Istanbul, TÜRKIYE.

EP-0487
 A new prognostic nomogram based on ¹⁸F-FDG PET/CT and clinical parameters in patients with newly diagnosed mucosa-associated lymphoid tissue lymphoma

Y. Han, X. Zhang, Z. Gao; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0488
 Defining the optimal volume of interest for response assessment in lymphoma: Evidence from two prospective multicentre trials and a real-world cohort

C.-A. Voltin¹, D. Hasenclever², U. Dührsen³, A. Hüttmann³, C. Hanoun³, M. Dietlein¹, P. J. Bröckelmann¹, P. Borchmann¹, A. Drzezga¹, C. Mauz-Körholz⁴, D. Körholz⁴, O. Sabir⁵, R. Kluge², L. Kurch⁵; ¹University Hospital Cologne, Cologne, GERMANY, ²University of Leipzig, Leipzig, GERMANY, ³University Hospital Essen, Essen, GERMANY, ⁴University Hospital Giessen and Marburg, Giessen, GERMANY, ⁵University Hospital Leipzig, Leipzig, GERMANY.

EP-0489
 Prognostic Accuracy of Semiquantitative Analysis of Interim PET/CT in PMBCL

L. Henzlová¹, V. Ičová¹, V. Hanáčková², K. Polgárová³, D. Zogala⁴, M. Trněný³, T. Papajik², V. Procházka², M. Kamínek¹; ¹Department of Nuclear Medicine, Palacky University and University Hospital Olomouc, Olomouc, CZECH REPUBLIC, ²Department of Hematooncology, Palacky University and University Hospital Olomouc, Olomouc, CZECH REPUBLIC, ³First Department of Internal Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, CZECH REPUBLIC, ⁴Institute of Nuclear Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, CZECH REPUBLIC.

EP-0490
 Quantitative ¹⁸F-FDG PET/CT parameters as predictors of CAR-T therapy response in large B-cell lymphoma: a preliminary study.

P. Stefaneli Mormandi, M. Calls-Calahorro, B. Serrallonga, Y. Delisau, M. Velasco-Nuño, A. Fernández-León, J. Duch, S. Asadurova, V. Camacho, S. Castejon, G. Guzman, A. Flotats-Giralt; Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

EP-0491
 Baseline PET/CT Metabolic Parameters as Predictors of Early Treatment Response in Pediatric Hodgkin Lymphoma

M. Cornide Carrallo, P. Dauden Onate, A. Berardinelli Isea, C. Wakfie Corieh, M. Zapardiel Martinez-Falero, R. Couto Caro, M. Romero Porras, G. Cuesta Domingo, M. Vaillant Lopez, M. Cabrera Martín; HCSC, Madrid, SPAIN.

EP-0492
 Prognostic Value of Diffusely Increased FDG Uptake in Spleen and/ or Bone Marrow due to Reticuloendothelial System Activation in Lymphoma Patients

Y. Song, Q. Zhao, W. Cai, Y. Dong, Y. Yang; General Hospital of Ningxia Medical University, Yinchuan, CHINA.

EP-0493
 Prediction Prognostic Models Based on ¹⁸F-FDG PET/CT and Clinical Parameters for Diffuse Large B cell Lymphoma with Interim Deauville Scores of 2-4

S. Chen, W. Chen, Y. Zhang; Fuzhou University Affiliated Provincial Hospital, Fuzhou, CHINA.

EP-0494
 Predictive Value of Interim and End-of-Treatment [¹⁸F]FDG PET/CT in Peripheral T-Cell Lymphoma

B. Hervás-Sanz¹, C. Martínez-Ramos¹, E. Domingo-Domenech², J. L. Díaz-Moreno¹, J. J. Robles-Barba¹, A. Tapias-Mesa¹, M. Pudis¹, M. Tormo-Ratera¹, P. C. Notta¹, C. García-Alcober³, E. M. González-Barca², M. Zamorano-Rivas¹, D. J. Tamayo-Ossa¹, M. Cortés-Romera¹; ¹Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Hematology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN, ³Radiopharmay Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EP-0495
 Evaluation of Bone Marrow in the Initial Staging of Peripheral T-cell Lymphoma: [¹⁸F]FDG PET/CT vs Bone Marrow Biopsy

B. Hervás-Sanz¹, C. Martínez-Ramos¹, E. Domingo-Domenech², M. Pudis¹, J. L. Vercher-Conejero¹, A. I. Fritsch-Medina¹, J. J. Robles-Barba¹, M. Crespi-Busquets³, F. Climent-Esteller⁴, E. M. González-Barca², A. Bagán-Trejo¹, B. Dacosta-Escobar¹, L. M. Gràcia-Sánchez¹, I. E. Sánchez-Rodríguez¹, M. Cortés-Romera¹; ¹Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Hematology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN, ³Radiopharmay Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ⁴Anatomical pathology, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EP-0496
 The prognostic value of MTV is retained in new proposed SUV 4 threshold: an international comparison of follicular and Hodgkin patient survival

S. Chauvie¹, F. Fallanca², R. Durmo³, E. Bergalla¹, V. Talini¹, A. Gallaminì⁴, S. Luminari⁵, L. Guerra⁶; ¹S. Croce e Carle Hospital, Cuneo, ITALY, ²IRCCS San Raffaele, Milano, ITALY, ³IRCCS Reggio Emilia, Reggio Emilia, ITALY, ⁴Lacassagne Cancer Center, Nice, FRANCE, ⁵IRCCS Reggio Emilia & University of Modena and RE, Reggio Emilia, ITALY, ⁶San Gerardo IRCC, Monza, ITALY.

EP-0497
 Immuno-metabolic stratification in newly diagnosed classical Hodgkin lymphoma: prognostic significance of FDG PET-derived tumor burden and immune-inflammatory parameters

D. Pizzuto¹, N. Messina², E. Maiolo³, F. D'Alò³, A. Guarneri⁴, L. Leccisotti⁴, V. Rufini⁴, S. Chiesa⁵, N. Dinapoli⁵, C. Mazzarella⁵, G. Macis⁶, S. Hohaus², S. Annunziata¹; ¹Nuclear Medicine Unit, GSteP Radiopharmacy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ²Hematology Section, Department of Radiological and Hematological Science, Università Cattolica del Sacro Cuore, Rome, ITALY, ³Hematology Unit,

Department of Radiology and Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY, ⁴Nuclear Medicine Unit, Department of Radiology and Radiotherapy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ⁵Radiotherapy Unit, Department of Radiology and Radiotherapy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ⁶Radiology Unit, Department of Radiology and Radiotherapy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY.

EP-0498
 To evaluate the role of ΔMTV at one month in assessing response after chimeric antigen receptor T-cell (CAR-T) therapy in diffuse large B-cell lymphoma.

C. Martínez, B. Hervás-Sanz, A. Bagan-Trejo, J. Diaz Moreno, M. Zamorano Rivas, M. Tormo Ratera, A. Mussetti, M. Cortés-Romera; Hospital Universitario de Bellvitge, Barcelona, SPAIN.

EP-25

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B22 Other Hemato-Oncology

EP-0499
 Baseline ¹¹C-acetate PET/CT predicts 3-year relapse post complete remission for newly diagnosed multiple myeloma

S. Chen, S. Cheung, Y. Wong, K. Wu, Y. Yip, K. Cheng, C. Ho; Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

EP-0500
 Head-to-head comparison of [¹⁸F]florbetapir and [¹⁸F]FDG PET for the early detection of amyloidosis in systemic amyloidosis and plasma cell dyscrasias

R. Ni¹, Y. Kong², L. Cao¹, B. He², Z. Zhou², Q. Zhang², M. Zhang², W. Wang², Q. Wang², H. Zhu², J. Xiao², A. Rominger³, Y. Guan², H. Tan²; ¹University of Zurich, Zurich, SWITZERLAND, ²Fudan University, Shanghai, CHINA, ³Inselspital, Bern, SWITZERLAND.

EP-0501
 FDG-PET/CT versus WB-MRI for bone disease assessment and management change in Smoldering and Symptomatic Multiple Myeloma.

D. Bezzi¹, A. Rossi², A. Prochowski Iamurri², F. Matteucci¹, M. Celli³, V. Rossetti³, G. Feliciani⁴, C. Cerchione⁵, P. Caroli³; ¹Nuclear Medicine Unit, AUSL Romagna, Forlì-Cesena, ITALY, ²Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, ITALY, ³Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, ITALY, ⁴Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, ITALY, ⁵Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, ITALY.

EP-0502
 [¹⁸F]FDG vs [⁶⁸Ga]Ga-PSMA-11 PET/CT in Multiple Myeloma(MM): Agreement Analysis in Staging and Response Assessment

M. Di Franco¹, D. Bezzi², M. Stasolla¹, M. Talarico³, E. Zamagni³, V. Cabitza⁴, F. Lodi⁴, S. Fanti^{1,4}, C. Nanni⁴;
¹Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine Unit, AUSL Romagna, Cesena, ITALY, ³Seràgnoli Institute of Hematology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0503
Prospective Comparison of [¹⁸F]FDG PET/CT and Whole-Body Diffusion-Weighted Magnetic Resonance for Staging and Treatment Response Assessment in Multiple Myeloma
M. Di Franco¹, D. Bezzi², M. Stasolla¹, M. Talarico³, E. Zamagni³, A. Cattabriga⁴, F. Galuppi⁴, S. Brocchi⁴, C. Mosconi⁴, S. Fanti^{1,5}, C. Nanni⁵;
¹Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine Unit, AUSL Romagna, Cesena, ITALY, ³Seràgnoli Institute of Hematology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0504
Prognostic Value of [¹⁸F]FDG PET/CT in Acute Lymphoblastic Leukemia
M. Stasolla¹, M. Di Franco¹, C. Sartor^{2,3}, C. Papayannidis³, J. Nanni², A. Curti³, A. Romagnoli², C. Nanni⁴;
¹Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, ITALY, ³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, ITALY, ⁴Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0505
Prognostic Value of ¹⁸F-FDG PET/CT Brain-to-Liver Uptake Ratio in Multiple Myeloma
C. D. Ramos, T. P. Santos, M. E. S. Takahashi, C. Cralcev, M. D. S. Silva, F. C. Souza, E. Miranda, C. A. Souza;
University of Campinas, Campinas, BRAZIL.

EP-0506
Assessing the relationship between quantitative ¹⁸F-FDG PET/CT and DWI MRI parameters in bone marrow imaging of multiple myeloma
Ö. Kilic^{1,2}, M. Hajjiyanni³, M. Wennmann^{1,4}, E. K. Mai³, L. John³, N. Weinhold³, M. Grözingen⁴, S. Sauer³, M. S. Raab³, H. Goldschmidt³, A. Dimitrakopoulou-Strauss¹, C. Sachpekidis¹;
¹Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ²Medical Faculty Heidelberg, Heidelberg University, Heidelberg, GERMANY, ³Internal Medicine V, Hematology, Oncology and Rheumatology, German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Heidelberg, GERMANY, ⁴Division of Radiology, German Cancer Research Center (DKFZ), Heidelberg, GERMANY.

EP-0507
Prognostic Value of Tumor Dissemination (Dmax) Derived from ¹⁸F-FDG PET/CT in Patients With Multiple Myeloma
S. Pellegrino¹, E. Di Donna¹, M. Lamagna², R. Della Pepa², S. Del Vecchio¹, R. Fonti¹;

¹Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, ²Department of Clinical Medicine and Surgery, University Federico II, Naples, ITALY.

EP-0508
Diagnostic Value of Whole-Body ¹⁸F-FDG PET/ MRI versus PET/CT in Systemic Histiocytosis: A Prospective Comparative Study
M. Pudis¹, G. Rocamora Blanch², J. A. Narváez³, X. Solanich-Moreno², B. Hervás-Sanz¹, J. Diaz-Moreno¹, A. Bagan-Trejo¹, M. Zamorano-Rivas¹, C. Martínez-Ramos¹, J. J. Robles-Barba¹, J. J. Marcuartu¹, M. Cortés-Romera¹;
¹Nuclear Medicine - PET (IDI), Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Internal Medicine, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, SPAIN, ³Radiology Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EP-0509
Comparison of 68Ga-Pentixafor and ¹⁸F-FDG PET/CT for initial evaluation of patients with newly diagnosed multiple myeloma.
S. Kumar, H. Kaur;
PGIMER, Chandigarh, INDIA.

EP-0510
PETBOT: An AI-Powered Patient-Centric Chatbot for Cancer Staging and Treatment Guidance according to NCCN from PET/CT Reports
S. Sagar¹, D. Khan¹, N. Kundu¹, A. Roy¹, A. Mahalik¹, L. Goriparti¹, A. Tilak¹, J. Krishna P.¹, A. Dhiman¹, A. Singh², A. Rout², S. K.V¹, R. Babu¹, J. Pathak¹, R. Kumar¹;
¹AIIMS, Delhi, INDIA, ²AIIMS, Bhubaneswar, INDIA.

EP-0511
Extramedullary Involvement in Multiple Myeloma: Can FDG PET/CT and Disease-Related Parameters Provide New Insights into Clinical Outcome?
K. Toplutas, A. B. Dere, E. M. Kaya, B. Esen Akkas;
University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, TÜRKIYE.

EP-0512
From Volume to Dissemination: Dmax and TMTV Drive Prognostic Assessment in Newly Diagnosed Multiple Myeloma Over Advanced Radiomic Approaches
L. Raffy¹, C. Etchegaray², E. Hindie¹, O. Saut², C. Hulin³, A. Schmitt⁴, C. Mesguich¹;
¹Department of nuclear medicine, University of Bordeaux, Bordeaux, FRANCE, ²Inria, Univ. Bordeaux, CNRS, Bordeaux INP, IMB, UMR 5251, Talence, FRANCE, ³Department of onco-hematology, University of Bordeaux, Bordeaux, FRANCE, ⁴Department of onco-hematology, Institut Bergonié, Bordeaux, FRANCE.

EP-0513
FDG PET/CT in Multiple Myeloma Staging: Standardization and Prognostic Impact of Imaging Parameters
M. Havel^{1,2}, L. Muronova^{3,4}, G. Havlova¹, D. Zihala^{3,4}, T. Popkova^{3,4}, G. Kascakova¹, S. Bobkova¹, K. Bukovansky¹, J. Mihalyova^{3,4}, H. Plonkova³, J. Golisova^{1,2}, R. Hajek^{3,4}, T. Jelinek^{3,4};
¹Department of Nuclear Medicine, University Hospital Ostrava, Ostrava, CZECH REPUBLIC, ²Department of Imaging Methods, Faculty of Medicine, University of Ostrava, Ostrava, CZECH REPUBLIC, ³Department of Hematooncology, University Hospital Ostrava, Ostrava,

CZECH REPUBLIC, ⁴Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, CZECH REPUBLIC.

EP-0514
AI-based vs Manual Segmentation in Multiple Myeloma: Are They Equally Prognostic?
M. Stasolla¹, D. Bezzi², M. Di Franco¹, S. Proto¹, M. Talarico³, E. Zamagni³, C. Malizia⁴, S. Fanti^{4,1}, C. Nanni⁴;
¹Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear medicine unit AUSL Romagna, Forlì-Cesena, ITALY, ³Seràgnoli Institute of Hematology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0515
Improved Initial Staging and Risk Stratification of Newly Diagnosed Multiple Myelomaby Targeting Chemokine Receptor CXCR4 using [⁶⁸Ga]Ga-Pentixafor PET/CT
J. Chen, C. Li, Y. He;
Zhongnan Hospital of Wuhan University, Wuhan, CHINA.

EP-26
e-Poster Area
B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B23 Bone and Soft Tissues

EP-0516
Inter-reader Agreement of The IMPeTus Criteria in Multipl Myeloma Patients
A. Tunç, F. Avcı, R. H. Tokak, Z. Burak;
Ege University Nuclear Medicine Department, Izmir, TÜRKIYE.

EP-27
e-Poster Area
B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B24 Melanoma

EP-0517
Machine learning based on ¹⁸F-FDG PET/CT parameters for prediction of lymph node metastasis in cutaneous stage I-III melanoma
Y. Jin¹, L. Lu², X. Chu³, T. Long¹, Y. Yang¹, S. Hu^{1,4,5};
¹Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, CHINA, ²Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, CHINA, ³Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, CHINA, ⁴National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, CHINA, ⁵Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Changsha, Hunan, CHINA.

EP-0518
First Evaluation of [⁶⁸Ga]FAPI PET/CT Imaging to Assess Fibroblast Activation Protein Expression in Melanoma Patients
Y. Yang, J. Su, X. Chen, S. Su;
Xiangya Hospital, Central South University, Changsha, CHINA.

EP-0519
Prognostic Value of TMTV and SUVmax from ¹⁸F-FDG PET/CT at Multiple Time Points in Melanoma Patients on Immunotherapy
K. Zevnik¹, A. Doma¹, A. Studen^{2,3}, K. Strašek², K. Škalič¹, R. Jeraj^{2,4}, M. Reberšek¹, N. Hribernik¹;
¹Oncology Institute Ljubljana, Ljubljana, SLOVENIA, ²Faculty of Mathematics and Physics University of Ljubljana, Ljubljana, SLOVENIA, ³Jozef Stefan Institute, Ljubljana, SLOVENIA, ⁴Department of Medical Physics University of Wisconsin School of Medicine and Public Health, Madison, WI, UNITED STATES OF AMERICA.

EP-0520
FDG avid bone metastases in patients with stage IV melanomas under immune checkpoint inhibitors (ICI) therapy: comparison with low dose CT
J. Heinen, C. Sachpekidis, J. Hassel, L. Pan, A. Dimitrakopoulou-Strauss;
Deutsches Krebsforschungszentrum, Heidelberg, GERMANY.

EP-0521
Adjuvant Therapy and FDG-PET/CT Follow-Up in High-Risk Patients with Cutaneous Melanoma: A Five-Year Retrospective Analysis
J. Aço, I. P. Carvalho, H. Nunes, P. Pereira, E. Gouveia, E. Sousa, D. Fraga, P. Jorge, D. Rombo, J. Pais, L. Salgado;
Instituto Português de Oncologia de Lisboa, Lisbon, PORTUGAL.

EP-0522
Prognostic Value of Clinical and Metabolic Parameters from ¹⁸F-FDG PET/CT in Malignant Melanoma: Impact on Overall and Progression-Free Survivalv
L. Cagua Ruiz, T. Aroui Luquin, J. Villa-Palacios, A. Piñero Donis, E. Dominguez-Polanco, R. Sánchez Sánchez;
Servicio Medicina Nuclear Hospital universitario Virgen de las Nieves, Hospital universitario virgen de las Nieves, SPAIN.

EP-0523
The Pseudoprogression Challenge in FDG PET/CT Response Evaluation of Malignant Melanoma Patients Receiving Immunotherapy:Which Immune Related Response Criteria Should We Trust?
G. Gedikli Turgut, S. Ince, U. M. Turan, H. Peker Yalcın, A. O. Karacalioglu;
Gulhane Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-0524
Immune-Related Adverse Events in Metastatic Melanoma Patients Treated with Combination Immunotherapy: The Role of PET/CT
G. Horvatic Herceg¹, V. Sabaric², K. Blazicevic², M. Ciglar-Hlasc¹, D. Herceg²;
¹Department of Nuclear Medicine and Radiation Protection, University Hospital Zagreb, Zagreb, CROATIA, ²Department of Oncology, University Hospital Zagreb, Zagreb, CROATIA.

EP-0525

Streamlined Monitoring of Immunotherapy Response in Metastatic Melanoma via Longitudinal PET Quantification and SemiAutomatic Tumor Delineation

C. Sachpekidis¹, T. P. Vagenas², J. C. Hassel³, A. Dimitrakopoulou-Strauss¹, G. K. Matsopoulos²;
¹German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ²Biomedical Engineering Laboratory, School of Electrical and Computer Engineering, National Technical University of Athens, Athens, GREECE, ³National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, GERMANY.

EP-28

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B25 Any Other Malignant (including Primary of Unknown Origin)

EP-0526

Evaluating the Clinical Accuracy of Half-Time^[18F] FDG PET/CT Acquisition: A Quantitative Assessment of Liver and Lesion Metrics in Oncology Imaging

N. AL Makhmari¹, S. Kheruka, N. AL Maymani, I. Collado, S. Al Rashdi, K. Al Riyami;
Radiology and Nuclear Medicine Department, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat, OMAN.

EP-0527

Novel Role of PSMA PET/CT Versus FDG PET/CT in Hepatocellular Carcinoma: A Comparative Diagnostic Study

S. Shekhar Singh¹, P. Wadhwa², A. K. Chaudhary¹, A. K. Singh¹, R. K. Pawar¹, S. K. Tandon¹;
¹Globe Healthcare, Lucknow, INDIA, ²United Imaging Healthcare, Delhi, INDIA.

EP-0528

Potential of [89Zr]Zr-girentuximab PET/CT for the routine clinical management of patients with suspicious, unspecified renal lesions

S. Rasul¹, I. Huebner-Resch, E. Patronas, L. Nics, S. F. Shariat, M. Schmidinger, M. Hacker;
Medical University of Vienna, Vienna, AUSTRIA.

EP-0529

Comparison of response assessment using morphological (iRECIST) and metabolic criteria (iPERCIST) in patients being treated with Immune checkpoint inhibitors in solid tumors.

D. Malik¹, M. Koley, J. Gupta, D. Thakrani, A. Uppal, N. Rana, P. Thakral, I. B. Sen;
Fortis Memorial research institute (FMRI), Gurugram, INDIA.

EP-0530

18F-FDG-PET/CT for staging Muscle-Invasive Urothelial Bladder Carcinoma: Impact on management using modified Deauville Score

O. Ajuria Illarramendi¹, P. Gajate Borau, A. Martinez Lorca, P. Azpeitia Hernandez, P. Guerrero Serrano, M. Gutierrez Guerrero, J. Braserio Burgos, I. Hernandez Perez, F. Lopez

Campos, U. Vera Schmülling, P. Paredes Rodriguez, T. Navarro Martinez, M. Orduña Diez;
H. U. Ramón y Cajal, Madrid, SPAIN.

EP-0531

Flow cytometry to validate the efficacy of multi-target PET tracer in early monitoring of ICI in lung cancer

R. Meng¹, F. Kang;
Military Medical University First Affiliated Hospital of No.4 Military Medical University, Shaanxi Xi'an, CHINA.

EP-0532

Head to head comparison of ⁶⁸Gallium-FAPI-PET/CT and ¹⁸Fluor-FDG-PET/CT for the assessment of single site cancer of unknown primary

M. Röhrich¹, D. Driess¹, A. Spektor¹, S. Zapata¹, A. Desuki¹, M. Schreckenberger¹, U. Haberkorn², A. Krämer³;
¹University hospital Mainz, Mainz, GERMANY, ²University hospital Heidelberg, Heidelberg, GERMANY, ³University hospital Heidelberg, Heidelberg, GERMANY.

EP-0533

Treatment monitoring of immunotherapy and targeted therapy using cluster of CD70-targeted positron emission tomography/computed tomography (PET/CT) in patients with advanced clear cell renal cell carcinoma(ccRCC)

Q. Wu¹, G. Huang, J. Liu, W. Wei;
Renji Hospital School of Medicine Shanghai Jiao Tong University, Department of Nuclear Medicine Institute of Clinical Nuclear Medicine, Shanghai, CHINA.

EP-0534

Improving Clinical Management of von Hippel-Lindau Syndrome with [⁸⁹Zr]Zr-DFO-Girentuximab PET Imaging

F. Gelardi¹, A. Larcher^{1,2}, L. Antunovic¹, F. Ce^{2,1}, C. Re^{2,1}, F. Belladelli^{2,1}, G. Guazzarotti¹, G. Brembilla¹, S. Calloni¹, N. Tenace¹, A. Piai¹, A. Tudda¹, U. Capitanio¹, F. Montorsi^{2,1}, A. Salonia^{2,1}, M. Sollini^{2,1}, A. Chiti^{2,1};
¹IRCCS Ospedale San Raffaele, Milan, ITALY, ²Università Vita-Salute San Raffaele, Milan, ITALY.

EP-0535

Diagnostic Utility of [18F]F-FAPI PET-CT in Patients with Carcinoma of Unknown Primary: A Prospective Multicentre Study in the Netherlands

S. Veldhuijzen van Zanten¹, E. Droogers¹, M. Hendriks², E. Verburg³, D. Robbrecht³, A. Glaudemans⁴, A. Glaudemans⁴, M. van Kruchten⁵, W. Vogel⁶, S. Marchetti⁶, S. Marchetti⁶, M. Lam⁷, H. Nienhuis⁷, A. Timmer-Bonte⁸, M. van Rijk⁸, J. Nin⁹, C. Mitea⁹, A. van den Hoven¹⁰, W. Kool², S. Veldhuijzen van Zanten³, FAPI for CUP study team;
¹Erasmus Medical Center, Rotterdam, NETHERLANDS, ²Northwest Clinics, Alkmaar, NETHERLANDS, ³Erasmus MC, Rotterdam, NETHERLANDS, ⁴UMC Groningen, Groningen, NETHERLANDS, ⁵UMC Groningen, Groningen, NETHERLANDS, ⁶AvL, Amsterdam, NETHERLANDS, ⁷UMC Utrecht, Utrecht, NETHERLANDS, ⁸Radboud UMC, Nijmegen, NETHERLANDS, ⁹Maastricht UMC, Maastricht, NETHERLANDS, ¹⁰Antonius Ziekenhuis, Nieuwegein, NETHERLANDS.

EP-0536

Head-to-Head Radiomics Comparison between ¹⁸F-PSMA and ¹⁸F-FDG PET/CT Imaging in Desmoid Tumor

C. D. Ramos¹, T. L. Reis, M. E. S. Takahashi, B. J. Amorim, M. C. L. Lima, C. A. Souza, J. B. C. Carvalheira;
University of Campinas, Campinas, BRAZIL.

EP-0537

Baseline Intelligence: Predicting Treatment Response in Esophageal Cancer via Machine Learning on PET/CT

D. Khan¹, S. Sagar, N. Kundu, J. Krishna P., A. Tilak, L. Goriparti, A. Roy, A. Mahalik, S. K V, J. Pathak, R. Kumar;
AIIMS Delhi, Delhi, INDIA.

EP-0538

^{99m}Tc-PSMA SPECT/CT in the detection of metastatic lesions in renal cell carcinoma

Y. Sánchez Vera¹, J. González Díaz;
Centro Médico Nacional Siglo XXI, IMSS, Mexico, MEXICO.

EP-0539

Implementing Gallium - 68 FAPI PET/CT in Kenya: Initial experience in a tertiary cancer centre.

N. Harish^{1,2}, K. Kallur¹, D. Muriuki¹, H. Ryatt¹, R. Prashanth¹, K. Rajkumar¹, T. Harsha¹, J. Kariuki¹;
¹HCG CCK Cancer Centre, Nairobi, KENYA, ²Kenyatta University Teaching Referral and Research Hospital, Nairobi, KENYA.

EP-0540

Organ-wise changes in ¹⁸F-AraG immunoPET uptake before and after ICI Therapy

T. Nobashi¹, Y. Shimizu, K. K. Miyake, R. Sakamoto, S. Yasumura, Y. Kitano, R. Nakamoto, H. Ajimizu, T. Nomizo, H. Yoshida, H. Ozasa, M. Nomura, C. Katada, M. Muto, Y. Nakamoto;
Kyoto University Hospital, Kyoto city, JAPAN.

EP-0541

Use of ¹⁸F-FDG PET/MR as an initial staging procedure for malignant tumors

Y. Xu¹;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0542

Evaluation of metastatic clear cell renal cell carcinoma: a head-to-head comparison of [¹⁸F] PSMA-1007 PET/CT and standard-of-care CT

D. Khodakova¹, A. Khalimon, V. Bobrov, A. Lokhova, G. Khamadeeva, M. Khodzhibekova, T. Lazutina, I. Pylova, A. Nikiforuk, A. Leontev;
P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EP-0543

Head to Head Comparison of F18 FDG with GA68 FAPI 2286 in Staging and Restaging Evaluation in Various Solid Malignancies

J. Bal¹, S. Jha², P. Dougal², K. Shanker², V. Semwal²;
¹Max Super Specialty Hospital, Delhi, INDIA, ²Max superspeciality hospital, Delhi, INDIA.

EP-0544

Head to head comparison of [⁶⁸Ga] FAPI PET/CT and [¹⁸F] FDG PET/CT in Urothelial carcinoma : A prospective study

H. Ng¹, A. Arya, M. Ora, S. Gambhir;
Sanjay Gandhi Postgraduate Institue of Medical Sciences, Lucknow, INDIA.

EP-0545

¹⁸F-FDG PET/CT in Suspected Paraneoplastic Syndromes: Clinical and Imaging Correlation

A. Mestre Fusco¹, S. Abouzian, D. A. López-Mora, L. Lozano-Murgas, J. C. Martín-Miramón, A. A. Rodríguez-Revuelto;
Parc Taulí Hospital Universitari, Sabadell, SPAIN.

EP-0546

Prospective Evaluation of ⁶⁸Ga-Trivehexin in Solid Tumors: A Pan-Cancer Study in Comparison with ¹⁸F-FDG PET/CT

L. Li¹, H. Wu, Z. Liu, C. Li, Y. He;
Department of Nuclear medicine, Zhongnan Hospital, Wuhan University, Wuhan, CHINA.

EP-0547

Serum vascular endothelial growth factor helps identify patients with clear cell renal cell carcinoma who benefit more from [68Ga]Ga-PSMA PET/CT

M. Zhang¹;
Xijing Hospital, the Fourth Military Medical University, Xi'an, CHINA.

EP-0548

The Impact of a Short-Time Fasting on Gastrointestinal Uptake in ^{99m}Tc-FAPI-46 Scintigraphy: Mitigating Interpretation Pitfalls

N. Raeisi¹, A. Saber Tanha, K. Aryana;
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-29

e-Poster Area

B: Imaging Clinical Studies -> B3 Other Oncological Clinical Study -> B31 Molecular image-guided interventions

EP-0549

Combination of Targeted Axillary Dissection (TAD) and Selective Sentinel Lymph Node Biopsy (SSNGB) in patients with metastatic axillary involvement prior to systemic treatment

M. García Aragón¹, A. Suazo Montero, B. Jaramillo López, F. Sebastian Palacid, M. González Soto, M. Alonso Rodríguez, M. Moral Cano, P. Suarez Mansilla, R. Ruano Pérez;
Hospital Universitario Clínico Valladolid, Valladolid, SPAIN.

EP-0550

Relevance of SPECT/CT in the combined technique of lymphoscintigraphy and axillary labeling with 125-I seeds in breast cancer with axillary response after neoadjuvant chemotherapy

M. García Aragón¹, B. Jaramillo López, A. Suazo Montero, C. Gamazo Laherran, F. Sebastian Palacid, M. González Soto, S. Cortes Pérez, M. Moral Cano, R. Ruano Pérez;
Hospital Universitario Clínico Valladolid, Valladolid, SPAIN.

EP-0551
Implementation and Outcomes of the ROLL Technique in Radioguided Surgery
Y. Delisau¹, M. Velasco-Nuño¹, S. Alfonso², A. Giménez², I. Pérez³, I. Casado³, J. Duch¹, M. Calls-Calahorra¹, P. Stefaneli¹, B. Serrallonga¹, D. Selva², G. Guzmán¹, V. Camacho¹, A. Flotats¹;
¹Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ²Radiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ³General Surgery Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

EP-0552
Radioguided Localization of Non-palpable Breast Lesions Using I-125 Radioactive Seeds: Initial 5 Months Experience
P. Paez Vargas, R. Salvador-Arthur, G. Martinez-Arias, M. Parra-Rina, A. L. Tardin-Cardoso, D. Nogueira-Souto, P. Razola-Alba, M. M. Delgado-Castro, L. Cáncer-Garza, T. Escalera-Temprado, A. Andres-Gracia;
 Hospital Clinico Universitario Lozano Blesa, Zaragoza, SPAIN.

EP-0553
Intraoperative Radiolabelling of Pulmonary Nodules Using Electromagnetic Navigation Bronchoscopy
L. León Ramírez¹, C. González Roiz², M. zapardiel¹, E. Fernández¹, C. Fraile¹, A. Berardinelli¹, P. Dauden¹, G. Cuesta¹, M. Vaillant¹, M. Cabrera Martin¹, S. Vidal-Sicart³;
¹Hospital Clínico San Carlos, Madrid, SPAIN, ²Hospital Puerta del Sur, Madrid, SPAIN, ³Hospital Clínic de Barcelona, Barcelona, SPAIN.

EP-0554
HPA Axis Activation Evaluated by ¹⁸F-FDG PETCT in Lung Cancer: From Clinical Discovery to Preclinical Validation
M. Liang^{1,2}, C. Cui¹, X. Li¹, J. Guo³, C. Yan^{3,2}, Z. Wu^{3,2};
¹Shanxi Medical University, Taiyuan, CHINA, ²Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Taiyuan, CHINA, ³Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA.

EP-0555
125I seeds implantation in malignant-suspected ¹⁸F-FDG PET/CT lymph nodes. Histopathological correlation.
E. Domínguez Polanco, J. Villa-Palacios, A. Piñeiro Donis, L. Cagua Ruiz, E. Triviño-Ibáñez, A. Salmerón Ruiz, N. Muñoz Pérez, C. Ramos-Font;
 Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0556
Safety and Diagnostic Yield of ¹⁸F-FDG PET/CT-Guided Biopsy in Solitary Pulmonary Nodule
D. Saraswat, P. Malik, R. Kumar, B. R. Mittal;
 Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA.

EP-0557
Characterisation of a Fluorescent Dye Library using a Dual-Labelled PSMA-617-based Tracer
P. Minges^{1,2,3}, L.-C. Domogalla^{1,2}, B. Thomas⁴, N. Steinacker^{1,2}, H. Müller⁴, M. Sulewska^{1,2}, A. Dietzel-Schaarschmidt⁵, P. Meyer^{1,2}, M. Eder^{1,2}, A.-C. Eder^{1,2};
¹University Medical Center Freiburg, Freiburg im Breisgau, GERMANY, ²German Cancer Consortium (DKTK), Freiburg

im Breisgau, GERMANY, ³University of Freiburg, Freiburg im Breisgau, GERMANY, ⁴XION GmbH, Berlin, GERMANY, ⁵Henke-Sass, Wolf GmbH, Tuttlingen, GERMANY.

EP-0558
Needle in the hotspot: Integrating SUVmax, Necrosis, and Technical Factors in PET-CT-Guided Biopsies
S. Shamim, B. Jain, Y. Khandelwal, S. Rastogi, P. Baberwal, P. Naranje, A. S. Bhalla, N. Kumar;
 AIIMS New Delhi, Delhi, INDIA.

EP-0559
Robotic arm-assisted, FDG-PET/CT guided percutaneous core-needle biopsies: Initial experience with inclusion of Pyrexia of unknown origin (PUO) patients.
B. Nayak, M. Tripathi, S. K. Velliangiri, M. Soneja, N. Nischal, G. Arora, V. Jain, S. Jain, A. Tyagi, A. Kakkar, N. A. Damle, A. Kumar, M. C. Sharma, A. Aravindh, C. Bal;
 All India Institute of Medical Sciences, New Delhi, New Delhi, INDIA.

EP-30

e-Poster Area

B: Imaging Clinical Studies -> B3 Other Oncological Clinical Study -> B32 Sentinel Node

EP-0560
Sentinel Lymph Node Biopsy Results in Head and Neck Tumors
E. Domínguez Polanco, A. Piñeiro Donis, J. Villa-Palacios, L. Cagua Ruiz, E. Triviño-Ibáñez, T. Balibrea-Zuñiga, S. Failde Balea, C. Ramos-Font;
 Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0561
Sentinel Lymph Node Biopsy as a Reliable Staging Tool Post-Neoadjuvant Chemotherapy in Breast Cancer- A Comparative Study from Northern India
P. Rawat, M. L. Narayan, F. Huda, M. Negi, N. Chowdhury;
 All India Institute of Medical Sciences, Rishikesh, INDIA.

EP-0562
Sentinel Lymph Node Biopsy in Head and Neck Melanoma Malignum: Our Institutional Experience
N. Kelemen¹, E. Kristófi¹, M. Piroška¹, P. Prekopp², K. Dános², E. Birtalan², G. Forgács², B. Baksa¹, T. Györke¹;
¹Semmelweis University, Medical Imaging Centre, Department of Nuclear Medicine, Budapest, HUNGARY, ²Semmelweis University, Department of Otorhinolaryngology, Head and Neck Surgery, Budapest, HUNGARY.

EP-0563
Hybrid SPECT/CT sentinel node mapping impact in early and post-neoadjuvant breast cancer: our experience
M. Mihaylova¹, E. Piperkova¹, L. Chavdarova¹, M. Zaharinov¹, V. Mitova²;
¹USHATO “Prof. Ivan Chernozemski”, Department of Nuclear medicine, Sofia, BULGARIA, ²USHATO “Prof. Ivan Chernozemski”, Department of Breast surgery, Sofia, BULGARIA.

EP-0564
Can SPECT/ CT Lymphoscintigraphy Influence Surgical Approach for Sentinel Lymph Node Biopsy in Head and Neck Melanoma
L. Radosavcev, M. Rajovic, M. Radulovic, B. Miljus, M. Rabrenovic, L. Kandolf;
 Military Medical Academy, Belgrade, SERBIA.

EP-0565
Standardised Protocol for Radioguided Surgery of Non-Palpable Breast Lesions Using Iodine-125 Seed: Experience at Our Centre
M. Ottino, P. Azpeitia Hernández, A. Martínez Lorca, O. Ajuria Illarramendi, M. Gutiérrez Guerrero, P. Paredes Rodríguez, T. Navarro Martínez, U. Vera Schmülling, I. Hernández Pérez, A. Torres Consiglieri, E. Pérez de los Ríos, M. Orduña Diez;
 Hospital Universitario Ramón y Cajal, Madrid, SPAIN.

EP-0566
Sentinel Node Biopsy in Laryngeal Cancer: A Systematic Review and Meta-Analysis
P. Sahafi¹, R. Sadeghi¹, E. Askari¹, A. Sahebkar¹, M. Ghahraman¹, V. Dabbagh¹, S. Harsini²;
¹Ghaem Hospital, Mashhad university of medical science, mashhad, IRAN, ISLAMIC REPUBLIC OF, ²BC Cancer Research Institute, Vancouver, BC, CANADA.

EP-0567
Accuracy of sentinel node mapping in Marjolin ulcer: Comparison of three different injection techniques
P. Sahafi, R. Sadeghi, V. Dabbagh;
 Ghaem Hospital, Mashhad University of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0568
Ex Vivo Sentinel Lymph Node Mapping in Colorectal Cancer Using [99mTc-HMPAO] Patent Blue Liposomes: A Hybrid Radiotracer/Dye Approach
P. Sahafi, H. Abbasian, K. Sadri, R. Sadeghi;
 Ghaem Hospital, Mashhad University of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0569
Tc-99m-nanocolloid scintigraphy in sentinel lymph node detection in patients with a history of conservative resection and prior lymph node biopsy.
A. Velidaki, S. Episkopopoulou, I. Sevaslidou, I. Vagios, N. Prosotsianiotis, E. Dagrakis, A. Kolindou;
 Laiko General Hospital of Athens, Athens, GREECE.

EP-0570
Feasibility of Sentinel Lymph Node Lymphoscintigraphy in Cutaneous Head and Neck Squamous Cell Carcinoma
P. Sahafi, A. Aghaee, K. Sadri, E. Soltani, E. Hasanzadeh Haddad, B. Rasoulilian, R. Sadeghi;
 Ghaem Hospital, Mashhad University of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-31

e-Poster Area

B: Imaging Clinical Studies -> B3 Other Oncological Clinical Study -> B33 External Radiotherapy Planning

EP-0571
Added value of ¹⁸FDG PET-CT in modern radiotherapy planning for Hodgkin Lymphoma: A Dosimetric Comparison
M. Ben Nasr, L. Zaabar, S. Yahyaoui, E. Zaidi, A. Mhiri;
 Salah Azaiez Institute of Tunis, Tunis, TUNISIA.

EP-32

e-Poster Area

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B41 Perfusion

EP-0572
Upright and Supine artefact locations in Myocardial Perfusion Imaging using a cardiac-dedicated CZT gamma camera
A. Carradus^{1,2}, M. Ulyatt¹, K. Jones^{1,2}, C. Paterson^{1,2}, J. Robinson^{1,2}, A. Laird¹, R. McDade¹, S. Han^{1,3};
¹DCPB, NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM, ²College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UNITED KINGDOM, ³School of Infection & Immunity, University of Glasgow, Glasgow, UNITED KINGDOM.

EP-0573
Myocardial Blood Flow and Ejection Fraction Measurement in Rb82-PET/CT shows high inter-observer reliability
S. Stolte, H. Geiger, O. Maas, F. Forrer;
 Kantonsspital St Gallen, St Gallen, SWITZERLAND.

EP-0574
Myocardial Prone Imaging In The SPECT/CT Era - The Need Is Still There: When CT-Attenuation Correction Is Not Enough
C. Fragkaki¹, S. Maragkoudakis², G. L. Lilikaki², A. T. Archontaki³;
¹Nuclear Medicine Department, Athens General Anti-Cancer/Oncology Hospital “Agios Savvas”, Athens, GREECE, ²Cardiology Department, Chania General Hospital “St. George”, Chania, GREECE, ³Nuclear Medicine Department, Chania General Hospital “St. George”, Chania, GREECE.

EP-0575
Analysis of factors affecting persistent perfusion defects in patients with pulmonary embolism
S. Niu¹, J. Cao², H. Liu¹, J. Cao³;
¹First Hospital of Shanxi Medical University, Taiyuan, CHINA, ²First Hospital of Shan Xi Medical University, Taiyuan, Shanxi, CHINA, ³First hospital of Shan Xi medical university, Taiyuan, Shanxi, CHINA.

EP-0576
 Dual-position Myocardial Perfusion Imaging: reducing the number of rest scans performed while increasing reporter confidence

M. Ulyatt¹, K. Jones^{1,2}, A. Carradus^{1,2}, J. Robinson^{1,2}, A. Laird¹, S. Han^{1,2}, C. Paterson^{1,2};

¹Department of Clinical Physics and Bioengineering, NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM, ²College of Medical, Veterinary and Life Science, University of Glasgow, Glasgow, UNITED KINGDOM.

EP-0577
 Assessment of Reversible Ischemia and Left Ventricular Function in Relation to SCORE2 Risk, COVID 19 History, and Vaccination: A Retrospective MPS Study

S. Demirtas Senlik¹, B. Bozca¹, A. Celik Arslan¹, S. Gulbahar Ates², O. Ozmen¹;

¹Ankara Etlik City Hospital, Ankara, TÜRKIYE, ²Gazi University Hospital, Ankara, TÜRKIYE.

EP-0578
 Prognostic Impact of Reverse Redistribution in Myocardial Perfusion Imaging, particularly in non-obstructive CAD

W. Yu, Y. Wang, X. Su;
 The Third Affiliated Hospital of Soochow University, Changzhou, CHINA.

EP-0579
 GATED-SPECT-Based Nomogram for Early Prediction of Major Cardiac Events in Ischemic Heart Disease

R. Zambrano Infantino, J. F. Piñerúa-Gonsálvez, B. M. Jaramillo López, F. Sebastian Palacid, Á. R. Suazo Montero, N. Álvarez Mena, M. Alonso-Rodríguez, R. Ruano-Pérez;
 Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EP-0580
 Prognostic Significance of Transient Ischemic Dilatation with Adenosine 99mTc Sestamibi SPECT/CT in Diabetic Patients with Normal Myocardial Perfusion

M. Juweid;
 University of Jordan, Amman, JORDAN.

EP-0581
 Prevalence of Ischemia with Non Obstructive Coronary Artery disease (INOCA) in patients with positive myocardial perfusion SPECT.

A. Manrique¹, M. Esnault¹, N. Coudrais¹, N. Catherine¹, P. Richard², R. Vincent¹, D. Agostini¹;
¹CHU de Caen, Caen, FRANCE, ²Hopital Privé Saint Martin, Caen, FRANCE.

EP-0582
 Change in myocardial perfusion does not correlate to change in peak oxygen uptake after coronary revascularization - a positron emission tomography study

A. Székely¹, S. Akil Engblom¹, H. Mosén¹, K. Steding-Ehrenborg¹, C. Hindorf², F. Hedeer¹, H. Arheden¹, H. Engblom¹;
¹Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, SWEDEN, ²Department of Medical Radiation Physics, Lund University, Lund, SWEDEN.

EP-0583
 Comparison of LVEF derived using four cardiac softwares on CZT cardiac camera and 2D-Echocardiography

J. Krishna P., D. Khan, S. Sagar, L. Goriparti, R. Wakankar, C. Patel, B. Chandra, P. Gupta, A. Roy, S. Yadav, S. Agstam, N. Parakh;
 All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0584
 Evaluation of Myocardial Perfusion Imaging Using AUC Guidelines: Adherence and Diagnostic Yield at a High-Volume Tertiary Care Center in Central India.

B. Vamshi Naik, M. Ravina, S. Singh, S. Raju, S. Thakur;
 All India Institute of Medical Sciences, Raipur, INDIA.

EP-0585
 Feasibility of functional analysis using myocardial perfusion SPECT/CT with a novel multifocal collimator, retrospective gating, and integrated corrections

S. Watanabe¹, K. Nakajima¹, T. Shibutani², S. Yoshida³, M. Onoguchi², S. Kinuya¹, F. Massanes⁴, T. Shimizu⁴, A. H. Vija⁴;
¹Department of Nuclear Medicine, Kanazawa University, Kanazawa, JAPAN, ²Department of Quantum Medical Technology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, JAPAN, ³Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, JAPAN, ⁴Molecular Imaging, Siemens Medical Solutions USA, Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA.

EP-0586
 Prediction of Cardiac Events in Patients with Diabetes Using Stress Myocardial Blood Flow and Coronary Flow Reserve

M. Havel^{1,2}, M. Kaminek^{1,3}, L. Quinn¹, L. Henzlova¹, V. Icova¹, G. Havlova²;
¹Department of Nuclear Medicine, University Hospital, Palacky University, Olomouc, CZECH REPUBLIC, ²University of Ostrava and University Hospital Ostrava, Department of Nuclear Medicine, Ostrava, CZECH REPUBLIC, ³International Clinical Research Center and Department of Internal Medicine/Cardiology, St. Anne's University Hospital, Faculty of Medicine, Masaryk University, Brno, CZECH REPUBLIC.

EP-0587
 The Minimum Scan Time for Gated Myocardial Perfusion Imaging Using a Dedicated Ultrafast Solid-state Cardiac Camera

D. Zhao, S. Sun, T. Wang, J. Song, X. Bi, T. Ye, Y. Wang, X. Xu, S. Yao, J. Liu, R. Wang;
 Chinese PLA General Hospital, Beijing, CHINA.

EP-0588
 Comparison of myocardial perfusion imaging and myocardial flow reserve using cadmium-zinc-telluride camera for the diagnosis of coronary artery disease

T. Niimi, K. Hirayama;
 Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, JAPAN.

EP-0589
 Evaluation and mitigation of false positives in inferior myocardial wall with CZT camera using complementary stress myocardial perfusion with hybrid Anger-type camera

F. Vauchot, T. Paunet, J. Dubois;
 CHU Gui de Chauliac, Montpellier, FRANCE.

EP-0590
 Post-PCI patients with persistent chest discomfort lacking immediate post-procedural caIMR-derived CMD and subsequent MPI-detected residual ischemia exhibited optimal prognosis

W. Yu, Y. Wang;
 The Third Affiliated Hospital of Soochow University, Changzhou, CHINA.

EP-0591
 Long-term prognostic value in nuclear cardiology: Expert scoring combined with automated measurements vs. angiographic score

G. Angelidis, S. Giannakou, V. Valotassiou, E. Panagiotidis, I. Tsougos, C. Tzavara, K. Sakellariou, D. Psimadas, E. Theodorou, C. Ziangas, J. Skoularigis, F. Triposkiadis, P. Georgoulas;
 University of Thessaly, Larissa, GREECE.

EP-0593
 Early Detection of Cardiac Involvement in Lipid Storage Myopathy:The Superior Role of Myocardial Perfusion Imaging

W. Zhengjie, L. Jia, T. Fangfang, Z. Xiaoyang, L. Mengdan, P. Hua;
 The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-0594
 Triglyceride is associated with coronary microvascular dysfunction in patients with obstructive coronary artery disease

Y. Wang, Y. Lu, X. Zhang;
 Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.

EP-0595
 The prognosis value of coronary microvascular dysfunction in chronic coronary syndrome patients compared with global coronary flow reserve

Y. Wang, Y. Zhao, X. Zhang;
 Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.

EP-0596
 Decrease in Ejection Fraction between Rest and Stress on Myocardial Perfusion Imaging Studies: Frequency and Potential Clinical Significance

F. Naeem, V. Pant, S. Salam, A. Chamnan, L. Yeung, S. Vinjamuri;
 Royal Liverpool University Hospital, Liverpool, UNITED KINGDOM.

EP-0597
 Myocardial Perfusion Scintigraphy with Regadenoson and Correlation with the Findings of Coronary Angiography

M. Ilic Tomas^{1,2}, K. Žepina², P. Stroglio², L. Fischer^{1,2}, I. Iskra^{1,2}, T. Bogović Crnčić^{1,1};
¹Clinical Hospital Centre Rijeka, Rijeka, CROATIA, ²University of Rijeka, Faculty of Medicine, Rijeka, CROATIA.

EP-0598
 Head-to-head comparison of Left Ventricular Ejection Fraction and Volumes from 3D-ring CZT and dedicated Cardiac CZT SPECT Cameras

V. Roelants¹, F. Dupont², A. Oulad Bouchetta², N. Laajimi², R. Lhomme², M. Hesse²;

¹Cliniques universitaires Saint-Luc, Brussels, BELGIUM, ²Cliniques universitaires Saint-Luc - Université Catholique de Louvain, Brussels, BELGIUM.

EP-0599
 Can Myocardial Perfusion Imaging Predict Heart Rhythm Disturbances After Coronary Revascularization?

L. Sobral Torres, R. Albergueiro, P. Dias, P. Soeiro;
 Unidade Local de Saúde São João, Porto, PORTUGAL.

EP-33

e-Poster Area

B: Imaging Clinical Studies -> B4
 Cardiovascular Imaging Clinical Study -> B42
 Metabolism and Innervation

EP-0600
 Nothing Else Matters? — The Predominant Association of BHB and Myocardial Glucose Metabolism Suppression

T. Korhonen¹, A. Valve-Dietz¹, T. Laitinen¹, S. Hartikainen²;
¹University of Eastern Finland, Kuopio, FINLAND, ²Kuopio University Hospital, Kuopio, FINLAND.

EP-0601
 Prognostic Value of ¹⁸F-FDG PET Myocardial Ischemic Memory Imaging in Patients with Non-Obstructive Coronary Artery Disease

F. Zhang, X. Yang, Y. Wang;
 the Third Affiliated Hospital of Soochow University, Changzhou, CHINA.

EP-0602
 Myocardial [¹⁸F]FDG uptake suppression after six hours fasting predicts 3-year overall survival in men

S. Hartikainen¹, S. Sillanmäki², M. Hedman², T. Tompuri³, T. M. Laitinen¹, T. P. Laitinen¹;
¹Kuopio University Hospital, Kuopio, FINLAND, ²University of Eastern Finland, Kuopio, FINLAND, ³North Karelia Central Hospital, Joensuu, FINLAND.

EP-0603
 A Prospective Clinical Study on the Diagnostic Value of ¹⁸F-FDG PET Ischemic Memory Imaging for Unstable Angina in Diabetic and Non-Diabetic Patients

f. Zhang, X. Yang, Y. Wang;
 the Third Affiliated Hospital of Soochow University, Changzhou, CHINA.

EP-0604
 Evaluation of Oral Versus Intravenous Glucose Loading Protocols on Image Quality in Cardiac FDG PET: A Comparative Qualitative and Quantitative Study

M. Calderon Tobar, A. Gümüş, K. Çağlar, F. Yılmaz, H. Önner;
 Selcuk University Faculty of Medicine Department of Nuclear Medicine, Konya, TÜRKIYE.

EP-0605

The Impact of Preoperative Phase Analysis, Hibernated Myocardium Percentage, and Inflammatory Parameters Derived from gMPS, F-18 FDG PET/CT, and Biochemistry on Postoperative Ejection Fraction and Wall Motion Abnormalities in Patients Undergoing Coronary Artery Bypass Grafting

H. Kalkan, A. Kılıçaslan, Ö. Bayrakcı, M. Serdengeçti, H. Şan; Ankara Bilkent City Hospital, Ankara, TÜRKIYE.

EP-0606

Optimized Fast Track Protocol: Enhancing ¹⁸F-FDG PET Myocardial Viability Imaging Quality While Minimizing Patient Preparation Time in Diabetic CAD Patients

A. Mandal, S. Taywade, A. K Majeed, R. Kumar; AIIMS Jodhpur, Jodhpur, INDIA.

EP-0607

The heart-to-mediastinum ratio of [¹²³I]-mIBG myocardial scintigraphy: planar versus reprojected planar images

J. Hagerman, S. Akil Engblom, F. Hedeer; Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, SWEDEN.

EP-0608

Myocardial [18F]FDG Uptake in Lymphoma Patients Undergoing Anthracycline-Based Chemotherapy: Association with Cumulative Doxorubicin Dose and Patient Characteristics

M. Kalnina^{1,2}, A. Nikolajevs^{3,4}, A. Vikentjeva^{3,4}, E. Vagalis^{3,4}, J. Perevozckikova⁴; ¹ARS Nuclear Medicine Clinic, Riga, LATVIA, ²University of Latvia, Riga, LATVIA, ³Riga East University Hospital, Riga, Latvia, ⁴Riga Stradins University, Riga, LATVIA.

EP-34

e-Poster Area

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B43 Heart Failure (including Sarcoidosis and Amyloidosis)

EP-0609

Stacking Ensemble Learning-based Models Enabling Accurate Diagnosis of Cardiac Amyloidosis using SPECT/CT:an International and Multicentre Study

Q. Mo¹, J. Cui², S. Jia³, Y. Zhang², Y. Xiao⁴, C. Liu⁴, C. Zhou¹, C. P. Spielvogel⁵, R. Calabretta⁵, W. Zhou⁶, K. Cao¹, M. Hacker⁵, X. Li⁵, M. Zhao¹; ¹Third Xiangya Hospital,Central South University, Changsha, CHINA, ²Fuwai Central China Cardiovascular Hospital, Zhengzhou, CHINA, ³Siemens Healthineers Ltd, Shanghai, CHINA, ⁴Xiangya Hospital,Central South University, Changsha, CHINA, ⁵Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, ⁶Michigan Technological University, Houghton, MI, UNITED STATES OF AMERICA.

EP-0610

Application of Gated Myocardial Perfusion Imaging in Evaluating Coronary Heart Disease-Related Heart Failure with Preserved Ejection Fraction

X. Shen¹, Z. Wang¹, H. Pang¹, C. Chen², X. Li², Z. Yao²; ¹The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA, ²Beijing Hospital, Beijing, CHINA.

EP-0611

Establishment of optimal quantitative thresholds using [^{99m}Tc]Tc-DPD SPECT/CT for the diagnosis of ATTR cardiac amyloidosis.

M. Díez¹, A. Palomar-Muñoz¹, M. Marusso Fizzani¹, O. Hernández Cristancho¹, M. Pizzi², A. Roque Pérez³, D. Sánchez-Artuñedo⁴, S. Aguadé-Bruix¹, C. Gámez-Cenzano¹; ¹Nuclear Medicine Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, SPAIN, ²Cardiology Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, SPAIN, ³Radiology Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, SPAIN, ⁴Physics and Radiation Protection Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, SPAIN.

EP-0612

Relationship between cardiac innervation and heart failure in patients with TTR amyloidosis: Evidence from gated SPECT with ¹²³I-MIBG and ^{99m}Tc-DPD

F. Sebastián Palacid, N. Álvarez Mena, M. García Aragón, R. C. Zambrano Infantino, B. M. Jaramillo López, Á. R. Suazo Montero, M. Alonso Rodríguez, B. Pérez López, R. Ruano Pérez; Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

EP-0613

P(ATTR)ONUS: Validation of a new classification system for cardiac TTR amyloidosis using ^{99m}Tc-DPD gated SPECT.

F. Sebastián Palacid, N. Álvarez Mena, B. M. Jaramillo López, R. C. Zambrano Infantino, M. García Aragón, Á. R. Suazo Montero, C. Gamazo Laherrán, M. J. González Soto, R. Ruano Pérez; Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

EP-0614

Prognostic Value of [^{99m}Tc]Tc-DPD Quantitative SPECT/CT in Patients with suspected Amyloid Transthyretin-Related Cardiomyopathy

F. Aghapour Zangeneh¹, N. Gözlügöl¹, A. Rominger¹, C. Gräni², F. Caobelli¹; ¹Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND, ²Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

EP-0616

A Prospective Pilot Study for Prognosis of CRT Super Response Using Electro-Mechanical Dyssynchrony Assessment in Patients with Strauss Left Bundle Branch Block Criteria

T. Atabekov, A. Smorgon, A. Mishkina, S. Krivolapov, S. Sazonova, M. Khlynin, R. Batalov, S. Popov; Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EP-0617

A Study on Risk Stratification of Heart Failure Severity Through the Evaluation of Mitochondrial Dysfunction in Patients with Cardiac Resynchronization Therapy Indications

T. Atabekov, V. Korepanov, A. Mishkina, S. Sazonova, S. Afanasiev, R. Batalov, S. Popov; Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EP-0618

Assessment of Cardiac Amyloidosis by Scintigraphy and Cardiac Magnetic Resonance Imaging: Quantitative Correlation and Interobserver Reproducibility

J. Díaz Moreno¹, I. Sánchez-Rodríguez¹, P. Notta-González¹, M. Cortés-Romera¹, A. Bagán-Trejo¹, E. Claver-Garrido², C. Díez-López², S. Yun-Viladomat³, F. De Frutos-Seminario², L. Herrador-Galindo², R. Ramos-Polo², A. Rodríguez-Gasén¹, J. Martín-Marcuart¹, M. Pudis¹, M. Perlaza-Jiménez¹, A. Fritsch-Medina¹, M. Tormo-Ratera¹, B. Hervás-Sanz¹, M. Zamorano-Rivas¹, A. Dacosta-Escobar¹, C. García-Alcober⁴, L. Gràcia-Sánchez¹; ¹Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, Barcelona, SPAIN, ²Cardiology Department, Bellvitge University Hospital-IDIBELL, Barcelona, SPAIN, ³Internal Medicine Department, Bellvitge University Hospital-IDIBELL, Barcelona, SPAIN, ⁴Radiopharmacy Department, Bellvitge University Hospital-IDIBELL, Barcelona, SPAIN.

EP-35

e-Poster Area

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B44 Other Cardiovascular Imaging (including Plaque)

EP-0619

¹⁸F-FAPI PET/CT in Chronic Liver Disease: Myocardial Fibroblast Activation and Its Correlates

Y. Wang, Y. Wang; The Third Affiliated Hospital of Soochow University, Changzhou, CHINA.

EP-0621

^{99m}Tc-FAPI SPECT/CT for Evaluation of Myocardial Fibrosis and Cardiac Function in Valvular Heart Disease

Y. Zhang, W. Chen; Department of Nuclear Medicine, Fuzhou University Affiliated Provincial Hospital, Fuzhou, CHINA.

EP-0622

Predictive Value of Coronary Sodium ¹⁸F-Fluoride Activity for Perioperative Myocardial Infarction post-CABG in Patients with a History of Previous Myocardial Infarction Multiple Coronary Artery Disease

X. Xu¹, Y. Zhao¹, B. Hu¹, M. Gao², H. Li², X. Zhang¹; ¹Laboratory for Molecular Imaging, Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical

University, Beijing, CHINA, ²Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.

EP-0623

Stratification of Non-Thromboembolic Pulmonary Hypertension by V/Q SPECT/CT Patterns: Hemodynamic and Radiologic Correlates

Z. Zhang, Z. Wang, H. Pang; The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-0624

Validating Rubidium-82 for LVEF Quantification: A Comparative Study with 3D Echocardiography

M. Nielsen^{1,2}, J. E. Larsson¹, N. Tietgen¹, L. L. Duchstein¹, P. G. Joergensen³, B. Kristensen¹, B. Zerahn¹, L. T. Jensen^{2,1}; ¹Dept. of Nuclear Medicine, Copenhagen University Hospital – Herlev and Gentofte, Herlev, DENMARK, ²Dept. of Clinical Medicine, University of Copenhagen, Copenhagen, DENMARK, ³Dept. of Cardiology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, DENMARK.

EP-0625

Combined PET and multiparametric MRI Radiomics with Machine Learning for Differentiating Symptomatic from Asymptomatic Carotid Plaques

C. Zheng¹, R. Qin¹, Z. Liu², Y. Yang³, J. Lu¹; ¹Xuanwu Hospital, Capital Medical University, Beijing, CHINA, ²Central Research Institute, United Imaging Healthcare, Shanghai, CHINA, ³Beijing United Imaging Healthcare, Beijing, CHINA.

EP-0626

Visualization of the inflammation-fibrosis communication mechanism of cardiovascular remodeling in pulmonary hypertension

B. Chen, M. Yang; Beijing Chao-Yang Hospital, Capital Medical University, Beijing, CHINA.

EP-0627

Atherosclerosis Detection in the Abdominal Aorta and Iliac Arteries Using AI Segmentation of 18F-NaF and ¹⁸F-FDG PET/CT Scans

O. Fanta^{1,2}, W. Lee^{1,3}, S. Patil¹, D. Patel¹, T. Werner¹, P. F. Høilund-Carlsen⁴, A. Alavi¹; ¹University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, ²Charles University, Prague, CZECH REPUBLIC, ³Drexel University College of Medicine, Philadelphia, PA, UNITED STATES OF AMERICA, ⁴Odense University Hospital, Odense, DENMARK.

EP-0628

Imaging of Acute Aortic Dissection and Intramural Hematoma by 18F-AIR-NOTA-FAPI PET/CT

Y. Lu, X. Zhang; Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.

EP-0629

Predicting Reverse Remodeling Following Valve Replacement in Patients with Valvular Heart Disease: A Longitudinal ^{99m}Tc-FAPISPECT/CT Imaging Study

K. Wang, Y. Gu, K. Han, C. Yan, W. Fang, L. Wang; Chinese Academy of Medical Sciences & Peking Union Medical College, Fuwai Hospital, Beijing, CHINA.

EP-0630
The enhancement of the sensitivity of ¹⁸F-FAPI-74 PET visualization for atherosclerosis based on Q.Clear image reconstruction.
J. Song, Y. Hong, W. Liu, L. Li, Q. Wu;
First Hospital of Shanxi Medical University, Shanxi, CHINA.

EP-0631
¹⁸F-FDG-PET/CT for Diagnosing Infective Endocarditis Within the First Few Months Following Cardiac Prosthesis Implantation
D. Ferraro^{1,2}, B. G. Padilha¹, R. A. de Camargo^{3,4}, C. F. Togni¹, L. F. T. Gonçalves¹, T. B. Teixeira¹, I. R. Brigo¹, D. A. M. Santos⁵, M. C. P. Giorgi¹, R. A. Kitamikado¹, L. T. Hyppolito¹, M. R. Paixão¹, T. M. V. Strabelli¹, A. J. Mansur¹, F. Tarasoutchi¹, R. F. Souza⁶, D. M. Gualandro¹, J. Soares Jr¹, R. F. Siciliano¹;
¹Heart Institute of the Clinics Hospital of the Medical Faculty of the University of Sao Paulo, Sao Paulo, BRAZIL, ²Hospital Israelita Albert Einstein, Sao Paulo, BRAZIL, ³Hospital Aliança Star - Rede D’Or São Luiz, Salvador, BRAZIL, ⁴Heart Institute of the Clinics Hospital of the Medical Faculty of the University of Sao Paulo, São Paulo, BRAZIL, ⁵Cancer Institute of the Clinics Hospital of the Medical Faculty of the University of Sao Paulo, Sao Paulo, BRAZIL, ⁶School of Economics, Business Administration and Accounting at Ribeirão Preto, Ribeirao Preto, BRAZIL.

EP-0632
Topographic Mismatch Between Inflammation Assessed by PET/CT and Topographic Localization of Atheroma Plaque Using Morphological Methods in Asymptomatic Carotid Artery Disease
A. Fernández León¹, M. Velasco-Nuño¹, M. Guasch-Jimenez², A. Lozano³, J. Fite-Matamoros⁴, M. Calls¹, M. Tecame³, M. Lloret-Cano⁴, A. Margall-Rodriguez², M. Gaspar-Sardon², J. Gubern¹, A. Flotats¹, P. Camps-Renom²;
¹Nuclear Medicine Department. Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ²Stroke Unit. Department of Neurology. Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ³Radiology Department. Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ⁴Vascular Surgery Department. Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

EP-0633
Diagnostic Value of ¹⁸F-FDG PET/CT in Infective Endocarditis
F. Gur¹, Ö. V. Topuz², B. E. Akkaş²;
¹Başakşehir Çam ve Sakura City Hospital, İstanbul, TÜRKIYE, ²Sağlık Bilimleri Üniversitesi, Başakşehir Çam ve Sakura Şehir Hastanesi, Nükleer Tıp Kliniği, İstanbul, TÜRKIYE.

EP-0634
The evaluation of splenic switch-off on Ammonia PET in patients with hemodialysis and renal transplantation
A. Yamamoto, M. Nagao, A. Inoue, R. Imakado, R. Nakao, Y. Maekawa, Y. Matsuo, A. Sakai, M. Momose, J. Yamaguchi, S. Sakai;
Tokyo Women’s Medical University Hospital, Tokyo, JAPAN.

EP-0635
Abnormal cardiac accumulation on FDG PET due to chemotherapy for breast cancer
Y. Izoë¹, M. Nagao², H. Tsukada², S. Watanabe², Y. Maekawa², A. Yamamoto², Y. Satoh³, H. Saya¹, S. Akashi-Tanaka², S. Sakai²;
¹Fujita Health University, Toyoake, JAPAN, ²Tokyo Women’s Medical University, Shinjuku-ku, JAPAN, ³Fujita Medical Innovation Center Tokyo, Ota-ku, JAPAN.

EP-36
e-Poster Area
B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B51 Neurodegeneration

EP-0637
[¹⁸F]FDG PET Outperforms MRI in Detecting Early Neurodegenerative Changes Linked to Neurofibrillary Tangle Pathology: An Imaging-Pathology Correlation Study
O. Vourkas, L. Zhang, A. Rabano, P. Sanchez-Juan, M. Grothe, J. Silva Rodriguez;
CIEN Foundation, Reina Sofia Alzheimer Center, ISCIII, Madrid, SPAIN.

EP-0638
Predicting Amyloid PET Positivity in Alzheimer’s Disease using ¹⁸F-Fluorodeoxyglucose PET and Explainable Artificial Intelligence
Ü. Akdemir¹, A. Öter², E. Balci¹, S. Sağiroğlu³, L. Ö. Atay¹;
¹Gazi University Medical Faculty, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Gazi University Faculty of Technology, Department of Energy Systems Engineering, Ankara, TÜRKIYE, ³Gazi University Faculty of Engineering, Department Of Computer Engineering, Ankara, TÜRKIYE.

EP-0639
Quantitative assessment of the evolution stages of Alzheimer’s disease in amyloid PET using an anatomical brain phantom
M. Pirozzi¹, E. Di Giorgio², A. Prinster³, A. Negro⁴, V. D’Agostino⁴, F. Squame², L. Mansi^{5,6}, B. Alfano⁷, M. Spadafora⁶, M. Quarantelli³;
¹Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, ITALY, ²Nuclear Medicine Unit, Ospedale del Mare, Naples, ITALY, ³Institute of Biostructures and Bioimaging, National Research Council, Naples, ITALY, ⁴Neuroradiology Unit, Ospedale del Mare, Naples, ITALY, ⁵CIRPS, Interuniversity Research Center for Sustainability, Rome, ITALY, ⁶Medicina Futura, Acerra, Naples, ITALY, ⁷Human Shape Technologies s.r.l, Naples, ITALY.

EP-0640
Quantification in the ¹⁸F fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) in prodromal dementia
Z. Koç¹, M. Arslan¹, P. Ozcan¹, A. Özge², H. Yanik³;
¹Mersin University Hospital Nuclear Medicine Dpt., Mersin, TÜRKIYE, ²Mersin University Neurology Dpt., Mersin, TÜRKIYE, ³Mersin University School of Applied Technology and Management, Information Systems and Technologies., Mersin, TÜRKIYE.

EP-0641
DaT-scanning on a CZT: distance is the enemy
V. Nuttens¹, D. Ooms¹, S. Vermeulen², M. Koole¹;
¹AZORG, Aalst, BELGIUM, ²AZORG Aalst, Aalst, BELGIUM.

EP-0642
Quantitative Study of Dopaminergic Neuron Integrity and MRI Relaxation Value Changes in Early-Onset versus Late-Onset Parkinson’s Disease Using PET/MR Imaging

J. Liu, R. Wang;
Department of Nuclear Medicine, The First Medical Center of Chinese PLA General Hospital, Beijing, CHINA.

EP-0643
Performance of ¹⁸F-SynVesT-1 versus ¹⁸F-FDG brain PET in differentiation of patients with cognitive decline
C. Carron¹, L. Degryse¹, L. Boeckxstaens¹, G. Vanderlinden¹, K. Nikkita², R. Vandenberghe¹, M. Vandenbulcke¹, K. Van Laere¹;
¹KU Leuven, Leuven, BELGIUM, ²Yale PET center, Yale, CT, UNITED STATES OF AMERICA.

EP-0644
A biological model combined individual tau-PET and FDG-PET molecular connectivity to predict disease progression for AD
L. Fu¹, Z. Zhou², T. Lu³, J. Gao¹, Y. Cheng³;
¹Department of Nuclear Medicine, China-Japan Friendship Hospital, Beijing, CHINA, ²Department of Neurology, China-Japan Friendship Hospital, Beijing, CHINA, ³School of information science, Beijing university of chemical technology, Beijing, CHINA.

EP-0645
Regional Centiloid Quantification of ¹⁸F-Florbetaben PET in a Multicenter Study Using Publicly Available Datasets.
C. Lin¹, L. Tang², C. Ko²;
¹Department of Nuclear Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, TAIWAN, ²Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, TAIWAN.

EP-0646
The Revealing of Aberrant Brain Metabolic Network Based on ¹⁸F-FDG PET in Patients with DLBCL
J. Wang, Q. Zhao, X. Ma, Y. Liu;
General Hospital of Ningxia Medical University, Ningxia Yinchuan, CHINA.

EP-0647
The Impact of APOE ε4 on Amyloid Deposition and Cerebral Blood Flow in Cognitively Normal Subjects using Dual-Phase ¹⁸F-Florbetaben PET Study
J. Kim¹, D. Kim², G. Kim¹, H. Yoon¹;
¹Ewha Womans University Mokdong Hospital, Seoul, KOREA, REPUBLIC OF, ²Research Institute, Neurophat Incorporation, Seoul, KOREA, REPUBLIC OF.

EP-0648
Statistical FDG PET Mapping and Quantitative MRI Volumetry of Limbic Age-Related TDP-43 Encephalopathy and Alzheimer Co-pathology
P. Ngam¹, Y. Anzai², S. Minoshima²;
¹National University Hospital Singapore, Singapore, SINGAPORE, ²University of Utah Hospital, Salt Lake City, UT, UNITED STATES OF AMERICA.

EP-0649
MRI-Informed Graph Learning on Amyloid PET Enhances Diagnosis and Staging of Alzheimer’s Disease
T. Sun¹, X. Chen¹, L. Chen², S. Wang¹, M. Wang²;
¹Chinese Academy of Sciences, Shenzhen, CHINA, ²Henan Provincial People’s Hospital, Zhengzhou, CHINA.

EP-0650
Multimodal topographic impairment in Parkinson’s disease
M. Wang¹, W. Han¹, Y. Jiao¹, Z. Lv¹, Y. Su¹, Y. Hu², Y. Yang³, C. Zhao¹, P. Fu¹;
¹Department of Nuclear Medicine, 1st Hospital of Harbin Medical University, Harbin, CHINA, ²Central Research Institute, United Imaging Healthcare, Shanghai, CHINA, ³Beijing United Imaging Research Institute of Intelligent Imaging, Beijing, CHINA.

EP-0651
Head-to-head comparison of the associations between imaging and plasma A-T-N biomarkers with synaptic density in Alzheimer’s disease
J. Wang;
Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA.

EP-0652
DTI-ALPS Index-assessed Glymphatic Dysfunction Mediates Alzheimer’s Cognitive Decline via Amyloid-β-dependent Pathways: Multimodal PET/MRI Study
Y. Zhang¹, G. Huang¹, J. Hao², L. Qi², J. Geng³, X. Li⁴, M. Xin¹, P. Yuan¹, Y. Wang¹, Q. Xu³, G. Wang³, G. Huang¹, J. Liu¹, C. Zhang¹;
¹Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ²United Imaging Healthcare, Shanghai, CHINA, ³Department of Neurology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ⁴Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

EP-0653
Utility of the Centiloid Scale in [¹⁸F]Flutemetamol PET/MRI: Correlation with Visual Assessment, Brain Morphology and Clinical Variables
L. Blanco-Verdejo¹, L. Rodríguez-Bel², M. Pudis², M. Suárez-Piñera², A. Jareno-Badenas³, F. Camba-Capitan⁴, M. Cos-Domingo³, G. Reynés-Llompart⁴, J. Díaz-Moreno², B. Hervás-Sanz², J. Gascón-Bayarri⁵, M. Cortés-Romera²;
¹Nuclear Medicine Department. Hospital Clínico Universitario de Valencia, Valencia, SPAIN, ²Nuclear Medicine Department. Hospital Universitario de Bellvitge, Barcelona, SPAIN, ³Neuroradiologist Department. Hospital Universitario de Bellvitge, Barcelona, SPAIN, ⁴Physics Department. Hospital Universitario de Bellvitge, Barcelona, SPAIN, ⁵Neurology Department. Hospital Universitario de Bellvitge, Barcelona, SPAIN.

EP-0654
Multimodal topographic properties of white matter functional segregation in Alzheimer’s disease: a simultaneous PET/MR study
Y. Jiao¹, M. Wang¹, Y. Hu², Y. Yang³, P. Fu¹;
¹Department of Nuclear Medicine, 1st Hospital of Harbin Medical University, Harbin, CHINA, ²Central Research Institute, United Imaging Healthcare Group Co., Ltd, Shanghai, CHINA, ³Beijing United Imaging Research Institute of Intelligent Imaging, Beijing, CHINA.

EP-0655

Evaluation of Amyloid PET Centiloid Scale by APOE4 Zygosity: Comparison among Non-Carriers, Heterozygotes, and Homozygotes

B. Choi¹, H.-C. Song²;

¹Department of Nuclear Medicine, Daegu Catholic University Hospital and Medical School, Daegu, KOREA, REPUBLIC OF, ²Department of Nuclear Medicine, Chonnam National University Hospital and Medical School, Gwangju, KOREA, REPUBLIC OF.

EP-0656

Dynamic ¹¹C-PIB PET evaluation of Cerebrospinal Fluid Flow in a population without cognitive impairment. Correlation with amyloid pathology in cerebrospinal fluid

J. Jiménez-Bonilla¹, S. López-García², M. De Arcocha-Torres¹, F. Gómez-De la Fuente¹, V. Mendi-Barcina¹, C. Lage², F. Martínez-Dubarbie², I. Martínez-Rodríguez¹, N. Martínez-Amador¹, A. Sánchez-Salmón¹, A. García-Ruiz¹, N. Carvalho-Duarte¹, M. Botanch-Domingo¹, L. Cabrera-Portillo¹, A. Clavilo-Umbarila¹, P. Andrade-Mejía¹, M. Fernández-Matarrubia², E. Rodríguez-Rodríguez², R. Quirce¹;

¹Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Research Group-IDIVAL. University of Cantabria, Santander, SPAIN, ²Neurology Service. Marqués de Valdecilla University Hospital, Santander, SPAIN.

EP-0657

Tau deposition is associated with white matter changes and mediates the effects of Aβ on white matter injury in Alzheimer’s disease

F. Jiao, Z. Wang, F. Tian, Z. Zhang, W. Li, K. Liao, H. Pang; Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-37

e-Poster Area

B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B52 Cognitive Impairment

EP-0658

Novel insights into cognitive network alterations in temporal lobe epilepsy: A [¹⁸F]SynVesT-1 PET study

L. Xiao¹, L. Feng¹, Y. Tang¹, S. Hu¹, K. Shi²;

¹Xiangya Hospital Central South University, Changsha, CHINA, ²University Hospital Bern, Bern, SWITZERLAND.

EP-0659

Spatiotemporal Cerebral Glucose Hypometabolism Progression Pattern in Alzheimer’s Disease

D. Seo¹, M. So¹, S. Seo¹, D. Kim², S. Lee³, M. Yun³;

¹Yonsei University College of Medicine, Seoul, Republic of Korea, Seoul, KOREA, REPUBLIC OF, ²Department of Artificial Intelligence, Yonsei University, Seoul, KOREA, REPUBLIC OF, ³Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0660

Coupling patterns of brain gray matter volume and FDG metabolism inpatients with impaired cognitive function: a multimodal imaging study

F. Tian, R. Wu, Z. Wang;

The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-0661

Predictive Value of Serum Biomarkers for Brain Amyloid Pathology in Patients with Mild Cognitive Impairment

Ü. Akdemir¹, Ö. Gülbahar², N. Canpunar², E. Balci¹, E. Erkoç Ataoğlu³, E. Saka⁴, L. Ö. Atay¹;

¹Gazi University Medical Faculty, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Gazi University Medical Faculty, Department of Medical Biochemistry, Ankara, TÜRKIYE, ³Gazi University Medical Faculty, Department of Neurology, Ankara, TÜRKIYE, ⁴Hacettepe University Medical Faculty, Department of Neurology, Ankara, TÜRKIYE.

EP-0662

¹⁸F-FDG PET Imaging Reveals GPR162-Mediated Hippocampal Glucose Metabolic Dysregulation in Aging and the Therapeutic Potential of BMMSCs

P. Li, T. Wang, Z. Yang, Z. Zhu, J. Quan, Y. Zhang, Y. Jiang, R. He, G. Zhu;

Department of Nuclear Medicine, The First Affiliated Hospital of Kunming Medical University, Kunming, CHINA.

EP-0663

Neurometabolic correlates of cognitive impairments in patients with meningioma

S. Goffinet, X. De Tiège, J. Bertels, F. Lefranc, O. De Witte, N. Sadeghi-Meibodi, H. Slama, P. Fery, A. Rovai, V. Wens, N. Trotta, G. Leurquin-Sterk; Université Libre de Bruxelles, Brussels, BELGIUM.

EP-0664

Periventricular White Matter Hyperintensities and Brain Metabolism Contribute to Cognitive Dysfunction in Amyloid-Negative Patients

M. So¹, S. Seo¹, S. Lee², H. Lim², Y. Yoon¹, D. Kim³, H. Han³, D. Seo¹, K. Choo⁴, Y. Jun³, S. Kang², D. Kim⁵, Y. Lee⁶, M. Yun²;

¹Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, ²Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, ³Department of Artificial Intelligence, Yonsei University, Seoul, KOREA, REPUBLIC OF, ⁴Department of Computer Science, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, ⁵Department of Nuclear Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, KOREA, REPUBLIC OF, ⁶Department of Neurology, Ilsan Paik Hospital, Inje University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0665

Exploring the Diagnostic Potential of ¹¹C-PiB PET Imaging in Primary Progressive Aphasia: A Preliminary Quantitative Analysis

I. Moretti¹, A. Capotosti¹, R. Moretti¹, L. Indovina^{1,2}, M. De Spirito^{1,2}, F. Cocciolillo³, D. Quaranta³, D. Di Giuda³, M. Calcagni^{3,4};

¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ²Università Cattolica del Sacro Cuore, Rome, ITALY, ³Dipartimento di Diagnostica per Immagini e Radioterapia Oncologica, UOC di Medicina Nucleare, Fondazione Policlinico Universitario Agostino Gemelli

IRCCS, Rome, ITALY, ⁴Dipartimento Universitario di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, ITALY.

EP-0666

A Deep Learning Model for Detecting Alzheimer’s Disease Using Structural MRI

Y. Zhang¹, F. Huang¹, J. Hao², L. Qi², J. Liu¹, C. Zhang¹;

¹Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ²United Imaging Healthcare, Shanghai, CHINA.

EP-0667

Predictive value of ¹⁸F-FDG PET/CT deep learning in radiomics for cancer-related cognitive impairment in patients with non-CNS DLBCL

J. Wang, Q. Zhao, Y. Dong, P. Ma, R. Wang;

General Hospital of Ningxia Medical University, Ningxia Yinchuan, CHINA.

EP-38

e-Poster Area

B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B53 Movement Disorders

EP-0668

Can [18F-FDG] PET imaging patterns determine the neuropathological substrate of Corticobasal Syndrome?

S. Alvarez, A. Mari, M. Casallas, S. Salcedo, G. Mera, E. Ardila, J. E. Orcajo, J. J. Ardila, I. Gomez, J. Alonso; Hospital General Universitario Gregorio Marañón, Madrid, SPAIN.

EP-0669

An Advanced Quantitative Analysis Approach in Dopaminergic SPECT Imaging: GÜDaTSPECT

E. Tuncay Ibis, E. Balci, Ü. Ö. Akdemir, L. Ö. Atay; Gazi University Faculty of Medicine, Ankara, TÜRKIYE.

EP-0670

Diagnosis of Parkinson Disease using ¹²³I-FP-CIT - how confident are we?

K. Ferreira^{1,2,3}, A. P. Robinson¹, K. M. Bradley⁴, D. R. McGowan^{2,3};

¹National Physical Laboratory, Teddington, UNITED KINGDOM, ²University of Oxford, Oxford, UNITED KINGDOM, ³Oxford University Hospitals NHS FT, Oxford, UNITED KINGDOM, ⁴Wales Research and Diagnostic PET Imaging Centre, Cardiff, Wales, UNITED KINGDOM.

EP-0671

The Mickey Mouse sign in 18F-FDOPA PET: significance and clinical usefulness in idiopathic Parkinson disease

J. Darcourt, M. Koulibaly, V. Comte, A. Schiazzza, C. Maurel, N. Sapin, O. Humbert; Centre Antoine Lacassagne, Nice, FRANCE.

EP-0672

Automated Quantitative [¹⁸F]FP-CIT PET/CT Analysis Without MRI for Distinguishing Parkinsonian Disorders

K. Park¹, J. Kim¹, H.-C. Song¹, B. Choi²;

¹Chonnam National University Medical School and Hospital, Gwangju, KOREA, REPUBLIC OF, ²Daegu Catholic University Medical Center, Daegu Catholic University School of Medicine, Daegu, KOREA, REPUBLIC OF.

EP-0673

Long-term ¹²³I-Ioflupane SPECT Follow-up in Asymptomatic Carriers of LRRK2-G2019S Mutation as Predictor of Parkinson Disease

I. Martínez-Rodríguez¹, A. Clavijo-Umbarila¹, P.

Andrade-Mejía¹, A. García-Ruiz¹, N. Carvalho-Duarte¹, L. Cabrera-Portillo¹, M. Botanch-Domingo¹, N. Martínez-Amador¹, F. Gómez-de la Fuente¹, A. Sánchez-Salmón¹, J. Jiménez-Bonilla¹, M. De Arcocha-Torres¹, V. Mendi-Barcina¹, M. Rivera-Sanchez², M. Sánchez-Pelaez², A. Sánchez Rodríguez³, J. Infante², R. Quirce¹;

¹Nuclear Medicine Department. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN, ²Neurology Department. Marqués de Valdecilla University Hospital. Neurodegeneratives Diseases Group (IDIVAL), Santander, SPAIN, ³Neurology Department. Hospital de Cabueñes, Gijón, SPAIN.

EP-0674

Distribution Patterns of ¹⁸FFlorzolotau PET and Midbrain Magnetic Resonance Parkinsonism Index in Patients with Progressive Supranuclear Palsy

M. Wang¹, X. Wei¹, J. Lu², R. Ling^{1,3}, J. Jiang³, L. Dong¹, X.

Yang¹, L. Wang¹, C. Zuo², J. Jiang¹; ¹Shanghai University, Shanghai, CHINA, ²PET center, Fudan University, Shanghai, CHINA, ³School of Medical Imaging, Shanghai University of Medicine & Health Science, Shanghai, CHINA.

EP-0675

Evaluation Of Executive Functions In Patients with Parkinsonism. Comparison Of Modified-Wisconsin Card Sorting Test With ¹²³I-Ioflupane Basal Ganglia SPECT Findings

D. Chattigkezou¹, K. Sakellariou², I. Sofianidis³, A. Diakakis¹, V. Siokas⁴, A. Provatas⁵, Z. Tsouris⁵, G. Angelidis², D. Psimadas², C. Ziogas², I. Tsougos⁶, P. Georgoulas², E. Dardiotis⁴, V. Valotassiou²;

¹Faculty of Medicine, University of Thessaly, Larissa, GREECE, ²Dpt of Nuclear Medicine, University Hospital of Larissa, Larissa, Greece, ³Aristotle University of Thessaloniki, Thessaloniki, GREECE, ⁴Neurology Dpt, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Larissa, GREECE, ⁵Neurology Dpt, University Hospital of Larissa, Larissa, GREECE, ⁶Dpt of Medical Physics, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Larissa, GREECE, ⁷Dpt of Nuclear Medicine, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Larissa, GREECE.

EP-39

e-Poster Area

B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B54 Neurotransmission and Receptors

EP-0676

Characterization of Major Psychiatric Disorders Using [¹¹C]K-2 PET Imaging of AMPA Receptors

M. Hatano¹, **W. Nakajima**¹, **H. Tani**², **H. Uchida**², **T. Miyazaki**¹, **T. Arisawa**¹, **Y. Takada**¹, **S. Tsugawa**¹, **H. Abe**¹, **A. Suda**³, **T. Asami**³, **A. Hishimoto**⁴, **N. Nagai**², **T. Koizumi**², **S. Nakajima**², **M. Jinzaki**⁵, **Y. Hirano**⁶, **R. Mitoma**⁶, **S. Tamura**⁶, **S. Baba**⁷, **O. Togao**⁷, **H. Kosaka**⁸, **H. Okazawa**⁹, **Y. Kimura**¹⁰, **M. Mimura**², **T. Takahashi**¹;

¹Department of Physiology, Yokohama City University Graduate School of Medicine, Yokohama, JAPAN, ²Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, JAPAN, ³Department of Psychiatry, Yokohama City University Graduate School of Medicine, Yokohama, JAPAN, ⁴Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, JAPAN, ⁵Department of Radiology, Keio University School of Medicine, Tokyo, JAPAN, ⁶Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, JAPAN, ⁷Department of Clinical Radiology, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, JAPAN, ⁸Department of Psychiatry, Faculty of Medical Sciences, University of Fukui, Fukui, JAPAN, ⁹Biomedical Imaging Research Center, University of Fukui, Fukui, JAPAN, ¹⁰Faculty of Informatics, Cyber Informatics Research Institute, Kindai University, Higashi-Osaka, JAPAN.

EP-40

e-Poster Area

B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B55 Other Neurological Imaging

EP-0677

Brain Connectivity Networks of Quantitative Kinetic Parameters from Dynamic ¹⁸F-FDG PET/CT Reveals Network-Level Differences in Surgical and Non-Surgical Epilepsy

Y. Duan¹, **Y. Ng**²;

¹The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, CHINA, ²United Imaging Healthcare Group Co., Ltd., Shanghai, CHINA.

EP-0678

Altered Glucose Metabolism in Default Mode Network and Prefrontal Circuit In Patients with Kallmann Syndrome

C. Zhou¹, **X. Wang**², **M. Men**², **X. YP**², **K. Cao**¹, **W. Pu**¹, **M. Hacker**³, **X. Li**³, **M. Zhao**¹;

¹The Third Xiangya Hospital, Central South University, Changsha, CHINA, ²Xiangya Hospital, Central South University, Changsha, CHINA, ³Medical University of Vienna, Vienna, AUSTRIA.

EP-0679

Microglial Activation and Glucose Hypometabolism in the Thalamus Following Traumatic Brain Injury

Y. Zhang, **X. Zhang**;

The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, CHINA.

EP-0680

¹⁸F-DPA714 PET/MR Reveals Neuroinflammation-Peripheral Immune Crosstalk in Depression

L. Xu¹, **K. Liao**¹, **X. Song**², **P. Zheng**², **H. Pang**¹;

¹Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing,

CHINA, ²Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-0681

Effect of ketogenic diet (KD) on brain metabolism goes beyond metabolic shifting

M. Mangia^{1,2}, **G. Rovera**^{1,2}, **M. Cioffi**^{1,2}, **F. Roveta**^{3,4}, **M. Zotta**², **A. Lesca**², **F. Giunta**², **E. Rubino**^{3,4}, **A. Cermelli**^{3,4}, **L. Sofia**^{5,6}, **S. Raffa**^{5,6}, **M. Bauckneht**^{5,6}, **D. Arnaldi**^{6,7}, **F. Massa**^{6,7}, **M. Pardini**^{6,7}, **I. Rainero**^{3,4}, **S. Morbelli**^{1,2};

¹Department of Medical Sciences, University of Turin, Turin, ITALY, ²Nuclear Medicine Unit, AOU Città della Salute e della Scienza di Torino, Turin, ITALY, ³Aging Brain and Memory Clinic, Department of Neuroscience "Rita Levi-Montalcini", University of Turin, Turin, ITALY, ⁴Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino, Turin, ITALY, ⁵Nuclear Medicine Unit, Department of Medical Sciences, University of Genoa, Genoa, ITALY, ⁶IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ⁷Department of Neurosciences, University of Genoa, Genoa, ITALY.

EP-0682

Neuroinflammation and Metabolism in Autoimmune Encephalitis: A Dual-Tracer PET Imaging Approach for Subgroup Differentiation

Y. Wang, **H. Shao**, **Y. Zhang**, **G. Huang**, **C. Zhang**, **J. Liu**;

Department of Nuclear medicine; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA.

EP-0683

AI-based denoising to fully exploit pathophysiological meaning and clinical impact of early perfusion amyloid PET imaging

A. Coccarelli^{1,2}, **M. Zotta**^{1,2}, **S. DeKeyser**³, **V. De Ridder**³, **M. Cioffi**^{1,2}, **G. Rovera**², **M. Pardini**⁴, **L. Sofia**^{5,6}, **S. Raffa**⁵, **L. Roccatagliata**^{6,5}, **F. Massa**^{6,4}, **D. Arnaldi**⁶, **B. Orso**⁴, **M. Losa**⁴, **A. Lesca**^{1,2}, **M. Bauckneht**^{5,6}, **M. Bozzali**⁷, **S. D. Morbelli**^{1,2,8};

¹AOU Città della Salute e della Scienza di Torino, Nuclear Medicine Unit, Turin, ITALY, ²Department of Medical Sciences, University of Turin, Turin, ITALY, ³Nuclivision, Ghent, BELGIUM, ⁴Department of Neuroscience, University of Genoa, Genoa, ITALY, ⁵Nuclear Medicine Unit, Department of Medical Sciences, University of Genoa, Genoa, ITALY, ⁶IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ⁷Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, ITALY, ⁸Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino, Turin, ITALY.

EP-0684

Head-to-Head Comparative Study of [¹⁸F]FDG, [¹⁸F]FMZ and [¹⁸F]DPA-714 for Localizing Epileptogenic Foci in Drug-Resistant Epilepsy

G. Li¹, **H. Huang**², **S. Mei**³, **W. Bao**¹, **S. Ren**¹, **S. Jiang**³, **Q. Huang**¹, **Z. Lin**², **Y. Yang**⁴, **Y. Guan**¹, **L. Chen**³, **F. Xie**¹;

¹Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ²Central Research Institute, United Imaging Healthcare Group Co., Ltd, Shanghai, CHINA, ³Department of Neurosurgery, Huashan Hospital, Fudan University, Neurosurgical Institute of Fudan University, National Center for Neurological Disorders, Shanghai, CHINA, ⁴Beijing United Imaging Research Institute of Intelligent Imaging, Beijing, CHINA.

EP-0685

Diagnostic utility and clinical impact of brain ¹⁸F-FDG PET/CT in the diagnosis of autoimmune encephalitis

O. Hernandez Cristancho¹, **S. Asadurova**¹, **M. Alanís-Bernal**², **C. Lorenzo**¹, **H. Ariño**³, **A. Zabalza**³, **A. Vilaseca**³, **E. Sáez de Gordo**⁴, **C. Auger**⁴, **C. Gamez**¹;

¹Nuclear Medicine Department, University Hospital Vall d'Hebron, Barcelona, SPAIN, ²Neurology Department, University Hospital Vall d'Hebron, Barcelona, SPAIN, ³CEMCat, Barcelona, SPAIN, ⁴Radiology Department, University Hospital Vall d'Hebron, Barcelona, SPAIN.

EP-0686

Brain [¹⁸F]FDG PET identifies evolving brain metabolism patterns correlating with outcomes in autoimmune encephalitis

F. Massa^{1,2}, **D. Cerne**¹, **S. Raffa**², **G. Benvenuto**¹, **G. Rebella**², **P. Mattioli**^{1,2}, **G. Bavestrello**¹, **A. Lechiara**², **E. M. Mobilia**², **D. Arnaldi**^{1,2}, **F. Villani**², **L. Roccatagliata**^{2,3}, **M. Pardini**⁴, **S. Morbelli**^{5,6}, **A. Uccelli**^{1,2,2}, **L. Benedetti**^{1,2};

¹Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genova, ITALY, ²IRCCS Policlinico San Martino Hospital, Genoa, ITALY, ³Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY, ⁴Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genova, Italy, Genoa, ITALY, ⁵Department of Medical Sciences, University of Turin, Italy, Turin, ITALY, ⁶Nuclear Medicine Unit, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, ITALY.

EP-0687

Dissociation between neurometabolic and neurovascular changes elicited by a sentence completion task: a PET-MRI study.

T. Vanbutsele^{1,2}, **A. Castiaux**^{1,2}, **N. Trotta**^{1,3,2}, **A. Rovai**^{1,3}, **V. Wens**^{1,3}, **S. Goldman**¹, **X. De Tiège**^{1,3}, **G. Leurquin-Sterk**^{1,3,2};

¹Université Libre de Bruxelles (ULB), ULB Neuroscience Institute (UNI), Laboratoire de Neuroanatomie et de Neuroimagerie translationnelles, Brussels, BELGIUM, ²Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B.), CUB Hôpital Erasme, Department of Nuclear Medicine, Brussels, BELGIUM, ³Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B.), CUB Hôpital Erasme, Department of Translational Neuroimaging, Brussels, BELGIUM.

EP-0688

Is the “Almond Sign” the Nut to Crack? Linking Amygdalae [¹⁸F]FDG Uptake to Lymph-Node Metastasis in Breast Cancer

A. Safarian^{1,2}, **T. Jung**¹, **H. Reza**³, **W. Hitz**^{4,5}, **G. Schweighofer Zwick**¹, **G. Rendl**¹, **C. Pirich**¹, **M. Beheshti**¹;

¹Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, AUSTRIA, ²Rajaie Cardiovascular Medical and Research Center, Rajaie Cardiovascular Institute, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Research center for Nuclear Medicine, Department of Nuclear Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Paracelsus Medical University Salzburg, Department of Ophthalmology and Optometry, Salzburg, AUSTRIA, ⁵Research Program Experimental Ophthalmology & Glaucoma Research, Paracelsus Medical University, Salzburg, AUSTRIA.

EP-0689

Association of Glymphatic Function with Glucose Metabolic Patterns in Patients with Prolonged Disorders of Consciousness

Y. Wang, **K. Guo**, **F. Kang**, **J. Wang**;

Xijing Hospital, Xi'an, CHINA.

EP-0690

First Atlas of Resting-State Networks Based on FDG-PET Data

D. Steenken¹, **C. Eierud**², **A. Sala**³, **N. Franzmeier**¹, **Y. Li**⁴, **A. Zwergal**¹, **I. Yakushev**⁴;

¹University Hospital of Munich, Munich, GERMANY, ²Georgia State University, Atlanta, GA, UNITED STATES OF AMERICA, ³University of Liège, Liège, BELGIUM, ⁴Hospital of Technical University of Munich, Munich, GERMANY.

EP-0691

Feasibility of Short Imaging Protocols for [¹⁸F]-D-Deprenyl PET in Autoimmune Encephalitis and Multiple System Atrophy

L. Tagnin¹, **J. S. Julia S. Dorneich**¹, **M. Zeinaki**¹, **L. Vogler**¹, **L. Sanzo**¹, **S. Katzdobler**^{2,3}, **A. Alexander Jäck**^{2,3}, **A. Bernhardt**³, **B. Rauchmann**^{4,5}, **S. Stoecklein**⁶, **M. Simmet**¹, **E. Joseph**¹, **S. Lindner**¹, **R. Schaefer**¹, **N. Koglin**⁷, **A. Mueller**⁷, **A. W. Stephens**⁷, **J. A. Gernert**⁸, **F. Hopfner**^{2,3}, **G. U. Höglinger**^{2,3,9}, **R. Perneczky**^{9,10,11}, **T. Kümpfel**⁸, **M. Kerschensteiner**^{8,9,12}, **F. Franziska**⁸, **J. Levin**^{2,3,9}, **M. Brendel**^{1,2,9};

¹Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, GERMANY, ²German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY, ³Department of Neurology, University Hospital of Munich, LMU Munich, Munich, GERMANY, ⁴Department of Neuroradiology, University Hospital of Munich, LMU Munich, Munich, GERMANY, ⁵Department of Psychiatry and Psychotherapy, University Hospital of Munich, LMU Munich, Munich, GERMANY, ⁶Department of Radiology, University Hospital of Munich, LMU Munich, Munich, GERMANY, ⁷Life Molecular Imaging GmbH, Berlin, GERMANY, ⁸Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, GERMANY, ⁹Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY, ¹⁰Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College, London, UNITED KINGDOM, ¹¹Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UNITED KINGDOM, ¹²Biomedical Center, Faculty of Medicine, LMU Munich, Munich, GERMANY.

EP-0692

Individual-Level Connectivity Biomarker from Sparse Inverse Covariance Estimation in [¹⁸F]-FDG PET

M. Doyen¹, **S. Heyer**², **A. Verger**³;

¹Nancyclotep / University of Lorraine, IADI INSERM U1254, Nancy, FRANCE, ²CHRU Nancy, Nancy, FRANCE, ³CHRU Nancy / University of Lorraine, IADI INSERM U1254, Nancy, FRANCE.

EP-0693

First-in-Human Application of ^{99m}Tc-CN7DG and Quantitative Comparison of SPECT/CT versus ¹⁸F-FDG PET/CT in intracranial space-occupying lesion

J. Wang, **C. Zhou**, **Z. Quan**, **F. Kang**, **G. Li**, **J. Wang**;

Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, CHINA.

EP-0694
Evaluation of Structural-Functional Connectivity Coupling and Metabolism in Adolescent with Bipolar Disorder and Major Depression Disorder
S. Liu¹, Y. Zhong¹, L. Liu², F. Hu¹, Y. Huo¹, J. Ma¹, Y. Zhang¹, C. Ma¹, E. Cong¹;
¹Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, CHINA, ²Central Research Institute, United Imaging Healthcare Group Co., Ltd, Shanghai, CHINA.

EP-0695
Structural-functional connectivity and metabolism analysis in adolescent depression with suicidal behavior
S. Liu¹, Y. Zhong¹, L. Liu², Y. Huo¹, Y. Jiang¹, J. Ma¹, C. Ma¹, E. Cong¹;
¹Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, CHINA, ²Central Research Institute, United Imaging Healthcare Group Co., Ltd, Shanghai, CHINA.

EP-0696
MRI-arterial spin labeling and FDG-PET reveal reduced whole brain perfusion and changes in regional glucose uptake in severe sustained hypoxia
H. Weis¹, J. Hönemann², F. Hoffmann², L. DeBonis³, L. Kessler⁴, C. Rischpler⁵, M. Schmitz⁶, D. Elmenhorst⁷, S. Beer⁷, A. Drzezga¹, J. Jordan³, J. Tank³, U. Limper³;
¹Department of Nuclear Medicine, Faculty of Medicine and University Hospital of Cologne, Cologne, GERMANY, ²Department of Internal Medicine III, Division of Cardiology, Pneumology, Angiology, and Intensive Care, University of Cologne, Cologne, GERMANY, ³Institute of Aerospace Medicine, German Aerospace Center (DLR), Cologne, GERMANY, ⁴Department of Nuclear Medicine, University Essen, Essen, GERMANY, ⁵Department of Nuclear Medicine, Klinikum Stuttgart, Stuttgart, GERMANY, ⁶Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), University of Bonn, Bonn, GERMANY, ⁷Institute of Neuroscience and Medicine (INM-2), Forschungszentrum Jülich, Jülich, GERMANY.

EP-0697
Metabolic Alterations in the Brain and Tumor Incidence of Patients with Long COVID: Insights from ¹⁸F-FDG PET Imaging
Y. Wang¹, M. Xin¹, H. Shao¹, Y. Zhang¹, X. Wu², J. Hao³, J. Liu¹, C. Zhang¹;
¹Department of Nuclear medicine; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA, ²Department of Respiratory medicine; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA, ³United Imaging Healthcare, Shanghai, CHINA.

EP-0698
[18F]fluorodeprenyl-D2 PET imaging as a new tool to detect disease activity in GAD65-Ab Autoimmune Encephalitis
J. S. Dorneich¹, M. Zeinaki¹, L. Tagnin¹, L. Vogler¹, L. Sanzo¹, S. Lindner¹, R. A. Werner¹, G. N. Bischof², J. A. Gernert³, T. Kümpfel^{3,4}, M. Kerschensteiner^{3,4,5}, E. Kaufmann^{6,7}, M. Brendel^{1,5}, F. Thaler³;
¹Department of Nuclear Medicine, University Hospital of Munich, Munich, GERMANY, ²Life Molecular Imaging (LMI), R&D, Berlin, GERMANY, ³Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, GERMANY, ⁴Biomedical Center, Faculty of Medicine, LMU Munich, Munich, GERMANY, ⁵Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY, ⁶Epilepsy

Center, Department of Neurology, LMU University Hospital, Munich, GERMANY, ⁷Department of Neurology, LMU University Hospital, LMU Munich, Munich, GERMANY.

EP-0699
Assessment of ¹⁸F-UCB-H as a biomarker in focal epilepsy
V. Pakula¹, C. Vollmar², L. Bartos¹, J. S. Dorneich¹, N. Fearn², S. Lindner¹, A. Zwergal², G. Höglinger², R. Werner¹, J. Rémi², M. Brendel¹, J. Gnörich¹;
¹Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY, ²Department of Neurology, LMU University Hospital, Munich, GERMANY.

EP-41

e-Poster Area

B: Imaging Clinical Studies -> B6
Endocrinological Imaging Clinical Study -> B61
Endocrinology (including Thyroid Benign)

EP-0700
How sure can we be? - Graves’ disease or Multi-nodular Goitre: Usefulness of isotope thyroid scan
A. Chamnan¹, V. Pant, F. Naeem, S. Salam, L. Yeung, S. Vinjamuri;
Royal Liverpool University Hospital, Liverpool, UNITED KINGDOM.

EP-0701
Revisiting Piga’s Criteria for Amiodarone-Induced Thyrotoxicosis Using ^{99m}Tc-Sestamibi Thyroid Scintigraphy: Interobserver Reproducibility and Semiquantitative Analysis
R. Sá e Silva¹, J. Escalera, L. Costa;
Centro Hospitalar Universitário do Porto, Porto, PORTUGAL.

EP-0702
SUVmax utility in parathyroid scintigraphy
M. Kocemba¹, M. Tulik, J. Kunikowska;
Medical University of Warsaw, Warsaw, POLAND.

EP-0703
Inter-reader Agreement and additive benefit of SPECT or SPECT/CT modality with [^{99m}Tc] Tc-Pertechnetate Scintigraphy Imaging for the Assessment of incidental Thyroid Nodules in a tertiary care center
E. Novruzov¹, K. Julian, K. Mattes-György, D. Schmitt, M. Muchalla, M. Schott, C. Antke, F. L. Giesel, E. Mamlins;
University Hospital Düsseldorf, Düsseldorf, GERMANY.

EP-0704
From Image to Outcome: Optimizing [I-131] Therapy in Hyperthyroidism Using Scintigraphic Patterns in Our Experience
S. Alvarez¹, G. Mera, E. Ardila, V. Castillo, S. Salcedo, M. Casallas, I. Gomez, J. C. Alonso;
Hospital General Universitario Gregorio Marañón, Madrid, SPAIN.

EP-0705
Effectiveness of 18F-Fluorocholine PET/CT (18F-FCH PET/CT) in the Localization of Multiglandular Disease (MGD) in Patients with Hyperparathyroidism.

P. Portilla Merino¹, C. Lancha Hernández², L. Giraldo Gonzalez¹, J. Otero Gonzalez¹, M. Coronado Poggio¹, S. Rizkallal Monzon¹, J. Cordero¹, L. Domínguez Gadea¹;
¹Hospital La Paz, Madrid, SPAIN, ²Hospital La Paz, Hospital Univeristario La Paz, SPAIN.

EP-0706
A study on the construction of a nomogram for predicting the postoperative outcome of unilateral primary aldosteronism based on ⁶⁸Ga-Pentixafor PET/CT imaging targeting CXCR4
Y. Jin¹, Y. Yang¹, Y. Yang¹, J. Yang¹, T. Long¹, S. Hu^{1,2,3};
¹Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, CHINA, ²Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, CHINA, ³Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, CHINA.

EP-0707
Tc99m-pertechnetate thyroid imaging on a 3D-ring CZT-based SPECT/CT system is a superior alternative to conventional thyroid scintigraphy
A. Harteveld¹, A. van de Burgt, M. Segbers, F. A. Verburg;
Erasmus MC, Rotterdam, NETHERLANDS.

EP-0708
Radioguided Occult Lesion Localization (R.O.L.L.) Technique for Minimal Invasive Parathyroidectomy (M.I.P.). Our Experience
M. Fornito¹, G. Giordano², M. Trovato³, M. Iago¹, S. Fiorino¹, F. Stracuzzi¹;
¹ARNAS GARIBALDI CATANIA Nuclear Medicine - PET/TC center dep., Catania, ITALY, ²ARNAS GARIBALDI CATANIA Interventional radiology, Catania, ITALY, ³ARNAS GARIBALDI CATANIA Oncological Surgery, Catania, ITALY.

EP-0709
Assessment of oral [¹⁸F]FDG administration for examining gastrointestinal glucose uptake, biodistribution and dynamic glucose metabolism using total-body PET/CT.
M. Brogaard¹, P. Cramon¹, T. Andersen¹, U. Lindberg¹, F. Andersen¹, J. Brittain¹, M. Sørensen², C. Nguyen², H. Larsson¹, J. Madsen¹, I. Law¹, L. Gasbjerg¹;
¹Rigshospitalet, 2100 Copenhagen, DENMARK, ²Nuklearmedicin, Rigshospitalet, Copenhagen, DENMARK.

EP-0710
Semiquantitative analysis of ¹⁸F-FCH PET/CT in the Dual-Time-Point protocol in patients with primary hyperparathyroidism
E. Campaña Díaz¹, P. García-Talavera San Miguel¹, F. Gómez-Caminero López¹, J. Álvarez Pérez¹, C. Montes Fuentes¹, E. Martin Gallardo², J. Badell Martínez¹, S. Rama Alonso¹, A. Peñaherrera Cepeda¹, J. Villanueva Curto¹, F. Caltagirone¹, B. Santos García¹, M. Tamayo Alonso¹, M. Martín Gómez¹;
¹Hospital Universitario de Salamanca, Salamanca, SPAIN, ²Professor at UCIII y UPComillas, Madrid, SPAIN.

EP-0711
Early-phase [¹⁸F]Fluorethyltyrosine positron emission tomography for localisation of corticotroph pituitary adenomas in Cushing's disease
F. Völter¹, J. R. O. L. Schweizer, I. Stüfchen, A. Bollenbacher, E. Nowak, K. Ritzel, J. Thorsteinsdottir, M. Theodoropoulou, M. Reincke, N. L. Albert;
Ludwig-Maximilian-Universität, Munich, GERMANY.

EP-0712
Metabolic imaging of brown adipose tissue in female patients treated for obesity with tirzepatide
L. Lezaic¹, R. Herman², U. Begus¹, S. Rep¹, I. Slodnjak¹, B. Trebec Lukman¹, M. Jensterle Sever², A. Janez²;
¹University Medical Centre Ljubljana, Division of Nuclear Medicine, Ljubljana, SLOVENIA, ²University Medical Centre Ljubljana, Department of Endocrinology, Diabetes and Metabolic Diseases, Ljubljana, SLOVENIA.

EP-0713
Diagnostic value of [¹⁸F]FET PET/CT in patients with negative or inconclusive MR imaging for pituitary neuroendocrine tumours
L. Lezaic¹, A. Kunst¹, K. Surlan Popovic², T. Kocjan³, R. Bosnjak⁴, S. Rep¹;
¹University Medical Centre Ljubljana, Division of Nuclear Medicine, Ljubljana, SLOVENIA, ²University Medical Centre Ljubljana, Institute of Radiology, Ljubljana, SLOVENIA, ³University Medical Centre Ljubljana, Department of Endocrinology, Diabetes and Metabolic Diseases, Ljubljana, SLOVENIA, ⁴University Medical Centre Ljubljana, Department of Neurosurgery, Ljubljana, SLOVENIA.

EP-0714
Assessing the value of [^{99m}Tc]Tc-MIBI/ Na[^{99m}Tc]TcO4 SPECT/CT in parathyroid imaging - a new approach on the dual-tracer method
A. Dyczka¹, A. Aulich, Z. Adamczewski;
Nuclear Medicine Department, Medical University of Lodz, Lodz, POLAND.

EP-0715
Concordance Between I-123/Tc-99m Sestamibi Subtraction SPECT/CT and Histopathology in Localizing Single Parathyroid Adenomas
A. Hassan¹, A. W. Alessi, E. Wahab, S. J. Hughes;
Queen Elizabeth Hospital Birmingham, Birmingham, UNITED KINGDOM.

EP-0716
New insights into malignancy risk in trapping-only versus hypofunctioning nodules
L. Sobral Torres¹, R. Nunes, J. Maria Veloso Trevisan, R. Albergueiro, A. Oliveira, P. Soeiro;
Unidade Local de Saúde São João, Porto, PORTUGAL.

EP-0717
Preoperative localisation of hyperfunctioning parathyroids: Scintigraphy or 4D Computed Tomography?
O. Silva¹, I. Ferreira, S. Carmona, A. I. Santos;
Hospital Garcia de Orta, Almada, PORTUGAL.

EP-0718
Incidence of Hypothyroidism Following Radioactive Iodine Therapy in Patients with Single Toxic Thyroid Nodules and evaluation of possible predictive factors.
H. Al-JNABI¹, T. Ball, I. Mitra, J. Philips, E. Sanverdi, A. Wren, A. DEDE, A. Meanhout;
Chelsea and Westminster NHS Foundation Trust, London, UNITED KINGDOM.

EP-0719
Parathyroid multitracer CZT SPECT/CT with Tc-99m MIBI and I-123 NaI for simultaneous imaging of parathyroid adenomas and thyroid tissue
D. Heute¹, J. D. Heute, A. J. Heute;
Nuklearmedizin Telfs GmbH, Telfs, AUSTRIA.

EP-0721
Correlation between biochemical parameters and quantitative indices on Ga68 DOTANOC PET/CT for localising the source of Cushing’s Syndrome- A Retrospective SingleCentre Analysis

N. Kundu, D. Khan, S. Sagar, A. Mahalik, A. Roy, R. Kumar; AIIMS New Delhi, Delhi, INDIA.

EP-0722
Dual-isotope subtraction scintigraphy and SPECT-CT for preoperative localization of parathyroid adenomas: A diagnostic study

P. Udholm, C. Eriksen, S. d’Este, P. Bach-Mortensen, S. Møller; Hvidovre Hospital, Region Hovedstaden, Hvidovre, DENMARK.

EP-0723
The Role of Ga-68 DOTA-Pentixafor PET/CT Imaging in the Diagnosis of Benign Functional Adrenal Cortical Masses: Preliminary Results
Ö. Sahin¹, Z. Tosunoğlu¹, A. E. Öztürk¹, E. Akgün¹, G. Alçın¹, T. F. Çermik², E. Arslan¹;
¹Istanbul Training and Research Hospital, Nuclear Medicine Clinic, Istanbul, TÜRKIYE, ²Acibadem Maslak Hospital, Nuclear Medicine Department, Istanbul, TÜRKIYE.

EP-0724
The effect of thyroid hormone medication on radioiodine-131 bio-kinetics in solitary toxic thyroid nodules
C. Happel, B. Bockisch, D. Groener; University Medical Center Frankfurt; Clinic for Radiology and Nuclear Medicine; Department of Nuclear Medicine, Frankfurt, GERMANY.

EP-0725
Alternation of Organic Metabolic Profiling in Obese Patients Following Bariatric Surgery Assessed by ¹⁸F-FDG PET/CT
Z. Wang, S. Xue, O. Kulterer, X. Li, M. Hacker; Medical University of Vienna Department of Biomedical Imaging and Image-guided Therapy, Vienna, AUSTRIA.

EP-0726
⁶⁸Ga-Pentixafor PET/CT Imaging Characteristics in Primary Aldosteronism with Coexisting Subclinical Cushing Syndrome: A Retrospective Cohort Study
S. Liu, H. Pang; The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-0727
First-in-Human Evaluation of [¹⁸F]AldoView: A Highly Selective PET Tracer for Aldosterone Synthase Imaging in Primary Aldosteronism
T. Long¹, G. Liu², M. Zhou¹, X. Xie³, Y. Jin¹, L. Liu⁴, X. Luo², T. Jiang², S. Hu¹;
¹Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, CHINA, ²Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, Hunan, CHINA, ³Hunan University of Information Technology, Changsha, Hunan, CHINA, ⁴Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, CHINA.

EP-0728
¹⁸F-FDG PET/CT in the Assessment of Indeterminate Adrenal Lesions
W. Schlötelburg¹, T. Jedamzik¹, S. Hahner², A. K. Buck¹, M. Fassnacht², P. E. Hartrampf¹;

¹University Hospital, Department of Nuclear Medicine, Würzburg, GERMANY, ²University Hospital, Medicine I, Division of Endocrinology and Diabetes, Würzburg, GERMANY.

EP-0729
¹⁸F-choline long-axial-field of view PET-CT accurately localises intrathyroid parathyroid adenoma in 5-month pregnant patient
T. Wagner¹, T. Willson², B. Ferreira², J. Edwards³, P. Wijewickrama⁴, B. Holman²;
¹Nuclear Medicine, London, UNITED KINGDOM, ²Nuclear Medicine department, Royal Free London NHS Trust, London, UNITED KINGDOM, ³Radiology department, Royal Free London NHS Trust, London, UNITED KINGDOM, ⁴University Hospital Sussex, Department of Endocrinology, Brighton, UNITED KINGDOM.

EP-0730
Diagnostic Value of MIBI Thyroid Washout Rate in Differentiating Types of Amiodarone-Induced Thyrotoxicosis
T. Bogovic Crncic^{1,2}, L. Fischer^{1,2}, M. Ilić Tomaš^{1,2}, I. Iskra^{1,2}, N. Girotto^{3,4}, M. Mavrinac⁵;
¹University of Rijeka, Faculty of Medicine, Rijeka, CROATIA, ²Clinical Hospital Centre Rijeka, Rijeka, CROATIA, ³University of Rijeka, Faculty of Health Studies, Rijeka, CROATIA, ⁴PET/CT Center Rijeka, Medikol Polyclinic, Rijeka, CROATIA, ⁵Faculty of Educational Sciences, Juraj Dobrila University of Pula, Pula, CROATIA.

EP-0731
Optimization of 3T PET/MRI Protocol with [¹⁸F] Fluorocholine in the Detection of Parathyroid Microadenomas.
V. Carrero-Vásquez, Á. Espigares-Santiago, J. Díaz-Moreno, M. Cortés Romera, M. Suárez-Piñera, L. Gracia-Sánchez, L. Rodríguez-Bel, I. Sanchez-Rodriguez; Nuclear Medicine, Bellvitge University Hospital, Barcelona, SPAIN.

EP-0732
Frequency of osteoporotic Trabecular Bone Score adjusted T-score in daily clinical practice compared to standard densitometric measurements
M. Jensen¹, B. Zerahn¹, C. K. Andersen¹, M. K. Skjødt^{2,3};
¹Dept. of Nuclear Medicine, Copenhagen University Hospital – Herlev and Gentofte, Herlev, DENMARK, ²Dept. of Medicine, Copenhagen University Hospital - Herlev and Gentofte, Herlev, DENMARK, ³Research Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense, DENMARK.

EP-0733
[¹⁸F]Fluorocholine-PET Imaging at Different Time Points in Patients with Primary Hyperparathyroidism
F. Hedeer¹, A. Stenval², E. Mellhammar², M. Matkovic¹, M. Nilsson³, J. Oddstig², M. Almquist³, U. Bitzén¹;
¹Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund University, Lund, SWEDEN, ²Radiation Physics, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, SWEDEN, ³Department of Surgery, Skåne University Hospital, Lund University, Lund, SWEDEN.

EP-0734
Evaluation of Dynamic C-X-C motif Chemokine Receptor 4-directed PET/CT Imaging in Primary Aldosteronism

J. Enke¹, F. Voelter², J. Baessler¹, K. Ritzel², R. A. Bundschuh³, N. Dreher¹, O. Viering¹, J. Tran-Gia⁴, C. H. Pfob¹, M. Kircher¹, A. Dierks¹, M. Reincke², C. Lapa¹;
¹Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY, ²Department of Medicine IV, Ludwig Maximilians University Hospital Munich, Munich, GERMANY, ³Department of Nuclear Medicine, University Hospital Carl Gustav Carus at the TU Dresden, Dresden, GERMANY, ⁴Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY.

EP-0735
Thyroid disorders in primary school children in North Macedonia: A cross-sectional study
N. Manevska^{1,2}, A. Jankulovska¹, B. Stoilovska Rizova¹, N. Kolovcevska Bozinovska¹, N. Stojkovska³, T. Makazlieva¹, S. Stojanoski¹;
¹Institute of Pathophysiology and Nuclear medicine, Faculty of Medicine, University of Ss Cyril and Methodius, Skopje, NORTH MACEDONIA, THE REPUBLIC OF, ²University Institute of positron emission tomography, Skopje, NORTH MACEDONIA, THE REPUBLIC OF, ³Institute of Histology and Embryology, Faculty of Medicine, University of Ss Cyril and Methodius, Skopje, NORTH MACEDONIA, THE REPUBLIC OF.

EP-0736
Minimally invasive radioguided parathyroidectomy using a handheld gamma detector probe: First experience with primary hyperparathyroidism - A pilot study
N. Bozhinovska¹, A. Jankulovska¹, B. Stoilovska Rizova¹, B. Antevski², S. Stojanoski¹, N. Manevska³, T. Makazlieva¹;
¹Institute of Pathophysiology and Nuclear Medicine "Isaac Tadzer", Skopje, NORTH MACEDONIA, THE REPUBLIC OF, ²University clinic for thoracic and vascular surgery, Skopje, NORTH MACEDONIA, THE REPUBLIC OF, ³University Institute of positron emission tomography, Skopje, NORTH MACEDONIA, THE REPUBLIC OF.

EP-0737
Possibly coexistence of Hashimoto thyroiditis (HT) and papillary thyroid carcinoma (PTC)
K. Zaplatnikov; MVZ Nuklearmedizin Mögeldorf, Nürnberg, GERMANY.

EP-0738
Added Value of MRI Multi-parameter Information for Diagnosing Subcentimeter Functional Adrenal Nodules using CXCR4-targeted PET/MRI imaging
X. Meng, Z. Quan, F. Kang; Xijing Hospital of Airforce Military Medical University, Xi'an, CHINA.

EP-0739
99mTc-Pertechnetate Scintigraphy predicts successful postoperative ablation in patients with low-risk differentiated thyroid carcinoma.
I. El Bez, R. Tulbah, S. Alhazza, R. Alsalah, K. Ibrahim, F. Algmilas, M. Alharbi; AAML, Riyadh, SAUDI ARABIA.

EP-42
e-Poster Area
B: Imaging Clinical Studies -> B7 Musculoskeletal, Infection and Inflammation Imaging Study -> B71 Bone Infection and Inflammation

EP-0740
Can We See More with Three-Phase Bone Scintigraphy in Patients with Prosthetic Infection?
J. Mendes, P. Soeiro; Hospital de São João, Porto, PORTUGAL.

EP-43
e-Poster Area
B: Imaging Clinical Studies -> B7 Musculoskeletal, Infection and Inflammation Imaging Study -> B72 Vasculitis and Endocarditis

EP-0741
Diagnostic Accuracy of ¹⁸F-FDG-Labelled Autologous Leukocyte Positron Emission Tomography - Computed Tomography in Suspected Cardiac Infections
P. Malik, A. Bhattacharya, R. Kumar, H. Singh, P. Panda, H. Singh, B. R. Mittal; Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA.

EP-0742
Sensitivity and Specificity of F-18 FDG PET/CT Imaging in IE; Usefulness of Dual Imaging
A. Çelik Arslan¹, C. Engür Uyanık¹, A. Çınar¹, D. Karamanlioğlu², N. Aydınbelge Dizdar¹, Ö. Özmen¹;
¹Etilik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Etilik City Hospital, Department of Clinical Microbiology and Infectious Diseases, Ankara, TÜRKIYE.

EP-0743
Evaluating the Role of [¹⁸F]FDG PET-CT in Infective Endocarditis: Correlations with Systemic Inflammatory Markers
A. Militaru¹, D. F. Militaru-Minea², A. Marin¹, M. M. Matei¹, D. Craciun¹, C. V. Mazilu¹, R. M. Mititelu^{1,3};
¹Clinic of Nuclear Medicine - Central University Emergency Military Hospital, Bucharest, ROMANIA, ²Clinic of Infectious Diseases- Central University Emergency Military Hospital, Bucharest, Bucharest, ROMANIA, ³Nuclear Medicine Department- University of Medicine and Pharmacy "Carol Davila" Bucharest, Bucharest, ROMANIA.

EP-0767
Development and Validation of a Nomogram for Predicting Pulmonary Embolism Recurrence Using Muscle and Fat Parameters
J. Cao¹, S. Niu¹, X. Li¹, H. Liu²;
¹Shanxi Medical University, Taiyuan, CHINA, ²First Hospital of Shanxi Medical University, Taiyuan, CHINA.

EP-0768
Revisiting Pituitary and Adrenal Physiological FDG Accumulation, Using Time-of-Flight PET/CT Scanner Equipped with Semiconductor Detectors and Deep Learning Reconstruction Technology
K. Nakatani¹, K. Yoshino², T. Kumazawa², H. Tanaka², T. Koyama², K. K. Miyake¹, Y. Nakamoto¹;
¹Kyoto University Graduate School of Medicine, Kyoto, JAPAN, ²Kurashiki Central Hospital, Kurashiki, JAPAN.

EP-0769
The Brain-White Adipose Tissue Axis May Play a Crucial Role in Diabetes Mellitus: A Metabolic Network Analysis Using Total-Body PET/CT Imaging
L. Sun;
 Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Zhengzhou, CHINA.

EP-0770
PET/CT with ¹¹C-Methionine and ¹⁸F-FDG in Multiple Myeloma Patients
V. Manukova, I. Aslanidis, Q. Mukhortova, M. Metelkina;
 A.N. Bakulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of Russia, Moscow, RUSSIAN FEDERATION.

EP-0771
Correlation Analysis of Inflammatory Markers, ¹⁸F-FDG PET/CT Metabolic Parameters and Skeletal Muscle Parameters in Advanced Epithelial Ovarian Cancer
Z. Zhang, H. Liu;
 First Hospital of Shanxi Medical University, Taiyuan, CHINA.

EP-0772
[^{99m}Tc]Tc-Besilesomab Scintigraphy in a Patient with Stuve-Wiedemann Syndrome
A. Marques^{1,2}, F. Abreu^{1,2}, J. Duarte², J. Carvalho², S. Pintão²;
¹Institute of Nuclear Medicine, Faculty of Medicine, University of Lisbon, Lisbon, PORTUGAL, ²Western Lisbon Hospital Centre, Lisbon, PORTUGAL.

EP-0773
Is [⁶⁸Ga]Ga-FAPI-46 PET/CT Safe? A Safety Evaluation of the FAPI PET/CT Procedure with Haemodynamic Measurements and Patient-Reported Outcomes
M. Bentestuen¹, C. Sylvest², M. Ladekarl³, O. Thorlacius-Ussing⁴, H. D. Zacho¹;
¹Department of Nuclear Medicine and Clinical Cancer Research Centre, Aalborg, DENMARK, ²Department of Gynaecology and Obstetrics, Aalborg University Hospital, Aalborg, DENMARK, ³Department of Oncology and Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, DENMARK, ⁴Department of Gastrointestinal Surgery and Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, DENMARK.

EP-0774
Clinical Utility Of Platelet Kinetics Studies In Patients With Idiopathic Thrombocytopenic Purpura (ITP).

S. Faílde Balea, E. Triviño-Ibáñez, T. Balibrea Zúñiga, A. Delgado García, L. Entrena Ureña, Á. Ramírez-Navarro, R. Sánchez-Sánchez;
 Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0775
Revealing the Unexpected: Urgent PET/CT Findings and Their Impact on Clinical Management-A Decade of Clinical Experience
M. Vaillant¹, G. Cuesta¹, A. Ortega¹, C. Rodríguez¹, R. Cano², P. Daudén¹, P. Nespral¹, M. Cornide¹, M. Romero¹, M. Zapardiel¹, C. Wakfie¹, P. Bascuñana³, M. Cabrera¹;
¹Nuclear Medicine Department, Hospital Clínico San Carlos, Madrid, SPAIN, ²Cardiology Department, Hospital Infanta Sofía, Madrid, SPAIN, ³Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, SPAIN.

EP-0776
Isotopic determination of Red Cell Mass to study the haematocrit increase in patients in treatment with SGLT-2 inhibitors
I. Romero-Zayas^{1,2}, N. Navarro-Niño¹, J. Álvarez-Doral¹, F. Campos Añón^{1,2}, A. Alvarez-Larrán^{3,2}, H. Brillembourg Cubillán³, M. Garrote Ordeig³, A. Farré Melero^{1,4}, A. Niñerola Baizán^{1,2,5}, E. Cano Cumellas¹, C. Santos Montero¹, J. Córdón del Pozo¹, D. Fuster Pelfort^{1,2};
¹Nuclear Medicine Department, Hospital Clínic, Barcelona, SPAIN, ²Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SPAIN, ³Hematology Department, Hospital Clínic, Barcelona, SPAIN, ⁴Faculty of Medicine and Health Sciences - University of Barcelona, Barcelona, SPAIN, ⁵Faculty of Medicine and Health Sciences - University of Barcelona,, Barcelona, SPAIN.

EP-0777
SeHCAT Protocol Optimisation: A Single-Scan Approach to Increased Capacity
K. Tallat-Szczotka, H. McMeekin, M. Costa, J. Hidalgo, T. Hussain, B. Riberio;
 Barts Health NHS Trust, London, UNITED KINGDOM.

EP-0778
A Comparative Analysis of Qualitative and Quantitative Findings in Lymphoscintigraphy for the Grading of Lymphedema
A. Pala, H. Pala, M. F. Bozkurt;
 Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-49

e-Poster Area

C: Therapy Clinical Study -> C1 Oncological Therapy Clinical Study -> C11 Neuroendocrine Therapy

EP-0779
One therapy, many measures: a comparative study of response evaluation methods to Peptide Receptor Radionuclide Therapy (PRRT) in patients with neuroendocrine tumors (NET)
P. Guglielmo^{1,2}, J. Jandric³, C. Vallone^{4,5}, M. Rodari³, C. Carnaghi⁶, A. Bertuzzi⁷, G. Tarullo³, K. Marzo³, M. Olivieri⁸, M. Marengo³, L. Evangelista^{3,1};
¹Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY, ²Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, ITALY, ³Nuclear Medicine

Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY, ⁴Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, ITALY, ⁵Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY, ⁶Oncology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY, ⁷Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY, ⁸Medical Physics Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY.

EP-0780
Improved Response of Advanced NET After Switching From ²²⁵Ac-Octreotate to ²²⁵Ac-LM3: A Preliminary Analysis
T. Speicher, M. B. Bastian, A. Blickle, S. Maus, M. Bartholomä, C. Burgard, F. Rosar, S. Ezziddin;
 Nuclear Medicine, Saarland University Hospital, Homburg, GERMANY.

EP-0781
Skeletal Muscle Uptake on [¹³¹I]-Metaiodobenzylguanidine Post-Therapy Imaging
B. Lumb Morollon, C. Brown;
 Department of Clinical Physics and Bioengineering, NHS Greater Glasgow & Clyde, Glasgow, UNITED KINGDOM.

EP-0782
Polish Registry of RLT - first report
M. Kolodziej¹, V. Rosiek², J. Musiałkiewicz³, A. Ledwon⁴, A. Lewczuk-Myślicka⁵, K. P. Sagan⁶, B. Kos-Kudła², M. Ruchala⁷, D. Handkiewicz-Junak⁴, R. Swiatkowska-Stodulska⁵, A. Syrenicz⁶, G. Kaminski¹;
¹Department of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, POLAND, ²Department of Endocrinology and Neuroendocrine Tumours, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, POLAND, ³Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Poznań, POLAND, ⁴Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, POLAND, ⁵Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Gdansk, POLAND, ⁶Department of Endocrinology, Metabolic and Internal Diseases, Pomeranian Medical University, Szczecin, POLAND, ⁷Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Poznan, POLAND.

EP-0783
Initial and re-challenge Lutetium-177-DOTATATE PRRT in a Metastatic Ovarian Neuroendocrine Tumour: a case report
N. Eftychiou, H. Ahmed, R. Fernandez, F. Hassan;
 Guy's and St Thomas Foundation Trust, London, UNITED KINGDOM.

EP-0784
Alpha Peptide Receptor Radionuclide Therapy (PRRT) with the somatostatin receptor (SSTR)-antagonist 225Ac-DOTA-LM3 as rescue therapy after failure of conventional treatments in neuroendocrine neoplasm G3
E. Perrone¹, K. Ghar², T. Parkar², A. Eismant², L. Greifenstein², M. Pavel³, R. P. Baum²;
¹Nuclear Medicine Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ITALY, ²CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular

Precision Oncology, Wiesbaden, GERMANY, ³Department of Medicine 1, Uniklinikum Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, GERMANY.

EP-0785
IPAX-2: Phase 1 safety and dose finding study of [¹³¹I]IPA plus standard of care in patients with newly diagnosed glioblastoma
J. Roetman¹, J. Pichler², N. Singhal³, H. Gan⁴, A. Braat⁵, W. Pullin⁶, B. Cerqueira¹;
¹Telix Pharmaceuticals, Melbourne, AUSTRALIA, ²Kepler University Hospital, Linz, AUSTRIA, ³Royal Adelaide, Adelaide, AUSTRALIA, ⁴Austin Health, Heidelberg, AUSTRALIA, ⁵UMC Utrecht, Utrecht, NETHERLANDS, ⁶Gold Coast University Hospital, Southport, AUSTRALIA.

EP-0786
The role of quantitative analysis of Post-Therapeutic CZT SPECT/CT Imaging in the Evaluation of Tumor Response to PRRT in Neuroendocrine Tumors
H. Noamen, Y. Cras, M. Longo, C. Garcia, J. Hadoux, L. Lamartina, S. Moog, E. Baudin, D. Deandreis;
 Gustave Roussy Cancer Campus, Villejuif, FRANCE.

EP-0787
Performance of Large Language Models in Answering Common Patient Questions on ¹⁷⁷Lu-DOTATATE Therapy for Neuroendocrine Tumors: A Comparative Evaluation by a Panel of Medical Experts
V. Habouzit¹, A. Durand², L. Al Mansour², B. Lachachi², M. Halilali³, M. Janier⁴, T. Walter⁴, T. Grenier⁵, A. Flaus⁴;
¹University Hospital of Saint Etienne, Saint Etienne, FRANCE, ²Hospices Civils de Lyon, Lyon, FRANCE, ³Université Claude Bernard Lyon 1, Lyon, FRANCE, ⁴Hospices Civils de Lyon and Faculté de médecine Université Claude Bernard Lyon 1, Lyon, FRANCE, ⁵Univ Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, CNRS, INSERM, CREATIS UMR 5220, Lyon, FRANCE.

EP-0788
Correlation between organs-at-risk dosimetry and toxicity in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with ¹⁷⁷Lu-DOTATATE: a single center experience
V. Gaudieri¹, L. Piscopo¹, E. Zampella¹, C. Nappi¹, F. Volpe¹, E. Caiazzo¹, T. Faiz¹, M. Caroprese¹, A. Barillaro¹, A. Varallo², S. Clemente², R. Pacelli¹, A. Cuocolo¹, M. Klain¹;
¹Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, ²Unit of Medical Physics and Radioprotection, University of Naples "Federico II", Naples, ITALY.

EP-0789
Is tailor-made RLT safe? - Preliminary results from the ongoing DUONEN study
M. Kolodziej¹, G. Kaminski¹, M. Opalinska², M. Dedecjus³, A. Kowalska⁴, M. Saracyn¹, P. Garnuszek⁴, I. Cieszykowska⁵, W. Lenda-Tracz⁶, D. Gasior-Perczak⁴, A. Budzynska⁷, A. Kubik⁷, K. Kacperski⁷, P. Pastusiak⁷, W. Chalewska³, A. Borkowska⁶, J. Januszkiewicz-Caulier³, J. Dlugosinska³, A. Sowa-Staszczak², P. Cegla³, A. Hubalewska-Dydejczyk², R. Mikołajczak⁵;
¹Department of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, POLAND, ²Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND, ³Department of Endocrine Oncology and Nuclear Medicine, National Institute of Oncology - National Research Institute, Warsaw, POLAND, ⁴Collegium Medicum, Jan Kochanowski University, Kielce, POLAND, ⁵Radioisotope

Center POLATOM, National Centre for Nuclear Research, Otwock, POLAND, ⁶Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, POLAND, ⁷Department of Nuclear Medicine, Military Institute of Medicine - National Research Institute, Warsaw, POLAND.

EP-0790
 Radiopharmaceutical Therapy in Neuroendocrine Carcinoma using Actinium-225, FAP-targeting, and somatostatin receptor antagonists: A new therapeutic perspective in patients progressing to standard therapies

E. Perrone¹, K. Ghai², T. Parkar², A. Eismant², L. Greifenstein², M. Pavel³, R. P. Baum²; ¹Nuclear Medicine Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ITALY, ²CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY, ³Department of Medicine 1, Uniklinikum Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, GERMANY.

EP-0791
 Visual comparison of reception expression before and after Lu177 Dotatate PRRT in patients with GEP-NET using 68Ga-DOTATATE PET-CT

J. Zivanovic¹, M. Vadrucchi², N. Mulholland², S. Reynolds²; ¹Center for Nuclear Medicine with PET, University Clinical Centre of Serbia, Belgrade, SERBIA, ²Department of Nuclear Medicine, King's College Hospital NHS Foundation Trust, London, UNITED KINGDOM.

EP-0792
 Sex-based Differences in response to 177Lu-DOTATATE in patients with stage IV Neuroendocrine Tumors: A comparative analysis from a National Registry

M. Mitjavila Casanovas¹, P. Bello², V. Pubul³, A. García-Burillo⁴, L. García-Cañamaque⁵, A. Piñeiro⁶, D. Balaguer⁷, A. Garrido⁸, J. Hernandez⁴, D. Gomez², J. Arbizu¹⁰, A. Repetto¹¹, M. Castellón¹², M. Tabuenca¹³, M. Orduña¹⁴, M. Riesco¹⁵, M. Velasco¹⁶, M. Nevares¹⁷, T. Alonso¹⁴, M. de la Rubia¹⁸, J. Ardila¹⁹, A. Carmona-Bayonas²⁰, P. Jimenez Fonseca²¹; ¹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, SPAIN, ²Hospital Universitario La Fe, Valencia, SPAIN, ³Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, SPAIN, ⁴Hospital Universitario Vall d'Hebron, Barcelona, SPAIN, ⁵Hospitales H.M. Sanchinarro, Madrid, SPAIN, ⁶Hospital Universitario Virgen de las Nieves, Granada, SPAIN, ⁷Hospital Universitario Doctor Pesset, Valencia, SPAIN, ⁸Complejo Hospitalario Universitario de Pontevedra, Pontevedra, SPAIN, ⁹Hospital Universitario de Navarra, Pamplona, SPAIN, ¹⁰Clínica Universitaria de Navarra, Pamplona, SPAIN, ¹¹Hospital Universitario Son Espases, Palma de Mallorca, SPAIN, ¹²Hospital Universitario Virgen de la Arrixaca, Murcia, SPAIN, ¹³Hospital 12 de Octubre, Madrid, SPAIN, ¹⁴Hospital Universitario Ramón y Cajal, Madrid, SPAIN, ¹⁵Hospital Universitario 12 de Octubre, Madrid, SPAIN, ¹⁶H. de la Santa Creu i Sant Pau, Barcelona, SPAIN, ¹⁷Hospital Universitario de Burgos, Burgos, SPAIN, ¹⁸Hospital Universitario de Getafe, Madrid, SPAIN, ¹⁹Hospital Universitario Gregorio Marañón, Madrid, SPAIN, ²⁰Hospital General Universitario Morales Meseguer, Murcia, SPAIN, ²¹Hospital Universitario Central de Asturias, Oviedo, SPAIN.

EP-0793
 PRRT with Lu-177-DOTATATE and monitoring with SSTR-PET/CT in patients with PPGL tumors

S. Kunte¹, A. Holzgreve¹, M. Schöll¹, V. U. Wenetr¹, G. T. Sheikh¹, M. Scheifele¹, F. J. Gildehaus¹, S. Lindner¹, M. K. Auer², C. Lottspeich², M. Kroiß², S. Nölting², F. Völter², C. Spitzweg²,

C. J. Auernhammer², R. A. Werner³, M. J. Zacherl¹; ¹Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY, ²Department of Internal Medicine IV, LMU University Hospital, Munich, GERMANY, ³Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY.

EP-0794
 “Rechallenge” peptide receptor radionuclide therapy (PRRT) may be less efficient than initial PRRT while safety profile is comparable

P. Hartrampf^{1,2}, A. Kosmala¹, S. Alwers¹, F. Lutz¹, S. Serfling¹, A. Meining³, A. Buck¹, A. Weich^{3,2}; ¹University Hospital Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY, ²University Hospital Würzburg, ENETS Center of Excellence, Würzburg, GERMANY, ³University Hospital Würzburg, Department of Internal Medicine II, Würzburg, GERMANY.

EP-0795
 First Real-World Evidence on the Safety and Effectiveness of ¹⁷⁷Lu-DOTATATE for Treating Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Insights from Post-Marketing Surveillance

Y.-i. Kim¹, H. Suh², Y. Kang², H. Cho³, S. Hyun⁴, Y. Song⁵, S. Ha⁶, K. Kang⁷; ¹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, ²Novartis Korea Ltd., Seoul, KOREA, REPUBLIC OF, ³Severance Hospital, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF, ⁵Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KOREA, REPUBLIC OF, ⁶Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF, ⁷Seoul National University Hospital, Seoul National University, Seoul, KOREA, REPUBLIC OF.

EP-0796
 Cycle-to-Cycle Reduction in External Dose Rate as a Predictor of Therapeutic Response in [177Lu] DOTATATE Therapy for Neuroendocrine Tumours

N. Wakabayashi^{1,2}, S. Watanabe^{1,2,3}, S. Takeuchi^{4,5}, S. Takeuchi^{5,6}, K. Hirata^{1,2,3}, R. Kimura^{2,7}, J. Takenaka^{2,8}, H. Koga^{1,2}, K. Kudo^{2,3,7}; ¹Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, JAPAN, ²Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN, ³Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Sapporo, JAPAN, ⁴Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN, ⁵Neuroendocrine Tumor Center, Hokkaido University Hospital, Sapporo, JAPAN, ⁶Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Hokkaido University, Sapporo, JAPAN, ⁷Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, JAPAN, ⁸Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, GERMANY.

EP-0797
 Study of the effectiveness of PRRT in 177 Lu-DOTATATE - treated patients

B. Kalman¹, Z. Ritter¹, E. Mezösi¹, A. Bos-Liedke², D. Dezső¹; ¹University of Pécs, Pécs, HUNGARY, ²Department of Biomedical Physics of Adam Mickiewicz University, Poznan, POLAND.

EP-0798
 Is There a Correlation between Metabolic Tumor Volume and Progression-free Survival in Neuroendocrine Tumors Treated with LU-177-Oxodotreotide?

S. Salcedo Cortes, E. Ardila Manjarrez, A. Mari Hualde, J. Guzmán Cruz, I. Gómez Fernández, J. Ardila Mantilla, L. Reguera Berenguer, V. Castillo Morales, J. Orcajo Rincón, D. Zamudio Rodriguez, S. Álvarez Lara, G. Mera Ovalle, J. Alonso Farto; Hospital General Universitario Gregorio Marañón, Madrid, SPAIN.

EP-50
 e-Poster Area

C: Therapy Clinical Study -> C1 Oncological Therapy Clinical Study -> C12 Prostate Cancer Therapy

EP-0799
 Appropriate selection of pretreatment PSMA-ligand PET/CT parameters helps in candidate selection for ¹⁷⁷Lu-PSMA radionuclide therapy in men with metastatic castration-resistant prostate cancer (mCRPC)

S. Chen, Y. Yip, S. Cheung, Y. Wong, K. Wu, K. Cheng, C. Ho; Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

EP-0800
 [177Lu]Lu-PSMA-617 in patients with mCRPC and brain metastases : a multicentric retrospective French study

D. Tonnelet¹, F. Sommes², K. Hebert³, M. Claudin⁴, K. Weyts⁵, P. Robin⁶, M. Lacombe⁷, N. De Leiris⁸, C. Baillet⁹; ¹Henri Becquerel Cancer Center, Rouen, FRANCE, ²Institut de Cancérologie Strasbourg Europe, Strasbourg, FRANCE, ³L'Institut du Cancer de Montpellier, Montpellier, FRANCE, ⁴Centre Hospitalier Régional et Universitaire de Nancy, Vandœuvre-lès-Nancy, FRANCE, ⁵Centre de Lutte Contre le Cancer François Baclesse, Caen, FRANCE, ⁶CHU Brest, Univ Brest, Inserm, UMR 1304, GETBO, Brest, FRANCE, ⁷Institut de Cancérologie de l'Ouest Angers-Nantes, Angers, FRANCE, ⁸Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, FRANCE, ⁹Centre Hospitalier Universitaire de Lille, Lille, FRANCE.

EP-0801
 Could BMI affect efficacy of LuPSMA in mCRPC patients? Data from a phase II clinical trial

I. Grassi¹, E. Giunta², I. Marini¹, S. Nicolini¹, P. Caroli¹, M. Celli¹, M. Casi³, C. Lollì², N. Brighi², G. Schepisi², S. Bleve², V. Di Iorio⁴, A. Sarnelli², M. Monti⁶, F. Foca⁶, J. Karabina⁶, A. Prochowski Iamurri⁷, F. Matteucci⁸, M. Sansovini¹; ¹Nuclear Medicine Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ²Medical Oncology Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ³Nuclear Medicine Department, Romagna Local Health Authority, Cesena FC, ITALY, ⁴Radiopharmacy - Pharmacy Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ⁵Medical Physics Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ⁶Biostatistics and Clinical Trials Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ⁷Nuclear Medicine Department, Romagna Local Health Authority Bufalini Hospital, Cesena FC, ITALY, ⁸Nuclear Medicine Department, Romagna Local Health Authority Bufalini Hospital, Cesena FC, ITALY.

Tumori “Dino Amadori”, (IRST), Meldola FC, ITALY, ⁷Radiology Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST) Meldola (FC) Italy, Meldola FC, ITALY, ⁸Nuclear Medicine Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Nuclear Medicine Department, Romagna Local Health Authority, Meldola FC, Cesena FC, ITALY.

EP-0802
 LuPSMA in mCRPC: beyond toxicity and clinical complications, why might it be necessary to delay treatment? Practical and realworld data from a prospective study

I. Grassi¹, I. Marini¹, S. Nicolini¹, V. Di Iorio², A. Sarnelli³, M. Monti⁴, P. Caroli¹, M. Celli¹, M. Casi⁵, F. Foca⁴, J. Karabina⁴, E. Gianì⁴, E. Giunta⁶, C. Lollì⁶, A. Rossi⁷, F. Matteucci⁸, M. Sansovini¹; ¹Nuclear Medicine Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ²Radiopharmacy - Pharmacy Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ³Medical Physics Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ⁴Biostatistics and Clinical Trials Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ⁵Nuclear Medicine Department, Romagna Local Health Authority Bufalini Hospital, Cesena FC, ITALY, ⁶Medical Oncology Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ⁷Radiology Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST) Meldola (FC) Italy, Meldola FC, ITALY, ⁸Nuclear Medicine Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Romagna Local Health Authority Bufalini Hospital, Meldola FC, Cesena FC, ITALY.

EP-0803
 LuPSMA in mCRPC used out of indication before AIFA indications: data and considerations from a prospective study

I. Grassi¹, I. Marini¹, E. Giunta², S. Nicolini¹, P. Caroli¹, L. Fantini¹, M. Casi³, C. Lollì², N. Brighi², G. Schepisi², S. Bleve², A. Sarnelli⁴, V. Di Iorio⁵, M. Monti⁶, F. Foca⁶, E. Gianì⁶, F. Ferroni⁷, F. Matteucci⁸, M. Sansovini¹; ¹Nuclear Medicine Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ²Medical Oncology Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ³Nuclear Medicine Department, Romagna Local Health Authority Bufalini Hospital, Cesena FC, ITALY, ⁴Medical Physics Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ⁵Radiopharmacy - Pharmacy Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ⁶Biostatistics and Clinical Trials Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola FC, ITALY, ⁷Nuclear Medicine Department, Romagna Local Health Authority Bufalini Hospital, Cesena FC, ITALY, ⁸Nuclear Medicine Department, Romagna Local Health Authority Bufalini Hospital, Meldola FC, Cesena FC, ITALY.

EP-0804
 Addition of ¹⁷⁷Lu-PSMA-617 in the treatment of hormone sensitive metastatic prostate cancer: a prospective pilot study

V. H., N. Pandit, S. Kayal;
Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, INDIA.

EP-0805
Hematological Safety of ¹⁷⁷Lu-PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: Real-World Evidence from a Developing Country

A. Gupta, A. H. Nazar, M. Ora, P. K. Pradhan;
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, INDIA.

EP-0806
Interim Analysis of Effect of Hypoxia on F-18 MISO PET to Response to Lu-177 PSMA Treatment (LuMISO)Trial

C. Soydal, E. Dursun Avci, B. Demir, G. İnal, M. Araz, N. O. Kucuk;
Ankara University Medical Faculty, Ankara, TÜRKIYE.

EP-0807
Do We Need to Reconsider Our Treatment Protocol for Metastatic Prostate Cancer With [¹⁷⁷Lu]Lu-PSMA-Radioligand?

T. Bogsrud^{1,2}, O. Engelsen¹, P. Iversen², P. F. Staantum², A. T. Kendi³, J. Zhang³, M. P. Thorpe³, F. J. Hernandez-Delima,³, O. Sartor⁴, J. M. Durski³;
¹PET Imaging Center, University Hospital of North-Norway, Tromsø, NORWAY, ²Aarhus University Hospital, Aarhus, DENMARK, ³Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA, ⁴Tulane University Department of Urology and Medicine, New Orleans, LA, UNITED STATES OF AMERICA.

EP-0808
Prediction of Treatment Response and Progression-Free Survival Based on Pre-Treatment PSA Levels and PET/CT Parameters in Prostate Cancer with Lu-177 PSMA Therapy

S. Ceylan, B. B. Demirel, G. Uçmak;
Ankara Oncology Training and Research Hospital Nuclear Medicine Clinic, Ankara, TÜRKIYE.

EP-0809
Assessment of Sequential Radium-223 and Docetaxel Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer: Insights from the Global REASSURE Study

Y. Du¹, S. Baldari², A. Versari³, S. Lastoria⁴, J. Bourre⁵, C. La Fougère⁶, E. Borsatti⁷, J. Meltzer⁸, M. J. Korn⁸, S. Dizdarevic⁹;
¹Royal Marsden Hospital, London, UNITED KINGDOM, ²University of Messina, Messina, ITALY, ³Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, ITALY, ⁴IRCCS National Cancer Institute, Fondazione Senatore G. Pascale, Naples, ITALY, ⁵Centre Hospitalier Métropole Savoie, Chambéry, FRANCE, ⁶University Hospital Tübingen, Tübingen, GERMANY, ⁷Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, ITALY, ⁸Bayer HealthCare Pharmaceuticals, Whippany, NJ, UNITED STATES OF AMERICA, ⁹University Hospitals Sussex NHS Foundation Trust, Brighton & Sussex Medical School, University of Sussex and Brighton, Brighton, UNITED KINGDOM.

EP-0810
[¹⁷⁷Lu]Lu-DOTA-HYNIC-panPSMA radioligand therapy for patients with metastatic castration-resistant prostate cancer

J. Roetman¹, Y. Omar², Y. Attaya², M. Elkanawaty², A. Ahmed³, G. Elhusseiny³, M. El Shazly³, A. Ameen³;

¹Telix Pharmaceuticals, Melbourne, AUSTRALIA, ²Misr Radiology Center, Cairo, EGYPT, ³Alexandria University, Alexandria, EGYPT.

EP-0811
Dual-Tracer Deep Learning-Based Prediction of Voxel-Wise Absorbed Dose for PSMA Radioligand Therapy in mCRPC

S. Xue¹, A. A. Nikolic², S. Wen¹, B. Jan², M. Hacker¹, C. Lapa², X. Li¹;
¹Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, AUSTRIA, ²Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY.

EP-0812
Radioligand therapy for metastatic prostate cancer: the first French qualitative study exploring patient perceptions, from experience to trust

C. Lachachi¹, P. Barthelemy², N. Houede³, E. Treuveur⁴, S. Chene⁵, M. de Loisy⁵, M. Wartski⁶;
¹Hospices civils de Lyon, Hopital Louis Pradel, Bron, FRANCE, ²ICANS, Strasbourg, FRANCE, ³CHU de Nîmes, Nîmes, FRANCE, ⁴AplusaResearch, Boulogne-Billancourt, FRANCE, ⁵Novartis Pharma SAS, Rueil-Malmaison, FRANCE, ⁶APHP, Hopital Cochin, Paris, FRANCE.

EP-0813
Long-Term Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [¹⁷⁷Lu]Lu-PSMA Therapy: A Real-World Study from a Resource-Constrained Southeast Asian Tertiary Care Center

A. Nazar, M. ora, P. Pradhan, S. Barai, A. Arya;
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, INDIA.

EP-0814
Association between early scintigraphic and biochemical response after one cycle of [177Lu] LuPSMA-617 radioligand therapy in metastatic castrationresistant prostate cancer patients

A. Silva, L. C. Silva, F. P. M. Oliveira, D. C. Costa;
Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL.

EP-0815
Linking Dual-Tracer Imaging and Lesion Dosimetry to Predict Outcomes in mCRPC Patients Treated with [¹⁷⁷Lu]Lu-PSMA Therapy

S. Wen¹, S. Xue¹, M. Hacker¹, X. Li¹, A. A. Nikolic², L. Constantin², B. Jan²;
¹Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, AUSTRIA, ²Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY.

EP-0816
Early Prediction of Response to Treatment With ¹⁷⁷Lu-iPSMA Using ¹⁸F-PSMA 1007 PET/CT in Castration-Resistant Prostate Cancer.

A. Arriaga Contreras, R. Hernández Ramírez, M. Corza Ayala, F. Solano Caballero, O. Lucio Baez;
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad De México, MEXICO.

EP-0817
Immediate Renal Response to ¹⁷⁷Lu-PSMA Radioligand Therapy: Insights from a Prospective Observational Study

A. Nazar, R. Mehra, M. ora, P. Pradhan;
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, INDIA.

EP-0818
Effect of tumor load on physiological organs uptake of 18-F PSMA in patients with distant metastatic prostatic carcinoma

R. Mostafa¹, T. Ahmed¹, M. T. Amin¹, G. El-Hennawy²;
¹South Egypt Cancer Institute, Assiut University, Assiut, EGYPT, ²National cancer Institute, Cairo University, Cairo, EGYPT.

EP-0819
Radium-223 (Xofigo) for the treatment of metastatic castration-resistant prostate cancer: our experience.

C. Galindo, M. De la Rubia Marcos, K. Guichay, D. Rodriguez Oviedo, M. Alvarez Moreno, J. Sanchez Calderón, M. Castillejos Rodriguez, A. Herrero Muñoz, C. Paniagua Correa, A. Ortega Valle, M. García Alonso, M. Tagliatori Nogueira;
Hospital Universitario de Getafe, Madrid, SPAIN.

EP-0820
¹⁷⁷Lu-PSMA-617 therapy in patients with mCRPC: First descriptive analysis of efficacy and safety from a single-oncology center in Greece.

V. Chatzipavlidou, D. Iakovoglou, T. Kalathas, I. Aisiopoulos, A. Vatalis, L. Zoglopitou, A. Paschali; Theagenio, Thessaloniki, GREECE.

EP-0821
Treatment with [²²³Ra]RaCl₂ in Metastatic Castration-Resistant Prostate Cancer Patients: Experience at Our Centre

M. Ottino, O. Ajuria Illarramendi, A. Martínez Lorca, P. Azpeitia Hernández, M. Gutierrez Guerrero, I. Hernández Pérez, T. Navaro Martínez, U. Vera Schmülling, M. Orduña Díez, E. Pérez de los Ríos, A. Torres Consiglieri, P. Paredes Rodríguez;
Hospital Universitario Ramón y Cajal, Madrid, SPAIN.

EP-0822
A Phase 1, first-in-human, dose-escalation study of [²²⁵Ac]-AZD2284 (AZD2284), a STEAP2-directed radiopharmaceutical, in patients with metastatic castration-resistant prostate cancer (mCRPC)

F. Almaguel^{1,2}, L. Nordquist³, B. Tran⁴, M. S. Hofman⁴, S. Allan³, K. Buchanan⁶, J. Charlton⁶, J. Dise⁵, G. Lunger⁵, N. Mueller⁷, M. A. Patel⁸, D. Slade⁶, M. Petruzzelli⁶, M. Nawinne⁶, M. Sathekge^{9,10};
¹Loma Linda University School of Medicine, Loma Linda, CA, UNITED STATES OF AMERICA ²Biogenix Molecular, Miami, FL, UNITED STATES OF AMERICA ³Xcancer, Omaha, NE, UNITED STATES OF AMERICA ⁴Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ⁵Fusion Pharmaceuticals, Boston, MA, UNITED STATES OF AMERICA ⁶AstraZeneca, Cambridge, UNITED KINGDOM, ⁷AstraZeneca, Gaithersburg, MD, UNITED STATES OF AMERICA ⁸AstraZeneca, New York, NY, UNITED STATES OF AMERICA ⁹Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA, ¹⁰Nuclear Medicine Department, University of Pretoria, Pretoria, SOUTH AFRICA.

EP-0823
The Effectiveness of Radium-223 on Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis

T. Chen, Y. Chang;
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TAIWAN.

EP-0824
PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to ¹⁷⁷Lu-PSMA and ²²⁵Ac -PSMA Radioligand Therapy

L. Gabela, L. Harry, T. Nxasana, N. Ndlovu, T. Mkhize, V. Pillay, S. Masikane, M. Patel, N. Madi, P. Chiumia, C. Kalowa, B. Hadebe, M. Vorster;
University of KwaZulu Natal, Durban, SOUTH AFRICA.

EP-0825
Linking Dual-Tracer Imaging and Lesion Dosimetry to Predict Outcomes in mCRPC Patients Treated with [¹⁷⁷Lu]Lu-PSMA Therapy

S. Wen¹, S. Xue¹, X. Li¹, M. Hacker¹, A. A. Nikolic², B. Jan², L. Constantin²;
¹Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, AUSTRIA, ²Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY.

EP-0826
A Model for ¹⁷⁷Lu-PSMA Therapy in Nuclear Medicine Departments Without Dedicated Shielding Rooms
A. Genova, F. Porcaro, M. Prisco, L. Turchetta, I. Annarumma, V. Piscopo, M. Catalano;
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Naples, ITALY.

EP-0827
Prognostic Value of a Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last ¹⁷⁷Lu-PSMA Therapy Injections Through Serial High-Speed Whole-Body 360° CZT-SPECT

C. Boursier, J. Kunsch, T. Zaragori, P. Olivier, M. Claudin, S. Heyer, P. Raymond, P.-Y. Marie, L. Imbert;
CHRU Nancy, Vandoeuvre-les-Nancy, FRANCE.

EP-0828
Which reference organ can be used on Post Therapeutic ¹⁷⁷Lu-PSMA SPECT/CT when images are performed at different timepoint?

L. Michaud¹, S. Gnesin², J. Delage³, M. Tissier¹, A. Fenter¹, J. O. Prior¹, N. Schaefer¹;
¹Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ²Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ³Radiopharmacy Unit, Department of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND.

EP-0829
Prognostic value of ¹⁸FDG and ⁶⁸Ga-PSMA PET parameters in mCRPC patients referred for ¹⁷⁷Lu-PSMA therapy

B. Adam, T. Zaragori, M. Claudin, A. Verger, P. Olivier, L. Imbert, C. Boursier;
Nancy University Hospital of Lorraine, Nancy, FRANCE.

EP-0830

Prognostic Value of Baseline PSMA and FDG PET Biomarkers in Patients Treated with Lutetium-177 [¹⁷⁷Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: A Real-World Analysis from the ProSTIC Registry.

N. Kovaleva¹, L. Kostos^{2,3}, N. Papa¹, J. Weindler¹, R. Alipour^{1,2}, B. Emmerson¹, G. Ghosh¹, G. Kong^{1,2}, E. Medhurst¹, A. S. Ravi Kumar^{1,2}, J. Saghebi^{1,2}, A. A. Azad^{2,3}, M. S. Hofman^{1,2}, J. P. Buteau^{1,2};

¹Prostate Cancer Theranostic and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, AUSTRALIA, ²Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, AUSTRALIA, ³Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, AUSTRALIA.

EP-0831

Influence of Chemohormonal History on Lu-177 PSMA Efficacy

S. Karabulut;

Dokuz Eylül Üniversitesi Hastanesi, İzmir, TÜRKİYE.

EP-51

e-Poster Area

C: Therapy Clinical Study -> C1 Oncological Therapy Clinical Study -> C13 Local Radionuclide Therapy (including Spheres)

EP-0832

Research on the Radiotherapy-Immunotherapy Effect of Sequential Combination of I¹³¹ with Transcription of the NIS Gene into Mouse Models of Pancreatic Cancer Based on Oncolytic Virus as the Delivery Vector

S. Yu, S. Xinhui;

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, CHINA.

EP-0833

Transarterial Radioembolization (TARE) with Yttrium-90 Microspheres in Primary Liver Lesions: Impact on Survival and Disease Progression

B. Jaramillo Lopez, A. Suazo Montero, M. García Aragón, R. Zambrano Infantino., F. Sebastián Palacid, C. Gamazo Laherrán., J. Gómez Hidalgo, N. Álvarez Mena., M. González Soto., R. Ruano Pérez.;
Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EP-0834

Dose-Response Relationship in Patients Who Received TARE with Y-90 Resin Microspheres for Hepatocellular Carcinoma

C. Soydal, E. Dursun Avci, I. Mesci, E. C. Celebioglu, N. O. Kucuk;
Ankara University Medical Faculty, Ankara, TÜRKİYE.

EP-0835

Body Surface Area Method vs Partition Dosimetry Model in Y-90 Radioembolisation: A retrospective Dosimetric Analysis

A. Cuderman, A. Štrok, J. Jamšek, L. Jensterle, P. Popovič;
University Medical Centre Ljubljana, Ljubljana, SLOVENIA.

EP-0836

Initial experience with ³²P microparticles in the treatment of advanced pancreatic cancer

D. Sánchez-Artuñedo¹, I. Navales-Mateu², M. Sebastián-Segura¹, R. Bellviure-Meiro², J. Suils-Ramón², M. Beltran-Vilagrasa¹, C. Gamez-Cenzano²;

¹Servei de Física i Protecció Radiològica. Hospital Universitari Vall d'Hebron, Barcelona, SPAIN, ²Servei de Medicina Nuclear. Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

EP-0838

MAA-Based Dosimetry for Predicting Tumor Response and Survival Post-TARE in Liver Metastasis Patients

F. Meisner¹, E. Can², S. Wirtz³, P. T. Meyer¹, C. Goetz¹;

¹Department of Nuclear Medicine, Medical Center of the University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY, ²Department of diagnostic and interventional radiology Medical Center of the University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY, ³Clinical Trials Unit, Medical Center of the University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY.

EP-0839

Therapeutic Outcomes of Radiosynoviorthesis: A Retrospective Analysis from a Tertiary Care Center in India

P. Baberwal, G. B. Priyanka, Y. Khandelwal, B. Jain, S. Shamim;

All India Institute of Medical Sciences, Delhi, INDIA.

EP-0840

Elevated Baseline C-Reactive Protein Is Associated with Treatment Failure and Shorter Survival After Radioembolization with Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma: Validation of LI-RADS R-TRA v2024

E. Kaya¹, B. Akkas¹, T. Güzelbey², C. Erdim², M. Arslan², C. Şin¹, H. B. Kapucu¹, M. Kaya¹;

¹Basaksehir Cam and Sakura City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKİYE, ²Basaksehir Cam and Sakura City Hospital, Department of Radiology, Istanbul, TÜRKİYE.

EP-0841

Rethinking Planning: MAA Outperforms CBCT in Predicting Final Dose in TARE

S. Salcedo Cortes¹, L. Ramos², J. Orcajo Rincon¹, L. Reguera Berenguer¹, J. Ardila Mantilla¹, E. Ardila Manjarez¹, A. Mari Hualde¹, I. Gómez Fernández¹, V. Castillo Morales¹, J. Guzmán Cruz¹, S. Álvarez Lara¹, G. Mera Ovalle¹, J. Alonso Farto¹;

¹Hospital General Universitario Gregorio Marañón, Madrid, SPAIN, ²Hospital Universitario de Canarias, Canarias, SPAIN.

EP-0842

Single-Center Experience Comparing Glass and Resin Microspheres in Lobar Y-90 SIRT for Early- to Intermediate-Stage Hepatocellular Carcinoma

X. Zheng, H. Xi, J. v. Sluis, M. W. Nijkamp, G. C. Bloemsm, M. Kater, S. J. Ruiter, W. Noordzij;
University Medical Center Groningen, Groningen, NETHERLANDS.

EP-0843

Does Aberrant Tumor Vascularization Pose an Obstacle to Radioembolization?

S. Omay^{1,2}, B. Esen Akkaş^{1,2}, M. Arslan^{1,2};

¹Basaksehir Çam ve Sakura Sehir Hastanesi, Istanbul, TÜRKİYE, ²University of Health Sciences Basaksehir Cam and Sakura City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKİYE.

EP-0844

A Novel Prognostic Model for Colorectal Cancer Patients Treated with Y-90: The CRP Kinetics Approach

A. Dere, E. M. Kaya, C. Sin, B. E. Akkas, M. Kaya;

University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKİYE.

EP-0845

Dose increase in perfused volumes in selective internal radiation therapy with microspheres labeled with holmium-166

J. Deportos, S. Lafuente-Carrasco, M. Salcedo-Pujantell, N. Canchumanya-Huatuco, M. Boronat De Ferrater, M. Solà, V. Vallejos, S. Ruiz-Llama, A. Caresia Aroztegui, G. Moragas;
Hospital Universitari Germans Trias i Pujol, Badalona, SPAIN.

EP-0846

Voxel-by-voxel multicompartment dosimetric model in predicting the response of hepatocellular carcinoma to radioembolization with 90-yttrium spheres

J. Villa-Palacios, E. Triviño-Ibáñez, A. Piñeiro-Donis, L. Cagua Ruiz, E. Domínguez-Polanco, J. Ciampi-Dopazzo, A. Rodríguez-Fernández;
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0847

Comparison of Yttrium-90 Resin and Glass microsphere Radioembolization Dosimetry and Correlation with Treatment efficacy in Hepatocellular Carcinoma

N. Too¹, S. Koo², P. K. H. Chow^{1,2,3}, F. N. N. Moe³, A. K. T. Tong^{1,2}, K. S. H. Loke^{1,2};

¹Duke-National University of Singapore Medical School, Singapore, SINGAPORE, ²Singapore General Hospital, Singapore, SINGAPORE, ³National Cancer Centre Singapore, Program in Translational and Clinical Liver Cancer Research, Singapore, SINGAPORE.

EP-0848

Comparison of ^{99m}Tc-MAA SPECT/CT and ⁹⁰Y LAFOV PET/CT-based dosimetry for patients with colorectal liver metastases

C. Schneider, L. W. van Golen, S. M. Jansen, A. J. A. T. Braat, R. G. H. Beets-Tan, E. G. Klompenhouwer, B. J. de Wit-van der Veen;
Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

EP-0849

Assesment of overall survival in patients with liver tumors undergoing yttrium-90 and holmium-166 radioembolization

L. Casas Fernández, M. Romero Otero, A. Palazón Palazón, P. Soto Muñoz, T. Peris Conejero;
Unidad de Radiofarmacia Hospital Clí Universitario de Valencia, Valencia, SPAIN.

EP-0850

Survival Outcomes in Transarterial Radioembolization with ⁹⁰Y-Resin for Hepatic Malignant Tumours

A. Bagán-Trejo¹, J. J. Martín-Marcuartu¹, J. L. Díaz-Moreno¹, G. Reynés-Llompарт², D. Rodríguez-Puig³, S. Maymó-Garrido³, M. Á. Crespi-Busquets³, E. Serrano-Alcalá⁴, B. Gener-Laquidán⁴, L. Lladó-Garriga⁵, E. Ramos-Rubio⁵, A. Amador-Navarrete⁶, M. R. Rota-Roca⁶, M. Cortés-Romera¹;
¹Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Medical Physics and Radiation Protection Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN, ³Radiopharmacy Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain, ⁴Diagnostic Imaging Centre, Vascular Interventional Radiology Section, Radiology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN, ⁵Liver Transplant Unit, General and Digestive Surgery Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN, ⁶Gastroenterology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EP-0851

The Role of RAI Treatment Selection and RAI Therapy in Papillary Thyroid Microcarcinoma in the Right Patient

E. Cansu Çay, B. B. Demirel, G. Uçmak;

Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, TÜRKİYE.

EP-0852

Thyroglobulin doubling time and prognosis in lung metastases of differentiated thyroid carcinoma

H. Wang, Y. Wang, R. Tian;

West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0853

Integrating Lenvatinib with High-Dose Radioiodine: A Promising Approach for Advanced well-differentiated thyroid cancer

S. Sharma, P. Chauhan, M. Ora, P. Pradhan, S. Barai, A. H.

Nazar, S. Gambhir;
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, INDIA.

EP-0854

Comparison of patients with differentiated thyroid cancer in a German and an American collective in tertiary treatment centers.

F. Eilsberger¹, A. C. Prietsch¹, A. Pfestroff¹, W. Bowl¹, A. Ebrahimifard¹, S. Bagheri¹, B. H. Yousefi¹, P. Di Fazio¹, M. Luster¹, R. M. Tuttle²;

¹University Hospital Marburg, Marburg, GERMANY, ²Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0855

A Study on the Dynamic Changes of Anti-Thyroid Peroxidase Antibodies Before and After the First ¹³¹I Treatment in Patients with Differentiated Thyroid Cancer After Surgery

W. Cao¹, H. Chen²;

¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²Department of Nuclear

Medicine, Union Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan,
CHINA.

EP-0857
**Evaluation of theTreatmentResponse to RAI Therapy
in Papillary Thyroid Cancer Patients with Pulmonary
Metastases**

A. Akil¹, A. Kibar¹, R. Alsabbagh², O. E. Şahin¹, S. Asa¹, R. L.
Uslu-Beşli¹, M. S. Sağer¹, K. Sönmezoğlu¹, H. B. Sayman¹;
¹Istanbul University – Cerrahpaşa, Cerrahpaşa Faculty
of Medicine, Department of Nuclear Medicine, Istanbul,
TÜRKIYE, ²Biruni University, Faculty of Medicine, Istanbul,
TÜRKIYE.

EP-0858
**Pretreatment Predictors of Short-Term Outcomes in
RAI-Treated Intermediate-Risk Thyroid Cancer**

G. B. Babacan^{1,2}, S. Saracoglu³, O. Guven², S. Sabuncu², M.
N. Acar Tayyar², T. Ozulker², M. C. Sahin², S. Karyagar²;
¹Sirnak State Hospital, Clinic of Nuclear Medicine, Sirnak,
TÜRKIYE, ²University of Health Sciences, Hamidiye Faculty
of Medicine, Prof. Dr. Cemil Tascioglu City Hospital,
Department of Nuclear Medicine, Istanbul, TÜRKIYE, ³Van
Training and Research Hospital, Department of Nuclear
Medicine, Van, TÜRKIYE.

EP-0859
**To compare the response of low- and high-dose
Lenvatinib in patients with radioiodine-refractory
thyroid cancer: A non-inferiority trial**

P. Chauhan, S. Sharma, R. Mehra, P. K. Pradhan, S.
Gambhir;
Sanjay Gandhi Post Graduate Institute of Medical Sciences,
Lucknow, INDIA.

EP-0860
**Association between early Tg elevation and
subsequent reduction after I-131 therapy in
differentiated thyroid carcinoma: A dynamic
biomarker study.**

Y. Li¹, K. Hirata^{1,2,3}, J. Takenaka^{1,2}, S. Watanabe^{1,2}, R. Kimura^{1,4},
K. Kudo^{1,2,4};
¹Department of Diagnostic Imaging, Graduate School
of Medicine, Hokkaido University, Sapporo, JAPAN,
²Department of Nuclear Medicine, Hokkaido University
Hospital, Sapporo, JAPAN, ³Global Center for Biomedical
Science and Engineering, Faculty of Medicine, Hokkaido
University, Sapporo, JAPAN, ⁴Department of Diagnostic and
Interventional Radiology, Hokkaido University Hospital,
Sapporo, JAPAN.

EP-0861
**Preablative Stimulated Thyroglobulin, Its Post-
131I Treatment Decline, and Nomogram-Based
Prediction of Clinical Outcomes in Differentiated
Thyroid Cancer Patients Without Distant Metastasis**

Y. Hou^{1,2,3}, J. Wang^{1,4}, R. Wu^{1,2,3}, J. Tan⁵, X. Xia^{1,2,3}, Z. Gao^{1,2,3};
¹Department of Nuclear Medicine, Union Hospital, Tongji
Medical College, Huazhong University of Science and
Technology, Wuhan, CHINA, ²Hubei Province Key Laboratory
of Molecular Imaging, Wuhan, CHINA, ³Key Laboratory
of Biological Targeted Therapy, the Ministry of Education,
Wuhan, CHINA, ⁴Department of Medical Imaging,
Henan Provincial People's Hospital, Zhengzhou, CHINA,
⁵Department of Breast and Thyroid Surgery, Union Hospital,
Tongji Medical College, Huazhong University of Science and
Technology, Wuhan, CHINA.

EP-0862
**Impact of Body Mass Index on Clinical Presentation
and Outcomes in Differentiated Thyroid Cancer: A
Retrospective Study**

Y. Hou^{1,2,3}, Y. Zhou^{1,2,3}, X. Xia^{1,2,3};
¹Department of Nuclear Medicine, Union Hospital, Tongji
Medical College, Huazhong University of Science and
Technology, Wuhan, CHINA, ²Hubei Province Key Laboratory
of Molecular Imaging, Wuhan, CHINA, ³Key Laboratory
of Biological Targeted Therapy, the Ministry of Education,
Wuhan, CHINA.

EP-0863
**Management of Low-Risk Differentiated Thyroid
Carcinomas in Nuclear Medicine: A retrospective
study of 280 cases**

M. Nacer Khodja, S. Rahal, S. Meza, M. Medjaher;
Central Hospital of the Army, Algiers, ALGERIA.

EP-0864
**The anti-thyroglobulin antibody trajectory and risk
of structural recurrence in patients with papillary
thyroid cancer**

H. Wang, R. Tian;
West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0865
**Predictive Value of Pre-ablation sTg/TSH Ratio and
Lateral Cervical Lymph Node Metastasis Ratio in
Initial 131I Treatment Response for Papillary Thyroid
Cancer**

R. Zhang, W. Li, Q. Jia, H. Wang, W. Zheng, J. Tan;
Department of Nuclear Medicine, Tianjin Medical University
General Hospital, Tianjin, CHINA.

EP-0866
**Multicenter Study of Spanish Therapy Units: Early
Side Effects of 131I Therapy**

L. Cagua Ruiz¹, T. Aroui Luquin¹, J. Villa-Palacios¹,
L. Menedez - Muros¹, P. Stefan², A. Piñero Donis¹, E.
Dominguez-Polanco¹, R. Sánchez Sánchez¹, M. Muros de
Fuentes¹;
¹Servicio Medicina Nuclear Hospital Universitario Virgen de
las Nieves, Hospital Universitario Virgen de las Nieves, SPAIN,
²Servicio Medicina Nuclear Hospital Universitario Virgen de
las Nieves, Hospital Universitario la Fe, SPAIN.

EP-0867
**Multicenter Study of Spanish Therapy Units. II. Late
Side Effects of 131I Therapy.**

E. Domínguez Polanco¹, J. Villa-Palacios¹, A. Piñeiro
Donis¹, L. Cagua Ruiz¹, C. Mallon Araujo², R. Sánchez
Sánchez¹, M. Muros de Fuentes¹;
¹Hospital Universitario Virgen de las Nieves, Granada, SPAIN,
²Hospital Clínico Universitario de Santiago, Santiago, SPAIN.

EP-0868
**Long-term clinical outcome of patients with
differentiated thyroid cancer and raised
antithyroglobulin antibody levels: a retrospective
study**

H. Shim, M. Kim;
Inje University, Haeundae Paik Hospital, Busan, KOREA,
REPUBLIC OF

EP-0869
**Immunological Alterations Following
Thyroidectomy in Differentiated Thyroid Carcinoma
Patients: A Comparative Study**

W. Zhang, H. Liu, S. Li, P. Wang;
Department of Nuclear Medicine, The First Hospital of
Shanxi Medical University, Taiyuan, CHINA.

EP-0870
**Predictors of Hypothyroidism Requiring
Levothyroxine Substitution after Radioiodine
Therapy in Unifocal Thyroid Autonomy**

K. Klimek^{1,2}, C. Happel², F. Grünwald², R. Werner¹, D.
Groener²;
¹Department of Nuclear Medicine, University Hospital, LMU
Munich, Munich, GERMANY, ²Goethe University Frankfurt,
University Hospital, Department of Nuclear Medicine, Clinic
for Radiology and Nuclear Medicine, Frankfurt, GERMANY.

EP-0871
**Analysis And Optimization Of Radioiodine Therapy
Based On The Study Of Radioiodine-131 Biokinetics
Data**

G. Grushka^{1,2}, A. Savchenko³, V. Bobrova⁴;
¹Kharkiv National Medical University, Kharkiv, UKRAINE, ²SO
«Grigoriev Institute for Medical Radiology and Oncology
of the National Academy of Medical Sciences of Ukraine»,
Kharkiv, UKRAINE, ³V. N. Karazin Kharkiv National University,
Kharkiv, UKRAINE, ⁴SO «Grigoriev Institute for Medical
Radiology and Oncology of the National Academy of
Medical Sciences of Ukraine», Kharkiv, UKRAINE.

EP-0872
**Oncocytic Thyroid Carcinoma on the Rise: Divergent
Evolution and Response to Radioiodine Treatment**

M. Zambrana-Delgadillo, M. Piñero Fernandez- Reyes, M.
Cardoso-Rodríguez, M. Jerez-Jaimes, A. Lara-Hernández, J.
Rodríguez-Rubio Corona, C. Quintana-Bolaño, Y. Santaella-
Guardiola, F. Partida-Palma, M. Gutiérrez-Amases, M.
Pajares-Vinardell;
Hospital Universitario Puerta del Mar, Cadiz, SPAIN.

EP-0873
**Recurrent differentiated thyroid cancer: predictive
factors and outcome**

J. Mihailovic¹, I. Starcevic¹, J. Roganovic²;
¹Faculty of Medicine University of Novi Sad, Novi Sad,
²Oncology Institute of Vojvodina, Sremska Kamenica,
SERBIA.

EP-0874
**Quantitative Assessment of Salivary Gland
Volumetric and Metabolic Changes Following
Radioiodine Therapy in Differentiated Thyroid
Carcinoma**

S. Watanabe^{1,2}, K. Hirata^{1,2}, H. Endo¹, J. Takenaka^{1,2,3}, N.
Wakabayashi^{1,2}, R. Kimura^{1,4}, H. Koga^{1,4}, K. Kudo^{1,4};
¹Department of Diagnostic Imaging, Graduate School
of Medicine, Hokkaido University, Sapporo, JAPAN,
²Department of Nuclear Medicine, Hokkaido University
Hospital, Sapporo, JAPAN, ³Comprehensive Heart Failure
Center, University Hospital Würzburg, Würzburg, GERMANY,
⁴Department of Diagnostic and Interventional Radiology,
Hokkaido University Hospital, Sapporo, JAPAN.

EP-0875
**Gender impact in Radioactive Iodine (131I) clearance
in Thyroid Cancer treatment**

J. Koutsikos, G. Thiveos, T. Petropoulos, I. Papantoniou, S.
Giourgouli, A. Kokkini - Paschou, E. Skoura, I. Datseris;
Henry Dunant Hospital Center, Athens, GREECE.

EP-53
e-Posre Area

**C: Therapy Clinical Study -> C1 Oncological
Therapy Clinical Study -> C15 Other
Oncological Treatments**

EP-0876
**Phase 1 dose-escalation study on astatine-211
labelled meta-astatobenzylguanidine ([211At]mABG)
for treatment of recurrent or refractory high-risk
neuroblastoma: study design and rationale**

L. Teles¹, B. van der Wildt^{1,2}, M. van Noesel^{1,3}, R. van Rooij^{1,2},
A. Poot^{1,2}, A. Braat^{1,2,4};
¹Princess Máxima Center for Pediatric Oncology, Utrecht,
NETHERLANDS, ²University Medical Center Utrecht /
Wilhelmina Children's Hospital, Utrecht, NETHERLANDS,
³Division Imaging and Cancer, University Medical Center
Utrecht, Utrecht, NETHERLANDS, ⁴Netherlands Cancer
Institute, Amsterdam, NETHERLANDS.

EP-0877
**Efficacy and safety of Lu177-EDTMP therapy for
bone pain palliation in cancer patients with multiple
skeletal metastasis**

K. Vidhya, M. Negi, V. K. Saini, D. Sundriyal, M. Gupta, F.
Huda, S. Sinha, V. K. Dhingra;
AIIMS, Rishikesh, Rishikesh, INDIA.

EP-0878
**Preliminary Evaluation of 225Ac/177Lu-DOTATATE
PRRT in Advanced Meningiomas: Efficacy,
Dosimetry, and Imaging Insights**

M. Assadi¹, R. Nemat², E. Jafari¹, N. Jokar¹, M. Peer-
Firozjaei³, S. Rekabpour⁴, M. Khazaei⁵;
¹The Persian Gulf Nuclear Medicine Research Center,
Department of Nuclear Medicine, Molecular Imaging, and
Theranostics, Bushehr Medical University Hospital, School of
Medicine, Bushehr University of Medical Sciences, Bushehr,
IRAN, ISLAMIC REPUBLIC OF, ²Department of Neurology,
Bushehr Medical University Hospital, School of Medicine,
Bushehr University of Medical Sciences, Bushehr, IRAN,
ISLAMIC REPUBLIC OF, ³Student Research Committee,
Babol University of Medical Sciences, Babol, IRAN, ISLAMIC
REPUBLIC OF, ⁴Department of Oncology, Salman Farsi
Hospital, Bushehr, IRAN, ISLAMIC REPUBLIC OF, ⁵Department
of Radiology, Bushehr Medical University Hospital, School of
Medicine, Bushehr University of Medical Sciences, Bushehr,
IRAN, ISLAMIC REPUBLIC OF.

EP-0879
**Peptide Receptor Radionuclide Therapy with
[177Lu]Lu-DOTATATE in Progressive Refractory
Meningiomas: A Single-Centre Retrospective
Analysis**

L. Degryse¹, L. Teles², S. De Vleeschouwer¹, L. Boeckxstaens¹,
S. Jentjens³, M. Lambrecht¹, J. Daisne⁴, K. Van Laere¹, P.
Clement¹, K. Goffin¹, C. M. Deroose¹;
¹University Hospitals Leuven, Leuven, BELGIUM, ²Princess
Máxima Center for Pediatric Oncology, Utrecht,
NETHERLANDS, ³Maastricht University Medical Center,
Maastricht, NETHERLANDS, ⁴ZAS, Antwerp, BELGIUM.

EP-0880
**Assessment of 177Lu-PSMA-617 Retention
in Inoperable/heavily pretreated Pancreatic
adenocarcinoma: Implication for Theranostic
Feasibility**

G. B. Priyanka, N. A. Damle, A. N. Singh, K. Kuradia, S. Mishra, S. J. Bharati, R. Yadav, M. Tripathi, S. A. Shamim, C. Ganapathy, A. Choudhary, M. Aishwarya;
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0881
FAP-directed Radiopharmaceutical Therapy in metastatic gastrointestinal carcinoma as rescue therapy after failure of conventional treatments: A retrospective analysis on safety, efficacy and survival

E. Perrone¹, K. Gha², T. Parkar², A. Eismant², R. Moretti³, L. Greifenstein², R. P. Baum²;
¹Nuclear Medicine Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ITALY, ²CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY, ³Unità della Fisica per le Scienze della Vita, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ITALY.

EP-0882
Sustained Tumor Retention of Lu-177 PSMA-617 in Recurrent High-Grade Gliomas: a step further in theranostics
V. Arunachalam Ragupathi, N. Damle, M. Tripathi, S. Shamim, V. Tandon, K. Haresh, S. Bharati, A. Kumar, S. Gupta, A. Singhal, S. Rastogi, A. Mohan;
All India Institute of Medical Sciences, Delhi, INDIA.

EP-0883
⁶⁸Ga/¹⁷⁷Lu-PSMA Theranostics in Recurrent High-Grade Glioma
A. Karlberg^{1,2}, B. E. Vindstad², H. Tøndel¹, H. Johansen¹, T. M. Keil¹, E. M. Berntsen^{1,2}, O. Solheim^{1,2}, S. Kjærnes Øen¹, T. Skeidsvoll Solheim^{1,2}, L. Eikenes²;
¹St. Olavs Hospital, Trondheim, NORWAY, ²Norwegian University of Science and Technology, Trondheim, NORWAY.

EP-0885
Potential impact of PRRT with Lutetium 177 DOTATATE in patients with recurrent high risk meningiomas
I. Dev¹, A. Puranik^{2,3}, A. Agrawal^{2,3}, N. Purandare^{2,3}, S. Shah^{2,3}, S. Choudhury^{4,3}, S. Ghosh^{4,3}, M. M V^{4,3}, V. Rangarajan^{2,3};
¹Advanced Center for Training, Research & Education in Cancer (ACTREC), Tata Memorial Center Homi Bhabha National Institute, Navi Mumbai, Mumbai, INDIA, ²Tata Memorial Hospital, Mumbai, INDIA, ³Bhabha National institute, Mumbai, INDIA, ⁴Advanced Centre for Treatment, Research and Education IN Cancer (ACTREC), Tata Memorial Hospital, Mumbai, INDIA.

EP-0886
Tumor dosimetry and correlations with pre-therapeutic SSSTR PET in patients receiving [¹⁷⁷Lu] Lu-DOTATATE treatment for recurrent meningioma
M. Mair^{1,2}, A. Delker¹, K. J. Müller³, V. Stoecklein⁴, L. Wiegand¹, A. C. Wehn⁴, V. Wenter¹, M. Zacherl¹, M. Preusser², M. Brendel¹, P. N. Harter^{5,6,7}, C. Schichor⁴, N. L. Albert^{1,6,7};
¹Department of Nuclear Medicine, LMU Univerisity Hospital, LMU Munich, Munich, GERMANY, ²Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, AUSTRIA, ³Department of Neurology, LMU University Hospital, LMU Munich, Munich, GERMANY, ⁴Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, GERMANY, ⁵Center of Neuropathology and Prion Research, LMU University Hospital, LMU Munich, Munich, GERMANY, ⁶Bavarian

Cancer Research Center (BZKF), Partner Site Munich, Munich, GERMANY, ⁷German Cancer Consortium (DKTK), Partner Site Munich, Munich, GERMANY.

EP-0887
Treatment with 188-Rhenium resin for non-melanoma skin cancer. First treatments performed in Spain.
D. Vega Perez, E. Martínez Albero, A. Saviatto Nardi, C. García Donoso, B. García Bracamonte, S. Angiolillo Grau, E. López Llobet, Á. Galiana Morón, B. Manzarbeitia Arroba, P. Zaragoza Ballester, X. Guarnizo, P. Ortiz Romero, M. Tabuenca Mateo;
Hospital 12 de Octubre, Madrid, SPAIN.

EP-0888
[¹⁷⁷Lu]Lu-FAP-2286 Treatment Response in Metastatic Lesions vs Local Recurrence Lesions in Breast Cancer Patients
M. Nasiri¹, R. Nami², S. Banihashemian³, G. Divband⁴, A. Abolhosseini Shahrnoy², S. Mazidi⁵, M. Akbari⁶;
¹Department of Cellular & Molecular Biology, School of Biology, Damghan University, Damghan, IRAN, ISLAMIC REPUBLIC OF, ²Parsisotop Company, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Khatam PET-CT Center, Khatam-al-Anbia Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵Parsisotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁶Cancer Research Center, Shahid Beheshti University of Medical Sciences, Damghan, IRAN, ISLAMIC REPUBLIC OF.

EP-0889
Disease control rate in patients with advanced meningioma performing PRRT: an updated meta-analysis
B. Muoio¹, C. Iacovitti², D. Bosetti¹, M. Cuzzocrea², G. Paone², G. Treglia²;
¹EOC IOSI Oncology Institute of Southern Switzerland, Bellinzona, SWITZERLAND, ²EOC Imaging Institute of Southern Switzerland, Bellinzona, SWITZERLAND.

EP-0890
Tumour-absorbed dose and efficacy of peptide receptor radionuclide therapy with ⁹⁰Y-DOTATOC in patients with refractory meningioma
L. Schweiger;
Medical University of Innsbruck, Department of Nuclear Medicine, Innsbruck, AUSTRIA.

EP-0891
Gastrointestinal Adverse Effects in ¹⁷⁷Lu-FAPI-2286 Radioligand Therapy: Contributing Factors and Strategies for Reducing Uptake-Related Symptoms
N. Raeisi, A. Saber Tanha, K. Aryana;
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-54

e-Poster Area

C: Therapy Clinical Study -> C2 Non-Oncological Treatments -> C21 Non-Oncological Treatments (including Thyroid Benign)

EP-0892
Efficacy of Radiosynoviorthesis in the Management of Non-Infectious Synovialitis Following Total Knee Arthroplasty
D. Simankova¹, M. Simanek², A. Simankova¹;
¹Institute of Nuclear Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, CZECH REPUBLIC, ²Orthopaedic Department of Sokolov Hospital, Sokolov, CZECH REPUBLIC.

EP-0893
Identification of risk factors for relapse of Graves-Basedow disease after radioiodine treatment
S. Adamantiadis¹, L. Urso¹, L. Manco², F. Sartori³, M. Borghesi⁴, V. Marino Picciola⁵, A. Gobbo⁵, L. Uccelli¹, M. C. Zatelli⁶, M. R. Ambrosio⁵, M. Bartolomei⁶, C. Cittanti¹;
¹Department of Translational Medicine, University of Ferrara, Ferrara, ITALY, ²Medical Physics Unit, University Hospital of Ferrara, Ferrara, ITALY, ³School of Medicine, University of Ferrara, Ferrara, ITALY, ⁴Department of Economy and Management, University of Ferrara, Ferrara, ITALY, ⁵Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, ITALY, ⁶Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, ITALY.

EP-0894
Feasibility of Tc-99m-based pre-treatment dosimetry in patient receiving radioidine therapy for hyperthyroidism: comparison with pre- and post-treatment assessments
M. Meraldi, C. Romanò, G. Muti, C. Carbonini, V. Piva, G. Cabrini, S. Capitanio, A. Franchini, E. Gay, A. F. Scarale, A. Spataro, C. Rossetti, P. E. Colombo;
ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY.

EP-0895
Functional assessment of post-radiation xerostomia therapy with allogeneic mesenchymal stromal stem cells in patients with head and neck cancer by salivary gland scintigraphy - a phase I clinical trial
L. Lezaic¹, A. Socan¹, G. Plavc², M. Kokalj², G. Mitrovic², O. Blatnik², A. Bavec³, N. Tesic⁴, K. Hartman⁴, U. Svajger⁴, P. Strojan²;
¹University Medical Centre Ljubljana, Division of Nuclear Medicine, Ljubljana, SLOVENIA, ²Institute of Oncology Ljubljana, Ljubljana, SLOVENIA, ³Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA, ⁴Blood Transfusion Centre of Slovenia, Ljubljana, SLOVENIA.

EP-0896
The evaluation of radioiodine therapy out come after five years in patient with subclinical hyperthyroidism
S. Abdelrazek, P. Szumowski, J. Mysliwiec, I. Sulima;
Medical University of Bialystok, Bialystok, POLAND.

EP-0897
Radioactive iodine therapy in hyperfunctioning thyroid nodules: who are doomed to hypothyroidism?
D. Carvalho, S. Barata, S. Paiva, I. Casimiro, J. Silva, L. Lemos, M. Monteiro, P. Lapa, G. Costa;
ULS Coimbra - HUC, Coimbra, PORTUGAL.

EP-0898
Ensemble learning model for the prediction of a response to ¹³¹I-Nal therapy in hyperthyroidism - ablative dose concept
N. Pantic¹, B. Radovic^{1,2}, B. Pantic³, M. Kotur¹, L. Grujicic¹, J. Zivanovic¹, A. Novkovic¹, J. Petrovic^{1,4}, I. Grozdic Milojevic^{1,4}, D. Sobic Saranovic^{1,4}, V. Artiko^{1,4}, S. Odalovic^{1,4};
¹Center for Nuclear Medicine with PET, University Clinical Center of Serbia, Belgrade, SERBIA, ²Faculty of Medicine, University of Pristina with temporary headquarters in Kosovska Mitrovica, Kosovska Mitrovica, SERBIA, ³Freelance IT researcher, Belgrade, SERBIA, ⁴Faculty of Medicine, University of Belgrade, Belgrade, SERBIA.

EP-0899
Early and sustained thyroid volume reduction following radioiodine therapy in Graves’ hyperthyroidism: A 6-month prospective study
R. Zhang, H. Wang, Q. Jia, P. Chang, J. Tan, W. Zheng;
Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, CHINA.

EP-0901
Radiation Synovectomy with ¹⁷⁷Lu-MAA in Patients with Inflammatory Knee Joint Disorders
K. Saglam¹, M. S. Sağer¹, S. Bilgiç², E. Karayel¹, H. Pehlivanoğlu¹, A. Aygün¹, N. Yeyin¹, M. K. Özşahin¹, M. Özer¹, C. D. Davulcu¹, H. Botanlioğlu¹, S. Asa¹, O. E. Şahin¹, R. L. Uslu¹, H. B. Sayman¹;
¹Istanbul University-Cerrahpasa, Istanbul, TÜRKIYE, ²Uludag University, Bursa, TÜRKIYE.

EP-0902
Graves’ Disease: Is Hyperthyroidism Still Present 6 Months After Radioactive Iodine Treatment Really a Failure?
M. Acar Tayyar, E. Uyanık, M. Mülazımoğlu, M. Ö. Tamam, S. Karyağar, M. Biçen Altın, F. Yıldız Kabaca, M. Cinoğlu Karaca, A. Vergili, T. Özülker;
University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, TÜRKIYE.

EP-55

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D11 SPECT and SPECT/CT

EP-0903
Impact of attenuation correction on SPECT/CT myocardial perfusion imaging in relation to Body mass Index (BMI)
S. Mammeri¹, A. Bouzidi²;
¹University Military Hospital of Ouargla Algeria, Ouargla, ALGERIA, ²University Military Hospital of Constantine, Constantine, ALGERIA.

EP-0904
 Towards 3D: an advanced flow phantom to validate dynamic renal SPECT imaging

H. Suoraniemi¹, M. Seppänen², T. Noponen¹;
¹Department of Clinical Physiology, Nuclear Medicine, Turku PET Centre and Medical Physics, Turku University Hospital and Wellbeing Services county of Southwest Finland, Turku, FINLAND, ²Department of Clinical Physiology, Nuclear Medicine and Turku PET Centre, Turku University Hospital and Wellbeing Services County of Southwest Finland, Turku, FINLAND.

EP-0905
 Evaluation of the SIMIND Monte Carlo Program on a planar and SPECT system using ¹⁷⁷Lu demonstrated potential for personalized dosimetry

M. Dias^{1,2}, P. Ferreira¹, R. Parafita¹, M. Costa¹, F. Oliveira¹, L. C. Silva¹, Â. Silva¹, J. Cruz², D. C. Costa¹;
¹Champalimaud Foundation, Lisboa, PORTUGAL, ²Faculdade de Ciências e Tecnologia, Universidade Nova de Lisbon, Lisbon, PORTUGAL.

EP-0906
 Breathing artifact remotion in SPECT/CT images of liver lesions: a phantom-based study

G. Abbatini^{1,2}, B. Cassano¹, M. D'Andrea¹, R. Sciuto³, A. Soriani¹, S. Ungania¹, L. Misoè⁴, G. Iaccarino¹;
¹Medical Physics Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY, ²Post Graduation School of Medical Physics, University of Rome “Tor Vergata”, Rome, ITALY, ³Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY, ⁴Medical Physics Service, USL Umbria 2, Foligno, ITALY.

EP-0907
 Optimization of ^{99m}Tc SPECT in the presence of ⁹⁰Y: towards a single-session radioembolization workflow

C. Kerckhaert, M. M. A. Dietze, R. van Rooij, M. B. M. Meddens, N. Wijnen, M. L. J. Smits, M. G. E. H. Lam, H. W. A. M. de Jong;
 University Medical Center Utrecht, Utrecht, NETHERLANDS.

EP-0908
 Use of myocardial SNR in optimisation of myocardial perfusion scintigraphy

T. Biggans, J. Asogan Vaishnavi, A. K. Raofi, P. Guntur Ramkumar;
 NHS Tayside, Dundee, UNITED KINGDOM.

EP-0909
 Incidental detection of ATTR cardiac amyloidosis by ^{99m}Tc-DPD bone scintigraphy and SPECT/CT

M. Corza Ayala, R. Hernandez Ramírez, K. Cárdenas Soto, A. Arriaga Contreras, F. Solano Caballero, O. Lucio Baez;
 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, MEXICO.

EP-0910
 Imaging the Impractical: Optimising Imaging for Therapies With Under 10 MBq of Beta-Emitting P32

C. Oldfield, S. Sargant;
 Manchester Foundation Trust, Manchester, UNITED KINGDOM.

EP-0911
 Clinical implementation of an Advanced SPECT/CT service on the GE Healthcare Aurora Gamma Camera

L. Rowley, E. Comber, C. Low, V. Leung, O. Adesanya;
 University Hospitals Coventry and Warwickshire, Coventry, UNITED KINGDOM.

EP-0912
 Impact of Reduced Acquisition Time on Quantitative Gated SPECT Parameters Using a Dedicated CZT Cardiac Camera

T. Cakir¹, A. Guner¹, V. Beylergil²;
¹Medipol University, Istanbul, TÜRKIYE, ²Memorial Sloan Kettering Cancer Center, Istanbul, TÜRKIYE.

EP-0913
 Optimization of Imaging Parameters for Posttherapeutic SPECT/CT in Patients with PSMA-Positive mCRPC Following ¹⁷⁷Lu-PSMA Radioligand Therapy

D. Sfiligoj Planjsek, K. Senica, A. Strok, B. Simonic, I. Slodnjak, S. Rep;
 UMC Ljubljana, Ljubljana, SLOVENIA.

EP-56

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D12 PET/CT

EP-0914
 Assessing Reduced Ga⁶⁸ Activity and Shortened Acquisition Times on Image Quality and Lesion Contrast in LAFOV PET/CT: A Phantom Study.

G. Muti¹, C. Romano¹, A. Didonna¹, M. Meraldi¹, C. Pettinato², C. Carbonini¹, C. Rossetti¹, P. Colombo¹;
¹ASST GOM Niguarda, Milan, ITALY, ²Fondazione IRCCS Ca' Granda, Milan, ITALY.

EP-0915
 Design and Initial Evaluation of a 2-Meter Axial FOV Total-Body PET System With Integrated DOI and TOF Capability

D. Liang, Y. Lin, Z. Zhao, H. Zou, Y. Xu, H. Liu, Y. Lin, W. Ma, W. Zhu, J. Tao, H. Zhao, W. Li, Y. Zhang, Q. Peng;
 Shenzhen Bay Laboratory, Shenzhen, CHINA.

EP-0916
 Optimisation of scanning protocols for the Siemens Biograph long-axial field-of-view scanner: Can higher patient throughput with improved image quality be achieved at reduced patient dose?

G. Krokos, S. Chicklore, J. MacKewn, J. John, S. Pereira, S. Gould, S. Jin, G. Testanera, A. Hammers, P. K. Marsden, G. Cook;
 King's College London, London, UNITED KINGDOM.

EP-0917
 Comparison of Detectability Between Digital LYSO and Digital BGO-Based PET/CT Scanners: A Phantom Study using an Anthropomorphic XL-Thorax Phantom

A. Stenvall¹, S. Kvernby^{1,2}, D. Minarik^{1,2};
¹Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, SWEDEN, ²Department of Translational Medicine and Wallenberg Centre of Molecular Medicine, Lund University, Malmö, SWEDEN.

EP-0918
 Development of ultrahigh sensitivity brain-PET system

A. Krol¹, W. Zheng¹, E. S. Harmon², M. O. Thompson³, C. R. Schmidtlein⁴;
¹SUNY Upstate Medical University, Syracuse, NY, UNITED STATES OF AMERICA, ²LightSpin Technologies, Inc., Norfolk, MA, UNITED STATES OF AMERICA, ³Cornell University, Ithaca, NY, UNITED STATES OF AMERICA, ⁴Memorial Sloan-Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0919
 First clinical J-PET positronium lifetime imaging in patients with neuroendocrine tumors

E. Stepień^{1,2}, M. Das^{1,2}, M. Opalińska³, A. Hubalewska-Dydejczyk³, S. Sharma^{1,2}, A. Sowa-Staszczak³, P. Moskał^{1,2}, J-PET collaboration;
¹Institute of Physics, Jagiellonian University, Krakow, POLAND, ²Center for Theranostics, Jagiellonian University, Krakow, POLAND, ³Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND.

EP-0920
 Simulation studies of performance of an advanced brain-PET system with novel multi-concentric-ring geometry

A. Krol¹, W. Zheng¹, E. S. Harmon², M. O. Thompson³, C. R. Schmidtlein⁴;
¹SUNY Upstate Medical University, Syracuse, NY, UNITED STATES OF AMERICA, ²LightSpin Technologies, Inc., Norfolk, MA, UNITED STATES OF AMERICA, ³Cornell University, Ithaca, NY, UNITED STATES OF AMERICA, ⁴Memorial Sloan-Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0921
 Impact of the hydration protocol on contrast enhancement in ¹⁸F-FDG whole-body PET/CT imaging of lymphoma lesions at Apeksha Hospital, Maharagama, Sri Lanka

J. M. A. D. Jayasinghe¹, D. D. N. Wimalaratne¹, H. G. D. Pasindu¹, W. S. N. Madhumali¹, W. C. Perera², S. P. D. Wijethunga²;
¹General Sir John Kotelawale Defence University, Ratmalana, SRI LANKA, ²Apeksha Hospital, Maharagama, SRI LANKA.

EP-0922
 Design and Evaluation of a Pediatric Total-Body PET Scanner for Enhanced Sensitivity and Reduced Dose

P. Sheikhzadeh¹, H. Rezaei²;
¹Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Shiraz University of Medical Science, Shiraz, IRAN, ISLAMIC REPUBLIC OF.

EP-0923
 Exploring the Clinical Feasibility of a Wearable Brain PET System: Early Imaging Results and Outlook

H. Liu, W. Qu, X. Yu, D. Liang, Z. Zhao, Y. Lin, J. Tao, W. Li, H. Zhao, Y. Zhang, Q. Peng;
 Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, CHINA.

EP-0924
 FDG PET/CT Based Radiomics Analysis in Endometrium Cancer: Correlation of Tumor Heterogeneity Parameters with Pathological Findings

F. Avci¹, A. Tunc¹, B. K. Erkek², A. A. Ozsaran³, G. Serin⁴, O. Zekioglu⁴, Z. Burak¹;

¹Ege University, Nuclear Medicine, Izmir, TÜRKIYE, ²Agri Training and Research Hospital, Nuclear Medicine, Izmir, TÜRKIYE, ³Ege University, Obstetrics and Gynecology, Izmir, TÜRKIYE, ⁴Ege University, Pathology, Izmir, TÜRKIYE.

EP-0925
 SUV and SUL Analysis in Ga-68 DOTATATE PET/CT: Is Liver or Spleen a More Reliable Reference?

F. Davarci, Y. Parlak, F. Gümüşer, E. Sayit Bilgin;
 Manisa Celal Bayar University, Faculty of Medicine, Department of Nuclear Medicine, Manisa, TÜRKIYE.

EP-0926
 Improving Brain PET/CT Accuracy with 3D Data-Driven Motion Compensation in Head CT

A. Ashfaq¹, R. Fulton², M. Luster¹;
¹Department of Nuclear Medicine, Philipps-University Marburg, Marburg, GERMANY, ²University of Sydney, Sydney, AUSTRALIA.

EP-0927
 Evaluation of the new-generation digital bismuth germanium oxide PET/CT system according to the Japanese brain tumor phantom test for ¹⁸F-fluciclovine imaging

F. Sasaki¹, S. Fuka², H. Daisaki¹, M. Sato¹, A. Yumoto¹, T. Kita¹, N. Imaizumi¹, M. Shiga², H. Yoshida², K. Motegi², N. Shimada², A. Osawa², T. Terauchi²;
¹Gunma Prefectural College of Health Sciences, Gunma, JAPAN, ²The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JAPAN.

EP-0928
 Feasibility and Comparative analysis of ultrafast F-18 imaging for enhanced bone scan efficiency in obese patients

L. Ghadhanfer¹, M. Alqabandi¹, E. Alawadhi¹, T. Alahmad¹, Z. Alqalla², A. Sadeq², F. Marafi²;
¹Kuwait University, Kuwait, KUWAIT, ²Ministry of Health, Kuwait, KUWAIT.

EP-57

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D13 PET/MR

EP-0929
 Extended Data-Driven Motion Detection Method for PET Imaging

N. Beriashvili¹, L. Tellmann¹, C. Régio Brambilla¹, J. Scheins¹, K. Ciantar^{1,2}, M. Chikhradze³, N. Shah^{1,4,5}, C. Lerche¹;
¹Institute of Neuroscience and Medicine 4 (INM-4), Forschungszentrum Jülich GmbH, Jülich, GERMANY, ²Institute of Imaging and Computer Vision, RWTH Aachen University, Aachen, GERMANY, ³Department of Engineering Physics, Georgian Technical University, Tbilisi, GEORGIA, ⁴Institute of Neuroscience and Medicine 11 (INM-11), Forschungszentrum Jülich GmbH, Jülich, GERMANY, ⁵Department of Neurology, RWTH Aachen University, Aachen, GERMANY.

EP-0930
 Evaluating the Impact of MR Contrast on ¹⁸F-FDG Quantification in Neuro PET-MR Studies through Comparison of Pre- and Post-Contrast Images

L. Westhead;
Sheffield Teaching Hospitals NHS Foundation Trust,
Sheffield, UNITED KINGDOM.

EP-58
 e-Poster Area

D: Technical Studies -> D1 Instrumentation
-> D14 Imaging Guided Surgery and Other Instruments

EP-0931
Targeted biopsy of bone metastases: an innovative technique in diagnostic evaluation
S. Rama Alonso, E. Campaña Díaz, F. Caltagirone Gutierrez, B. Santos García, J. Badell Martínez, P. García-Talavera San Miguel, E. Casillas Sagrado, J. Cañadas Salazar, L. Díaz González, E. Martín Gómez, J. Villanueva Curto, A. Peñaherrera Cepeda, F. Gómez-Camínero López;
Salamanca University Hospital, Salamanca, SPAIN.

EP-59
 e-Poster Area

D: Technical Studies -> D1 Instrumentation
-> D15 Quality Control, Performance and Standardization

EP-0932
The impact of EARL harmonization on interscanner variability of volume-based PET metrics: a phantom study and patient validation
A. Khalimon¹, A. Nikiforuk¹, A. Shakirova¹, I. Baltabaev¹, M. Khodzhibekova¹, G. Khamadeeva¹, D. Khodakova¹, T. Lazutina¹, I. Pylova¹, A. Leontev¹, A. Pronin², E. Bezumova²;
¹P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION, ²N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EP-0933
Leveraging Vision-Language Models for Automated Reporting of ^{99m}Tc-MAG3 Scintigraphy
W. B. Bosbach¹, C. L. Clement¹, F. Strunz¹, N. Gözlügöl¹, F. Aghapour Zangeneh¹, C. M. Bregenzer¹, C. Mingels¹, C. Beisbart², P. Koller¹, K. Zeimpekis¹, K. Shi¹, A. Rominger¹, R. Seifert¹;
¹Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND, ²Institute of Philosophy, University of Bern, Bern, SWITZERLAND.

EP-0934
Uncertainties in ILP leakage monitoring: residual activities and effective half-lives
A. Rintala, K. Nousiainen, T. Miettinen, M. Tenhunen, P. Vikatmaa, M. Laine, A. Granvik, A. Ristikankare, V. Reijonen;
Helsinki University Hospital, Helsinki, FINLAND.

EP-0935
Nuclear medicine equipment standardisation for clinical translation: a case study with Tb-161

K. Baete^{1,2}, W. Claeys², J. Noben², W. Deckers¹, C. Terwinghe¹, J. Kleynhans², F. Cleeren², C. M. Deroose^{1,2};
¹UZ Leuven, Leuven, BELGIUM, ²KU Leuven, Leuven, BELGIUM.

EP-0936
Homogeneity of the radioactivity distribution in 3D-printed PET phantoms
N. Jörg¹, A. J. Zounek¹, G. Palumbo¹, R. Oos¹, F. J. Gildehaus¹, N. L. Albert^{1,2,3}, K. Parodi⁴, S. Ziegler^{5,1}, L. Kaiser¹;
¹Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, ²German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ³Bavarian Cancer Research Center (BZKF), Erlangen, GERMANY, ⁴Department of Medical Physics, LMU Munich, Munich, GERMANY, ⁵Department of Nuclear Medicine, Hannover Medical School (MHH), Hannover, GERMANY.

EP-0937
Assessment of the Accuracy and Linearity of Radionuclide Calibrators for I-131 and Lu-177 Theranostic Radioisotopes in nuclear medicine therapy centers in Iran During 2024
E. Farajzadeh¹, S. Golshaiyan¹, M. Sadeghi², A. Shirzadi Golzar¹, M. Akbari¹, N. Habibi³, M. Davarpanah³;
¹Secondary Standard Dosimetry Laboratory (SSDL), Pars Isotope Co., Karaj, IRAN, ISLAMIC REPUBLIC OF, ²Shiraz University, Shiraz, IRAN, ISLAMIC REPUBLIC OF, ³Pars Isotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0938
Activity painting with 3D Printer for arbitrary PET phantom
J. Kiss¹, P. Szuszik², K. Kukuts³, A. Forgács³, I. Gara², L. Balkay²;
¹Division of Radiology and Imaging Science, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY, ²Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY, ³Mediso Ltd., Budapest, HUNGARY.

EP-0939
Standardizing Breast-Specific PET Imaging: Insights from Phantom and Clinical Studies in a Multicenter Japanese Trial
Y. Satoh¹, K. K. Miyake², M. Kataoka³, K. Itagaki⁴, S. Aoyama⁵, Y. Naoi⁵, Y. Inui⁶, H. Nosaka⁷, S. Ito⁸, Y. Inaoka⁹, Y. Kato¹, K. Miwa¹⁰, K. Kubota¹¹, M. Uno⁶, K. Hanaoka¹²;
¹Fujita Medical Innovation Center Tokyo, Ota-ku, Tokyo, JAPAN, ²Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine Kyoto University, Kyoto, JAPAN, ³Preventive Medicine and Lifestyle-related Disease Research Center, Kyoto University Hospital, Kyoto, JAPAN, ⁴Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, JAPAN, ⁵Clinical Imaging Center for Healthcare, Nippon Medical School, Tokyo, JAPAN, ⁶Department of Radiology, Fujita Health University Hospital, Aichi, JAPAN, ⁷Department of Radiological Technology and Science, Ibaraki Prefectural University of Health Science, Ibaraki, JAPAN, ⁸Mirai Imaging Ltd., Fukushima, JAPAN, ⁹Medical Systems Division, Shimadzu Corporation, Kyoto, JAPAN, ¹⁰Department of Radiological Sciences, School of Health Sciences, Fukushima, JAPAN, ¹¹Department of Radiology, Dokkyo Medical University Saitama Medical Center, Saitama, JAPAN, ¹²Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osaka, JAPAN.

EP-0940
Implementing a computer model of a Capintec ionisation chamber in GEANT4
H. Benderz, J. O'Brien, B. Thomson;
Sandwell and West Birmingham NHS Trust, Birmingham, UNITED KINGDOM.

EP-0941
Validation of a vented well-type ionization chamber with specifically designed vial holders for in-house Lu-177 reference activity samples
V. Reijonen¹, P. Toroi², R. Nyland², M. Tenhunen¹;
¹Helsinki University Hospital, Helsinki, FINLAND, ²STUK - Radiation and Nuclear Safety Authority, Vantaa, FINLAND.

EP-0942
A Calibration Workflow for Accurate Quantification of Rhenium-188 in RHN001-Tx for Theranostic Applications.
M. Qebetu¹, J. Cardinale², K. Banda¹, P. Goorhoo¹, K. M. Legodi¹, H. Ndlovu¹, C. Davis¹, L. Smith¹, S. Sibiya¹, A. Mdlophane¹, S. Mdanda¹, M. Shungube¹, M. Sathekege¹, K. Ramonaheng¹;
¹Nuclear Medicine Research Infrastructure, Pretoria, SOUTH AFRICA, ²Department of Nuclear Medicine, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, Düsseldorf, GERMANY.

EP-0943
Sensitivity and count rate performance studiesof a UHF-MRI compatible BrainPET insert with standard and non-standard tracers
D. Niekämper^{1,2}, J. Scheins¹, L. Tellmann¹, C. Hoffmann³, S. Spellerberg³, E. Pfähler¹, N. Beriashvili¹, N. Shah^{1,4,5}, C. Lerche¹;
¹Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine 4, Jülich, GERMANY, ²RWTH Aachen University, Department of Physics, Aachen, GERMANY, ³Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine 5, Jülich, GERMANY, ⁴RWTH Aachen University, Department of Neurology, Aachen, GERMANY, ⁵Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine 11, Jülich, GERMANY.

EP-0944
Impact of the manufacturer new scatter correction for the market oldest CZT ring SPECT-CT on ^{99m}Tc contrast of small hot and cold objects
A. Seret¹, C. Bernard²;
¹University of Liege, Liege, BELGIUM, ²CHU of Liege, Liege, BELGIUM.

EP-0945
Establishing metrologically traceable activity measurements for alpha-emitter astatine-211 to improve the accuracy of equipment routinely used in the clinic
E. Leidermark^{1,2}, B. Sabot³, H. Jensen⁴, T. Bäck¹, L. Persson⁵, S. Palm¹;
¹Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, ²Department of Radiation Physics in Nuclear Medicine, Sahlgrenska University Hospital, Gothenburg, SWEDEN, ³CEA, LIST, Laboratoire National Henri Becquerel, Gif-sur-Yvette Cedex, FRANCE, ⁴Department of Clinical Physiology and Nuclear Medicine, Cyclotron and Radiochemistry Unit, Rigshospitalet, Copenhagen, DENMARK, ⁵Swedish Radiation Safety Authority, Stockholm, SWEDEN.

EP-0946
Novel Scatter and Tail Corrections Improve Low-Activity Lu-177-PSMA Imaging in Digital 3D Ring SPECT/CT
L. Kääriä¹, M. Seppänen², T. Nojonen¹;
¹Department of Clinical Physiology, Nuclear Medicine, Turku PET Centre and Medical Physics, Turku University Hospital and Wellbeing Services County of Southwest Finland and University of Turku, Turku, FINLAND, ²Department of Clinical Physiology, Nuclear Medicine and Turku PET Centre, Turku University Hospital and Wellbeing Services County of Southwest Finland and University of Turku, Turku, FINLAND.

EP-0947
Cross calibration of a dose calibrator with a gamma counter for ⁶⁸Ga and ¹⁸F activity measurements
T. Assoignon¹, M. Hesse², F. Dupont²;
¹UCLouvain, Woluwe-Saint-Lambert, BELGIUM, ²Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, BELGIUM.

EP-0948
Exploring Activity and Scan Time Reduction of [¹⁸F] PSMA-1007 within EARL2 Standards
L. Kloosterboer, L. Heijmen, J. W. J. van Brecht, P. Dibbets-Schneider, T. Ruytenberg, L. de Geus-Oei, D. D. D. Rietbergen, F. H. P. van Velden;
Leiden University Medical Center, Leiden, NETHERLANDS.

EP-0949
3D Printed PET/CT Phantom with Mixed Target Uptake Characteristics to Investigate Lesion Development
O. Caselles^{1,2}, S. Nalla^{1,3}, Q. Maronnier¹, T. Palchan-Hazan⁴, J. Kennedy^{4,5};
¹Oncopole Claudius REGAUD - IUCT Oncopole, Toulouse, FRANCE, ²Tachyons SAS, Toulouse, FRANCE, ³Universite de Toulouse, Toulouse, FRANCE, ⁴Rambam Health Care Campus, Haifa, ISRAEL, ⁵Technion Israel Institute of Technology, Haifa, ISRAEL.

EP-0950
Quantitative accuracy of clinical PET systems in the UK (2019-2023)
A. Fenwick, A. Robinson, A. Denis Bacerlar, K. Ferreira, D. Deidda, D. Roddy, W. Heetun;
National Physical Laboratory, Teddington, UNITED KINGDOM.

EP-0951
Development and Evaluation of a 3D-Printed Thyroid Phantom for Simulating Hot and Cold Nodules in SPECT Imaging
J. Kiss¹, K. Kukuts², A. Forgács²;
¹Division of Radiology and Imaging Science, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY, ²Mediso Ltd., Budapest, HUNGARY.

EP-0952
Manufacturer improvement of ^{99m}Tc scatter correction for its long bore collimator CZT ring SPECT-CT
A. Seret¹, K. Di Bartolomeo², C. Bernard³;
¹University of Liege, Liege, BELGIUM, ²GE Healthcare, Brussels, BELGIUM, ³CHU of Liege, Liege, BELGIUM.

EP-0953
FDG Extravasation in PET/CT Imaging: A Visual Grading Approach Based on Clinical Observations

S. Bilgic;
Bursa Uludag University, Bursa, TÜRKIYE.

EP-0954
Evaluation of Costs and Accuracy a 3D-Printed Four-Organ Phantom Using a Commercial Desktop Printer for Standardized Dosimetry in Molecular Radiotherapy

A. Yumoto¹, F. Sasaki¹, T. Kita¹, N. Imaizumi¹, M. Sato¹, M. Shiga², S. Fukai², Y. Tajika¹, H. Daisaki¹;
¹Gunma Prefectural College of Health Sciences, Gunma, JAPAN, ²The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JAPAN.

EP-0955
The impact of EARL harmonization on PET kinetic parameters

G. Khamadeeva, A. Khalimon, I. Baltabaev, A. Shakirova, M. Khodzhibekova, T. Lazutina, I. Pylova, D. Khodakova, A. Leontev;
P. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EP-0956
Harmonization of Quantitative Values in Bone SPECT/CT for Medication-related Osteonecrosis of the Jaw

T. Kita¹, I. Kuromori¹, H. Daisaki¹, M. Sato¹, F. Sasaki¹, A. Yumoto¹, N. Imaizumi¹, Y. Owaki², T. Tsuchitani³, N. Hayashi⁴, M. Tsujimoto⁵, Y. Maeda⁶, N. Ueno⁷, Y. Iwabuchi², T. Norikane⁸, Y. Inui³, H. Kaida⁷, K. Ito⁹, K. Kitajima³;
¹Gunma Prefectural College of Health Sciences, Gunma, JAPAN, ²Keio University School of Medicine, Tokyo, JAPAN/JAPAN, ³Hyogo College of Medicine College Hospital, Hyogo, JAPAN, ⁴Kochi Medical School Hospital, Kochi, JAPAN, ⁵Fujita Health University Hospital, Aichi, JAPAN, ⁶Tokushima Bunri University, Tokushima, JAPAN, ⁷Kindai University Hospital, Osaka, JAPAN, ⁸Kagawa University Hospital, Kagawa, JAPAN, ⁹National Cancer Center Hospital, Tokyo, JAPAN.

EP-60

e-Poster Area

D: Technical Studies -> D2 Data Analysis and Artificial Intelligence -> D21 Image Reconstruction / Denoising / Filtering

EP-0957
Brain MRI-guided PET Reconstruction in a New PET/ MRI System with State-of-the-art TOF resolution

J. Cabello¹, K. Kettless², P. Lehmann^{2,3}, A. B. Rodell², J. Schaefferkoetter¹, I. Law⁴, F. L. Andersen^{4,5}, T. L. Andersen^{4,5}, P. Schleyer¹;
¹Siemens Medical Solutions USA, Inc, Knoxville, TN, UNITED STATES OF AMERICA, ²Siemens Healthcare A/S, Ballerup, DENMARK, ³Research & Clinical Translation, Magnetic Resonance, Siemens Healthineers AG, Erlangen, GERMANY, ⁴Department of Clinical Physiology and Nuclear Medicine,

Copenhagen University Hospital—Rigshospitalet, Copenhagen, DENMARK, ⁵Department of Clinical Medicine, University of Copenhagen, Copenhagen, DENMARK.

EP-0958
Robustness of Radiomics Parameters to Respiratory Motion: a Phantom Study

H. Halvorsen¹, L. M. Bonney^{1,2}, G. M. Kalisvaart³, F. H. P. van Velden³, W. Grootjans³, D. R. McGowan^{1,4};
¹Oxford University Hospitals NHS Foundation Trust, Oxford, UNITED KINGDOM, ²Sir William Dunn School of Pathology, University of Oxford, Oxford, UNITED KINGDOM, ³Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS, ⁴Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM.

EP-0959
Preliminary results from a deep learning PET-derived attenuation correction of paediatric FDG brain images

I. Armstrong¹, A. Coates¹, L. Partin², R. Fahmi², J. Schaefferkoetter², B. Spottiswoode², S. Muthu¹;
¹Manchester University NHS Foundation Trust, Manchester, UNITED KINGDOM, ²Siemens Medical Solutions, Knoxville, TN, UNITED STATES OF AMERICA.

EP-0960
Monte Carlo Based SPECT Reconstruction: Improvements to Quantitative Imaging

L. Polson¹, J. Grudzinski², S. Kurkowska³, P. Esquinas⁴, C. Uribe¹, A. Rahmim¹;
¹University of British Columbia, Vancouver, BC, CANADA, ²University of Wisconsin – Madison, Madison, WI, UNITED STATES OF AMERICA, ³Pomeranian Medical University, Szczecin, POLAND, ⁴BC Cancer, Vancouver, BC, CANADA.

EP-0961
AI-based denoising of multi-scanner fast-acquisition brain [¹⁸F]FDG PET allows for reliable regional quantification

L. C. Silva, C. S. Constantino, F. P. M. Oliveira, D. C. Costa;
Champalimaud Foundation, Lisbon, PORTUGAL.

EP-0962
AI generated attenuation correction maps for DaT SPECT image reconstruction outperforms Chang method.

Z. Wilson¹, A. Sohlberg^{1,2}, J. Lilja^{2,1}, K. M. Bradley³, D. McGowan^{1,4};
¹Oxford University Hospital NHS FT, Oxford, UNITED KINGDOM, ²HERMES Medical Solutions, Stockholm, SWEDEN, ³Cardiff University, Cardiff, UNITED KINGDOM, ⁴University of Oxford, Oxford, UNITED KINGDOM.

EP-0963
Reconstruction of dual-tracer PET images for the simultaneous acquisition of 68Ga and 18F

E. Pfaehler, D. Niekämper, J. J. Scheins, J. N. Shah, C. W. Lerche;
Forschungszentrum Jülich, Jülich, GERMANY.

EP-0964
Deep Learning-Driven Total-Body PET Imaging with Concurrent Tracer and CT Dose Reduction

H. Wang^{1,2}, G. Chen², C. Kong², X. Qiao¹, W. Ding², M. Zhang¹, Q. Huang², B. Li¹;
¹Department of Nuclear Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA, ²School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, CHINA.

EP-0965
Null space evaluation for multi-focal collimator SPECT on a digital brain phantom

M. Nau^{1,2}, A. Vija³, M. P. Reymann^{1,2}, A. Maier¹;
¹Pattern Recognition Lab, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GERMANY, ²Siemens Healthineers AG, Molecular Imaging, Forchheim, GERMANY, ³Siemens Medical Solutions Inc., Molecular Imaging, Hoffman Estates, IL, UNITED STATES OF AMERICA.

EP-0966
3D diffusion models for synthesizing CT image volumes from uncorrected PET data

J. Schaefferkoetter, P. Schleyer, M. Conti;
Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

EP-0967
Cross-scanner transfer learning of deep learning-based partial volume correction for quantitative ¹⁷⁷Lu SPECT/CT imaging

S. Kamrani^{1,2}, A. Gehring¹, M. Salas Ramirez¹, M. Lassmann¹, J. Leube¹, P. Sheikhzadeh³, J. Gustafsson⁴, J. Tran-Gia¹;
¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Department of Medical Radiation Engineering, Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Nuclear Medicine, IKHC, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Medical Radiation Physics, Lund, Lund University, Lund, SWEDEN.

EP-0968
Feasibility of artificial deep learning based 220 ps time-of-flight (TOF)

F. Kaser^{1,2,3}, M. Pires¹, S. Gutschmayer¹, D. Ferrara¹, B. Geist⁴, W. Langsteiger⁴, T. Beyer¹, I. Rausch¹;
¹QIMP Team, Medical University of Vienna, Vienna, AUSTRIA, ²University of Kaiserslautern-Landau, Kaiserslautern, GERMANY, ³OMS HTS GmbH, Wels, AUSTRIA, ⁴Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.

EP-0969
Accelerated PET Imaging with a Gated Autoregressive Diffusion Network

X. Xie^{1,2}, Y. Gao^{1,2}, N. Zhang³, Y. Yang^{1,2}, H. Zheng^{1,2}, D. Liang^{1,2}, Z. Hu^{1,2};
¹Research Center for Medical AI, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, CHINA, ²Key Laboratory of Biomedical Imaging Science and System, Chinese Academy of Sciences, State Key Laboratory of Biomedical Imaging Science and System, Shenzhen, CHINA, ³Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, CHINA.

EP-0970
A Quantitative CT-less Reconstruction Workflow for Long-axial Field-of-view PET Scanners with Enhanced Scaling

M. Teimoorisichani¹, J. Schaefferkoetter¹, V. Panin¹, H. Sari^{2,3}, A. Rominger²;
¹Siemens Medical Solutions USA Inc., Knoxville, TN, UNITED STATES OF AMERICA, ²Bern University Hospital, Bern, SWITZERLAND, ³Siemens Healthineers International AG, Zurich, SWITZERLAND.

EP-0971
Segment-wise loss function and object informed deep learning improves the preservation of small details in PET image denoising

Y. Salimi, Z. Mansouri, H. Zaidi;
Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, SWITZERLAND.

EP-0972
High-Quality Cardiac SPECT Reconstruction from Half-Projections Using a U-Net with Difference Mask: A Deep Learning Approach for Fast Cardiac Scan

P. Sheikhzadeh¹, S. Khalili¹, N. Seyyedi²;
¹Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Health Management Research Institute, Iran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0973
Deep Learning Denoising of Cardiac SPECT: A Dual-Domain Approach in Sinogram and Projection Space

V. Menezes¹, C. Queiroz², M. Machado³, B. Anjos⁴, A. Pino², R. Lemes⁵;
¹Hospital das Clinicas da UFPE, Recife, BRAZIL, ²Hospital Universitário Professor Alberto Antunes, Maceió, BRAZIL, ³Hospital Universitário Professor Edgard Santos - HUPES, Salvador, BRAZIL, ⁴Nuclearis, Recife, BRAZIL, ⁵UFBA, Salvador, BRAZIL.

EP-0974
PET quantification accuracy using FastPET in ultra-short frames on the Biograph Vision Quadra PET/CT

V. Nadig^{1,2}, D. Darian¹, Y. Zheng³, M. Zhang³, D. Bharkhada³, M. Millardet^{4,3}, G. Krokos², L. Davies², P. Marsden², M. Conti³, P. Schleyer³;
¹Siemens Healthcare Limited, Camberley, UNITED KINGDOM, ²PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM, ³Siemens Medical Solutions USA Inc., Knoxville, TN, UNITED STATES OF AMERICA, ⁴Department of Radiology, University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

EP-0975
Low-Dose to Standard-Dose PET Reconstruction Using Cross-Slice Diffusion TransformerAim/ Introduction

T. Sun, X. Chen, S. Wang;
Chinese Academy of Sciences, Shenzhen, CHINA.

EP-0976
Feasibility of Pediatric Brain Imaging with a Palm-Sized Dual-Head PET: Monte Carlo-based Evaluation of Limited Angle and Attenuation Effects

V. Sihotang^{1,2}, M. George^{3,2}, K. Brazenski^{4,2}, Y. Ni⁵, C. Zorraquino², M. Nemallapudi^{6,2}, H. Lin^{1,2};
¹Chang Gung University, Taoyuan, TAIWAN, ²PraanaTech, Chicago, IL, UNITED STATES OF AMERICA, ³Institute of Physics Academia Sinica, Taipei, TAIWAN, ⁴Instituto de Fisica Corpuscular (IFIC), Universitat de València, Valencia, SPAIN, ⁵National Atomic Research Institute, Taoyuan, TAIWAN, ⁶University of Chicago, Chicago, IL, UNITED STATES OF AMERICA, ⁷Chang Gung Memorial Hospital Linkou Branch, Taoyuan, TAIWAN.

EP-0977
Clinical Reliability of Half-dose Rubidium-82 Perfusion Imaging with Positron Range Correction
M. Omayyenc¹, Y. Kadoya¹, M. E. Casey², M. Conti², R. S. B. Beanlands¹, R. A. DeKemp¹;
¹University of Ottawa Heart Institute, Ottawa, ON, CANADA, ²Siemens Medical Solutions, Knoxville, TN, UNITED STATES OF AMERICA.

EP-0978
Robust self-supervised deep learning reconstruction model for reduced ⁸⁹Zr-girentuximab PET scan time
C. Pain^{1,2}, S. Wail³, T. Sepehrizadeh³, Z. Chen^{1,2};
¹Monash Biomedical Imaging, Melbourne, AUSTRALIA, ²Faculty of Information Technology, Monash University, Melbourne, AUSTRALIA, ³Telix Radiopharmaceuticals, Melbourne, AUSTRALIA.

EP-0979
Wavelet Diffusion Modeling Enables Individualized FDG-PET Synthesis for Early Diagnosis of Neurodegenerative Diseases
J. Ding¹, X. Song², M. Marcus², X. Li², J. Zhao¹;
¹Department of Nuclear Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, CHINA, ²Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

EP-0980
PET-like images from ¹⁷⁷Lu-PSMA post-therapeutic SPECT showing increased contrast of metastatic lesions
F. Moradi, T. Otani, H. Song, G. Davidzon, K. Guja, A. Iagaru; Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

EP-0981
Low-Dose Dynamic [¹⁸F]FDG Brain PET Imaging: Near Real-Time Reconstruction with FastPET
M. Kvistholm¹, N. Overbeck¹, A. B. Rodell², D. Bharkhada², N. Murthy², Y. Zheng², M. Conti², U. Lindberg¹, T. L. Andersen^{1,3}, F. L. Andersen^{1,3};
¹Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Copenhagen, DENMARK, ²Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA, ³Department of Clinical Medicine, Copenhagen University, Copenhagen, DENMARK.

EP-0982
The Clinical Application of Brain Motion Management for Improving Quantification of Brain Amyloid PET
Y. Li, J. Li, Z. Wang, X. Lu, H. Pang; Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-0983
Enhancing Deep Learning-based Partial-Volume Correction for ¹⁷⁷Lu SPECT by Incorporating Multiple Reconstruction Convergence Stages
A. Gehring¹, J. Leube¹, M. Laßmann¹, J. Gustafsson², M. Salas-Ramirez¹, J. Tran-Gia¹;
¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Medical Radiation Physics, Lund University, Lund, SWEDEN.

EP-0984
Joint dual modality information for¹³¹I SPECT/CT images enhancement based on a deep-learning method allows 75% reduction of scan time
H. Yang¹, M. Guo², L. Xiang²;
¹Nuclear Medicine Department, Southwest Hospital (the First Affiliated Hospital), Third Military Medical University (Army Medical University), Chongqing, CHINA, ²Subtle Medical Inc., Shanghai, CHINA.

EP-0985
Breaking Barriers in PET: Deep Progressive Reconstruction Achieves Diagnostic-Quality ¹⁸F-FDG Imaging at Half the Dose and Time in India
N. Jain¹, S. S. Singh², A. Agarwal¹, D. Kumar³, P. Wadhwa³;
¹Molecular Imaging & Therapy, New Delhi, INDIA, ²Globe Healthcare, Lucknow, INDIA, ³United Imaging Healthcare, New Delhi, INDIA.

EP-0986
Impact of Deep Learning Denoising on Image Quality and Semiquantitative Parameters in Low-Count/Reduced-Time ¹⁸F-FDG Digital PET/CT Scans
S. Shekhar Singh¹, N. Jain², S. Nigam¹, P. Wadhwa³;
¹Globe Healthcare, Lucknow, INDIA, ²Molecular Imaging & Therapy, Delhi, INDIA, ³United Imaging Healthcare, Delhi, INDIA.

EP-0987
Quantitative Accuracy in Preclinical SPECT/CT Imaging: Partial Volume Effects, Reconstruction Parameters, and Radiotracer Concentration
A. Ebrahimifard¹, S. Bagheri¹, D. Librizzi², F. Eilsberger¹, M. Luster¹, B. Hooshyar Yousefi^{1,3};
¹Department of Nuclear Medicine, School of Medicine, Philipps university Marburg, Marburg, GERMANY, ²Department of Nuclear Medicine, University Hospital OWL, Evangelical Hospital Bethel, Bielefeld, GERMANY, ³Preclinical Imaging of Core Facility, Center for Tumor Biology and Immunology (ZTI), Philipps University Marburg, Marburg, GERMANY.

EP-0988
Enhanced parametric imaging from low-dose dynamic Long-Axial-Field-of-View PET studies using a suitably weighted 3-D gaussian smoothing process
Q. Wu^{1,2}, F. Gu³, K. Shi⁴, A. Rominger⁴, F. O’Sullivan¹;
¹School of Mathematical Sciences, University College Cork, Cork, IRELAND, ²Insight SFI Centre for Data Analytics, Cork, IRELAND, ³School of Mathematics and Physics, North China Electric Power University, Beijing, CHINA, ⁴Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, SWITZERLAND.

EP-0989
Color of Radiation: Redesign of Established Colormaps in the Oklab Color Space for Perceptual Accuracy and Inclusive Design for Color Vision Deficiency
M. Gammel¹, W. A. Weber¹, S. G. Nekolla¹, B. M. Gammel²;
¹TUM Klinikum, Rechts der Isar, Department of Nuclear Medicine TUM School of Medicine and Health, Munich, GERMANY, ²Infineon Technology AG, Munich, GERMANY.

EP-0990
Evaluation of FastPET reconstruction method using multiple tracers and LAFOV PET
N. Overbeck¹, U. Lindberg¹, I. Law¹, Y. Zheng², D. Bharkhada², M. Zhang², V. Panin², P. Schleyer², M. Millardet³, T. L. Andersen¹, F. L. Andersen¹;
¹Copenhagen University Hospital, Rigshospitalet, Copenhagen, DENMARK, ²Siemens Healthineers, Knoxville, TN, UNITED STATES OF AMERICA, ³University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

EP-0991
Optimal reconstruction algorithm for amyloid PET with short acquisition time
K. Tsuda¹, K. Koyama¹, S. Takemoto², K. Onuki², S. Kimura², T. Harada³;
¹Juntendo University, Tokyo, JAPAN, ²Juntendo Hospital, Tokyo, JAPAN, ³PDRadioPharma, Tokyo, JAPAN.

EP-0992
The Impact of Reconstruction Parameters on Radiomic Features in ¹⁸F-FET-PET Imaging of Glioma
D. Kalaeva^{1,2}, G. Danilov¹, N. Vikhrova¹, I. Pronin¹;
¹National Medical Research Center for Neurosurgery named after N.N. Burdenko, Moscow, RUSSIAN FEDERATION, ²National Research Nuclear University MEPhI, Moscow, RUSSIAN FEDERATION.

EP-0993
Optimisation of 123I FP-CIT SPECT-CT Reconstruction for a multi-site clinical service
J. Dixon, C. Brown, R. Gillen, J. Dennis, N. Fullerton, F. Hendry, I. Andrews, A. Nicol; NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.

EP-0994
Systematic Optimization of PET Quantitative Imaging using Realistically Inserted Synthetic Lesions: A Standardized Approach
N. Aghakhanolia¹, A. Rahmim¹, P. L. Esquinas²;
¹UBC - School of Biomedical Engineering, Vancouver, BC, Canada, ²BC Cancer - Molecular Imaging and Therapy, Vancouver, BC, CANADA.

EP-0995
Quantitative Evaluation of Motion Correction for ¹⁸F-FEMPA PET Brain Imaging in Huntington’s and Friedrich Ataxia
G. Yar¹, C. Pain¹, H. Peiris¹, I. Harding², J. Jones³, I. Hong³, D. Staeb⁴, H. Moradi⁴, K. O’Brien⁴, Z. Chen¹;
¹Faculty of IT, Monash University, Melbourne, AUSTRALIA, ²QIMR Berghofer Medical Research Institute, Brisbane, AUSTRALIA, ³Siemens Medical Solutions, Knoxville, TN, UNITED STATES OF AMERICA ⁴Siemens Healthcare Pty Ltd, Melbourne, AUSTRALIA.

EP-0996
Machine Learning-based denoising of low-count [¹⁷⁷Lu] Lutetium SPECT/CT images: evaluating the quantitative accuracy of denoised outputs for dosimetry¹
C. Gascoigne¹, A. L. Smith², E. Varzakis¹, K. Thielemans¹, J. C. Dickson², S. Arridge¹, J. Bomanji², D. Deidda³, B. Fongenié⁴, H. A. Williams^{5,6};
¹University College London (UCL), London, UNITED KINGDOM, ²University College London Hospitals NHS Foundation Trust, London, UNITED KINGDOM, ³National Physical Laboratory (NPL), Teddington, UNITED KINGDOM,

⁴Blue Earth Therapeutics Ltd, Oxford, UNITED KINGDOM, ⁵The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, ⁶The University of Manchester, Manchester, UNITED KINGDOM.

EP-61
e-Poster Area
D: Technical Studies -> D2 Data Analysis and Artificial Intelligence -> D22 Image Classification / Segmentation / Anomaly Detection

EP-0997
MedMimic: A Physician-Inspired Multimodal Fusion Framework for Early Diagnosing Fever of Unknown Origin
Y. Zhou; West China Hospital, Chengdu, CHINA.

EP-0998
Organ Network Disruptions in Parkinson’s Disease Revealed by [18F]-FEOBV Whole-Body PET Imaging
M. Rusaas^{1,2}, J. Horsager¹, N. Okkels^{1,3}, P. Borghammer^{1,2}, O. L. Munk^{1,2};
¹Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, DENMARK, ²Department of Clinical Medicine, Aarhus University Hospital, Aarhus, DENMARK, ³Department of Neurology, Aarhus University Hospital, Aarhus, DENMARK.

EP-0999
Impact Of The Healthy Control Database On Brain [¹⁸F]FDG PET Quantification
E. Fernández-Zorrilla¹, C. Domínguez-Borrero¹, J. Silva-Rodríguez², A. Moscoso¹, P. Aguiar¹;
¹IDIS Research Institute, Santiago de Compostela, SPAIN, ²Fundación CIEN, Madrid, SPAIN.

EP-1000
Automated clinical AI workflow for real-time detection of myocardial uptake in bone scintigraphy
H. Halme, V. Uusitalo, E. Hippeläinen; Clinical Physiology and Nuclear Medicine, Helsinki University Hospital and University of Helsinki, Helsinki, FINLAND.

EP-1001
Automated DICOM-Based Quantitative Assessment of NEMA PET IQ Phantom Images for Harmonized Recovery Coefficient Analysis According to EARL Standards
A. Silva Oliveira, V. de Oliveira Menezes, A. dos Santos Filho; Hospital das Clínicas, Federal University of Pernambuco, Recife, BRAZIL.

EP-1002
Automatic diagnosis of obstruction in Tc99m-EC renal scanning by the aid of deep learning
A. Aghaee, P. Sahafi, S. Bagheri, S. Soltani, T. Shooshtari; Nuclear Medicine Research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1003
Lung Cancer Classification from PET-CT Images Using Transfer Learning

M. Azizkhani¹, P. Azarbar², M. Shahrabaki Mofrad³, M. Sharbatdar¹, P. Sheikhzadeh⁴;
¹K. N. Toosi University of Technology, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Department of Nuclear Medicine, IKHC, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-1004
Development of an automatic detection tool for hyperfunctioning parathyroid glands in dual-isotope parathyroid scintigraphy
L. Hassler¹, D. Chardin¹, D. Benisvy¹, G. D'andrea^{1,2}, J. Darcourt¹, O. Humbert¹;
¹Centre Antoine Lacassagne, Nice, FRANCE, ²Institut de Lla Faceit du Cou, Nice, FRANCE.

EP-1005
Contrast agnostic AI-based extraction of image-derived input function from dynamic PET scans
T. Andersen, N. Evenstuen, C. Ladefoged, U. Lindberg; Rigshospitalet, Dept. of Clinical Physiology & Nuclear Medicine, Copenhagen, DENMARK.

EP-1006
Improving Planar Lung Scintigraphy Interpretation with artificial intelligence (AI): An Educational and Clinical Utility Tool for Pulmonary Embolism Detection
B. Duchaj¹, L. Noskovičová², J. Veselý¹, S. Balogová^{2,3};
¹St. Elisabeth Oncology Institute, Bratislava, SLOVAKIA, ²Department of Nuclear Medicine, Comenius University Bratislava, St. Elisabeth Oncology Institute and Bory Hospital, Bratislava, SLOVAKIA, ³Department of Nuclear Medicine, Hôpital Tenon GH APSU, Paris, FRANCE.

EP-1007
Radiomics Analysis for Differentiate Benign and Malign Pulmonary Nodules Using Tumoral, Peritumoral and Peribronchovascular Segmentation with Machine Learning Approaches
A. Inanir¹, K. Dizdar², N. Dizdar¹, N. Coşkun³, E. Tatçı¹, Ö. Özmen¹;
¹Etilik City Hospital, Ankara, TÜRKIYE, ²ASELSAN INC. Software Engineering, Ankara, TÜRKIYE, ³Ankara City Hospital, Ankara, TÜRKIYE.

EP-1008
FDG PET/CT-Based Machine Learning Modelling and Texture Features in Risk Stratification of Thymomas
B. Bozca¹, K. Dizdar², N. Aydinbelge Dizdar¹, E. Tatçı¹, T. Inal Cengiz³, O. Ozmen¹, N. Gurcay⁴, P. Tari⁵, U. Yilmaz³, L. Acar⁶;
¹Etilik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Department of Software Engineering, ASELSAN Inc., Ankara, TÜRKIYE, ³Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Chest Diseases, Ankara, TÜRKIYE, ⁴Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Pathology, Ankara, TÜRKIYE, ⁵Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ⁶Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Thoracic Surgery, Ankara, TÜRKIYE.

EP-1009
Automated AI-Based PET/CT Analysis for Monitoring Immunotherapy Response in Metastatic Melanoma
L. Förner^{1,2}, J. Bäßler¹, C. Sulski¹, J. Enke¹, C. Lapa¹, T. Wendler^{1,2}, LF and JB are first authors with equal contribution;
¹University Hospital Augsburg, Augsburg, GERMANY, ²Technical University of Munich, Munich, GERMANY.

EP-1010
AI automation in Segmentation and Interpretation of PSMA PET-CT Imaging
K. Doornhof, S. Koolen, A. Schrik, S. Veldhuijzen van Zanten, M. Segbers, M. Konijnenberg;
 Erasmus MC, Rotterdam, NETHERLANDS.

EP-1011
AI-assisted treatment response assessment to disease-modifying therapy in 99mTc-DPD SPECT/CT markers in transthyretin cardiac amyloidosis enabled by artificial intelligence
C. Spielvogel, M. Koefler, D. Haberl, J. Ning, J. Yu, Z. Jiang, K. Kluge, R. Calabretta, M. Hacker, R. Rettl;
 Medical University of Vienna, Vienna, AUSTRIA.

EP-1012
Accuracy and Precision of Lung Lobe Function Measurements from SPECT/CT Using Openly Available and Task Trained AI Segmentation Models
E. Amini¹, R. Klein²;
¹Ottawa Hospital Research Institute, Ottawa, ON, CANADA, ²The Ottawa Hospital, Ottawa, ON, CANADA.

EP-1013
Providing anatomical context for longitudinal lesion assessment: comparison of two deep learning models
P. Patil¹, P. Khobragade², H. Yerebakan³, G. Platsch⁴, N. Vargese², M. Rashmi¹, M. S. Chakragiri², A. Shanker², B. Spottiswoode⁵, A. Soliman⁵;
¹Manipal Institue of Technology, Manipal, INDIA, ²Siemens Healthcare Private Ltd., Bangalore, INDIA, ³Siemens Medical Solutions USA, Inc., Malvern, PA, UNITED STATES OF AMERICA, ⁴Siemens Healthcare GmbH, Erlangen, GERMANY, ⁵Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

EP-1014
PET Radiotracer Image-based Classification Using Convolutional Neural Network
L. Partin¹, K. Chiam², B. Spottiswoode¹, R. Fahmi¹, V. Shah¹;
¹Siemens Medical Solutions, Knoxville, TN, UNITED STATES OF AMERICA, ²Department of Bioengineering, University of California, Los Angeles, CA, UNITED STATES OF AMERICA.

EP-1015
Revisiting the Segmentation Threshold for Lu-177 SPECT
Y. Liu¹, J. Yang², P. Wang^{2,1}, Y. Wang², K. Shi³, Y. Chen², G. Mok¹;
¹Biomedical Imaging Laboratory (BIG), Department of Electrical and Computer Engineering, Faculty of Science and Technology, University of Macau, Macao Sar, MACAO, ²Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, CHINA, ³Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

EP-1016
Enabling Lesion-Level Dose-Response Analysis in RPTs: Topology-Aware Tracking of Metastases Using Spectral Graph Matching
F. Yousefirizi¹, P. Fernandez², S. Kurkowska¹, F. Benard¹, A. Rahmim¹, C. Uribe²;
¹BC Cancer Research Institute, Vancouver, BC, CANADA, ²BC Cancer, Vancouver, BC, CANADA.

EP-1017
Evaluation of combined or separate automatic segmentation models for ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT
S. Perret^{1,2}, L. Albe³, A. Edet-Sanson^{3,1}, D. Tonnelet³, T. Carlier^{4,5}, C. Kohi⁴, M. Barbaud⁴, R. Modzelewski^{3,1}, P. Vera^{3,1}, C. Bailly^{4,5}, A. Dieudonné^{3,1}, P. Decazes^{3,1};
¹QuantIF-AIMS, University of Rouen, Rouen, FRANCE, ²Siemens Healthineers, Courbevoie, FRANCE, ³Nuclear Medicine Department, Henri Becquerel, Rouen, FRANCE, ⁴Nuclear Medicine Department, University Hospital, Nantes, FRANCE, ⁵Nantes Université, INSERM, CNRS, CRCINA, Université d'Angers, Nantes, FRANCE.

EP-1018
A method for separating lesions from physiological uptake in PET segmentation
A. Soliman¹, H. Yerebakan², B. Spottiswoode¹;
¹Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA, ²Siemens Medical Solutions USA, Inc., Malvern, PA, UNITED STATES OF AMERICA.

EP-1019
Comparison of SUVmax threshold Based vs. Patient-Specific Segmentation for Lesion Delineation in Post¹⁷⁷Lu-DOTATATE whole body 3D SPECT/CT in Neuroendocrine Tumors
H. Noamen, Y. Cras, M. Longo, C. Garcia, J. Hadoux, L. Lamartina, S. Moog, E. Baudin, D. Deandreis;
 Gustave Roussy Cancer Campus, Villejuif, FRANCE.

EP-1020
Automated lesion segmentation in ¹⁸F-FDG PET/CT scans of patients with esophageal cancer
A. Soliman¹, A. Nawwar^{2,3,4}, N. Thompson², V. Shah¹, B. Spottiswoode¹, I. Lyburn^{2,5,6};
¹Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA, ²Cobalt Medical Charity, Cheltenham, UNITED KINGDOM, ³University Hospitals Bristol and Weston, NHS Foundation Trust, Bristol, UNITED KINGDOM, ⁴Clinical Oncology and Nuclear Medicine Department, Cairo University, Cairo, EGYPT, ⁵Gloucestershire Hospitals, NHS Foundation Trust, Gloucestershire, UNITED KINGDOM, ⁶Cranfield Forensic Institute, Cranfield University, Wiltshire, UNITED KINGDOM.

EP-1021
Automated NSCLC Segmentation with Deep Learning: Evaluating ¹⁸F-FDG PET/CT Volumetric Consistency and Proposing Optimal Thresholdsfor ⁶⁸Ga-FAPI Quantification
Y. Liu¹, X. Zhou¹, Y. Liu¹, Y. Cui¹, Y. Song¹, Z. Cao², N. Li¹;
¹Peking University Cancer Hospital, Beijing, CHINA, ²Siemens Healthineers Ltd., Shanghai, CHINA.

EP-1022
Comparison of direct Patlak parametric imaging with early and late SUV imaging in metastatic uveal melanoma patients with a long axial field-of-view (LAFOV) PET/CT

L. Pan¹, C. Sachpekidis¹, J. Hassel², A. Dimitrakopoulou-Strauss¹;
¹German Cancer Research Center, Heidelberg, GERMANY, ²University Hospital Heidelberg, Heidelberg, GERMANY.

EP-1023
Deep Learning-Based Detection and Classification of Thyroid Scintigraphy Images Using Convolutional Neural Networks
I. Rogic¹, D. Huic^{1,2};
¹University Hospital Centre Zagreb, Zagreb, CROATIA, ²School of medicine, Zagreb, CROATIA.

EP-1024
Decoupling Alzheimer's Disease Pathology from Physiological Uptake in Brain PET via Interpretable Adversarial Decomposition Learning
A. Tang, C. Tang, W. Ruan, Z. Liang, X. Sun, X. Lan;
 Huazhong University of Science and Technology, Wuhan, CHINA.

EP-1025
Classification of Lower Extremity Deep Vein Thrombosis Using Ensemble Deep Learning on Radionuclide Venography
H.-j. Chen^{1,2}, C.-Y. Wang³, Y.-H. Huang³, Y.-C. Huang², S.-Y. Hsu¹;
¹Department of Information Engineering, I-Shou University, Kaohsiung, TAIWAN, ²Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TAIWAN, ³Department of Medical Imaging and Radiological Sciences, I-Shou University, Kaohsiung, TAIWAN.

EP-1026
PSMA PET Evaluation with a Deep Learning Platform Compared to a Standard Image Viewer and Histopathology
D. Koehler¹, F. Shenas¹, M. Sauer¹, I. Apostolova¹, L. Budäus², F. Falkenbach², T. Maurer²;
¹Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY, ²Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY.

EP-62

e-Poster Area

D: Technical Studies -> D2 Data Analysis and Artificial Intelligence -> D23 Image Registration / Fusion

EP-1027
First Real-world Clinical Evaluation of a Deep Learning-based Respiratory Motion Correction Algorithm of ¹⁸F-FDG PET/CT in Lung Lesions
J. Wang¹, J. Wang², Z. Quan¹, Y. Wang¹, F. Zhang¹, T. Ma¹, G. Li¹, M. Liu¹, Y. Li², Y. Lu², F. Kang¹, J. Wang¹;
¹Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, CHINA, ²United Imaging Healthcare, Shanghai, CHINA.

EP-1028
A new approach to PET/CT registration which accounts for region-specific motion constraints

J. Schaefferkoetter, P. Schleyer, M. Conti;
Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

EP-1029
 Improving data-driven gated (DDG) PET and CT registration in thoracic lesions: a comparison of AI registration and DDG CT

T. Pan¹, M. A. Thomas², Y. Lu¹, D. Luo¹;
¹The University of Texas, Houston, TX, UNITED STATES OF AMERICA, ²Washington University School of Medicine, St. Louis, MO, UNITED STATES OF AMERICA.

EP-1030
 Improved attenuation correction registration for FDG PET/CT images using data-driven gating (DDG)-based motion match.

Z. Wilson¹, M. Kuhar², K. Su³, R. Johnsen³, K. M. Bradley^{4,1}, D. McGowan^{1,5};
¹Oxford University Hospital NHS FT, Oxford, UNITED KINGDOM, ²University Hospital Southampton NHS, Southampton, UNITED KINGDOM, ³GE HealthCare, Waukesha, WI, UNITED STATES OF AMERICA, ⁴Cardiff University, Cardiff, UNITED KINGDOM, ⁵University of Oxford, Oxford, UNITED KINGDOM.

EP-1031
 Integrating PET/CT Imaging and Machine Learning to Enhance Early Diagnosis of Pulmonary Nodules in various types of cancers

N. Kapsoritakis¹, F. Tsitoura², G. Barmparis², S. Koukouraki¹, G. Tsironis²;
¹Nuclear Medicine Department, Medical School Univercity of Crete, Heraklion, Crete, GREECE, ²Department of Physics, Medical School, University of Crete, Heraklion, Crete, GREECE.

EP-63

e-Poster Area

D: Technical Studies -> D2 Data Analysis and Artificial Intelligence -> D24 Outcome Prediction

EP-1032
 The Impact of Post-reconstruction Filtering on Radiomics-Based Coronary Artery Disease Prediction Using Myocardial Perfusion SPECT

R. Huang^{1,2}, B. Wang^{1,2}, M. Gutierrez³, G. Hung⁴, G. Mok¹;
¹Biomedical Imaging Laboratory (BIG), Department of Electrical and Computer Engineering, Faculty of Science and Technology, University of Macau, Macau SAR, MACAO, ²Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, CHINA, ³Biomedical Informatics Lab, Heart Institute, University of São Paulo Medical School, São Paul, BRAZIL, ⁴Department of Nuclear Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua, TAIWAN.

EP-1033
 AI for Cardiac PET Imaging: Predicting Summed Rest Scores Using Stress PET Image

M. Mokri¹, D. Juneau¹, A. Sanaat², S. Kaviani¹, C. Cohalan³, M. Léger³, J. Carrier¹;

¹University of Montreal, Montreal, QC, CANADA, ²Geneva University Hospital, Geneva, SWITZERLAND, ³Hospital Center of University of Montreal, Montreal, QC, CANADA.

EP-1034
 Quantifying the relationship between [¹⁷⁷Lu]Lu-PSMA-I&T exposure and neutrophil dynamics using a population pharmacokinetic-pharmacodynamic analysis

D. van Asten^{1,2}, M. Dotinga², B. J. de Wit-van der Veen², A. D. R. Huitema^{1,3,4}, H. Huisman-Siebinga^{1,2};
¹Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ²Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ³Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, NETHERLANDS, ⁴Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS.

EP-1035
 [¹⁸F]FET PET Radiomics-Based Prediction of IDH Mutation Status in Glioma Patients: Impact of Inter-scanner Harmonisation, Clinical Data and Integration of [¹⁸F]FET-negative Cases

A. Zounek¹, E. Barci¹, E. Istrefi¹, J. Isakaji¹, K. J. Mueller², M. J. Mair^{1,3}, I. von Polenz¹, S. Ziegler^{4,1}, N. L. Albert^{1,5,6}, L. Kaiser¹;
¹Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ²Department of Neurology, LMU University Hospital, LMU Munich, Munich, GERMANY, ³Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, AUSTRIA, ⁴Department of Nuclear Medicine, Hannover Medical School (MHH), Hannover, GERMANY, ⁵German Cancer Consortium (DKTK), Partner Site Munich, a partnership between German Cancer Research Center (DKFZ) and LMU Munich, Munich, GERMANY, ⁶Bavarian Cancer Research Center (BZKF), Partner Site Munich, Munich, GERMANY.

EP-1036
 Genetic algorithm vs. gradient descent for training a novel neural network architecture with low trainable parameters count for small datasets

A. Boukhari^{1,2}, B. Ecsedi^{3,4}, Z. Ritter⁵, L. Papp⁶, M. Hatt^{1,2};
¹Laboratory of medical information processing (LaTIM), Brest, FRANCE, ²University of Western Brittany, Brest, FRANCE, ³Georga Institute of Technology, Atlanta, GA, UNITED STATES OF AMERICA, ⁴University of Vienna, Vienna, AUSTRIA, ⁵Medical University of Pécs, Pécs, HUNGARY.

EP-1037
 Obstructive Coronary Artery Disease Prediction from Myocardial Perfusion SPECT: Radiomics vs. Deep Learning

G. Mok¹, B. Wang^{1,2}, Y. Du³, C. Lin⁴, J. Shang⁵, C. Li^{6,7}, X. Hao⁵, L. Hu^{6,8}, G. Hung²;
¹Biomedical Imaging Laboratory (BIG), Department of Electrical and Computer Engineering, Faculty of Science and Technology, University of Macau, Macau SAR, MACAO, ²Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, CHINA, ³Department of Nuclear Medicine, The First Affiliated Hospital of Army Medical University, Chongqing, CHINA, ⁴Department of Nuclear Medicine, Show Chwan Memorial Hospital, Changhua, TAIWAN, ⁵Department of Nuclear Medicine and PET/CT-MRI Centre, The First Affiliated Hospital of Jinan University, Guangzhou, CHINA, ⁶Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, TAIWAN, ⁷Department of Biomedical Imaging and Radiological

Sciences, National Yang Ming Chiao Tung University, Taipei, TAIWAN, ⁸School of Medicine, National Yang Ming Chiao Tung University, Taipei, TAIWAN, ⁹Department of Nuclear Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua, TAIWAN.

EP-1038
 Radiomic Analysis of Tumor Invasiveness and Staging in Nasopharyngeal Carcinoma Using a FAPI PET/CT Dataset

D. Ruan¹, Z. Luo¹, R. Su¹, W. Zhou², L. Yu¹, J. Cai¹, Q. Lin¹, L. Zhao¹, Y. Pang¹, L. Sun¹, H. Ye², H. Chen¹;
¹The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, CHINA, ²Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CHINA.

EP-1039
 Prediction of EGFR Mutation Status and Subtypes in Lung Adenocarcinoma Using PET/CT Deep Learning stacked with Radiomics

L. Huang¹, J. Liu¹, J. He², Y. Luo¹;
¹The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, CHINA, ²Lanzhou University of Finance and Economics, Lanzhou, CHINA.

EP-1040
 Prediction of 3-year overall survival based on dissemination features of bone scintigraphy in metastatic prostate cancer

J. Ning¹, D. Haberl¹, M. Hacker², L. Kenner¹, C. Spielvogel²;
¹Christian Doppler Lab for Applied Metabolomics, Vienna, AUSTRIA, ²Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

EP-1041
 FDG PET/CT radiomics-based prognostic models for early-stage Non-Small Cell Lung Cancer: impact of segmentation method

J. Meynen¹, K. Claesen¹, E. Derveaux¹, R. Boellaard², L. Mesotten³;
¹Hasselt University, Diepenbeek, BELGIUM, ²Amsterdam UMC, Amsterdam, NETHERLANDS, ³Ziekenhuis Oost-Limburg, Genk, BELGIUM.

EP-1042
 Prognostic value of primary tumour quantitative indices on ⁶⁸GaDOTANOC PET/CT in pediatric patients with neuroblastoma

N. Kundu, D. Khan, S. Sagar, A. Mahalik, A. Roy, A. K. Pandey, R. Kumar;
AIIMS New Delhi, Delhi, INDIA.

EP-1043
 CNN-based prediction of Clinical Relapse in Takayasu Arteritis from [¹⁸F]FDG PET scans

C. Bezzi¹, A. Tomelleri², S. Resta³, F. Fallanca¹, C. Campochiaro², E. Baldissera², S. Ghezzi¹, L. Dagna², A. Chiti¹, P. Mapelli¹, M. Masseroli³, M. Picchio¹;
¹Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ³Department of Electronics, Information and Bioengineering (DEIB), Politecnico di Milano, Milan, ITALY.

EP-1044
 Prognostic Value of First Order Radiomic Features in Multiple Myeloma: Data Analysis from the CONPET Trial

J. Blakkisrud¹, J. Nørgaard^{2,3}, J. Connelly¹, M. Revheim^{1,4}, F. Schjesvold², C. Stokke^{1,5};
¹Division for Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, ²Oslo Myeloma Center, Oslo University Hospital, Oslo, NORWAY, ³Institute of Clinical Medicine, University of Oslo, Oslo, NORWAY, ⁴The Intervention Centre, Oslo University Hospital, Oslo, NORWAY, ⁵Department of Physics, University of Oslo, Oslo, NORWAY.

EP-1045
 Single-time-point dosimetry during [¹⁷⁷Lu]Lu-PSMA-617 therapy using machine learning and population-based model selection with non-linear mixed-effects modelling

D. Hardiansyah¹, T. M. Y. Polem¹, E. Yousefzadeh-Nowshahr², U. Nemer³, F. Kind³, A. J. Beer², P. T. Meyer², G. Glatting², M. Mix³;
¹Universitas Indonesia, Depok, INDONESIA, ²Ulm University, Ulm, GERMANY, ³University of Freiburg, Freiburg, GERMANY.

EP-1046
 An interpretable machine learning model assists in predicting bone marrow invasion for lymphoma using ¹⁸F-FDG PET/CT: a multicenter study

X. Mu, X. Zhu, W. Fu;
Department of Nuclear Medicine, Affiliated Hospital of Guilin Medical University, Guilin, CHINA.

EP-1047
 ¹⁷⁷Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: external validation of a baseline⁶⁸Ga-PSMA-11 PET-based prediction models using ¹⁸F-Flotufolastat PET

Ö. Coban¹, A. Karimzadeh^{1,2}, C. Fütterer³, K. Hansen¹, M. Heck⁴, R. Tauber⁴, C. D´Alessandria¹, W. Weber¹, M. Eiber¹, I. Rauscher¹;
¹Technical University Munich (TUM) - Department of Nuclear Medicine, Munich, GERMANY, ²Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY, ³Technical University Munich (TUM) - Institute of AI and Informatics in Medicine, Munich, GERMANY, ⁴Technical University Munich (TUM) - Department of Urology, Munich, GERMANY.

EP-1048
 Incorporating deep features in radiomics for predicting coronary artery disease using myocardial perfusion stress/rest SPECT

B. Wang^{1,2}, Y. Du³, C. Lin⁴, M. Gutierrez⁵, G. Hung⁶, Z. Hu², G. S. P. Mok¹;
¹Biomedical Imaging Laboratory (BIG), Department of Electrical and Computer Engineering, Faculty of Science and Technology, University of Macau, Macau SAR, MACAO, ²Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, CHINA, ³Department of Nuclear Medicine, The First Affiliated Hospital of Army Medical University, Chongqing, CHINA, ⁴Department of Nuclear Medicine, Show Chwan Memorial Hospital, Changhua, TAIWAN, ⁵Biomedical Informatics Lab Heart Institute, University of São Paulo Medical School, São Paulo, BRAZIL, ⁶Department of Nuclear Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua, TAIWAN.

EP-1049
Evaluation of locoregional invasiveness of early lung adenocarcinoma manifesting as ground-glass nodules via ⁶⁸Ga-FAPI-46 PET/CT imaging

D. Ruan, S. Shi, W. Guo, Y. Pang, L. Yu, J. Cai, Z. Wu, H. Wu, L. Sun, L. Zhao, H. Chen;
The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, CHINA.

EP-1050
Optimized Ensemble Learning Models for Predicting ISUP>3 in Prostate Cancer A Radiomics and Clinical Integration Study

C. Jianbo^{1,2,3}, C. Zhang¹, G. Wang¹, J. Zhang¹, Y. Han¹, Y. Liu¹, B. Xu¹;
¹Chinese PLA General Hospital, Beijing, CHINA, ²Nuclear Medicine Department, The 983rd Hospital of the Joint Logistic Support Force, TianJin, CHINA, ³Graduate School, Chinese PLA General Hospital, Beijing, CHINA.

EP-1051
The prognostic value of PSMA-PET-derived information in predicting ADT-free survival in oligorecurrent prostate cancer treated with metastasis-directed SBRT

T. D. van Bergen¹, Y. E. van den Heuvel², A. J. A. T. Braat³, C. A. T. van den Berg¹, T. F. W. Soeterik²;
¹Computational Imaging Group for MR Diagnostics and Therapy, Center for Image Sciences, University Medical Center Utrecht, Utrecht, NETHERLANDS, ²Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, NETHERLANDS, ³Department of Radiology and Nuclear Medicine, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, NETHERLANDS.

EP-1052
Unsupervised clustering of short-chain fatty acid transcellular flux identifies oligoclonal metabolic phenotypes in intracratial metastatic disease

M. Inglese^{1,2}, S. Islam², L. McLeavy², F. Mauri², T. M. Barwick², A. D. Waldman^{2,3}, K. O'Neill², M. Williams², E. O. Aboagye², N. Toschi^{1,4};
¹University of Rome Tor Vergata, Rome, ITALY, ²Imperial College London, London, UNITED KINGDOM, ³University of Edinburgh, Edinburgh, UNITED KINGDOM, ⁴Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA, UNITED STATES OF AMERICA.

EP-1053
Uncertainty-Quantified Dynamic PET Biomarker for Robust Prediction of Treatment Response and Survival in Precision Breast Cancer Medicine

F. Gu¹, Q. Wu^{2,3}, F. O'Sullivan², M. Muzi⁴, D. Mankoff⁵;
¹School of Mathematics and Physics, North China Electric Power University, Beijing, CHINA, ²School of Mathematical Sciences, University College Cork, Cork, IRELAND, ³Insight SFI Center for Data Analytics, Cork, IRELAND, ⁴Department of Radiology, University of Washington, Seattle, WA, UNITED STATES OF AMERICA, ⁵Department of Radiology, University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

EP-1054
Exploring Contrast-Enhanced Computed Tomography as a Local Predictor of Lung Shunt Fraction in ⁹⁰Y Liver Radioembolization

B. Mehadji¹, T. Marx¹, A. Carter¹, R. Goldman¹, C. Vu¹, E. Roncali²;

¹University of California Davis, Sacramento, CA, UNITED STATES OF AMERICA, ²University of California Davis, Davis, CA, UNITED STATES OF AMERICA.

EP-1055
Interest of ¹⁸F-FDG PET/CT Radiomics for Overall Survival Prediction in Newly Diagnosed Multiple Myeloma Treated by Daratumumab in the CASSIOPET Study

S. Ahrari¹, B. Jamet¹, S. Zweegman², A. Perrot³, C. Hulin⁴, D. Caillot⁵, T. Facon⁶, X. Leleu⁷, K. Belhadj⁸, E. Itti⁹, L. Karlin¹⁰, C. Bailly^{1,11}, M. Levin¹², M. C. Minnema¹³, C. Bodet-Milin^{1,11}, B. De Keizer¹⁴, J. Corre¹⁵, P. Sonneveld¹⁶, C. Touzeau^{17,11}, P. Moreau^{17,11}, F. Kraeber-Bodéré^{1,11}, T. Carlier^{1,11};
¹Service de Médecine Nucléaire, University Hospital Hôtel-Dieu, Nantes, FRANCE, ²Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Department of Hematology, Amsterdam, NETHERLANDS, ³CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, FRANCE, ⁴Department of Hematology, Hôpital Haut Lévêque, University Hospital Bordeaux, Pessac, FRANCE, ⁵CHU Dijon, Hôpital Du Bocage, Dijon, FRANCE, ⁶University of Lille, CHU Lille, Service des Maladies du Sang, Lille, FRANCE, ⁷CHU Poitiers, Hôpital la Milétrie, Poitiers, FRANCE, ⁸Hôpital Henri Mondor, Lymphoid Malignancies Unit, Créteil, FRANCE, ⁹Department of Nuclear Medicine, Hôpital Henri Mondor, Créteil, FRANCE, ¹⁰Centre Hospitalier Lyon-Sud Hématologie (HCL), Pierre-Bénite, FRANCE, ¹¹CRCI2NA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, FRANCE, ¹²Albert Schweitzer Ziekenhuis, Dordrecht, NETHERLANDS, ¹³Department of Hematology, University Medical Center Utrecht, Utrecht, NETHERLANDS, ¹⁴Department of Nuclear Medicine and Radiology, University Medical Center Utrecht, Utrecht, NETHERLANDS, ¹⁵Unité de Genomique du Myélome, IUC-T Oncopole, Toulouse, FRANCE, ¹⁶Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS, ¹⁷Hematology, University Hospital Hôtel-Dieu, Nantes, FRANCE.

EP-1056
Prospective Dual-Tracer ¹⁸F-FDG/⁶⁸Ga -FAPI PET/CT Biomarkers Enable Early Prediction of Immunotherapeutic Response in Advanced Gastric Adenocarcinoma

C. Zhang¹, X. Lin¹, J. Hao², H. Zhao¹, T. Han¹, L. Qi², C. Wang¹, Y. Zhang¹, M. Xin¹, J. Liu¹, X. Xiao¹;
¹Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, CHINA, ²United Imaging Healthcare, Shanghai, China, Shanghai, CHINA.

EP-1057
Development of a Clinical-Radiomic Model for Recurrence Prediction in Head and Neck Cancer Using Multi-Scanner PET Imaging

N. González-Cuesta¹, G. Reynés-Llompart², L. Rodriguez-Bel¹, V. Carrero-Vásquez¹, M. Zamorano-Rivas¹, A. Bagán-Trejo¹, I. Martínez-Zalacain³, P. Naval-Baudín⁴, M. Cortés-Romera¹;
¹Nuclear Medicine Department, ICS-IDI, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN, ²Medical Physics Department, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ³Department of Clinical Sciences/School of Medicine, University of Barcelona, Barcelona, SPAIN, ⁴Radiology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EP-1058
Predictive Accuracy and Clinical Benefit of a Nomogram Aimed at Predicting Radioiodine-Refractory Differentiated Thyroid Cancer: Independent External Validation Using a Single Institution Database

F. Yu;
Department of Nuclear Medicine, Xijing Hospital, Air Force Military Medical University, Xi'an, CHINA.

EP-1059
Differentiation between bipolar and major depressive disorders with [¹¹C]K-2 AMPA receptor PET imaging

H. Abe¹, S. Tsugawa¹, Y. Kimura², J. Chikazoe³, T. Arisawa¹, M. Hatano¹, W. Nakajima¹, T. Miyazaki¹, T. Takahashi¹;
¹Yokohama City University, Yokohama, JAPAN, ²Kindai University, Higashi Osaka, JAPAN, ³Hiroshima University, Hiroshima, JAPAN.

EP-64

e-Poster Area

D: Technical Studies -> D2 Data Analysis and Artificial Intelligence -> D25 Tracer Kinetic Analysis

EP-1060
Impact of Scan Duration on Kinetic Modelling Parameters in Dynamic [⁶⁸Ga]-PSMA-11 PET Imaging for Prostate Cancer

E. A. M. Kile^{1,2}, R. Sundset^{1,2}, S. Kuttner^{1,2,3};
¹The PET Imaging Center, University Hospital of North Norway, Tromsø, NORWAY, ²Nuclear Medicine and Radiation Biology Research Group, Department of Clinical Medicine, UiT the Arctic University of Norway, Tromsø, NORWAY, ³UiT Machine Learning Group, Department of Physics and Technology, UiT the Arctic University of Norway, Tromsø, NORWAY.

EP-1061
Comparison of uncertainty quantification methods for kinetic parameters derived from dynamic long-axial-field-of-view PET scans.

F. Gu¹, Q. Wu^{2,3}, F. O'Sullivan², A. Rominger⁴, K. Shi⁴;
¹School of Mathematics and Physics, North China Electric Power University, Beijing, CHINA, ²School of Mathematical Sciences, University College Cork, Cork, IRELAND, ³Insight SFI Center for Data Analytics, Cork, IRELAND, ⁴Department of Nuclear Medicine, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

EP-1062
Discriminating Inflammation from Malignancy with Short-Dynamic Patlak Parametric FDG PET/CT

A. Artesani¹, J. Jandric², L. Leonardi², R. Barisonzi², C. Vallone², L. Muraglia², M. Rodari², L. Evangelista¹;
¹Humanitas University, Pieve Emanuele, ITALY, ²IRCCS Humanitas Research Hospital, Rozzano, ITALY.

EP-1063
Spill-over correction in [¹⁵O]H₂O small animal studies

R. Siekkinen¹, T. Uurasmaa^{2,1}, I. Heinonen¹, H. Iida¹;
¹Turku PET Centre, Turku, FINLAND, ²Department of Biology, University of Turku, Turku, FINLAND.

EP-1064
A Simple Bone Marrow Kinetic Modelling Method in Patients with Symptomatic Multiple Myeloma

C. Nanni¹, I. Brusa¹, D. Dall'olio², S. Peluso², M. Di Franco³, M. Stasolla³, E. Zamagni², M. Talarico², G. Wang⁴, B. Spencer⁴, A. Farolfi¹, M. Assenza⁵, E. Fortunati¹, S. Civollani¹, L. Nardo⁴, G. Castellani², S. Fanti¹;
¹Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ²Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITALY, ³Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ⁴Department of Radiology, University of California Davis, Sacramento, CA, UNITED STATES OF AMERICA, ⁵Professional Development and Implementation of Research in Health Professional Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-1065
A comparison of renograms: posterior only and geometric mean imaging

R. Feathers, W. Morton, P. Bartholomew;
South Tyneside and Sunderland Foundation Trust, Sunderland, UNITED KINGDOM.

EP-1066
Comparative Performance of ⁶⁸Ga-FAPI-04 Versus ¹⁸F-FDG PET/CT in Thyroid-Associated Orbitopathy: A Prospective Pilot Study with Dynamic/Static Parametric Validation

L. Yang, L. Guan;
Nuclear Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-65

e-Poster Area

D: Technical Studies -> D2 Data Analysis and Artificial Intelligence -> D26 Other Data Analysis

EP-1067
Organ-based normative values in healthy subjects derived from whole-body [18F]FDG-PET/CT

C. Loisel¹, M. Pires², R. Seban³, F. Orlhac⁴, S. Gutschmayer⁵, I. Buvat⁴, T. Beyer²;
¹Institut Curie, Orsay, FRANCE, ²Medical University of Vienna, Vienna, AUSTRIA, ³Dpt of Nuclear Medicine, Institut Curie, Saint Cloud, FRANCE, ⁴Institut Curie, Inserm, Orsay, FRANCE, ⁵Dept of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.

EP-1068
A Novel Variance Reduction Technique for Efficient Monte Carlo Simulation of SPECT Images

D. Sarrut, A. Etxebeste, M. Jacquet, J. Letang;
CREATIS CNRS, Villeurbanne, FRANCE.

EP-1069
Artificial Intelligence Analysis of Nuclear Medicine Perception on Social Media

D. Yahiro, C. T. Mesquita;
Universidade Federal Fluminense, Niterói, BRAZIL.

EP-1070

Identification and Validation of Robust FDG-PET/MR Texture Biomarkers in Uterine Cervical Cancer

U. Björelund^{1,2}, K. Sandgren², S. Strandberg²;

¹Medical Physics, Sundsvall Hospital, Sundsvall, SWEDEN,

²Department of Diagnostics and Intervention, Umeå University, Umeå, SWEDEN.

EP-1071

Artificial intelligence for opportunistic detection of immune checkpoint inhibitor-related adverse events using [¹⁸F]FDG PET/CT

C. Spielvogel, L. Zisser, A. Lazarevic, D. Haberl, C. Eseroglou, M. Hacker, R. Calabretta;

Medical University of Vienna, Vienna, AUSTRIA.

EP-1072

Investigating AD and non-AD ¹⁸F-flortaucipir distribution patterns in a memory clinic cohort

F. Piva¹, C. Boccalini², N. Ashton³, H. Zetterberg³, K. Blennow³, G. B. Frisoni⁴, M. Veronese¹, V. Garibotto⁴, D. E. Peretti²;

¹University of Padova, Padua, ITALY, ²University of Geneva, Geneva, SWITZERLAND, ³University of Gothenburg, Mölndal, SWEDEN, ⁴Geneva University Hospitals, Geneva, SWITZERLAND.

EP-1073

A Non-Invasive Method for Measurement of Cerebral Glucose Transport Capacity and Metabolic Rate Using [¹⁸F]FDG and a Pre-bolus Scan of the Heart

N. Hansen¹, S. A. S. Kjeldsen¹, M. N. Lonsdale², I. L. Rasmussen², S. Fuglsang², C. S. Meyhoff^{3,4}, R. Boellaard⁵, J. Rungby^{6,4}, N. J. Wewer Albrechtsen^{1,4}, L. Marner^{2,4,7};

¹Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, DENMARK, ²Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, DENMARK, ³Department of Anaesthesia and Intensive Care, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, DENMARK, ⁴Department of Clinical Medicine, University of Copenhagen, Copenhagen, DENMARK, ⁵Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, NETHERLANDS, ⁶Steno Diabetes Center Copenhagen, Herlev, DENMARK, ⁷Department of Nuclear Medicine, Copenhagen University Hospital - Herlev Hospital, Herlev, DENMARK.

EP-1074

Deep Learning-based attenuation correction of myocardial perfusion imaging studies

D. Apostolopoulos¹, N. Papatathanasiou¹, T. Spyridonidis¹, M. Spiliotopoulou¹, I. Apostolopoulos²;

¹University General Hospital of Patras, Patras, GREECE,

²Department of Medical Physics, School of Medicine, University of Patras, Patras, GREECE.

EP-1075

Navigating complexity: effective workflow management for high throughput PET-CT imaging in a multi-tracer multi-machine theranostic nuclear medicine department.

T. Henry, L. Ferreol, C. Balleyguier, D. Deandreis; Gustave Roussy, Villejuif, FRANCE.

EP-1076

Estimation of Relative Renal Function on DMSA Scans via Deep Regression

M. Abdi¹, A. BELAID², Y. Ghedbane³, S. YAHIAOUP², M. HABBACHE¹, Q. NAILI¹;

¹Centre d'imagerie scintigraphique (CIS) Blida, Blida, ALGERIA, ²Centre de Recherche sur L'Information Scientifique et Technique (CERIST), Algiers, ALGERIA, ³Centre d'imagerie scintigraphique (CIS) Setif, Setif, ALGERIA.

EP-1077

Evaluating the accuracy of different absorbed dose rate estimation methods for kidney and bone marrow dosimetry in [¹⁷⁷Lu]Lu-DOTATATE therapy

J. Bao, A. Theisen, J. Leube, A. Gehring, M. Lassmann, M. Salas-Ramirez, J. Tran-Gia;

Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY.

EP-1078

Monte Carlo bootstrapping to estimate statistical power for published tumor dose-response relationships in peptide receptor radionuclide therapy (PRRT)

T. Husevåg¹, C. Stokke^{1,2}, M. Kvassheim^{1,2};

¹Oslo University Hospital, Oslo, NORWAY, ²University of Oslo, Oslo, NORWAY.

EP-1079

Age-Related Metabolic Changes in Japanese Healthy Controls undergoing [18F]-PET/CT Imaging

S. Gutschmayer¹, M. Pires¹, T. Beyer¹, D. Ferrara¹, Z. Chen², Y. Xinzhu², J. Taki³, S. Kinuya², L. K. S. Sundar^{1,4}, S. Takeda³, H. Wakabayashi²;

¹QIMP Team, Medical University of Vienna, Vienna, AUSTRIA, ²Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN, ³PET Center, Kanazawa Advanced Medical Center, Kanazawa, JAPAN, ⁴DIGIT-X Lab, Department of Radiology, LMU Munich, Munich, GERMANY.

EP-1080

Unravelling Amyotrophic Lateral Sclerosis FDG PET patterns using graph-based manifold partition

T. Zaharia^{1,2}, J. Hong³, R. Ni³, A. Rominger³, S. Hu⁴, Y. Tang⁴, K. Shi³;

¹Center of Artificial Intelligence in Medicine, University of Bern, Bern, SWITZERLAND, ²ARTORG Center for Biomedical Engineering Research, University of Bern, Bern, SWITZERLAND, ³Department of Nuclear Medicine, InselSpital, University of Bern, Bern, SWITZERLAND, ⁴Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, CHINA.

EP-1081

FMEA (Failure Mode and Effects Analysis) for ¹⁷⁷Lu marked PSMA and DOTATATE/TOC therapies for risk treatment assessment

M. L. Belli¹, M. Golinucci², G. M. Volpe³, I. Marini⁴, V. Di Iorio⁵, F. Matteucci⁴, E. Prati⁶, M. T. Montella³, A. Sarnelli¹;

¹IRST - Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS - Medical Physics Unit, Meldola, ITALY, ²IRST - Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS - Nurse Unit, Meldola, ITALY, ³IRST - Istituto Romagnolo per lo Studio dei Tumori, Meldola, ITALY, ⁴IRST - Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS - Nuclear Medicine Unit, Meldola, ITALY, ⁵IRST - Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS - Oncology Pharmacy Unit,

Meldola, ITALY, ⁶IRST - Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS - Healthcare Direction, Meldola, ITALY.

EP-1082

ICSH Formulas for Normal Blood Volume: 30 Years Later, a Descriptive Population Study Comparing the Reference Cohort to Actual Patients Explored for Isotopic Blood Volume Determination

M. Ragot¹, J. Dubois², L. Drevon³, A. Salabert⁴, L. Guiheneuc⁵, C. Rouet⁶, S. Mackowiak⁷, Z. Mauduit⁸, M. Jung¹, M. Tempier¹, P. Orhon¹, A. Revy¹, S. Levesque¹;

¹Centre Jean Perrin, Clermont-Ferrand, FRANCE, ²CHU de Montpellier, Montpellier, FRANCE, ³Assistance Publique – Hôpitaux de Paris, St Louis, Paris, FRANCE, ⁴CHU de Toulouse, Toulouse, FRANCE, ⁵CHU de Nantes, Nantes, FRANCE, ⁶CH Métropole Savoie, Chambéry, FRANCE, ⁷CHU d'Amiens, Amiens, FRANCE, ⁸CHU de Grenoble, Grenoble, FRANCE.

EP-1083

Reproducibility study of tumor lesion features in [⁶⁸Ga]Ga-PSMA PET/CT images

M. Alfaiate^{1,2}, C. Constantino¹, F. Oliveira¹, L. C. Silva¹, R. Vigário², D. C. Costa¹;

¹Champalimaud Foundation, Lisbon, PORTUGAL, ²NOVA School of Science and Technology, Caparica, PORTUGAL.

EP-1084

Structured Ground Truth Extraction from Robot-Assisted Radical Prostatectomy (RARP) Histopathology report to Support AI-Based Prostate Cancer Staging

J. Chaudhary, A. K. Pandey, S. Kumar, S. Kaushal, P. D. Sharma, H. K. P. R. Kumar;

All India Institute of Medical Sciences, AIIMS, New Delhi, New Delhi, INDIA.

EP-1085

Potential of Large Language Models for Proofreading PET Reports

W. Roll¹, L. Kober¹, D. Ventura¹, M. Masthoff¹, C. Backhaus¹, M. Schäfers¹, K. Rahbar¹, L. Plagwitz², P. Schindler¹;

¹University Hospital Münster, Münster, GERMANY, ²University of Münster, Münster, GERMANY.

EP-1086

Artificial Intelligence as a New Research Ally? Performing AI-Assisted Systematic Literature Reviews in Nuclear Medicine

S. van Mossel^{1,2}, M. Oude Wolcherink², R. de Feria Cardet³, L. De Geus-Oei^{1,2,4}, D. Vriens⁵, H. Koffijberg², S. Saing^{2,3};

¹Leiden University Medical Center, Leiden, NETHERLANDS, ²University of Twente, Enschede, NETHERLANDS, ³University of Technology Sydney, Sydney, AUSTRALIA, ⁴Delft University of Technology, Delft, NETHERLANDS, ⁵Radboud University Medical Center, Nijmegen, NETHERLANDS.

EP-1087

Deep Learning Reorientation for Myocardial Perfusion Imaging SPECT

T. Huxohl¹, R. Borgschulze²;

¹Heart and Diabetes Center NRW, Bad Oeynhausen, GERMANY, ²Bielefeld University, Bielefeld, GERMANY.

EP-1088

Development and Validation of an Artificial Intelligence Assistant for PET Phantom Analysis

T. Palchan Hazan¹, J. A. Kennedy^{1,2}, T. Hazan³, Z. Keidar^{1,2};

¹Rambam Health Care Campus, Haifa, ISRAEL, ²Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, ISRAEL, ³Technion, Haifa, ISRAEL.

EP-1089

Monitoring Health with Whole-Body [18F]-FDG PET/CT

S. Gutschmayer¹, D. Ferrara¹, B. K. Geist², Ö. Özer^{1,2}, J. Yu^{1,2}, M. Pires¹, I. Rausch¹, M. Hacker², L. K. S. Sundar^{1,3}, W. Langsteiger², T. Beyer¹;

¹QIMP Team, Medical University of Vienna, Vienna, AUSTRIA, ²Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, ³DIGIT-X Lab, Department of Radiology, LMU Munich, Munich, GERMANY.

EP-1090

Bridging the Gap between SPECT and PET using AI: Proof of concept on 99mTc-PSMA SPECT to 68Ga-PSMA PET synthesis

A. Lopez Montes¹, L. Lopes¹, K. Hlongwa², M. Rivombo², O. Israel³, A. Afshar-Oromieh¹, A. Rominger¹, S. More², K. Shi¹;

¹University of Bern, Bern, SWITZERLAND, ²Cape Town University, Cape Town, SOUTH AFRICA, ³Technion Rappaport School of Medicine, Haifa, ISRAEL.

EP-1091

Explain Yourself! A Multi-Institutional PET/CT Reporters' Perspective on Explainable AI

C. Baskerville^{1,2}, J. M. Y. Willaime², V. Prakash^{1,3,4}, T. Ali⁵, S. Bhuvu⁶, G. Ellul⁷, R. Frood^{8,9}, S. Kamat¹⁰, S. Maitra³, D. Rosewarne¹¹, A. Scarsbrook^{8,9}, P. D. Strouhal⁴, A. Zare⁸, K. Wells¹;

¹Centre for Vision, Speech and Signal Processing, The University of Surrey, Guildford, UNITED KINGDOM, ²Mirada Medical Ltd., Oxford, UNITED KINGDOM, ³Royal Surrey NHS Foundation Trust, Guildford, UNITED KINGDOM, ⁴Alliance Medical Ltd., Warwick, UNITED KINGDOM, ⁵The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UNITED KINGDOM, ⁶Oxford University Hospitals NHS Foundation Trust, Oxford, UNITED KINGDOM, ⁷East Kent Hospitals University NHS Foundation Trust, Canterbury, UNITED KINGDOM, ⁸Leeds Teaching Hospitals NHS Trust, Leeds, UNITED KINGDOM, ⁹Faculty of Medicine and Health, University of Leeds, Leeds, UNITED KINGDOM, ¹⁰King's College London NHS Foundation Trust, London, UNITED KINGDOM, ¹¹The Royal Wolverhampton NHS Trust, Wolverhampton, UNITED KINGDOM.

EP-1092

Reimagining Administrative Workflows: ChatGPT o1 Optimizes ICD-10 Coding in Nuclear Medicine.

T. Ruhwedel, J. Rogasch, P. Dahlke, C. Furth, C. Wetz, S. Shnayien, I. Schatka, H. Amthauer, N. Beetz; Charité Universitätsmedizin Berlin, Berlin, GERMANY.

EP-1093

Short-Term Variation in Body Composition in Healthy Adult Volunteers Undergoing Long Axial Field-of-View [¹⁸F]FDG-PET/CT

E. Sullivan¹, G. Cook^{2,3}, A. Hammers^{2,3}, D. Ferrara⁴, B. Geist⁵, S. Gutschmayer⁴, M. Hacker⁵, M. Pires⁵, J. Yu^{4,5}, L. Shiyam Sundar⁴, T. Beyer⁴;

¹Department of Nutritional Sciences, Faculty of Life Science & Medicine, King's College London, London, UNITED KINGDOM, ²School of Biomedical Engineering

and Imaging Sciences, King's College London, London, UNITED KINGDOM, ³King's College London and Guy's and St Thomas' PET Centre, St Thomas' Hospital, London, UNITED KINGDOM, ⁴QIMP Team, Medical University of Vienna, Vienna, AUSTRIA, ⁵Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.

EP-1094
Statistical Preprocessing of PET Radiomic Features: Normalisation, Outlier Filtering, and Correlation-Based Pruning for Robust Machine Learning Applications in a Hodgkin Lymphoma Cohort
S. Nikolovski, G. Spirov, S. Tasevski, N. Manevska; University Institute of Positron- Emission Tomography, Skopje, NORTH MACEDONIA, THE REPUBLIC OF..

EP-1095
Improved Imaging of Hemodynamics from Dynamic FDG PET-CT studies with Bolus Venous injection of the Tracer.
F. O'Sullivan¹, Q. Wu¹, F. Gu², K. Shi³, A. Rominger³; ¹University College, Cork, IRELAND, ²School of Mathematics and Physics, North China Electric Power University, Beijing, CHINA, ³Bern University Hospital, University of Bern, Bern, SWITZERLAND.

EP-1096
Unsupervised Learning of Obesity-Associated Metabolic Patterns from Whole-Body ¹⁸F-FDG PET/CT
R. JIANG^{1,2,3}, X. Xie^{1,2}, M. Dong⁴, Q. Sun⁴, Z. Li⁴, Y. Xiao⁵, N. Ma⁴, J. Li⁴, H. Yang⁴, X. Lin⁴, H. Yan⁴, H. Zheng^{1,2}, D. Liang^{1,2}, N. Zhang², C. C. Liu³, Z. Hu^{1,2}; ¹Research Center for Medical AI, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, CHINA, ²Key Laboratory of Biomedical Imaging Science and System, Chinese Academy of Sciences, State Key Laboratory of Biomedical Imaging Science and System, Shenzhen, CHINA, ³Department of Data Science and Artificial Intelligence, The Hong Kong Polytechnic University, Hong Kong, CHINA, ⁴Peking University Shenzhen Hospital, Shenzhen, CHINA, ⁵Shenzhen Exit-Entry Frontier Inspection Station General Hospital, Shenzhen, CHINA.

EP-1097
Body composition analysis of [18F]FDG-PET/CT images: The L3 vertebra region as a surrogate for whole-body quantification
M. Pires¹, D. Ferrara¹, S. Gutschmayer¹, J. Yu², A. Frille^{3,4}, B. Geist², M. Hacker², S. Hesse³, L. K. S. Sundar⁵, T. Beyer¹; ¹QIMP Team, Medical University of Vienna, Wien, AUSTRIA, ²Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Wien, AUSTRIA, ³Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, GERMANY, ⁴Department of Respiratory Medicine, University Hospital Leipzig, Leipzig, GERMANY, ⁵DIGIT-X Lab, Department of Radiology, LMU, Munich, GERMANY.

EP-1098
Development of an Explanation-Supporting AI for Nuclear Medicine Procedures Using Open-Source LLMs and Retrieval-Augmented Generation Technologies
N. Imaizumi, M. Sato, T. Kita, F. Sasaki, A. Yumoto, H. Daisaki; Gunma Prefectural College of Health Sciences, Maebashi, JAPAN.

EP-67

e-Poster Area

D: Technical Studies -> D4 Dosimetry and Radiobiology -> D41 Clinical Dosimetry

EP-1099
Investigation of the Dosimetry Differences Between Pre-Therapy SPECT/CT and Post-Therapy PET/CT Scan in Selective Internal Radiation Therapy (SIRT)
E. Urwin^{1,2}, D. Morgan¹, D. McGowan¹, L. Livieratos²; ¹Churchill Hospital, Oxford, UNITED KINGDOM, ²King's College London, London, UNITED KINGDOM.

EP-1100
Site specific calibration factor removes reduces over-estimation of dose from single time point dosimetry when compared to 3 time point bi-exponential
B. Driscoll¹, R. Wong², A. Shesse², D. Laidley³, S. Myrehaug⁴, R. Juergens⁵, T. Farncombe⁵, K. Zukotynsk⁶, R. Stodilka³, J. Beauregard⁷, U. Metser², P. Veit-Haibach², A. Hendler², S. Ezzat², K. Lajkosz², J. Gabrys², O. Levine⁵, R. Mohan², A. Mesc², J. Publicover¹, I. Yeung²; ¹TECHNA Institute, University Health Network, Toronto, ON, CANADA, ²University Health Network, Toronto, ON, CANADA, ³London Health Sciences Centre, London, ON, CANADA, ⁴Odette Cancer Centre, Toronto, ON, CANADA, ⁵Juravinski Cancer Centre, Hamilton, ON, CANADA, ⁶McMaster University, Hamilton, ON, CANADA, ⁷Cancer Research Centre and Department of Radiology and Nuclear Medicine, Universite Laval, Laval, QC, CANADA.

EP-1101
PBPK-Driven Digital Twinning in Radiopharmaceutical Therapies enabling Predictive Dosimetry from Dynamic Pre-Therapy PET Data
M. Sabouri, A. Rafiei Sardouei, J. Fowler, O. Gharibi, H. Abdollahi, C. Uribe, A. Rahmim; University of British Columbia, Vancouver, BC, CANADA.

EP-1102
Radioimmunotherapy of Non-Hodgkin Lymphoma with Lilotomab Conjugated to Different Radionuclides: A Simulation Study
H. Ramsvik¹, J. Blakkisrud¹, M. Kvassheim^{1,2}, A. Løndalen^{3,4}, C. Stokke^{1,5}; ¹Department of Physics and Computational Radiology, Oslo University Hospital, Oslo, NORWAY, ²Institute of Clinical Medicine, University of Oslo, Oslo, NORWAY, ³Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, ⁴Division of Radiology and Nuclear Medicine, Innlandet Hospital Trust, Elverum, NORWAY, ⁵Department of Physics, University of Oslo, Oslo, NORWAY.

EP-1103
Prediction of tumor kinetics of [⁹⁰Y]Y-FAPI-46 using [⁶⁸Ga]Ga-FAPI-46 PET CT imaging
M. Watanabe^{1,2}, W. Jentzen², D. Kersting², K. Herrmann², W. P. Fendler², P. F. Costa²; ¹Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Hospital, Kyoto, JAPAN, ²Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY.

EP-1104
Dosimetry and safety of the PDGFRb PET tracer [⁶⁸Ga]Ga-DOTA-Cys-ATH001: first-in-human data in patients with liver fibrosis and healthy subjects
M. Lubberink¹, T. G. Lohith², Z. Derdak², P. Wilkens², H. Wennbo², E. Palmer^{3,4}, A. Ramolli⁴, B. Mitran^{5,6}, A. Abouyzed^{5,6}, L. Johansson⁶, F. Rorsman^{1,7}, J. Vessby^{1,7}, O. Eriksson^{1,5}; ¹Uppsala University, Uppsala, SWEDEN, ²Takeda Pharmaceutical Company Limited, Cambridge, MA, UNITED STATES OF AMERICA, ³Karolinska Institutet, Stockholm, SWEDEN, ⁴Karolinska University Hospital, Stockholm, SWEDEN, ⁵Antaros Tracer AB, Uppsala, SWEDEN, ⁶Antaros Medical AB, Gothenburg, SWEDEN, ⁷Uppsala University Hospital, Uppsala, SWEDEN.

EP-1105
Comparison of dosimetry in I-131 therapy for benign thyroid diseases using Marinelli and Häscheid Methods
M. Mamach, T. L. M. Felgenhauer, L. Geworski; Department for Medical Physics and Radiation Protection, Hannover, GERMANY.

EP-1106
PBPK model to predict [¹⁷⁷Lu]Lu-DOTA-TATE time-integrated activity with single-time-point [⁶⁸Ga]Ga-DOTA-TATE PET/CT imaging
V. Vasic¹, J. Gustafsson², E. Yousefzadeh-Nowshahr¹, A. Beer¹, K. Sjögreen Gleisner², G. Glatting¹; ¹Department of Nuclear Medicine, Ulm University Medical Centre, Ulm, GERMANY, ²Medical Radiation Physics, Lund University, Lund, SWEDEN.

EP-1107
Single-Time-Point Dosimetry using Nonlinear Mixed-Effects Modelling in Sparse [¹⁷⁷Lu]Lu-PSMA-617 Therapy Data
F. Ananda¹, D. Hardiansyah¹, R. Ritawidya², A. J. Beer³, N. Varmentot⁴, L. Ferrer⁴, G. Glatting^{3,5}; ¹Medical Physics and Biophysics, Physics Department, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, INDONESIA, ²Center for Research on Radioisotope, Radiopharmaceutical, and Biodistribution Technology, National Research and Innovation Agency (BRIN), Tangerang Selatan, INDONESIA, ³Department of Nuclear Medicine, Ulm University, Ulm, GERMANY, ⁴Médecine Nucléaire, ICO René-Gauducheau, Saint-Herblain, FRANCE, ⁵Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY.

EP-1108
A Novel Single-Time-Point Dosimetry Approach in ¹⁷⁷Lu-Labeled Somatostatin Analog Therapy: Feasibility and Clinical Validation
E. Farajzadeh¹, M. Sadeghi², J. Aghamohammadi³, M. Akbari¹, N. Habib³, M. Davarpanah³; ¹Secondary Standard Dosimetry Laboratory (SSDL), Pars Isotope Co., Karaj, IRAN, ISLAMIC REPUBLIC OF, ²Shiraz University, Shiraz, IRAN, ISLAMIC REPUBLIC OF, ³Pars Isotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-1109
Revolutionizing personalized dosimetry in Targeted Radionuclide Therapy: first-in-human results of the WIDMApp approach
F. Collamati¹, R. Mirabelli², B. Caccia³, F. Censi³, M. Carruzzo⁴, B. Cassano⁵, M. De Simon³, C. D'Angeli³, R. Faccini⁶, G. Iaccarino⁵, C. Mancini-Terracciani⁶, E. Mattei³, S. Morganti¹, F. Nicolanti⁶, S. Pozzi³, A. Soriani⁵, E. Solfaroli-Camilloci³, L. Campana⁷; ¹INFN Rome, Roma, ITALY, ²Università sapienza, Roma, Roma, ITALY, ³ISS Rome, Roma, ITALY, ⁴Univesrità Sapienza Roma, Roma, ITALY, ⁵IRCCS Regina Elena National Cancer Institute in Rome, Roma, ITALY, ⁶Università Sapienza Roma, Roma, ITALY, ⁷Campus Bio Medico Roma, Roma, ITALY.

EP-1110
Fast Patient-Specific Dosimetry for PRRT Using GPU-Accelerated Monte Carlo Simulation: A Comparative Study Between irtGPUMCD and GATE
H. Jozi^{1,2}, R. Lefol^{1,2}, Y. Lemaréchal^{1,2,3}, J. M. Beauregard^{2,4,5}, P. Després^{1,2,3}; ¹Département de physique, de génie physique et d'optique- Université Laval, Québec, QC, CANADA, ²Centre de recherche du CHU de Québec-Université Laval, Québec, QC, CANADA, ³Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, Québec, QC, CANADA, ⁴Department of Radiology and Nuclear Medicine, and Cancer Research Centre-Université Laval, Québec, QC, CANADA, ⁵Department of Medical Imaging, CHU de Québec-Université Laval, Québec, QC, CANADA.

EP-1111
The Clinical Impact of Specific Activity and Precursor Mass content on Absorbed Doses to Tumours and Organs-at-risk for a novel PSMA targeting RLT
B. Fongenie¹, N. Scott¹, A. Rinscheid², C. Lapa², J. Sykes³, T. Mauch¹, D. Stevens¹; ¹Blue Earth Therapeutics, Oxford, UNITED KINGDOM, ²Augsburg University Hospital, Augsburg, GERMANY, ³Blue Earth Diagnostics, Oxford, UNITED KINGDOM.

EP-1112
Test-Retest Comparison of Total-Body ⁹⁰Y PET for Post-SIRT Dosimetry: Evaluating Scanner Performance Across Platforms
M. Santoro¹, I. Gabucci¹, C. Macis¹, G. Della Gala¹, F. Bisello¹, F. Zagni¹, I. Brusa², A. Golemi², E. Lodi Rizzini³, A. G. Morganti^{3,4}, S. Fant^{2,5}, L. Strigari¹; ¹Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ⁵Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY.

EP-1114
Whole-body single-time-point ¹⁷⁷Lu-PSMA-617 lesions and bone marrow dosimetry at first cycle is significantly associated with biological and imaging outcomes

A. Dieudonne¹, A. Terro², A. Dumouchell¹, S. Perret¹, A. Edet-Sanson¹, P. Vera¹, F. Di Fiore³, L. Augusto-Pelegrin³, P. Decazes², D. Tonnelet¹;
¹Centre Henri Becquerel, Rouen, FRANCE, ²University of Rouen Normandy, Rouen, FRANCE, ³University Hospital of Rouen, Rouen, FRANCE.

EP-1115
Dosimetric comparison between ¹⁷⁷Lu-PSMA-617 and ¹⁷⁷Lu-PSMA I&T in patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) using a ring-shaped CZT-based camera

L. D'Ambrosio, F. Manna, C. Maisto, R. de Marino, A. Morisco, M. Aurilio, V. Porfidia, A. Prisco, R. De Migno, M. Raddi, F. De Lauro, F. Di Gennaro, S. Lastoria;
National Cancer Institute IRCCS Pascale, Naples, ITALY.

EP-1116
Quantitative ^{99m}Tc-SPECT/CT Dosimetry Using a CZT Gamma Camera: Initial Clinical Experience

K. Ramonaheng¹, M. Qebetu¹, J. Cardinale², K. Schmidt³, K. Banda¹, P. Goorhoo¹, M. K. Legodi¹, H. Ndlovu¹, C. Davis¹, L. Smith¹, S. Sibiya¹, A. Mdlophane¹, S. Mdanda¹, T. De Bruin¹, C. Kaoma¹, J. Kabunda¹, K. Mokoala¹, F. Giesel², M. Sathekege¹;
¹Nuclear Medicine Research Infrastructure (NuMeRI), University of Pretoria and Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA, ²Department of Nuclear Medicine, Medical Faculty and University Hospital, Heinrich Heine University, Dusseldorf, GERMANY, ³ABX - CRO advanced pharmaceutical services Forschungsgesellschaft mbH, Dresden, GERMANY.

EP-1117
Estimation of long-term radiation toxicity risk to normal organs in radiopharmaceutical therapy.

P. McCormack¹, Z. Mulyukov², D. lu³, F. Yang³;
¹Novartis Pharmaceuticals, Manchester, UNITED KINGDOM, ²Novartis Pharmaceuticals, Basel, SWITZERLAND, ³Novartis Pharmaceuticals, Cambridge, MA, UNITED STATES OF AMERICA.

EP-1118
Application of post-reconstruction partial volume correction techniques for quantitative SPECT imaging of ²²⁵Ac

G. Liubchenko¹, G. Boening¹, M. Rumiantcev¹, M. Zacherl¹, G. T. Sheikh¹, S. Resch¹, R. A. Werner^{1,2}, S. I. Ziegler^{1,3}, A. Delker¹;
¹Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ²Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Sciences, Division of Nuclear Medicine and Molecular Imaging, Baltimore, MD, UNITED STATES OF AMERICA, ³Clinic for Nuclear Medicine, Hannover Medical School, Hannover, GERMANY.

EP-1119
Bayesian individual fitting versus population fitting with non-linear mixed-effects modelling in single-time-point dosimetry: A comparative evaluation

I. Budiansah¹, D. Hardiansyah¹, B. B. Patrianesha^{1,2}, S. M. B. Peters³, S. Ardjo Pawiro¹, B. Privé^{3,4}, J. Nagarajah^{3,5}, M. W. Konijnenberg^{3,6}, A. Ambros J. Beer⁷, G. Glatting^{7,8};

¹Universitas Indonesia, Depok, INDONESIA, ²Research Center for Safety, Metrology, and Nuclear Quality Technology, National Research and Innovation Agency (BRIN), Tangerang Selatan, INDONESIA, ³Radboud University Medical Centre, Nijmegen, NETHERLANDS, ⁴Department of Radiology and Nuclear Medicine, Erasmus Medical Centre, Rotterdam, NETHERLANDS, ⁵Röntgeninstitut Düsseldorf, Düsseldorf, GERMANY, ⁶Department of Radiation Oncology, Erasmus Medical Centre, Rotterdam, NETHERLANDS, ⁷Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY, ⁸Department of Nuclear Medicine, Ulm University, Ulm, GERMANY.

EP-1120
Impact of Temporal Sampling and Software Tools on Dosimetry in Radioligand Therapy

S. Peric¹, M. Avanzo¹, A. Drigo¹, C. Avigo¹, G. Pirrone¹, L. Barresi¹, G. Fanetti², E. Borsatti³, A. Dassie¹;
¹Medical Physics Department, Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano, ITALY, ²Radiation Oncology Department, Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano, ITALY, ³Nuclear Medicine Department, Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano, ITALY.

EP-1121
GPU-Accelerated Monte Carlo Dosimetry for Yttrium-90 and Holmium-166 Radioembolization: Validation of Torch MC Against Geant4 in Heterogeneous Anatomies

O. Kwon¹, J. Grudzinski^{1,2}, B. Bednarz^{1,2}, P. Wickre²;
¹University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA, ²Voximetry, Madison, WI, UNITED STATES OF AMERICA.

EP-1122
One-Minute 360° CZT SPECT Enables Reliable Organ Dosimetry for ⁹⁰Y-SIRT Planning

Z. Mansouri, Y. Salimi, N. Bianchetto Wolf, I. Mainta, V. Garibotto, H. Zaidi;
Geneva University Hospital, Geneva, SWITZERLAND.

EP-1123
Motion corrected PET compared to static PET in post ⁹⁰Y resin TARE imaging: Potential towards improved ⁹⁰Y dosimetry

M. W. M. van Wijk, C. D. E. Van Speybroek, M. G. J. de Bakker, J. Roosen, M. J. R. Janssen, S. M. B. Peters, J. F. W. Nijsen;
Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS.

EP-1124
Gastro-intestinal LuPSMA scintigraphy uptake patterns and dosimetry in patients with metastatic prostate cancer treated with LuPSMA: a single center retrospective study

V. Ludwig¹, Z. Ells¹, C. Meyer¹, L. M. Unterrainer^{1,2}, P. G. Maliha^{1,3,4}, T. Grogan¹, M. Dahlbom¹, J. Czernin¹, J. Calais¹;
¹UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, ²LMU Klinikum München, Munich, GERMANY, ³Centre Hospitalier de l'Université de Montréal Centre de Recherche, Université de Montréal, Montréal, Montreal, QC, CANADA, ⁴Centre Hospitalier de l'Université de Montréal, Montreal, QC, CANADA.

EP-1125
Feasibility of single-time-point dosimetry application in ¹⁷⁷Lu -DOTATATE/DOTATOC-treated pediatric neuroblastoma

X. Sun¹, F. Zheng¹, X. Sun²;
¹Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CHINA, ²Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Jinan, CHINA.

EP-1126
Fast and reliable response evaluation of [¹⁷⁷Lu] Lu-PSMA-I&T therapy using between-cycle [¹⁷⁷Lu] Lu-SPECT/CT scanning

V. Nuttens, D. Ooms, M. Koole;
AZORG, Aalst, BELGIUM.

EP-1127
Comparison of ^{99m}Tc MAA SPECT/CT-Based Predosimetry and ⁹⁰Y SPECT/CT-Based Postdosimetry in TARE with Resin Microspheres

Z. Balaban Genc¹, O. Erez¹, S. Beykan Schürrie², E. Soydemir¹, E. Arik¹, S. Cetin¹, N. Schürrie², T. Erdil¹, T. Ones¹;
¹Marmara University, School of Medicine, Istanbul, TÜRKIYE, ²Oncosia Scientific GmbH, Durrwangen, GERMANY.

EP-1128
Estimation of Renal Time-Integrated Activity of [¹⁷⁷Lu]Lu-PSMA-I&T Using Single-Time-Point [⁶⁸Ga] Ga-PSMA-HBED-CC PET/CT and Physiologically-Based Pharmacokinetic and Population-Based Pharmacokinetic Modeling

D. Hardiansyah¹, A. Riana¹, E. Yousefzadeh-Nowshahr², A. Allmann³, A. J. Beer², M. Eiber³, G. Glatting²;
¹Universitas Indonesia, Depok, INDONESIA, ²Ulm University, Ulm, GERMANY, ³Technische Universität München, Munich, GERMANY.

EP-1129
Few-Time-Points Non-Linear Mixed-Effects Dosimetry: Accuracy and Precision of [¹⁷⁷Lu]Lu-PSMA-617 in Kidneys

A. Hakim¹, D. Hardiansyah^{1,2}, E. Yousefzadeh-Nowshahr^{2,3}, U. Nemer⁴, R. Ritawidya^{1,5}, F. Kind⁴, A. J. Beer³, P. T. Meyer⁴, G. Glatting^{2,3}, M. Mix⁴;
¹Medical Physics and Biophysics, Physics Department, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, INDONESIA, ²Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY, ³Department of Nuclear Medicine, Ulm University, Ulm, GERMANY, ⁴Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY, ⁵Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, National Research and Innovation Agency (BRIN), Tangerang Selatan, INDONESIA.

EP-1130
Assessing the Feasibility of Early Post-Treatment Dosimetry in ¹⁶⁶Ho Radioembolization

A. Didonna^{1,2}, G. Muti², C. Romano², S. Capitanio², C. Carbonini², C. Rossetti², P. E. Colombo²;
¹Università degli Studi di Milano, Milano, ITALY, ²ASST Grande Ospedale Metropolitano Niguarda, Milano, ITALY.

EP-1131
Is 1D Whole-Body Dosimetry Still Worth It? A Pilot Study on Red Marrow Dose Estimation in [¹⁷⁷Lu]Lu-DOTATATE Therapy

T. Kracmerova^{1,2}, J. O. Zmek¹, D. Prchalova¹, S. Buresova¹, A. Kenova¹, T. Rehacek¹;
¹Motol University Hospital, Prague, CZECH REPUBLIC, ²Military University Hospital, Prague, CZECH REPUBLIC.

EP-1132
Monte Carlo Calculation Of Patient Effective Dose For ¹⁸F-FDG PET Examinations

M. Baker;
Clatterbridge Cancer Centre, Liverpool, UNITED KINGDOM.

EP-1133
Dosimetry of Organs at Risk of Patients Treated with [¹⁷⁷Lu]Lu-PSMA Suggests Margins for Dose Escalation

M. Almeida^{1,2,3}, L. C. Silva¹, M. Costa¹, R. Parafita¹, F. Oliveira¹, Â. Silva¹, J. M. Sampaio^{2,3}, P. Ferreira¹, D. Costa¹;
¹Champalimaud Foundation, Nuclear Medicine-Radiopharmacology, Lisboa, PORTUGAL, ²Faculdade de Ciências da Universidade de Lisboa, Lisboa, PORTUGAL, ³Laboratório de Instrumentação e Física Experimental de Partículas, Lisboa, PORTUGAL.

EP-1134
Personalized dosimetry in ¹⁸⁸Re-SIRT using gafchromic film derived conversion factor- A comparison of mono-compartmental method with commercial tools

S. Chopra, A. S. Oinam, G. Singh, K. Kaur, S. R. Shovan, B. R. Mittal, J. Shukla;
Postgraduate Institute of Medical Education and Research, Chandigarh, INDIA.

EP-1135
Mathematical evaluation of therapeutic index as a function of radionuclide half-life in radiopharmaceutical therapy

J. Hesterman, B. Schuller, K. Orcutt, J. Babich, J. Hoppin;
Ratio Therapeutics, Boston, MA, UNITED STATES OF AMERICA.

EP-1136
First Cycle Dosimetry as a Prediction Metric of ¹⁷⁷Lu-PSMA Therapy Outcomes

A. Al-Balushi, N. Al-Maymani, T. Al-Raii, S. Kheruka, H. Al-Saidi;
Sultan Qaboos Comprehensive Cancer Care & Research Center - University Medical City, Muscat, OMAN.

EP-1137
Patient-Specific Dose Assessment in Whole-Body CT Imaging during PET-CT Procedures

P. Sheikhzadeh¹, M. Asami¹, M. Shahrabaki Mofrad¹, N. Kasraie²;
¹Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²UT Southwestern Medical Center, Dallas, TX, UNITED STATES OF AMERICA.

EP-1138
Patient-Specific Internal Dose Calculation Based on ⁶⁸Ga-Citrate PET Images: Validation of a Monte Carlo Approach and Comparison to Conventional Analytical Method

S. Asidkar¹, S. Yavari¹, M. Abbasi¹, M. Jahanbin¹, A. Parach², P. Sheikhzadeh¹;

¹Tehran university of medical science, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Regional Medical Physics Service, Belfast Health & Social Care Trust, Belfast, UNITED KINGDOM.

EP-1139
Automated Hybrid Dosimetry for Precise [¹⁷⁷Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Z. Dong¹, X. Jin², X. Meng², J. Yu², Z. Xie²;
¹National Biomedical Imaging Center, College of Future Technology, Peking University, Beijing, CHINA, ²Department of Nuclear Medicine, Peking University Cancer Hospital, Beijing, CHINA, ³Institute of Medical Technology, Peking University Health Science Center, Peking University, Beijing, CHINA.

EP-1140
Feasibility of single-time-point dosimetry in Lu-177-based cocktail radiopharmaceutical therapy
W. Peng^{1,2}, Y. Liu², Y. Chen¹, G. Mok²;
¹Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, Luzhou, CHINA, ²Biomedical Imaging Laboratory (BIG), Department of Electrical and Computer Engineering, Faculty of Science and Technology, University of Macau, Macau SAR, MACAO.

EP-1141
A Comparison of ⁹⁰Y-SPECT/CT and ⁹⁰Y-PET/CT Imaging in Voxel-Based Dosimetry for TARE with Resin ⁹⁰Y-Microspheres
Z. Balaban Genc¹, A. Eroglu¹, S. Beykan Schürrl², O. Erez¹, S. Cetin¹, N. Schürrl², E. Arik¹, E. Soydemir¹, T. Erdil¹, T. Ones¹;
¹Marmara University, School of Medicine, Istanbul, TÜRKIYE, ²Oncosia Scientific GmbH, Durrwangen, GERMANY.

EP-1142
Effects of imaging time points on precision in absorbed dose to the kidneys in patients with neuroendocrine tumours receiving ¹⁷⁷Lu-DOTATATE therapy
M. Sandström¹, E. Ilan, M. Lubberink;
Uppsala University Hospital / Uppsala University, Uppsala, SWEDEN.

EP-1143
Absorbed dose estimates in tumors and organs at risk from ¹⁷⁷Lu-PSMA-617 therapy in patients with metastatic castration resistant prostate cancer: results from the prospective phase 2 RESIST-PC Trial (NCT03042312)
Z. Ellis¹, C. Meyer¹, K. Masri¹, D. Sennung¹, K. Kimura¹, D. Mirando², I. Tworowska³, R. Esfandiari⁴, M. Auerbach¹, M. Lassmann⁵, K. Hermann⁶, M. Eiber⁷, W. P. Fendler⁶, E. Delpassand^{4,3}, J. Czernin¹, M. Dahlborn¹, J. Calais¹;
¹University of California - Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ²MIM Software, Beachwood, OH, UNITED STATES OF AMERICA, ³RadioMedix Inc., Houston, TX, UNITED STATES OF AMERICA, ⁴Excel Diagnostics & Nuclear Oncology Center, Houston, TX, UNITED STATES OF AMERICA, ⁵University of Wurzburg, Wurzburg, GERMANY, ⁶University of Essen, Essen, GERMANY, ⁷Technical University of Munich, Munich, GERMANY.

EP-1144
Comparison of ultra-fast Monte Carlo (MC) dosimetry calculations with standard method in Y-90 post-therapy PET/CT studies
K. Knesaurek¹, J. Grudzinski²;
¹Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA, ²Voximetry, Inc, Madison, WI, UNITED STATES OF AMERICA.

EP-1145
Evaluating the Effect of Respiratory Motion Correction in Yttrium-90 Positron Emission Tomography Imaging for Accurate Dosimetry
C. D. E. Van Speybroeck¹, L. E. L. Westlund Gotby¹, M. Boswinkel¹, M. W. M. van Wijk¹, A. Cordon Avila², M. Abayazid², S. M. B. Peters¹, J. F. W. Nijsen¹;
¹Department of Medical Imaging, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, NETHERLANDS, ²Department of Robotics and Mechatronics, Faculty of Electrical Engineering, Mathematics and Computer Science, University of Twente, Enschede, NETHERLANDS.

EP-1146
Bridging diagnosis and dosimetry: investigating the predictive role for ⁶⁸Ga-DOTATOC PET/CT in ¹⁷⁷Lu-DOTATATE PRRT
C. Ingraito^{1,2}, A. Monaci³, M. Cuomo¹, G. Argiroffi¹, M. Kirienco¹, A. Lorenzoni¹, F. Rubino¹, C. Chiesa¹, M. Maccauro¹;
¹Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY, ²Post Graduate Specialisation School for Medical Physics, Università degli Studi di Milano, Milan, ITALY, ³Post Graduate Specialisation School for Nuclear Medicine, Università degli Studi di Firenze, Firenze, ITALY.

EP-1147
Correlation between absorbed dose, SUVmax and Krenning Score after Peptide Receptor Radionuclide Therapy (PRRT) treatment in neuroendocrine tumors
A. Barrera Cerpa¹, M. Ribelles Segura, A. Fernández Iglesias, L. Paruta Araez, C. Villaprado Meza, K. Sanabria Ramírez, P. Boya Román, I. Blanco Saiz, F. Lozada Delgado, Á. Rosero Enríquez, D. Gómez Sánchez, E. Anda Apiñaniz, R. Vera García, E. Goñi Gironés;
Hospital Universitario de Navarra, Navarra, SPAIN.

EP-1148
Outcome-Driven Timing Optimization of Single Time Point Dosimetry for PSMA-Directed Radiopharmaceutical Therapy
J. Hu¹, R. Seifert¹, C. Vinicius Gomes¹, Y. Chen¹, W. Jutidamrongphan¹, M. Amon², J. Wang¹, S. Xue¹, A. Afshar-Ormiehal¹, A. Rominger¹, K. Shi¹;
¹Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, Bern, SWITZERLAND, ²Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, Bern, SWITZERLAND.

EP-1149
Correlation Between Tumor-Absorbed Radiation Dose and Tumor Volume Reduction in Sarcoma Patients Treated With [¹⁷⁷Lu]Lu-FAP-2286
R. Nami¹, M. Nasiri², S. Banihashemian³, A. Abolhosseini Shahrnoy¹, G. Divband⁴, M. Akbari³;
¹Parsisotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Cellular & Molecular Biology, School of Biology, Damghan University, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Khatam PET-CT Center, Khatam-al-Anbia Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-1150
Single time point approaches for salivary gland dosimetry and correlation with PET follow-up
A. Noto¹, X. Shen¹, M. Zacherl¹, M. Rumiantcev¹, G. Liubchenko¹, G. Böning¹, R. Werner^{1,2}, G. Sheikh¹, A. Delker¹, S. Resch¹;

¹Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, ²Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Sciences, Division of Nuclear Medicine and Molecular Imaging, Baltimore, MD, UNITED STATES OF AMERICA.

EP-1151
Patient-Specific Dosimetry of ¹⁷⁷Lu-FAPI-2286 in Peptide Receptor Radionuclide Therapy Using GATE Monte Carlo Simulations: A Pilot Study
S. Shafiee Dastgerdi¹, L. Hassanzadeh², G. Divband³, H. Sharifi⁴;
¹University of Isfahan, Isfahan, IRAN, ISLAMIC REPUBLIC OF, ²Department of Nuclear Medicine, School of Medicine, Rajaie Cardiovascular, Medical & Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Nuclear Medicine, Jam Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Department of Molecular Imaging, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-1152
Personalized ¹⁷⁷Lu-FAPI-2286 Peptide Receptor Radionuclide Therapy Dosimetry in a Metastatic Rectal Cancer Patient: A Simulation Study
H. Sharifi¹, L. Hassanzadeh², G. Divband³, S. Shafiee Dastgerdi⁴;
¹Department of Molecular Imaging, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Nuclear Medicine, School of Medicine, Rajaie Cardiovascular, Medical & Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Nuclear Medicine, Jam Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Faculty of physics, University of Isfahan, Isfahan, IRAN, ISLAMIC REPUBLIC OF.

EP-1153
Accuracy, Efficiency and Clinical Validation of GATE and GAMOS-based Monte Carlo dosimetry framework for 99mTc Radiopharmaceutical
A. Alshehri^{1,2};
¹Najran University, Najran, SAUDI ARABIA, ²Radiology sciences department | Collage of applied medical science | Najran University, Najran, SAUDI ARABIA.

EP-1154
The effect of glucocorticoids on radioiodine-131 bio-kinetics in patients suffering from Graves' Disease
C. Happel¹, B. Bockisch, D. Groener;
University Medical Center Frankfurt; Clinic for Radiology and Nuclear Medicine; Department of Nuclear Medicine, Frankfurt, GERMANY.

EP-1155
Evaluation of different methods for determining the intra-renal effective half-life during ¹⁷⁷Lu-PSMA-617 Radioligand Therapy
C. Happel¹, B. Bockisch, K. Klimek, D. Groener;
University Medical Center Frankfurt; Clinic for Radiology and Nuclear Medicine; Department of Nuclear Medicine, Frankfurt, GERMANY.

EP-1156
Thyroid dosimetry in two common ¹²³I-based neurological studies: a retrospective study

W. Morton¹, R. Feathers, J. Freeman, P. Bartholomew;
South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UNITED KINGDOM.

EP-1157
Evaluation of Voxel-Based Dosimetry Using Different Calculation Algorithms in ¹⁷⁷Lu-PRRT
M. Masubuchi^{1,2}, K. Miwa^{2,3}, N. Miyaji³, T. Yamao³, N. Akiya², K. Wachi², S. Kimura², K. Furuya¹, T. Nakamura¹, Z. Wu¹, A. Iwasaka¹, S. Hashimoto¹, Y. Hirano¹;
¹Department of Radiology, University of Tsukuba Hospital, Tsukuba, JAPAN, ²Department of Radiological Sciences, Graduate School of Health Sciences, Fukushima Medical University, Fukushima, JAPAN, ³Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University, Fukushima, JAPAN.

EP-1158
Computational and Nuclear Data Evaluation of an Emerging Therapeutic Copper Radioisotope for Imaging and Dosimetry
M. Mehrabi¹;
Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-1159
Avidination for RadionuclideTherapy in Nonpalpable Breast Cancer (ARTHE): Dosimetry of a New Locoregional Approach
A. Sarnelli¹, M. Cremonesi², E. D'Andrea³, M. Sansovini¹, V. Di Iorio¹, M. Monti¹, P. Sanna⁴, M. Amadori⁴, A. Curcio⁴, P. Possanzini⁴, I. Grassi¹, P. Caroli¹, I. Marini¹, S. Nicolini¹, M. Belli¹, V. Mautone¹, E. Scarpi¹, L. Fabbri¹, A. Miserocchi¹, G. Paganelli², F. Falcini⁴, F. Matteucci¹;
¹Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, ITALY, ²Istituto Europeo di Oncologia, Milano, ITALY, ³Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma, ITALY, ⁴AUSL Romagna, Forli, ITALY, ⁵Istituto Oncologico Romagnolo, Forli, ITALY.

EP-1160
Optimizing CD44v6-Targeted Radioimmunotherapy: A Retrospective Red Marrow Dosimetry Comparison of ¹⁸⁶Re, ¹⁷⁷Lu, and ¹⁶¹Tb
J. Hemmingsson¹, M. Nestor², A. Lundgren Mortensen³, F. Y. Frejd⁴, P. Bernhardt¹;
¹University of Gothenburg - Sahlgrenska Academy, Gothenburg, SWEDEN, ²Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala, SWEDEN, ³Department of Molecular Medicine and Surgery, Karolinska Institutet, Gothenburg, SWEDEN ⁴Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, Uppsala, SWEDEN.

EP-68
e-Poster Area
D: Technical Studies -> D4 Dosimetry and Radiobiology -> D42 Clinical Radiobiology

EP-1161
Deep Longitudinal Immunophenotyping of Immune Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ²¹²Pb-based PSMA-Targeted Alpha Therapy

A. Soderholm¹, A. Karmann¹, A. Hansen², S. Sandhu³, C. Sweeney⁴, L. Leveque-El Mouttie⁵, D. Wyld⁶, M. Baronet¹, N. Esteban¹, M. Crumbaker¹, L. Skingley¹, T. Kryza¹, P. Santoro¹, G. Li¹, S. Puttick¹, S. Shakti¹, S. Rose¹;
¹AdvanCell Pty Ltd, Sydney, AUSTRALIA, ²Princess Alexandra Hospital, Brisbane, AUSTRALIA, ³Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ⁴University of Adelaide, Adelaide, AUSTRALIA, ⁵Translational Research Institute, Brisbane, AUSTRALIA, ⁶Royal Brisbane and Women's Hospital, Brisbane, AUSTRALIA.

EP-1162
Optimizing Radiopharmaceutical Dosage in Pediatric SPECT-CT
M. Weymeskirch, F. Hubele, O. Allegrini, J. Salvadori, C. Porot;
Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, FRANCE.

EP-69
e-Poster Area
D: Technical Studies -> D5 Radiopharmacy/ Radiochemistry -> D51 Radionuclide Production

EP-1163
Improving the target design for enriched Iridium-192 production for brachytherapy
S. Kashi, A. Nourouzi, M. Dehghan, A. Naserbegi, M. Behzadi, M. Mehrabi, M. Asadian;
Advanced Technologies Company of Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-1164
Innovative cation-exchange strategies towards cost-effective terbium/gadolinium separations
A. Moiseeva¹, P. V. Grundler¹, Z. Gao², J. W. Engle², N. P. van der Meulen¹;
¹Paul Scherrer Institute, Villigen PSI, SWITZERLAND, ²University of Wisconsin–Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-1165
High efficiency isolation of theranostic terbium radioisotopes from gadolinium with cation exchange chromatography
Z. Gao¹, E. Aluicio-Sarduy¹, A. N. Moiseeva², T. E. Barnhart¹, N. P. van der Meulen^{2,3}, J. W. Engle^{1,4};
¹University of Wisconsin – Department of Medical Physics, Madison, WI, UNITED STATES OF AMERICA, ²PSI Center for Life Sciences - Center for Radiopharmaceutical Sciences, Villigen, SWITZERLAND, ³PSI Center of Nuclear Engineering and Sciences - Laboratory of Radiochemistry, Villigen, SWITZERLAND, ⁴University of Wisconsin - Department of Radiology, Madison, WI, UNITED STATES OF AMERICA.

EP-1166
Prospects of Tb-161 production
U. Köster¹, I. Cieszykowska², R. Mikołajczak², N. Buczkó³, K. Gmélíng³, Z. Kis³, B. Maróti³, M. Capogni⁴, L. Lepore⁵, L. Spagnuolo⁵, B. Ponsard⁶, M. Van de Voorde⁷, P. V. Grundler⁸, N. P. van der Meulen^{8,9};
¹Institut Laue-Langevin, Grenoble, FRANCE, ²NCBJ, POLATOM, Otwock, POLAND, ³HUN-REN EK-CER, Budapest, HUNGARY, ⁴ENEA, NUC-INMRI, Casaccia, ITALY, ⁵ENEA, NUC-IRAD-CRGR, Casaccia, ITALY, ⁶SCK CEN, BR2 Reactor,

Mol, BELGIUM, ⁷SCK CEN, Nuclear Medical Applications, Mol, BELGIUM, ⁸PSI Center for Life Sciences, Villigen-PSI, SWITZERLAND, ⁹PSI Center for Nuclear Engineering and Sciences, Villigen-PSI, SWITZERLAND.

EP-1167
Preparation of Large-Area 203TI Targets for Medical Radionuclide Production
J. Chen, Z. Liu;
Peking University, Beijing, CHINA.

EP-1168
Cyclotron-Based ⁶⁴Cu Production from ⁶⁴Ni: MCNPX Simulation and theoretical Validation
Z. Karimi, H. Azizakram, A. Abolhosseini Shahrnoy;
Parsisotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF,

EP-1169
Development of a New Solid-State ²²⁹Th/²²⁵Ac Generator Design
E. Yalcintas Bethune, A. Cosby, A. Younes, C. Dunckley, J. Larrabee, J. Camacaro, P. de Roos, R. Sumner, S. Tanzey, Q. Pham, L. Lilley;
TerraPower, Bellevue, WA, UNITED STATES OF AMERICA.

EP-1170
Investigation of ¹⁶¹Tb radionuclide production for therapy application via neutron induced reaction
H. Azizakram, Z. Karimi;
Pars Isotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-1171
Ensuring Radionuclidic and Chemical purity of Actinium-225 from Thorium-229 generator
J. Camacaro, C. P. Dunckley, P. de Roos, Q. Pham, R. Sumner, S. Tanzey, A. L. Lakes, E. Yalcintas Bethune, L. M. Lilley, A. Younes;
TerraPower Isotopes, Bellevue, WA, UNITED STATES OF AMERICA.

EP-1172
Critical Control Points study in the production process of Mo-99/Tc-99m generators in Ezeiza Atomic Centre
D. Camporotondi;
Comisión Nacional de Energía Atómica, Buenos Aires, ARGENTINA.

EP-1173
Production and separation of ⁶⁴Cu and ¹⁶¹Tb in a Nuclear Reactor to Support Hospital Research: A TRIGA Mark II Experience
L. Canziani¹, G. Grosso¹, A. Gandini¹, A. Salvini¹, G. Pepe²;
¹Laboratory of Applied Nuclear Energy - Università di Pavia, Pavia, ITALY, ²Fondazione IRCCS Policlinico San Matteo, Pavia, ITALY.

EP-1174
Small-scal production of ¹⁶¹Tb
D. Pawlak, M. Żółtowska, I. Cieszykowska, P. Saganowski, A. Filiks, R. Mikołajczak;
National Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock, POLAND.

EP-70
e-Poster Area
D: Technical Studies -> D5 Radiopharmacy/ Radiochemistry -> D52 Radiopharmaceutical Preparation and Quality Control

EP-1175
cGMP-complaint implementation of high-yield automated [18F]FAPI-74 production with optimized quality control
W. Storms¹, S. Celen², J. Maes², K. Serdons², K. Goffin², T. De Groot², L. Trimp³, C. Warnier³, T. Gendron⁴, R. Gerardy³, K. Van Laere², C. M. Deroose², J. Kleynhans¹, F. Cleeren¹;
¹Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BELGIUM, ²Nuclear Medicine, University Hospital Leuven, Leuven, BELGIUM, ³Trasis, Ans, BELGIUM, ⁴University of Liège, Liège, BELGIUM.

EP-1176
A new fluorine-18 radiolabelled inhibitor of TRPC6 receptor for PET imaging of glioblastoma.
M. Iannone¹, C. Papotto², S. Stucchi^{1,2}, E. Turolla^{1,2}, E. Vino¹, S. Todde^{1,2};
¹Tecnomed Foundation - University of Milan Bicocca, Monza, ITALY, ²School of Medicine and Surgery - University of Milan Bicocca, Monza, ITALY.

EP-1177
A radiopharmacist's guide to gallium: Implementing ⁶⁸Ga kit labeling in Your Radiopharmacy
A. Mihelcic, B. Hudomalj;
Institute of Oncology Ljubljana, Ljubljana, SLOVENIA.

EP-1178
Feasibility and comparative evaluation of a candidate hydroxyethyl starch-based sedimentation agent for (^{99m}Tc)Tc-HMPAOutologous white blood cellslabelling
A. Deschavannes, T. Pitaud-Renaud, A. Clotagatide, C. Rioufol, M. Piquemal;
Hospices Civils de Lyon, Lyon, FRANCE.

EP-1179
Synthesis and Validation of [⁶⁸Ga]Ga-DOTA-Siglec-9 for Non-invasive PET Imaging
S. Migliari¹, A. Guercio¹, A. Gagliardi¹, S. Bruno², M. Scarlattei¹, G. Baldari¹, A. Roivainen³, S. Forsback³, L. Ruffini¹;
¹Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY, ²Food and Drug Department, University of Parma, Parma, ITALY, ³Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Finland, Turku, FINLAND.

EP-1180
Content analysis of deviation reports in the in-house manufacture of PET radiopharmaceuticals
S. Forsback¹, R. V. Kivelä², A. M. Juppo³;
¹University of Turku, Turku, FINLAND, ²Hospital Pharmacy, Turku University Hospital, Turku, FINLAND, ³University of Helsinki, Faculty of Pharmacy, Division of Pharmaceutical Chemistry and Technology, Helsinki, FINLAND.

EP-1181
Improvement of the ¹⁷⁷Lu-PSMA¹⁸T Labelling Method for Clinical Production
P. Bohn, A. Coussirou, M. Six, A. Salles, F. Basuyau, A. Edet-Sanson, P. Vera, D. Tonnelet;
Centre Henri Becquerel, Rouen, FRANCE.

EP-1182
Compassionate Use of [⁶⁸Ga]Ga-NODAGA[40Lys]-Exendin-4: Validation of an Automated Synthesis in a Sodium Acetate Buffer
M. Ragot, M. Jung, P. Orhon, A. Revy, S. Levesque, M. Tempier;
Centre Jean Perrin, Clermont-Ferrand, FRANCE.

EP-1183
Stability Evaluation of I-131 Radiolabeled Ferulic and Caffeic Acids: Effects of Storage Conditions and Stabilizing Agents
M. Radovic, M. Peric, D. Stankovic, A. Vukadinovic, S. Vranjes-Djuric, D. Jankovic, M. Mirkovic;
„VINCA” Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Belgrade, SERBIA.

EP-1184
Optimization of Automated Synthesis of [¹⁸F] AIF-NOTA-FAPI-4 for Clinical Radiopharmacy Applications
L. Pires^{1,2}, K. Zirbesegger², J. Giglio², J. Gambini², P. Duarte², V. Cardoso¹, S. Fernandes¹, E. Savio²;
¹Universidade Federal de Minas Gerais, Belo Horizonte, BRAZIL, ²Centro Uruguayo de Imagenología Molecular, Montevideo, URUGUAY.

EP-1185
Towards clinical implementation of radiolabeled orally inhaled drug products: preliminary feasibility study using a Next Generation Cascade Impactor and [¹⁸F] radiopharmaceuticals
J. Wolfert¹, M. Konijnenberg¹, S. P. J. M. Tsai¹, I. van de Merwe¹, N. H. Hendrikse¹, L. Ruijgrok¹, T. A. Mulders¹, B. R. Lavon², F. A. Verburg¹, E. de Blois¹;
¹Erasmus MC, Rotterdam, NETHERLANDS, ²FLUIDDA NV, Kontich, BELGIUM.

EP-1186
Taking radioimmunoconjugate manufacturing to the next level: a universal cassette-based process for the Lu-177 radiolabeling of mAbs
C. Vanasschen, A. Dubart, J. Masset, E. Duray, M. Hawotte, S. Degueldre, C. Warnier;
Trasis, Ans, BELGIUM.

EP-1187
Optimization of 4-[¹⁸F]fluoro-1-naphthol ([¹⁸F]4FN) production and quality controls
M. Riondato^{1,2}, J. Martinelli², R. Guelfo³, L. Palio⁴, C. Marini⁵, G. Sambuceti²;
¹IRCCS Policlinic Hospital of Genoa, Genoa, ITALY, ²Dept. Health Sciences, University of Genoa, Genoa, ITALY, ³Dept. Chemistry and Chemical Technologies, University of Genoa, Genoa, ITALY, ⁴Dept. of Science and Technological Innovation University of Piemonte Orientale, Alessandria, ITALY, ⁵Institute of Molecular Biomimaging and Physiology (IBFM), National Research Council (CNR), Milan, ITALY.

EP-1188
Independent verification of activity determination for radiopharmaceutical preparations

K. Baete^{1,2}, L. Mihailescu³, W. Deckers¹, C. Terwinghe¹, R. Aarts³, W. Claeys², J. Kleynhans², C. M. Deroose^{1,2};
¹UZ Leuven, Leuven, BELGIUM, ²KU Leuven, Leuven, BELGIUM, ³Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM.

EP-1189
Feedback of [⁶⁸Ga]Ga-FAPI-46 radiosynthesis for clinical applications

C. Provost, C. Schmitt, M. Steffann, B. Irumva, M. Delion, J. Fouque, O. Madar;
Institut Curie, Saint Cloud, FRANCE.

EP-1190
GMP Standardized Automated Synthesis and Quality Control of [⁶⁸Ga]Ga-PSMA-11, [⁶⁸Ga]Ga-FAPI-04, [⁶⁸Ga]Ga-DOTA-NOC and [⁶⁸Ga]Ga-PentixaFor for Clinical PET Imaging

M. Zhang;
Xijing Hospital, Xi'an, CHINA.

EP-1191
Automated Radiosynthesis and Quality Control of [⁶⁸Ga]Ga-DOTA-NOC for Clinical PET Imaging

M. Zhang;
Xijing Hospital, Xi'an, CHINA.

EP-1192
Automated Radiosynthesis and Quality Control of [⁶⁸Ga]Ga-PentixaFor for Clinical PET Imaging

M. Zhang;
Xijing Hospital, Xi'an, CHINA.

EP-1193
Liquid target production of Gallium-68 by a low energy medical cyclotron, post-bombardment purification and radiosynthetic yield of Gallium-68 DOTATATE as compared with Ge68/Ga68 generator

J. Cheung, N. Ng, K. Liu, P. Lee, C. Ho;
Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

EP-1195
Transfer Of The [¹⁸F]FMPEP-d₁ From a Fixed-line Device To a Disposable Cassette System

E. Kerminen¹, N. Rajala¹, A. K. Kirjavainen^{1,2};
¹Turku PET Centre, Turku, FINLAND, ²Department of Chemistry, University of Turku, Turku, FINLAND.

EP-1196
Residual solvents analysis on fully automated quality control system - Method validation and comparability with compendial methods (Ph Eur & USP)

X. Franci, S. Leloux, N. Godeau, Y. Zandona, N. Verbrugge; Trasis, Ans, BELGIUM.

EP-1197
Radio-TLC Linearity in the Range of Concentrations Used

C. Piedelobo Vaquero, E. Dobra Neacsu, L. Cebollada Cameo, G. Rubio Fernández, J. Pérez Iruela;
Servicio de Radiofarmacia. Hospital Universitario Ramón y Cajal, Madrid, SPAIN.

EP-1198
Determine Radiochemical Purity of [^{99m}Tc]Tc-Nanocolloids in an Analytical Method with Accuracy, Precision and Specificity

C. Piedelobo Vaquero, E. Dobra Neacsu, G. Rubio Fernández, L. Cebollada Cameo, P. Ortega Cuadrado, M. Rodríguez Gómez, J. Pérez Iruela;
Servicio de Radiofarmacia. Hospital Universitario Ramón y Cajal., Madrid, SPAIN.

EP-1199
Towards Advanced Imaging of Cardiac Amyloidosis: Reassessing Aprotinin with ⁶⁴Cu Radiolabeling

L. Canziani¹, G. Manfrinato¹, A. Gandini², G. Pepe¹;
¹Fondazione IRCCS Policlinico San Matteo, Pavia, ITALY, ²Laboratory of Applied Nuclear Energy - Università di Pavia, Pavia, ITALY.

EP-1200
Production optimisation and quality control testing of RHN001-Tx (¹⁸⁸Re-PSMA) per GMP standards

S. Sibiya^{1,2,3}, A. Mdlophane^{1,2,3}, S. Mdanda^{1,2,3}, K. Ramonaheng^{1,2,3}, M. Qebetu^{1,2,3}, H. Ndlovu^{1,2,3}, J. Zeevart^{1,4}, F. Giesel⁵, M. Sathekge^{1,2,3}, J. Cardinale⁵;
¹NuMeRI NPC, Pretoria, SOUTH AFRICA, ²Department Of Nuclear Medicine, Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA, ³Department of Nuclear Medicine, Faculty of Health Science, University of Pretoria, Pretoria, SOUTH AFRICA, ⁴The South African Energy Corporation (NECSA), Pelindaba, SOUTH AFRICA, ⁵Department of Nuclear Medicine, Medical Faculty and University Hospital Heinrich Heine University Dusseldorf, Dusseldorf, GERMANY.

EP-1201
Process Validation of [¹⁸F]Fluoroestradiol and [¹⁸F]PSMA-1007 Production on next-gen Automated Module following Regulatory-Compliant Transition Requirements

M. B. Silveira, E. Cortez, A. F. Castro, C. L. S. Costa, L. T. C. Nascimento;
Center for the Development of Nuclear Technology (CDTN/CNEN), Belo Horizonte, BRAZIL.

EP-71

e-Poster Area

E: Other Studies -> E1 Case Reports

EP-1202
Imaging of Widespread Manifestations of Erdheim-Chester Disease with Ga-68 FAPI PET/CT and F-18 FDG PET/CT

C. Turkan¹, Ö. Karadağ², Y. Büyükaşık³, M. Tuncel¹;
¹Hacettepe University Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Hacettepe University Department of Internal Medicine, Divison of Rheumatology, Ankara, TÜRKIYE, ³Hacettepe University Department of Internal Medicine, Divison of Hematology, Ankara, TÜRKIYE.

EP-1203
Pitfall in ¹⁸F-FDG PET/CT: Muscular Uptake Does Not Always Mean Inadequate Preparation - A Case Report of Antisynthetase Syndrome

V. Heringer, E. Lima, T. Alves, C. Torricelli, N. Silva, G. Barbosa, E. Etchebehere;
UNICAMP, Campinas, BRAZIL.

EP-1204
Incidental Detection of Hemorrhagic Stroke with Luxury Perfusion on a ^{99m}Tc-MDP Bone Scan in a Breast Cancer Patient: A Case of Hidden Neurological Sequelae

A. Akhter, S. Sharmin, S. Islam;
Institute of Nuclear Medicine and Allied Sciences (INMAS) Dhaka, BAEC, Dhaka, BANGLADESH.

EP-1205
From Prostate to Pulmonary Malignancy: A Case of Incidental Lung Adenocarcinoma detected by PSMA PET/CT with a significant impact on clinical management

D. Barbosa, J. Ferro, H. Duarte, D. Silva, N. Vasconcelos, R. Marão, I. Sampaio;
IPO, Oporto, PORTUGAL.

EP-1206
Renal Cell Carcinoma Masquerading as a Cervical Paravertebral Abscess: A Rare Case Report

C. S, L. Goriparti, C. Bal, S. L.S., J. Krishna;
All India Institue of Medical Science, New Delhi, INDIA.

EP-1207
FDG PET/CT in Disseminated Cryptococcosis Mimicking Malignancy with Chest Wall Infiltration and Rib Destruction: A Rare Case of Fungal Pseudotumor

A. Mahalik, A. Roy, N. Kundu, K. Jain, G. Lalitha, J. Krishna P., V. R. Singh, R. Kumar;
All India Institute of Medical sciences, New Delhi, INDIA.

EP-1208
A Rare Metastatic Journey: From Lower Limb to Heart in Cutaneous Squamous Cell Carcinoma Revealed by ¹⁸F-FDG PET/CT

A. Akhter¹, S. Sharmin¹, A. Haque², T. Hasan¹, S. Biswas¹;
¹Institute of Nuclear Medicine and Allied Sciences (INMAS) Dhaka, BAEC, Dhaka, BANGLADESH, ²Dhaka Medical College Hospital, Dhaka, BANGLADESH.

EP-1209
Functional Tumor Heterogeneity Revealed by Discordant 18F FDG and 18F FES PET/CT in ER-Positive Breast Cancer: A Case of Imaging-Guided Insight into Endocrine Resistance

A. Mahalik, N. Kundu, A. Roy, M. Tripathi, R. Kumar;
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-1210
Targeting the rare: ¹⁸F-FDG PET/CT in pediatric bilateral orbital Rosai-Dorfman disease

K. Jain, A. Mahalik, N. Kundu, J. Choudhary, S. Singh, V. R. Singh, R. Kumar;
AIIMS New Delhi, Delhi, INDIA.

EP-1211
68Ga-DOTATATE PET/MRI for the Diagnosis of Optic Nerve Sheath Meningioma in an Adolescent with Progressive Unilateral Vision Loss

A. Giarratana, M. Larson;
University of Wisconsin - Madison, Madison, WI, WI, UNITED STATES OF AMERICA.

EP-1212
A rare case of extramammary Paget’s disease of the vulva: [¹⁸F]FDG PET/CT in the evaluation of Radiotherapy efficacy and 30-months follow-up

M. Ricci¹, A. Cimini², M. Ullo¹, M. Grivet Fojaja¹, F. Zarrelli¹, F. Perrotta³, E. Lubrano di Scorpaniello³;
¹Cardarelli Hospital, Nuclear Medicine Unit, Campobasso, ITALY, ²Nuclear Medicine Unit, St. Salvatore Hospital, L'Aquila, ITALY, ³Department of Medicine and Health Sciences “Vincenzo Tiberio”, University of Molise, Campobasso, ITALY.

EP-1213
A rare case of metastatic Well differentiated Neuroendocrine Tumor of Prostate on hemodialysis treated with Concurrent Long Acting Octreotide and 177Lutetitium DOTATATE therapy achieving complete response- Case report and Literature Review

J. Bal, S. Jha, P. Dougall;
Max Super Specialty Hospital, Delhi, INDIA,

EP-1214
The Role of FDG PET/CT in Treatment-Related Neuroendocrine Prostate Cancer: An Unusual Case of PSA and PSMA Double-Negative Disease with Squamous Differentiation

Y. Li, Y. Tang, S. Hu;
Xiangya Hospital, Central South University, Changsha, CHINA.

EP-1215
“Splenic Superscan” on [¹⁸F]FDG PET/CT in a rare case of hepatosplenic T-cell lymphoma

N. Aydinbelge- Dizdar¹, U. Han², D. Cayir², Y. Sari Cataldas²;
¹Ankara Etlik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Ankara Etlik City Hospital, Department of Pathology, Ankara, TÜRKIYE, ³University of Health Sciences, Ankara Etlik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-1216
Metastatic Prostate Cancer with Pulmonary Involvement Mimicking Pneumonia: Findings on ¹⁸F-FDG PET/CT s and ⁶⁸Ga-PSMA PET/CT

N. Aydinbelge- Dizdar¹, E. Tatci², A. Cinar¹, B. Bozca¹, O. Ozmen²;
¹Department of Nuclear Medicine, Ankara Etlik City Hospital, Ankara, TÜRKIYE, ²Department of Nuclear Medicine, University of Health Sciences, Ankara Etlik City Hospital, Ankara, TÜRKIYE.

EP-1217
Prostate cancer associated with polyostotic Paget disease : diagnostic challenges and the value of multimodal imaging

D. Tahmi, F. Agboton, H. Labiod, A. Amimour;
Service de Médecine Nucléaire CHU Bab El Oued, Algiers, ALGERIA.

EP-1218
Unveiling Bile Leaks: The Power of Hepatobiliary Scintigraphy in Post-Traumatic Liver Injury

R. Solanki;
Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA.
EP-1219
Utility of Radiolabeled Red Blood Cell SPECT/CT in Diagnosing Urinary Bladder Hemorrhage: A Case Report
K. Resuello, P. Bautista-Peñalosa, A. Domingo;
St. Luke’s Medical Center - Global City, Taguig, PHILIPPINES.

EP-1220

Multimodal Treatment in Advanced Hepatocellular Carcinoma: Yttrium-90 Radioembolization Following Stereotactic Body Radiation Therapy and TACE

M. Mutuleanu^{1,2}, I. Ioana¹, I. Taciuc¹, C. Petroiu¹, M. Gherghel^{1,2};
¹Institute of Oncology “Prof. Dr. Alexandru Trestioreanu”, Bucharest, Romania, Bucharest, ROMANIA, ²University of Medicine and Pharmacy “Carol Davila”, Bucharest, ROMANIA.

EP-1221

“Blessing in disguise” Lu177-PSMA-617 for chemo naïve mCRPC patient with parkinsonism and embarrassing sialorrhea

M. Gupta¹, P. Sarathi Choudhury¹, S. Goyal², A. Pathak¹, M. Seth¹, S. Rawal³;
¹Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA, ²Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA, ³Department of GenitoUro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA.

EP-1222

Splenic hemangioma intensive uptake on 99mTc-PSMA scintigraphy - caution required in interpretation

I. Sisko Markos^{1,2}, M. Romić^{1,2}, I. Blazekovic^{1,2}, T. Jukić¹, A. Frobe¹;
¹UHC Sestre Milosrdnice, Zagreb, CROATIA, ²Croatian Catholic University, School of Medicine, Zagreb, CROATIA.

EP-1223

^{99m}Tc-Ubiquicidin SPECT/CT in Diabetic Foot: Detection of Subclinical Infection in a Patient with Chronic Venous Ulcer

V. Heringer, B. Alencar, T. Agnello, M. Osmak, E. Etchebehere, C. Ramos, M. Lima, B. Juarez, A. Santos; UNICAMP, Campinas, BRAZIL.

EP-1224

Multisystemic malakoplakia revealed by ¹⁸F-FDG PET/CT : A case of concomitant bilateral osteomyelitis and genitourinary involvement

F. Yasser, P. Maliha, M. Morin;
University of Montreal, Montreal, QC, CANADA.

EP-1225

A Rare Case of Small Cell Lung Cancer Presenting with a Breast Mass

N. Aydinbelge Dizdar¹, D. Cayir², H. Turksoy Karaca³, A. T. Arikok³;
¹Ankara Etlik City Hospital, Ankara, TÜRKIYE, ²University of Health Sciences, Ankara Etlik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ³Ankara Etlik City Hospital, Department of Pathology, Ankara, TÜRKIYE.

EP-1226

FDG-Negative but FES-Positive Vertebral Metastasis in ER-Positive Breast Cancer: A Case Highlighting the Complementary Role of Functional Receptor Imaging

A. Mahalik, N. Kundu, K. Jain, M. Tripathi, R. Kumar;
All India Institute of Medical sciences, New Delhi, INDIA.

EP-1227

Significance of ¹⁸F-FDG PET/CT in Detecting Rare Breast Metastasis from Cervical Cancer: A Case Report

A. Leiva Montejo, I. Sime Loayza, C. Balbin Garcia, B. Cueto Cañadas, A. Montellano Fenoy, J. Sanchez Catalicio, J. Delgado Moreno, M. Guerrero Ortiz;
Hospital Universitario Torrecárdenas, Almeria, SPAIN.

EP-1228

Quantitative [¹⁵O]H₂O PET perfusion hybrid imaging reveals the correct diagnosis in a patient with cardiac amyloidosis and chest pain

V. Uusitalo;
Helsinki University Hospital, Helsinki, FINLAND.

EP-1229

Osteomesopyknosis, a Great Mimic of Osteoblastics Metastasis in Bone Scintigraphy.

M. Feriche Aragon, C. Mas Pascasio, E. Espinosa Muñoz, A. Adarve Castro, T. Rudolphi Solero, S. Sanz Viedma;
Hospital Virgen de la Victoria, Málaga, SPAIN.

EP-1230

Benign But Avid: Ga-68 DOTATATE Uptake In Lip Chondroid Syringoma Mimicking Neuroendocrine Tumor Metastasis

E. Pasini Nemir, M. Pesorda, D. Huic;
University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-1231

From back pain to bone lesion: A case of disseminated tuberculosis uncovered by PET/CT

G. Rakia, A. Ezzine, S. Mensi, T. Dardouri, R. Mehri, K. Chatti;
CHU Sahloul, Sousse, TUNISIA.

EP-1232

Challenges in diagnosis of hepatocellular adenoma - a case study

Z. Zychowicz, P. Cichocki, Z. Adamczewski;
Medical University of Lodz, Nuclear Medicine Department, Lodz, POLAND.

EP-1233

Total-body [¹⁸F]AIF-RESCA-T4 ImmunoPET/CT in Patients with Solid Tumors: Initial Experience and Potential Value in Navigating Clinical Decision-making

S. An, G. Huang, J. Liu, W. Wei;
Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA.

EP-1234

Negative ^{99m}Tc-Ubiquicidin SPECT/CT in the Evaluation of Suspected Osteoradionecrosis of the Mandible in a Patient with Recurrent Tongue Carcinoma

V. Heringer, B. Alencar, T. Agnello, M. Osmak, E. Etchebehere, C. Ramos, M. Lima, B. Amorim, A. Santos; UNICAMP, Campinas, BRAZIL.

EP-1235

Renal Ewing Sarcoma: “TripleMismatch” NuclearMedicine Signature

N. Kundu, D. Khan, S. Sagar, A. Mahalik, A. Roy, K. Jain, V. Singh, J. Choudhary, J. Krishna, R. Kumar;
AIIMS New Delhi, Delhi, INDIA.

EP-1236

Multifocal avascular necrosis unmasked by Tc99m MDP Bone scan

N. Kundu, D. Khan, S. Sagar, A. Mahalik, K. Jain, J. Krishna, V. Singh, J. Choudhary, R. Kumar;
AIIMS New Delhi, Delhi, INDIA.

EP-1237

Unexpected [¹⁸F] Fluciclovine Uptake in Pilocytic Astrocytoma: A Paediatric Case Report

H. Koga^{1,2}, S. Watanabe^{1,2}, K. Hirata^{1,2}, T. Harada¹, Y. Ishi³, S. Yamaguchi³, N. Wakabayashi^{1,2}, L. Hashimoto², K. Kudo¹;
¹Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, JAPAN, ²Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, Hokkaido, JAPAN, ³Department of Neurosurgery, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, JAPAN.

EP-1238

Scintigraphic Patterns of Renal Osteodystrophy: Two Case Reports with Differential Diagnostic Challenges

G. Bianciardi¹, G. A. Fusco¹, E. Greco¹, C. M. P. Sgro¹, P. E. Orlandi², A. Romeo³, S. Fanti^{1,3};
¹Nuclear Medicine, Alma Mater Studiorum, University of Bologna, Bologna, ITALY, ²Unit of Radiology, Maggiore Hospital, Bologna, ITALY, ³Nuclear Medicine, IRCSS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-1239

Unexpected Diagnosis of Papillary Thyroid Carcinoma Following Degeneration of a Thyroglossal Duct Cyst in a Child

M. Ben Nasr, D. Ben Sellem, L. Zaabar, A. Mhiri;
Salah Azaiez Institute of Tunis, Tunis, TUNISIA.

EP-1240

Two synchronous primary malignant neoplasms (lung cancer and thymoma) detected by FDG PET/CT in a patient undergoing initial workup for prostate cancer: A case report

J. Zivanovic¹, M. Stojiljkovic^{1,2}, K. Petrovic¹, N. Pantic¹, D. Sobic Saranovic^{1,2}, V. Artiko^{1,2}, S. Odalovic^{1,2};
¹Center for Nuclear Medicine with PET, University Clinical Center of Serbia, Belgrade, SERBIA, ²Faculty of Medicine, University of Belgrade, Belgrade, SERBIA.

EP-1241

[¹⁷⁷Lu]Lu-PSMA Radioligand Therapy to Prolong Androgen Deprivation Therapy Free Survival in Patient With Hormone-Sensitive Metastatic Prostate Cancer: a case report

I. Langrate¹, H. Einspieler¹, E. Kretschmer-Chott¹, S. Schmitl¹, L. Nics¹, S. Shariat^{2,3}, M. Hacker¹, G. Kramer², S. Rasul¹;
¹Medical University of Vienna, Vienna, AUSTRIA, ²Department of Urology, Medical University of Vienna, Vienna, AUSTRIA, ³Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, AUSTRIA.

EP-1242

Post-treatment Inflammation with Foamy Macrophages Mimicking Lymphoma Relapse on Sequential FDG PET

S. Howladar, W. Zeng;
University of Ottawa, Ottawa, ON, CANADA.

EP-1243

Predictive Value of ¹⁸F-FDG PET/CT in Early Detection of Pulmonary Squamous Cell Carcinoma: A Case Report

D. Silva, D. Barbosa, N. Vasconcelos, R. Marão, I. Lopo, H. Duarte, I. Lucena Sampaio;
Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PORTUGAL.

EP-1244

[¹⁸F]FDG PET/CT imaging in two patients with diffuse skeletal muscle metastasis of thyroid carcinoma

Y. Wang, J. Xiang, R. Li, X. Zhang, Y. Lin, Z. Zhu;
Peking Union Medical College Hospital, Beijing, CHINA.

EP-1245

^{99m}Tc-Ubiquicidin SPECT/CT in Suspected Periprosthetic Infection: Case Series in Patients with Complex Orthopedic and Inflammatory Backgrounds

V. Heringer, B. Alencar, T. Agnello, M. Osmak, E. Etchebehere, C. Ramos, M. Lima, B. Amorim, A. Santos; UNICAMP, Campinas, BRAZIL.

EP-1246

Rare atypical case of Mayer Rokitansky Kuster Hauser (MRKH) type II syndrome with ectopic hydronephrotic renal disease on radionuclide scintigraphy

D. Singh, P. Kumar, S. Jain;
All India Institute of Medical Sciences, Bhopal, INDIA.

EP-1247

Metabolic Imaging of Pembrolizumab-Associated Biliary Inflammation: A Case of Spontaneous Resolution on [¹⁸F]FDG PET/CT

I. Ferreira¹, O. L. Silva¹, M. Simões², J. A. Sequeira¹, A. I. Santos¹;
¹Unidade Local de Saúde de Almada-Seixal, E.P.E, Almada, PORTUGAL, ²Unidade Local de Saúde do Arco Ribeirinho, E.P.E, Montijo, PORTUGAL.

EP-1248

A Case Of Skeletal Tuberculosis

M. Mehesen, R. Shera;
National Cancer Institute, Cairo university, Cairo, EGYPT.

EP-1249

A Rare Case of Osteopoikilosis Differentiated from Sclerotic Metastatic Lesions by Bone Scintigraphy

G. Inal¹, N. Aydinbelge Dizdar¹, A. Cinar¹, C. O. Engur Uyanik¹, O. Ozmen²;
¹Ankara Etlik City Hospital Nuclear Medicine Clinic, Ankara, TÜRKIYE, ²University of Health Science, Ankara Etlik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-1250

Utility of complimentary functioning and cortical imaging scintigraphy in assessing delayed graft function in a paediatric patient with suspected vascular thrombosis: A Case Report

K. Hlongwa, A. Al-Marrani, M. P. Rivombo, A. Coetzee, S. More;
University of Cape Town, Cape Town, SOUTH AFRICA.

EP-1251

Unmasking Synchronous Primaries: The Crucial Role of ¹⁸F-FDG PET/CT in Diagnosing Concurrent Breast and Small Cell Lung Cancer with Atypical Metastases

A. Leiva Montejo, B. Cueto Cañadas, C. Balbin Garcia, I. Sime Loayza, J. Delgado Moreno, J. Sánchez Catalicio, A. Montellano Fenoy, M. Guerrero Ortiz; Hospital Universitario Torrecárdenas, Almeria, SPAIN.

EP-1252

Local perinerural invasion in sacral plexus in recurrent metastatic adenocarcinoma prostate as seen on ⁶⁸Ga PSMA PET-CT; a rare finding. Local perinerural invasion in sacral plexus in recurrent metastatic adenocarcinoma prostate as seen on ⁶⁸Ga PSMA PET-CT; a rare finding.

J. Bal, S. Jha, K. Shanker, P. Dougall; Max Super Specialty Hospital, Delhi, INDIA.

EP-1253

Prostatic adenocarcinoma masquerading as rectal primary- diagnostic dilemma aided by ⁶⁸Ga PSMA scan to reach conclusion.

J. Bal, K. Shanker, P. Dougall; ¹Max Super Specialty Hospital, Delhi, INDIA.

EP-1254

A case of diffuse bone tracer myocardium uptake after thoracic trauma in a patient with suspected Transthyretin-related cardiomyopathy.

I. Badrane¹, C. Cittanti¹, L. Urso¹, L. Uccelli¹, M. Bartolomei²; ¹Department of Translational Medicine, University of Ferrara, Ferrara, ITALY, ²Nuclear Medicine Unit, Department of Onco-Hematology, Ferrara, ITALY.

EP-1255

Postoperative Complications in Scimitar Syndrome: The Role of Lung Scintigraphy

J. Duarte¹, J. P. Carvalho¹, A. Marques^{1,2}, F. Abreu^{1,2}, S. Pintão¹; ¹Unidade Local de Saúde de Lisboa Ocidental, Lisbon, PORTUGAL, ²Instituto de Medicina Nuclear da Faculdade de Medicina de Lisboa, Lisboa, PORTUGAL.

EP-1256

Diagnostic complexity of Hepatopulmonary Syndrome: a case report

I. Casimiro, D. Carvalho, S. Barata, S. Paiva, J. Silva, M. Monteiro, A. Moreira, T. Saraiva, G. Costa; Unidade Local de Saúde de Coimbra, Coimbra, PORTUGAL.

EP-1257

Posterior Reversible Encephalopathy Syndrome In a Child with Langerhans cell histiocytosis

M. Mehesen, R. Shera; National Cancer Institute, Cairo University, Cairo, EGYPT.

EP-1258

¹⁸F-Choline PET-CT as a Decisive Tool for Detecting HCC Recurrence After Icoregional therapy: When Morphological Imaging Falls Short

A. Genova, F. Porcaro, L. Turchetta, M. Prisco, V. Piscopo, I. Annarumma, M. Catalano; Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Naples, ITALY.

EP-1259

¹⁸F-FDG PET/CT in Renal Cell Carcinoma Presenting as Urinary Retention with Extensive Local Invasion and IVC Tumor Thrombus: A Rare and Illustrative Case

A. Mahalik, N. Kundu, A. Roy, G. Lalitha, J. Krishna P., S. Singh, R. Kumar; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-1260

Primary breast malignancy presenting as paraneoplastic dermatomyositis role of ¹⁸fdg pet-ct in primary staging and response evaluation- a case report

J. Bal, S. Jha, P. Dougall; ¹Max Super Specialty Hospital, Delhi, INDIA.

EP-1261

Incidentally diagnosed synchronous vaginal adenocarcinoma on SSTR imaging (⁶⁸Ga DOTANOC) done for primary Gastric NET

J. Bal, S. Jha; Max Super Specialty Hospital, Delhi, INDIA.

EP-1262

Sacral Neurolymphomatosis In Refractory Diffuse Large B-Cell Lymphoma: Multimodal Imaging Including PET/CT and MRI For Diagnosis And CAR-T Response Monitoring

L. Henrich Malizia¹, A. Roteta Unceta Barrenechea¹, F. Arraut Serrano¹, A. Garin Rodriguez¹, N. Etxabeguren Gallo¹, I. Cillero Etxebeeste¹, B. Mendibil Esquisabel¹, I. Olazabal Eizaguirre², I. Zeberio Etxetxipia², V. Rodriguez Ortega¹, I. Sanchez Oscoz¹, S. Sanchez Eguiguren¹, I. Jauregui Larrea¹, G. Rodriguez Rodriguez¹, I. Leon Zubizarreta¹, A. Iztueta Iturbe¹, I. Lopez Sanchez¹, A. Gomez Lopez¹; ¹Hospital Universitario Donostia - Onkologikoa, San Sebastian, SPAIN, ²Hospital Universitario Donostia, San Sebastian, SPAIN.

EP-1263

Complete Resolution Of Severe Refractory Hypoglycaemia Following Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy In A Metastatic Dual Insulinoma-Gastrinoma Pancreatic Neuroendocrine Tumour: A Case Report

L. Henrich Malizia¹, A. Gomez Lopez¹, A. Roteta Unceta Barrenechea¹, F. Arraut Serrano¹, A. Garin Rodriguez¹, N. Etxabeguren Gallo¹, B. Sanchez Casi¹, M. Perez de Ciriza Cordeu², V. Rodriguez Ortega¹, I. Sanchez Oscoz¹, S. Sanchez Eguiguren¹, I. Jauregui Larrea¹, G. Rodriguez Rodriguez¹, I. Leon Zubizarreta¹, A. Iztueta Iturbe¹, I. Lopez Sanchez¹, I. Cillero Etxebeeste¹; ¹Hospital Universitario Donostia - Onkologikoa, San Sebastian, SPAIN, ²Hospital Universitario Donostia, San Sebastian, SPAIN.

EP-1264

Renal involvement in diffuse large B-cell lymphoma detected by ¹⁸F-FDG PET/CT: analysis of three clinical cases

J. Charfi, H. Boudriga, R. Sfar, K. Ayed, M. Nouira, K. Chatti; Sahloul Hospital, Sousse, TUNISIA.

EP-1265

The Diagnostic Value of Bone Scan in Tertiary Syphilis With Skeletal Involvement

J. Duarte¹, A. Marques^{1,2}, J. P. Carvalho¹, F. Abreu^{1,2}, S. Pintão¹;

¹Unidade Local de Saúde de Lisboa Ocidental, Lisbon, PORTUGAL, ²Instituto de Medicina Nuclear da Faculdade de Medicina de Lisboa, Lisboa, PORTUGAL.

EP-1266

Uncommon penile metastasis emerges in patient with mCRPC during Radium223 radioligand therapy : A Rare Case Highlighted by PSMA PET/CT

D. Nakro¹, L. Augusto², F. Nouhaud³, S. Makhloufi-martinage⁴, D. Tonnelet¹; ¹Service de médecine nucléaire, Centre Henri Becquerel, Rouen, FRANCE, ²Département d'oncologie urologique et digestive, CHU Rouen, Rouen, FRANCE, ³Service d'Urologie, Clinique du Cèdre, Bois Guillaume, FRANCE, ⁴Service d'oncologie médicale, Clinique Saint Hilaire, Rouen, FRANCE.

EP-1267

Functional Evaluation of Musculoskeletal Infections with ^{99m}Tc-Ciprofloxacin SPECT/CT in Complex Patients Undergoing Limb Amputation: Case Series

V. Heringer, B. Alencar, T. Agnello, M. Osmak, R. Tineo, E. Etchebehere, C. Ramos, M. Lima, B. Amorim, A. Santos; UNICAMP, Campinas, BRAZIL.

EP-1268

Dynamic [⁶⁸Ga]Ga-DOTANOC LAFOV PET/CT in a Synchronous Ileum Metastatic NET

E. Fortunati¹, I. Brusa¹, G. Bianciardi², M. Di Franco², D. Dall'Olio³, M. Assenza⁴, D. Campana⁵, E. Andriani⁵, C. Ricci⁶, S. Fanti^{1,2}, V. Ambrosini^{1,2}; ¹Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ²Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ³Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITALY, ⁴Professional Development and Implementation of Research in Health Professional Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Department of Medical and Surgical Sciences (DIMEC), Medical Oncology Unit, Alma Mater Studiorum-University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁶Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, ITALY.

EP-1269

Complementary Imaging and Targeted Therapy in Progressive Metastatic MTC: A Clinical Case

R. Marão, D. Barbosa, D. Silva, N. Vasconcelos, S. Gil Santos, R. Calheiros, J. Ferro, S. Fontão de Castro, I. Inácio, R. Ferreira, A. Santos, I. Lucena Sampaio; Instituto Português Oncologia do Porto Francisco Gentil, Porto, PORTUGAL.

EP-1270

A Rare Case of Abernethy Type I Malformation: Is FDG PET/CT a Valuable Tool in Pre-Transplant Evaluation of Hepatic Lesions?

I. Ozturk, B. Esen Akkas, M. Kaya; S.B.U Basaksehir Cam ve Sakura Sehir Hastanesi, Istanbul, TÜRKIYE.

EP-1271

Sacral Malignant Proliferating Trichilemmal Tumor: A Rare Case Evaluated by F-18 FDG PET/CT

H. Eroglu Elden, A. Akbulut, K. Demirel, G. Koca, M. Korkmaz; University of Health Sciences, Ankara Training and Research Hospital, Ankara, TÜRKIYE.

EP-1272

Pitfall in ¹⁸F-FES PET/CT: A Case of ¹⁸F-FDG Avid Hepatic Metastasis Masked by Physiological Tracer Uptake in ER-Positive Breast Cancer

A. Mahalik, N. Kundu, K. Jain, M. Tripathi, R. Kumar; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-1273

Chilaiditi Syndrome Mimicking Hepatic Metastases on FDG PET/CT in a Patient with Metastatic Lung Adenocarcinoma

A. Giarratana¹, M. Larson¹, K. Capaccione²; ¹University of Wisconsin - Madison, Madison, WI, WI, UNITED STATES OF AMERICA, ²Columbia University, New York, NY, UNITED STATES OF AMERICA.

EP-1274

Osteonecrosis of the Jaw Detected on Bone Scan in a Patient with Metastatic Breast Cancer Receiving Denosumab

A. Giarratana¹, M. Larson¹, K. Capaccione²; ¹University of Wisconsin - Madison, Madison, WI, UNITED STATES OF AMERICA, ²Columbia University, New York, NY, UNITED STATES OF AMERICA.

EP-1275

A case of invasive fibromatosis misdiagnosed as a metastatic tumor

X. Li^{1,2}; ¹Department of Nuclear Medicine, the First Hospital of Shanxi Medical University, Taiyuan, CHINA, ²Collaborative Innovation Center for Molecular Imaging of Precision Medicine Shanxi Medical University, Taiyuan, CHINA.

EP-1276

Intense FDG Uptake Mimicking Hepatic Metastasis on PET/CT: Focal Hepatic Steatosis

F. Yildiz Kabaca¹, M. Acar Tayyar¹, M. Biçen Altın¹, T. Özüker¹, T. Öğuzsoy²; ¹Department of Nuclear Medicine, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, TÜRKIYE, ²Department of Pathology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, TÜRKIYE.

EP-1277

Rapidly Progressive Cutaneous Metastases in Recurrent Breast Cancer Detected on F-18 FDG PET/ CT

H. Eroglu Elden, K. Demirel, A. Akbulut, G. Koca, M. Korkmaz; University of Health Sciences, Ankara Training and Research Hospital, Ankara, TÜRKIYE.

EP-1278

Resolving Curve-Image Discordance: A Case of Rising Renogram Pattern with Preserved Delayed Clearance in Post-Neobladder Pediatric Patient

J. Choudhary, A. Mahalik, N. Kundu, K. Jain, S. Singh, J. Krishna P., V. Singh, R. Kumar; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-1279

Evaluating ⁶⁸Ga-Trivehexin PET/CT Avidity in Hyperparathyroidism with Inconclusive Standard Imaging

A. Sadeq, S. Dashti, F. Marafi; Jaber AlAhmad center for Molecular Imaging, Shuwaikh medical area, KUWAIT.

EP-1280

The Role of FDG PET/CT in the Staging of a Poorly Differentiated Malignant Epithelioid and Spindle Cell Neoplasm of the Pleura

A. Giarratana¹, M. Larson¹, K. Capaccione²;
¹University of Wisconsin - Madison, Madison, WI, UNITED STATES OF AMERICA, ²Columbia University, New York, NY, UNITED STATES OF AMERICA.

EP-1281

A case of bone inflammation in a Patient with prostate cancer on PSMA-PET imaging: a possible pitfall in ¹⁸F-PSMA-1007 PET/CT interpretation

F. Russo¹, A. Cimini¹, G. Grimaldi², M. De Feo³, A. Marzullo¹, H. Dadgar⁴, H. Arabi⁵, A. Di Sibio⁶, M. Menichini¹;
¹Nuclear Medicine Unit, St. Salvatore Hospital, L'Aquila, ITALY, ²Radiation Oncology, San Pietro Fatebenefratelli Hospital, Rome, ITALY, ³Nuclear Medicine Unit, Department of Radiological Sciences, Oncology and Anatomic Pathology, Sapienza University of Rome, Rome, ITALY, ⁴RAZAVI Hospital, Imam Reza International University, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ⁵Department of Medical Imaging, Geneva University Hospital, Geneva, SWITZERLAND, ⁶Department of Radiology, St. Salvatore Hospital, L'Aquila, ITALY.

EP-1282

Bone Scintigraphy Characteristics in Patients with Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome

X. Wang, Q. Li, M. Chen;
The First Hospital of Lanzhou University, Lanzhou, CHINA.

EP-1283

FDG-PET imaging results of a large BMI (~77) patient with colon adenocarcinoma

S. Lokitz, T. Bartel, K. Harris, L. White;
Center for Molecular Imaging and Therapy, Shreveport, LA, UNITED STATES OF AMERICA.

EP-1284

Role of [¹⁸F]FDG PET/CT in Pulmonary Epithelioid Hemangioendothelioma

K. L. Chiu, T. K. Chow, K. M. Ma, W. H. Ma;
Tuen Mun Hospital, Hong Kong, HONG KONG.

EP-1285

Vanishing lung syndrome pattern on lung perfusion scintigraphy - significance of the hybrid imaging.

O. Lang¹, M. Salomanina²;
¹Dept Nucl Med, Praha 1 – Nové Mesto, CZECH REPUBLIC, ²Cardiology and angiology Ltd., Praha 10, CZECH REPUBLIC.

EP-1286

Myasthenia gravis-like syndrome: 18FFDG-PET/CT findings in a patient with breast cancer treated with Pembrolizumab.

M. Tagliatori Nogueira, M. de la Rubia Marcos, A. Herrero Muñoz, C. Paniagua Correa, L. Castillejos Rodriguez, S. Perez Quiros, A. Ortega Valle, D. Rodriguez Oviedo, C. Galindo Fernandez, K. Guichay, J. Sanchez Calderon, P. Garcia Alonso;
Hospital Universitario de Getafe, Madrid, SPAIN.

EP-1287

A rare case of metastatic prostate cancer to the external auditory canal evaluated with ¹⁸F-Piflufolostat PET/CT

A. Cimini¹, F. Russo¹, A. Marzullo¹, M. Menichini¹, L. Travascio², G. Amiconi³, E. Lupi⁴, M. Ricci⁵;
¹Nuclear Medicine Unit, St. Salvatore Hospital, L'Aquila, ITALY, ²Nuclear Medicine Unit, P.O. Spirito Santo, Pescara, ITALY, ³Oncology Unit, Civil Hospital of Avezzano, Avezzano, ITALY, ⁴Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, ITALY, ⁵Nuclear Medicine Unit, Cardarelli Hospital, Campobasso, ITALY.

EP-1288

Acute Pulmonary Embolism and Brachiocephalic Vein Thrombus Detected on 99mTc-MDP Bone Scan-A Case Series

J. Lanctôt-Bédard, A. Ciarallo, K. Provost;
Centre Hospitalier de l'Université de Montréal, Montréal, QC, CANADA.

EP-1289

Plasmablastic transformation of multiple myeloma-An unusual entity detected with ¹⁸F-FDG PET/CT

T. Moreno-Monsalve, M. I. Castellon-sanchez, L. Frutos-Esteban, J. L. Navarro-Fernandez, L. Mohamed-Salem, T. E. Rodriguez-Locarno, M. J. Ibañez-Ibañez, A. C. Hernandez-Martinez, N. Sanchez-Izquierdo, J. F. Contreras-Gutierrez;
Hospital Universitario Virgen De La Arrixaca, Murcia, SPAIN.

EP-1290

Müller-Weiss Syndrome on ^{99m}Tc-MDP Bone Scintigraphy

D. Alami, M. Zekri, A. Taalabi, N. Mahrsi, L. Taoussi, I. Zehfir, M. Aboussabr, Z. Laadissi, O. Ait Sahel, A. Doudouh;
Mohamed V Military Instruction Hospital, Rabat, MOROCCO.

EP-1291

Pulmonary Metastasis of Grade 1 Meningioma Mimicking a Carcinoid Tumor: A Case Report with FDG PET/CT, DOTATATE PET/CT and Pathological Confirmation

X. Rabbath, C.-H. Shih, M.-A. Morin;
Centre Hospitalier de l'Université de Montréal, Montréal, QC, CANADA.

EP-1292

Increased PSMA expression in synchronous high-grade pleomorphic sarcoma of the thigh and a rare giant liver hemangioma detected on ⁶⁸Ga-PSMA PET/CT staging of prostate cancer (PC)

M. Dyankova^{1,2}, T. Stoeva¹, S. Chausheva¹, Z. Dancheva¹, T. Yordanova¹, B. Chaushev¹, A. Klisarova¹;
¹St. Marina University Hospital, Varna, Bulgaria, ²Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Nuclear Medicine, Metabolic Therapy and Radiotherapy, Varna, BULGARIA.

EP-1293

PSMA-Avid Osteitis Deformans in Pelvic Bones Mimicking Prostate Cancer Metastasis on ⁶⁸Ga-PSMA PET/CT Imaging: A Case Report

M. Dyankova^{1,2}, T. Stoeva¹, S. Chausheva¹, Z. Dancheva¹, T. Yordanova¹, B. Chaushev¹, A. Klisarova¹;
¹St. Marina University Hospital, Varna, BULGARIA, ²Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Nuclear Medicine, Metabolic Therapy and Radiotherapy, Varna, BULGARIA.

EP-1294

PSMA-positive incidental parathyroid adenoma in a prostate cancer (PC) patient detected during a routine staging PET/CT scan using the newly

synthesized radiopharmaceutical ¹⁸F-siPSMA-14

M. Dyankova^{1,2}, T. Stoeva¹, S. Chausheva¹, Z. Dancheva¹, T. Yordanova¹, B. Chaushev¹, A. Klisarova¹;
¹St. Marina University Hospital, Varna, BULGARIA, ²St. Marina University Hospital, Department of Nuclear Medicine., Varna, BULGARIA.

EP-1295

FDG PET/MRI Demonstration of Extensive Spinal Cord Metastases in a Patient with Ovarian Carcinoma

C. Güneren, S. Asa, H. B. Sayman;
Istanbul University-Cerrahpasa Cerrahpasa Medical Faculty Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-1296

Incidental Detection of Pulmonary Carcinoid Tumor During Cardiac SPECT Perfusion Imaging: A Case Report

E. Gharepapagh¹, S. Rezaei¹, S. Dabiri¹, M. Karbasi²;
¹Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF, ²Department of radiology, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF.

EP-1297

Left Frontal Lobe Hypoperfusion and Progressive Speech Impairment: A Case Study Using SPECT Imaging

E. Gharepapagh¹, S. Rezaei¹, M. Karbasi²;
¹Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF, ²Department of radiology, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF.

EP-1298

Vertebral Hemangioma in Disguise: A Ga-68 DOTATATE False Positive

M. Pešorda, E. Pasini Nemir, D. Huic;
University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-1299

Splenic Hemangioma: A Noteworthy Incidental Finding on ¹⁸F-PSMA PET/CT

O. Bourogianni¹, G. Lamprakopoulos¹, N. Kapsoritakis¹, M. Stathaki¹, S. Koukouraki²;
¹Nuclear Medicine Department, University Hospital of Crete, Heraklion, GREECE, ²Nuclear Medicine Department, School of Medicine, University of Crete, Heraklion, GREECE.

EP-1300

Perineural dissemination in head and neck epidermoid carcinoma on ¹⁸F-FDG PET/CT

P. Guardia Jimena, A. Santos Bueno, M. Sanchez Torrente, S. Martin Aguilar, M. Ureña Lara;
Hospital Universitario de Jaén, Jaén, SPAIN.

EP-1301

Silent Intramedullary Metastasis From Lung Carcinoma : Early Detection by ¹⁸F-FDG PET/CT

M. Aboussabr, I. Zahfir, M. Zekri, N. Mahrsi, Z. Laadissi, A. Taalabi, D. Alami, L. Taoussi, Y. Benameur, A. Doudouh;
Department of Nuclear Medicine, Mohammed V Military Teaching Hospital, Rabat, MOROCCO.

EP-1302

Unmasking Tuberculosis in a Patient with Sarcoidosis : The Pivotal Role of ¹⁸F-FDG PET/CT

M. Aboussabr, I. Zahfir, M. Zekri, Z. Laadissi, N. Mahrsi, D. Alami, L. Taoussi, A. Taalabi, S. Oueriagli, A. Doudouh;
Department of Nuclear Medicine, Mohammed V Military Teaching Hospital, Rabat, MOROCCO.

EP-1303

Giant Parathyroid Adenoma: a Multidisciplinary Clinical Case

I. Grierosu^{1,2}, A. Florescu^{1,3}, R. Danila^{1,4}, C. Stefanescu^{1,2};
¹University of Medicine and Pharmacy „Grigore T. Popa”, Iasi, ROMANIA, ²Nuclear Medicine Laboratory, County Emergency Hospital „Sf. Spiridon”, Iasi, ROMANIA, ³Endocrinology Department, County Emergency Hospital „Sf. Spiridon”, Iasi, ROMANIA, ⁴Surgery Department, County Emergency Hospital „Sf. Spiridon”, Iasi, ROMANIA.

EP-1304

Complete response of HCV-associated primary extranodal Diffuse Large B-cell Lymphoma to direct-acting antiviral therapy alone assessed by [¹⁸F]FDG PET/CT

L. Atakishieva¹, A. Khalimon², N. Kadymova¹, V. Bobrov², A. Leontev²;
¹N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION, ²P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EP-1305

Peritoneal Gliomatosis vs. Carcinomatosis in Immature Ovarian Teratoma: Diagnostic Challenges of ¹⁸F-FDG PET/CT

T. Moreno-Monsalve, M. I. Castellon-Sanchez, L. Frutos-Esteban, J. L. Navarro-Fernandez, L. Mohamed-Salem, N. Sanchez-Izquierdo, T. E. Rodriguez-Locarno, A. C. Hernandez-Martinez, M. J. Ibanez-Ibanez, J. Contreras-Gutierrez;
Hospital Universitario Virgen De La Arrixaca, Murcia, SPAIN.

EP-1306

PSMA PET/CT uptake in metastatic melanoma: a case report

G. Barbosa, T. Alves, C. Torricelli, L. Macedo, D. Mendanha, H. Sousa, E. Nogueira-Lima, V. Heringer, N. Tobar, J. Sousa, C. Lima, E. Etchebehere;
Unicamp, Campinas, BRAZIL.

EP-1307

Bilateral Cerebellar Atrophy and Hypometabolism on Brain FDG PET/CT in a Case Using Antiepileptic Drugs for 38 Years Due to Drug-Resistant Epilepsy

B. Bozca¹, N. Aydinbelge Dizdar¹, E. Tatci¹, A. Cilliler², D. Cayir¹, A. Cinar¹, O. Ozmen¹;
¹Etilik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Etilik City Hospital, Department of Neurology, Ankara, TÜRKIYE.

EP-1308

Differential diagnosis of a pancreatic lesion in a pediatric patient: contribution of Nuclear Medicine - A case report

A. Sagastegui Alca, G. Martínez Gomez, C. Ruiz Corbalán, T. Rodríguez Locarno, M. Castellón Sánchez, A. Hernández Martínez, N. Sánchez Izquierdo, L. Frutos Esteban, L. Mohamed Salem, M. Ibáñez Ibáñez, J. Navarro Fernandez, T. Moreno Monsalve, J. Contreras Gutiérrez; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-1309
 Silent Until Late: the Diagnostic Power of 24-hour ^{99m}Tc-PYP RBC Scintigraphy in Gastrointestinal Angiodysplasia

M. Epure¹, I. Grierosu^{1,2}, C.-M. Antohie¹, A.-M. Statescu¹, W. Jalloul^{1,2}, C.-R. Stolniceanu^{1,2}, R.-R. Ion¹, S. Dejmasu¹, A.-M. Nistor¹, C. Stefanescu^{1,2}; ¹Nuclear Medicine Laboratory, „Sf. Spiridon” County Emergency Hospital, Iasi, ROMANIA, ²Grigore T. Popa University of Medicine and Pharmacy, Iasi, ROMANIA.

EP-1310
 Ectopic Thyroid Tissue in the Hepatic Hilum: A Rare Case of a 40-Year-Old Woman Presenting with Epigastric Pain

B. Yilmaz, E. Gokdemir, M. Kaya, B. E. Akkas; University of Health Sciences Basaksehir Cam and Sakura City Hospital, Department of Nuclear Medicin, Istanbul, TÜRKIYE.

EP-1311
 Use of [^{99m}Tc]Tc-heat-denatured red blood cells scintigraphy in the evaluation of renal metastases versus splenic implants in a patient with renal carcinoma

A. Sagastegui Alca, G. Martínez Gomez, C. Ruiz Corbalán, M. Castellón Sánchez, T. Rodríguez Locarno, N. Sánchez Izquierdo, T. Moreno Monsalve, J. Navarro Fernandez, A. Hernández Martínez, M. Ibáñez Ibáñez, L. Frutos Esteban, L. Mohamed Salem, J. Contreras Gutiérrez; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-1312
 Chylothorax After Pericardiectomy: A Case Study Utilizing Lymphoscintigraphy for Diagnosis and Follow-up

G. Martínez Gómez, C. Ruiz Corbalán, A. Sagastegui Alca, T. Rodríguez Locarno, N. Sánchez Izquierdo, T. Moreno Monsalve, M. Castellon Sánchez, A. Hernández Martínez, L. Mohamed Salem, L. Frutos Esteban, J. Navarro Fernández, M. Ibáñez Ibáñez, J. Contreras Gutiérrez; Hospital Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-1313
 The importance of radiosynoviorthesis in the treatment of pigmented villonodular synovitis in pediatric patients

J. Weissensteiner¹, D. Genšor²; ¹Department of Nuclear Medicine, Hospital Poprad, Poprad, SLOVAKIA, ²Clinic of Children and Adolescents, Jessenius Faculty of Medicine in Martin, University Hospital Martin, Martin, SLOVAKIA.

EP-1314
 Incidental Occipital Spur Uptake on Tc-99m PYP Scintigraphy: An Uncommon Finding in Cardiac Amyloidosis

B. Arca, E. G. Isik, E. Inal, Y. Sanli; Istanbul University, Istanbul Faculty of Medicine, Nuclear Medicine Department, Istanbul, TÜRKIYE.

EP-1315
 When Conventional Imaging Does not Reveal the Etiology: ¹⁸F-FDG PET-CT Diagnosis of Spondylodiscitis in Recurrent Fever

G. Martínez Gómez, C. Ruiz Corbalán, A. Sagastegui Alca, T. Moreno Monsalve, T. Rodríguez Locarno, N. Sánchez Izquierdo, M. Castellon Sánchez, A. Hernández Martínez, M. Ibáñez Ibáñez, L. Mohamed Salem, J. Navarro Fernández, L. Frutos Esteban, J. Contreras Gutiérrez; Hospital Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-1316
 Beyond Lytic Lesions: A Rare Case of Sclerotic Multiple Myeloma Without POEMS Syndrome

P. Spiridon^{1,2}, T. Cristica², C. Mazilu^{3,2}; ¹Carol Davila University of Medicine and Pharmacy, Bucharest, ROMANIA, ²Affidea, Bucharest, ROMANIA, ³Carol Davila Central Emergency Military University Hospital, Bucharest, ROMANIA.

EP-1317
 Lost in Migration: A Rare Case of Ectopic Parathyroid Adenoma

R.-. Ion¹, I. Grierosu^{1,2}, A. Ungureanu³, E. Palade^{4,5}, I. Titu^{4,5}, M. Mlesnite⁵, M. Epure¹, S. Dejmasu¹, A. Nistor¹, C. Stefanescu^{1,2}; ¹Nuclear Medicine Laboratory, „Sf. Spiridon” County Emergency Hospital, Iasi, ROMANIA, ²”Grigore T. Popa” University of Medicine and Pharmacy, Iasi, ROMANIA, ³Emergency Clinical Hospital, Piatra Neamt, ROMANIA, ⁴Department of Surgery, ”Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania, ⁵Thoracic Surgery Clinic, ”Leon Daniello” Clinical Hospital of Pneumology, Cluj-Napoca, ROMANIA.

EP-1318
 Necrotizing external otitis - Can ⁶⁸Ga-citrate PET/CT have a role?

J. Rebelo¹, A. Moreira¹, R. Silva¹, G. Costa^{1,2}, S. Barata¹, S. Paiva¹, L. Diogo¹, C. Isabel¹; ¹Unidade Local de Saúde de Coimbra - CHUC, Coimbra, PORTUGAL, ²Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

EP-1320
 The role of ¹⁸F-FDG PET in Familial Fatal Insomnia

J. Rebelo¹, M. Cunha¹, R. Silva¹, G. Costa^{1,2}, S. Barata¹, S. Paiva¹, D. Lameirão¹, I. Casimiro¹; ¹Unidade Local de Saúde de Coimbra - CHUC, Coimbra, PORTUGAL, ²Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

EP-1321
 FDG PET/CT in the Localization of Cardiac Device Infections: Discriminating Between LVAD and ICD Infection

E. Isleyen Çolak, S. Bilgic, E. Alper; Bursa Uludag University, Bursa, TÜRKIYE.

EP-1322
 Detection Using ¹⁸F-FDG PET-CT of Rare Metastases in a Patient with Endometrioid Endometrial Carcinoma

S. Perez Quiros, C. Paniagua Correa, L. Castillejos Rodriguez, M. Tagliatori Nogueira, A. Ortega Valle, K. Guichay Duran, M. García Alonso, C. Galindo Fernández; Hospital Universitario de Getafe, Getafe-Madrid, SPAIN.

EP-1323
 When Endocarditis Isn’t What It Seems: Cardiac Hemangiosarcoma with Multiple Metastases- A case report

A. Militaru¹, C. M. Popescu¹, A. Marin¹, R. M. Mititelu^{1,2}; ¹Clinic of Nuclear Medicine- Central University Emergency Military Hospital, Bucharest, Bucuresti, ROMANIA, ²Nuclear Medicine Department- University of Medicine and Pharmacy ”Carol Davila” Bucharest, Bucuresti, ROMANIA.

EP-1324
 ¹⁸F-PSMA PET/CT and ¹⁸F-FDG PET/CT in the evaluation of desmoid tumors: A case report

E. Nogueira Lima, M. B. Silva, T. Freire, C. Torricelli, G. Barbosa, T. Alves, V. Heringer, N. Tobar, A. Santos, M. Lima, J. Barreto, M. Etchebehere, E. Etchebehere; University of Campinas, Campinas, BRAZIL.

EP-1325
 Rare and Challenging: ¹⁸F-FDG Uptake in Femoral Vein Leiomyosarcoma

I. Zahfir, M. Aboussabr, M. Zekri, Z. Laadissi, N. Mahersi, L. Taoussi, A. Taalabi, D. Alami, S. Nabih Oueriagli, A. Doudouh; Mohammed V Military teaching Hospital, Rabat, MOROCCO.

EP-1326
 The Added Value of [¹⁸F] FDG PET/CT in Assessing Malignant Degeneration in Patients with Hereditary Multiple Exostoses : A Case Report

I.-A. Ioana¹, A. Barabas¹, R. Lita¹, M. Mutuleanu^{1,2}, M. Gherghe^{1,2}; ¹Institute of Oncology ”Prof. Dr. Alexandru Trestioreanu”, Bucharest, ROMANIA, ²University of Medicine and Pharmacy „Carol Davila”, Bucharest, ROMANIA.

EP-1327
 Molecular Imaging with ^{99m}Tc-EDDA-HYNIC-TOC in Tumour-Induced Osteomalacia: Diagnostic Impact in a Challenging Case

M. Nistor¹, D.-M. Ionescu¹, M. Abas¹, A. Badea-Selea¹, M. Gherghe^{1,2}; ¹Institute of Oncology ”Prof. Dr. Alexandru Trestioreanu”, Bucharest, ROMANIA, ²University of Medicine and Pharmacy ”Carol Davila”, Bucharest, ROMANIA.

EP-1328
 Synchronous Malignancies in Bloom Syndrome: The Value of Molecular Imaging

M. Abas¹, M. Paunescu¹, M. Mutuleanu^{1,2}, M. Gherghe^{1,2}; ¹Bucharest Oncology Institute ”Prof. Dr. Alexandru Trestioreanu”, Bucharest, ROMANIA, ²University of Medicine and Pharmacy ”Carol Davila”, Bucharest, ROMANIA.

EP-1329
 An [¹⁸F]FDG PET-CT Conundrum. Adrenal Oncocytoma: A Case Report

M. Matei¹, S. Solomon¹, C. Mazilu¹, R. Mititelu^{1,2}; ¹Clinic of Nuclear Medicine, Central University Emergency Military Hospital, Bucharest, ROMANIA, ²Department of Nuclear Medicine, University of Medicine and Pharmacy Carol Davila, Bucharest, ROMANIA.

EP-1330
 Reactive Imaging Changes Following CAR-T Cell Therapy in Multiple Myeloma: A Diagnostic Challenge

T. Stoeva, M. Dyankova, Z. Dancheva, S. Chausheva, T. Yordanova, B. Chaushev, A. Klisarova; UMHAT ”Sveta Marina”, Varna, BULGARIA.

EP-1331
 Can You Guess The Source? Metastatic Bone Lesion as a Rare First Presentation of Hepatocellular Carcinoma- a Case Report

S. Chausheva^{1,2}, M. Dyankova³, T. Stoeva³, Z. Dancheva³, A. Klisarova³, B. Chaushev³, T. Yordanova³; ¹University Hospital St Marina Varna, Varna, BULGARIA, ²Medical University Varna, Varna, BULGARIA, ³UMBAL St. Marina Hospital-Varna, University Hospital St Marina Varna, Varna, BULGARIA.

EP-1332
 Time Is Tissue: Early Nuclear Imaging and Prognostic Markers in Cardiac Amyloidosis. A Case Report

B. Constantinescu¹, C. Mazilu¹, S. Stanciu^{2,3}; ¹Clinic of Nuclear Medicine, Central University Emergency Military Hospital, Bucharest, ROMANIA, ²Clinic of Cardiology, Central University Emergency Military Hospital, Bucharest, ROMANIA, ³University of Medicine and Pharmacy Carol Davila, Bucharest, ROMANIA.

EP-1333
 The clinical role of ⁶⁸GaPSMA/⁶⁸GaDOTA PET/CT imaging in patient with prostate adenocarcinoma with neuroendocrine differentiation

K. Verbanova, S. Sergieva, V. Marinov; Acibadem City Clinic Tokuda, Sofia, BULGARIA.

EP-1334
 Unmasking the Silent Progression: The Role of Serial [¹⁸F]FDG PET/CT in the Surveillance of Recurrent Klatskin Tumor

A. Marin, A. M. Budau, A. S. Militaru, C. V. Mazilu; Clinic of Nuclear Medicine, Central University Emergency Military Hospital, Bucharest, ROMANIA.

EP-1335
 Benign Cause or Malignancy Progression? Rethinking PET/CT Findings in a Burkitt Lymphoma Case

A. Constantin¹, A. I. Taciuc¹, M. Gherghe^{1,2}; ¹Institute of Oncology ”Prof. Dr. Alexandru Trestioreanu”, Bucharest, ROMANIA, ²University of Medicine and Pharmacy ”Carol Davila”, Bucharest, ROMANIA.

EP-1336
 Subcutaneous Splenosis Mimicking Malignancy: A Very Rare Complication of Laparoscopic Splenectomy for Hereditary Spherocytosis Identified on ^{99m}Tc-Colloid SPECT/CT

P. Gadzicki, A. Aulich, M. Kwapisz, Z. Adamczewski; Medical University of Lodz, Nuclear Medicine Departament, Lodz, POLAND.

EP-1337
 Role of ¹⁸F-FDG PET/CT in the Evaluation of a Patient with Pulmonary Artery Sarcoma: Case Report

K. Guichay Duran, M. De la Rubia Marcos, C. Galindo Fernández, D. Rodríguez Oviedo, J. Sanchez Calderón, A. Herrero Muñoz, M. Castillejos Rodriguez, A. Ortega Valle, C. Paniagua Correa, S. Peréz Quirós, M. Álvarez Moreno, M. García Alonso, M. Tagliatori Nogueira; Department of Nuclear Medicine, Getafe University Hospital, Madrid, SPAIN.

EP-1338
Paraganglioma - a New Approach of Metastatic vs. Multifocal Disease. A Case Report.

Z. Patko^{1,2}, E. Kocsak³, B. Bako³, S. Barna⁴, J. Gombos³;
¹Helse Møre og Romsdal, Ålesund, Norway, ²University of Miskolc, Miskolc, HUNGARY, ³Borsod County Central Hospital and University Teaching Hospital, Miskolc, HUNGARY, ⁴ScanoMed Debrecen, Debrecen, HUNGARY.

EP-1339
FAPI-Based Theranostics in Medullary Thyroid Cancer: A Viable Alternative When Somatostatin Receptor Based Theranostics Show Limited Efficacy—A Clinical Experience

A. Saber Tanha, F. Jafari Zarrin Ghabaei, N. Raeisi, K. Aryana, s. shafiei;
Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1340
Langerhans Cell Histiocytosis with cutaneous presentation: a case report

K. Kapansahin, B. Okudan Tekin;
Ankara Bilkent Şehir Hastanesi, Ankara, TÜRKYE.

EP-1341
Primary neurolymphomatosis: Value of 18F-FDG-PET/CT in the diagnosis and assessment of response to treatment

S. Georgia¹, D. Katsampoukas¹, V. Mpalaris¹, A. Morfesi¹, M. Spilioti², G. Zafeiridou², N. Vavlas¹, G. Kaiafa³, E. Moralidis¹, G. Arsos¹;
¹3rd Department of Nuclear Medicine, Aristotle University Medical School, Papageorgiou General Hospital, Thessaloniki, GREECE, ²1st Neurology Department, Aristotle University Medical School, AHEPA General Hospital, Thessaloniki, GREECE, ³1st Propaedeutic Department of Internal Medicine, Aristotle University Medical School, AHEPA General Hospital, Thessaloniki, GREECE.

EP-1342
Exploring the potential role of ¹⁸F-FDG and ¹⁸F-PSMA PET/CT in detecting neurofibromas: a case report

C. Torricelli, T. Alves, G. Barbosa, M. Silva, E. Nogueira-Lima, V. Heringer, N. Tobar, M. Etchebehere, E. Etchebehere;
University of Campinas (UNICAMP), Campinas, BRAZIL.

EP-1343
Osteoid Osteoma - Presenting Two Cases of Rare Localizations and Diagnostic Challenges

Z. Patko^{1,2}, E. Kocsak³, L. Kostya³, J. Gombos³;
¹Helse Møre og Romsdal, Ålesund, Norway, ²University of Miskolc, Faculty of Health Sciences, Miskolc, HUNGARY, ³Borsod County Central Hospital and University Teaching Hospital, Miskolc, HUNGARY.

EP-1344
¹⁸F-FDG PET/CT in sporadic Creutzfeldt-Jacob disease: A case report

C. Caldas¹, D. Isasi¹, N. Laines², L. Apaza³, L. Apaza³;
¹EsSalud, Lima, PERU, ²Universidad Nacional Mayor de San Marcos, Lima, PERU ³Instituto Nacional de Ciencias Neurológicas, Lima, PERU.

EP-1345
Uncommon Presentation of Primary Adrenal Lymphoma with Bilateral Adrenal Hypermetabolic Activity on ¹⁸F-FDG PET/CT: A Case Report

P. Sahafi¹, F. Karamian¹, F. Emami², M. Samadi¹, R. Sadeghi¹;
¹Ghaem Hospital, Mashhad university of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ²Nuclear Medicine and Molecular Imaging Department, Imam Reza International University, Razavi Hospital, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1346
FAPI Uptake in Malignant Ascites: A Case Report

P. Sahafi, M. Samadi, A. Aghaee;
Ghaem Hospital, Mashhad university of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1347
Simultaneous visualization of a Meckel’s diverticulum and its active bleeding on Tc-99m Pertechnetate scintigraphy: an unusual presentation

P. Sahafi, M. Samadi, R. Sadeghi;
Ghaem Hospital, Mashhad university of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1348
Complete Pathological Response After Neoadjuvant Radioligand Therapy in a Case of Pancreatic Neuroendocrine Tumor: A Case Report

P. Sahafi, M. Samadi, M. Ghahraman, E. Soltani, A. Aghaee;
Ghaem Hospital, Mashhad university of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1349
Enhancing Restaging of a Colorectal Cancer Patient: The Advantage of ^{99m}Tc-FAPI-46 over Conventional CT in Detecting Metastases

M. Ahmadi, A. Aghaee, M. Samadi, P. Sahafi, E. Soltani;
Nuclear medicine research center, Mashhad university of medical sciences, Mashhad, Khorasan Razavi, IRAN, ISLAMIC REPUBLIC OF.

EP-1350
PSMA Scintigraphy in Metastases of Prostate Cancer Within the Genital Tract

F. Rabani, M. Samadi, A. Saber Tanha, N. Afshari, A. Aghaee;
Mashhad University of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1351
⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT: Complementary Imaging Modalities for Detecting Unusual Metastasis in a Patient with Osteosarcoma

P. Sahafi¹, G. Divband², H. Amini³, E. Askari¹, A. Noferesti¹;
¹Ghaem Hospital, Mashhad university of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF of, ²Jam Nuclear Medicine Center, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Khatam PET/CT Center, Tehran, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1352
Significant ^{99m}Tc-MDP uptake in metastatic lymph nodes of a patient with synovial sarcoma, a case report

P. Sahafi, F. Karamian, A. Aghaee;
Ghaem Hospital, Mashhad university of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1353
Comparison of ^{99m}Tc-FAPI, ^{99m}Tc-octerotide, and ⁶⁸Ga-DOTATATE PET/CT in the Evaluation of a Patient with Neuroendocrine Tumor

P. Sahafi, A. Aghaee;
Ghaem Hospital, Mashhad university of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1354
Tumor Lysis Syndrome After Radioligand Therapy in a Case of Metastatic Prostate Cancer

P. Sahafi, M. Samadi, K. Aryana, E. Askari;
Ghaem Hospital, Mashhad university of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1355
Incidental Detection Of Double Chilaiditi Sign During Myocardial Perfusion Imaging: A Case Report

G. Prisacariu¹, I. Sandu¹, M. Matei¹, C. Mazilu¹, R. Mititelu^{1,2};
¹Central Military University Emergency Hospital “Carol Davila”, Bucharest, ROMANIA, ²University of Medicine and Pharmacy Carol Davila, Bucharest, ROMANIA.

EP-1356
Remarkable 99mTc-FAPI-46 Uptake in a Patient With Anaplastic Thyroid Carcinoma: A Promising Step in Theranostic Field

A. Aghaee, M. Ghahreman, P. Sahafi, M. Samadi, K. Aryana;
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1357
^{99m}Tc-DMSA Uptake in the Thoracic Region Mimicking Ectopic Kidney in a Case of Crossed Fused Renal Ectopia

M. Ahmadi, R. Sadeghi, M. Samadi, A. Ardeshirzadeh, F. Taheri;
Nuclear medicine research center, Mashhad university of medical sciences, Mashhad, Khorasan Razavi, IRAN, ISLAMIC REPUBLIC OF.

EP-1358
FDG PET CT in the diagnosis of testosterone secreting Sertoli-Leydig cell tumor of ovary

D. Todorova-Stefanovski, S. Tasevski, S. Beshliev, G. Spirov, N. Manevska;
University Institute of Positron Emission Tomography, Skopje, NORTH MACEDONIA, THE REPUBLIC OF.

EP-1359
Unexpected metastasis from sigmoid cancer-where? a case report

T. Yordanova, A. Klisarova, T. Stoeva, M. Dyankova, S. Chausheva, Z. Dancheva, B. Chaushev;
Medical University Prof. dr. P. Stoyanov, Deparment of nuclear medicine, Varna, Bulgaria, Varna, BULGARIA.

EP-1360
Unexpected Extrarenal Uptake of Tc-99m EC on Renal Scintigraphy in a Patient with Renal Transplantation

M. Ahmadi, S. Barashki, A. Saber Tanha, H. Elahifard;
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1361
^{99m}Tc-PSMA Uptake in Neurofibroma

M. Samadi, P. Sahafi, H. Elahifard, E. Askari, S. Davoodi;
Mashhad university of medical sciences, mashahd, Iran, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1362
Radio-Guided Monitoring of Systemic Leakage With ^{99m}Tc-MAA Uptake in a Patient With Melanoma During Isolated Limb Perfusion

M. Samadi, S. Khezri, E. Hasanzadeh Hadad, R. Sadeghi, A. Aghaee;
Mashhad university of medical sciences, mashahd, Iran, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1363
The Quiet Life-Threatening Event: Sudden Respiratory Failure During a Prolonged Dynamic Scintigraphy Procedure

M. Samadi, S. Khezri, P. Sahafi, A. Aghaee;
Ghaem Hospital, Mashhad university of medical sciences, Mashahd, Iran, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1364
Radiation recall pneumonitis following durvalumab immunotherapy in a lung cancer patient detected by ¹⁸F-FDG PET/CT.

N. Vavlas, A. Morfesi, V. Mpalaris, D. Katsampoukas, S. Georga, E. Moralidis, G. Arsos;
3rd Department of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Papageorgiou General Hospital, Thessaloniki, GREECE.

EP-1365
Incidental finding of Medullary Thyroid Carcinoma on 18F-DCFPyL PET/CT performed in the staging of High-Risk Prostate Cancer

L. Mena Bares, M. Sánchez Torrente, E. Moratalla Aranda, S. Martín Aguilar, M. Ureña Lara;
Hospital Universitario Jaén, Jaén, SPAIN.

EP-1366
Unusual Presentation of a Pancreatic Neuroendocrine Tumour

A. Bagán-Trejo¹, J. L. Vercher-Conejero¹, J. J. Martín-Marcuartu¹, M. Tormo-Ratera¹, J. C. Ruffinelli², I. Peiró³, B. Hervás-Sanz¹, J. L. Díaz-Moreno¹, M. Zamorano-Rivas¹, M. Á. Crespi-Busquets⁴, C. García-Alcober⁴, M. Cortés-Romera¹;
¹Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN, ³Endocrinology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN, ⁴Radiopharmacy Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EP-1367
Exceptional ¹⁸F-FDG Uptake in White Adipose Tissue Induced by Systemic Glucocorticoid Therapy

M. Ulucay, A. Dere, H. B. Kapucu, I. Ozturk, B. E. Akkas;
Health Sciences University,Basaksehir Cam and Sakura City Hospital, Istanbul, TÜRKIYE.

EP-1368
The value of sequential imaging review in localizing an occult primary Neuroendocrine Tumor: A Case Report

L. Castillejos, C. Paniagua, S. Pérez Quirós, A. Ortega Valle, M. Tagliatori, A. Herrero, M. de la Rubia, D. Rodríguez Oviedo, C. Galindo, K. Guichay, M. García Alonso; Hospital Universitario de Getafe, Madrid, SPAIN.

EP-1369
Fibrous Dysplasia with 99m Tc-FAPI Uptake in a Patient Under Long-Term antiresorptive Therapy
M. Samadi, P. Sahafi, A. Aghaee; Ghaem Hospital, Mashhad university of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1370
Lipomatous Hypertrophy of the Interatrial Septum: Long-term ¹⁸F-FDG Uptake variation on serial PET/CT scans in a Lung Cancer patient
A. Morfesi, N. Vavlas, D. Katsampoukas, V. Mpalaris, S. Georga, E. Moravidis, G. Arsos; 3rd Department of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Papageorgiou General Hospital, Thessaloniki, GREECE.

EP-1371
Radioiodine Treatment Failure in Toxic Adenoma: Marine-Lenhart Syndrome
A. Vergili¹, M. Acar Tayyar¹, E. Uyanik¹, F. Yıldız Kabaca¹, T. Özüiker²; ¹Prof Dr Cemil Taşcıoğlu City Hospital, İstanbul, TÜRKIYE, ²Prof Dr Cemil Tascioğlu City Hospital, İstanbul, TÜRKIYE.

EP-1372
Radiation-Induced Osteoradionecrosis of the Ribs in a Patient with Breast Cancer: A Case Report
G. Fuso¹, G. Bianciardi¹, C. M. P. Sgro¹, E. Greco¹, P. E. Orlandi², A. Romeo³, S. Fanti^{4,3}; ¹Policlinico Sant’Orsola-Malpighi, University of Bologna, Bologna, ITALY, ²Ospedale Maggiore, Bologna, ITALY, ³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴University of Bologna, Bologna, ITALY.

EP-1373
An atypical case of angiosarcoma in a breast cancer patient in [¹⁸F]FDG PET-CT imaging
S. Özdemir, A. Akbulut, M. Daşar, K. Demirel, G. Koca, M. Korkmaz; University of Health Sciences, Ankara Training and Research Hospital, Nuclear Medicine Department, Ankara, TÜRKIYE.

EP-1374
Extensive abdominal splenosis more than half a century after traumatic splenic rupture: the way from CT to ¹⁸F-FDG PET/CT and to precise diagnosis with Tc-99m-labelled heat denatured red blood cell SPECT/CT
S. Georga, N. Vavlas, A. Morfesi, V. Mpalaris, D. Katsampoukas, E. Moravidis, G. Arsos; 3rd Department of Nuclear Medicine, Aristotle University Medical School, Papageorgiou General Hospital, Thessaloniki, GREECE.

EP-1375
Multimodal Imaging in Corticobasal Syndrome with Alzheimer’s Pathology: A Case Report
M. Sanchez Torrente¹, A. Sanchez Torrente², P. Guardia Jimena¹, M. Ureña Lara¹; ¹Department of Nuclear Medicine - Hospital Universitario de Jaén, Jaén, SPAIN, ²Department of Radiology - Hospital Universitario Torrecardenas, Almeria, SPAIN.

EP-1376
Incidental Detection of Pacemaker Lead Infection with ¹⁸F-FDG PET-CT in a Breast Cancer Patient Undergoing Evaluation for Suspected Recurrence
A. Genova, F. Porcaro, M. Prisco, L. Turchetta, I. Annarumma, V. Piscopo, M. Catalano; Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Naples, ITALY.

EP-1377
Multifocal Osteonecrosis in Pediatric-onset Systemic Lupus Erythematosus
H. Elahifard¹, M. Samadi¹, E. Askari¹, F. Taheri¹, M. Vahedi²; ¹Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ²Department of Pediatrics, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1378
Rare Presentation of Baker’s Cyst in an Infant: A Case Report
H. Elahifard¹, M. Vahedi², F. Rabani¹, F. Taheri¹, V. Dabbagh¹; ¹Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ²Department of Pediatrics, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1379
Secondary Syphilis with Skull Bone Lesions: A Rare Clinical Manifestation
I. Sevaslidou¹, S. Episkopopoulou¹, A. Velidaki¹, A. Anastasopoulou², A. Perissi², E. Dagrakis¹, T. Kostou¹, A. Kolindou¹; ¹Nuclear Medicine Department , Genaral Hospital of Athens “LAIKO”, Athens, GREECE, ²First Department of Internal Medicine, “LAIKON”Hospital, Athens, GREECE.

EP-1380
Diffuse FAPI-46 Uptake in Bone Marrow: A Case of Primary Myelofibrosis with Superscan Pattern on Bone Scintigraphy
H. Elahifard¹, N. Raeisi¹, A. Saber Tanha¹, N. Ataei², E. Askari¹; ¹Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ²Department of pathology, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-1381
Splenic Hemangioma as a Pitfall in 18F-PSMA PET-CT Imaging for Prostate Cancer: A Case Report
M. Sanchez Torrente, S. Martin Aguilar, L. Mena Bares, E. Moratalla Aranda, M. Ureña Lara; Department of Nuclear Medicine - Hospital Universitario de Jaén, Jaén, SPAIN.

EP-1382
Occipital Bone Lesion Mimicking Malignancy: The Importance of Multimodal Imaging
J. Mendes, L. Torres, P. Soeiro; Hospital de São João, Porto, PORTUGAL.

EP-1383
99mTc-HMPAO Brain SPECT in Intracranial Carotid Artery Occlusion: Functional Imaging to Support ClinicalDecision-Making

A. Genova, F. Porcaro, M. Prisco, L. Turchetta, I. Annarumma, V. Piscopo, M. Catalano; Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Naples, ITALY.

EP-1384
Rediscovering the Forgotten: ¹⁸F-FDG PET/CT Detection of Metabolically Active Echinococcal Cyst in the Pubic Bone with a History of Ovarian Echinococcosis- A Case Report
S. Chausheva^{1,2}, T. Stoeva¹, M. Dyankova¹, T. Yordanova¹, Z. Dancheva¹, A. Klisarova¹, B. Chaushev¹; ¹University Hospital St Marina Varna, Varna, BULGARIA, ²Medical University Varna, Varna, BULGARIA.

EP-1385
Detection of Recurrent ACTH-Secreting Pituitary Adenoma Using ^{99m}Tc-EDDA/HYNIC-TOC- A Case Report and Literature Review
A. Bajenaru¹, A. Baican^{1,2}, R. Mititelu^{3,4}; ¹Clinical Hospital “Prof. Dr. Theodor Burghele”, Bucharest, ROMANIA, ²Faculty of Physics, University of Bucharest, Magurele, ROMANIA, ³Central Emergency Military University Hospital “Dr. Carol Davila”, Bucharest, ROMANIA, ⁴University of Medicine and Pharmacy “Carol Davila”, Bucharest, ROMANIA.

EP-1386
Isolated Cutaneous Metastatic Breast Cancer Detected by FDG PET/CT
M. Kartal¹, V. Dere², B. Okudan Tekin²; ¹Elaziğ Fethi Sekin City Hospital, Elaziğ, TÜRKIYE, ²Ankara Bilkent City Hospital, Ankara, TÜRKIYE.

EP-1387
A Hot Signal, a Cold Trail: False-Positive 99mTc-Ethambutol Uptake in Bilateral Psoas Abscess Mimicking Tuberculosis
A. Roy, N. A. Damle, A. Mahalik, N. Kundu; AIIMS New Delhi, New Delhi, INDIA.

EP-1388
Metastasis or Silicosis? The Role of PET/CT in Thoracic Evaluation of Colorectal Cancer
E. Moratalla-Aranda, L. Mena Bares, S. Martin Aguilar, M. Sanchez Torrente, M. Ureña Lara; Hospital Universitario de Jaen, Jaen, SPAIN.

EP-1389
Misleading 68Ga-PSMA Uptake in Bone Metastases of Esophageal Adenocarcinoma in a Patient with Synchronous Prostate Cancer
L. Milišić Kelava, M. Pešorda, D. Huić; University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-1390
When One Cancer Reveals Another: The Role of ¹⁸F-FDG PET/CT in Detecting Synchronous Tumors.
R. Mehri, M. Nouira, Z. Missaoui, R. Ghannem, A. Mazhoud, R. Sfar, K. Chatti; Sahloul Hospital, Sousse, TUNISIA.

EP-1391
Silent Persistence in the Shadow of Time: Late Renal Metastasis of Differentiated Thyroid Cancer
M. Zambrana-Delgadillo, M. Piñero Fernandez- Reyes, J. Rodríguez-Rubio Corona, M. Pajares-Vinardell; Hospital Universitario Puerta del Mar, Cadiz, SPAIN.

EP-72
 e-Poster Area

E: Other Studies -> E2 Covid Studies

EP-1392
Did the Pandemic Cast a Long Shadow on Lung-Cancer Survival? A 918-Patient [¹⁸F]FDG PET/CT Cohort
D. Nak¹, O. Bülbül¹, B. Demir², S. Göksele³; ¹Recep Tayyip Erdoğan University Training and Research Hospital, Rize, TÜRKIYE, ²Mehmet Akif İnan Research and Training Hospital, Şanlıurfa, TÜRKIYE, ³Adnan Menderes University Faculty of Medicine, Aydın, TÜRKIYE.

EP-73
 e-Poster Area

E: Other Studies -> E3 Other Study (including Training, Projects)

EP-1393
Implementation of a Relative Value Unit-Based System in a Nuclear Medicine Department
M. Meneses Navas¹, S. Guzmán Ortiz¹, M. Granados Alcobendas², M. Amo-Salas³, L. García Zoghby¹, I. García Megías¹, J. Bonilla Plaza¹, M. Cruz Montijano¹, J. Montalvá Pastor¹, A. García Vicente¹; ¹Hospital Universitario de Toledo, Toledo, SPAIN, ²Gerencia de Atención Especializada de Toledo. Hospital Universitario de Toledo, Toledo, SPAIN, ³Departamento de Matemáticas. Universidad de Castilla-La Mancha., Ciudad Real, SPAIN.

EP-1394
Economic Impact of 18F-DCFPyl PET/CT on the Detection of Biochemical Recurrence of Prostate Cancer in Spain
M. Godbole¹, T. Matos², R. Badinedi³, N. Tchouen⁴, A. Berthon⁵; ¹Alira Health, Barcelona, SPAIN, ²Alira Health, Basel, SWITZERLAND, ³Alira Health, London, UNITED KINGDOM, ⁴Curium Pharma, Paris, FRANCE, ⁵Curium Pharma, Lyon, FRANCE.

EP-1395
Establishment of the Dutch National FAPI Working Group: Coordinated Advancement of FAPI Theranostics in Nuclear Medicine
S. Veldhuijzen van Zanten¹, E. Droogers¹, L. de Geus-Oei², R. Slart³, B. Zwezerijnen⁴, B. Windhorst⁴, M. Lam⁵, T. Ververs⁵, D. Wyndaele⁶, J. de Klerk⁷, L. Andrews⁷, M. Wondergem⁸, W. Kool⁹, W. Vogel¹⁰, D. Oprea-Lager¹¹, V. Rijk¹¹, L. Heijmen², T. van Nijnatten¹², L. Weijs¹³, A. van den Hoven¹⁴, S. Veldhuijzen van Zanten¹⁵; ¹Erasmus Medical Center, Rotterdam, NETHERLANDS, ²LUMC, Leiden, NETHERLANDS, ³UMCG, Groningen, NETHERLANDS, ⁴Amsterdam UMC, Amsterdam, NETHERLANDS, ⁵UMC Utrecht, Utrecht, NETHERLANDS, ⁶Catharina Hospital, Eindhoven, NETHERLANDS, ⁷Meander Medical Center, Amersfoort, NETHERLANDS, ⁸Northwest Hospital Group, Alkmaar, NETHERLANDS, ⁹Northwest Hospital Group & Cyclotron Northwest BV, Alkmaar, NETHERLANDS, ¹⁰Netherlands Cancer Institute - AvL, Amsterdam, NETHERLANDS, ¹¹Radboud UMC, Nijmegen,

NETHERLANDS, ¹²MUMC+, Maastricht, NETHERLANDS, ¹³ZGT, Hengelo/Almelo, NETHERLANDS, ¹⁴Sint Antonius Hospital, Nieuwegein, NETHERLANDS, ¹⁵Erasmus MC, Rotterdam, NETHERLANDS.

EP-1396
Current Status of Theranostics in the Asia-Pacific Region

A. Brink¹, E. Estrada-Lobato¹, D. Paez¹, F. Giammarile¹, A. Korde², D. Subbotnitskiy³, G. Karthikeyan⁴;
¹International Atomic Energy Agency, Nuclear Applications Human Health, Division of Nuclear Medicine and Diagnostic Imaging, Vienna, AUSTRIA, ²International Atomic Energy Agency, Department of Nuclear Sciences and Applications, Division of Physical and Chemical Sciences, Vienna, AUSTRIA, ³International Atomic Energy Agency, Department of Technical Cooperation, Division for Asia and the Pacific, Vienna, AUSTRIA, ⁴All India Institute of Medical Sciences, New Delhi, INDIA.

EP-1397
Screen-Sharing with AI in VR: A Novel Approach to Radiology Learning and Interpretation

J. Olsson, J. P. Connelly, H. Ramsdal Hol; Oslo University hospital, Oslo, NORWAY.

EP-1398
Implementation of a customised software tool for proposal and project management dedicated to an experimental Radiopharmacy Facility within a private academic research institute in Italy

R. Visentini¹, C. Franciosi¹, G. Iachetti^{1,2}, S. Fusaro¹, M. Lopatriello¹, A. Moretti¹, M. De Summa¹, S. Spinosa¹, S. Annunziata²;
¹Medipass Ergea, Integrative Clinical Solutions - Radiopharmacy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, ITALY, ²Nuclear Medicine Unit, GStEP Radiopharmacy, Department of Diagnostic Imaging and Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, ITALY.

EP-1399
The experience of [¹⁸F]MC225 trial authorisation in Italy: the academic journey towards a non-profit clinical trial authorisation from precursor production to clinical trial approval

A. Simonetti^{1,2}, A. Moretti³, N. Colabufo^{4,5}, M. Leopoldo^{4,5}, C. Filosa³, D. Pantaleo³, V. Ceccarelli³, M. Lopatriello³, C. Franciosi³, M. Calcagni⁶, A. Giordano⁶, G. Sani^{1,7}, S. Annunziata⁸, R. Visentini³;
¹Department of Neuroscience, Sensory Organs and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, ITALY, ²Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, UNITED STATES OF AMERICA, ³Medipass Ergea, Integrative Clinical Solutions - Radiopharmacy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, ITALY, ⁴Department of Pharmacy-Pharmaceutical Sciences, University of Bari “Aldo Moro”, Bari, ITALY, ⁵Biofordrug, Spin-off of the University of Bari “Aldo Moro”, Bari, ITALY, ⁶Nuclear Medicine Unit, GStEP Radiopharmacy, Department of Diagnostic Imaging and Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, ITALY, ⁷Department of Neuroscience, Sensory Organs and Chest, Section of Psychiatry, Università Cattolica del Sacro Cuore, Roma, ITALY.

EP-1400
Designing and Building a Brand New Molecular Therapy Facility: Our experience.

E. Crick¹, J. Mohammed-Gayle¹, H. Buschhold¹, M. Draper², D. Gallacher³, R. Fernandez¹;
¹Guy’s and St Thomas’ NHS Foundation Trust, London, UNITED KINGDOM, ²Cambridge University Hospitals NHS Foundation trust, Cambridge, UNITED KINGDOM, ³King’s College London, London, UNITED KINGDOM.

EP-1401
Can Researchers Rely on Large Language Models to Write a Systematic Review? A Direct Comparison between Humans and Six LLMs

C. Pini¹, M. Sollini^{1,2}, A. Lazar¹, F. Gelardi¹, G. Ninatti^{2,3}, M. Bauckneht^{4,5}, A. Chiti^{1,2}, M. Kirienko⁶;
¹Vita-Salute San Raffaele University, Milan, ITALY, ²Department of Nuclear Medicine, IRCCS Ospedale San Raffaele, Milan, ITALY, ³School of Medicine and Surgery, University of Milano-Bicocca, Milan, ITALY, ⁴Department of Healt Sciences (DISSAL), University of Genoa, Genoa, ITALY, ⁵Department of Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ⁶Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, ITALY.

EP-1402
Challenges in Access to Peptide Receptor Radionuclide Therapy in Developing countries: Insights from patient advocacy perspective

S. Dureja;
Theranostics India Centre, New Delhi, INDIA.

EP-1403
Expanding Global Equitable Access to Radioligand Therapy

S. Nogueira, A. Armesto, C. Carreras, I. Hume, Y. Omar, E. Cannarozzo, A. F. Viana;
Oncidium Foundation, Auderghem, BELGIUM.

EP-1404
Addressing the Challenges of Radiopharmacy: A specialized certifying program for French-speaking pharmacists in Switzerland

J. Delage¹, M. Schottelius², M. Straub³, J. Prior⁴, M. Lebreux⁵, A. Hammadi⁶, F. Sadeghipour^{7,8,9};
¹Radiopharmacy Unit, Department of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ²Translational Radiopharmaceutical Sciences, Depts. of Nuclear Medicine and of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ³Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ⁴Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ⁵Department of Pharmacy, University Hospital of Québec, Laval University, Laval, QC, CANADA, ⁶National Institute for Nuclear Science and Technology (INSTN), Atomic Energy Center (CEA) of Saclay, Gif-sur-Yvette, FRANCE, ⁷Department of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ⁸Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ⁹Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Lausanne, SWITZERLAND.

EP-1405
Establishing Traceability Routes in Nuclear Medicine: The ETrain starts its journey ...

A. Fenwick¹, J. de Pooter², P. Toroi³, J. Rusnak⁴, K. Sjogreen Gleisner⁵;
¹National Physical Laboratory, Teddington, UNITED KINGDOM, ²VSL, Delft, NETHERLANDS, ³STUK, Helsinki, FINLAND, ⁴CMI, Prague, CZECH REPUBLIC, ⁵Lund University, Lund, SWEDEN.

EP-1406
Enhancing Diagnostic Accuracy in Dementia: Standardized Protocols for FDG PET-CT Brain Imaging

A. Hassan, A. W. Alessi, E. Wahab, S. J. Hughes;
Queen Elizabeth Hospital Birmingham, Birmingham, UNITED KINGDOM.

EP-1407
Thyroid Scintigraphy in Congenital Hypothyroidism

K. Auf der Springe, R. Dias Correia, N. Testart, M. Jreige, N. Schaefer, J. O. Prior, M. Nicod-Lalonde;
CHUV, Lausanne, SWITZERLAND.

EP-1408
Association Between Whole-Body Composition Variables and Abdominal Fat Distribution with Bone Mineral Content in a Healthy Population (ReBoMiDe Study).

M. Cruz Montijano¹, S. Pérez Luque², J. Pérez Beteta², J. Montalva Pastor¹, A. Gutiérrez Crespo³, J. Bonilla Plaza¹, L. García Zoghby¹, M. Meneses Navas¹, S. Guzmán Ortiz¹, I. García Megías¹, C. La Fay³, M. Caballero Campos⁴, A. García Vicente¹;
¹Complejo Hospitalario de Toledo, Toledo, SPAIN, ²Department of Mathematics, University of Castilla-La Mancha, Ciudad Real, SPAIN, ³GE Healthcare, Madrid, SPAIN, ⁴University of Córdoba, Cordoba, SPAIN.

EP-1409
(Radio)Theranostics: XXIst Century Nuclear Medicine Creating Hope for Oncological Patients

L. Metello¹, R. R. Johnson¹, D. Jolly¹, A. Uhlending², V. Hugenberg², V. Gupta³, C. Scheiber¹, G. Romanowicz¹, M. Capoulas¹, I. V. Costa¹, D. Fraga¹, L. Cunha¹;
¹IsoPor Group, Portugal, PORTUGAL, ²Herz und Diabeteszentrum HDZ - NRW, Univ der Ruhr - Univ. Bochum, Bad Oeynhausen, GERMANY, ³University of Heidelberg, DKFZ, Heidelberg, GERMANY.

EP-1410
Study protocol update: A randomized phase 2 trial of FLEXible and extended dosing of ¹⁷⁷Lu-PSMA-617 Molecular Radioligand Therapy in mCRPC (FLEX-MRT)

A. Holzgreve^{1,2}, A. Delker², Z. Ells¹, J. Brosch-Lenz³, L. M. Unterrainer^{1,2,4}, J. Nikitas¹, S. Zhu¹, M. M. Contreras¹, H. Alam¹, R. M. Nabong¹, S. Lira¹, A. Vasilyev⁵, L. Chen⁵, T. Grogan⁵, D. Elashoff⁶, C. A. Meyer¹, M. Dahlbom¹, J. Czernin¹, J. Calais¹;
¹Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, ²Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY, ³Institute of Nuclear Medicine, Bethesda, MD, GERMANY, ⁴Bavarian Cancer Research Center (BZKF), partner site Munich, Munich, GERMANY, ⁵Department of Medicine Statistics Core (DOMStat), Department of Medicine’s

Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, UCLA, Los Angeles, CA, UNITED STATES OF AMERICA.

EP-1411
Start-up of early-phases trials in radiopharmacy unit since begining 2024

S. Maymó Garrido¹, D. Rodríguez-Puig¹, C. García-Alcober¹, E. Ricart-Paredes¹, M. Crespi-Busquets¹, C. Munuera-Sañudo¹, E. Pineda-Fernández¹, M. Bueno-Raspall¹, M. Cortés-Romera²;
¹Radiopharmacy Department. Hospital Universitari de Bellvitge - Ilibell, L’hospitalet de Llobregat, SPAIN, ²Nuclear Medicine-PET (IDI) Department. Hospital Universitari de Bellvitge - Idibell, L’hospitalet de Llobregat, SPAIN.

EP-1412
Hepatocellular carcinoma transarterial radioembolization: a single centre experience

A. Genova, F. Porcaro, M. Prisco, I. Annarumma, L. Turchetta, V. Piscopo, M. Catalano;
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Naples, ITALY.

EP-1413
Study of Dosimetric Parameters of Treatment of Inoperable Lung Tumors Using Brachytherapy Based on Hydrogel Containing Radioisotope ¹⁸⁸Re

A. Kazemi¹, H. Poorbaygi²;
¹Shiraz University of Medical Science, Shiraz, IRAN, ISLAMIC REPUBLIC OF, ²Radiation Application Research School, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-1414
Bridging Competency and Clinical Practice: The Role of Entrustable Professional Activities in Theranostics-Oriented Nuclear Medicine Training

T. Pascual;
Department of Science and Technology- Philippine Nuclear Research Institute, Pasig, PHILIPPINES.

EP-1415
Evaluation of the European Kidney Function Consortium (EKFC) GFR predicting equation in Chronic Kidney Disease staging using ^{99m}Tc-DTPA measured GFR as the reference standard

G. Arsos¹, A. Morfesi¹, N. Vavlas¹, I. Kalaitzoglou¹, D. Katsampoukas¹, K. Lazaridis¹, E. Manou², E. Moravidis¹;
¹3rd Department of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Papageorgiou General Hospital, Thessaloniki, GREECE, ²Nephrology Clinic, Papageorgiou General Hospital, Thessaloniki, GREECE.

EP-1416
Awareness of Green Imaging and Sustainability Among Nuclear Medicine Professionals: A Cross-Sectional Study

E. Alawadhi¹, A. Khalaf¹, L. Ghadanfer¹, M. Awadh¹, F. Busakher¹, A. Almutairi¹, A. Aldousari¹, M. Rawashdeh²;
¹Kuwait University, Kuwait, KUWAIT, ²Gulf Medical University, Ajman, UNITED ARAB EMIRATES.

EP-1417
Tc^{99m}DPD SPECT/CT in Adults With ATTR CM: Three Years Experience in a Private Medical Diagnostic Center

P. Karampina¹, A. Antonopoulos², D. Venetsanos², M. Triantafyllou³, V. Penesopoulou⁴, S. Christodoulou¹, C. Vlachopoulos²;
¹KOSMOIATRIKI SA, Nuclear medicine dpt, Athens, GREECE,

²Cardiogenetics Unit, 1st Cardiology Department, National and Kapodistrian University of Athens, Athens, GREECE, ³KOSMOIATRIKI SA, radiology dpt, Athens, GREECE, ⁴KOSMOIATRIKI SA, cardiology dpt, Athens, GREECE.

EP-1418
Head-to-Head Comparison of ¹⁸F-PSMA-1007 and ¹⁸F-FDG PET/CT in Metastatic Colorectal Cancer
R. Tineo, A. Portilho, F. Zarpelao, J. Carvalheira, C. Ramos; University of Campinas, Campinas, BRAZIL.

EP-74

e-PosterArea

Technologists e-Poster

EP-1419
Investigating the Radiobiological Response of Combinations of DNA Repair Inhibitors with AR Suppression in Advanced Prostate Cancer
A. Alshehri; Radiological Sciences Department, Collage of Applied SScience, Najran University, Najran, SAUDI ARABIA.

EP-1420
Ga-68 Fatty Acids as Myocardial Perfusion PET Agents
T. Ertay, M. Kuzucu; Dokuz Eylul University, Izmir, TÜRKIYE.

EP-1421
PET/CT protocol for Hepatocellular Carcinoma (HCC) evaluation: a multi-phase approach to improve diagnostic sensitivity
K. Shyli, F. Firinu, A. Sotgiu, F. Casaburo, C. Serra, F. Oliverio, A. Lomartire, G. Paolacci, S. Fraschina, M. Mantovani, G. Cafiero, I. Papagni; ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY.

EP-1422
Deep Learning-Based Non-Invasive Histological Grading of Hepatocellular Carcinoma via Multi-Modal Fusion of Dual-Tracer PET/CT and Clinical Data
K. Li¹, H. Chen², C. Ho¹, J. Yoo², L. Lin²; ¹Hong Kong Sanatorium and Hospital, Hong Kong, HONG KONG, ²The Hong Kong Polytechnic University, Hong Kong, HONG KONG.

EP-1423
Impact of Patient Hydration on Urinary Bladder Activity in ⁶⁸Ga-PSMA-11 PET/CT Imaging
R. Fendi, A. Nasr, I. Ceric Andelius, F. Hedeer; Lund University Hospital, Lund, SWEDEN.

EP-1424
Impact of different Chemotherapeutic agents on baseline SUV of Liver and Blood Pool in Hodgkin Lymphoma Patients.
R. Nawaz, S. Nausheen, N. Ihsan, R. Kaleemi, N. Ahmed, T. Mahmood; Jinnah Postgraduate Medical Center, Karachi, PAKISTAN.

EP-1425
Role of FDG PET-CT in Planning Therapeutic Intervention in Hepatocellular Carcinoma (HCC).
R. Nawaz, R. Kaleemi, S. Nausheen, N. Ihsan, N. Ahmed, T. Mahmood; Jinnah Postgraduate Medical Center, Karachi, PAKISTAN.

EP-1426
Comparison of two vs one CT for attenuation correction in myocardial MPS SPECT/CT imaging on a system with Smartzoom collimators
C. Kullberg¹, S. Kvernby², F. Hedeer¹, H. Mosén¹, S. Saran¹; ¹Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, SWEDEN, ²Radiation Physics, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden, Department of Translational Medicine and Wallenberg Centre of Molecular Medicine, Lund University, Malmö, Sweden, Lund, SWEDEN.

EP-1427
Intergrated Nuclear Medicine Imaging Assessment of Amyloid Burden, Sympathetic innervation, and Microvascular function in ATTR-CM
T. Lee¹, Y. Chen¹, Y. Huang¹, A. Yu², C. Tsai², M. Su³, S. Hsieh⁴, C. Chao⁴, Y. Lin², K. Ko⁵, M. Cheng¹; ¹Department of Nuclear Medicine National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN, ²Department of Internal Medicine, Division of Cardiology National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN, ³Department of Medical Imaging National Taiwan University Hospital, Taipei City, TAIWAN, ⁴Department of Neurology National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN, ⁵Department of Nuclear Medicine National Taiwan University Cancer Center, Taipei City, TAIWAN.

EP-1428
Semi Automated fusion technique to create PET-MRI like dataset in Cardiac & Pelvic pathologies, in a limited resource setting.
R. Nawaz, S. Nausheen, R. Kaleemi, N. Ihsan, N. Ahmed, T. Mahmood; Jinnah Postgraduate Medical Center, Karachi, PAKISTAN.

EP-1429
Comparison of Specific Binding Index of Regional DaTSCAN Imaging vs. MRI Striatal Volumetric Measurements
K. Priftis¹, M. Paphiti², A. Zafeirakis³, K. Roussopoulos^{4,1}, G. S. Limouris^{4,3}; ¹Nucl Med Dept, Central Clinic, Athens, GREECE, ²Cyclotron Section, Pharmazac SA, Athens, GREECE, ³Nucl Med Dept, Army Share Fund Hospital of Athens, Athens, GREECE, ⁴Nuclear Medicine, Medical School, National and Kapodistrian University, Athens, GREECE.

EP-1430
Specific Challenges and Considerations in Pediatric Nuclear Medicine imaging
S. Kosta¹, F. Mitsikoudi¹, E. Konstantarogianni¹, I. Sevaslidou²; ¹Children Hospital Agia Sofia Athens, Athens GREECE, ²General Hospital Laiko, Athens, GREECE.

EP-1431
Evaluation of the Efficacy of Treatment of Metaiodobenzylguanidine (131I-mIBG) in Pediatric Neuroblastoma
M. Garcia Arevalo, E. Martínez Montalbán, R. Maestre Cutillas, J. García Álvaro, J. Nieto Margareto, B. Martínez de Miguel; Hospital Universitario La Paz, Madrid, SPAIN.

EP-1432
Evaluation of BroadQuant Quantification accuracy for Lu-177 post-therapy SPECT-CT dosimetry
E. C. Streefkerk, M. C. Dekker, M. Dotinga, E. A. Aalbersberg; The Netherlands Cancer institute, Amsterdam, NETHERLANDS.

EP-1433
The Optimization of Lutitium-177 Tomography for Systems Lacking Medium Energy Collimator
L. Jicheng¹, J. Li²; ¹lanzhou university, lanzhou, CHINA, ²Department of Nuclear Medicine of the Second Hospital of Lanzhou University, lanzhou, CHINA.

EP-1434
Implementation of the double-contrast protocol to facilitate intraoperative detection of the sentinel lymph node in robotic laparoscopic prostate surgery
A. Afonso de Matos¹, S. Castanyer Serra², M. Negre Busó², M. Santiesteban Gutiérrez², N. Ferran Sureda², A. Rubió Rodríguez²; ¹Medicina Nuclear-ICS, Hospital Universitario Dr. Josep Trueta, Girona, SPAIN, ²Medicina Nuclear-IDI, Hospital Universitario Dr. Josep Trueta, Girona, SPAIN.

EP-1435
Uncertainty in a simplified method for quantifying the in vivo distribution of radiopharmaceuticals
H. Sagara^{1,2}, K. Takizawa², K. Tan², K. Inoue²; ¹Department of Radiological Technology, Tsukuba International University, Ibaraki, JAPAN, ²Department of Radiological Sciences, Tokyo Metropolitan University, Tokyo, JAPAN.

EP-1436
The Impact of Reconstruction Parameters on Image Quality and Quantification in PET/CT Using a Wax Phantom
S. Hadzimusic, A. Begić, A. Beganović, A. Skopljak-Beganović, N. Salkica, Š. Cerić, S. Agić-Bilalagić, A. Arnautović-Halimić, B. Tukić; Clinical Center of the Sarajevo University, Sarajevo, BOSNIA AND HERZEGOVINA.

EP-1437
A Promising Alternative: 2-Minute Respiratory-Gated Total-Body PET Fast Imaging Protocol for Malignancy Patients
X. Hou, G. Liu, S. Chen, H. Shi; Zhongshan Hospital Fudan University, Shanghai, CHINA.

EP-1438
Impact of uptake time on image quality in Positron Emission Tomography /Computed Tomography (PET/CT) among Non-Hodgkin's Lymphoma (NHL) patients
H. J. K. V. Y Wijerama¹, D. D. N. Wimalarathne¹, R. R. K. Prabash¹, K. K. I. N. Somasiri¹, W. C. Perera², S. P. D.

Wijethunga², J. M. C. Udugama³; ¹General Sir John Kotelawale Defence University, Ratmalana, SRI LANKA, ²Apeksha Hospital, Maharagama, SRI LANKA, ³Lanka Hospital PLC, Colombo 05, SRI LANKA.

EP-1439
Optimized Workflow in PET/CT Using Variable Speed Continuous Motion and Predicted Attenuation Values
G. Walker; IDX Group Lake Imaging, Ballarat, AUSTRALIA.

EP-1440
Improved PET/CT with 2mm Voxel Reconstruction
S. Rep, I. Slodnjak, B. Trebec Lukman, U. Sprajcer, L. Lezaic; University Medical Centre Ljubljana, Ljubljana, SLOVENIA.

EP-1441
Impact of AI-Enhanced Compressed Sensing on T2W Dark Blood Imaging in FAPI PET/MR for Ischemic Cardiomyopathy
X. Wang¹, Y. Jiang¹, Y. Bian¹, C. Song¹, X. Su², Y. Yang², X. Du¹, H. Feng¹, S. Zhang¹; ¹First Affiliated Hospital of Dalian Medical University, Dalian, CHINA, ²Beijing United Imaging Healthcare Co., Ltd., Beijing, CHINA.

EP-1442
Effect of Scan Angle On Quantification and Reproducibility of Multigated Acquisition Scan (MUGA)
J. Halttunen, M. Hakulinen, H. Gröhn; Kuopio University Hospital, Kuopio, FINLAND.

EP-1443
Graph-based denoising for emission images
R. Kasai, H. Otsuka; Institute of Biomedical Sciences, Tokushima University, Tokushima, JAPAN.

EP-1444
Noise-Robust SPECT Reconstruction Using Graph Diffusion
R. Kasai, H. Otsuka; Institute of Biomedical Sciences, Tokushima University, Tokushima, JAPAN.

EP-1445
NEMA Phantom Study on PET Textural Features Variability with Different Reconstructions in Digital PET/CT
P. Dwivedi^{1,2,3}, S. Barage², V. Dubey^{1,3}, A. Jha^{4,3}, S. Choudhury^{1,3}, A. Agrawal^{1,3}, V. Rangarajan^{1,4,3}; ¹Advanced Centre for Treatment Research and Education in Cancer,Tata Memorial Centre, Mumbai, INDIA, ²Amity Institute of Biotechnology, Amity University, Mumbai, INDIA, ³Homi Bhabha National Institute, Mumbai, INDIA, ⁴Tata Memorial Hospital, Mumbai, INDIA.

EP-1446
Optimization Study of Low-Dose Brain PET/MR Imaging Based on Deep Progressive Learning Reconstruction
X. Wang¹, Y. Jiang¹, Y. Bian¹, C. Song¹, X. Su², Y. Yang², X. Du¹, H. Feng¹, S. Zhang¹; ¹First Affiliated Hospital of Dalian Medical University, Dalian, CHINA, ²Beijing United Imaging Healthcare Co., Ltd., Beijing, CHINA.

EP-1447

Dynamic ElasticNet regularization with adaptive gradient descent for enhanced emission CT image reconstruction

R. Kasai, H. Otsuka;
Institute of Biomedical Sciences, Tokushima University,
Tokushima, JAPAN.

EP-1448

Deep Progressive Learning Reconstruction in Non-Small Cell Lung Cancer: Improving Image Quality and Radiomic Feature Robustness

T. Shiiba¹, M. Watanabe²;
¹Fujita Health University, Toyoake, JAPAN, ²Fujita Health University Hospital, Toyoake, JAPAN.

EP-1449

Lesion detectability evaluation of a deep learning-based time of flight image enhancement algorithm on BGO-based PET/CT scans

K. Itagaki¹, K. K. Miyake², K. Mitsumoto¹, K. Nakatani², R. Nakamoto³, T. Nobashi³, S. Koyasu², A. Katsuki⁴, H. Kawakami⁴, F. Kotasidis⁵, Y. Nakamoto²;
¹Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, JAPAN, ²Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine Kyoto University, Kyoto, JAPAN, ³Preemptive Medicine and Lifestyle Related Disease Research Center, Kyoto University Hospital, Kyoto, JAPAN, ⁴GE HealthCare, Japan, Tokyo, JAPAN, ⁵GE HealthCare, Zurich, SWITZERLAND.

EP-1450

Overcoming respiratory motion artifacts: Gated PET/CT for improved visualization of juxtadiaphragmatic lesions

K. Shyli, F. Firinu, F. Casaburo, F. Oliverio, A. Sotgiu, C. Serra, M. Mantovani, S. Fraschina, A. Lomartire, G. Paolacci, G. Cafiero, I. Papagni;
ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY.

EP-1451

Evaluation of Machine Learning Models for Automated Segmentation of SPECT MPI Scans

A. Alenezzi¹, **E. Alawdhi**¹, A. Jodeir², A. Mayya³;
¹Kuwait University, Kuwait, KUWAIT, ²Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF, ³Tishreen University, Latikiya, SYRIAN ARAB REPUBLIC.

EP-1452

Development of a Muscle Masking Technique for Reducing the Influence of Physiological FDG Uptake in PET Imaging

M. Sato, N. Imaizumi, F. Sasaki, A. Yumoto, T. Kita, H. Daisaki;
Gunma Prefectural College of Health Sciences, Maebashi, JAPAN.

EP-1453

Cross-Validation of Quantitative Accuracy in ¹³N-Ammonia PET Using Different Software and Compartment Models

N. Akiya¹, K. Miwa¹, A. Ando², N. Miyaji¹, T. Yamao¹, K. Wachi¹, M. Masubuchi¹, S. Kimura³, R. Ito¹, A. Komatsu¹, T. Horikawa¹;
¹Fukushima Medical University, Fukushima, JAPAN, ²Sapporo Kojinkai Memorial Hospital, Hokkaido, JAPAN, ³Fukushima Medical University Aizu Medical Center Hospital, Fukushima, JAPAN.

EP-1454

Relationship Between Visual Braak Staging and the Quantitative Tau PET Methods CenTauR and STOC

K. Wachi¹, T. Yamao¹, K. Miwa¹, N. Miyaji¹, N. Akiya¹, M. Masubuchi¹, T. Horikawa¹, A. Komatsu¹, R. Ito¹, H. Matsuda²;
¹Fukushima Medical University, Fukushima, JAPAN, ²Nippon Medical School, Clinical Imaging Center for Healthcare, Tokyo, JAPAN.

EP-1455

Feasibility of renal function assessment using dynamic ⁶⁸Ga-EDTA PET-CT imaging

P. Khobragade¹, N. Varghese¹, P. Varekar², A. Shanker¹, R. Krishnappa³, B. Spottiswoode⁴, K. Kallur³;
¹Siemens Healthcare Private Ltd., Bangalore, INDIA, ²Manipal Institute of Technology, Manipal, INDIA, ³Healthcare Global Enterprises Ltd, Bangalore, INDIA, ⁴Siemens Medical Solutions, Inc, Bangalore, INDIA.

EP-1456

Optimisation of Dosage for Myocardial Perfusion Imaging Using an Anthropometric Formula and Predicted Attenuation Values

G. Walker;
IDX Group Lake Imaging, Ballarat, AUSTRALIA.

EP-1457

Evaluation of Radiation Extremity Exposure in ¹⁷⁷Lu PSMA(IT) Production and Quality Control Using Two Ring Dosimeters

T. Häkkinen¹, S. Pellinen¹, M. Hakulinen^{1,2};
¹Wellbeing services county of North Savo, Kuopio university hospital, Kuopio, FINLAND, ²Department of Technical Physics, University of Eastern Finland, Kuopio, FINLAND.

EP-1458

Implementation for quantitative SPECT imaging of At-211: Becquerel calibration with a germanium semiconductor

T. Kamiya¹, H. Sasaki¹, T. Watabe², S. Naka³, K. Ooe⁴, Y. Shirakami⁴, I. Yabata¹, K. Isohashi², K. Fujino¹;
¹Department of Medical Technology, The University of Osaka Hospital, Suita, JAPAN, ²Department of Radiology, Graduate School of Medicine, The University of Osaka, Suita, JAPAN, ³Department of Pharmacy, The University of Osaka Hospital, Suita, JAPAN, ⁴Institute for Radiation Sciences, The University of Osaka, Suita, JAPAN.

EP-1459

Kidney Dosimetry in mCRPC Patients Undergoing Lu-177 PSMA Therapy: Insights from a Single-Center Study

R. Mishra, A. Nazar, S. Barai, M. Ora, A. Arya, M. Dixit, P. Pradhan, S. Dhania;
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, INDIA.

EP-1460

Assessment of collimator-detector-response for absolute quantification and dosimetry of ¹⁸⁸Re-microsphere SIRT in hepatocellular carcinoma using quantitative SPECT/CT: Addressing the technical challenges in theranostic imaging

K. Kaur, S. Chopra, J. Shukla, R. Kumar, V. D. Chadha, B. R.Mittal;
Postgraduate Institute of Medical Education and Research, Chandigarh, INDIA.

EP-1461

Biodistribution, dosimetry, and pharmacokinetics of ⁶⁸Ga-PSFA-01: First-in-human evaluation of a dual-target PET tracer

J. Li, Y. Li, X. Zhang, H. Pang;
The First Affiliated Hospital of Chongqing Medical University, ChongQing, CHINA.

EP-1462

Enhancing Operational Efficiency and Patient Care: The Aerosol Solution for Lung Ventilation Imaging

A. Moura, C. Rodrigues;
Imperial College NHS Healthcare Trust, London, UNITED KINGDOM.

EP-1463

An Innovative Design for Patient-Centred Care: Establishing the First Molecular Imaging and Therapy Center in Regional New Zealand

P. Lamerton;
Molecular Imaging and Therapy, Canopy Imaging, Hastings, NEW ZEALAND.

SATELLITE SYMPOSIA

Sunday, October 5, 2025 (Available via Livestream and On Demand)

13:15-14:45, Room 113

Symposium by Medscape Global Oncology:
Optimizing Outcomes With Radiopharmaceuticals in
mCRPC Care: From Evidence to Execution



	13:15: Welcome and Introduction 13:25: The Fine Print: Exploring the Nuances Behind the Latest Clinical Evidence 13:40: Tailored Care in mCRPC: A Tumor Board Approach to Addressing Unique Patient Needs 14:25: Future Outlook and Key Takeaways from Today 14:35: Closing Remarks and Q&A
Moderator/ Course Director:	Joe O'Sullivan , PhD, MD, BAO, BCH, FRCR, FFRRCSI, FRCPI Professor of Radiation Oncology Queen's University Belfast Consultant Prostate Oncologist The Northern Ireland Cancer Centre Belfast City Hospital Belfast, Northern Ireland
Speakers:	Irene Burger , MD Head Department of Nuclear Medicine, Cantonal Hospital Baden, Baden, Switzerland Elena Castro , MD, PhD Consultant Medical Oncologist, GU unit – Dpt. of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain Bertrand Tombal , MD, PhD Chairman, Department of Surgery. Professor of Urology Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium

Sunday, October 5, 2025 (Available via Livestream and On Demand)

13:15-14:45, Room 114

Symposium by ITM Isotope Technologies Munich SE:
SSTR-Targeting Theranostics in NETs and Beyond: Milestones and
New Frontiers



Learn more about the development and emerging clinical role of 177Lu-edotreotide in the treatment of neuroendocrine tumors, focusing on its scientific origins and current evidence supporting its use in gastroenteropancreatic NETs. Additionally, the session will explore future directions in SSTR-targeted therapies.

Symposium Host	Prof. Ken Herrmann , M.D., MBA Nuclear Medicine, University Clinic Essen, Essen, Germany
Talk Titels/Speakers:	From Concept to Clinic: the Origins of 177LU-Edotreotide in Nets Prof. Vikas Prasad , M.D., PhD Nuclear Medicine, Mallinckrodt Institute of Radiology, St. Louis, USA Translating Evidence Into Practice: the Role of 177lu-Edotreotide in Nets Dr. Rocío García-Carbonero , M.D., PhD Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain Exploring the Future of The SSTR-Targeting Landscape Prof. Damian Wild , M.D., PhD Nuclear Medicine, University Hospital of Basel, Basel, Switzerland

Sunday, October 5, 2025 (Available via Livestream and On Demand)

13:15-14:45, Room 111

Symposium by Siemens Healthineers:
Changing the Care Paradigm



Emerging radiopharmaceuticals and novel therapies are increasing the demand for molecular imaging. Simultaneously, advancements in hybrid imaging are unlocking new levels of possibility. Join us for a series of talks on how clinical teams are utilizing technology to reimagine their approach to patient care. Physicians from three renowned institutions will highlight strategies for leveraging innovations in SPECT/CT, PET/CT, and PET/MR to embrace change and lead the way.

Sunday, October 5, 2025 (Available via Livestream and On Demand)

13:15-14:45, Room 115

Symposium by ABX Advanced Biochemical Compounds



Moderation:	Prof. Dr. Frederik Giesel , Department of Nuclear Medicine University Hospital Düsseldorf, Germany
Talk Titels/Speakers:	PSMA-PET/CT in prostate cancer: an overview of the current landscape and ongoing studie Dr. Bastiaan Privé , MD, PhD, Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands Clinical Study Results of [¹⁸F]PSMA-1007 in South Korea: Advancing Approval and Diagnostic Innovation Dr. Mijin Yun , CEO of New Curem, Seoul, South Corea ¹⁸F-PSMA-1007 PET Imaging in Primary Prostate Cancer Staging: Case Insights and Handling Tricky Uptakes Dr. Pedro José Lopez , Medical Director Nuclear Medicine, Hospital del Mar, Barcelona, Spain Detecting Biochemical Recurrence with 18F-PSMA-1007: Insights, Case Studies, and Managing Unspecific Bone Uptakes Prof. Dr. Wolfgang Schäfer , Chief Physician of the Clinic for Nuclear Medicine Maria Hilf Clinics, Mönchengladbach, Germany PSMA PET instead of painful biopsies – can we put the urologists out of business? Prof. Dr. Tobias Maurer , Urologist at Martini Klinik Hamburg, University Hospital Hamburg Eppendorf, Germany

Sunday, October 5, 2025 (Available via Livestream and On Demand)

13:15-14:45, Room 116

Symposium by Telix Pharmaceuticals:



Sunday, October 5, 2025

13:15-14:45, Room 212

Symposium by PharmaLogic:



Monday, October 6, 2025

13:15-14:45, Room 113

Symposium by Pfizer:
Improving outcomes through early identification and intervention in ATTR-CM



5 min: Welcome and introduction
20 min: ATTR amyloidosis: from clinical suspicion to evidence-based intervention
20 min: Nuclear imaging in ATTR-CM: current practice and future directions
15 min: From imaging to intervention: case-based diagnosis and management of ATTR-CM
5 min: Q&A

- Meeting Objectives:
- Enhance understanding of both wild-type and hereditary ATTR amyloidosis, with a focus on cardiac involvement, clinical presentation, prognosis and the critical importance of early and accurate detection
 - Reinforce the role of nuclear imaging in the evaluation of suspected ATTR-CM, emphasizing its place in the diagnostic pathway and the potential for emerging imaging techniques to enhance detection and disease characterization
 - Review the supporting evidence for ATTR-CM management based on robust clinical data and real-world outcomes
 - Showcase practical, case-based examples that integrate imaging, genetic testing and multidisciplinary collaboration to optimize patient outcomes

Monday, October 6, 2025

13:15-14:45, Room 114

Symposium by Eli Lilly and Company:



Monday, October 6, 2025

13:15-14:45, Room 211

Symposium by GE HealthCare:
Advancing radiotheranostics: precision medicine of today and the path forward



Join us for a focused satellite symposium exploring the evolving role of radiotheranostics in modern patient care. The session will highlight current clinical applications, breakthroughs in targeted diagnostics and therapies, and the strategic steps needed to integrate radiotheranostics into broader precision medicine frameworks. From today's innovations to tomorrow's possibilities, discover how this transformative approach is reshaping healthcare.

Chairperson:

Dr. Ilya Gipp, Medical Director, GE HealthCare

Speakers:

Prof. Gustav von Schulthess, Chairman of the Department of Medical Radiology at University Hospital Zurich
Prof. Lisa Rowley, head of nuclear medicine, University Hospital Coventry & Warwickshire
Prof. Diego Cecchin, head of nuclear medicine, Padova University Hospital

Monday, October 6, 2025 (Available via Livestream and On Demand)

13:15-14:45, Room 116

Symposium by Curium:
Can Nuclear Medicine and Its Referrers Allow the PSMA PET Access Gaps to Persist?



Despite its demonstrated clinical benefits PSMA PET is insufficiently accessible. A better NMS-Uro relationship is needed to improve patient care.

- Speakers:
- Accessibility of PSMA PET, a challenge that has not been overcome yet.
Prof Vineet Prakash, UK
- Extended access to PSMA PET is needed to improve the clinical patient management.
Ass Prof Juan Gomes Rivas, Spain
- Experience sharing of a full PSMA PET adoption fostered by strong Uro-NMS relations.
Dr Filmont, France

Monday, October 6, 2025

13:15-14:45, Room 115

Symposium by United Imaging Healthcare:
Seeing More: Transforming Care with Molecular Imaging



Molecular imaging (MI) is transforming care by enabling practitioners to see more. Discover how next-generation MI technologies are redefining and advancing precision medicine outcomes. Experts will share their opinions and experience on how high-resolution scanning, low-count high-quality imaging, and advanced quantitative analytics unlock new clinical potential. Join us to gain deeper insights across patient populations through enhanced detection capabilities, and translating the findings into actionable treatment monitoring and optimized therapeutic pathways.

Moderator:

Stewart Young,
Lead Research Collaboration Scientist, United Imaging Healthcare Europe

- Speakers:
- Low-dose Imaging – Initial Clinical Experience using uMI Panorama PET/CT
Dr. Thomas Mognetti, MD, Head of Nuclear Medicine Department, Centre Léon Bérard, Lyon, France
- High-resolution Brain PET/CT at Xing Imaging using uNeuroEXPLORER
Prof. Dr. Roger Gunn, PhD, Chief Science Officer, Xing Imaging, New Haven, USA
- Beyond Static: First Clinical Experience with Dynamic LAFOV PET at Niguarda Milan
Dr. Claudio Rossetti, MD, Director of Nuclear Medicine Department, ASST Grande Ospedale Metropolitano Niguarda, Italy
- Dynamic by Design – Where do we go with LAFOV PET?
Prof. Dr. Frank M. Bengel, MD, Director of Nuclear Medicine Department, Medizinische Hochschule Hannover, Germany

Monday, October 6, 2025

13:15–14:45, Room 111

Symposium by Spectrum Dynamics Medical:



Monday, October 6, 2025

13:15–14:45, Room 133+134

Symposium by Blue Earth Diagnostics:



GET INVOLVED!

Become part of EANM's volunteer community

- Create your profile
- Receive updates on new opportunities
- Join activities that shape the field of Nuclear Medicine



Ready to
make an impact?
SIGN UP NOW!

www.eanm.org



SHAPING THE FUTURE OF NUCLEAR MEDICINE TOGETHER

The **EANM** brings the voices and experiences of **Nuclear Medicine** healthcare professionals into European negotiations and debates, ensuring that our expertise and perspectives help shape better policymaking. As a trusted and recognised partner, **EANM** has actively contributed to several EU-funded projects and tenders. Thanks to our in-depth knowledge of nuclear medicine and our wide professional network, we are well-positioned to engage in and strengthen European initiatives in this field.



EU AFFAIRS AT EANM'25:

- **Dedicated booth** in the EANM Village
- **2 Policy symposia**
(From Policy to Patients & Integrating HTA in NucMed)
- **EU Track showcasing**
5 different ongoing projects
- A special **Policy Workshop**



LIST OF EXHIBITORS

(A – Z)

	Booth Nr.	Exhibiting Company
CM	26	ABX advanced biochemical compounds
CM	124	ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH
	115	Acom Advanced Center Oncology Macerata S.R.L.
	56	Advanced Cyclotron Systems Inc.
	E18	AIMN – Asiazione Italiana di Medicina Nucleare ed imaging molecolare
	52	Aixial UK Limited
CM	44	Alliance Medical GmbH
	E02	Almac Group
	E26	ANZSNM – Australian & New Zealand iety of Nuclear Medicine
	107	Argonsoft LTD.
	E28	ASNC – American iety of Nuclear Cardiology
	59	AtomVie Global Radiopharma Inc.
CM	79 a	AWEX – Wallonia Export & Investment Agency
	20	Bayer Healthcare Pharmaceuticals Inc.
	89	Becquerel & Sievert Co., Ltd.
	13 b	Berthold Technologies GmbH & Co. KG
	13 a	Best Cyclotron Systems, Inc
	108	Bianco Sağlık Ürünleri Ticaret Pazarlama Sanayi Limited Şirketi
	61	Bioemtech
CM	80	Blue Earth Diagnostics Ltd.
	E23	BNMS – British Nuclear Medicine iety
	80	Bracco Imaging SpA
	14	Brightonix Imaging
CM	3	Bruker BioSpin GmbH & Co. KG
	76 b	BV Cyclotron VU
	123	C Ray Therapeutics Co., Ltd.
	E20	CANM-ACMN – Canadian Asiation of Nuclear Medicine
CM	46	Capintec, a Mirion Medical Company
	101	Cedars Sinai Medical Center
	45	CGN Isotope Co., Ltd
	100	Chelatec
	124	CHEMATECH
	109	China Isotope & Radiation Corporation
CM	65	CMR – Center of Molecular Research Corporation GmbH
	37	Colibri Isotopes Corporation
CM	5	COMECER SPA

	73 a	CRL – Central Research Laboratories
	122	Crystal Photonics GmbH
	28 d	CUP Laboratorien Dr. Freitag GmbH
CM	29	Curium PET Europe
	94	Cyclife Aquila Nuclear
CM	2	Cyclomedica
	E25	DGN – German iety of Nuclear Medicine
	22	Dixit Srl
	104	DOSIsoft
	23	DSD Pharma GmbH
	E15	EARL – Resarch4Life
	E14	EAU – European As. Of Urology
CM	69	Eckert & Ziegler
	E13	ECR/EIBIR – European Institute for Biomedical Imaging Research
	E21	Edizioni Minerva Medica
	126	EDL (Edition et Développement de Logiciels)
	E12	EFOMP – European Federation of Organizations for Medical Physics
	E09	EFRS – European Federation of Radiographer ieties
	97	Eichrom Technologies
	90	EITA European Isotopes Transport Asiation IVZW
CM	36	ELSE Solutions S.r.l.
	79 b	Elysia Raytest
	76 c	Epsilon Elektronik Sanayi ve Ticaret A.Ş.
	76 f	EuroMedical Instruments
	47	Gamma Medical Technology – GbR
CM	4 & 30	GE HealthCare
	103	Guangzhou Diqi Trading Co., Ltd
CM	72	Hermes Medical Solutions AB
	76 d	Hidex
	76 i	HOY Scandinavian ApS
CM	9	IBA SA
	121	ICPO Foundation
	41	Institute of Isotopes Co. Ltd. / Izotop
	50	Inter Medical Medizintechnik GmbH
	49	International Isotopes, Inc. / RadQual
	96	Invia Medical Imaging Solutions
	88	Inviscan
	112	Ionetix Alpha Corporation
	93	Iotron Medical Inc
	116	iPHASE technologies
	79 c	IRE Elit
CM	73 c	Isotopia Molecular Imaging
	83	ITEL Telecomunicazioni Srl
CM	71	ITM Isotope Technologies Munich SE
CM	87	Jiangsu Huayi Technology Co., Ltd.
	33	Jiangsu Sinogram Medical Technology Co.,Ltd.
	E03	Jiaxing Huahe Pharmaceutical Co., Ltd.
	E17	JSNM – Japanese iety of Nuclear Medicine
	128	Kev Medical Imaging

	64	LabLogic Systems Limited
	21	LaCalhene (Getinge Life Science France)
CM	27	Lemer Pax
	55	Life Couriers
CM	11	Life Molecular Imaging Ltd.
	76 e	LYLA B.V.
	111	Lynax s.r.o.
	E30	MDPI
CM	70	Medi-Radiopharma Ltd.
CM	40 & 41	Mediso Ltd.
	54	MedTrace Pharma A/S
	15	Mias Pharma LTA
	28 a	MiE medical imaging electronics GmbH
	60	MILabs
CM	32	MIM Software Inc.
	17	Mindview / General Equipment for Medical Imaging
	117	Minerva Imaging ApS
	28 b	MNT Healthcare Services Inc
	118	MR Solutions LTD
CM	39	Narodowe Centrum Badań Jądrowych, Ośrodek Radioizotopów POLATOM
	E06	National Physical Laboratory
	28 d	NorthStar Medical Radioisotopes, LLC
CM	43	Novartis
	75	NPPI / Medicines Discovery Catapult Ltd.
	76 a	NucAdvisor / MEDraysintell
	127	Nuclear Medicine Europe
	19	Nuclear Shields B.V.
	76 g	Nuvia
CM	102	OncoBeta GmbH
	124	Oncodesign Services
CM	7	OncoSil Medical Europe GmbH
	E04	Optimized Radiochemical Applications
	13 c	PAIRE
CM	81	Pars Isotope Co.
	105	PBL SRL
	91	Perceptive
	62	PHSE s.r.l.
	76 h	PI Medical
	23	piCHEM
	66	PMB-ALCEN
	74 & E01	Positrigo AG
	92	PSI CRO AG
	120	R2Pharma
	106	RayXpert
	E08	RECIP Educational Platform
	E29	RLT Angels
	57	Rotem GmbH
CM	28 c	ROTOP Pharmaka GmbH

	99	RoweMed Ag-Medical 4 Life
	51	RQS Alexander Ruffani
	E10	Scanxiety
	18	schneschu UG / Voximetry Inc.
	8	Scintomics Molecular, ATT GmbH
CM	25	SCK CEN
	E19	SFMN – French iety of Nuclear Medicine
CM	6	SHINE Medical Technologies, LLC
	58	Sichuan Longevious Beamtech Co., Ltd
CM	31 & 34 & 35	Siemens Healthineers
	53	Sirtex Medical Europe GmbH
	E22	SNMMI – iety of Nuclear Medicine and Molecular Imaging
	E16	iety of Nuclear Medicine, India
	64	Southern Scientific
	1	Special Cargo Services
	12	SpectronRX
CM	10	Spectrum Dynamics Medical Inc.
CM	68	Stichting NRG PALLAS
CM	24	Sumitomo Heavy Industries, Ltd.
	73 b	Synthermed, Inc.
	84	Synthra GmbH
	110	Taiyo Nippon Sanso Corporation
	48	Tecnicas Radiofisicas, S.L.U.
CM	78	Telix Innovations SA
CM	77	Tema Sinergie S.p.A.
CM	70	TerThera b.v.
	79 d	The Oncidium Foundation
	38	Theragenics Corporation
	E05	Time Matters GmbH
	95 & 98	Trasis
CM	85	Triskem International
	125	Truking Technology Limited
	E24	TSNM – Turkish iety of Nuclear Medicine
	63	U.S. Department of Energy Isotope Program
CM	42	United Imaging Healthcare
CM	86	Urenco Isotopes
	76 j	Van Der Wilt Techniques
	113	VICI AG International
CM	82	Von Gahlen Nederland B.V.
	16	Wälischmiller Engineering GmbH
	E07	WARMTH
	E11	WFNMB 2026 – Cartagena de Indias
	E27	Wisepress
	114	Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd
	67	Wuxi SunMao Medical Technology Co. Ltd.
	119	XEOS Medical NV

LIST OF EXHIBITORS (SORTED BY BOOTH NO.)

	Booth Nr.	Exhibiting Company
	1	Special Cargo Services
CM	2	Cyclomedica
CM	3	Bruker BioSpin GmbH & Co. KG
CM	4 & 30	GE HealthCare
CM	5	COMECER SPA
CM	6	SHINE Medical Technologies, LLC
CM	7	OncoSil Medical Europe GmbH
	8	Scintomics Molecular, ATT GmbH
CM	9	IBA SA
CM	10	Spectrum Dynamics Medical Inc.
CM	11	Life Molecular Imaging Ltd.
	12	SpectronRX
	13 a	Best Cyclotron Systems, Inc
	13 b	Berthold Technologies GmbH & Co. KG
	13 c	PAIRE
	14	Brightonix Imaging
	15	Mias Pharma LTA
	16	Wälischmiller Engineering GmbH
	17	Mindview / General Equipment for Medical Imaging
	18	schneschu UG / Voximetry Inc.
	19	Nuclear Shields B.V.
	20	Bayer Healthcare Pharmaceuticals Inc.
	21	LaCalhene (Getinge Life Science France)
	22	Dixit Srl
	23	DSD Pharma GmbH
	23	piCHEM
CM	24	Sumitomo Heavy Industries, Ltd.
CM	25	SCK CEN
CM	26	ABX advanced biochemical compounds
CM	27	Lemer Pax
	28 a	MiE medical imaging electronics GmbH
	28 b	MNT Healthcare Services Inc
CM	28 c	ROTOP Pharmaka GmbH
	28 d	CUP Laboratorien Dr. Freitag GmbH
	28 d	NorthStar Medical Radioisotopes, LLC
CM	29	Curium PET Europe

CM	31 & 34 & 35	Siemens Healthineers
CM	32	MIM Software Inc.
	33	Jiangsu Sinogram Medical Technology Co.,Ltd.
CM	36	ELSE Solutions S.r.l.
	37	Colibri Isotopes Corporation
	38	Theragenics Corporation
CM	39	Narodowe Centrum Badań Jądrowych, Ośrodek Radioizotopów POLATOM
CM	40 & 41	Mediso Ltd.
	41	Institute of Isotopes Co. Ltd. / Izotop
CM	42	United Imaging Healthcare
CM	43	Novartis
CM	44	Alliance Medical GmbH
	45	CGN Isotope Co., Ltd
CM	46	Capintec, a Mirion Medical Company
	47	Gamma Medical Technology – GbR
	48	Tecnicas Radiofisicas, S.L.U.
	49	International Isotopes, Inc. / RadQual
	50	Inter Medical Medizintechnik GmbH
	51	RQS Alexander Ruffani
	52	Aixial UK Limited
	53	Sirtex Medical Europe GmbH
	54	MedTrace Pharma A/S
	55	Life Couriers
	56	Advanced Cyclotron Systems Inc.
	57	Rotem GmbH
	58	Sichuan Longevous Beamtech Co., Ltd
	59	AtomVie Global Radiopharma Inc.
	60	MLabs
	61	Bioemtech
	62	PHSE s.r.l.
	63	U.S. Department of Energy Isotope Program
	64	LabLogic Systems Limited
	64	Southern Scientific
CM	65	CMR – Center of Molecular Research Corporation GmbH
	66	PMB-ALCEN
	67	Wuxi SunMao Medical Technology Co. Ltd.
CM	68	Stichting NRG PALLAS
CM	69	Eckert & Ziegler
CM	70	Medi-Radiopharma Ltd.
CM	70	TerThera b.v.
CM	71	ITM Isotope Technologies Munich SE
CM	72	Hermes Medical Solutions AB
	73 a	CRL – Central Research Laboratories
	73 b	Synthermed, Inc.
CM	73 c	Isotopia Molecular Imaging
	74 & E01	Positrigo AG
	75	NPIP / Medicines Discovery Catapult Ltd.
	76 a	NucAdvisor / MEDraysintell
	76 b	BV Cyclotron VU

	76 c	Epsilon Elektronik Sanayi ve Ticaret A.Ş.
	76 d	Hidex
	76 e	LYLA B.V.
	76 f	EuroMedical Instruments
	76 g	Nuvia
	76 h	PI Medical
	76 i	HOY Scandinavian ApS
	76 j	Van Der Wilt Techniques
CM	77	Tema Sinergie S.p.A.
CM	78	Telix Innovations SA
CM	79 a	AWEX – Wallonia Export & Investment Agency
	79 b	Elysia Raytest
	79 c	IRE Elit
	79 d	The Oncidium Foundation
CM	80	Blue Earth Diagnostics Ltd.
	80	Bracco Imaging SpA
CM	81	Pars Isotope Co.
CM	82	Von Gahlen Nederland B.V.
	83	ITEL Telecomunicazioni Srl
	84	Synthra GmbH
CM	85	Triskem International
CM	86	Urenco Isotopes
CM	87	Jiangsu Huayi Technology Co., Ltd.
	88	Inviscan
	89	Becquerel & Sievert Co., Ltd.
	90	EITA European Isotopes Transport Association IVZW
	91	Perceptive
	92	PSI CRO AG
	93	Iotron Medical Inc
	94	Cyclife Aquila Nuclear
	95 & 98	Trasis
	96	Invia Medical Imaging Solutions
	97	Eichrom Technologies
	99	RoweMed Ag-Medical 4 Life
	100	Chelatec
	101	Cedars Sinai Medical Center
CM	102	OncoBeta GmbH
	103	Guangzhou Diqi Trading Co., Ltd
	104	DOSIsoft
	105	PBL SRL
	106	RayXpert
	107	Argonsoft LTD.
	108	Bianco Sağlık Ürünleri Ticaret Pazarlama Sanayi Limited Şirketi
	109	China Isotope & Radiation Corporation
	110	Taiyo Nippon Sanso Corporation
	111	Lynax s.r.o.
	112	Ionetix Alpha Corporation
	113	VICI AG International


	114	Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd
	115	Acom Advanced Center Oncology Macerata S.R.L.
	116	iPHASE technologies
	117	Minerva Imaging ApS
	118	MR Solutions LTD
	119	XEOS Medical NV
	120	R2Pharma
	121	ICPO Foundation
	122	Crystal Photonics GmbH
	123	C Ray Therapeutics Co., Ltd.
CM	124	ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH
	124	CHEMATECH
	124	Oncodesign Services
	125	Truking Technology Limited
	126	EDL (Edition et Développement de Logiciels)
	127	Nuclear Medicine Europe
	128	Kev Medical Imaging
	E02	Almac Group
	E03	Jiaxing Huahe Pharmaceutical Co., Ltd.
	E04	Optimized Radiochemical Applications
	E05	Time Matters GmbH
	E06	National Physical Laboratory
	E07	WARMTH
	E08	RECIP Educational Platform
	E09	EFRS – European Federation of Radiographer Societies
	E10	Scanxiety
	E11	WFNMB 2026 – Cartagena de Indias
	E12	EFOMP – European Federation of Organizations for Medical Physics
	E13	ECR/EIBIR – European Institute for Biomedical Imaging Research
	E14	EAU – European Assoc. Of Urology
	E15	EARL – Resarch4Life
	E16	Society of Nuclear Medicine, India
	E17	JSNM – Japanese Society of Nuclear Medicine
	E18	AIMN – Associazione Italiana di Medicina Nucleare ed imaging molecolare
	E19	SFMN – French Society of Nuclear Medicine
	E20	CANM-ACMN – Canadian Association of Nuclear Medicine
	E21	Edizioni Minerva Medica
	E22	SNMMI – Society of Nuclear Medicine and Molecular Imaging
	E23	BNMS – British Nuclear Medicine Society
	E24	TSNM – Turkish Society of Nuclear Medicine
	E25	DGN – German Society of Nuclear Medicine
	E26	ANZSNM – Australian & New Zealand Society of Nuclear Medicine
	E27	Wisepress
	E28	ASNC – American Society of Nuclear Cardiology
	E29	RLT Angels
	E30	MDPI

EXHIBITION HALLS

Exhibition Hall



Entrance Hall



CM	26	ABX advanced biochemical compounds
CM	124	ABX-CRO advanced pharmaceutical services Forschungs-gesellschaft GmbH
	115	Acom Advanced Center Oncology Macerata S.R.L.
	56	Advanced Cyclotron Systems Inc.
	E18	AIMN – Associazione Italiana di Medicina Nucleare ed imaging molecolare
	52	Aixial UK Limited
CM	44	Alliance Medical GmbH
	E02	Almac Group
	E26	ANZSNM – Australian & New Zealand Society of Nuclear Medicine
	107	Argonsoft LTD.
	E28	ASNC – American Society of Nuclear Cardiology
	59	AtomVie Global Radiopharma Inc.
CM	79 a	AWEX – Wallonia Export & Investment Agency
	20	Bayer Healthcare Pharmaceuticals Inc.
	89	Becquerel & Sievert Co., Ltd.
	13 b	Berthold Technologies GmbH & Co. KG
	13 a	Best Cyclotron Systems, Inc
	108	Bianco Sağlık Ürünleri Ticaret Pazarlama Sanayi Limited Şirketi
	61	Bioemtech
CM	80	Blue Earth Diagnostics Ltd.
	E23	BNMS – British Nuclear Medicine Society
	80	Bracco Imaging SpA
	14	Brightonix Imaging
CM	3	Bruker BioSpin GmbH & Co. KG
	76 b	BV Cyclotron VU

	123	C Ray Therapeutics Co., Ltd.
	E20	CANM-ACMN – Canadian Association of Nuclear Medicine
CM	46	Capintec, a Mirion Medical Company
	101	Cedars Sinai Medical Center
	45	CGN Isotope Co., Ltd
	100	Chelatec
	124	CHEMATECH
	109	China Isotope & Radiation Corporation
CM	65	CMR – Center of Molecular Research Corporation GmbH
	37	Colibri Isotopes Corporation
CM	5	COMECER SPA
	73 a	CRL – Central Research Laboratories
	122	Crystal Photonics GmbH
	28 d	CUP Laboratorien Dr. Freitag GmbH
CM	29	Curium PET Europe
	94	Cyclife Aquila Nuclear
CM	2	Cyclomedica
	E25	DGN – German Society of Nuclear Medicine
	22	Dixit Srl
	104	DOSIsoft
	23	DSD Pharma GmbH
	E15	EARL – Resarch4Life
	E14	EAU – European Assoc. Of Urology
CM	69	Eckert & Ziegler
	E13	ECR/EIBIR – European Institute for Biomedical Imaging Research
	E21	Edizioni Minerva Medica
	126	EDL (Edition et Développement de Logiciels)
	E12	EFOMP – European Federation of Organizations for Medical Physics
	E09	EFRS – European Federation of Radiographer Societies
	97	Eichrom Technologies
	90	EITA European Isotopes Transport Association IVZW
CM	36	ELSE Solutions S.r.l.
	79 b	Elysia Raytest
	76 c	Epsilon Elektronik Sanayi ve Ticaret A.Ş.
	76 f	EuroMedical Instruments

	47	Gamma Medical Technology – GbR
CM	4 & 30	GE HealthCare
	103	Guangzhou Diqi Trading Co., Ltd
CM	72	Hermes Medical Solutions AB
	76 d	Hidex
	76 i	HOY Scandinavian ApS
CM	9	IBA SA
	121	ICPO Foundation
	41	Institute of Isotopes Co. Ltd. / Izotop
	50	Inter Medical Medizintechnik GmbH
	49	International Isotopes, Inc. / RadQual
	96	Invia Medical Imaging Solutions
	88	Inviscan
	112	Ionetix Alpha Corporation
	93	Iotron Medical Inc
	116	iPHASE technologies
	79 c	IRE Elit
CM	73 c	Isotopia Molecular Imaging
	83	ITEL Telecomunicazioni Srl
CM	71	ITM Isotope Technologies Munich SE
CM	87	Jiangsu Huayi Technology Co., Ltd.
	33	Jiangsu Sinogram Medical Technology Co.,Ltd.
	E03	Jiaxing Huahe Pharmaceutical Co., Ltd.
	E17	JSNM – Japanese Society of Nuclear Medicine
	128	Kev Medical Imaging
	64	LabLogic Systems Limited
	21	LaCalhene (Getinge Life Science France)
CM	27	Lerner Pax
	55	Life Couriers
CM	11	Life Molecular Imaging Ltd.
	76 e	LYLA B.V.
	111	Lynax s.r.o.
	E30	MDPI
CM	70	Medi-Radiopharma Ltd.
CM	40 & 41	Mediso Ltd.
	54	MedTrace Pharma A/S
	15	Mias Pharma LTA
	28 a	MIe medical imaging electronics GmbH
	60	MILabs
CM	32	MIM Software Inc.
	17	Mindview / General Equipment for Medical Imaging
	117	Minerva Imaging ApS
	28 b	MNT Healthcare Services Inc
	118	MR Solutions LTD
CM	39	Narodowe Centrum Badań Jądrowych, Ośrodek Radioizotopów POLATOM
	E06	National Physical Laboratory
	28 d	NorthStar Medical Radioisotopes, LLC
CM	43	Novartis
	75	NPIP / Medicines Discovery Catapult Ltd.
	76 a	NucAdvisor / MEDraysintell
	127	Nuclear Medicine Europe
	19	Nuclear Shields B.V.
	76 g	Nuvia
CM	102	OncoBeta GmbH
	124	Oncodesign Services
CM	7	OncoSil Medical Europe GmbH
	E04	Optimized Radiochemical Applications
	13 c	PAIRE
CM	81	Pars Isotope Co.
	105	PBL SRL
	91	Perceptive
	62	PHSE s.r.l.

	76 h	PI Medical
	23	piCHEM
	66	PMB-ALCEN
	74 & E01	Positrgo AG
	92	PSI CRO AG
	120	R2Pharma
	106	RayXpert
	E08	RECIP Educational Platform
	E29	RLT Angels
	57	Rotem GmbH
CM	28 c	ROTOP Pharmaka GmbH
	99	RoweMed Ag-Medical 4 Life
	51	RQS Alexander Ruffani
	E10	Scanxiety
	18	schneschu UG / Voximetry Inc.
	8	Scintomics Molecular, ATT GmbH
CM	25	SCK CEN
	E19	SFMN – French Society of Nuclear Medicine
CM	6	SHINE Medical Technologies, LLC
	58	Sichuan Longeovus Beamtech Co., Ltd
CM	31 & 34 & 35	Siemens Healthineers
	53	Sirtex Medical Europe GmbH
	E22	SNMMI – Society of Nuclear Medicine and Molecular Imaging
	E16	Society of Nuclear Medicine, India
	64	Southern Scientific
	1	Special Cargo Services
	12	SpectronRX
CM	10	Spectrum Dynamics Medical Inc.
CM	68	Stichting NRG PALLAS
CM	24	Sumitomo Heavy Industries, Ltd.
	73 b	Synthermed, Inc.
	84	Synthra GmbH
	110	Taiyo Nippon Sanso Corporation
	48	Tecnicas Radiofisicas, S.L.U.
CM	78	Telix Innovations SA
CM	77	Terna Sinergie S.p.A.
CM	70	TerThera b.v.
	79 d	The Oncidium Foundation
	38	Theragenics Corporation
	E05	Time Matters GmbH
	95 & 98	Trasis
CM	85	Triskem International
	125	Truking Technology Limited
	E24	TSNM – Turkish Society of Nuclear Medicine
	63	U.S. Department of Energy Isotope Program
CM	42	United Imaging Healthcare
CM	86	Urenco Isotopes
	76 j	Van Der Wilt Techniques
	113	VICI AG International
CM	82	Von Gahlen Nederland B.V.
	16	Wälischmiller Engineering GmbH
	E07	WARMTH
	E11	WFNMB 2026 – Cartagena de Indias
	E27	Wisepress
	114	Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd
	67	Wuxi SunMao Medical Technology Co. Ltd.
	119	XEOS Medical NV

PALMA DE MALLORCA, SPAIN

FEBRUARY 5-7, 2026

EANM
FOCUS 7

MOLECULAR IMAGING
FOR A PERSONALISED TREATMENT
IN ALZHEIMER'S DISEASE



EA 26
NM
WORLD
LEADING
MEETING

39th

Annual Congress of the
European Association of Nuclear Medicine

VIENNA

OCTOBER 17 – 21, 2026

eanm26.eanm.org

COMPANY PROFILES

A.C.O.M. - Advanced Center Oncology Macerata - S.R.L.

Loc. Cavallino 39/A-B 62010 Montecosaro (Mc), Italy
www.acompet.it/

ACOM SRL is a company operating in the nuclear medicine sector founded in 1999. Research is the driving force of the company, with 20 years of commitment and experience in the development of innovative radiopharmaceuticals to be included in the international market. The main area of interest and development is oncology, but the activities also involve neurodegenerative and cardiovascular diseases. The focus of the research is theranostic medicine, and in particular the development of Copper(64Cu) Chloride as a theranostic agent: a real integration of a diagnostic method with a specific therapeutic intervention. ACOM SRL is the first company in Europe to have brought in the market the radionuclide Copper-64 as a radiopharmaceutical precursor. ACOM SRL has recently obtained orphan designation in Europe for the treatment of glioblastoma with Copper(64Cu)Chloride. The professional skills of the team, the capacity to operate in critical contexts and an innovative approach demonstrated by constant investment in research and development, are just some of the distinctive features developed in these years of business. For any further information please visit our stand and our WEB page (www.acompet.it) where you can find the most updated information.

ABX advanced biochemical compounds

Heinrich-Gläser-Str. 10-14 01454 Radeberg, Germany
www.abx.de

ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with focus on positron emission tomography (PET) tracers.

We develop and optimize:

- Your lead compound/ your peptide
- The radiochemical labelling process, including purification and formulation
- Quality control methods

We offer:

- Precursor and reference standards
- Your reagent kits with corresponding cassette
- Accessories for radiochemical syntheses
- ¹⁸O-water for ¹⁸F-Fluorid production
- Customized syntheses and products
- Your radiopharmaceutical medicinal product with shipment worldwide

We support:

- Completion of CMC documents or Drug Master Files for your clinical studies
- Audits ABX is a global success story: As market leader for radiopharmaceutical consumables we developed over the last years the ¹⁷⁷Lu-PSMA-617 – until phase II (then sublicensed to Endocyte, now Novartis) as well as ¹⁸F-PSMA-1007 – now approved in several countries in Europe.

ABX-CRO advanced pharmaceutical services

Schössergasse 19 01067 Dresden, Germany
www.abx-cro.com/

ABX-CRO is an international CRO providing standard & specialised clinical and non-clinical studies, with emphasis on neuroscience, oncology and diagnostic imaging. With a unique translational medicine approach, we are happy to develop products from first non-clinical to late-stage multicentre human studies, or to support marketing authorisation.

Our dedicated Molecular and Functional Imaging Core Lab provides comprehensive turn-key solutions covering all aspects of pre-clinical and clinical imaging and dosimetry. We provide solutions for radiolabelling, dosimetry, regulatory issues and the intricacies of functional imaging that are frequently seen as major obstacles in the conduct of oncology and imaging trials.

Whether you represent a clinical trial site or want to find out how your project could benefit from our experience, come over and get an idea of our comprehensive services and expertise!

Advanced Cyclotron Systems Inc.

150-7280 River Rd. V6X 1X5 Richmond, BC, Canada
www.advancedcyclotron.com/

Advanced Cyclotron Systems, Inc. (ACSI) is a world leader in the design and manufacturing of cyclotron systems. With over 30 years of experience and more than 60 cyclotron systems installed, ACSI can provide a wide range of equipment and services worldwide. ACSI cyclotrons are used for the commercial production of PET and SPECT nuclides by internationally recognized companies and leading universities and research facilities. ACSI cyclotrons are designed, manufactured, and assembled in Richmond, Canada. ACSI offers a full spectrum of cyclotron systems ranging from PET cyclotrons to medium and high energy accelerators. All ACSI manufactured cyclotrons have variable energy and employ external ion source technology, offering the highest beam current output available on the market. The versatility, high beam current and exceptional quality of ACSI cyclotrons are some of the reasons why many of the world's most prestigious universities and research centres, as well as some of the most successful commercial radioisotope producers have chosen ACSI cyclotrons to meet their radioisotope production needs. For more information, please visit www.advancedcyclotron.com

Aixial Group Limited

Unit 15 City Business Centre, 6 Brighton Road
RH13 5BB Horsham, United Kingdom

www.aixialgroup.com/

The Aixial Group is an international Contract Research Organization (CRO) providing services in phase I-IV clinical trials and non-interventional studies. As a CRO, Aixial Group collaborates with sponsors to develop oncology, radiopharmaceutical, cell & gene and rare disease therapies. We provide innovative solutions to overcome the challenges and complexities faced by global biotech and pharma companies. As a CRO leader in radiopharmaceutical development, over the last ten years, Aixial has successfully managed 45 radiopharmaceutical trials in a variety of indications, with 27 of these in oncology, involving numerous radioisotopes. Our portfolio of work has involved both diagnostic and therapeutic products including nanoparticles and theranostics.

Alliance Medical GmbH

Westring 168
44575 Castrop-Rauxel, Germany

www.alliancemedical.eu

Alliance Medical is an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. These combined services allows physicians, pharma industry and academia greater access to established and innovative imaging agents for clinical trials and clinical routine.

Almac Group

20 Seagoe Industrial Estate
BT635QD Craigavon, United Kingdom

www.almacgroup.com/

Almac has >20 years' experience supplying peptides to both the research community and for clinical trials. Our scientists have developed a high level of technical expertise enabling manufacture of peptides with a wide range of complexity, including high-throughput manufacture, long peptides, conjugation and peptide cocktails. Almac has intimate knowledge of all the required steps to progress a peptide radiopharmaceutical precursor from initial concept to first in human testing, and through the entire clinical journey. We have ongoing programs from Phase 0 through to Process Validation and supported a commercial radiopharmaceutical launch in 2023.

ArgonSoft Ltd.

H-1133 Budapest, Váci út 76. Capital Square
1133 Budapest, Hungary

www.argonsoft.hu/en/

ArgonSoft, was established in 2008 with the primary objective of offering custom software development services. Since then, we have successfully completed over 150 projects for more than 30 clients across 9 countries. Our exceptional results can be attributed to the hard work of our team of over 40 IT experts, our client-focused approach, and our strong relationships with our clients. The scope of our projects varies from 100 man-days to 10,000 man-days. Several of our national IT systems have been in continuous use by thousands of users for over a decade. We have developed sophisticated IT solutions for various industries including healthcare, public services, and financial institutions. In addition to our domestic projects, we have collaborated with numerous international companies worldwide. As part of our high-quality service portfolio, we provide our clients with IT consultancy, project management, quality assurance, various outsourcing services, and long-term system support. Based on the knowledge gained from our diverse and large-scale projects, we have also established a product development division. Expanding our service and product portfolio, ArgonSoft has ventured into the healthcare sector and since 2016, we have been actively increasing our involvement in this area, particularly in the field of nuclear medicine. With our extensive development skills, our experience and proficiency in the healthcare sector and our relationships with universities, ASIS.TO LIMS has been developed as a unique, innovative, flexible, production-supporting IT system. By combining ASIS.TO LIMS's capabilities with ArgonSoft's custom software development services and expertise in medical device software, we can offer our clients a unique solution when needed. In addition, we also provide software development services in the field of Software as a Medical Device (SaMD) for device manufacturing partners.

AtomVie Global Radiopharma Inc.

1280 Main Street West NRB-A316
L8S 4K1 Hamilton, Ontario, Canada

www.atomvie.com/

AtomVie Global Radiopharma (AtomVie) is a leading global CDMO specializing in GMP-compliant manufacturing and distribution of radiopharmaceuticals. With the ability to work with all isotopes, AtomVie provides a comprehensive range of scientific, technical, regulatory, quality, and logistics expertise to support the development of your radiopharmaceuticals from Phase 1 to market. AtomVie is constructing a state-of-the-art, purpose-built, and scalable 72,300 sq. ft. cGMP facility, which will be ready by the end of 2025 for clinical and commercial-scale production of radiopharmaceuticals.

AWEX - Wallonia Trade and Investment Agency

Place Sainctelette 2
1080 Brussels, Belgium

www.awex.be/en

The Wallonia Foreign Trade and Investment Agency, also known as AWEX, is Wallonia's - Region of Belgium - government agency in charge of foreign Trade and foreign investment. Wallonia is home to many nuclear medicine companies of various sizes, from SMEs to large companies, such as IBA and IRE, including spinoffs, suppliers and service providers. Our regional government supports the development of existing or newly established innovative activities with regard to R&D and production in the radiopharma and radiotherapy industry. AWEX is a one-stop shop for all foreign companies interested in setting up or expanding their business in Wallonia, as well as a partner for all Walloon companies wishing to develop their activities outside Belgium. If you're interested to know more, we will provide you with tailor-made information. Our partner BioWIN, the Health Cluster of Wallonia since 2006, encourages innovation and international development of Walloon actors active in this sector. BioWIN connects some 250 key players: universities, research units and centers, R&D as well as manufacturing companies, incubators, capital providers, hospitals. To find out more about BioWIN's activities, please visit <https://biowin.org/>.

Bayer Healthcare Pharmaceuticals Inc.

100 Bayer Boulevard, PO Box 915
07981 Whippany, NJ, United States of America

www.bayer.com

Bayer is committed to delivering SCIENCE FOR A BETTER LIFE through innovative cancer treatments. Its oncology portfolio includes XOFIGO (radium-223 dichloride), a targeted alpha therapy for metastatic castration-resistant prostate cancer with bone metastases*(1). Bayer continues to advance its oncology pipeline through clinical trials, including a portfolio of targeted radiopharmaceuticals for prostate cancer.
*progressing after ≥2 lines of systemic therapy, or ineligible for systemic treatment for mCRPC
References: (1)Xofigo (radium Ra 223 dichloride) solution for injection Summary of Product Characteristics (SmPC). 51368 Leverkusen, Germany: Bayer AG; August 2024
https://www.ema.europa.eu/en/documents/product-information/xofigo-epar-product-information_en.pdf. Accessed June 2025.

Becquerel & Sieveret Co., Ltd

3f-1, NO 56, Ln. 258, RuiGuang Rd.
11491 Taipei City, Taiwan

www.bqsv.com/RWD/htm/en/enindex.html

Radiation safety and dose accuracy is our primary concerns”
Becquerel & Sievert Co. Ltd (as named BqSv) was established on year 1993, has been constantly devoted on the new technology and innovated equipment of radiation safety and protection, automation and quality control in the application of radiology, nuclear medicine, oncology, radiopharmaceutical GMP facility, and nuclear industry. We have successfully provided a total solution and turnkey service from site plan design, radiation safety evaluation, equipment manufacture, and system installation to our customers to comply with the highest standard and guideline in worldwide, we also concern the climate change and develop Green shielding products for saving our planet.

Berthold Technologies GmbH & Co. KG

Calmbacher Straße 22, 75323 Bad Wildbad,
Germany

www.berthold.com

Berthold Technologies is a global technology leader in life sciences, process control and radiation protection. We deliver integrated measuring solutions that have been trusted by scientists, technicians and engineers since more than 70 years.

BIOEMTECH

271 Kleisthenous St
153 44 Athens, Greece

www.bioemtech.com/

BIOEMTECH's mission and passion is accelerating preclinical research of promising drugs, towards clinical translation, through precisely targeted services and products. BIOEMTECH leverages its own boutique laboratories to drive innovation and ensure quality, for evaluating new compounds in all stages of preclinical testing, GLP toxicology and alpha emitters therapy schemes. It has developed the eyesTM desktop cameras for real-time in vivo imaging of SPECT and PET radionuclides and dyes. The eyesTM offer unmatched excellence in the challenging in vivo imaging of alpha emitters (212Pb & 225Ac) for oncological models, in short scanning times and clinically relevant doses. Both in BIOEMTECH's services and products, fast screening applications are a core company value towards accelerating drug development.

Blue Earth Diagnostics Ltd.

Magdalen CentreOxford Science Park
OX4 4GA Oxford, United Kingdom

www.blueearthdiagnostics.com

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company's success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. Blue Earth Diagnostics' expanding portfolio encompasses a variety of disease states, including oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in diagnostic imaging. For more information, please visit: www.blueearthdiagnostics.com.

Bracco Imaging

Via Egidio Folli, 50
20134 Milano,
Italy

www.bracco.com/

Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures, and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems, and dose-management software.

Brightonix Imaging

#1705, SK V1 Tower, 25,
Yeonmujang 5ga-gil, Seongdong-gu
04782 Seoul, Korea, Rep. of South

www.brtnx.com/en/

Brightonix Imaging is an innovative healthcare company dedicated to providing society with cutting-edge biomedical imaging systems. We currently offer a range of preclinical and clinical PET systems, along with advanced medical imaging AI solutions. PHAROS is a high-performance, multifunctional digital PET system equipped with state-of-the-art detector technology. SimPET is the most compact and reliable MRI-compatible SiPM PET insert, enabling truly simultaneous PET/MRI studies in small animals. BTXBrain is an AI-powered, fully automated software solution for quantification of brain PET and SPECT imaging.

What's new this year is ELIOS, Brightonix Imaging's latest addition to our preclinical product portfolio. ELIOS is a preclinical PET/CT system for small animals, designed to deliver high-quality imaging performance with precision and reliability. We are proud to present ELIOS for the first time at EANM, with a full-scale demonstration system available at our booth. Come visit us to experience it firsthand.

Bruker

Rudolf-Plank-Str. 23
76275 Ettlingen, Germany

www.bruker.com/en/

Bruker BioSpin, a global leader in preclinical imaging solutions, empowers researchers and clinicians with cutting-edge technologies for in vivo imaging. Their comprehensive portfolio supports drug discovery, disease research, and translational medicine. Notably, Bruker acquired MOLECUBES NV, specializing in benchtop preclinical nuclear molecular imaging (NMI) systems. MOLECUBES' modular PET, SPECT, and CT CUBES™ imagers enhance high-throughput research, strengthening Bruker's NMI position. Additionally, Bruker's renowned PMOD™ PET data analysis software aids accurate quantification, image processing, and modeling in preclinical studies and clinical trials. Recently, Bruker expanded their offerings by acquiring Spectral Instruments Imaging LLC, a leader in preclinical optical imaging systems, broadening their solutions for disease research. Collaborating with these partners, Bruker continues to drive scientific advancements and improve patient outcomes.

BV Cyclotron VU

Van der Boechorststraat 6A
1081 BT Amsterdam, Netherlands

www.cyclotron.nl

BV Cyclotron VU produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Strategically located in Amsterdam next to Amsterdam UMC we produce GMP-compliant medical isotopes in our state-of-the-art manufacturing facilities. Our long-standing track record on supplying daily to the customers, our great expertise combined with strong collaborations makes us a reliable partner for hospitals, pharmaceutical companies and research centers all over the world.

C-Ray Therapeutics (Chengdu) Co.,Ltd.

198 haida road, Wenjiang district, Chengdu,
Sichuan province, Chinanan Chengdu, China

www.c-raytherapeutics.com

C-Ray is a one-stop CRDMO service provider for radiopharmaceuticals. Since its founding in 2021, C-Ray has established 28, 000+m^2 R&D(with a GLP-like animal facility) and multi-product manufacturing facility in Chengdu, China, which meets the cGMP requirements of the FDA, EMA, and NMPA. Under the Class A Radiation Safety Permit in China, C-Ray can operate over 30 types of radionuclides and supports your radiopharmaceutical candidates' screening, pre-clinical studies, process development, clinical & commercial-scale manufacturing, and Phase 0 clinical trial in China.

C-Ray is also the leading radiopharmaceutical company.In 2024, its Series A+ financing round exceeded \$100 million. Since the launch of CRDMO, (Contract Research,Development, and Manufacturing Organization) services,C-Ray has successfully delivered 5 CDMO projects, 20+ theranostics and molecular imaging CRO projects, and multiple ongoing R&D programs “Lu-177/Ac-225/Cu-64/Ga-68/Zr-89-labeled radiopharmaceuticals to worldwide partners.

Capintec, a Mirion Medical Company

7 Vreeland Rd
07932 Florham Park, United States of America

www.capintec.com/

Capintec™, a Mirion Medical company, offers advanced nuclear medicine and molecular imaging instrumentation that enhances safety and efficiency. From dose preparation to patient administration and radiation protection, our products better the human condition by protecting people from exposure during potentially life-saving imaging and therapy. Visit our booth to learn more.

CGN Isotope Co.,Ltd.

No.9 Kangxin Road, Youxian Street, Youxian District
621000 Mianyang, China

www.cgn-healthcare.com

CGN Isotope is a leading innovator in the R&D, production, and supply of medical isotopes, dedicated to building a complete nuclear medicine value chain and driving next-generation radiopharmaceutical applications. Leveraging both reactor and accelerator technologies, CGN Isotope has the capability to produce and supply a wide range of isotopes, including 68Ge, 68Ge/68Ga generators, 123I, 64Cu, 89Zr, 177Lu, 226Ra, and 18O, among others. We are also committed to developing new products by drawing on the extensive resources of our parent company, CGN Group.

CGN Isotope operates under CGN Healthcare, which specializes in applying nuclear technology to cancer diagnosis and treatment, and is part of CGN Group (China General Nuclear Power Group), the largest nuclear power conglomerate in China and second largest globally.

Our mission is to empower healthcare providers worldwide with cutting-edge nuclear medicine solutions that improve patient outcomes and advance the diagnosis and treatment of cancer.

CHELATEC

1 rue Aronnax
44800 Saint-Herblain, France

www.chelatec.com/

Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of targeted radiotherapeutics to pharma and biotech. With state-of-the-art fully equipped laboratories for radiolabeling, radioanalyses, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo investigations capabilities.

Specializing in radiopharmaceutical R&D, Chelatec will provide you with information on your Investigational Medicinal Product to be part of the documentation package. All quality and non-clinical safety data required for translation of a radiopharmaceutical.

Our services include:

- Bioconjugation
- Radioactive labeling (177Lu, 90Y, 111In, 225Ac, 161Tb...)
- Analytical controls (HPLC, iTLC/TLC, SDS-PAGE...) - Stability studies (storage stability, plasma stability)
- In vitro assays (Binding affinity, IRF, internalization, cytotoxicity, autoradiography on tissue sections)
- In vivo investigations (Pharmacokinetics, biodistribution, efficacy, dosimetry)

CHEMATECH

2 rue Pauline Kergomard
21000 Duon, France

www.chematech-mdt.com

CheMatech is a world-leading company specializing in the design and synthesis of bifunctional chelating agents such as DOTA, NOTA and NODAGA derivatives. These molecules are widely used for peptides or antibodies labeling with 67/68Ga, 111In, 64/67Cu, 89Zr, ... for PET/SPECT imaging, 177Lu, 225Ac, 212Pb, 90Y,... for therapy. CheMatech offers a wide range of functionalized and protected chelating agents from milligrams to kilograms scale. CheMatech offers cGMP production, custom syntheses of chelators and bioconjugation services.

China Isotope & Radiation Corporation (CIRC)

66 Changwa Zhongjie Street, Haidian District 100089 Beijing, China
www.circ.com.cn/

China Isotope & Radiation Corporation (CIRC) is the member company of China National Nuclear Corporation(CNNC) and the largest enterprise in the aspects of R&D, manufacture, distribution and service of civil nuclear products in China. CIRC is mainly engaged in research, production and application of radioisotope and radiation technology, covering radioisotopes, radiopharmaceuticals, radioactive sources, radiation engineering and processing etc. There are more than 50 production lines capable of supplying over 70 nuclides and 300 kinds of products all together.

CMR Corporation GmbH

Bldg 638b, Cargo City South 60549 Frankfurt, Germany
isotope-cmr.com

Center of Molecular Research (CMR) - one of the leading global suppliers of nuclear medicine products. CMR Group was established in 2001 and during more than 20 years has been specialized in the development, production and distribution of isotopes, lyophilizates, reagents, peptides and a wide range of other products for radionuclide diagnostic and therapy. Today, CMR is not only one of the world's largest producers of Oxygen-18 water, but also a qualified supplier of a wide range of products, including STABLE AND RADIOACTIVE ISOTOPICS, CHEMICAL RADIOPHARM PRECURSORS and COLD KITS, which fully cover the needs of medical facilities, scientists and technologists in the field of nuclear medicine and radiochemistry. Full Product List always available on our website.

Colibri Isotopes Corporation

Texas, United States of America
colibriso.com

Colibri Isotopes Corporation (USA) is a medical isotopes research, development and supply company specializing in therapeutic isotopes production through state-of-the-art target designs and physicochemical separation technologies for nuclear reactor-based and accelerator-based production methods. Colibri is focusing on production of Lu-177, Ac-225, Ra-223, Tb-161 and Pb-212. Colibri's Lu177 nca proprietary production technology allows to set up the most reliable supply chain for the customers all over the world and to do it in the most cost effective way. Colibri is developing an accelerator-based Ac-225 production route with the use of physicochemical separation technologies providing the purest final product on the market. Current scope of products / services offered includes:
- Lu-177, Ac-225, Ra224 and Ra223 supply
- RnD collaboration for production facility set up
For more information, please visit our website: colibriso.com

COMECER SPA

Via Maestri del Lavoro, 90 48014 Castel Bolognese (RA), Italy
www.comecer.com/

Comecer develops and manufactures high-tech systems in the Radiopharmaceutical field, offering customized equipment and special solutions for Therapeutical, GMP Radiopharmacy, and Nuclear Medicine applications, as well as isolation technology solutions in the field of Aseptic Processing and Containment for the Pharmaceutical industry. In particular, Comecer excels in the field of radiochemistry where, on behalf of large industrial groups or research institutes, it manufactures shielding systems for special applications. Radiopharmaceuticals are radioactive substances used to identify a specific part of the body through the emission of radio particles captured by gamma chambers and PET tomographs capable of offering accurate functional morphological images. In the Nuclear Medicine sector, Comecer products such as shielded hot cells, synthesis and dispensing isolators, solid target systems, and radiopharma injectors, are used in the most advanced and prestigious research centers, universities, hospitals, and pharmaceutical companies worldwide.

Crystal Photonics GmbH

Albert-Einstein-Straße 16
12489 Berlin, Germany

www.crystal-photonics.com

Crystal Photonics is engaged in Nuclear Medicine for highly qualified products of Molecular Imaging and intraoperative and transcutane sentinel lymph node localization (SLNE) since 25 years. The product range includes our excellent mini-USB Hand-Held-Gamma-Camera “CrystalCam”, the surgical Gamma Probe System “Crystal Probe - automatic” with various kinds of cable and wireless probes. We are worldwide the first company, who is presenting complete autoclavable gamma probes without compromises! Since this year is also available the very new detection system CrystalGuard for Isolated Limb Perfusion (ILP), as well as the very new CrystalAnalyzer for HPLC-investigation in coincidence mode for any PET-drugs are available. Additionally, we present our very new mini-Laparoscopic gamma probe for robotic-assisted minimal-invasive surgeries, (Drop-in-Probe) special designed for the DaVinci robotic operation system. This probe is very small (D 1 cm x 5 cm) was developed in the course of the new PSMA-technology for Prostate Cancer and has excellent medical-technical properties. The product portfolio is completed by a large variety of miniaturized Gamma- and Beta-detectors for any kind of application, particularly systems for the production and dose-rate controlling of medical radioisotopes with high activities. For more information, please visit our websites: www.crystal-photonics.com

CUP Contract Labs

Carl-Eschbach-Strasse 7
01454 Radeberg, Germany

www.cup-contract-labs.com

CUP Contract Labs, located in Radeberg, Germany, is a leading contract laboratory and strategic partner for complex pharmaceutical analysis. We support start-ups and manufacturers of next generation pharmaceuticals on their path to excellence. When it gets complex, that’s when things really get going for us. Whether narcotics, orphan drugs, high-potent drugs, radiopharmaceuticals or targeted therapeutics: We are your competent partner for all aspects of their analysis. We are a provider of GMP-compliant contract testing services for the radiopharmaceutical industry. Our core competencies include sterility testing of radioactive pharmaceuticals and we are also experts in the analysis of Leachables and Extractables (E&L), identifying and quantifying potential impurities that may leach from manufacturing materials or packaging. In addition to these services, CUP Contract Labs offers a wide range of testing options for medical radionuclides and precursors for radiopharmaceutical preparations. Our advanced analytical techniques and equipment enable us to accurately characterize and evaluate the purity and activity of these vital components, ensuring optimal performance and safety in radiopharmaceutical products. We take pride in our commitment to quality and regulatory compliance. CUP has been inspected by the US Food and Drug Administration (FDA) and has earned GMP certification, demonstrating our adherence to the highest industry standards. At CUP Contract Labs we are driven by a passion for excellence in radiopharmaceutical testing and a commitment to supporting our clients in their quest to develop life-changing therapies. With our extensive experience, cutting-edge facilities, and unwavering dedication to quality, we are the trusted partner for radiopharmaceutical testing and quality assurance. Your trailblazer for the safe and rapid development, approval and quality control of complex pharmaceuticals. CUP Contract Labs.

Curium

12 rue Lord Byron
75008 Paris, France

www.curiumpharma.com/

Curium is the world’s largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for potentially life-threatening diseases to over 15 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. The tagline ‘Life Forward’ represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team. To learn more, visit www.curiumpharma.com

Cyclomedica

Unit 4, 1 The Crescent, Kingsgrove
2208 New South Wales, Australia

www.cyclomedica.com/

Cyclomedica is a global leader in nuclear medicine and molecular imaging, redefining respiratory diagnostics through innovation, collaboration, and clinical impact. Since 1986, we have remained at the forefront of nuclear pulmonology with our flagship product, Technegas®, used in over 66+ countries and impacting the lives of millions. The recent FDA approval of Technegas® in the United States marks a pivotal milestone in our growth, opening new opportunities to support clinicians in diagnosing and managing pulmonary embolism and other respiratory diseases. We are actively expanding its clinical utility through international research, development, and clinical trials-broadening its application across multiple respiratory indications. At Cyclomedica, we work closely with a network of global partners-including TEMA Sinergie, Jubilant Radiopharma, ROTOP, and ABX-to bring an extended portfolio of innovative solutions to market. These alliances allow us to push boundaries, deliver complementary Nuclear Medicine, PET and theranostic products, and support customers with an integrated, future-ready offering. Whether in Molecular Imaging, PET, or Theranostics, our mission remains clear: to aspire to better care, inspire scientific progress, and illuminate new pathways in health. We provide end-to-end support, from early-stage project planning to installation, applications training, and long-term service. Whether introducing a new system or expanding an existing one, our team is committed to helping customers deliver the best in patient care. As we continue to grow, we remain focused on meaningful progress-aspiring to higher standards, inspiring clinical confidence, and illuminating smarter pathways in nuclear medicine. Learn more about our story and solutions at cyclomedica.com

Dixit S.r.l.	DOSIsoft
Via Agostino da Montefeltro 2 10134 Turin, Italy	45/47 Avenue Carnot 94230 Cachan, France
www.dixitsolutions.com	www.dosisoft.com

Dixit is an ISO 9001certified company and certified imaging CRO focused on building efficient medical applications and services for multicentre clinical trials, based in Turin, the first capital city of Italy and a technological hub. Its main product, WIDEN (www.dixitsolutions.com/widen), is a SaaS product designed to implement the management, quality assurance and review of imaging studies in clinical trials in a secure, simple, effective and reliable way. Trials can easily scale in size and their interim results are monitored in real time, optimizing control and achieving statistical significance in a short time. Dixit works with leading international imaging and oncological societies and cooperative groups that use qualitative and quantitative imaging, especially PET/CT, in their cancer treatment protocols. Since 2012, WIDEN has been adopted by more than 50 multi-centre clinical trials, whose coordinating institutions reside in Austria, France, Switzerland, UK, Poland, Italy, Canada and Australia. WIDEN users are located in 27 different countries and more than 250 clinical centres. WIDEN is also suitable for retrospective imaging-based clinical trials, that could be simply configured and operated. Data can be quickly collected, assessed and analysed, and the results are precious input for designing more ambitious, prospective trials.

Founded in 2002, DOSIsoft is a leading provider of dosimetry software solutions in Radiation Oncology and Nuclear Medicine, dedicated to improving cancer patient safety and treatment quality. Through continuous innovation, DOSIsoft designs, develops, delivers, and supports some of the most advanced patient-specific quality assurance and medical imaging tools—successfully adopted by over 600 hospital centers across 60 countries worldwide. DOSIsoft is a spin-off between Gutave Roussy and Curie Institute, with offices in France, Argentina, and the U.S., and a broad network of distributors. DOSIsoft collaborates with leading cancer institutes and research centers worldwide. www.dosisoft.com

DSD Pharma GmbH	Eckert & Ziegler Medical
Schuhmeierstraße 24 1140 Purkersdorf, Austria	Robert-Roessle-Str.10 13125 Berlin, Germany
dsd-pharma.com/	medical.ezag.com/en/

DSD Pharma is a GDP certified distributor of radiopharmaceuticals and medical devices in the field of nuclear medicine and radiopharmacy, respectively, and ADR transportation based in Austria close to Vienna.

Eckert & Ziegler Medical is one of two business segments of the Eckert & Ziegler Group, with headquarters in Berlin, Germany. With more than three decades of experience in the field, Medical represents the combined expertise in nuclear medicine, molecular imaging, radiation therapy and beyond, while always focusing customer success. We complement our wide-ranging portfolio of innovative high-quality technical solutions with the provision of versatile services such as development and contract manufacturing. With our global network of GMP suites we offer fully licensed radioisotope labs, stable supply arrangements for almost all pharmaceutical radioisotopes, a state-of-the-art infrastructure including logistics, and a highly experienced staff that can be seconded to help with your preclinical and clinical projects. As a one-stop-shop for all your radiopharmaceutical needs, using alpha, beta or gamma emitters, our products include everything from hot cell solutions to various radionuclides in radiochemical (e.g., Lu-177, Ac-225) or radiopharmaceutical grade (Yttriga, GalliaPharm®, Theralugand®), radiosynthesis technology (Modular-Lab, KitLab) and radiochromatography equipment (e.g., AR-2000). Contact us for GMP Suites, CDMO, CMC, GalliaPharm, Ac-225, Lu-177, Y-90, Theralugand®, radioisotopes, hot cell solutions, IGG100, UniFill, SWB-15, rTLC, rHPLC, Flow-Count, Mini-Scan, MiniScanPRO, FlowCountPRO, AR-2000, IsoSeed and more.

EDL	Eichrom Technologies
509 Av. de La Victoire du 8 Mai 1945 13130 Berre-L'Étang, France	1955 University Lane 60532 Lisle, United States of America
www.edl.fr	www.eichrom.com

Launched in 1994, EDL's software solutions have already attracted more than 600 medical imaging departments. EDL also publishes integrated applications covering all the modern needs of imaging services such as: RIS, PACS, DACS, VINA, Teleradiology, IA, Radiopharmacy and WEB portals.

Eichrom is a global leader in nuclear separation chemistry for analytical radiochemistry, isotope geochemistry and nuclear medicine. Eichrom is characterized by integrity, responsive customer service and high standards for product quality. We are a difference-making supplier because of our collaborative approach and the continual growth of our technical competence. Eichrom has an experienced team of radiochemists that continually strives to improve efficiency and lower costs for our customers.

EITA - European Isotopes Transport Association	ELSE Solutions srl
c/o Vandelanotte Buro & Design Center Esplanade 1/85 1020 Brussels, Belgium	via Carlo Goldoni, 18 20090 Trezzano sul Naviglio (MI), Italy
www.eita.org	www.elsesolutions.com/

EITA is a non-profit association, which was founded in 1998 by European logistics providers trained, licensed and specialized in the handling and transport by Road, Air and Sea of radioactive isotopes, which are mainly used for medical purpose.

Mission

Establishment of harmonized regulations and standards

Aiming for harmonized national and international regulations and legislations to guarantee the free market access in every state for the EITA members.

Compliance with applicable regulations

To ensure all EITA member activities are carried out in full compliance with all applicable legal requirements.

Safety, Security and traceability

To ensure safety and security and full traceability at all times during the complete supply chain.

Quality

To ensure high quality of handling, packing and transport of radioactive isotopes in accordance with required standards.

Competence centre

To provide a forum to exchange information and knowledge to increase awareness.

ELSE Solutions Srl is an Italian company founded in 1990 which boasts a long experience in the design and production of radiation detection systems, shielded manipulation systems and passthrough, automations and plants for Nuclear Medicine, Radiopharmacy, Radiotherapy and other applications in the Medical and Industrial fields. ELSE Solutions technology is designed to meet the most advanced standards, safety, and environment care.

SmartEye Platform is a flexible and expandable platform for all Radiation Measuring applications, featuring PoE support, Web based user interface, integrated visual and acoustic indications, shielded manipulation systems and passthrough are featuring fully encapsulated lead and PLC controlled ECO functions (standby) to reduce the electrical consumption, the patented automatic dispensing system is designed to work with any isotope with zero loss of radioactivity and is certifying the prepared patient dose through a medical device dose calibrator, all automations and plants are meeting the most updated international standards, PLC control is featuring advanced functions with User-Friendly remote interface, digital ovens for Radiotherapy masks are designed to work without water, significantly reducing preparation time and maximizing safety and hygiene of the process.

ELSE Solutions' vision is to be an international reference for the design and supply of innovative and state-of-art solutions in the Medical and Industrial fields.

ELYSIA S.A.

rue du Sart-Tilman 375
B - 4031 ANGLEUR, Belgium

www.elysia-raytest.com/

Elysia is a provider of hard- and software solutions for the full integrated quality control of your radio-pharmaceutical production. GINA X and SARA offer a user friendly and fully GMP compliant solution to your QC problems. We provide LIMS solutions, services, chromatography and quality control systems to the pharmaceutical, agrochemical and nuclear/PET industries.

We design, manufacture, sell and service instruments used for measurement of radioactivity and quality control. We work in close collaboration with radiopharmaceutical and cyclotron providers to develop new products and improve existing solutions. In 2015 Elysia has purchased the Raytest Isotopenmessgeräte GmbH to increase the R&D, service and production capacity.

Since the integration of raytest, Elysia has extended the product line with cassette based synthesis module especially for the peptide labelling with Ga68, Lu177 and other radio-metals.

This allows us to plan and offer complete GMP and European Pharmacopeia compliant, turnkey solutions for the quality control of a huge variety of PET and SPECT tracers.

Our mission is to make the measurement of radioactivity, the peptide labelling and quality control of radiopharmaceuticals easier, faster and safer. Radiopharmaceuticals should be accessible world-wide and affordable. We help our customers accelerate their R&D and to validate QC methods for existing and new molecules.

Our team is customer-oriented and composed of radiochemists, IT and QA specialists. Their professional background ensures high-efficacy answers for all radiopharmaceutical, software and instrument questions.

For more information about the company and its products, please visit our website at www.elysia-raytest.com

EPSILON RADIOACTIVE SOURCES - (ERS)

Ferhatpasa Mahallesi 15. Sokak No:126-128
3488 Istanbul, Türkiye

www.epsilonsources.com

ERS designs and manufactures a comprehensive portfolio of sealed reference and quality assurance sources compatible with leading OEM systems in PET, PET/CT, PET/MR, and SPECT imaging. The product range includes Ge-68, Na-22, Co-57, and Gd-153 sources in various geometries and activity levels, tailored to system-specific calibration and quality control requirements.

In addition, ERS offers I-125 localization seeds for non-palpable metastasis, as well as radio decontamination solutions including decontamination liquids, soaps, and wipes designed for safe and effective cleanup of radioactive contamination.

Customized configurations are available upon request. Please get in touch with your local distributor or ERS headquarters for product availability and additional information

EuroMedical Instruments

1, rue du Centre
93160 Noisy-le-Grand, France

www.em-instruments.com/en/home-en/

EuroMedical Instruments is the exclusive worldwide sales and marketing company of the Europrobe, a state-of-the-art surgical gamma probe manufactured by Eurorad SA, Strasbourg, France. Founded in 1982, Eurorad is a company specialised in R&D, Service and Production of mono and polycrystalline semiconductors for radiation detectors, and one of the main manufacturers for this type of equipment in the world.

for-med.nl

Parallelweg Zuid 33-02
5281LB Boxtel, Netherlands

www.for-med.nl

Design and Production of customized medical accessories. We create a wide range of products for patient positioning, fixation, shielding and more.

Gamma Medical Technology

Friesdorfer Straße 194A
53175 Bonn, Germany

www.gamma-mt.com

Welcome to Gamma Medical Technology, a pioneering supplier of advanced gamma probes for Sentinel Lymph Node Biopsy (SLNB) and radio-guided surgery. Our objective is to transform cancer treatment with precision-focused surgical tools that elevate patient outcomes and streamline surgical processes. Founded by a team of visionary medical experts and engineers, we are devoted to ongoing innovation, research, and development in radio-guided surgery. Our skilled team is dedicated to designing user-friendly gamma probes that meet the complex demands of modern surgical procedures. Our flagship product, the CENNA-500W, exemplifies our commitment to quality and innovation. This next-gen gamma probe offers unmatched accuracy, sensitivity, and ease of use, enabling surgeons to confidently identify sentinel lymph nodes during SLNB. Its state-of-the-art design ensures precise gamma radiation detection, minimizing false-negative risks and reducing surgery times. Gamma Medical Technology is renowned for quality, reliability, and exceptional customer support. We collaborate with surgeons and medical facilities worldwide, offering training, education, and ongoing assistance to optimize product use. As we expand globally, we remain committed to our core values of innovation, excellence, and customer satisfaction. Discover the difference our products make in radio-guided surgery and join us in revolutionizing cancer treatment worldwide.

GE HealthCare

283 rue de la miniere
78530 Buc, France

www.gehealthcare.co.uk/

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services and data analytics to make clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing connected and compassionate care, while simplifying the patient's journey across the care pathway. Together, we're creating a world where healthcare has no limits.

Getinge Life Science France (LaCalhene)

1 rue du comte de Donegal
41100 VENDOME, France

www.lacalhene.com/fr/

Since the 1960s, LaCalhene has been designing equipment for protecting operators and safely handling contaminated materials in the nuclear industry, research, and medicine. We offer complete solutions for hot cells, and glove boxes:

- Remote manipulators: a wide range of mechanical and electrical remote handling systems for multiple applications allowing work in hot cells of all sizes.
- Transfer systems: safely transfer small, medium, and large volumes of contaminated materials and waste without breaking containment.
- Transport Casks: shielded containers designed for a wide variety of transfers (waste or materials, underwater or in hot cells) and for on-site transport or on public roads.
- Manipulation Devices: a complete range of easy-to-use and safe manipulation solutions for glove boxes.

LaCalhene is there from A to Z to provide expert advice, safe products, comprehensive training, and maintenance support. Learn more about our solutions here: www.lacalhene.com.

Global Morpho Pharma

8 Rue de la Fionie
44240 la Chapelle-sur-Erdre,
France

morphopharma.com/

Global Morpho Pharma is a turnkey technology and service provider for the production and distribution of medical radioisotopes. We develop innovative technologies and automated equipments to produce medical radioisotopes at industrial scale, specifically for nca Lu-177 and Tb-161. We also distribute radioisotopes (nca Lu-177, Ac-225, Mo-99, I-131, Th-228....) and stable isotopes (Yb-176) linked to radiotheranostic, and offer irradiation services through our network of nuclear reactors. More information: <https://morphopharma.com/> Come and visit us booth 27

Guangzhou Diqi Trading Co., Ltd

Room 503-3, 5th Floor, No.2086, Kaichuang Avenue, Huangpu District
51000 Guangzhou, China

www.diqisohub.com

DiqisoHUB | Established in 2012, is transforming into a 3rd party platform dedicated to supplying Radioisotopes (Lu-177, Tc-99m generator, etc.), enriched stable isotopes (Zn-68, Ni-64, etc.), and High-tech equipment (cyclotrons, Industry CT, etc.) in China and for ROW.
Our AI-empowered DiqisoHUB.com platform offers unparalleled real-time tracking for logistics/supply chain, enabling global compliance and partnerships with industry-leading players worldwide.

Hermes Medical Solutions AB

Strandbergsgatan 16
112 51 Stockholm, Sweden

www.hermesmedical.com

Since its establishment in 1976 in Stockholm, Sweden, Hermes Medical Solutions has continuously innovated to enable faster and more personalized diagnosis and therapies in molecular imaging.
The company was the first to develop SPECT reconstruction software and dual-head whole-body scanning, and the first to introduce medical image fusion software for combined viewing of images from different scanners. We empower healthcare professionals by providing state-of-the-art software for all clinical scenarios in ONE vendor-neutral platform: Hermia.
Our mission is to combine innovation leadership in nuclear medicine/molecular imaging software with customer-driven service, and our success lies in our close and longstanding collaboration with our customers to meet their software, support and service needs.
The result is improved quality in patient management and decision support that benefits thousands of healthcare providers and their patients worldwide
Visit us at booth F10 to discover how our Hermia software can make a difference for your facility!

Hidex

Lemminkäisenkatu 62
FIN-20520 Turku, Finland

www.hidex.com/

Hidex is a manufacturer of high-performance analysis equipment for life science research, radiation measurement, and nuclear medicine. As a world leader in detecting alpha, beta, and gamma emitters, Hidex offers optimized gamma counters for molecular imaging isotope energies. Our gamma counters are designed to streamline workflow, sample tracking, and ensure GxP compliance. Hidex liquid scintillation counters are used globally in the development and quality control of radiopharmaceuticals, utilizing isotopes such as actinium, radium, thorium, lutetium, strontium, yttrium, and more.
At EANM 2025, we are showcasing the following solutions:
Hidex Automated gamma counter: The Hidex AMG, equipped with a NaI well detector and onboard sample balance, is ideal for metabolic studies, blood input function curves, Glucomerase filtration rate, and general nuclear medicine applications.
Hidex Radiowater Generator: The Hidex Radiowater Generator is an online system for preparing oxygen-15 labelled water ([O-15]-H2O) infusions. With approximately 50 installations worldwide, Hidex is a pioneer in ¹⁵O water technology.
Hidex Sense: The Hidex Sense microplate reader comes equipped with radiometric and non-radiometric detection modes. The multi-well reader is ideal for a multi-user environment and provides uncompromised performance, usability and sensitivity.
Liquid Scintillation Counting: Our Liquid scintillation counters, Hidex 300SL, Hidex 600SL, and Hidex ULLA are used for versatile applications including radiopharmaceutical production facilities for development and quality control of medical use isotopes, detection of impurities, contamination control with wipe tests, as well as activity standardization.
To learn more about our solutions, please book a meeting with our specialists and visit our booth # 76!

HOY Scandinavian ApS

Jacob Møllersgade 4
9560 Hadsund, Denmark

www.hoyscandinavian.dk

COMPANY PROFILE
HOY Scandinavian was founded in 1991 as a supplier and distributor for Nuclear Medicine and radiochemistry department in Scandinavia
The "HOY Exclusive" product range was launched in 2006. The head office is located in Hadsund Denmark, and all the HOY Exclusive product range are produced in Hadsund Denmark.
Today HOY Scandinavian is an international business that supplies products to nuclear medicine and oncology departments at hospitals and laboratories all over the world. We are known for supplying very highquality products and are now a market leader in many markets – particularly in Scandinavia and Europe.
Our home market is primarily Denmark and Sweden. We are represented in other markets by a distributor network. Products and activities
At HOY we develop and manufactures "Hoy Exclusive", an all-in-house product design - offering quality products for radiation protection in nuclear medicine and PET departments. The "HOY Exclusive" product portfolio has a modern timeless Scandinavian design, and offers maximum ergonomic comfort aligned to European standards.
Key products are: Vial glass Shields – Syringe Shielding – Syringe handling – Syringe Carrier and transports - Waste Containers – Tongs for Vials

Huahe Pharmaceutical Co., Ltd.

Room 432-1, Building 1, No. 1 Jinhe Road
nan Jiaxing, China

Huahe Pharmaceutical Co., Ltd. is a China-based radiopharmaceutical company specializing in the development and production of therapeutic and diagnostic radioisotopes. With internal supply chains of key isotopes including Lu-177, C-14, and Mo-99/Tc-99m, we provide integrated solutions covering GMP production, radiolabeling, and clinical translation services.

We operate an 8500 m² GMP-compliant facility equipped with automated radiolabeling lines and advanced quality control systems. Our infrastructure supports both early-phase clinical evaluation and commercial-scale manufacturing.

As the authorized domestic distributor of isotopes from Qinshan Nuclear Power Base, one of China's major nuclear power and isotope production centers, Huahe guarantees a stable and high-purity isotope supply for both therapeutic and diagnostic applications.

Our mission is to empower global nuclear medicine innovation by delivering reliable, scalable, and high-quality isotope solutions to partners worldwide.

IBA

Chemin du Cyclotron 3
1348 Louvain la Neuve, Belgium

www.iba-radiopharmasolutions.com/

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals, and dosimetry. The company is based in Louvain-la-Neuve, Belgium and employs approximately 2000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

ICPO Foundation

Humboldtstrasse 29
65189 Wiesbaden, Germany

www.icpo.foundation

The International Centers for Precision Oncology Foundation (ICPO) is a non-profit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO Foundation is helping to build momentum to scale global patient access to Radiomolecular Precision Oncology to support this shift.

Therefore, the ICPO Foundation aims to develop an international network of physical diagnostic and therapeutic Centers for Precision Oncology organized in a Social Franchise model based on shared know-how, certified education with the ICPO Academy for Theranostics, and design and process standardization that enables best clinical practice globally.

Furthermore, it is the ICPO Foundation's objective to empower its Centers by embedding them in a highly inclusive Community that spearheads its model and lives up to the Precision Oncology promise by making it available to all patients in need, irrespective of country or social status. Virtual: November 14 & 15, 2024

Register for our ICPO THERANOSTICS VIRTUAL SUMMIT 2024

Join our world-class scientific program with 30+ invited experts from academia and industry in the field of theranostics in precision oncology. The first day will be dedicated to alpha therapies and the second day to new radiopharmaceuticals, FAP and beyond. Our objective will be to sketch together the contours of a new era in cancer care, ultimately benefiting patients around the globe. Please register here: www.icpovirtualsummit.com

Germany, Munich, May 15 & 16, 2025

ICPO FORUM 2025 in the Science Center in Garching by Munich Talks and panels with leading specialists and partners from academia, industry and non-profit organizations, topped with exclusive networking opportunities. Please pre-register here: <https://www.icpo.foundation/icpo-forum-summit/>

Institute of Isotopes Co. Ltd.

Konkoly-Thege Miklós u. 29-33.
1121 Budapest, Hungary

www.izotop.hu

Institute of Isotopes Co. Ltd. is on the frontline of radioisotope technology collaborating with long-term partners and customers. Over the years we have developed numerous products from diagnostic kits to radioactive sources for various radioactive applications. Our company provides varied and flexible services in this unique field. Our production complies with the highest quality standards: GMP, ISO9001, ISO13485, ISO14001 We are also engaged in product development projects and offer contract manufacturing, OEM services for our customers.

Izotop looking forward to new products to widen our portfolio.

Fields of expertise: Radiopharmaceuticals, radiochemicals, Immunoassay / In vitro products for human diagnosis and life science, Synthesis / Radiosynthesis, Radiation technique

Main products, services: Thyrotop I-131 sodium iodide hard capsules, I-131 sodium iodide sterile solution, I-131 MIBG injection for therapy and for diagnostic use, Radiochemicals /I-125, I-131/, Cold kits for Tc-99m-labelling: DMSA, DTPA, PYRON, FYTON, MDP, TECHIDA, EC, Sm-153-labelling MULTIBONE kit

Ready to take part in R&D and manufacturing of active pharmaceutical ingredients, cold kits as well as investigational products for clinical trials.

In Vitro diagnostics (RIA, IRMA), Research Immunoassay kits;

C-14 radiolabeled drug substances, GMP custom radiosynthesis;

Radiation technique solutions for medical, research and industrial applications, Multipurpose irradiators

Inter Medical Medizintechnik GmbH

Daimlerstr. 34-36
32312 Lübbecke, Germany

www.intmed.de

The Inter Medical Medizintechnik GmbH Company is specialized in medicine software and hardware with the focal point in Nuclear Medicine technique. Long time experience in product innovations, development and production of Nuclear systems makes Inter Medical to a competent partner for all technical requirements in the Nuclear Medicine and other medical departments.

Are you looking for a special camera or software for heart and brain examinations? With the MultiCam 3000 and our in-house software such as AutoCardio 4D, 3D rendering and the 3D neurological brain evaluation package, we offer what you are looking for. Would you like to evaluate interdisciplinary data? With the Multimodality Fusion software, you can use data from different systems such as ultrasound, PET, MR. We offer the possibility of merging and evaluating data from different manufacturers.

Visit our booth to see how we can enhance your institute with our product portfolio of 1-2-3-n Head Gamma Cameras, partly with MDR Certification.

INVIA Medical Imaging Solutions

3025 Boardwalk Drive, Suite 200
48108 Ann Arbor, United States of America

www.inviasolutions.com

Built on decades of peer-reviewed research and clinical validation, clinicians use our advanced imaging tools for perfusion, function, viability, and flow analysis. 4DM integrates seamlessly with leading imaging systems and supports all major tracers. Originally developed at the University of Michigan, 4DM was designed with one goal: to improve patient care. Today, it's the application of choice for nuclear cardiac imaging for many major hospitals, academic medical centers, and cardiology practices worldwide. Start a conversation about how we can support your nuclear cardiology imaging needs at conferences@INVIAolutions.com

inviscan imaging systems

5 Rue Georges Guynemer
67120 Altorf (near Strasbourg), France

www.inviscan.fr

Inviscan imaging systems is a high technology company located in France. inviscan develops and manufactures preclinical imaging systems used in medical research. Products of inviscan include PET/CT and CT systems for imaging rodents and larger animals (NHP), as well as novel MRI compatible PET technology. Inviscan is the original manufacturer of IRIS PET/CT systems and is the leading provider of preclinical PET/CT systems in a number of countries such as France and China. The systems are fully developed by inviscan and manufactured in France. Inviscan is a highly innovative company with several R&D programs on new technologies and applications. Inviscan is partner in several projects with high profile institutions including CNRS, INSERM, Helmholtz Institute in Germany, as well as CNR and University of Pisa in Italy.

lotron Medical Inc

55 Madison Ave.Ste. 400 New Jersey
07960 Morristown, United States of America

www.iotronmedical.com

As the first commercial supplier of Copper-67, lotron Medical is committed to quality, quantity, reliability and support. It is our mission to optimize the quality and accessibility of Copper-67 for the radiopharmaceutical community.

Copper-67 is a proven and effective radioisotope for theranostic cancer treatment, particularly when paired with the imaging isotopes Copper-64 or Copper-61. This “perfect pairing” of identical elements delivers key advantages, including:

- Identical in-vivo distribution and behavior - for imaging and therapy
- Patient dose optimization - for personalized medicine
- Optimum half-life for small therapeutics - for dose delivery optimization
- Convenient off-site central manufacturing - for minimal treatment site investment
- No reliance on nuclear reactors for production - for safety and scalability

lotron Medical is now supplying Copper-67 to the US, Canada, and Europe, facilitating the development of next generation theranostic treatments. Stop by our booth (Nr 93) at the 2025 EANM to learn more!

iPHASE Technologies

Unit 5/899 Wellington Rd
3178 Rowville, Australia

www.iphase.com.au

iPHASE technologies was created in 2003 and has grown into one of the world class leaders in manufacturing of high quality automated radiopharmaceutical equipment for radiolabelling of F-18, C-11, Ga-68, Lu-177, Zr-89, Cu64, I-124, PB-212 & Ac-225 compounds. iPHASE also provide cutting edge solution for QC, Dispensing solutions and specialise in developing custom PET & Nuclear Medicine automation solutions.

IRE ELiT

Avenue de l'Espérance, 1
B - 6220 Fleurus, Belgium

www.ire.eu/en/

IRE ELiT, the innovation subsidiary of the Institute for Radioelements, is a radiopharmaceutical company established in 2010. It focuses on developing radiopharmaceuticals for molecular imaging and targeted therapy. Its flagship product, the Ge-68/Ga-68 generator, is a simple and innovative PET imaging solution, primarily used for neuroendocrine tumors (NETs) and recurrent prostate cancer. IRE ELiT's Ge-68/Ga-68 generator is a simple and innovative solution inspired by the principles of Tc-99m generators. The generator eluate - a gallium chloride solution (Ga-68) - is used for in vitro radiolabeling of various radiopharmaceutical kits developed for positron emission tomography (PET) imaging. The generator is suitable for manual use as well as for automatic use with synthesis modules and is compatible with all synthesis modules available on the market. IRE ELiT's Ge-68/Ga-68 Generator is available worldwide through an extensive distributor network. The company holds Marketing Authorization in Europe and Canada, and a Drug Master File (DMF) is also available in the United States.

Isotopia Molecular Imaging

Alexander Yanai 39 Petach Tikva
4927735 Petach Tikva, Israel

isotopia-global.com/

Empowering Healthcare with Next-Generation Radiopharmaceuticals Isotopia empowers healthcare providers worldwide with advanced radiopharmaceutical solutions, combining scientific excellence and hands-on operational expertise to accelerate cancer care and improve patient outcomes. About Isotopia Since 2007, Isotopia has been at the forefront of radiopharmaceutical innovation, specializing in the development, manufacturing, and commercialization of cutting-edge diagnostic and therapeutic products in nuclear medicine. Operating a Central Radiopharmacy, we use our own products in daily practice, gaining real-world insights and a deep understanding of our customers' needs. This unique perspective ensures our solutions are both innovative and practical for clinical use. What Sets Us Apart Proven Expertise: Over 15 years of experience in radiopharmaceuticals, with a robust track record of operational excellence. Global Reach: Manufacturing facilities in the EU and USA, meeting growing international demand. Regulatory Trust: Supply of 177-Lutetium under GMP conditions, supported by a comprehensive Drug Master File. Trusted Partnerships: Collaborations with leading hospitals, research centers, and participation in pivotal clinical trials.

ITEL Telecomunicazioni SRL

Via Antonio Labriola, snc
70037 Ruvo di Puglia, Italy

itelpharma.com/

Itelpharma is a dynamic and trusted radiopharmaceutical company, part of the Italian healthcare group ITEL Telecomunicazioni srl. Established as a GMP-certified pharmaceutical facility and authorized by the Italian Medicines Agency (AIFA), Itelpharma specializes in the production of high-quality radiopharmaceuticals for diagnostic imaging in oncology, neurology, and cardiology. With two state-of-the-art production lines operating in parallel, we ensure continuous and efficient output to meet the growing demand in precision diagnostics. Our facility also includes two cyclotrons and a fully integrated in-house microbiological laboratory, both designed and implemented entirely by our expert team. Recognized among the most reliable manufacturers and suppliers of radiopharmaceuticals, Itelpharma not only develops and markets its own products, but also partners with major pharmaceutical companies as a contract manufacturer and distributor. Over more than a decade of experience, we have steadily expanded our capabilities in manufacturing, research, and product development, refining our expertise across the scientific, regulatory, technical, and commercial domains. Driven by a commitment to quality and innovation, we operate in full compliance with the highest standards, continuously expanding our pipeline of molecular products and tailored services to support the evolving needs of modern healthcare.

ITM Isotope Technologies Munich SE

Walther von Dyck Strasse 4
85748 Garching, Germany

www.itm-radiopharma.com/home

Founded in 2004, ITM is a vertically integrated radiopharmaceutical biotech company dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM strives to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and global supply. ITM advances a broad precision oncology pipeline, including multiple Phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging two decades of pioneering radiopharmaceutical expertise, a central industry position, and an established global network, ITM aims to provide patients with more effective targeted treatments to improve clinical outcomes and quality of life.

Jiangsu Huayi Technology Co., Ltd.

18 Fuyu Road, Haiyu Town
215522 Changshu City, China

www.huayitec.net

"Jiangsu Huayi Technology Co., Ltd. is a fully integrated provider of radiopharmaceuticals in China. We develop, manufacture, and distribute high-quality radiopharmaceutical products. CDMO services are offered to our global clients. We support projects from initial research phase to commercial production. One of the divisions, Huayi Isotopes Co. (HIC), manufactures and distributes stable isotopes, PET and SPECT precursors, reagents kits, cassettes, and sterile vials etc. Products of HIC are supplied to clients around the world. We are client-oriented and determined to build and foster long-term partnerships with our clients. Since the company was established in 2001, we have been dedicated to serving the nuclear medicine industry. Since 2014, we have been setting up nuclear medicine manufacturing sites strategically. Our integrated radiopharmaceutical manufacturing and distribution network will enable us to reach most of the patients in China. Follow us on LinkedIn, Twitter, Facebook, for the latest newsProducts and Services•Radiopharmaceuticals• CDMO Services for Radiopharmaceuticals• O-18 Water• T o t a l Solutions for PET Consumables• Biochemicals• Sterile Vials• CMO Services (API, Reagents Kit & Cassettes, FIII/Finish)"

Jubilant Radiopharma

790 Township Line Rd Suite 325, PA 19067
Yardley, United States of America

www.jubilantradiopharma.com

Jubilant Radiopharma is a global leader in radiopharmaceuticals, committed to delivering better clinical outcomes through strategic investment in our pipeline, infrastructure, and people. Our team is united by an uncompromising passion for advancing the utility and sustainability of nuclear medicine.

Kev Medical Imaging

Sokratous 3
11147 Galatsi, Greece

www.kevimaging.gr

KeV Medical Imaging is the proud manufacturer of QDOSE, an advanced dosimetry software designed for radiopharmaceutical dose management in nuclear medicine. With MDR approval, QDOSE ensures compliance with stringent regulatory standards while empowering healthcare providers worldwide, wherever MDR is required, reliable tools to optimize patient diagnostics and therapeutic outcomes. Primarily based in Greece, KeV Medical Imaging offers comprehensive sales, service, and support for nuclear medicine systems, including planning, system sales, technical support, and upgrades for near-zero downtime and optimal performance. Our 24/7 service model reflects our commitment to excellence, ensuring our clients' success by delivering tailored solutions to nuclear medicine departments in Greece and beyond the region.

LabLogic Systems Limited

Innovation House, 6 Europa View
S9 1XH Sheffield, United Kingdom

lablogic.com/

LabLogic has over 40 years' experience of designing and manufacturing instruments and software for PET and Nuclear Medicine applications. At EANM'25 we will be showcasing our range of market leading products for Radiopharmacy QC, including r-TLC and r-HPLC instruments, plus our single point of control radiochromatography software package – Laura Radiopharma. Furthermore we offer dedicated LIMS systems for PET and Nuclear medicine applications. PETra, a PET LIMS system designed to improve efficiency and compliance, SPECTra, a dedicated Radiopharmacy LIMS, and Orla, an online radiopharmaceutical order communication system. Visit our stand #64 at the show to see demonstrations of these and other products in our nuclear medicine range.

Lemer Pax

72 rue de Lorraine ZA Erdre Active - Malabry BP
54201
44242 La Chapelle-sur-Erdre, France

www.lemerpax.com/en/

With over 50 years of innovation, Lemer Pax is a worldwide leader in innovation in the radiation protection sector. It creates, designs, and engineers efficient radiation protection solutions for medical, research, industry, and nuclear applications with eco-aware and cutting-edge of technology radiation protection products. Over the years, Lemer Pax has built up a solid reputation in terms of safety, ergonomics, and reliability with its wide range of solutions, such as shielded hot cells for nuclear medicine and radiopharmaceutical industry or shielded radiopharmaceutical injection and preparation units. We have become a provider of global solutions that bring together all the expertise along the entire value chain of a nuclear facility when it comes to radiation protection. From the production of the radionuclide to the management of your radioactive waste and contamination, Lemer Pax provide its expertise throughout the entire life cycle of a radionuclide to protect what is most important: life !

Life Couriers

Alois-Wolfmüller-Straße 8
80939 Munich, Germany

lifecouriers.com/

Life-saving therapies. Critical diagnostics. Breakthrough clinical trials. Life Couriers places hope in the hands of patients everywhere by being the world's most trusted logistics partner for crucial pharmaceutical and medical products. The worldwide market leader for radiopharmaceutical and stem cell logistics. We understand a fundamental reality - that missing a delivery can mean losing a life. Biopharmaceuticals, cell and gene therapies, lab specimens, clinical trials, organ transplant, medical devices and more. We are Life Couriers - Logistics for Life.

Life Molecular Imaging Ltd.

25 Barnes Wallis Road
PO15 5TT Fareham, Hampshire, United Kingdom

life-mi.com/

Life Molecular Imaging Ltd., together with its affiliates in Germany and the US (LMI) is a radiopharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. To learn more about LMI, please visit <https://life-mi.com>. LMI, a member of the Life Healthcare group of companies, is being acquired by Lantheus Holdings, Inc. For more information, please visit: <https://life-mi.com/>

Longevious Beamtech Co.Ltd

No.120 Wen Wu Road, Economic Development
Zone 621000 Mianyang, China

www.long-beam.com

Longevious Beamtech Co.,Ltd is China's leading company in the research and development of medical cyclotrons. It provides comprehensive solutions that include multi-energy level medical cyclotrons, drug synthesis and dispensing modules, and full-chain positron drug preparation centers. We focus on the development of high-end nuclear medicine equipment. Our quality management system has passed ISO13485:2016. Our products are CE marked and are compliant with ISO9001:2015, ISO45001:2018, and ISO14001:2015. Longevious Beamtech provides reliable, flexible, and high-ROI cyclotron products and services to clients from more than 40 countries worldwide.

LYLA B.V.

Molengraaffsingel 12
2629 JD Delft, Netherlands

lyla.systems/

Quality control in Targeted Radionuclide Therapy (TRT) lacks critical and time-constrained insights, risking treatment outcomes. LYLA solves this incomplete quality control with a novel measurement method! This approach provides an extra layer of information to ensure cancer therapies are safer and more effective. The result: fast, efficient, and user-friendly quality control that integrates seamlessly into routine TRT workflows. Care about quality in your process? Visit our booth and get in touch!

Medi-Radiopharma Ltd.

Szamos u. 10-12.
2030 Érd, Hungary

www.mediradiopharma.com/

Medi-Radiopharma (MRP) has more than 25 years of experience in developing, manufacturing, and supplying radiopharmaceutical products to customers around the globe. Our purpose is to serve the healthcare and improve patient outcomes through a wide portfolio of high-quality products. MRP specializes in the production and supply of generic in-vivo kits for Tc99m labelling used in nuclear medicine. By potentially enabling accurate early diagnosis and treatment of cancer, as well as heart, brain and bone diseases, our world-class products – registered in more than 80 countries worldwide - empower our customers with effective treatment and proven patient outcomes. We are also involved in the development of therapeutic radiopharmaceuticals. MRP holds valid Manufacturer's Authorization, Certificate of GMP Compliance of a Manufacturer, Wholesale Distribution Authorization, Certificate of GDP Compliance of a Wholesaler Distributor, GLP and ISO Certificate and relevant authorization for the manufacture and wholesale distribution of radiopharmaceuticals.

Mediso Medical Imaging Systems

Laborc u. 3.
1037 Budapest, Hungary

mediso.com/

Mediso works in the field of medical imaging for 35 years with a profile of development, manufacturing, selling and servicing standalone and multi-modality imaging devices. With more than 1400 clinical and 350 preclinical systems in over 100 countries worldwide, Mediso is the only company offering molecular imaging systems for both clinical patient care and scientific research. Its clinical portfolio ranges from Gamma Cameras developed for routine examinations, through SPECT and SPECT/CT systems intended for general diagnostic use, to complex hybrid equipment uniquely integrating three modalities. The latest AnyScan® TRIO-TheraMAX SPECT/CT features extreme sensitivity with uncompromised PET-like image quality ensuring ultra-fast, quantitative, total-body scans in theranostic applications even at high energies. Its innovative preclinical products serve the highest level of molecular imaging needs. In addition to the market-leading nanoScan® PET/CT and SPECT/CT, Mediso also offers standalone MRI and integrated PET/MRI systems based on a cryogen-free magnet with 3T or 7T field strength and a PET insert for simultaneous PET/MRI imaging.

MEDraysintell

76 route de la Demi-lune, Les Collines de l'Arche,
Bâtiment OPERA E 92057 Paris - La Défense,
France

www.medraysintell.com/

MEDraysintell is a team of international experts, created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann, providing first-rate strategic intelligence in nuclear medicine, radiopharmaceutical, cyclotron, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, with over 4,900 pages of unrivalled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the utmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, the competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeatedly satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and university research laboratories. In 2024, MEDraysintell was integrated into NucAdvisor, which is a nuclear consulting company, a subsidiary of Soletanche Freyssinet (VINCI Group), established in France by a group of senior executives from across the nuclear research and industry. Following this acquisition, MEDraysintell has become the nuclear medicine brand of NucAdvisor.

MedTrace Pharma A/S

Agern Allé 5A
2970 Hørsholm, Denmark

medtracepharma.com

Striving to Make O-15 Water Clinically Available - MedTrace Pharma is a development stage radiopharmaceutical and device company with headquarters in Hoersholm, Denmark and Minneapolis, MN (US). We are committed to transforming cardiac diagnostics by making oxygen-15 water (O-15 H₂O) readily available for routine use in PET imaging. Our O-15 water and automated manufacturing technology is being investigated under a FDA approved Phase 3 clinical trial: the RAPID-WATER-FLOW study (NCT05134012), a multicenter, open-label investigation assessing the diagnostic potential of intravenously administered [15-O]-H₂O for identifying coronary artery disease during pharmacological stress and rest using PET imaging. The study is conducted under FDA IND #135360. We welcome collaboration and research inquiries, particularly from those exploring novel applications of O-15 water in diagnostic imaging. For more information, please contact our Chief Medical Officer, Dr. Nicholas Borys, at nicholas@medtracepharma.com. Brands: MedTrace Pharma, [15-O]-H₂O injection, O-15 Water, O-15 H₂O for diagnostic PET imaging, [O-15]-Water PET Myocardial Perfusion Imaging (MPI), novel PET imaging agent labeled with the radioisotope [15-O], aQuant quantitative imaging software, P3 System (MT-100)

MIAS Pharma

Suite 1, Stafford House, Strand Road,
Portmarnock
D13 WC83 Dublin, Ireland

miaspharma.com/

MIAS Pharma Ltd was set up in 2016 to enable pharma and bio-pharma companies to manufacture and import products into the EU / EEA in a compliant manner, at optimal cost, with no significant investment in licence application activities or office / personnel costs. The company focuses on helping small to medium pharma and bio-pharma companies that look to enter the EU market but do not have required Manufacturing and Importation licence or the quality/regulator expertise to comply with complex EU / UK regulations. It also supports CMOs, CROs, Packaging companies and Testing companies with QP solutions to take the burden off internal resources. MIAS Pharma delivers two main solutions:
1. A licensing framework to enable pharmaceutical importation and batch certification (required before each batch of a medicine can be made available in the EU/EEA marketplace)
2. Qualified Person (QP) services to oversee the release of investigational medicinal product for Clinical Trials and commercial product to the market. MIAS Pharma also provides the following services to help pharma companies grow their business:
- European Qualified Person (QP) services
- Regulatory compliance of manufacturing activities
- Regulatory compliance of Repackaging / Relabelling services
- Regulatory compliance of Shipment and Transportation activities
- Compliance with responsibilities as a Market Authorisation Holder (MAH)
MIAS operates in a hub and spoke model with a core group of MIAS employee being able to rely on a group of associated to flex up/down capacity depending on clients requirements.

MiE medical imaging electronics GmbH

Hauptstrasse 112
23845 Seth,
Germany

mie-scintron.com

MiE has been a trusted name in the market since 1981, with over 40 years of experience as a leading service provider and partner in the field of nuclear medicine. Based in Germany, we are an established manufacturer of gamma cameras and workstations, offering a comprehensive product portfolio that meets the diverse needs of our customers. In addition to our hardware, we also develop our own software solutions which are continuously updated to incorporate the latest advancements and ensure optimal performance for our clients. Our dense service network and long-standing partnerships highlight our commitment to quality and reliability, resulting in strong customer acceptance worldwide. In 2023, we expanded our solutions by partnering with United Imaging to offer digital PET/CT systems in the D-A-CH region, further reinforcing our position as a key player in the imaging industry. With extensive expertise in nuclear medicine and a proven track record, MiE remains dedicated to delivering exceptional service and cutting-edge technology to healthcare professionals around the globe.

MILabs	MIM Software, a GE HealthCare Company
Duwboot 7A 3991CD Houten, Netherlands	25800 Science Park Dr.Ste 180 44122 Cleveland, United States of America
www.milabs.com	www.mimsoftware.com

MILabs offers high-performance standalone and integrated SPECT, PET, CT, and Optical Imaging systems for preclinical molecular imaging and in vivo research. Our advanced multimodal imaging technology, featuring four-dimensional imaging capabilities, empowers researchers to enhance diagnostics and therapy development through complementary, data-rich, co-registered images. Each modality independently provides data surpassing any other standalone system.

Our mission is to make molecular imaging clear. Through continuous innovation and exceptional service, the MILabs team is committed to providing small details for big discoveries across various imaging research programs. With over 300 installed modules worldwide, our rapidly growing company partners with leading universities, hospitals, contract research organizations, and pharmaceutical companies.

Our systems have significantly contributed to developing new diagnostic solutions and therapies in various fields of biology and medicine, including metabolic disorders, oncology, cardiology, neurology, and more. Discover how our cutting-edge preclinical imaging technologies can accelerate your research discoveries at www.milabs.com

MIM Software, a GE HealthCare Company, makes vendor-neutral imaging software to standardize workflows in Theranostics, Molecular Imaging, Radiation Oncology, and more. Leading global healthcare organizations use MIM to simplify increasingly complex clinical scenarios and give patients more precise, personalized care.

Focus on improving patient care, not on managing multiple image platforms: MIM Molecular Imaging Solutions provide one vendor-neutral platform to help streamline data management, viewing, and advanced quantitation—regardless of camera vendor or imaging modality.

Seize opportunities and prepare for the future: MIM Theranostics Solutions aim to make the promise of precision with Theranostics attainable. Practical solutions for treatment decision-making, therapy response monitoring, dosimetry, and reporting can help clinics visualize the entire Theranostics pathway on a single, comprehensive software platform.

Find out more at www.mimsoftware.com.

Mindview - Oncovision	Minerva Imaging
Calle Jerónimo de Monsoriu, 92 bajo izq 46022 Valencia, Spain	Lyshøjvej 21 3650 Ølstykke, Denmark
oncovision.com	www.minervaimaging.com

MINDVIEW is the new business unit of Oncovision for personalized molecular brain imaging and care. Its first product, CAREMIBRAIN, ULTRA-HIGH RESOLUTION dedicated brain PET, perfected since 2017, has proven clinical outcomes in >600 PATIENTS at leading hospitals in Spain, Germany and the United States, and FDA APPROVAL (since 2023).

ADVANCED, ACCESSIBLE and AFFORDABLE, CareMiBrain is combining ultra-high resolution 1,5 mm, 10% sensitivity, powerful quantification / dynamic capabilities, award-winning patient experience, vastly reduced radiotracer dose and very short study time

Compact, light, energy-efficient, CareMiBrain is enabling access to the BEST brain PET that every person deserves, with unequalled productivity, ease of use, seamless multimodal integration, minimum initial / ongoing costs and turnkey options. Unprecedented screening, clinical diagnosis, therapy guidance, treatment results assessment, advanced neurological research and synergy imaging / tracer / therapy opportunities for EVERYONE, EVERYWHERE.

Minerva Imaging is an integrated CRO and CDMO specialised in targeted radionuclide therapies. The company focusses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best-in-industry fully integrated radiopharmaceutical research, drug development and manufacturing services.

Follow us on LinkedIn for the latest news updates or visit minervaimaging.com for more information.

MNT Healthcare Services Inc.

19 Mayıs Mah. Dr.Şevkey Bey Sk. No:5 Şişli /
Istanbul / Turkey
34360 Istanbul, Türkiye

www.mnt.com.tr

Since 1990, MNT has been providing professional nuclear medicine and radiation oncology solutions to healthcare organizations. Currently, MNT operates 63 centers in Turkey and 9 centers in Europe, offering specialized diagnostic and therapeutic services throughout all stages of nuclear medicine and radiation oncology. With a dynamic and innovative approach, MNT is recognized as one of the most experienced healthcare service providers in the field. Its services reach patients in numerous NM and RT Centers within universities, state hospitals, and private hospitals. MNT also directly caters to cancer patients through its own branded centers, Neolife. Neolife is rapidly expanding its global presence and establishing itself as a formidable international brand. MNT operates 6 Neolife centers in Romania, 1 center in Moldova, and 2 centers in Bulgaria. Additionally, MNT is actively pursuing further projects in Africa, the Balkans, the Middle East, and Central Asia. MNT adheres to the gold standards in medicine and leads in theragnostic applications. By utilizing cutting-edge technology, such as advanced imaging, molecular probes, and minimal radiation doses, MNT enables precise diagnosis and targeted therapies across its centers. MNT ensures the smooth and timely completion of turn-key projects by offering the following services:

- Project Design and Installation
- Equipment Investment and Maintenance
- Personnel Recruitment
- Radiation Safety and Training
- Project Management

Mortenon Smart Technology Co., Ltd

No. 35-202, Changjiang South Road, Xinwu
District, Wuxi City (Research and Production
Center)
214100 Wuxi City, Jiangsu Province, China

www.norroybiopharm.com/

Mortenon Smart is committed to providing global clients with comprehensive smart radiopharmaceutical solutions and technologies. As an integrated developer, manufacturer, and supplier, our core team possesses over 15 years of expertise in radiochemical process R&D and automated module development. We operate a 32,000-square-foot R&D and production base in Wuxi, Jiangsu Province, equipped with cutting-edge hardware and software facilities. With full-stack R&D and manufacturing capabilities, we have achieved commercial deployment of multiple automated radiopharmaceutical equipment systems across diverse client sectors. By pioneering Industry 4.0-compliant automated nuclide/drug synthesis systems, modern production lines, and smart radiopharmacies, we drive end-to-end intelligent, automated, and unmanned transformations throughout the radiopharmaceutical lifecycle. This innovation empowers new quality productive forces (global advanced manufacturing paradigms) and advances worldwide radiopharmaceutical Industry 4.0.

MR Solutions Ltd.

Ashbourne House Old Portsmouth Road
GU3 1LR Guildford,
United Kingdom

mrsolutions.com

MR SOLUTIONS GROUP is a global leader in advanced imaging solutions, offering a comprehensive range of MR, CT, PET, and SPECT products. All scanners are modular, allowing seamless integration for multi-modality imaging. The company leads in high-field, cryogen-free MR technology, powered by its proprietary dry magnet systems. The MRS*DRYMAG line provides MR up to 9.4T with a bore size up to 42 cm. Unique features include variable, rampable field and a rotating capability. The dry magnet technology eliminates the need for helium lines or shielded rooms, minimizing installation costs. MR SOLUTIONS' imaging solutions support up to 9.4T simultaneous PET/MR imaging. SPECT can be combined with PET/MR to create a tri-modality scanner for advanced theranostic applications. With our CLIP-ON technology, PET and SPECT scanners can be easily removed from MR systems and reattached to CT systems, conserving space and reducing the need for multiple scanners. Models are available in benchtop, high-resolution, and large-bore sizes for up to 12 kg animals. Additionally, MR SOLUTIONS can refurbish and upgrade components on any MR system. The company has received numerous awards, including the prestigious Queen's Awards, the Institute of Physics Innovation Award, and the global R&D 100 Award. MR SOLUTIONS has a worldwide presence with offices and support staff to serve its customers globally.

National PET Imaging Platform (NPIP)

Block 35, Alderley Park
SK10 4TG Macclesfield, Cheshire,
United Kingdom

npip.org.uk/

The National PET Imaging Platform (NPIP) is the UK's first-of-its-kind national total-body PET imaging platform for drug discovery. It is funded by a £32m investment from the UKRI Infrastructure Fund and managed through a partnership between Medicines Discovery Catapult, the Medical Research Council, and Innovate UK. NPIP brings together cutting-edge imaging infrastructure and clinical intelligence to provide a more complete picture of patients and how they respond to novel drugs and treatments, and connects insights from research programmes and trials. Its next-generation total-body PET imaging scanners, located in London and Scotland, provide superior functional imaging, capturing highly sensitive imaging data of the entire body. The national platform connects projects to build a rich bank of data for improved sharing and knowledge transfer, helping academics, industry and clinicians to improve their studies. By encouraging greater collaboration across the clinical research community, NPIP is unlocking more opportunities for drug discovery and development. NPIP provides the unique opportunity to transform medical research, improve the quality and speed of drug discovery, and benefit patients now and in the long term. For more information about NPIP, please visit www.npip.org.uk.

NorthStar Medical Radioisotopes, LLC

1800 Gateway Blvd.
53511 Beloit, WI, United States of America

www.northstarm.com/

NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer and other serious diseases. NorthStar's expanding industry-leading position in the emerging field of radiopharmaceutical therapy is supported by its unique capabilities in the sophisticated production of radioisotopes, proven management team, and state-of-the-art, environmentally preferable technologies. NorthStar produces copper-67 (Cu-67) and is poised to be one of the first commercial-scale producers of non-carrier added actinium-225 (n.c.a. Ac-225). The Company's Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. For more information about NorthStar's comprehensive portfolio and patient-focused services. Visit: www.northstarm.com.

Novartis Pharma AG

Forum 1, Novartis Campus
CH-4056 Basel, Switzerland

www.novartis.com/

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

NRG PALLAS | Nuclear. For Life.

Westerduinweg 3
1755 LE Petten, Netherlands

www.nrgpallas.com/medical-isotope-solutions

BOOMING NUCLEAR MEDICINE MARKET
The field of nuclear medicine is undergoing a revolution. With promising treatments emerging for a wide range of indications, and a robust clinical pipeline filled with new therapies, the market is attracting increasing interest from big pharma. Startups and academic spin-outs are driving innovation, offering fertile ground for partnerships and growth. At first glance, the opportunities seem boundless.

COMPLEX IN PRACTISE
But entering and scaling up in this market is far from straightforward. Behind the scenes, companies face a complex reality. We hear it almost daily: despite the promise, many players struggle to meet their timelines. Operational hurdles mount. Growth slows. To succeed, companies must navigate a maze of challenges:

- Scaling up production while managing radioactive waste
- Securing critical target materials, often through recycling
- Building resilient supply chains with multi-sourcing strategies
- Operating and maintaining a global fleet of specialised containers for radioactive shipments
- Managing radiation safety and licensing

These are not minor obstacles — they are make-or-break factors. Even established global players have recently exited the market, unable to overcome the operational and logistical demands. The promise of nuclear medicine is real, but so are the risks.

SOLUTION WITH LONG TERM PARTNERSHIP
That's where NRG PALLAS comes in. We've made medical isotopes our top priority, forging long-term, strategic collaborations with key partners. Our unique infrastructure is designed to deliver predictable, high-quality, end-to-end supply of radioisotopes and radiochemical precursors — so our customers can focus on what they do best: developing life-saving therapies.

Nuclear Medicine Europe

Avenue Louise 65
1050 Brussels, Belgium

nuclearmedicineeurope.eu/

Nuclear Medicine Europe (ex AIPES) represents many of the major pharmaceutical & Imaging equipment companies in the field of Nuclear Medicine in Europe. The combination of radiopharmaceuticals & state-of-the-art imaging permits noninvasive visualization of organs, function & structure within the body. Nuclear medicine is used in the diagnosis, management, treatment & prognosis of diseases across a broad range of medical specialties, such as oncology, cardiovascular & neurology to name a few, and as such is an integral part of patient care.

Nuclear Shields B.V.

Akkervoortweg 29
5827 AP Vortum-Mullem, Netherlands

www.nuclear-shields.com

Nuclear Shields BV
Welcome to Nuclear Shields BV, a leader in radiation protection and nuclear safety. Our mission is to safeguard people and the environment from radiation hazards through innovative solutions and superior customer service.
Our Expertise
We design, manufacture, and install radiation shielding products for:
Healthcare: Protecting patients & personnel and professionals during medical procedures.
Nuclear Power: Enhancing safety in nuclear power plants.
Industrial Applications: Providing customized shielding for industrial uses.
Research and Education: Equipping labs and institutions for safe scientific work.
Innovation and Service
Our experienced team continuously improves our products, staying at the forefront of radiation protection technology. We prioritize long-term client relationships, offering personalized solutions and exceptional support.
Contact Us
Learn more about how Nuclear Shields BV can enhance your radiation safety. Contact us today for top-tier protection solutions.

NUVIA Instruments GmbH

Dornblüthstrasse 14 A
01277 Dresden, Germany

www.nuviatech-healthcare.com

NUVIA Instruments GmbH, formerly known as MED Nuklear-Medizintechnik Dresden GmbH is a member of the NUVIA Group since 2014. With 2 sites in Dresden and Dülmen, NUVIA Instruments GmbH designs and manufactures laboratory counters and radiation monitoring systems for nuclear medicine, PET-centres and therapy stations, including:
- Dose Calibrators, Well-Counters
- Thyroid Uptake-Counters, Incorporation Counters,
- Waste Water Counters (single and inline)
- Patient and Area Monitoring Systems
- Contamination Monitors (portable and hand-foot)
- Waste and Release Monitors
- Laboratory Furniture (standard and customized)
- Service, maintenance and training

About the NUVIA Group:
NUVIA is the nuclear branch of Soletanche Freyssinet, a subsidiary of Vinci Construction Group. Even though the NUVIA name was created in 2007, its history goes back to the beginning of the French and British nuclear industry. Today, with more than 30 years of experience and approx. 3,000 employees worldwide, the NUVIA Group offers engineering, services and products at all stages of a nuclear facility's lifecycle: design, construction, operations, maintenance, decommissioning. The NUVIATECH HEALTHCARE brand was created in 2017 to offer the Group's complete portfolio of instruments, systems and solutions for healthcare applications.
For more information about the NUVIA Group and its activities in the healthcare sector, please visit www.nuviatech-healthcare.com.

ONCIDIUM FOUNDATION

av. Herrmann-Debroux, 40
B - 1160 Brussels, Belgium

www.oncidiumfoundation.org/

The Oncidium foundation is dedicated to support the development of radiotheranostics (RLT) for cancer care. 3 pillars :ACCESS through a wide network of ambassador experts and a worldwide map of therapy centers. EDUCATION & awareness are essential as it helps to bring a better understanding of the functioning & benefits of RLT.HOPE – The foundation is evaluating all possibilities to support clinical developments of efficient RLT & individual cases to reduce treatment overall costs in low-income countries. Come and meet us !

OncoBeta GmbH

Schleißheimer Str. 91
85748 Garching bei München, Germany

www.oncobeta.com

OncoBeta® GmbH with its headquarters located in Garching, near Munich, is a privately held medical device and radiochemical company specialized in the development and commercialization of state-of-the-art, innovative skin cancer therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapyRhenium-SCT®(SkinCancerTherapy),targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified, TGA-Australia approved and certified by SAPHRA – South Africa. Furthermore, having the patient in focus,OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT® significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.

ONCODESIGN SERVICES

20 rue Jean Mazen
21000 Dijon, France

www.oncodesign-services.com

Oncodesign Services partners with biotech and biopharma companies to support the drug development journey from early discovery through preclinical candidate selection. We offer state-of-the-art pharmaco-imaging services and a robust preclinical research infrastructure, with particular expertise in Oncology, Immuno-oncology, and Inflammatory diseases. Our services also include comprehensive support for the development of novel radiopharmaceuticals and the repositioning of oncology candidates into molecular radiotherapy programs. This is backed by over a decade of experience in molecular radiotherapy and a secured radionuclide supply chain. Our flexible business models and nimble project execution allow us to deliver high-quality research efficiently, driven by a core commitment to scientific excellence. With extensive experience collaborating with big pharma, biotech, public research institutions, and investment groups, we are dedicated to advancing the development of innovative therapeutic agents.

OncoSil Medical

Level 5, 7 Eden Park Drive Macquarie Park NSW
2113 Sydney, Australia

www.oncosil.com

OncoSil Medical is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilising the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in combination with chemotherapy. OncoSil™ is our brachytherapy device. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs. We believe in our technology and its ability to have a truly positive impact in Oncology.

Optimized Radiochemical Applications

Rue de la Salette 15
5600 Neuville, Belgium

www.oraneptis.com

With over 20+ years of experience, ORA has been at the forefront of the radiopharmaceutical industry providing multi-purpose radiochemistry synthesizers to a global community of academic and commercial institutions. Whether you are looking to double or quadruple your FDG tracer production and have unmatched synthesizers in your radiochemistry lab, look no further than NEPTIS®. ORA's proven expertise in the radiopharmaceutical field, paired with the NEPTIS® open platform and its extensive regulatory documentation make it possible to maximize the production of PET tracers and advance the development of new pharmaceuticals to market. ORA is a ISO13485:2016 certified company, headquartered in Neuville, Belgium. To learn more about our radiochemistry synthesizers come visit us at Booth #E04. Evolve into NEPTIS®. Brands: NEPTIS® Perform. NEPTIS® RS. NEPTIS® LC. NEPTIS® DB. NEPTIS® NaF. NEPTIS® SP. NEPTIS® xSeed. NEPTIS® Designer. NEPTIS® Virtual Synthesizer. NEPTIS® Trending. Quality Control. Custom services. Categories: Accessories, Automated Synthesis Systems, Cyclotrons, Nuclear Medicine Workstations, Other, PET, PET/CT, PET/MR, Pharmaceuticals, Precursors and Reference Compounds, Radioisotopes, Radiopharmaceuticals, Services, Technetium Generators

Optimized Radiochemical Applications

Rue de la Salette 15
5600 Neuville, Belgium

www.oraneptis.com

PAIRE is a MedTech company specializing in artificial intelligence for nuclear medicine. Founded in 2021, it develops software as a medical device (SaMD) to assist nuclear physicians in diagnosis, focusing on PET-CT imaging at the moment. By combining medical expertise, cutting-edge deep learning, and seamless integration into clinical workflows, PAIRE delivers pragmatic solutions that save time, improve measurement accuracy, reduce diagnostic variability, and enable access to advanced quantitative biomarkers. With a strong focus on interoperability and user experience, PAIRE's results are fully integrated, vendor-neutral, and available in less than five minutes, helping meet the growing imaging workload while maintaining high clinical standards. The Product - Pionus Pionus is PAIRE's first commercial product: an AI-powered software for FDG PET-CT examinations that automatically detects, segments, and quantifies suspicious lesions. Built on one of the largest annotated PET-CT databases, it is trained on thousands of cases from multiple centers to ensure robust, representative performance across scanners, protocols, and patient profiles. In 2025, it has seen its scope extended with the integration of all PSMA tracers to its indication. Once PET-CT series are received, Pionus processes the data without manual intervention, outputs DICOM-compatible results such as secondary captures or RT-struct files, and sends them directly into the physician's usual viewer or PACS. It provides reproducible quantitative biomarkers including Total Metabolic Tumor Volume (TMTV), Total Lesion Glycolysis (TLG), Dmax, PROMISE Scores, SUVmax, and lesion volumes, bringing these advanced indicators into daily practice. Validated through extensive performance testing, Pionus achieves high sensitivity and strong correlation with expert measurements, helping nuclear medicine physicians work faster, more accurately, and with reduced variability — ultimately enabling better and more precise patient care.

PARS ISOTOPE

No. 88, West 23rd St., Azadegan Blvd., South
Sheikh Bahaie Ave. 1439955416 Tehran, Iran,
Islamic Republic of

www.parsisotope.com

Pars Isotope Co. is the only producer and supplier of radiopharmaceuticals and radiopharmaceutical kits in Iran and the leading one in the Middle East. Pars Isotope produces more than 50 different types of diagnostic and therapeutic products in the field of nuclear medicine. Based on the knowledge and experience of our specialists, we have succeeded in producing unique radiopharmaceuticals and introducing various solutions to international markets. Variety, extent and quality are the main features of our products. Among our valuable products, we can mention Tc-99m and Ga-68 generators, which are known under the brand names of PARS-TEC II and PARS-GalluGen, respectively. Also, the variety of our radiopharmaceutical kits reaches more than 20 different types. In order to improve the quality and quantity of medical products based on cGMP regulations, Pars Isotope participates in a project to implement new modern RRP, CKP and PET facilities in Iran. In addition, we focus on the following activities according to our profession and abilities:

- Production of more than 20 types of Tc-99m radiopharmaceutical kits.
- Production of 4 types of radionuclide generators to be used in PET & SPECT imaging.
- Production of new ready to use PET radiopharmaceuticals.
- Production of more than 22 ready to use theranostic, bone pain palliation and radio-synovectomy radiopharmaceuticals.
- Development and optimization of separation methods for different types of radioisotopes used in the production of radiopharmaceuticals.
- Development and optimization of advanced methodologies in the production of new radiopharmaceuticals.
- Production and development of industrial radioisotopes and radiation equipment used in various industries.

PBL Srl

Via Alessandro Volta, 8
43046 Rubbiano di Solignano, Italy

www.pbl.it/

PBL was born from an entrepreneurial investment started in 1979, when the first automation solutions for the beverage, chemical and pharmaceutical sectors were designed, built and installed. The experience gained in over 40 years of technological research has allowed PBL to consolidate its position in the markets of interest, gaining the trust of new customers around the world. PBL is investing in three main fields: PHARMA DIVISION We offer flexibility, innovation, technical expertise, and value on your investments for pharma, radio-pharma, and cosmetic custom solutions applied to primary and secondary packaging. CONSUMER DIVISION We design and supply filling and packaging lines for single-serve coffee pods. These lines can satisfy any client request and promptly react to the continuous market developments. HEALTHCARE DIVISION Our expertise in Artificial Intelligence and Deep Learning is offered to companies in need of dedicated industrial solutions based on innovative and efficient technologies.

Perceptive

55 Blue Sky Drive
01803 Burlington, United States of America

www.perceptive.com/

A next-generation quantitative imaging biomarker company focused on accelerating the discovery and development of life-changing medicines. With laboratories in the US, UK, India, Japan and China, Invicro is a global research partner to numerous pharmaceutical, biotech and contract research organizations, leveraging its platform to combine best-in-class expertise, imaging biomarkers, core lab services, analytics, and software. Its medical imaging capabilities are helping to achieve better patient outcomes in key therapeutic areas including oncology, central nervous system and respiratory, as well as meet the growing demand for enhanced imaging and new therapies in fast-growing specialties such as radiotherapy, gastroenterology, inflammation, fibrosis and mitochondrial imaging.

PHSE s.r.l.

Via del Lavoro
26817 San Martino in Strada, Italy

www.phse.com

PHSE is today one of the world's leading operators in temperature-controlled healthcare transport and distribution (from -180°C to +25°C), with a strong focus on hospital, homecare, and clinical laboratory channels. The company ships and handles high-value pharmaceuticals, clinical trials, biological samples, biopharmaceuticals, APIs, radiopharmaceuticals, and advanced therapy products (cell and gene therapies) via a solid and continuous cold chain by land, air, and sea. PHSE has distinguished itself in the logistics sector through its exclusive use of owned vehicles and personnel, as well as strong in-house Quality and IT competencies—ensuring a high level of service quality and operational reliability. The company also has its own subsidiaries in the USA, UK, India, Singapore, Brazil, Spain, and Germany, along with a global network of qualified agents, enabling full worldwide coverage.

PI Medical

Forellenweg 7
4941 SJ Raamsdonksveer, Netherlands

www.pi-medical.nl

PI Medical offers a wide range of instruments and accessories for the nuclear medicine market. The product range includes FDG dispensing systems, dose calibrators, contamination and radiation monitors, PET and SPECT phantoms, calibration sources and other QA devices, radiation shielding materials, Surgical equipment, Breast cancer localization products, patient positioning devices, etc. PI Medical is stands for high quality products and a high quality service. With our own Service department, all highly trained and educated, we can provide the best service, support and advice to our end users. Together with our partners, we can give you the best products and service for your needs. PI Medical Diagnostic Equipment B.V. – a Medical Imaging Specialist !

piCHEM Forschungs- und Entwicklungs GmbH

Parkring 3
8074 Raaba-Grambach, Austria

www.pichem.at

Having more than three decades of experience piCHEM is a reliable partner for the manufacturing of synthetic peptides and peptide related molecules. The company is privately owned and located in Austria. piCHEM provides peptides and complex organic molecules for medical, biochemical and pharmaceutical research as well as full GMP service for peptides used as active pharmaceutical ingredients (APIs). In addition to basic research and pharmaceutical development piCHEM offers a wide range of value-added services including process scale-up, process validation, analytical services, stability studies and regulatory support.

PMB-ALCEN

CD 56, Route des Michels, Lieu-dit "La Corneirelle"
13790 Peynier, France

www.pmb-alcen.com/

PMB-ALCEN is a French company specialized in advanced technologies for nuclear medicine. It designs and manufactures high-precision equipment for radioisotope production and targeted cancer therapies, supporting innovation in both diagnostics and treatment.

POLATOM - National Centre for Nuclear Research, Radioisotope Center POLATOM

Andrzej Soltana 7
05-400 Otwock, Poland

www.polatom.pl

National Centre for Nuclear Research, Radioisotope Center POLATOM is a Polish producer and distributor of isotope preparations used in medicine, science, industry and environmental protection. It also conducts research and development works of an application nature and concern radiopharmacy, chemistry and nuclear technology as well as scientific disciplines such as radiochemistry, biochemistry, and immunology, resulting in development of our own products and technologies. Our offer for nuclear medicine includes: - ready-made radiopharmaceuticals, used in cancer therapy and in the treatment of benign thyroid diseases; - technetium scintigraphy kits used in oncological diagnostics, intended for imaging of: kidneys, liver, bile ducts, spleen, heart, bones; - labeling precursors; - radionuclide generators ^{99m}Tc; - accessories necessary in Departments of Nuclear Medicine; - as well as various GMP and GMP compliant products and components for medical research. NCBJ Radioisotope Center POLATOM holds the ISO 9001:2015 Quality System Certificate and the Internal Control System for trade in dual-use goods, as well as a Certificate confirming compliance with the GMP requirements. Moreover, in our Radioactivity Standards Laboratory, a management system compliant with the international standard ISO/IEC 17025:2018 has been implemented and maintained. Our RSL's technical competence – as a calibration laboratory – is confirmed by the accreditation certificate AP 120 granted by the Polish Center for Accreditation.

Positrigo AG

Technoparkstrasse 1
8005 Zurich, Switzerland

www.positrigo.com

Positrigo is a pioneer in nuclear medical imaging technologies. Headquartered in Switzerland, the medical device company was founded in 2018. NeuroLF® - the company's first device - is an ultra-compact brain PET scanner which has applications in assessment of causes of dementias, such as Alzheimer's disease and other brain related disorders.

PSI CRO

Baarerstrasse 113a
6300 Zug, Switzerland

www.psi-cro.com

PSI is the leading pivotal-stage radiopharmaceutical CRO, currently running over 40% of the industry's registrational nuclear medicine trials. We specialize in delivering complex diagnostic and theragnostic trials across diverse geographies with precision and reliability. Our strength lies in seamlessly coordinating multidisciplinary site teams, ensuring regulatory and logistical readiness, specialized site support, and developing tailored recruitment strategies to meet the unique demands of radiopharmaceutical research. With deep expertise, unwavering focus, and dedicated RLT teams around the world, PSI successfully supports sponsors embarking on registrational radiopharm trials globally. In 2025, PSI is celebrating its 30th year of business as the only fully independent and privately owned mid-sized CRO. PSI employs over 3,000 people across 56 countries as of December 31, 2024. Global headquarters are in Switzerland at Baarerstrasse 113a, 6300 Zug. For more information, visit www.psi-cro.com.

R2PHARMA

6681 Ipiranga Avenue – TECNOPUC - Building 93,
Office 201
90619-900 Porto Alegre, Brazil

www.r2pharma.com/

R2PHARMA was established through the merger of two leading players in the sector — the RPH Group and the R2IBF Group — representing a significant milestone in the advancement of healthcare in Brazil, particularly in the field of Nuclear Medicine. This union reflects a shared commitment to excellence, innovation, and ethical responsibility, combining strong values and complementary expertise. Together, these forces strengthen our mission to transform access to cutting-edge diagnostic and therapeutic solutions. With a strong focus on innovation and patient-centered care, R2PHARMA ensures that the latest technologies are rapidly and responsibly brought to market. The company is the leading supplier of cold kits in Brazil, operating a GMP-certified manufacturing facility, two Nuclear Pharmacies, and five cyclotrons strategically located across the country. R2PHARMA is also actively expanding its international presence, already exporting cold kits to approximately 15 countries. With a commitment to regulatory compliance, quality, and long-term partnerships, the company continues to grow its global reach and contribute to the advancement of Nuclear Medicine worldwide.

Radqual

4137 Commerce Circle
83401 Idaho Falls, United States of America

Radqual.com

RadQual - Calibrated for Quality. RadQual develops, manufactures, and distributes innovative quality control, calibration, and reference products for the nuclear medicine, radiopharmacies, and radioisotope industries. Our products are manufactured in Idaho Falls, Idaho, USA, and distributed globally by our OEM partners and distributors network. RadQual products are NIST traceable and made with pride to ensure we always live up to our Calibrated for Quality ethos. RadQual is a part of the International Isotopes, Inc. (OTCQB: INIS) family of brands; which also includes Radnostix, RadVent, EasyFill, and PhanQual product lines. To learn more, visit www.radqual.com

RayXpert

907 l'Occitane
31670 Labège, France

www.rayxpert.com/

Our company, TRAD Tests and Radiations, develops and markets RayXpert, a 3D modeling and dose calculation software based on the Monte Carlo method.

For which applications?

- Designing shielding for electronic components, equipment, and buildings to ensure operator radiation protection and guarantee the lifespan of equipment
- Conducting workstation studies and radiation zoning assessments for regulatory submissions
- Simulating and optimizing industrial processes using gamma sources, X-ray and electron generators (e.g., sterilization, non-destructive testing, cross-linking, etc.)
- Anticipating storage and transport constraints for radioactive sources
- Calculating doses deposited in materials and electronic components
- Developing measurement instruments

Rotem GmbH

Franz-Flemming-Str. 39A
04179 Leipzig, Germany

rotem-medical.com

Rotem, a longtime global leader in consumables for PET imaging, supplies cyclotrons around the world with complete packages for radiotracer production. Our product range is centered on Oxygen-18 enriched water, plastic cassettes, precursors and complete reagent kits for various synthesis modules. All products are manufactured in compliance with cGMP requirements according to EU & PIC/S and are produced in our US FDA-inspected facility. Rotem's cGMP certified Mannose Triflate holds a certificate of suitability from the EDQM.

Production is supported by Rotem's in-house certified analytical laboratory which has a wide array of equipment and QC method development capabilities. Our highly skilled staff provides users with comprehensive technical and regulatory support as well as excellent customer service.

Rotem is particularly active in the design and production of consumables for radiotracers under development. These projects benefit from our interdisciplinary expertise, which is the result of many years of close collaboration with radiopharmaceutical companies worldwide. Furthermore, Rotem specializes in the development, production, and marketing of radiation detection and monitoring technology.

Rotem GmbH in Leipzig serves customers all over Europe.

ROTOP Pharmaka GmbH

Bautzner Landstraße 400
01328 Dresden, Germany

www.rotop-pharmaka.com

ROTOP has strong expertise in product development and application, as well as commercial cGMP production, including distribution. At our facility, we combine comprehensive know-how in pharmaceutical development, including regulatory affairs, cGMP manufacturing of APIs/ drug substance precursors and sterile drug products, and an independent quality unit with several Qualified Persons (QPs) to release drug products.

For more information about our products and CDMO services, visit us at booth 28 c to meet our experts.

We look forward to connecting with you in person!

RoweMed AG - Medical 4 Life

Juri-Gagarin-Ring 4
19370 Parchim, Germany

www.rowemed.de

RoweMed AG – Medical 4 Life is an innovative MedTech company. Our focus is on developing and producing customized single use systems for fluid transfer, especially handling of sensitive pharmaceuticals.

R&D: The development of systems is closely coordinated with the customer, from first sketch up to a market-ready product, including CAD construction, prototyping (3D printing), first series and product tests.

Production: We offer injection molding, assembling and packaging under one-roof. In our clean room production facility (ISO class 7) in Parchim our employees carry out single-part, small series and automated mass production. At the assembling department, all common welding and gluing technologies are implemented.

Regulatory Affairs: In addition to the technical services, we offer the complete technical documentation according to international regulations and customer requirements.

RQS Alexander Ruffani

Kantstrasse 15
01809 Heidenau, Germany

www.rqs-ar.com

RQS Alexander Ruffani was founded in 2017 and has years of experience in radiochemistry, radiopharmacy and analytical instrumentation. A growing team of experienced and motivated professionals with expertise in synthesis development, radiochemistry, GMP-compliant production processes and chromatography instrumentation will help you find the best possible solution for your work application. In 2020, RQS expanded to the USA and established Ruffani Quality Solutions, LLC. to provide timely and flexible local service. Our colleagues are specialized in the planning of production facilities as well as their construction, for this purpose they have been involved in several projects especially on the East Coast. The team is ready to support you with all your requests and is looking forward to get in contact with you. Thanks to deep experience in the various fields of nuclear medicine and radiochemistry, it is possible to offer a wide range of services of the highest quality. • Support in laboratory planning, construction and commissioning • Qualification, maintenance and repair of instruments for the production of (radio-)pharmaceuticals • GMP documentation for radiopharmacy for quality management system • Method development for various syntheses and quality control processes in radiopharmacy • Validation of methods in production and quality control

schneschu UG/Voximetry Inc.

8517 Excelsior Drive, Ste 207
53717 Madison, United States of America

www.voximetry.com

Fighting Cancer. Making it Personal. Realize the full potential of radiopharmaceutical therapy through more informed treatments guided by advanced dosimetry. Our pioneering approach moves beyond population-based models to provide unprecedented insight into patient-specific response to radiotherapeutics. Voximetry's Torch® Dose Assessment is the leader in accuracy and speed, offering the only GPU-accelerated, full Monte Carlo dose calculation to provide patient-specific dose assessment in seconds. Torch® demystifies complex dosimetry with a simple, 5-step workflow and comprehensive dose assessment tools. Our team of dosimetry experts provide unmatched customer support, delivering advanced dosimetry guidance with clinical, scientific and operational insight. Voximetry is committed to delivering uncompromised, personalized RPT through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Visit us to discover more and join the conversation to help redefine the standard of care. Let's talk. We're listening.

SCINTOMICS Molecular, Applied Theranostics Technologies GmbH

Lindach 4
82256 Fürstenfeldbruck, Germany

sci-att.com/

SCINTOMICS Molecular, Applied Theranostics Technologies (SCI-att), is a prominent and fast-growing player in the radiopharmaceutical industry. With a strategic focus on ensuring a consistent supply and comprehensive support for proprietary and innovative tracer technology and non-IP protected precursors, such as PSMA I&T and next-generation PSMA inhibitors like siPSMA-14 and SiFAlinTATE, SCI-att stands at the forefront of cutting-edge theranostics solutions. The GRP Module Series is an extremely capable and cost-efficient solution for the production of radiopharmaceuticals. We are dedicated to expanding our portfolio and providing our customers with an unparalleled array of products and services. Additionally, SCI-att offers proprietary cassettes and reagents for the production of F18, G68, and Lu177 tracers. With an extensive network of distributors and partners all over the world, SCI-att ensures broad accessibility and support for our cutting-edge solutions. At SCI-att, we pride ourselves on delivering top-notch quality and exceptional customer support. We invite you to visit us at booth 08, where our knowledgeable team will be delighted to share information about our latest and exciting projects.

SCK CEN

Boeretang 200
2400 MOL, Belgium

www.sckcen.be

70 years of experience in nuclear research and technology With more than 70 years of expertise in nuclear research and technology, SCK CEN is one of Belgium's largest research institutions. Every day, over 900 employees dedicate themselves to developing peaceful applications of radioactivity. Our research focuses on three core areas: innovative nuclear systems, nuclear waste management and dismantling, and the resolute fight against cancer. For decades, SCK CEN has played a key role in the global production of medical radioisotopes thanks to our research Belgian Reactor 2 (BR2). To accelerate progress in the fight against cancer, we are building on this leading role by taking the next step: actively conducting research on therapeutic radioisotopes. These radioisotopes are essential components of radiopharmaceuticals used for radioligand therapy (RLT), a cutting-edge approach to nuclear cancer treatment. These treatments use carrier molecules to deliver radioactive isotopes directly to tumours, precisely targeting and shrinking tumours while sparing healthy tissues. This approach reduces side effects and offers a more humane alternative to conventional cancer treatments. SCK CEN is evolving into a full-fledged radiopharmaceutical player, engaged in both pre-clinical research and pilot-scale production of new radiopharmaceuticals for cancer therapies. Our ambition is to help bring new radiopharmaceuticals to life. To that end, we have established our own dedicated cancer research programme, focusing on innovative treatments for three specific cancers: glioblastoma (brain cancer), colon cancer, and ovarian cancer. In addition to our internal research efforts, we also actively contribute to external research projects, fostering strong collaborations with partners worldwide. By integrating in-house expertise with external collaborations, SCK CEN aims to be a global leader not only in nuclear technology but also in the advancement of cancer treatment.

SHINE

3400 Innovation Court
53546 Janesville, United States of America

www.shinefusion.com

Headquartered in Janesville, Wisconsin, SHINE stands as an industry leader in next-generation nuclear fusion and separation technology. SHINE deploys innovative fusion and fusion-based technology that seamlessly combines safety, cost-efficiency, and environmental responsibility. Distinguished by its proprietary medical isotope production processes, SHINE is at the forefront of creating n.c.a. lutetium-177—a vital component in cutting-edge medical treatments. Anticipating further advancements, the company's forward-looking vision includes the creation of molybdenum-99, a diagnostic tool that plays a pivotal role in medical procedures aimed at detecting heart disease and cancer. SHINE's commitment to innovation extends beyond the realms of industry and healthcare. Drawing on its fusion-technology expertise, the company has set its sights on addressing one of energy's most complex challenges—nuclear waste recycling. With a comprehensive and visionary approach, SHINE is steadfastly driving advancements across multiple sectors, leaving an indelible mark on the domains of technology, healthcare, and sustainable energy solutions.

Siemens Healthineers

Siemensstr. 3
91301 Forchheim, Germany

www.siemens-healthineers.com/molecular-imaging

At Siemens Healthineers, we pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. As a market leader, we want to advance a world in which breakthroughs in healthcare create new possibilities with a minimal impact on our planet. We've been pushing the boundaries in medical technology for more than 125 years. By consistently bringing innovations to the market, we enable healthcare professionals to innovate personalized care, achieve operational excellence, and transform the system of care. With the unique combination of our strengths in patient twinning*, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the greatest challenges in healthcare. We will continue to build on these strengths to help overcome the world's most threatening diseases, enable efficient operations, and expand access to care. Our portfolio, spanning in vitro and in vivo diagnostics to image-guided therapy and cancer care, is crucial for clinical decision-making and treatment pathways. We are committed to improving healthcare access for all, limiting our environmental impact as we pioneer breakthroughs, and engaging our diverse Healthineers to achieve this impact on a global scale. Motivated by our purpose and guided by our values, we are building an inclusive culture, where we embrace diversity in all its forms. We are a team of 73,000 Healthineers in over 70 countries passionately pushing the boundaries of what is possible in healthcare to help improve the lives of people around the world. * Personalization of diagnosis, therapy selection and monitoring, aftercare, and managing health.

Sirtex Medical Europe GmbH

Joseph-Schumpeter-Allee 33
53227 Bonn, Germany

www.sirtex.com/eu/

Sirtex Medical is a global healthcare business with offices in the US, Australia, Germany and Singapore, working to improve outcomes in people with cancer. Sirtex' current lead product is SIR-Spheres® Y-90 resin microspheres, a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy. Sirtex also distributes EmboCept® S DSM 50 µm, Degradable Starch Microspheres (DSM) used as adjuvant in the intra-arterial treatment of inoperable liver tumours and lung tumours in combination with cytostatic agents. SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd. EmboCept® is a registered trademark of Magle PharmaCept GmbH.

Southern Scientific

United Kingdom

www.southernscientific.co.uk

Southern Scientific manufacture a range of probes and contamination monitors for medical applications. This includes the Care Wise C-Trak Galaxy Gamma Probe System. This system provides accurate and precise detection of gamma radiation and is used during sentinel node biopsies in breast, melanoma and other types of cancer. Our contamination monitor range includes the Radhound and Handhound. The Radhound monitor is available with a wide range of probes suitable for detecting Alpha, Gamma and Beta isotopes. The Handhound is a voice-activated hand monitor. All measurements are logged against a user and are easily exported for compliance purposes. Southern Scientific is also a distributor for Mirion Capintec, Hoy, LemerPax and Tracerco. We are actively looking for commercial partners in certain countries, so if you are interested, please visit our stand and speak to one of our team.

Special Cargo Services

Breguetlaan 9 1438BA Oude meer, Netherlands
www.specialcargo.com

Special Cargo Services – Experts in Radioactive Logistics

With over 25 years of experience, Special Cargo Services is a recognized authority and trusted knowledge partner for both government agencies and private companies. We specialize in the safe transport, documentation, packing, logistics, and storage of radioactive materials, always prioritizing quality and safety.

Our strength lies in transforming complex logistical challenges into clear answers and practical solutions. Whether your shipments are national or international, by air, road, or sea – we always go the extra mile. Partnering with Special Cargo Services means contributing to a safer logistics chain.

Our services include:

Safe Transportation: We adhere to the highest safety standards for transporting radioactive materials.

Regulatory Compliance: We ensure full compliance with all applicable international and local regulations.

Timely Deliveries: We guarantee prompt and reliable deliveries, critical for supporting essential medical treatments.

Customized Solutions: Our logistics services are tailored to meet the specific needs of the nuclear medicine sector and other specialized industries.

Education and Training: We provide comprehensive training in the safe handling and transportation of radioactive materials.

Choose Special Cargo Services – making the logistics world safer, one shipment at a time.

Spectrum Dynamics Medical

Rue de Lausanne 31 1110 Morges, Switzerland
spectrum-dynamics.com/

Spectrum Dynamics is spearheading the transformation of Nuclear Medicine from analog to digital technology, enabling clinicians to provide superior healthcare services with improved image quality and efficiency at lower doses.

Spectrum launched the world's first digital cardiac SPECT system: the D-SPECT® in 2007. It is the world's first digital cardiac SPECT system based on Broadview Technology: swiveling CZT digital detectors. It is the platform for advanced applications such as TruCorr Attenuation Correction, TruFlow 3D dynamic SPECT imaging for Myocardial Flow Reserve (MFR) analysis, Simultaneous Dual Isotope Imaging (SDI).

Spectrum's latest innovation is the VERITON-CT®. It is The world's first digital 360°CZT-based, ring-shaped gantry design SPECT/CT, with high-resolution 16 or 64 slice CT. It's 80cm wide bore accommodates patients of all sizes. VERITON features TruFlow 3D dynamic SPECT/CT imaging for SPECT MFR, bone, renal, and general studies. VERITON-CT continues to evolve with an energy range up to 400 KeV and multiple peak imaging, providing highest quality and quantitation-ready images.

Syntermed, Inc.

A333 Sandy Springs Circle, Suite 107, 30328 Atlanta, United States of America
www.syntermed.com

Syntermed, Inc. (Stand 73B), is a global leader in providing Cardiac, NeuroRadiology, and Oncology solutions. Syntermed solutions power over 50% of the nuclear medicine departments worldwide. Signature products include NeuroQ™ and Cardiac Toolbox™ (eCTB). We are introducing the next generation of NeuroQ -Version 4. Along with a brand new UI, NeuroQ V4 includes Centiloid calculations for Amyloid studies, significant enhancements for DaTscan, improved diagnostic output, and much more. NeuroQ is one of the most widely used solutions for quantifying NeuroRadiology studies. We will also introduce the VHRisk (Vall d'Hebron in Barcelona) extensions to eCTB's powerful Intelligent Decision Support (IDS), full support for Flyrcado, Longitudinal Strain, and more. Please visit Stand 73B to learn more. Syntermed products and services are available worldwide from leading OEMs, Distributors, and Value-added Resellers. For more information about Syntermed Innovation, please visit www.syntermed.com, or email info@syntermed.com

Synthra GmbH

Albert-Einstein-Ring 21 22761 Hamburg, Germany
www.synthra.com

Synthra is a worldwide leading and specialized manufacturer of branded radio synthesizers and concentrates over 40 years of experiences in the field of radiopharmaceutical production, quality control and lab automation. We are committed to automated production of molecular imaging tracers and continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET).

Our portfolio comprises C-11, F-18, N-13, Ga-68, Lu-177, I-123, I-124, I-131 and other radioisotopes. It includes radio synthesizers with self-cleaning systems, customized modules, quality control equipment, e.g. HPLC, spare parts and services.

Our radio synthesizers combine high performance and efficiency with high flexibility that enables the reliable production of radiopharmaceuticals. Moreover, our software and synthesizers are highly user-friendly and meet the latest GMP regulations.

We are happy to present our Synthra Photoreactor, which enables you to expand your Synthra labelling opportunities.

Meet us at our booth H41.

TAIYO NIPPON SANSO Corporation

Minato Mirai Grand Central Tower 7F, 4-6-2
Minatomirai, Nishi-ku
220-8561 Yokohama, Kanagawa, Japan

stableisotope.tn-sanso.co.jp/english/index.html

Water-18O Stable Supply with the World Largest Capacity

Two decades ago, TNSC developed a revolutionarily efficient process of oxygen isotope separation utilizing our cryogenic air separation technology and have been providing Water-18O as well as Oxygen-18O2 gas to the global market since 2004. Our products are highly valued for their highest quality in enrichment, chemical purity and consistency especially in the Positron Emission Tomography (PET) community. We possess the world's largest Water-18O capacity of 600kg/year for 98atom% .These three independent plants ensure the stable supply of quality 18O products to our global customers.

Tema Sinergie

via Malpighi, 120
48018 Faenza,
Italy

www.temasinergie.com

Tema Sinergie represents one of the most qualified companies worldwide in the production of systems for manipulation and dosage of radiopharmaceuticals used in Nuclear Medicine.

Over 30 years of experience, together with continuous research, have allowed to develop a complete range of products and services that represent, both in Italy and worldwide, a fundamental reference point for all professionals dealing with ionizing radiation: not only hospitals, but also research institutes, universities, industries, and so on.

Fom synthesis and dispensing hot cells, to dose drawing systems, radiopharmaceutical injectors, monitoring systems and much more, Tema Sinergie is the ideal partner for each and every application within Nuclear Medicine.

TerThera b.v.

Minervum 7070
4817ZK Breda, Netherlands

www.terthera.com

Therthera was founded in 2021, TerThera strives to meet the growing global demand for radionuclides in cancer healthcare by providing a highly sustainable and uninterrupted supply of Terbium-161 for use in radioligand therapy.

The scarcity of radionuclides for use in radioligand therapy impacts the lives of many cancer patients, with a secured stock of highly enriched gadolinium-160 our team promises to deliver therapeutic quantities of GMP-grade Terbium-161, expanding the options available for patient treatments.

Having resolved the scarcity of Terbium-161, we aim to enable Terbium-161 radioligand therapy by supporting academic partners, preclinical, and clinical research towards patient treatment, ultimately working towards understanding the underlying mechanisms of internal radiation therapy.

time:matters

Gutenbergstr. 6, 62362 Neu-Isenburg
63263 Neu-Isenburg, Germany

www.time-matters.com/

time:matters, a subsidiary of Lufthansa Cargo, is a specialist in providing reliable, time-critical logistics solutions for sensitive medical goods. We offer specialized solutions for one of the most demanding areas of logistics in the healthcare sector: radiopharmaceuticals

Our benefits at a glance:

- Patient-centered supply chain specifically for nuclear medicine
- Specialized processes and extensive experience in handling sensitive and regulated goods
- Fast handling of dangerous goods (DG check < 3 hours) at central hubs (Frankfurt & Munich)
- Direct delivery to the aircraft for maximum reliability during unloading
- 24/7 monitoring and proactive status communication for full transparency
- Cat. 7 trained staff in service and operations
- Own Courier Terminal at Frankfurt Airport for maximum control and flexibility for radiopharma shipments
- Individual backup solutions to minimize risk in the event of irregularities
- Unique airfreight setups with Lufthansa, United Airlines and LATAM Airlines

Responsibility meets precision

We understand that every transport in the radiopharmaceutical sector is critical - for doctors, clinics and, above all, for patients. time:matters stands for logistical safety, reliability and innovation in a highly sensitive medical environment.

Trasis	TrisKem International
Rue Gilles Magnée 90 4430 Ans, Belgium	3 rue des Champs Geons 35170 Bruz, France
www.trasis.com/en/	www.triskem-international.com/

At Trasis, we are dedicated to helping the medical community access new radio-labelled therapeutic and diagnostic substances easily and faster. We address the entire value chain of radiopharmaceuticals, from early development to production, quality control, dose preparation, and even injection.

To this end, we design, manufacture, sell and support high performance synthesizers (AllinOne, AllinOne mini, AllinOne S and EasyOne), radiopharmaceutical quality control instruments (QC1), sterility testing solution (Sterinow), dose preparation equipment (Unidose and Quickfill dispensers), their shielding and accessories. We also develop customized synthetic methods and instruments. As certified GMP Part I and Part II, we can provide GMP Active Pharmaceutical Ingredients (API) and support our customers with their regulatory affairs.

Our proven radiopharmaceutical expertise, coupled with our high-end instruments, allow us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorization.

Brands: AllinOne, Mini-AllinOne, AllinOne S and EasyOne chemistry synthesizers, Shielding Solutions: Unidose & Quickfill dispensers, QC1 for radiopharmaceutical Quality Control, and (radio) chemical Custom Development and manufacturing Services.

TrisKem International
3 rue des Champs Geons 35170 Bruz, France
www.triskem-international.com/

TrisKem International develops, manufactures and commercializes highly selective resins for the separation and quality control of radionuclides such as Lu-177, Tb-161, Ga-67/8, Zr-89, Cu-61/4/7, Ac-225, Ge-68, Ti-44/5, Sc-43/4/7, Pb-212 and many other radionuclides for use in nuclear medicine – in diagnosis as well as in therapy. Further to its range of resins TrisKem also develops and provides selective thin layer chromatography paper (i.e. DGA Sheets) for quality control of radionuclides and generator effluents (Ra-223, Ac-225, Pb-212, Ga-68,...) with respect to their radionuclidic purity, as well as for the control of presence of free radionuclides after labeling (i.e. CU Sheets). TrisKem's resins are increasingly finding use in the production of radionuclides for radiopharmacy and are employed by leading radionuclide manufacturers worldwide. Our R&D team is constantly working on the development of new resins and methods to help you with your separation needs. If you have a special separation need, need help with your method development, you are interested in participating in R&D projects or you are looking for a partner to commercialize a new technology you have developed, please do not hesitate to contact us!

U.S. Department of Energy Isotope Program	United Imaging Healthcare
1000 Independence Ave., S.W. 20585 Washington, D.C., United States of America	2258 Chengbei Rd., Jiading District 201807 Shanghai, China
isotopes.gov/	global.united-imaging.com/en/

The U.S. Department of Energy Isotope Program, within the Office of Science, supports the production, as well as the development of production techniques, of radioactive and stable isotopes that are in short supply. Isotopes are high-priority commodities of strategic importance for the Nation and are essential for energy, medical, and national security applications and for basic research. A goal of the program is to make critical isotopes more readily available to meet domestic needs.

The National Isotope Development Center (NIDC) is funded by the U.S. Department of Energy Isotope Program (DOE IP). It serves as an interface with the user community and manages the coordination of isotope production across the program facilities at Argonne, Brookhaven, Idaho, Los Alamos, Oak Ridge, and Pacific Northwest National Laboratories. These facilities produce stable and radioactive isotopes in short supply using reactors, accelerators, and other methods.

To learn more visit www.isotopes.gov

United Imaging Healthcare Technology Group Co., Ltd. (United Imaging Group) is a global leader in healthcare technology. With innovative solutions from prevention to diagnosis, treatment, and rehabilitation, United Imaging Group aims to build an intelligent healthcare ecosystem to benefit patients all over the world. Supported by the Central Research Institute and subsidiaries, United Imaging Group develops and produces a full portfolio of advanced medical imaging and radiotherapy equipment, life science instruments, medical robotics, smart wearables, e-medicine solutions, medical artificial intelligence (AI) solutions, medical 3D printing solutions, as well as medical imaging diagnostic center and health management center. United Imaging Group is committed to creating more value for our customers and constantly improving the global accessibility of high-end medical equipment and services through in-depth cooperation with hospitals, universities, research institutions, and industry partners.

Our vision: Leading Healthcare Innovation
Our mission: To Bring Equal Healthcare for All

Urenco Isotopes

Drienemansweg 1
7601PZ Almelo, Netherlands

www.urencoisotopes.com

At Urenco Isotopes we are on a mission to drive advancements in healthcare, research and beyond. We have been delivering innovation in isotopes for more than three decades. Guided by a qualitydriven culture and a commitment to operational excellence. Bases in the Netherlands, we deliver reliable, high-quality solutions that support life-saving treatments, fuel progress in cutting-edge industries, and make a meaningful impact on people's lives and the world around us. Leveraging the most advanced ultracentrifuge technology globally, we can enrich materials to exceed 99% purity or below 1%, tailored to the most demanding applications.

VICI AG International

Parkstrasse 2
CH-6214 Schenkon, Switzerland

www.vici.com/

For more than 50 years, the VICI companies have been a leading designer and manufacturer of components for precision analytical, biomedical, and biocompatible instrumentation. Companies under the VICI umbrella serve five continents with a diverse product line that includes liquid and gas valves, sample injectors and selectors, pneumatic and electric actuators, tubing, syringes, temperature controllers, gas generators, gas purifiers, and GC detectors. With over 150 state-of-the-art CNC machines, our instruments and components are manufactured to exacting standards. VICI produces a complete line of valves for analytical chemistry. We specialize in zero dead volume fittings and filters for the separation sciences and are the original creators of the pulse discharge detector (PDD). Our miniPDD consumes less than one-fifth the amount of helium required by the PDDs used on complete GC systems. It has similar sensitivity to the original PDD with a slightly lower dynamic range. Our VICI Metronics division produces PEEK, FEP, PFA, and ETFE tubing, ambient temperature gas purifiers, ValcoBond GC capillary columns, and Dynacal gas calibration standards. VICI Precision Sampling manufactures analytical quality syringes, sampling probes, as well as standard and custom formed stainless and special alloy tubing. VICI AG International produces some Valco products as well as the Jour line of HPLC fittings and lab safety products. VICI DBS builds our new line of laboratory hydrogen, nitrogen and zero air gas generators. Our newest products include the C82 line of UHPLC valves, fittings that permit direct connection of 360 um tubing, the Universal valve actuator, and the C52 platform integrated HPLC injectors and selectors.

Von Gahlen Nederland B.V.

Kelvinstraat 9
6902 PW ZEVENAAR, Netherlands

www.vongahlen.com

Von Gahlen designs and manufactures lead shielding products for the radiopharmacy and nuclear medicine industry. Our products range from transportation solutions to complete manufacturing lines, including automated dispensing systems. Since its founding over 5 decades ago, Von Gahlen has become a world leader in these industries. With our strong customer focus, we have managed to provide high quality products that meet or exceed industry standards and safety requirements. Von Gahlen hot cell installations may be found all over the world, including many of the largest turnkey installations in the field. In our approach we not only focus on developing the best radiation-shielding lead products and solutions, but also on optimizing their lifecycle. We are your partner in the development of hot cells (also for special purposes) and complete laboratory facilities for nuclear medicine. We understand better than anyone the continuing need to guarantee long-lasting solutions, improve operational management and control costs. Our team of professionals includes highly qualified technical designers as well as experienced manufacturing and installation personnel. Our modern factory is equipped with the latest computerized equipment. Von Gahlen is an ISO 9001 Certified Company. Our quality assurance program has been audited and approved by numerous customers. With Von Gahlen you can be assured of safe solutions, a reliable partnership and a lasting relationship.

Wälischmiller Engineering GmbH

Schießstattweg 16
88677 Markdorf, Germany

www.hwm.com

Wälischmiller Engineering is the provider of the nuclear medicine industry most innovative and reliable nuclear manipulators. The company has a hard earned international reputation for performance, excellence in engineering and exceptional robotic hardware. FULL RANGE SUPPLIER: • robot system TELBOT® with unique capabilities which includes unlimited rotation in all axes, no wiring inside or outside the TELBOT® arm, and unlimited fast and precise movement • mechanical telemanipulators for a wide range of applications (models A100 and A200) • universal grippers • custom solutions ranging from simple tools to custom automation. PRODUCTS FROM A SINGLE SOURCE: • engineering including product design and development • high manufacturing including single part assembly • all required specialised staff available within the company • installation at sites • worldwide service and maintenance By working closely with our specialist engineers and project managers, you can be confident of receiving not just an off-the shelf product, but a custom-tailored solution to your problems that offers highest quality and guarantee of long-term operational safety to even most-demanding customers. The company is certified according ISO 9001:2015, ISO 19773:2018, ISO 14001:2015, DIN 150 45001:2018, KTA 1401, ATEX and CEFRI-E. Brands: HWM, Wälischmiller Engineering, TELBOT®

Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd.

No.20 Qianrong Road
214063 Wuxi, China

www.jysy.cc

Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd is a high-tech enterprise owned by Jiangsu Institute of Nuclear Medicine and Key Laboratory of Nuclear Medicine of Ministry of Health.

Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd specializes in the R&D and production of radiopharmaceuticals and medical devices. It is a high-tech enterprise integrating positron drugs, radioimmunoassay, single photon drug production and R&D. Advanced equipment such as cyclo-tron, micro-PET/CT, optical imaging and synthesis module are deployed for the re-search and production of positron drugs, undertaking or participating in major research projects of various countries and provinces. Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd has a large-scale and diverse production base of radiopharmaceuticals in vivo in China, and has successfully passed GMP certification. The company also produces PET precursors, kits, sterile vacuum vials and accessories. Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd also cooperates with other scientific research institutions to provide the best quality service support.

XEOS Medical NV

Ottergemsesteenweg-Zuid 808 b358
9000 Gent, Belgium

www.xeos.care

XEOS wants to tackle the limitations of today's available imaging techniques applied in surgical oncology, by using the transformative power of molecular Imaging intra-operatively. The AURA 10 is the first-ever PET-CT specimen imager for the operating room, offering surgeons and imaging specialists the sensitivity of PET imaging at submillimeter spatial resolution. Thanks to the AURA 10 mobile scanner, a specimen does no longer need to be transported to the radiology or pathology department during surgery. High-quality specimen images can now be obtained in the OR within 10 minutes after excision. Founded in 2019 in Ghent, Belgium, XEOS is an expert in specimen imaging and focuses on improving outcomes in surgical oncology through innovations in intraoperative imaging. The XEOS team is passionate about expanding the use of molecular imaging to optimize clinical workflows and improve patient outcomes. The company has an admirable track record of in-house PET & CT design. XEOS is an ISO 13485 certified company.




The EANM VILLAGE

Your Place to Connect, Discover and Get Involved!

Meet experts, discover our projects, and explore the future of Nuclear Medicine – all in one vibrant space.

Scan to learn more:




Come find us daily in the Entrance Hall

CORPORATE MEMBERS

We gratefully acknowledge the support of the following companies (in alphabetical order):

	ABX advanced biochemical compounds GmbH
	ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH
	Alliance Medical GmbH
	AWEX – Wallonia Export & Investment Agency
	Blue Earth Diagnostics Ltd.
	Bruker BioSpin GmbH & Co. KG
	Capintec, a Mirion Medical Company
	CMR – Center of Molecular Research Corporation GmbH
	COMECER SPA
	Curium PET Europe
	Cyclomedica

	Eckert & Ziegler
	ELSE Solutions S.r.l.
	GE HealthCare
	Hermes Medical Solutions AB
	IBA SA
	Isotopia Molecular Imaging
	ITM Isotope Technologies Munich SE
	Jiangsu Huayi Technology Co., Ltd.
	Lemer Pax
	Life Molecular Imaging Ltd.
	Medi-Radiopharma Ltd.

CORPORATE MEMBERS

We gratefully acknowledge the support of the following companies (in alphabetical order):

	Mediso Ltd.
	MIM Software Inc.
	Narodowe Centrum Badań Jądrowych, Ośrodek Radioizotopów POLATOM
	Novartis
	OncoBeta GmbH
	OncoSil Medical Europe GmbH
	Pars Isotope Co.
	ROTOP Pharmaka GmbH
	SCK CEN
	SHINE Medical Technologies, LLC
	Siemens Healthineers

	Spectrum Dynamics Medical Inc.
	Stichting NRG PALLAS
	Sumitomo Heavy Industries, Ltd.
	Telix Innovations SA
	Tema Sinergie S.p.A.
	TerThera b.v.
	Triskem International
	United Imaging Healthcare
	Urenco Isotopes
	Von Gahlen Nederland B.V.

USEFUL CONTACTS

Scientific Programme

EANM Executive Office

Andrea Csismazia

Schmalzhofgasse 26,

1060 Vienna, Austria

Phone: +43 1 890 44 27

E-mail: a.csismazia@eanm.org

Web: eanm25.eanm.org

Industry Exhibition

EANM Executive Office

Alexander Berger

Andreas Felser

Schmalzhofgasse 26,

1060 Vienna, Austria

Phone: +43 1 890 44 27

E-mail: a.berger@eanm.org

Web: eanm25.eanm.org

Registration

EANM Executive Office

Jessica Filippi

Petra Wurzinger

Schmalzhofgasse 26,

1060 Vienna, Austria

Phone: +43 1 890 44 27

E-mail: registration@eanm.org

Web: eanm25.eanm.org

IMPRINT

Publisher

European Association of Nuclear Medicine

Schmalzhofgasse 26,

1060 Vienna, Austria

Phone: +43 1 890 44 27

E-mail: office@eanm.org

Web: www.eanm.org

Editors

Valentina Garibotto, EANM Congress Chair 2023–2025

Andreas Felser,

Andrea Csismazia,

EANM Executive Office

Content

No responsibility will be taken by the EANM Executive Office regarding the correctness of the information provided. Last updated in September 2025.

Layout & Design

Olga Dogadina,

EANM Executive Office